<SEC-DOCUMENT>0001193125-15-112108.txt : 20150330
<SEC-HEADER>0001193125-15-112108.hdr.sgml : 20150330
<ACCEPTANCE-DATETIME>20150330172414
ACCESSION NUMBER:		0001193125-15-112108
CONFORMED SUBMISSION TYPE:	40-F
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150330
DATE AS OF CHANGE:		20150330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		40-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		15735568

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>40-F
<SEQUENCE>1
<FILENAME>d891272d40f.htm
<DESCRIPTION>FORM 40-F
<TEXT>
<HTML><HEAD>
<TITLE>Form 40-F</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 40-F
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2014</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36421 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA
PHARMACEUTICALS INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Alberta, Canada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Province or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary standard industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>classification code number,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>if applicable)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer identification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>number, if applicable)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>#1203-4464 Markham Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Victoria, British Columbia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V8Z 7X8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(250) 708-4272
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principle executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CT Corporation System </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>111 &#150; 8th Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) 590-9331 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address (including zip code) and telephone number (including area code) of agent for service in the United States) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:151.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which registered:</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Shares, no par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Shares, no par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Toronto Stock Exchange</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities for which there is a reporting obligation pursuant to Section&nbsp;15(d) of the Act: None </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For annual reports, indicate by check mark the information filed with this form: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B>&nbsp;&nbsp;Annual Information Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B>&nbsp;&nbsp;Audited Annual Financial Statements</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate the number of outstanding shares of the issuer&#146;s classes of capital or common stock as of the close of the period covered by the annual report:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31,817,989 Common Shares (as at December&nbsp;31, 2014). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past 90 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<B></B><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (s.232.405 of this chapter) during the preceding 12
months (or for such shorter period that the Registrant was required to submit and post such files). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<B></B><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B> </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL DOCUMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are filed as part of this Annual Report on Form 40-F: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A.&nbsp;Annual Information Form </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
Registrant&#146;s Annual Information Form for the year ended December&nbsp;31, 2014, see Exhibit 99.1 of this Annual Report on Form 40-F. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B.&nbsp;Audited Annual Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
the Registrant&#146;s Audited Consolidated Financial Statements for the year ended December&nbsp;31, 2014, including the report of its Independent Auditor with respect thereto, see Exhibit 99.2 of this Annual Report on Form 40-F. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C.&nbsp;Management&#146;s Discussion and Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Registrant&#146;s Management&#146;s Discussion and Analysis of the operating and financial results for the year ended December&nbsp;31, 2014, see
Exhibit&nbsp;99.3 of this Annual Report on Form 40-F. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTROLS AND PROCEDURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A.&nbsp;Certifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is
included in Exhibits 99.4, 99.5, 99.6 and 99.7 of this Annual Report on Form 40-F. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B.&nbsp;Disclosure Controls and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the end of the Registrant&#146;s year ended December&nbsp;31, 2014, an internal evaluation was conducted under the supervision of and with the
participation of the Registrant&#146;s management, including the President and Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Registrant&#146;s &#147;disclosure controls and
procedures&#148; as defined in Rule 13a-15(e) under Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;).&nbsp;Based on that evaluation, the President and Chief Executive Officer and the Chief Financial Officer concluded
that the design and operation of the Registrant&#146;s disclosure controls and procedures were effective in ensuring that the information required to be disclosed in the reports that the Registrant files with or submits to the Securities and
Exchange Commission (the &#147;Commission&#148;) is recorded, processed, summarized and reported, within the required time periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It should be noted
that while the President and Chief Executive Officer and the Chief Financial Officer believe that the Registrant&#146;s disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that the
Registrant&#146;s disclosure controls and procedures will prevent all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are
met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C.&nbsp;Management&#146;s Annual Report on Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant&#146;s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed by, or under the supervision of, the President and Chief Executive Officer and the Chief Financial Officer and effected by the Registrant&#146;s Board of Directors, management and other personnel to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Financial Reporting Standards as issued by the International Accounting
Standards Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management assessed the effectiveness of the registrant&#146;s internal control over financial reporting as of December&nbsp;31, 2014,
based on the criteria set forth in <I>Internal Control &#150; Integrated Framework (1992)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on this assessment, management concluded that, as of December&nbsp;31, 2014, the Registrant&#146;s internal control over financial reporting was
effective. In addition, management determined that there were no material weaknesses in the Registrant&#146;s internal control over financial reporting as of December&nbsp;31, 2014. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>D.&nbsp;Attestation of Report of Independent Auditor </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This annual report does not include an attestation report of the Registrant&#146;s registered public accounting firm due to a transition period established by
rules of the Commission for newly public companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>E.&nbsp;Changes in Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2014, there were no changes in the Registrant&#146;s internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, the Registrant&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDIT
COMMITTEE FINANCIAL EXPERT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant&#146;s Board of Directors has determined that Mr.&nbsp;Charles&nbsp;A. Rowland, Jr. is an &#147;audit
committee financial expert&#148; (as that term is defined in paragraph 8(b) of General Instruction B to Form 40-F) serving on its audit committee and is &#147;independent&#148; (as defined by the New York Stock Exchange corporate governance
rules&nbsp;applicable to foreign private issuers).&nbsp;For a description of Mr.&nbsp;Rowland&#146;s relevant experience in financial matters, see the biographical description for Mr.&nbsp;Charles&nbsp;A. Rowland, Jr. under &#147;Directors and
Officers&#148; in the Registrant&#146;s Annual Information Form for the year ended December&nbsp;31, 2014, which is filed as Exhibit 99.1 to this Annual Report on Form 40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has indicated that the designation of Mr.&nbsp;Charles&nbsp;A. Rowland, Jr. as an audit committee financial expert does not make him an
&#147;expert&#148; for any purpose, impose any duties, obligations or liability on him that are greater than those imposed on members of the audit committee and board of directors who do not carry this designation or affect the duties, obligations
or liability of any other member of the audit committee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CODE OF ETHICS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has adopted a &#147;code of ethics&#148; (as that term is defined in paragraph 9(b) of General Instruction B to Form 40-F) (&#147;Code of
Ethics&#148;), which is applicable to the directors, officers, employees and consultants of the Registrant and its affiliates (including, its principal executive officer, principal financial officer, principal accounting officer or controller, and
persons performing similar functions).&nbsp;The Code of Ethics entitled &#147;Code of Ethics and Conduct&#148; is available on the Registrant&#146;s website at <U>www.auriniapharma.com. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past fiscal year, the Registrant has not granted any waiver, including an implicit waiver, from any provision of its Code of Ethics. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL ACCOUNTANT FEES AND SERVICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is included under the heading &#147;External Auditor Services Fees&#148; on Schedule 1 &#150; Audit Committee Information in the
Registrant&#146;s Annual Information Form for the year ended December&nbsp;31, 2014, filed as Exhibit 99.1 to this Annual Report on Form 40-F, and is incorporated herein by reference. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFF-BALANCE SHEET ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant does not have any &#147;off-balance sheet arrangements&#148; (as that term is defined in paragraph 11(ii) of General Instruction B to Form
40-F) that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is
material to investors. For a discussion of the Registrant&#146;s other off-balance sheet arrangements, see page 13 of the Registrant&#146;s Management&#146;s Discussion and Analysis for the fiscal year ended December&nbsp;31, 2014, attached as
Exhibit 99.3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is included under the heading &#147;Contractual Obligations&#148; in the Registrant&#146;s Management&#146;s Discussion and Analysis
of the operating and financial results for the year ended December&nbsp;31, 2014, filed as Exhibit 99.3 to this Annual Report on Form 40-F, and is incorporated herein by reference. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDENTIFICATION OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has a separately designated standing audit committee established in accordance with Section&nbsp;3(a)(58)(A) of the Exchange Act.&nbsp;The
Registrant&#146;s Audit Committee members consist of Mr.&nbsp;Charles&nbsp;A. Rowland, Jr., Dr.&nbsp;Richard&nbsp;A. Glickman and Mr.&nbsp;Benjamin Rovinski. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIFFERENCES IN NASDAQ AND CANADIAN CORPORATE GOVERNANCE REQUIREMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant is a foreign private issuer and its common shares are listed on the NASDAQ Stock Market (&#147;NASDAQ&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ Rule 5615(a)(3) permits a foreign private issuer to follow its home country practice in lieu of the requirements of the Rule 5600 Series, the
requirement to distribute annual and interim reports set forth in Rule 5250(d), and the Direct Registration Program requirement set forth in Rules 5210(c) and 5255; provided, however, that such a company shall comply with the Notification of
Material Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640), have an audit committee that satisfies Rule 5605(c)(3), and ensure that such audit committee&#146;s members meet the independence requirement in Rule
5605(c)(2)(A)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant does not follow Rule 5620(c) (shareholder quorum) but instead follows its home country practice, as described below.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shareholder Meeting Quorum Requirements: The NASDAQ minimum quorum requirement under Rule 5620(c) for a shareholder meeting is 33-1/3% of
the outstanding shares of common stock. In addition, a registrant listed on NASDAQ is required to state its quorum requirement in its by-laws. The Registrant&#146;s quorum requirement is set forth in its by-laws. A quorum for a meeting of
shareholders of the Registrant is shareholders or proxyholders holding ten percent of the issued and outstanding shares entitled to be voted at the meeting. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Registrant does not follow Rule 5635, which establishes shareholder approval requirements prior
to the issuance of securities in certain circumstances. In lieu of following Rule 5635, the Registrant follows the rules of the Toronto Stock Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is consistent with the laws, customs and practices in Canada. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
statements in this Annual Report on Form 40-F are forward-looking statements within the meaning of Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act of 1933, as amended. Please see &#147;Forward Looking
Information&#148; in the Annual Information Form of the Registrant for the year ended December&nbsp;31, 2014, filed as Exhibit 99.1 to this Annual Report on Form 40-F for a discussion of risks, uncertainties, and assumptions that could cause actual
results to vary from those forward-looking statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERTAKING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish
promptly, when requested to do so by the Commission staff, information relating to the securities in relation to which the obligation to file an annual report on Form 40-F arises or transactions in said securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT TO SERVICE OF PROCESS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Registrant has previously filed a Form F-X in connection with the class of securities in relation to which the obligation to file this report arises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
change to the name or address of the Registrant&#146;s agent for service shall be communicated promptly to the Commission by amendment to Form F-X referencing the file number of the Registrant. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused
this report to be signed on its behalf by the undersigned, thereto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;March 30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Aurinia Pharmaceuticals Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Document</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex991.htm">99.1</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annual Information Form of the Registrant for the fiscal year ended December&nbsp;31, 2014.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex992.htm">99.2<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Audited Consolidated Financial Statements of the Registrant for the year ended December&nbsp;31, 2014 together with the Auditors&#146; Report thereon.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex993.htm">99.3<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Management&#146;s Discussion and Analysis of the operating and financial results of the Registrant for the year ended December&nbsp;31, 2014.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex994.htm">99.4<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer under Section 302 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex995.htm">99.5<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer under Section 302 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex996.htm">99.6<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer under Section 906 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex997.htm">99.7<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer under Section 906 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d891272dex998.htm">99.8<BR></A>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, Independent Auditor</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d891272dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g891272ex1.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc"></A>TABLE OF CONTENTS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_1">BASIS OF PRESENTATION</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_2">FORWARD&#150;LOOKING INFORMATION</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_3">OVERVIEW</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_4">STRATEGY</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_5">THREE YEAR HISTORY</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_6">REGULATORY AND BUSINESS MATTERS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_7">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_9">CAPITAL STRUCTURE</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_10">TRADING PRICE AND VOLUME OF AURINIA SHARES</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_11">ESCROWED SECURITIES</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_12">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_13">DIRECTORS AND OFFICERS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_14">CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_15">LEGAL PROCEEDINGS AND REGULATORY ACTIONS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_16">INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_17">CONFLICTS OF INTEREST</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_18">TRANSFER AGENT AND REGISTRAR</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_19">MATERIAL CONTRACTS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_20">INTERESTS OF EXPERTS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_21">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_22">SCHEDULE 1 - AUDIT COMMITTEE INFORMATION</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_23">SCHEDULE 2 - AUDIT COMMITTEE CHARTER</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1891272_24">SCHEDULE 3 - GLOSSARY OF TERMS AND DEFINITIONS</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_1"></A>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this AIF is as of March&nbsp;26, 2015, unless otherwise stated or where information in documents incorporated by reference has a different
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This AIF describes the Company and its operations, its prospects, risks and other factors that affect its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to the &#147;<B>Company</B>&#148; in this AIF refer to Aurinia Pharmaceuticals Inc. (&#147;<B>Aurinia</B>&#148;) after October&nbsp;22, 2013 and to
Isotechnika Pharma Inc. (&#147;<B>Pharma</B>&#148;) prior to October&nbsp;22, 2013. Pharma changed its name to Aurinia on October&nbsp;23, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
references herein to &#147;dollars&#148; and &#147;$&#148; are to United States dollars, unless otherwise indicated. All references to CDN$ are to Canadian dollars. On March&nbsp;25, 2015 the exchange rate for conversion of US dollars into Canadian
dollars was US$1.00 = CDN$1.2513 based upon the Bank of Canada noon rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, the information set forth in this annual information
form is as of December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms that are not otherwise defined in this AIF have the meanings attributed thereto in Schedule 3 to
this AIF. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_2"></A>FORWARD&#150;LOOKING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement is forward-looking when it uses what we know and expect today to make a statement about the future. Forward-looking statements may include words
such as &#147;<I>anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;goal&#148;, &#147;may&#148;, &#147;outlook&#148;, &#147;plan&#148;, &#147;seek&#148;, &#147;should&#148;, &#147;strive&#148;, &#147;target&#148;,
&#147;could&#148;, &#147;continue&#148;, &#147;potential&#148; </I>and <I>&#147;estimated&#148;</I>, or the negative of such terms or comparable terminology. You should not place undue reliance on the forward-looking statements, particularly those
concerning anticipated events relating to the development, clinical trials, regulatory approval, and marketing of the Company&#146;s products and the timing or magnitude of those events, as they are inherently risky and uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities laws encourage companies to disclose forward-looking information so that investors can get a better understanding of the Company&#146;s future
prospects and make informed investment decisions. These statements may include, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund the Company&#146;s operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials, plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of completion of patient enrollment in the Company&#146;s AURA-LV and AURION studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek additional corporate alliances to support the commercialization of its products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation with first-in-class status for the treatment of LN outside
of Japan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to use the LN Phase 2b clinical trial program to gain a clearer understanding of voclosporin&#146;s time to onset of action in patients suffering from LN; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements are forward-looking because they are based on current expectations, estimates and assumptions.
It is important to know that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Forward-looking statements in this AIF describe the Company&#146;s expectations as of March&nbsp;26, 2015; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Actual results could be materially different from what the Company expects if known or unknown risks affect its business, or if the Company&#146;s estimates or assumptions turn out to be inaccurate. As a
result, the Company cannot guarantee that any forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements; </I></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made may have on the Company&#146;s
business. For example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the forward-looking
statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Accordingly, the expected impact cannot be meaningfully
described in the abstract or presented in the same manner as known risks affecting the Company&#146;s business; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>The Company disclaims any intention and assume no obligation to update any forward-looking statements even if new information becomes available, as a result of future events or for any other reason.
</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The factors discussed below and other considerations discussed in the &#147;Risk Factors&#148; section of this AIF could cause the
Company&#146;s actual results to differ significantly from those contained in any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements involve
known and unknown risks, uncertainties, and other factors that may cause the Company&#146;s actual results, performance, or achievements to differ materially from any further results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause such differences include, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The need for additional capital in the longer term to fund the Company&#146;s development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays, or failures the Company may experience in the conduct of and reporting of results of its clinical trials for voclosporin, and in particular its current LN Phase 2b clinical trial.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties the Company may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays, or failures in obtaining appropriate reimbursement of voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties that the Company may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of its products. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results,
levels of activity, performance or achievements. The forward-looking statements are made as of the date hereof and the Company disclaims any intention and have no obligation or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_3"></A>OVERVIEW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE STRUCTURE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical stage
pharmaceutical company with its registered office located at #201, 17904 &#150; 105 Avenue, Edmonton, Alberta T5S 2H5. The Company&#146;s head office is located at #1203-4464 Markham Street, Victoria, British Columbia and incorporates the clinical,
regulatory and business development functions of the Company. The office of the Chief Executive Officer is located in Bellevue, Washington. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia
Pharmaceuticals Inc. is organized under the <I>Business Corporations Act </I>(Alberta). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s common shares are currently listed and traded
on the NASDAQ under the symbol &#147;AUPH&#148; and on the TSX under the symbol &#147;AUP&#148;. The Company&#146;s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular LN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following wholly owned subsidiaries: Aurinia Pharmaceuticals, Inc. (Delaware incorporated), Aurinia Pharma Limited (UK incorporated) and
Aurinia Pharma Corp. (inactive). Aurinia Pharma Corp. had one wholly owned subsidiary, Aurinia Holdings Corp. (Barbados), which in turn had one wholly owned subsidiary, Aurinia Development Corp. (Barbados). These inactive Barbados subsidiaries were
dissolved in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s By-Law No.&nbsp;2 was amended at a shareholder&#146;s meeting held on August&nbsp;15, 2013 to include provisions
requiring advance notice for any nominations of directors by shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUMMARY DESCRIPTION OF BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, which is a next generation CNI. It has been
studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an ophthalmic disease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has rebranded,
restructured and refocused itself since September&nbsp;20, 2013 and modified its strategy to focus on the development of voclosporin for the treatment of LN. The mechanism of action of voclosporin, a CNI, has been validated with certain first
generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including dermatitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. The Company
believes that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation with first-in-class status for the treatment of LN outside of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>LN Clinical Development Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June, 2014,
AURINIA announced the initiation of its global 258 patient LN Phase 2b clinical trial to evaluate the efficacy of voclosporin as a treatment for LN. LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage
renal disease, the requirement for life-long dialysis, or death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The LN Phase 2b clinical trial, called &#147;<B>AURA&#150;LV</B>&#148; (Aurinia Urine
protein Reduction in Active Lupus with voclosporin) or AURA, is being conducted in approximately 22 countries and is a randomized, controlled, double-blind study comparing the efficacy of voclosporin against placebo in achieving remission in
patients with active LN. The AURA-LV study is designed to demonstrate that voclosporin can induce a rapid and sustained reduction of proteinuria in the presence of extremely low steroid exposure and fulfill specific regulatory requests. It will
compare two dosage groups of voclosporin (23.7mg and 39.5mg) administered with MMF vs. MMF alone. All patients will also receive oral corticosteroids as background therapy. There will be a primary analysis to determine complete remission at week 24
and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In support of this large, randomized, LN Phase 2b
clinical trial, the Company announced on February&nbsp;9, 2015, the initiation of an open label, exploratory study to assess short term predictors of response using voclosporin in combination with MMF, in patients with active LN.
&#147;<B>AURION</B>&#148; (Aurinia early Urinary protein Reduction Predicts Response) will examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from the AURION study will contribute to the growing base of clinical data derived from the entire ongoing LN Phase 2b clinical trial program. A
more clear understanding of voclosporin&#146;s time to onset of action in patients suffering from LN may be gained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_4"></A>STRATEGY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s business strategy is to optimize the clinical and commercial value of voclosporin, its late stage clinical candidate. In particular, the
Company is focused on the development of voclosporin as an add-on therapy to the current standard of care, CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which was developed by the Aurinia Pharma Corp. management team during its
tenure at Aspreva.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key elements of the Company&#146;s corporate strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Focusing the Company&#146;s resources on advancing voclosporin through a robust LN Phase 2b clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mitigate development risk by leveraging the ALMS database and management team&#146;s experience &#150; The Company has certain rights to utilize the ALMS database including its use in planning, designing and informing
the LN Phase 2b clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate other voclosporin indications &#150; while the Company intends to deploy its operational and financial resources to develop voclosporin for LN, the Company believes that recent granted formulation patents
regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value. The Company will explore its strategic options to exploit shareholder value from this intellectual property.
The Company also believes that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection. Management will consider strategic opportunities for these other potential
indications on an ongoing basis. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Status of the Company&#146;s Development Program in LN </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s clinical strategy involves layering voclosporin on top of the current standard of care
(CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF and steroids) as a MTT approach to induce and maintain remission in patients suffering from active LN. In 2012, the Company gained alignment with both the Cardio-Renal and
Pulmonary, Allergy, and Rheumatology Products divisions of the FDA on its proposed Phase 2b protocol. The Company has an active IND and is currently recruiting patients for the LN Phase 2b clinical trial and AURION study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the existing evidence that supports the utility of CNIs in combination with MMF in treating LN, the robust safety data base of voclosporin and the fact
that CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF in combination with the other CNIs is the standard of care in transplant, it is reasonable to consider that voclosporin is a risk-mitigated clinical asset for the treatment
of LN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About Lupus Nephritis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lupus
Foundation of America estimates that approximately 1.5&nbsp;million people in the United States of America, and up to 5.0&nbsp;million people worldwide, suffer from SLE. Approximately 90% of patients suffering from SLE are women of child-bearing
age. The disease causes severe impairments on quality of life and wellbeing. Of the patients suffering from SLE, 40-60% experience renal manifestations of the disease resulting in inflammation of the kidney. These patients are considered to have LN
and have a high probability of advancing to end stage renal disease and dialysis if left untreated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the work performed by the former Aspreva
team, the ALMS data has been reported in several respected journals, including, the New England Journal of Medicine (<I>Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Solomons, N et al; ALMS Group. Mycophenolate versus azathioprine
as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95</I>) and the Journal of the American Society of Nephrology <I>(Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N et al; Aspreva Lupus
Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103-12. Epub 2009 Apr 15.) </I>These publications and subsequent alterations in treatment strategies
by physicians caring for patients suffering from LN have established CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF as the standard of care for the treatment of LN. This shift in the treatment paradigm for LN and the
establishment of CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> use as a relatively uniform treatment approach for these patients has, in the view of the Company, caused the LN market to evolve into an attractive and mature
market opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> being the current standard of care for the treatment of
LN, it remains far from adequate with fewer than 20% of patients on therapy actually achieving disease remission after six months of therapy. Data suggests that a LN patient who does not achieve rapid disease remission upon treatment is more likely
to experience renal failure or require dialysis at 10 years <I>(Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; the Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol.
2008;3:46-53</I>.). Therefore, it is critically important to achieve disease remission as quickly and as effectively as possible. The data suggests that the majority of patients in the United States suffering from lupus will not achieve complete
remission and are not adequately treated (BioTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Research Group In., ChartTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE, December 2010). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CNIs and Lupus Nephritis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia&#146;s lead drug, voclosporin, belongs to a class of drugs called CNIs. There are only two other oral marketed CNIs available, cyclosporine and
tacrolimus. Cyclosporine was introduced to the marketplace in the early 1980s while tacrolimus was first marketed in the mid-1990s. Both cyclosporine and tacrolimus have lost key patent protection and have not been approved for the treatment of LN
outside of Japan. For the past 20 years these products, in combination with CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF and steroids have been the cornerstone for the prevention of renal transplant rejection with greater
than 90% of all renal transplant patients leaving hospital on lifelong CNI plus MMF therapy (UNOS database). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2008, the Japanese Health Authority
became the first major jurisdiction in 50 years to approve a pharmaceutical agent for the treatment of LN. This product was the CNI tacrolimus. In addition to this approval, a substantial amount of recent data has been generated, primarily from
investigator initiated trials, that support the use of either cyclosporine or tacrolimus for the treatment of various forms of lupus including LN. The addition of tacrolimus, layered on top of MMF and steroids akin to the widely accepted and
utilized transplantation regimen, appears to dramatically improve complete response/remission rates in LN (<I>Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc
Nephrol. 2008 Oct;19(10):2001-10. Epub 2008 Jul 2 and .Liu , Zhi-Hong et al., 2012 ASN Abstract SA-OR097)</I>. This approach to treatment can be considered a MTT approach to treating LN as is routinely used in transplantation. Complete remission
rates of up to 50% have been reported utilizing this approach. Long term follow-up studies in LN suggest that the early reduction in proteinuria as seen in complete remission leads to improved renal outcome at ten years. <I>(Houssiau FA, Vasconcelos
C, D&#146;Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long-term followup of patients in the Euro-lupus nephritis trial.
Arthritis Rheum. 2004 Dec;50(12):3934-40).</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to utilize this MTT approach to treating LN patients with voclosporin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About Voclosporin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin is an oral drug,
administered twice daily. It is structurally similar to cyclosporine A (&#147;<B>CsA</B>&#148;), but is chemically modified on the amino acid-1 residue. This modification leads to a number of advantages the Company believes offer relevant clinical
benefits as compared to the older off-patent CNIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voclosporin Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Voclosporin reversibly inhibits immunocompetent lymphocytes, particularly T-Lymphocytes in the G0 and G1 phase of the cell-cycle, and also reversibly
inhibits the production and release of lymphokines. Through a number of processes voclosporin inhibits and prevents the activation of various transcription factors necessary for the induction of cytokine genes during T-cell activation. It is
believed that the inhibition of activation of T-cells will have a positive modulatory effect in the treatment of LN. In addition to these immunologic impacts recent data suggests that CNIs have another subtle but important impact on the structural
integrity of the podocytes<B></B><I> (Faul C,&nbsp;et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med.&nbsp;2008 Sep;14(9):931-8. doi: 10.1038/nm.1857).</I><B></B> This data
suggests that inhibition of calcineurin in patients with autoimmune kidney diseases helps stabilize the cellular actin-cytoskeleton of the podocytes thus having a structural impact on the podocyte and the subsequent leakage of protein into the
urine, which is a key marker of patients suffering from LN.<B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Voclosporin Clinical Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that voclosporin has shown a number of key clinical benefits over the existing commercially available CNIs (tacrolimus&nbsp;&amp;
cyclosporine). Firstly, CNI assay results have indicated that voclosporin is approximately four times more potent than its parent molecule cyclosporine, which would indicate an ability to give less drug and produce fewer potentially harmful
metabolites. Secondly, cyclosporine inhibits the enterohepatic recirculation of MPA. The net effect of co-administration of CsA with MMF is reduced MPA systemic exposure by as much as 50% (<I>D. Cattaneo et al. American Journal of Transplantation,
2005:12(5);2937-2944.</I>). This drug interaction has not been observed with voclosporin and it is not expected that MPA blood exposure levels will be reduced with voclosporin co-administration. This is an extremely important fact to consider as
most patients being treated with voclosporin for LN will already be taking MMF. Furthermore, pharmacokinetic and pharmacodynamics (&#147;<B>PK-PD</B>&#148;) analysis indicate lower PK-PD variability for voclosporin versus tacrolimus or cyclosporine,
to the extent that the Company believes flat-dosing can be achieved for voclosporin. The currently available CNIs require extensive therapeutic drug monitoring which can often be costly, confusing and time consuming for treating physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a head-to-head study comparing voclosporin against cyclosporine in the treatment of psoriasis, cyclosporine was shown to cause significant increases in
lipid levels as compared to voclosporin. The difference was statistically significant. This is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
important considering the fact that most lupus patients die of cardiovascular disease. In another study comparing voclosporin against tacrolimus in patients undergoing renal transplantation, the
voclosporin group experienced a statistically significantly lower incidence of glucose intolerance and diabetes than tacrolimus treated patients. Additionally, in the Japanese tacrolimus study that led to the approval of this drug in Japan, almost
15% of tacrolimus patients experienced glucose intolerance <I>(Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606-15. Epub 2009
Aug 18</I>). This is a major limitation for physicians wanting to use this agent in lupus and is a well described side effect of tacrolimus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
believes that voclosporin can be differentiated from the older CNIs and thus possess a unique position with the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voclosporin Development
History </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More than 2,600 patients have been in voclosporin clinical trials including studies where voclosporin was compared to placebo or active
control. The safety and tolerability profile of the drug therefore is well characterized. Phase 2 or later clinical studies that have been completed include studies in the following indications: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Psoriasis:</B> To date, two Phase 3 studies in patients with moderate to severe psoriasis have been completed. The primary efficacy endpoint in both
studies was a reduction in Psoriasis Area and Severity Index, which is a common measure of psoriasis disease severity. The first study treatment with voclosporin resulted in statistically significantly greater success rates than treatment with
placebo by the twelfth week. In a second study comparing voclosporin against cyclosporine, the drug was not shown to be statistically non-inferior to cyclosporine in terms of efficacy; however voclosporin proved superior in terms of limiting
elevations in hyperlipidemia. Due to the evolving psoriasis market dynamics and the changing standard of care for the treatment of this disease the Company has decided not to pursue further Phase 3 development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Renal Transplantation:</B> A Phase 2b clinical trial in de novo renal transplant recipients was completed. Study ISA05-01, the PROMISE Study <I>(Busque S,
Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, et al; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011
Dec;11(12):2675-84</I>) was a six month study with a six month extension comparing voclosporin directly against tacrolimus on a background of MMF and corticosteroids. Voclosporin was shown to be equivalent in efficacy, but superior to tacrolimus
with respect to the incidence of new onset diabetes after transplantation. In 2010, tacrolimus lost its exclusivity in most world markets and as a result, the competitive pricing environment for voclosporin for this indication has come into
question. Additionally, the more expensive development timelines for this indication has made it a less attractive business proposition as compared to the LN indication, even when considering the fact that a Special Protocol Assessment has been
agreed to by the FDA for this indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Uveitis:</B> Multiple studies in various forms of non-infectious uveitis have been completed over the past
several years by a licensee of the Company indicating mixed efficacy. In all but one of the studies, completed by the licensee, an impact on disease activity was shown in the voclosporin group. However achievement of the primary end-points in
multiple studies could not be shown. Uveitis is a notoriously difficult disease to study due to the heterogeneity of the patient population and the lack of validated clinical end-points. However in all of the uveitis studies completed, the safety
results were consistent and the drug was well tolerated as expected. The Company has now successfully terminated its licensing agreement with Lux. In conjunction with this termination the Company has retained a portfolio of additional patents that
Lux had been prosecuting that are focused on delivering effective concentrations of voclosporin to various ocular tissues. The Company will continue to evaluate these patents and make strategic recommendations on how they fit into the ongoing
strategic directives of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scientific Rationale for Treatment of LN with voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SLE including LN is a heterogeneous autoimmune disease with often multiple organ and immune system involvement. T-cell mediated immune response is an important
feature of the pathogenesis of LN while the podocyte injury that occurs in conjunction with the ongoing immune insult in the kidney is an important factor in the clinical presentation of the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of voclosporin in combination with the current standard of care for the treatment of LN provides a multi-targeted approach to treating this
heterogenous disease (similar to the standard approach in preventing kidney transplant rejection). Voclosporin has shown to have potent effects on T-cell activation leading to its immunomodulatory effects. Additionally, recent evidence suggests that
inhibition of calcineurin has direct physical impacts on the podocytes within the kidney. Inhibition of calcineurin within the podocytes can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin
cytoskeletion within the podocyte. This process is expected to have a direct impact on the levels of protein in the urine which is a key marker of LN disease activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_5"></A>THREE YEAR HISTORY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN 2014 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing on NASDAQ -
September&nbsp;2, 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received approval from the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ and
commenced trading on September&nbsp;2, 2014 under the trading symbol &#147;AUPH&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing on the TSX - June&nbsp;2, 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applied to the TSX for relist of its common shares and subsequently the common shares were listed on the TSX as of the open of trading on
June&nbsp;2, 2014. The common shares of the Company continue to trade on the TSX under the trading symbol &#147;AUP&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement
Financing - February&nbsp;14, 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014 the Company completed a $52 million private placement (the
&#147;<B>Offering</B>&#148;). The proceeds from the Offering are being used for the LN Phase 2b clinical trial currently underway, general corporate and working capital purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners, and Apple Tree Partners, with
participation from various other institutional investors, including existing shareholders Lumira Capital, ILJIN and Difference Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms
of the Offering, the Company issued 18.92&nbsp;million units (the &#147;<B>Units</B>&#148;) at a subscription price per Unit of $2.7485, each Unit consisting of one common share and one-quarter (0.25) of a common share purchase warrant (a
&#147;<B>Warrant</B>&#148;), exercisable for a period of five years from the date of issuance at an exercise price of $3.2204. All securities issued in connection with the Offering were subject to a four-month hold period from the date of issuance
in accordance with applicable securities law, which expired on June&nbsp;15, 2014 for the securities issued at closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC acted as
lead placement agent and Canaccord Genuity Inc. acted as co-placement agent for the Offering. The placement agents were paid a 7.5% cash commission on subscriptions excluding those from existing shareholders for a total commission of $3.86 million.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Distribution and License Agreement with Lux &#150; February&nbsp;27, 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2014 the Company signed a Termination and Assignment Agreement with Lux which returned worldwide rights to develop and commercialize
voclosporin for the treatment and prophylaxis of all ophthalmic diseases back to the Company. The return of this license further consolidates the intellectual property related to voclosporin which was a key consideration in the acquisition of
Aurinia Pharma Corp. by the Company in 2013. Coincident with the termination of the Lux agreement the Company has retained a portfolio of patents focused around delivering voclosporin in high concentrations to various tissues of the eye. The Company
will evaluate this intellectual property and define its role as it relates to the defined corporate strategy of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN
2013 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Change - November&nbsp;6, 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, 2013 the Company announced the appointment of Stephen W. Zaruby as the Company&#146;s President and CEO. Mr.&nbsp;Zaruby has an
accomplished history of strategic operations, sales and marketing, research and development, and general management success in the global biotechnology and pharmaceutical industries. Previously, he was President of Seattle-based ZymoGenetics Inc.,
which was acquired by Bristol-Myers Squibb for $885 million in 2010. Mr.&nbsp;Zaruby joined ZymoGenetics from Bayer. There, his 20 years of progressive leadership experience included executive roles managing Bayer&#146;s domestic and international
anti-infectives, quinolone and hospital/surgical business franchises. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Consolidation and Name Change - October&nbsp;23, 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2013, the Company proceeded with a consolidation of its common shares on a 50:1 basis. In conjunction with the share consolidation, the
Company changed its name from Isotechnika Pharma Inc. to Aurinia Pharmaceuticals Inc. Both the name change and the share consolidation were approved by the shareholders of the Company at its shareholder meeting held on August&nbsp;15, 2013. In
connection with its name change, the Company&#146;s trading symbol on the TSXV was changed to &#147;AUP&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan of Arrangement and Acquisition of Aurinia Pharma Corp - September&nbsp;20, 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2013 the Company announced that it had signed a binding term sheet (the &#147;<B>Term Sheet</B>&#148;) with Aurinia Pharma Corp. for the
merger of the two companies, creating a clinical development stage pharmaceutical company focused on the global nephrology market. The Term Sheet set forth the main criteria to be incorporated into a definitive merger agreement under which the
Company would acquire 100% of the outstanding securities of Aurinia Pharma Corp. The merger was expected to be effected by the exchange of shares in the Company for securities of Aurinia Pharma Corp. resulting in an estimated 65:35 post merger
ownership split, on a warrant diluted basis, between the Company and Aurinia Pharma Corp. shareholders, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;3, 2013, the Company
and Aurinia Pharma Corp. negotiated a tripartite settlement agreement (the &#147;<B>Settlement Agreement</B>&#148;) with ILJIN pursuant to which, upon the successful completion of the proposed merger, the combined company would re-acquire the
voclosporin license previously granted to ILJIN and therefore obtain full rights to voclosporin for autoimmune indications including lupus, and transplantation in the United States, Europe and other regions of the world, outside of Canada, Israel,
South Africa, China, Taiwan and Hong Kong. In return, ILJIN would be entitled to receive certain predefined future milestone payments and would also own approximately 25% of the issued and outstanding shares of the merged company on a diluted basis,
calculated to give effect to the dilution by the exercise of Warrants but excluding the exercise of stock options. On August&nbsp;6, 2013, an arrangement agreement was prepared implementing the arrangement (the &#147;<B>Arrangement
Agreement</B>&#148;). The Arrangement Agreement was intended to implement the terms of the Settlement Agreement, whereby ILJIN would receive a further ownership interest in the Company in exchange for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">returning to the Company and terminating: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">all of its rights, licenses and obligations under the DDLA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">all other licenses and sublicenses between ILJIN and any of the Company, Aurinia Pharma Corp. or Vifor; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">suspending all of its current or contemplated legal or financial claims against the Company, Aurinia Pharma Corp. or Vifor. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company completed the merger and related transactions (&#147;Plan of Arrangement&#148;) on September&nbsp;20, 2013 that its shareholders had approved on
August&nbsp;15, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon closing of the Plan of Arrangement on September&nbsp;20, 2013, the Company issued common shares to ILJIN. In addition ILJIN is
entitled to receive certain predefined future success based clinical and marketing milestone payments in the aggregate amount of up to $10 million, plus up to $1.6 million upon the merged company reaching certain financing milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also acquired all of the issued and outstanding common shares of Aurinia Pharma Corp. at a ratio of approximately 19.83 pre-consolidated common
shares for each Aurinia Pharma Corp. share held by an Aurinia Pharma Corp. shareholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Second Unit Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the completion of the transaction described above, the Company completed a second private placement (the &#147;<B>Second Unit
Offering</B>&#148;) of 2.67&nbsp;million units (&#147;<B>Second Offering Units</B>&#148;) at a price of CDN$2.25 per Second Offering Unit for gross proceeds of CDN$6.0 million. Each Second Offering Unit is comprised of one common share and one-half
of a whole Warrant (each a &#147;<B>Second Offering Warrant</B>&#148;), with each whole Second Offering Warrant exercisable for one common share at a price of CDN$2.50 per common share for a period of three years from their date of issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing on the TSXV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The arrangement transaction
among the Company, ILJIN and Aurinia Pharma Corp. was determined by the TSX to constitute a &#147;backdoor listing&#148; under the rules of the TSX due to the significant increase in the ownership position in the Company by ILJIN. The result of that
determination was that the Company was required to meet the TSX&#146;s original listing requirements following completion of the arrangement. The Company did not meet the TSX&#146;s original listing requirements and, as a result, the common shares
were delisted from the TSX as of the end of trading on September&nbsp;27, 2013. The Company applied to the TSXV for listing of the common shares on that exchange and subsequently the common shares were listed on the TSXV as of the open of trading on
September&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Restructuring </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Plan of Arrangement, the Company made changes to its management team which included the appointments of Dr.&nbsp;Richard Glickman as
interim CEO, Dr.&nbsp;Neil Solomons as CMO, and Michael Martin as COO which resulted in either the termination or position change of certain previous officers and employees </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN 2012 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Partial Award in
Arbitration Proceedings with ILJIN &#150; November 2012 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;28, 2011 (the &#147;<B>Effective Date</B>&#148;) the Company
completed a DDLA with ILJIN for the further clinical and commercial development of voclosporin for use in transplant indications applicable to voclosporin. The Company granted to ILJIN an exclusive license to voclosporin for transplant and
autoimmune indications for the United States and other regions outside of Europe, Canada, Israel, South Africa, China, Taiwan and Hong Kong. The Company retained the rights over voclosporin in Europe for future development and commercialization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DDLA, the Company was to receive a total license fee of $5.0 million. In addition, ILJIN was to purchase 90.7&nbsp;million common shares
(pre-consolidation) of the Company for gross proceeds of $19.87 million in three tranches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was obligated under the terms of the agreement to
complete a single Phase 3 clinical trial for the prevention of kidney transplant rejection. The Company received $4.5 million of the license fee and the first private placement tranche of $2.37 million on January&nbsp;28, 2011 which was the
Effective Date of the Agreement. The Company issued 11.5&nbsp;million common shares (pre-consolidation) at a price of $0.207 per share to ILJIN pursuant to the subscription agreement for securities. On or before January&nbsp;28, 2012 ILJIN was to
pay $500,000 to the Company as the Second Development Payment and purchase 39.6&nbsp;million common shares (pre-consolidation) of the Company issued from treasury for an aggregate subscription price of $8.5 million. On or before January&nbsp;28,
2013, ILJIN was to purchase the final tranche of 39.6&nbsp;million common shares (pre-consolidation) of the Company issued from treasury for an aggregate subscription price of $9.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the January&nbsp;28, 2012 date, ILJIN verbally indicated their intent to alter the economics of the DDLA. Consequently, payment under the DDLA was
not received as required per the agreement of January&nbsp;28, 2011. The Company on January&nbsp;30, 2012 notified ILJIN that it was terminating the DDLA. At that time the Company believed that the termination of the original DDLA was valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received notification in March, 2012 that ILJIN submitted a request for arbitration to the International Chamber of Commerce (&#147;ICC&#148;)
Court of Arbitration relating to the Company&#146;s termination of the DDLA. The Arbitration hearing to determine the Company&#146;s right to terminate the agreement was held early in the fourth quarter of 2012. In November, 2012 the Company
received notification from the ICC that a Partial Award regarding its right to terminate the DDLA with ILJIN had been issued to the parties. In the result, the Partial Award provided that the DDLA had not been terminated and, therefore, the
Company&#146;s contractual relationship with ILJIN still existed. As such the Partial Award rejected the Company&#146;s interpretation of the DDLA&#146;s termination provision. In January of 2013, ILJIN formally notified the Company and the arbitral
tribunal that ILJIN had withdrawn all claims for damages in the parties&#146; pending arbitration. The Company completed the Plan of Arrangement on September&nbsp;20, 2013, which included a settlement with ILJIN, as discussed above in
<B><I>Corporate Developments in 2013</I></B><I>.</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_6"></A>REGULATORY AND BUSINESS MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REGULATORY REQUIREMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development, manufacturing
and marketing of voclosporin is subject to regulations relating to the demonstration of safety and efficacy of the products as established by the government (or regulatory) authorities in those jurisdictions where this product is to be marketed. The
Company would require regulatory approval in Canada, the United States, and Europe where activities would be conducted by the Company or on the Company&#146;s behalf. Depending upon the circumstances surrounding the clinical evaluation of the
product candidate, the Company itself may undertake clinical trials, contract clinical trial activities to contract research organizations, or rely upon corporate partners for such development. The Company believes this approach will allow the
Company to make cost effective developmental decisions in a timely fashion. The Company cannot predict or give any assurances as to whether regulatory approvals will be received or how long the process of seeking regulatory approvals will take. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although only the jurisdictions of the United States and Europe are discussed in this section, the Company also intends to seek regulatory approval in other
jurisdictions in the future and will initiate clinical studies where appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, all drugs are regulated under the Code of Federal Regulations and are enforced by the FDA. The regulations are similar to those in Canada
and require that non-clinical and clinical studies be conducted to demonstrate the safety and effectiveness of products before marketing, and that the manufacturing be conducted according to Good Manufacturing Practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the initial proof-of-concept and preliminary safety studies, the application submitted to the FDA prior to conducting human clinical trials of
new drugs is referred to as an IND application. This application contains similar information to the Canadian CTA, and the FDA has 30 days in which to notify the Company if the application is unsatisfactory. If the application is deemed
satisfactory, then the Company may proceed with the clinical trials. As in Canada, before a clinical trial can commence at each participating clinical trial site, the site&#146;s IRB/REB must approve the clinical protocol and other related
documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After completing all required non-clinical and clinical trials, and prior to selling a novel drug in the United States, the Company must also
comply with NDA procedures required by the FDA. The NDA procedure includes the submission of a package containing similar information as to that required in the new drug submission in Canada to indicate safety and efficacy of the novel drug and
describe the manufacturing processes and controls. FDA approval of the submission is required prior to commercial sale or shipment of the product in the United States. Pre- and/or post-approval inspections of manufacturing and testing facilities are
necessary. The FDA may also conduct inspections of the clinical trial sites and the non-clinical laboratories conducting pivotal safety studies to ensure compliance with good clinical practice and good laboratory practice requirements. The FDA has
the authority to impose certain post-approval requirements, such as post-market surveillance clinical trials. In addition, FDA approval can be withdrawn for failure to comply with any post-marketing requirements or for other reasons, such as the
discovery of significant adverse effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the evaluation of new products is coordinated by the EMA. The regulations are similar to those in Canada and the United States and require that
non-clinical and clinical studies be conducted to demonstrate the safety and effectiveness of products before marketing, and that the manufacturing be conducted according to good manufacturing practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the initial proof-of-concept and preliminary safety studies, and prior to conducting human clinical trials, a CTA must be submitted to the
competent authority in the country where the clinical trial will be conducted. This application contains similar information to the Canadian CTA and United States IND. In Europe, the clinical trials are regulated by the European Clinical Trial
Directive (2001/20/EC). As in Canada and the United States, before a clinical trial can commence at each participating clinical trial site, the site&#146;s IRB/REB must approve the clinical protocol and other related documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A major difference in Europe, when compared to Canada and the United States, is with the approval process. In Europe, there are different procedures that can
be used to gain marketing authorization in the EU. The first procedure is referred to as the centralized procedure and requires that a single application be submitted to the EMA and, if approved, allows marketing in all countries of the EU. The
centralized procedure is mandatory for certain types of medicines and optional for others. The second procedure is referred to as national authorization and has two options; the first is referred to as the mutual recognition procedure and requires
that approval is gained from one member state, after which a request is made to the other member states to mutually recognize the approval, whilst the second is referred to as the decentralised procedure which requires a member state to act as the
reference member state through a simultaneous application made to other member states. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DRUG DEVELOPMENT PROCESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of an investigational pharmaceutical product to individuals under the supervision of qualified medical
investigators. Clinical studies are conducted in accordance with protocols that detail the objectives of a study, the parameters to be used to monitor safety, and the efficacy criteria to be evaluated. Each protocol is submitted to the appropriate
regulatory body and to a relevant IRB/REB prior to the commencement of each clinical trial. Clinical studies are typically conducted in three sequential phases which may overlap in time-frame. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, the following steps must be completed prior to obtaining approval for marketing in Canada, the United States and Europe: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B>Nonclinical Animal Studies</B> - These studies evaluate the safety and potential efficacy of a therapeutic product and form part of the application which must be reviewed by the appropriate regulatory authority prior
to initiation of human clinical trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 1 Clinical Trials</B> - These trials test the product in a small number of healthy volunteers to determine toxicity (safety), maximum dose tolerance, and pharmacokinetic properties. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 2 Clinical Trials</B> - These trials are conducted in the intended patient population and include a larger number of subjects than in Phase 1. The primary goal is to determine the safety of a product in a
larger number of patients and ultimately in the intended patient population. These trials may also provide early information on the potential effectiveness of a product. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 3 Clinical Trials</B> - These trials are conducted in an expanded patient population at multiple sites to determine longer-term clinical safety and efficacy of the product. It is from the data generated in
these trials that the benefit/risk relationship of a product is established and the final drug labelling claims are defined. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course
of conducting clinical trials for a drug candidate, a company may conduct more than one trial of a particular phase in order to evaluate the drug against a variety of indications or in different patient populations. In such a case, industry practice
is to differentiate these trials by way of designations such as &#147;Phase 2a&#148; or &#147;Phase 2b&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key factor influencing the rate of
progression of clinical trials is the rate at which patients can be recruited to participate in the research program. Patient recruitment is largely dependent upon the incidence and severity of the disease and the alternative treatments
available.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after marketing approval for a drug has been obtained, further trials may be required (referred to as Phase 4 trials). Post-market trials
may provide additional data on safety and efficacy necessary to gain approval for the use of the product as a treatment for clinical indications other than those for which the product was initially tested. These trials may also be used for marketing
purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MANUFACTURING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voclosporin
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug supply costs are comprised of third party charges for manufacturing, encapsulating and packaging of voclosporin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2004, the Company signed a manufacturing agreement with Lonza Ltd. (&#147;<B>Lonza</B>&#148;) to manufacture voclosporin for clinical trial
and regulatory purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2007 Lonza completed the manufacture of the API validation batches of voclosporin required for regulatory approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently Lonza manufactured the API for the Company&#146;s LN Phase 2b clinical trial currently underway. It will also manufacture the API required
for commercial supply purposes. Lonza manufactures the API in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paladin was responsible for the API drug supply function with the Company
until December&nbsp;31, 2014 when the Supply Agreement ended. Effective January&nbsp;1, 2015 Aurinia has full control over the supply chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia has
contracted Catalent to encapsule, package and distribute voclosporin for its LN Phase 2b clinical trial program </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTELLECTUAL PROPERTY RIGHTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and other proprietary rights are essential to the Company&#146;s business. The Company&#146;s policy has been to file patent applications to protect
technology, inventions, and improvements to its inventions that are considered important to the development of its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company owns the patents
and patent applications related to voclosporin in the United States, Europe and in other jurisdictions around the world except for Canada, South Africa and Israel which belong to Paladin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at March&nbsp;26, 2015 there are 196 granted patents for voclosporin worldwide. These patents cover synthesis, composition of matter, method of use and
formulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has six ophthalmic patents acquired upon the return of the ophthalmic indications of voclosporin as result of the Company
signing a Termination and Assignment Agreement with Lux on February&nbsp;27, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPETITIVE ENVIRONMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. Many companies, including major
pharmaceutical as well as specialized biotechnology companies, are engaged in activities focused on medical conditions that are the same as, or similar to, those targeted by the Company. Many of these companies have substantially greater financial
and other resources, larger research and development staff, and more extensive marketing and manufacturing organization than the Company does. Many of these companies have significant experience in preclinical testing, human clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials, product manufacturing, marketing and distribution, and other regulatory approval procedures. In addition, colleges, universities, government agencies, and other public and private
research organizations conduct research and may market commercial products on their own or through collaborative agreements. These institutions are becoming more active in seeking patent protection and licensing arrangements to collect royalties for
use of technology that they have developed. These institutions also compete with the Company in recruiting and retaining highly qualified scientific personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYEES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2014 the Company employed 11 employees, eight of whom held advanced degrees in science and business,
including one with a Ph.D. degree and one with an MD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the Company&#146;s total 10.7 full-time equivalent employees as at December&nbsp;31, 2014, 4.7
full-time equivalent employees were engaged in, or directly support, clinical trial activities; and six full-time equivalent employees were engaged in corporate, administration and business development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s employees are not governed by a collective agreement. The Company has not experienced a work stoppage and believes its employee relations
are satisfactory given the current economic conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FACILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement, effective June&nbsp;1, 2014, to sublease 4,418 square feet of office and storage space at its head office location in
Victoria, British Columbia. The sublease is for a term of five years, with the Company having the right to terminate after the third year at no cost. Therefore the estimated base rent plus operating costs cost on a monthly basis for the three year
period is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;1, 2014 to May&nbsp;31, 2015 - $9,000 per month; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;1, 2015 to May&nbsp;31, 2016 - $9,000 per month; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;1, 2016 to May&nbsp;31, 2017 - $10,000 per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;1, 2013 the Company reduced its leased lab premises cost in Edmonton, Alberta by entering into a three year sublease with the head lessee for approximately 9,000 square feet while vacating the remaining 16,318 square feet it had
previously been leasing. The sublease cost is approximately $19,000 per month and includes base rent, utilities and operating costs. The Company has paid the head lessee a deposit of $145,000 for the last 7.4 months of rent. The Company in turn,
effective October&nbsp;15, 2014, has subleased out this 9,000 square feet space for approximately $7,000 per month for the remaining term of the sublease until September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement on November&nbsp;14, 2014 to lease 1,247 square feet of office space for the Edmonton, Alberta registered office where
the Company&#146;s finance group is located. The lease is for a term of two years commencing on January&nbsp;1, 2015 at a cost of approximately $1,500 per month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also entered into a one year agreement to rent an office in a shared office facility in Bellevue, Washington commencing November&nbsp;1, 2014 at a
cost of approximately $2,000 per month. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_7"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in the Company&#146;s securities involves a high degree of risk. You should carefully consider the following risks in addition to the other
information included in this AIF, the Company&#146;s historical consolidated financial statements and related notes, before you decide to purchase the Company&#146;s common shares. The risks and uncertainties described below are those that the
Company currently believes may materially affect the Company and are set out in no particular order. Additional risks and uncertainties that the Company is unaware of or that it currently deems immaterial may also become important factors that
materially and adversely affect its business, financial condition and results of operations. If any of the following events were to actually occur, the Company&#146;s business, operating results or financial condition could be adversely affected in
a material manner. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO THE COMPANY&#146;S BUSINESS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trial Progress and Results - Dependence on Voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has invested a significant portion of its time and financial resources in the development of voclosporin. The Company anticipates that its ability
to generate revenues and meet expectations will depend on the successful development and commercialization of voclosporin. The successful development and commercialization of voclosporin will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and other regulatory authorities with a commercially viable label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing and maintaining partners with sufficient expertise and resources to help in the continuing development and eventual commercialization of voclosporin for autoimmune indications and/or transplant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining suitable manufacturing and supply agreements to ensure commercial quantities of the product through validated processes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance and adoption of the product by the medical community and third-party payors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that
the Company may decide to discontinue the development of voclosporin at any time for commercial, scientific, or regulatory reasons. If voclosporin is developed, but not marketed, the Company will have invested significant resources and its future
operating results and financial conditions would be significantly adversely affected. If the Company is not successful in commercializing voclosporin, or significantly delayed in doing so, its business will be materially harmed and the Company may
need to curtail or cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Goals and Time Frames </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sets goals for, and makes public statements regarding, timing of the accomplishment of objectives material to its success, such as the commencement
and completion of clinical trials, anticipated regulatory approval dates, and time of product launch. The actual timing of these events can vary dramatically due to factors such as delays or failures in clinical trials, the uncertainties inherent in
the regulatory approval process, and delays in achieving product development, manufacturing, or marketing milestones necessary to commercialize its products. There can be no assurance that the Company&#146;s clinical trials will be completed, that
regulatory submissions will be made or receive regulatory approvals as planned, or that the Company will be able to adhere to the current schedule for the validation of manufacturing and launch of any of its products. If the Company fails to achieve
one or more of these milestones as planned, the price of the Company&#146;s common shares could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Pre-Clinical Studies and
Initial Clinical Trials Are Not Necessarily Predictive of Future Results </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of pre-clinical studies and initial clinical trials are not
necessarily predictive of future results, and the Company&#146;s current product candidates may not have favourable results in later trials or in the commercial setting. Pre-clinical tests and Phase 1 and Phase 2 clinical trials are primarily
designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in pre-clinical or animal studies and early clinical trials does not ensure that
later large scale efficacy trials will be successful nor does it predict final results. Favourable results in early trials may not be repeated in later trials. A number of companies in the life sciences industry have suffered significant setbacks in
advanced clinical trials, even after positive results in earlier trials. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Negative or inconclusive results or adverse
medical events during a clinical trial could cause a clinical trial to be delayed, repeated or terminated. In addition, failure to construct appropriate clinical trial protocols could result in the test or control group experiencing a
disproportionate number of adverse events and could cause a clinical trial to be repeated or terminated. Pre-clinical data and the clinical results the Company has obtained may not predict results from studies in larger numbers of subjects drawn
from more diverse populations or in a commercial setting, and also may not predict the ability of its products to achieve their intended goals, or to do so safely. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Assurance of Successful Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has not completed the development of any therapeutic products and in particular, voclosporin, and therefore there can be no assurance that any product will be successfully developed. None of the Company&#146;s therapeutic products have
received regulatory approval for commercial use and sale in any jurisdiction. The Company cannot market a pharmaceutical product in any jurisdiction until it has completed thorough preclinical testing and clinical trials in addition to that
jurisdiction&#146;s extensive regulatory approval process. In general, significant research and development and clinical studies are required to demonstrate the safety and effectiveness of its products before submission of any regulatory
applications. The Company may never obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the required regulatory approvals for any of its products. Product candidates require significant additional research and development efforts, including clinical trials, prior to regulatory
approval and potential commercialization, however, there can be no assurance that the results of all required clinical trials will demonstrate that these product candidates are safe and effective or, even if the results of all required clinical
trials do demonstrate that these product candidates are safe and effective, or even if the results of the clinical trials are considered successful by the Company, that the regulatory authorities will not require the Company to conduct additional
clinical trials before they will consider approving such product candidates for commercial use. Approval or consent by regulatory authorities to commence a clinical trial does not indicate that the device, drug, or treatment being studied can or
will be approved. Preparing, submitting, and advancing applications for regulatory approval is complex, expensive, and time intensive and entails significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the Company&#146;s completed preclinical studies and clinical trials may not be indicative of future clinical trial results. A commitment of
substantial resources to conduct time-consuming research, preclinical studies, and clinical trials will be required if the Company is to complete the development of its products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that unacceptable toxicities or adverse side effects will not occur at any time in the course of preclinical studies or human
clinical trials or, if any products are successfully developed and approved for marketing, during commercial use of its products. The appearance of any such unacceptable toxicities or adverse side effects could interrupt, limit, delay, or abort the
development of any of the Company&#146;s products or, if previously approved, necessitate their withdrawal from the market. Furthermore, there can be no assurance that disease resistance or other unforeseen factors will not limit the effectiveness
of its products. Any products resulting from the Company&#146;s programs are not expected to be successfully developed or made commercially available in the near term and may not be successfully developed or made commercially available at all.
Should one of the Company&#146;s products prove to have insufficient benefit and/or have an unsafe profile, its development will likely be discontinued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future performance of the Company will be impacted by a number of important factors, including, in the short-term, its ability to continue to generate
cash flow from equity financings, and in the longer term, its ability to generate royalty or other revenues from licensed technology and bring new products to the market. The Company&#146;s future success will require efficacy and safety of its
products and regulatory approval for these products. Future success of commercialization of any product is also dependant on the ability of the Company to obtain patents, enforce such patents and avoid patent infringement. There can be no assurance
that the Company will successfully develop such products, or these products will be developed in a timely manner or that the Company will achieve significant revenues from such products if they are successfully developed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Funding may not be Available on Favorable Terms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Company believes it has sufficient funding to conduct the planned LN Phase 2b clinical trial as a result of completing the $52 million private
placement on February&nbsp;14, 2014, the Company&#146;s longer term funding needs may vary depending upon a number of factors including progress on the Company&#146;s voclosporin development program (s), the costs associated with completing future
clinical trials and the regulatory process, the Company potential decision to in-license or acquire additional products for development and defending or enforcing the Company&#146;s patent claims and other intellectual property rights. There can be
no assurance that such funds will be available on favorable terms or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents and Proprietary Technology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and other proprietary rights are essential to the Company&#146;s business. The Company&#146;s policy has been to file patent applications to protect
technology, inventions, and improvements to its inventions that are considered important to the development of its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s success
will depend in part on its ability to obtain patents, defend patents, maintain trade secret protection and operate without infringing on the proprietary rights of others. Interpretation and evaluation of pharmaceutical patent claims present complex
and often novel legal and factual questions. Accordingly, there is some question as to the extent to which biopharmaceutical discoveries and related products and processes can be effectively protected by patents. As a result, there can be no
assurance that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patent applications will result in the issuance of patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional proprietary products developed will be patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will provide adequate protection or any competitive advantages; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will not be successfully challenged by third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents issued do not infringe the patents or intellectual property of others. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of pharmaceutical, biotechnology, medical device companies and research and academic institutions have
developed technologies, filed patent applications or received patents on various technologies that may be related to the business of the Company. Some of these technologies, applications or patents may conflict with or adversely affect the
technologies or intellectual property rights of the Company. Any conflicts with the intellectual property of others could limit the scope of the patents, if any, that the Company may be able to obtain or result in the denial of patent applications
altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, there may be uncertainty as to whether the Company may be able to successfully defend any challenge to its patent portfolio.
Moreover, the Company may have to participate in interference proceedings in the various jurisdictions around the world. An unfavorable outcome in an interference or opposition proceeding could preclude the Company or its collaborators or licensees
from making, using or selling products using the technology, or require the Company to obtain license rights from third parties. It is not known whether any prevailing party would offer a license on commercially acceptable terms, if at all. Further,
any such license could require the expenditure of substantial time and resources and could harm the business of the Company. If such licenses are not available, the Company could encounter delays or prohibition of the development or introduction of
the products of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may need to obtain additional licenses for the development of its products. If available, these licenses may
obligate the Company to exercise diligence in the development of technology and may obligate the Company to make minimum guarantees, milestone payments or purchases from specific suppliers. These diligence and milestone payments may be costly and
affect the business of the Company. The Company may be obligated to make royalty payments on the sales, if any, of products resulting from licensed technology and may be responsible for the costs of filing and prosecuting patent applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dependence on Key Personnel </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is highly
dependent upon certain members of its senior management team, the loss of whose services might impede the achievement of the Company&#146;s business objectives and have an adverse effect on the Company&#146;s operating results and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Supply and Manufacture of Raw Materials </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s lead drug, voclosporin, requires a specialized manufacturing process. Lonza is currently the sole source manufacturer of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
FDA and other regulatory authorities require that drugs be manufactured in accordance with the current good manufacturing practices regulations, as established from time to time. Accordingly, in the event the Company receives marketing approvals for
voclosporin, it may need to rely on a limited number of third parties to manufacture and formulate voclosporin. The Company may not be able to arrange for its products to be manufactured on reasonable terms or in sufficient quantities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up initial production. These problems include
difficulties with production costs and yields, stability, quality control and assurance, and shortages of qualified personnel, as well as compliance with strictly enforced federal, provincial and foreign regulations. The Company relies on a limited
number of third parties to manufacture and supply raw materials for its products. The third parties the Company chooses to manufacture and supply raw materials for its products are not under its control, and may not perform as agreed or may
terminate their agreements with the Company, and the Company may not be able to find other third parties to manufacture and supply raw materials on commercially reasonable terms, or at all. If either of these events were to occur, the Company&#146;s
operating results and financial condition would be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anticipated Revenues may be Derived from Licensing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company anticipates that its revenues in the foreseeable future may be derived primarily from products licensed to pharmaceutical and biotechnology
companies. Accordingly, these revenues will depend, in large part, upon the success of these companies, and the Company&#146;s operating results may fluctuate substantially due to reductions and delays in their research, development and marketing
expenditures. These reductions and delays may result from factors that are not within the Company&#146;s control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the regulatory environment, including governmental pricing controls affecting health care and health care providers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing pressures; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors affecting research and development spending. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of Operating Profits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and anticipates that its losses will increase as it continues its development and clinical trials and seeks regulatory approval
for the sale of its therapeutic products. There can be no assurance that it will have earnings or positive cash flow in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at
December&nbsp;31, 2014, the Company had an accumulated deficit of $236.39 million. The net operating losses over the near-term and the next several years are expected to continue as a result of initiating new clinical trials and activities necessary
to support regulatory approval and commercialization of its products. There can be no assurance that the Company will be able to generate sufficient product revenue to become profitable at all or on a sustained basis. The Company expects to have
quarter-to-quarter fluctuations in expenses, some of which could be significant, due to research, development, and clinical trial activities, as well as regulatory and commercialization activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability and Insurance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing, marketing
and sale of human pharmaceutical products involves unavoidable risks. If the Company succeeds in developing new pharmaceutical products, the sale of such products may expose the Company to potential liability resulting from the use of such products.
Such liability might result from claims made directly by consumers or by regulatory agencies, pharmaceutical companies or others. The obligation to pay any product liability claim in excess of whatever insurance the Company is able to acquire, or
the recall of any of its products, could have a material adverse effect on the business, financial condition and future prospects of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these indemnification agreements is unlimited. However, the Company currently maintains director and
officer liability insurance coverage of CDN$15million to reduce the exposure of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competition and Technological Change </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The industry in which the Company operates is highly competitive and the Company has numerous domestic and foreign competitors, including major pharmaceutical
and chemical companies, specialized biotechnology companies, universities, academic institutions, government agencies, public and private research organizations and large, fully-integrated pharmaceutical companies which have extensive resources and
experience in research and development, process development, clinical evaluation, manufacturing, regulatory affairs, distribution and marketing. Many of the Company&#146;s potential competitors possess substantially greater research and development
skills, financial, technical and marketing expertise and human resources than the Company, and may be better equipped to develop, manufacture and market products. There is a risk that new products and technologies may be developed which may be more
effective or commercially viable than any products being developed or marketed by the Company, thus making the Company&#146;s products non-competitive or obsolete. There may also be market resistance to the acceptance of any of the Company&#146;s
new products and a risk that a product, even though clinically effective, is not economically viable in the commercial production stage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance
on Partners and other Third Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Partners </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s strategy and success for the research, development, and commercialization of voclosporin in China (partner - 3SBio), Canada, South Africa
and Israel (partner &#150; Paladin) is dependent upon these partners performing their respective contractual responsibilities. The amount and timing of resources such third parties will devote to these activities may not be within the Company&#146;s
control. There can be no assurance that its partners will perform their obligations as expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The license and research and development agreements with
the third parties noted above include indemnification and obligation provisions that are customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of
third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature of the potential obligations prevents the Company from making a reasonable estimate of the maximum
potential amount it could be required to pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to seek additional collaborative arrangements to develop and commercialize voclosporin
for the transplant indication. There can be no assurance that the Company will be able to negotiate collaborative arrangements on favorable terms, or at all, in the future, or that current or future collaborative arrangements will be successful.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Third Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some products, the Company depends on third parties for the sourcing of components or for the product itself. Furthermore, as with other pharmaceutical
companies, the Company relies on medical institutions for testing and clinically validating its prospective products. The Company does not anticipate any difficulties in obtaining required components or products or any difficulties in the validation
and clinical testing of its products but there is no guarantee that they will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently relies on CROs for the conduct of its
clinical trials. All of the Company&#146;s CROs operate in accordance with good clinical management practices mandated by the regulatory authorities and are subject to regular audits by regulatory authorities and by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has arrangements for the encapsulation, packaging and labeling of voclosporin through a third party supplier. Contract manufacturers must
operate in compliance with regulatory requirements. Failure to do so could result in, among other things, the disruption of product supplies. The Company&#146;s dependence upon third parties for the manufacturing of its therapeutic products may
adversely affect the Company&#146;s profit margins and its ability to develop and deliver such products on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing and Distribution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
limited experience in the sales, marketing, and distribution of pharmaceutical products. There can be no assurance that the Company will be able to establish sales, marketing, and distribution capabilities or make arrangements through
collaborations, licensees, or others to perform such activities, or that such efforts would be successful. If the Company decides to market any of its products directly, the Company must either acquire or internally develop a marketing and sales
force with technical expertise and provide supporting distribution capabilities. The acquisition or development of a sales and distribution infrastructure would require substantial resources, which may divert the attention of management and key
personnel, and have a negative impact on product development. If the Company contracts with third parties for the sales and marketing of its products, the Company&#146;s revenue will be dependent on the efforts of these third parties, whose efforts
may not be successful. If the Company fails to establish successful marketing and sales capabilities or to make arrangements with third parties, the business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Acceptance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the Company&#146;s
products are approved for sale, they may not be successful in the marketplace. Market acceptance of any of the Company&#146;s products will depend upon a number of factors, including demonstration of clinical effectiveness and safety; the potential
advantages of its products over alternative treatments; the availability of acceptable pricing and adequate third party reimbursement; and the effectiveness of marketing and distribution methods for the products. If the Company&#146;s products do
not gain market acceptance among physicians, patients, and others in the medical community, the Company&#146;s ability to generate significant revenues from its products would be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Health Care Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both domestic and
foreign markets, sales of the Company&#146;s products, if any, will be dependent in part on the availability of reimbursement from third party payors, such as government and private insurance plans. Third party payors are increasingly challenging
the prices charged for medical products and services. There can be no assurance that the Company&#146;s products will be considered cost effective by these third party payors, that reimbursement will be available or if available that the
payor&#146;s reimbursement policies will not adversely affect the Company&#146;s ability to sell its products on a profitable basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government
Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The production and marketing of the Company&#146;s products and its ongoing research and development activities are subject to
regulation by numerous federal, provincial, state and local governmental authorities in Canada, the United States and any other countries where the Company may test or market its products. These laws require the approval of manufacturing facilities,
including adhering to &#147;good manufacturing&#148; and/or &#147;good laboratory&#148; practices during production and storage, the controlled research and testing of products, governmental review and approval of submissions requiring
manufacturing, pre-clinical and clinical data to establish the safety and efficacy of the product for each use sought in order to obtain marketing approval, and the control of marketing activities, including advertising and labeling. The process of
obtaining required approvals (such as, but not limited to, the approval of the FDA in the United States, the EMA and Health Canada) can be costly and time consuming and there can be no assurance that future products will be successfully developed,
proven safe and effective in clinical trials or receive applicable regulatory approvals. Potential investors should be aware of the risks, problems, delays, expenses and difficulties which may be encountered by the Company in view of the extensive
regulatory environment which controls its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there can be no assurance that the Company will be able to achieve or maintain regulatory compliance
with respect to all or any part of its current or future products or that the Company will be able to timely and profitably produce its products while complying with applicable regulatory requirements. If the Company fails to maintain compliance,
regulatory authorities may not allow the continuation of the drug development programs, or require the Company to make substantial changes to the drug. Any such actions could have a material adverse effect on the business, financial condition, and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unauthorized Disclosure of Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be an unauthorized disclosure of the significant amount of confidential information under the Company&#146;s control. The Company maintains and
manages confidential information relating to its technology, research and development, production, marketing and business operations and those of its collaborators, in various forms. Although the Company has implemented controls to protect the
confidentiality of such information, there can be no assurance that such controls will be effective. Unauthorized disclosures of such information could subject the Company to complaints or lawsuits for damages or could otherwise have a negative
impact on its business, financial condition, results of operations, reputation and credibility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Hazardous Materials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The drug manufacturing processes involve the controlled use of hazardous materials. The Company and its third party manufacturing contractors are subject to
regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although the Company believes that its third party manufacturers have the required safety procedures for handling and disposing
of such materials and comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held
liable for any damages that result and such liability could exceed the Company&#146;s resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO THE COMPANY&#146;S SECURITIES
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Volatility of Share Price </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading
price of the Company&#146;s common shares has been highly volatile and could continue to be subject to wide fluctuations in price in response to various factors, many of which are beyond the Company&#146;s control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated period-to-period fluctuations in financial results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to achieve, or changes in, financial estimates by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements regarding new or existing products or services or technological innovations by competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">comments or opinions by securities analysts or major shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions or trends in the pharmaceutical, biotechnology and life science industries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by the Company of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by the Company of results of, and developments in, its research and development efforts, including results and adequacy of, and development in, clinical trials and applications for regulatory approval;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic and other external factors or disasters or crises; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limited daily trading volume; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if any of the Company&#146;s products do not become commercially viable for any reason, including the failure of preclinical studies and clinical trials, the Company may not achieve profitability and the Company&#146;s
share price would likely decline; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments regarding the Company&#146;s licensed intellectual property or that of the Company&#146;s competitors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the market for biotechnology companies in particular, have experienced significant price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been significant volatility in the market prices of securities of biotechnology companies. Factors such as the results and
adequacy of the Company&#146;s preclinical studies and clinical trials, as well as those of its collaborators, or its competitors; other evidence of the safety or effectiveness of the Company&#146;s products or those of its competitors;
announcements of technological innovations or new products by the Company or its competitors; governmental regulatory actions; developments with collaborators; developments (including litigation) concerning patent or other proprietary rights of the
Company or competitors; concern as to the safety of the Company&#146;s products; period-to-period fluctuations in operation results; changes in estimates of the Company&#146;s performance by securities analysts; market conditions for biotechnology
stocks in general; and other factors not within the control </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company could have a significant adverse impact on the market price of the Company&#146;s securities, regardless of its operating performance. In the past, following periods of volatility
in the market price of a company&#146;s securities, securities class action litigation has often been instituted. A class action suit against the Company could result in substantial costs, potential liabilities and the diversion of management&#146;s
attention and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that an active trading market for the Company&#146;s common shares will be maintained on the TSX and /or
NASDAQ. Investors may not be able to sell their shares quickly or at the latest market price if the trading in the Company&#146;s common shares is not active. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to issue common shares in the future. Holders of stock options may elect to exercise their options into common shares depending on the
stock price. Future issuances of common shares, or the perception that such issuances are likely to occur, could affect the prevailing trading prices of the common shares. Future issuances of the Company&#146;s common shares could result in
substantial dilution to its shareholders. In addition, the existence of Warrants may encourage short selling by market participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of common
shares could cause a decline in the market price of the Company&#146;s common shares. Two of the Company&#146;s major shareholders (venBio and ILJIN) own an aggregate of approximately 31% of the Company&#146;s outstanding common shares as at
March&nbsp;26, 2015. Any sales of common shares by these shareholders or other existing shareholders or holders of options may have an adverse effect on the Company&#146;s ability to raise capital and may adversely affect the market price of its
common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aurinia may be a &#147;Passive Foreign Investment Company&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Aurinia may be a &#147;passive foreign investment company&#148; under the U.S. Internal Revenue Code, which may result in material adverse U.S. federal
income tax consequences to investors in common shares that are U.S. taxpayers: </I>Investors in common shares that are U.S taxpayers should be aware that Aurinia believes that it was not for the financial year ended December&nbsp;31, 2014 , a
&#147;passive foreign investment company&#148; under Section&nbsp;1297(a) of the U.S. Internal Revenue Code (a &#147;PFIC&#148;). However, there is no certainty that taxation authorities in the United States would agree with the Company&#146;s
determination, and there is no certainty that the Company will not be a PFIC at some point in the future. If Aurinia is determined to be or becomes a PFIC, generally any gain recognized on the sale of the common shares and any &#147;excess
distributions&#148; (as specially defined) paid on the common shares must be ratably allocated to each day in a U.S. taxpayer&#146;s holding period for the common shares. The amount of any such gain or excess distribution allocated to prior years of
such U.S taxpayer&#146;s holding period for the common shares generally will be subject to U.S federal income tax at the highest tax applicable to ordinary income in each such prior year, and the U.S. taxpayer will be required to pay interest on the
resulting tax liability for each such prior year, calculated as if such tax liability had been due in each such prior year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, a U.S taxpayer
that makes a &#147;qualified electing fund&#148; (a &#147;QEF&#148;) election with respect to Aurinia generally will be subject to U.S. federal income tax on such U.S. taxpayer&#146;s pro rata share of Aurinia&#146;s &#147;net capital gain&#148; and
&#147;ordinary earnings&#148; (as specifically defined and calculated under U.S. federal income tax rules), regardless of whether such amounts are actually distributed by Aurinia. U.S. taxpayers should be aware, however, that there can be no
assurance that Aurinia will satisfy record keeping requirements under the QEF rules or that Aurinia will supply U.S. taxpayers with required information under the QEF rules, in the event that Aurinia is a PFIC and a U.S. taxpayer wishes to make a
QEF election. As a second alternative, a U.S. taxpayer may make a &#147;mark-to-market election&#148; if Aurinia is a PFIC and the common shares are &#147;marketable stock&#148; (as specifically defined). A U.S. taxpayer that makes a mark-to-market
election generally will include in gross income, for each taxable year in which Aurinia is a PFIC, an amount equal to the excess, if any, of (a)&nbsp;the fair market value of the common shares as of the close of such taxable year over (b)&nbsp;such
U.S. taxpayer&#146;s adjusted tax basis in the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above paragraphs contain only a brief summary of certain U.S. federal income tax
considerations. Investors should consult their own tax advisor regarding the PFIC rules and other U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not paid dividends on its outstanding common shares in the past and has no established dividend policy for its common shares. The Company
plans to use future earnings, if any, to finance further research and development and the expansion of its business and does not anticipate paying out dividends on its common shares in the foreseeable future. The payment of dividends in the future
will depend upon the earnings and financial condition of the Company and such other factors as the Board considers appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_9"></A>CAPITAL STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s authorized share capital consists of an unlimited number of common shares, all without nominal or par value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of common shares are entitled to receive notice of and attend all meetings of shareholders, with each common share held entitling the holder to
vote on any resolution to be passed at such shareholder meetings. The holders of common shares are entitled to dividends if, as and when declared by the Board. The common shares are entitled upon liquidation, dissolution or winding up of Aurinia, to
receive the remaining assets of Aurinia available for distribution to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at March&nbsp;26, 2015, the Company had 31,985,341 common shares
issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition as of March&nbsp;26, 2015 there were 2,302,910 common shares issuable upon the exercise of outstanding stock options
and 892,969 common shares reserved for future grant or issuance under the Company&#146;s stock option plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has 6,311,605 Warrants
outstanding as at March&nbsp;26, 2015. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_10"></A>TRADING PRICE AND VOLUME OF AURINIA SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company commenced trading on the NASDAQ on September&nbsp;2, 2014 under the trading symbol &#147;AUPH&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia&#146;s common shares were traded on the TSXV from January&nbsp;1, 2014 to May&nbsp;30, 2014 under the symbol &#147;AUP&#148;. On June&nbsp;2, 2014,
the Company&#146;s common shares commenced trading on the TSX under the symbol &#147;AUP&#148; and continue to trade on the TSX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth, for the periods indicated, the reported high and low prices (in Canadian dollars) and volume on shares traded for each month. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>TSXV
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>TSX </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January , 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February , 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 1-25, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">March&nbsp;25, 2015 was the last trading day prior to the date of this AIF. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the reported high and low prices (in United States
dollars) and the volume of shares traded for each month on NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>NASDAQ </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price Range (US $)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.4992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 1-25, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,595,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">March&nbsp;
25, 2015 was the last trading day prior to the date of this AIF. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_11"></A>ESCROWED SECURITIES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no securities of the Company subject to escrow. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_12"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the distribution of securities other than common shares that were issued during the most recently completed financial year,
identifying the type of security, the price per security, the number of securities issued, expiry date and the date on which the securities were issued. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Type of Security</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price per<BR>Security</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiry Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;14, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Warrants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.22US</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,729,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;14,&nbsp;2019</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;18, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50&nbsp;CDN</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,192,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">February 18, 2019</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;18, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.91 CDN</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">November&nbsp;18,&nbsp;2019</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_13"></A>DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors of the Company are elected by the shareholders at each annual meeting and typically hold office until the next annual meeting, at which time
they may be re-elected or replaced. The officers are appointed by the Board and hold office pursuant to individual contractual obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at
March&nbsp;26, 2015, the names and municipalities of residence of the directors and officers of the Company and their principal occupations within the five preceding years are set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and Municipality of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:89.45pt; font-size:8pt; font-family:Times New Roman"><B>Residence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Position with the</B><br><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director/Officer<BR>since</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation for Five Preceding Years</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen W. Zaruby</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Woodinville, Washington U.S.A.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">President&nbsp;and&nbsp;CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">November&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">President and CEO of the Company since November 6, 2013; prior thereto was President of ZymoGenetics Inc.; Vice President, Global Head, Hospital Surgical Business Unit at Bayer Schering Pharma.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault<I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Edmonton, Alberta, Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CFO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">May 1998</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CFO of the Company since May, 1998.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and Municipality of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:89.45pt; font-size:8pt; font-family:Times New Roman"><B>Residence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Position with the</B><br><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director/Officer<BR>since</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation for Five Preceding Years</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael R. Martin</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Victoria, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">COO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September,&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">COO of the Company since September 2013; prior thereto was CEO of privately-held Aurinia Pharmaceuticals Inc.; Director, Global Business Development &amp; Licensing at Vifor Pharma, formerly Aspreva Pharmaceuticals.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil Solomons</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Victoria, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CMO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CMO of the Company since September 2013; prior thereto was Vice President, Research and Development at Vifor Pharma, formerly Aspreva Pharmaceuticals.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Huizinga</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>North Saanich,
British</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Columbia,</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice&nbsp;President,<BR>Clinical&nbsp;Affairs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President, Clinical Affairs of the Company since August 2011, prior thereto was Senior Director of Clinical Affairs of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawrence D. Mandt</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Qualicum Beach, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President,<BR>Regulatory and<BR>Quality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President Regulatory and Quality of the Company since September 2013; independent regulatory consultant from 2010-2013; Senior Vice President, Global Regulatory Affairs at Vifor Pharma; Vice President Regulatory Affairs at
Aspreva Pharmaceuticals.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Glickman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Victoria, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director;&nbsp;Chairman<BR>of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Chairman of the Board Aurinia Pharmaceuticals Inc.; Chairman of the Board Aspreva Pharmaceuticals Inc.; CEO Aspreva Pharmaceuticals Inc.; CEO StressGen Pharmaceuticals Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Thornhill, Ontario</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Managing Director, Lumira Capital</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel S. Park</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Seoul, South
Korea</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">July 2014 to present &#150; CEO/President of ILJIN Composites, January to July, 2014 - President of ILJIN Group; Executive Vice President of ILJIN Group 2010-2013; prior thereto was Senior Vice President of ILJIN Group.</TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Kim</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Seoul, South Korea</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CEO, Lumirich Co. and Fibrane Co. of Korea.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles A. Rowland, Jr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Furlong,
Pennsylvania USA</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">July 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Certified Public Accountant.2008 to 2014 Vice President and CFO of Viro-Pharma Incorporated, an international biopharmaceutical company.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors and officers of the Company, as of March&nbsp;26, 2015, beneficially own, directly or indirectly, 2,342,140 common
shares representing 7.33% of the outstanding common shares of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXECUTIVE OFFICERS AND DIRECTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are brief biographies of the Company&#146;s executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stephen W. Zaruby, President and CEO </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen
Zaruby has over 20 years&#146; experience in the highly complex biopharmaceutical industry. Expertise has been demonstrated in the executive general management of fully-integrated biotechnology and pharmaceutical corporations in both the U.S. and
Europe, with over-sight including business development, finance, product development, regulatory affairs, manufacturing, various general and administrative functions, and global commercial operations incorporating sales, marketing, and product
distribution. Mr.&nbsp;Zaruby was president of ZymoGenetics Inc., a publically-traded, Seattle-based biotechnology company, until the time of its acquisition by Bristol-Myers Squibb. Prior to this he worked within the pharmaceutical division of
Bayer Healthcare for many years, holding several different positions with leadership of one of their global strategic business units as his last operational posting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dennis Bourgeault, C.A., CFO </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault
has been the CFO of the Company since 1998 and is responsible for the financial operations of the Company. He was the controller for a private industrial distribution company for six years from 1992 to 1998 and prior to this time he was a senior
manager in public accounting at KPMG. Mr.&nbsp;Bourgeault obtained his Chartered Accountant designation in 1984 and earned a Bachelor of Commence Degree from the University of Alberta. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael R. Martin, COO </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Martin was
formerly CEO, director and co-founder of the privately held Aurinia Pharma Corp. which was acquired in 2013 by the Company.&nbsp;In his current role with Aurinia, Mr.&nbsp;Martin is responsible for managing company functions such as corporate and
business development, alliance management, investor relations, intellectual property and pre-commercial market planning.&nbsp;Mr.&nbsp;Martin is a biotech/pharmaceutical executive with over 19 years industry experience. Mr.&nbsp;Martin joined
Aurinia from Vifor Pharma where he held the position of Director, Global Business Development&nbsp;&amp; Licensing.&nbsp;Prior to Vifor, Mr.&nbsp;Martin was a key member of the business development team that saw Aspreva sold to Galenica for
$915M.&nbsp;Upon joining Aspreva in 2004, Mr.&nbsp;Martin initiated the strategic launch planning process for CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in &#147;less-common&#148; autoimmune diseases.&nbsp;These included such
indications as pemphigus vulgaris, myasthenia gravis, and lupus nephritis.&nbsp;Prior thereto, Mr.&nbsp;Martin held a variety of progressively senior commercial positions at Schering-Plough.&nbsp;Mr.&nbsp;Martin spent time in Europe where he was
responsible for the rheumatology business unit for Remicade<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in France.&nbsp;In addition while at Schering-Plough, Mr.&nbsp;Martin was the brand manager responsible for the Canadian launch of
Remicade (infliximab). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Neil Solomons, M.D., CMO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Neil Solomons is responsible for managing, developing, guiding and coordinating Aurinia&#146;s clinical development group and its activities. He is
also Aurinia&#146;s senior medical spokesperson to investigators, scientific advisors and investors. Dr.&nbsp;Solomons is an experienced pharmaceutical physician with more than 15 years of clinical development and medical affairs experience in both
big pharma and biotech. He is a recognized expert in rare-disease drug development and is widely published in this field. Prior to Aurinia Dr.&nbsp;Solomons worked at Vifor Pharma, formerly Aspreva Pharmaceuticals Inc., where he held the position of
Vice President, Research and Development being the lead clinician in the development of CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in rare diseases.&nbsp;Dr.&nbsp;Solomons led CellCept Clinical Development teams of over 50
people that saw the completion, reporting and publication of studies in pemphigus vulgaris, myasthenia gravis, both industry firsts, and the successful landmark LN study called the Aspreva Lupus Management Study (ALMS).&nbsp;He was responsible for
all clinical development activities from Phases 1 to 3, as well as participating in the formulation of R&amp;D strategy, portfolio management, and due diligence efforts. Prior to Vifor&nbsp;&amp; Aspreva, Dr.&nbsp;Solomons held a variety of
positions at Roche in both Global Clinical Development and Medical Affairs in transplantation, virology and auto-immune diseases.&nbsp;While at Roche, Dr.&nbsp;Solomons led a diverse team in the development and implementation of post-marketing
studies with a budget exceeding $15 million for its transplantation (CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Zenapax<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and virology (Cytovene<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) franchises. Dr.&nbsp;Solomons qualified in medicine in 1991 receiving his MB BS (MD) at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing
specialist training in anesthesia and intensive care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Robert B. Huizinga, RN NNC, MSc(Epi), CNeph(C), Vice President, Clinical Affairs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Huizinga has been with the Company since 2002, focused on managing the global clinical development of voclosporin.&nbsp;Before joining the Company,
Mr.&nbsp;Huizinga was a Nephrology and Transplantation nursing specialist with 14 years of clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and research experience where he was involved in more than 60 clinical trials from Phase I through Phase IV.&nbsp;He has acted as a consultant to nephrology and transplantation pharmaceutical
companies, and has lectured extensively.&nbsp;Mr.&nbsp;Huizinga holds a M.Sc. in medicine (epidemiology) from the University of Alberta, is a registered nurse, certified in nephrology, and a member of Sigma Theta Tau (Honor Society of Nursing). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lawrence D. Mandt, Vice President Regulatory and Quality </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Vice President Quality&nbsp;&amp; Regulatory Affairs, Mr.&nbsp;Mandt is responsible for regulatory strategy, as well as implementation of the Company&#146;s
regulatory projects.&nbsp;Mr.&nbsp;Mandt brings over 30 years&#146; experience in global regulatory affairs, in large and small companies, across a variety of therapeutic areas.&nbsp;Prior to Aurinia, Mr.&nbsp;Mandt worked as an independent
regulatory consultant after leaving Vifor Pharma as Senior Vice President, Global Regulatory Affairs in 2010.&nbsp;During his time with Vifor Pharma, he served as a member of the Leadership Team (LST) and successfully led the consolidation of the
regulatory affairs function after the acquisition of Aspreva Pharmaceuticals where he was Vice President, Regulatory Affairs.&nbsp;While with Aspreva, Mr.&nbsp;Mandt was a key contributor to the regulatory strategies, tactics and operational
activities associated with the CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> autoimmune programs, conducted in collaboration with Roche.&nbsp;Before joining Aspreva in 2004, Mr.&nbsp;Mandt was Senior Vice President, Regulatory
and Quality Affairs at QLT, Inc.&nbsp;During his time with QLT, QLT gained approval of Visudyne, the first drug ever approved for the treatment of age related macular degeneration.&nbsp;Approvals were obtained in the USA, the EU and 70+ other
countries.&nbsp;Prior to QLT, Mr.&nbsp;Mandt led the regulatory and medical affairs function for CIBA Vision Opthalmics (ultimately became Novartis Ophthalmics) for eight years, gaining approval of that company&#146;s first entirely internally
developed new drug, Zaditor, for the treatment of ocular allergies.&nbsp;In addition to the development activities underway, applications for 25 ANDA/NDA products were effectively managed to extend life cycle and meet the needs of the
business.&nbsp;Previous to his time at CIBA/Novartis, Mr.&nbsp;Mandt worked in research and development and regulatory positions of increasing responsibilities at Bausch&nbsp;&amp; Lomb Inc, first in the SOFLENS division and then in the
pharmaceuticals division of the company, eventually becoming Director, Regulatory Affairs.&nbsp;Highlights during his career at Bausch include launching major new OTC and Rx products and gaining approval for a new state of the art manufacturing
facility.&nbsp;Mr.&nbsp;Mandt began his career as a microbiologist at Merck, Sharp and Dohme, at their vaccine facility in West Point, PA, USA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Richard M. Glickman, L.L.D. (Hon), Director, Chairman of the Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Glickman presently serves as the Company&#146;s Chairman of the Board. He previously was a co-founder and has served as the Executive Chairman of the
Company for the period September&nbsp;20, 2013 to February&nbsp;28, 2014 and as CEO for the period October&nbsp;22, 2013 to November&nbsp;5, 2013. He was a co-founder, Chairman and CEO of Aspreva Pharmaceuticals (&#147;Aspreva&#148;).&nbsp;Prior to
establishing Aspreva, Dr.&nbsp;Glickman was the co-founder and CEO of StressGen Biotechnologies Corporation.&nbsp;Since 2000, Dr.&nbsp;Glickman has served as the Chairman of the Board of Vigil Health Solutions Inc., a healthcare services company, as
Lead Director for Cardiome Pharmaceuticals Inc., as founding Chairman of the Board of&nbsp;Essa Pharmaceuticals Inc., and Chairman of the Board of Engene Inc.&nbsp;Dr.&nbsp;Glickman was also the founder and a director of Ontario Molecular
Diagnostics, a diagnostic facility that evolved into the largest molecular diagnostic laboratories in Canada.&nbsp;He co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first
licensed DNA-based forensic and paternity testing services in Canada.&nbsp;He has served on numerous biotechnology and community boards including roles as Chairman of Life Sciences B.C. (formerly the British Columbia Biotechnology Alliance),
Director of the Canadian Genetic Disease Network, a member of the federal government&#146;s National Biotechnology Advisory Committee, a member of the British Columbia Innovation Council and as a Director for the Vancouver Aquarium.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benjamin Rovinski, Ph.D., Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Benjamin Rovinski has 27 years of investment, operational, managerial and research experience in the healthcare sector. He joined Lumira Capital in
2001, where he is a Managing Director, with an investment focus on mid-to late-stage private and public life sciences companies. Prior to joining Lumira Capital, Dr.&nbsp;Rovinski held several senior management positions in the biotechnology sector,
including 13 years at Sanofi Pasteur where he was a senior scientist and director of molecular virology. He led global R&amp;D programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical-stage.
Dr.&nbsp;Rovinski received a PhD in biochemistry from McGill University in Montr&eacute;al and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. He obtained his undergraduate degree from
Rice University in Houston. Dr.&nbsp;Rovinski&#146;s current and past board roles and investment responsibilities include several private and public companies, including KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Cervelo
Pharmaceuticals; Health Hero Network (acquired by Bosch); Avalon Pharmaceuticals (NASDAQ: AVRX; acquired by Clinical Data, Inc.); Inovise Medical, Inc.; Protana; Signature Biosciences; and SGX Pharmaceuticals (NASDAQ: SGXP; acquired by Eli Lilly).
He also serves on the board of directors of Life Sciences Ontario. Dr.&nbsp;Rovinski is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 29 issued patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Daniel Park, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Park is currently CEO and President of ILJIN Composites. He served as President of ILJIN Group from January, 2014 to July, 2014; Executive Vice
President of ILJIN Group 2010-2013; prior thereto was Senior Vice President of ILJIN Group. He started his management career with ETEX Corp, an advanced biomaterials company focusing on products that promote bone repair and enable controlled
delivery therapies in 1988. ETEX is one of the subsidiaries of ILJIN Group, and Mr.&nbsp;Park has since worked in numerous ILJIN Group companies including ILJIN Display Co., Ltd. and ILJIN Diamond Co., Ltd. in senior management positions. He is
presently in the Planning Office of ILJIN Group which contains multiple subsidiary companies ranging from the Jeonju Television Co., Ltd. to ILJIN Electricity Co., Ltd. Mr.&nbsp;Park holds Masters of Business Administration (University of California
at Los Angeles), along with a Masters and a Bachelor&#146;s degree in Economics from Seoul National University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chris Kim, Ph.D., Director
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kim is currently CEO, Lumirich Co. and Fibrane Co., both in Korea dating from 2008 to present. Prior to that, Dr.&nbsp;Kim was
Vice-president, Sales and Marketing at Samsung SDI Co, Korea, where he was in charge of Samsung SDI&#146;s worldwide display panel sales and marketing. During his tenure with Samsung SDI Co., Dr.&nbsp;Kim had increasing responsibilities from 1986 to
1999 while at companies including NSF Polymer Research Center, VPI, in Blacksburg, Virginia, USA; Exxon-Mobil Corp., in Rochester, NY, USA; Corning Inc., in Corning, NY, USA; Lam Research Corp., in Fremont, California, USA, and Fujitsu Inc., in San
Jose, California, USA. Dr.&nbsp;Kim has an undergraduate science degree in chemical engineering from Seoul National University (1985)&nbsp;and a PhD in chemical engineering (1989)&nbsp;from Virginia Tech., Blacksburg, Virginia, USA. He also has more
than ten technical publications, one book chapter, and numerous worldwide patents, and is fluent in three languages. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Charles A. Rowland, Jr., CPA,
MBA, Director, Chair of the Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Charles&nbsp;A. Rowland, Jr., CPA, MBA, was most recently the Vice President and CFO of
ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014.&nbsp;He has 34 years of diversified experience across a broad field of financial areas. Mr.&nbsp;Rowland has experience in all
areas of finance and accounting, including financial reporting, tax, treasury, and strategic financial planning, as well as investor relations and IT.&nbsp;Prior to joining ViroPharma in 2008, Mr.&nbsp;Rowland was the Executive Vice President and
CFO, as well as the interim Co-CEO, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management, where he served from 2006 to 2008.&nbsp;Mr.&nbsp;Rowland previously held positions of increasing
responsibility at Biovail Corporation, Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. Mr.&nbsp;Rowland joined the board of directors and chairs the audit committee of Bind Therapeutics, as of May 2014,
Vitae Pharmaceuticals, as of September 2014. In addition, he is also a member of the supervisory board and chairs the audit committee of Nabriva Therapeutics, a privately held company based in Vienna, Austria as of January 2015. On March&nbsp;20,
2015 he joined the board of Blueprint Medicines, a private company based in Boston, Massachusetts and chairs the audit and compensation committees. He is also a board member of the Philadelphia chapter of Financial Executives International.
Previously, he served on the board of Idenix Pharmaceuticals until its acquisition by Merck. Mr.&nbsp;Rowland holds an M.B.A. with a finance concentration from Rutgers University and a B.S. in Accounting from Saint Joseph&#146;s University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMMITTEES OF THE BOARD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has three standing
committees: the Audit Committee, the Governance Committee and the Compensation Committee. Current members of these committees are identified in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.70pt; font-size:8pt; font-family:Times New Roman"><B>Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:32.40pt; font-size:8pt; font-family:Times New Roman"><B>Members</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Audit Committee <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles A. Rowland, Jr. (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin
Rovinski</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard Glickman</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Governance Committee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Glickman (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel S. Park</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stephen Zaruby</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Compensation Committee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel S. Park</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard Glickman</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Detailed information on the Audit Committee is attached as Schedule 1. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_14"></A>CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise disclosed in this AIF, to the knowledge of the directors and officers of the Company, no director or executive officer of the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">is, or has been within 10 years before the date of this AIF, a director, chief executive officer or chief financial officer of any company that, while that person was acting in that capacity </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation, that was issued while the proposed director
was acting in the capacity as a director, chief executive officer or chief financial officer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation, that was issued after the proposed director
ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while he was acting in the capacity of a director, chief executive officer or chief financial officer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">is, or has been within 10 years before the date of this AIF, a director, chief executive officer or chief financial officer of any company that while that person was acting in that capacity, or within a year of that
person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or was subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver,
receiver manager or trustee appointed to hold its assets; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">has, within 10 years before the date of this AIF, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or
compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
director has been subject to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable security holder in deciding whether to vote for a proposed director. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_15"></A>LEGAL PROCEEDINGS AND REGULATORY ACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not aware of, as of March&nbsp;26, 2015, any legal proceedings against the Company that would involve a claim for damages that exceed ten per
cent of the current assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No penalties or sanctions have been imposed against the Company by a court relating to securities legislation
or any securities regulatory authority in 2014, nor has the Company entered into any settlement agreements with a court relating to securities legislation or with a securities regulatory authority during such financial year ended December&nbsp;31,
2014. No other penalties or sanctions have been imposed by a court or regulatory body against the Company which would likely be considered important to a reasonable investor in making an investment decision respecting the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_16"></A>INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section includes a description of the material interest, direct or indirect, of directors or executive officers of the Company, persons or companies that
beneficially own, control, or direct more than 10% of the voting securities of the Company, or an associate or affiliate of any of such directors, executive officers, persons or companies, in the transactions conducted by the Company within the
three most recently completed financial years or during the current financial year that has materially affected or is reasonably expected to materially affect the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The Company and ILJIN entered into the DDLA, effective January&nbsp;28, 2011, for the further clinical and commercial development of voclosporin for
use in transplant indications applicable to voclosporin. Mr.&nbsp;Chin-Kyu Huh was elected a director of Pharma on December&nbsp;15, 2010 at a special meeting of the shareholders. Mr.&nbsp;Huh was appointed Chairman of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Board on March&nbsp;18, 2011 and resigned from the Board on July&nbsp;28, 2011. The DDLA was terminated in connection with the Plan of Arrangement transaction which closed on
September&nbsp;20, 2013. For additional information on the DDLA, please see section <I>Three Year History </I>earlier in this document. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_17"></A>CONFLICTS OF INTEREST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>To the knowledge of Aurinia, and other than as disclosed herein, there is no known existing or potential material conflicts of interest among Aurinia,
its directors and officers, or a subsidiary of Aurinia or other members of management as a result of their outside business interests, except that certain of its directors may serve as directors of other companies and therefore it is possible that a
conflict may arise between their duties to Aurinia and their duties as a director of such other companies. <I>See &#147;Risk Factors-The Company is dependent upon its key personnel to achieve its business objectives&#148;. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_18"></A>TRANSFER AGENT AND REGISTRAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The co- transfer agents and co-registrars of Aurinia Pharmaceuticals Inc. are Computershare Investor Services Inc. located at its principal offices in
Calgary, Alberta and Toronto, Ontario and Computershare Trust Company, N.A. located at its principal offices in Golden, Colorado. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_19">
</A>MATERIAL CONTRACTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently has the following material contracts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Paladin currently has the rights to market, sell, and distribute voclosporin in Canada, Israel and South Africa and is required to make payments to the Company equal to: (i)&nbsp;20% of net sales, in the Canada, Israel
and South Africa, less manufacturing costs until June&nbsp;18, 2016; and (ii)&nbsp;20% of net royalties received from third party sales, in the Paladin Territories until June&nbsp;18, 2016. In addition, Paladin will receive 2% of any milestone
payments, development payments, royalties, and net profit splits paid to the Company, related to voclosporin outside Canada, Israel and South Africa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Under the terms of an agreement dated February&nbsp;14, 2014 whereby Dr.&nbsp;Robert Foster&#146;s employment as CSO was terminated by the Company, it was confirmed that effective March&nbsp;8, 2012 pursuant to a
resolution of the Board, Dr.&nbsp;Foster was entitled to receive 2% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.3% of net sales of voclosporin sold directly by the Company, to be paid
quarterly as that revenue is received by the Company. Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger in a manner such that this payment obligation is no
longer operative, then Dr.&nbsp;Foster will be entitled to receive 0.3% of the value attributable to voclosporin in the transaction. As Dr.&nbsp;Foster&#146;s employment was terminated without just and sufficient &#147;cause&#148; as set forth in
his CSO employment agreement, he is entitled to receive the royalty licensing revenues he would have been entitled to receive had his employment not been terminated. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Under the terms of the subscription agreement for the February&nbsp;14, 2014 private placement offering, the Company granted the subscribers, in the aggregate, the right to nominate two persons for election to the
Company&#146;s board of directors. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_20"></A>INTERESTS OF EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s independent auditors are PricewaterhouseCoopers LLP, who have issued an independent auditor&#146;s report dated March&nbsp;26, 2015 in
respect of the Company&#146;s Consolidated Financial Statements, which comprise the Consolidated Statements of Financial Position as at December&nbsp;31, 2014,&nbsp;December&nbsp;31, 2013 and January&nbsp;1, 2013 and the Consolidated Statements of
Operations and Comprehensive Loss, Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) and Cash Flows for the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013, and the related notes. PricewaterhouseCoopers LLP has
advised that they are independent with respect to the Company within the meaning of the Rules of Professional Conduct of the Institute of Chartered Accountants of Alberta and the rules of the United States Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_21"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information with respect to the Company, including directors&#146; and officers&#146; remuneration and indebtedness, principal holders of the
Company&#146;s common shares and securities authorized for issuance under equity compensation plans will be contained in the management information circular that will be prepared and filed in connection with the 2015 annual general meeting.
Additional financial information is also available in the Company&#146;s comparative audited consolidated financial statements, together with the auditor&#146;s report thereon, and the related Management Discussion and Analysis for its most recently
completed fiscal year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information regarding the Company is available on the SEDAR website located at
www.sedar.com, on EDGAR at <U>www.sec.gov</U>, or on the Company&#146;s corporate website located at <U>www.auriniapharma.com</U>, or upon request addressed to Michael Martin, COO, at #1203, 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_22"></A>SCHEDULE 1 - AUDIT COMMITTEE INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>The Audit Committee&#146;s Charter </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Audit Committee Charter is available in the
governance section of the Company&#146;s website at <U>www.auriniapharma.com</U> and is attached as Schedule 2 to this AIF. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Composition and Relevant Education and Experience </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is comprised of three independent
directors: Charles A. Rowland, Jr. (Chair), Richard M. Glickman and Benjamin Rovinski. A description of the education and experience of each Audit Committee member that is relevant to the performance of his responsibilities as an Audit Committee
member may be found above under the heading &#147;Directors and Executive Officers&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SEC rules implementing the Sarbanes-Oxley Act of
2002, Canadian issuers filing reports in the United States must disclose whether their audit committees have at least one audit committee financial expert. The Board has determined that Charles A. Rowland, Jr. qualifies as an audit committee
financial expert under such rules. In addition, all members of the Audit Committee are considered financially literate under applicable Canadian and U.S. laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Pre-approval Policies and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is authorized by the Board to review the
performance of the Company&#146;s external auditors and approve in advance the provision of services other than auditing and to consider the independence of the external auditors, including reviewing the range of services provided in the context of
all consulting services bought by the Company. Such advance approval authority may be delegated by the Audit Committee to the Chair of the Audit Committee who is &#147;independent&#148; and &#147;unrelated&#148;. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>External Auditor Service Fees (By Category) </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate fees recorded for professional services
rendered by PricewaterhouseCoopers LLP for the Company and its subsidiaries for the years ended December&nbsp;31, 2014 and 2013, respectively are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:59.50pt; font-size:8pt; font-family:Times New Roman"><B>Fiscal year ended</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B><br><B>(in&nbsp;CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Total<BR>Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B><br><B>(in&nbsp;CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Total<BR>Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees (for audit of the Company&#146;s annual financial statements and services provided in connection with statutory and
regulatory filings)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit related fees, including review of the Company&#146;s quarterly financial
statements<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees (tax compliance, tax advice and planning)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">43,987<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">26,775<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total fees</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>322,867</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>158,130</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>These fees include professional services provided by the external auditor for the statutory audits of the annual financial statements. The total for 2014 ($185,000) consists of $42,000 related to interim billings
for the 2014 audit and $143,000 related to the fees for the 2013 audit. The total of $79,380 for 2013 related to fees for the 2012 audit. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>These fees relate to performing review engagement services on the Company&#146;s quarterly financial statements and other audit related services. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>These fees include professional services for tax compliance, tax advice, tax planning and various taxation matters. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>These fees include professional services for assistance with the Filing of Form 40-F Registration Statement as required in conjunction with obtaining the NASDAQ listing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>These fees include professional services for reporting and filing requirements related to the Plan of Arrangement with Aurinia Pharma Corp. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_23"></A>SCHEDULE 2 - AUDIT COMMITTEE CHARTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AUDIT COMMITTEE CHARTER </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;<B>Company</B>&#148; refers to Aurinia Pharmaceuticals Inc., the term &#147;<B>Board</B>&#148; refers to the board of directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PURPOSE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee (the
&#147;<B>Committee</B>&#148;) is a standing committee appointed by the Board to assist the Board in fulfilling its oversight responsibilities with respect to the Company&#146;s financial reporting including responsibility to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversee the integrity of the Company&#146;s consolidated financial statements and financial reporting process, including the audit process and the Company&#146;s internal accounting controls and procedures and
compliance with related legal and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversee the qualifications and independence of the Company&#146;s external auditors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversee the work of the Company&#146;s financial management and external auditors in these areas; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide an open avenue of communication between the external auditors, and the Board and the officers (collectively, &#147;<B>Management</B>&#148;) of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Committee will review and/or approve any other matter specifically delegated to the Committee by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPOSITION AND PROCEDURES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the procedures
and powers set out in any resolution of the Board, the Committee will have the following composition and procedures: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Composition </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall consist of no fewer than three (3)&nbsp;members. None of the members of
the Committee shall be an officer or employee of the Company or any of its subsidiaries, and each member of the Committee shall be an &#147;independent director&#148; (in accordance with the definition of &#147;independent director&#148; established
from time to time under the requirements or guidelines for audit committee service under applicable securities laws and the rules of any stock exchange on which the Company&#146;s shares are listed for trading). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Appointment and Replacement of Committee Members </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any member of the Committee may be removed or replaced
at any time by the Board and shall automatically cease to be a member of the Committee upon ceasing to be a director. The Board may fill vacancies on the Committee by election from among its members. The Board shall fill any vacancy if the
membership of the Committee is less than three directors. If and whenever a vacancy shall exist on the Committee, the remaining members may exercise all its power so long as a quorum remains in office. Subject to the foregoing, the members of the
Committee shall be elected by the Board annually and each member of the Committee shall hold office as such until the next annual meeting of shareholders after his or her election or until his or her successor shall be duly elected and qualified.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial literacy </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All members of the Committee should be &#147;financially literate&#148; (as that
term is interpreted by the Board in its reasonable judgment or as may be defined from time to time under the requirements or guidelines for audit committee service under securities laws and the rules of any stock exchange on which the Company&#146;s
shares are listed for trading) or must become financially literate within a reasonable period of time after his or her appointment to the Committee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Separate Executive Meetings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will endeavour to meet at least once every quarter, if
required, and more often as warranted, with the Chief Financial Officer and the external auditors in separate executive sessions to discuss any matters that the Committee or each of these groups believes should be discussed privately. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Professional Assistance </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may retain special legal, accounting, financial or other
consultants to advise the Committee at the Company&#146;s expense. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Reliance </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Absent actual knowledge to the contrary (which will be promptly reported to the Board), each
member of the Committee shall be entitled to rely on (i)&nbsp;the integrity of those persons or organizations within and outside the Company from which it receives information, (ii)&nbsp;the accuracy of the financial and other information provided
to the Committee by such persons or organizations and (iii)&nbsp;representations made by the Chief Financial Officer, the Company, senior management and the external auditors, as to any information, technology, internal audit and other non-audit
services provided by the external auditors to the Company and its subsidiaries. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Review of Charter </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will periodically review and reassess the adequacy of this Charter as
it deems appropriate and recommend changes to the Board. The Committee will evaluate its performance with reference to this Charter. The Committee will approve the form of disclosure of this Charter, where required by applicable securities laws or
regulatory requirements, in the annual proxy circular or annual report of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Delegation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may delegate from time to time to any person or committee of persons any of
the Committee&#146;s responsibilities that lawfully may be delegated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Reporting to the Board </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will report through the Committee Chair to the Board following
meetings of the Committee on matters considered by the Committee, its activities and compliance with this Charter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SPECIFIC MANDATES OF THE COMMITTEE
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>In Respect of the Company&#146;s External Auditors </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">review the performance of the external auditors of the Company who are accountable to the Committee and the Board as the representatives of the shareholders of the Company, including the lead partner of the independent
auditor team and make recommendations to the Board as to the reappointment or appointment of the external auditors of the Company to be proposed in the Company&#146;s proxy circular for shareholder approval and shall have authority to terminate the
external auditors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">review the reasons for any proposed change in the external auditors of the Company which is not initiated by the Committee or Board and any other significant issues related to the change, including the response of the
incumbent auditors, and enquire as to the qualifications of the proposed replacement auditors before making its recommendation to the Board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">approve the terms of engagement and the compensation to be paid by the Company to the Company&#146;s external auditors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">review the independence of the Company&#146;s external auditors, including a written report from the external auditors respecting their independence and consideration of applicable auditor independence standards;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">approve in advance all permitted non-audit services to be provided to the Company or any of its affiliates by the external auditors or any of their affiliates, subject to any <I>de minimus</I> exception allowed by
applicable law; the Committee may delegate to one or more designated members of the Committee the authority to grant pre-approvals required by this subsection; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">review the disclosure with respect to its pre-approval of audit and non-audit services provided by the Company&#146;s external auditors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">approve any hiring by the Company or its subsidiaries of employees or former employees of the Company&#146;s external auditors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">review a written or oral report describing: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">critical accounting policies and practices to be used in the Company&#146;s annual audit, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">alternative treatments of financial information within generally accepted accounting principles that have been discussed with Management and that are significant to the Company&#146;s consolidated financial statements,
ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the external auditors, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">other material written communication between the Company&#146;s external auditors and Management, such as any management letter or schedule of unadjusted differences; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">review with the external auditors and Management the general audit approach and scope of proposed audits of the consolidated financial statements of the Company, the objectives, staffing, locations, co-ordination and
reliance upon Management in the audit, the overall audit plans, the audit procedures to be used and the timing and estimated budgets of the audits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top">if a review engagement report is requested of the external auditors, review such report before the release of the Company&#146;s interim consolidated financial statements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top">discuss with the external auditors any difficulties or disputes that arose with Management during the course of the audit, any restrictions on the scope of activities or access to requested information and the adequacy
of Management&#146;s responses in correcting audit-related deficiencies; </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>In Respect of the Company&#146;s Financial Disclosure </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">review with the external auditors and Management: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s audited consolidated financial statements and the notes and Managements&#146; Discussion and Analysis relating to such consolidated financial statements, the annual report, the annual information
form, the financial information of the Company contained in any prospectus or information circular or other disclosure documents or regulatory filings of the Company, the recommendations for approval of each of the foregoing from each of the
Chairman of the Board, President and Chief Executive Officer, and Chief Financial Officer of the Company and based on such recommendations provide, where applicable, its own recommendations to the Board for their approval and release of each of the
foregoing to the public; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s interim consolidated financial statements and the notes and Managements&#146; Discussion and Analysis relating to such consolidated financial statements, and either, in the discretion of the Audit
Committee, (A)&nbsp;approve and release each of the foregoing to the public, or (B)&nbsp;provide, where applicable, its own recommendation to the Board for their approval and release of each of the foregoing to the public; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the quality, appropriateness and acceptability of the Company&#146;s accounting principles and practices used in its financial reporting, changes in the Company&#146;s accounting principles or practices and the
application of particular accounting principles and disclosure practices by Management to new transactions or events; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">all significant financial reporting issues and judgments made in connection with the preparation of the Company&#146;s consolidated financial statements, including the effects of alternative methods in respect of any
matter considered significant by the external auditor within generally accepted accounting principles on the consolidated financial statements and any &#147;second opinions&#148; sought by Management from an independent or other audit firm or
advisor with respect to the accounting treatment of a particular item; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">the effect of regulatory and accounting initiatives on the Company&#146;s consolidated financial statements and other financial disclosures; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">any reserves, accruals, provisions or estimates that may have a significant effect upon the consolidated financial statements of the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">the use of special purpose entities and the business purpose and economic effect of off balance sheet transactions, arrangements, obligations, guarantees and other relationships of the Company and their impact on the
reported financial results of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">any legal matter, claim or contingency that could have a significant impact on the consolidated financial statements, the Company&#146;s compliance policies and any material reports, inquiries or other correspondence
received from regulators or governmental agencies and the manner in which any such legal matter, claim or contingency has been disclosed in the Company&#146;s consolidated financial statements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">review the treatment for financial reporting purposes of any significant transactions that are not a normal part of the Company&#146;s operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top">the use of any &#147;pro forma&#148; or &#147;adjusted&#148; information not in accordance with generally accepted accounting principles; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">review and resolve disagreements between Management and the Company&#146;s external auditors regarding financial reporting or the application of any accounting principles or practices; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">review earnings press releases, as well as financial information and earnings guidance provided to analysts and ratings agencies, it being understood that such discussions may, in the discretion of the Committee, be
done generally (i.e., by discussing the types of information to be disclosed and the type of presentation to be made) and that the Committee need not discuss in advance each earnings release or each instance in which the Company gives earning
guidance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">establish and monitor procedures for the receipt and treatment of complaints received by the Company regarding accounting, internal accounting controls or audit matters and the anonymous submission by employees of
concerns regarding questionable accounting or auditing matters and review periodically with the Management these procedures and any significant complaints received; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">review and discuss the Company&#146;s major financial risk exposures and the steps taken to monitor and control such exposures, including the use of any financial derivatives and hedging activities. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>In Respect of Insurance </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">review periodically insurance programs relating to the Company and its investments; </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>In Respect of Internal Controls </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">review the adequacy and effectiveness of the Company&#146;s internal accounting and financial controls based on recommendations, if any, from Management and the external auditors for the improvement of accounting
practices and internal controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">oversee compliance with internal controls and the Code of Business Conduct; </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>In respect of Other Items </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">on an annual basis review and assess committee member attendance and performance and report thereon to the Board and review this Charter and, if required implement amendments to this Charter; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">on a quarterly basis review compliance with the Disclosure Policy of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">on a quarterly basis review any related-party transactions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OVERSIGHT FUNCTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Committee to plan or conduct audits or to
determine that the Company&#146;s consolidated financial statements are complete and accurate or are in accordance with IFRS and applicable rules and regulations. These are the responsibilities of Management and the Company&#146;s external auditors.
The Committee, its Chair and any Committee members identified as having accounting or related financial expertise are members of the Board, appointed to the Committee to provide broad oversight of the financial, risk and control related activities
of the Company, and are specifically not accountable or responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation or performance of such activities. Although the designation of a
Committee member as having accounting or related financial expertise for disclosure purposes or otherwise is based on that individual&#146;s education and experience which that individual will bring to bear in carrying out his or her duties on the
Committee, such designation does not impose on such person any duties, obligations or liability that are greater than the duties, obligations and liability imposed on such person as a member of the Committee and Board in the absence of such
designation. Rather, the role of a Committee member who is identified as having accounting or related financial expertise, like the role of all Committee members, is to oversee the process, not to certify or guarantee the internal or external audit
of the Company&#146;s financial information or public disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1891272_24"></A>SCHEDULE 3 - GLOSSARY OF TERMS AND DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this annual information form, the following capitalized words and terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>3SBio</B>&#148; means 3SBio, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>AIF</B>&#148; means the Annual Information Form of the Company dated March&nbsp;26, 2015 for the fiscal year ended December&nbsp;31, 2014; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;ALMS&#148;</B> means the Aspreva Lupus Management Study; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>API</B>&#148; means active pharmaceutical ingredient; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Aspreva&#148;</B> means Aspreva Pharmaceuticals Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148;, means the board of directors of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Calcineurin</B>&#148; means a specific enzyme (phosphatase enzyme) that can have its activity inhibited by immunosuppressive (anti-organ rejection)
drugs, including, for example, cyclosporine; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B>&#148; means the brand name
of MMF; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CEO</B>&#148; means Chief Executive Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CFO</B>&#148; means Chief Financial Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CMO</B>&#148; means Chief Medical Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CNI</B>&#148; means calcineurin inhibitors, the cornerstone of therapy for the prevention of organ transplant rejection; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means Aurinia Pharmaceuticals Inc. and (unless the context specifies or implies otherwise) its subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>COO</B>&#148; means Chief Operating Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CRL</B>&#148; means Complete Response Letter; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CRO</B>&#148; means Contract Research Organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;CSO&#148;</B> means Chief Scientific Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CTA</B>&#148; means Clinical Trial Application; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Cyclosporine</B>&#148; means a drug that suppresses the immune system and is used to prevent rejection following organ transplantation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>DDLA</B>&#148; means the Development, Distribution and License Agreement between the Company and ILJIN effective January&nbsp;28, 2011; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EMA</B>&#148; means the European Medicines Agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;EU&#148;</B> means European Union; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the Food and Drug Administration of the United States Government; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ILJIN</B>&#148; means ILJIN Life Science Co., Ltd.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IND</B>&#148; means investigational new drug; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IRB</B>&#148; means Institutional Review Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;LN&#148;</B> means lupus nephritis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lonza</B>&#148; means Lonza Ltd.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lux</B>&#148; means Lux BioSciences, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>MAA</B>&#148; means Marketing Authorization Application; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MMF&#148;</B> means mycophenolate mofetil; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MPA&#148;</B> means mycophenolic acid, the active metabolite of MMF; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MTT&#148;</B> means multi-targeted therapeutic; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;NASDAQ&#148;</B> means the NASDAQ Global Market Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>NDA</B>&#148; means New Drug Application made to a regulatory agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Paladin</B>&#148; means Paladin Labs Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Paladin Territories</B>&#148; means Canada, Israel, Central and South America, South Africa and Mexico prior to January&nbsp;28, 2011; and Canada,
Israel and South Africa after January&nbsp;28, 2011; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Phamacokinetics</B>&#148; means the processes of drug absorption, distribution, metabolism
and escretion in a living system (e.g., in humans); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>REB</B>&#148; means Research Ethics Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SEDAR</B>&#148; means the System for Electronic Document Analysis and Retrieval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SLE&#148;</B> means systemic lupus erythematosus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Supply Agreement&#148;</B> means the Supply Agreement dated the 18<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June, 2009 between
Paladin and the Company for the supply of API for use in clinical studies and other research and development projects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>TSX</B>&#148; means the
Toronto Stock Exchange; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>TSXV</B>&#148; means TSX Venture Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Vifor</B>&#148; means Vifor (International) AG; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrants</B>&#148; means warrants to purchase common shares in the capital of the Company, with each whole warrant being exercisable to purchase one
common share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d891272dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g891272ex99_2cov.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2014
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars) </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MANAGEMENT&#146;S RESPONSIBILITY FOR FINANCIAL REPORTING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of <B>Aurinia Pharmaceuticals Inc. </B>are the responsibility of management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board and reflect where appropriate, management&#146;s best estimates and judgments based on currently available information. Management has prepared the financial information presented elsewhere in the Management&#146;s
Discussion and Analysis and has ensured it is consistent with the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains systems of internal accounting
and administrative controls. These systems are designed to provide reasonable assurance that the financial information is relevant, reliable and accurate and that the Company&#146;s assets are appropriately accounted for and adequately safeguarded.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors exercises its responsibility over the consolidated financial statements and over financial reporting and internal controls
principally through the Company&#146;s Audit Committee. The Board appoints the Audit Committee and its members are outside and unrelated directors. The Audit Committee meets periodically with management, to discuss internal controls over the
financial reporting process and financial reporting issues and to satisfy itself that each party is properly discharging its responsibilities. The Audit Committee reviews the annual consolidated financial statements with both management and the
independent auditors and reports its findings to the Board of Directors before such statements are approved by the Board. The Audit Committee also considers, for review by the Board and approval by the shareholders, the engagement or re-appointment
of the external auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been audited by PricewaterhouseCoopers LLP, the Company&#146;s independent auditors,
in accordance with Canadian Auditing Standards on behalf of the shareholders. Their report outlines the scope of their audit and gives their opinion on the consolidated financial statements. PricewaterhouseCoopers LLP has full and free access to the
Audit Committee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signed) &#147;Stephen Zaruby</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">(Signed) &#147;Dennis Bourgeault&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Victoria, British Columbia</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26,
2015</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891272ex99_2pg05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;PwC&#148; refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891272pwc.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2015 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independent Auditor&#146;s Report </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To the Shareholders
of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited
the accompanying consolidated financial statements of Aurinia Pharmaceuticals Inc. and its subsidiaries, which comprise the consolidated statements of financial position as at December&nbsp;31, 2014,&nbsp;December&nbsp;31, 2013 and January&nbsp;1,
2013 and the consolidated statements of operations and comprehensive loss, changes in shareholders&#146; equity (deficit) and cash flows for the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013, and the related notes, which comprise a
summary of significant accounting policies and other explanatory information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s responsibility for the consolidated financial
statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with
International Financial Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free
from material misstatement, whether due to fraud or error. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditor&#146;s responsibility </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian
generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material
misstatement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial
statements. The procedures selected depend on the auditor&#146;s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the
auditor considers internal control relevant to the entity&#146;s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the entity&#146;s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the audit evidence we have obtained in our audits is
sufficient and appropriate to provide a basis for our audit opinion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891272ex99_2pg06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;PwC&#148; refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891272pwc.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Aurinia Pharmaceuticals Inc. and its
subsidiaries as at December&nbsp;31, 2014,&nbsp;December&nbsp;31, 2013 and January&nbsp;1, 2013 and their financial performance and their cash flows for the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013 in accordance with
International Financial Reporting Standards as issued by the International Accounting Standards Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Signed) &#147;PricewaterhouseCoopers LLP&#148;
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chartered Accountants </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Financial Position </P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(in thousands of US dollars) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2014</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;1,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents (note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investment (note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current assets</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment </B>(note 8)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Intangible assets </B>(note 9)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prepaid deposits</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investment </B>(note 10)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities (note 11)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue (note 13)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for restructuring costs (note 17)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug supply loan (note 12)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration (note 14)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current liabilities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue (note 13)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for restructuring costs (note 17)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration (note 14)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Equity (Deficit)</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share capital</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares (note 15)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants (note 15)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contributed surplus</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated other comprehensive loss</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deficit</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies </B>(note 24)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Subsequent event </B>(note 27)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approved by the Board of Directors </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(signed)&nbsp;Richard&nbsp;Glickman</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center">(signed) Charles A. Rowland Jr.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Operations and Comprehensive Loss </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013 </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, in thousands, except per
share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2014</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue </B>(note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development &#150; net (note 16)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development (note 16)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and restructuring costs (note 17)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of intangible assets (note 9)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income) &#150; net (note 18)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax (recovery) </B>(note 19)<B></B></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the year</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item that will not be reclassified subsequently to loss Translation adjustment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share </B>(note 20) (expressed in $ per share)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013 </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, thousands) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Warrants<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Contributed<BR>surplus</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deficit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated<BR>other<BR>comprehensive<BR>loss</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shareholders&#146;<BR>equity<BR>(deficit)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of units (note 15(a))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants (note 15(b))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiry of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation (note 15(c))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of first offering units (note 15(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of second offering units (note 15(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common shares to ILJIN (note 15(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Common shares and warrants on acquisition of Aurinia Pharma Corp. (note 15(b))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation (note 15(c))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income for the period</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Cash Flows </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended
December&nbsp;31, 2014 and December&nbsp;31, 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flow provided by (used in)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in provision for restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs allocated to warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred lease inducements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange loss related to non-operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on acquisition of Aurinia Pharma Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on contract settlement with ILJIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in other operating assets and liabilities (note 22)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in short-term investment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired from Aurinia Pharma Corp. (note 5(b))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds on disposal of equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of equipment and leaseholds</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized patent costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of financing milestone to ILJIN</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of units, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of promissory notes</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments under capital lease</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Increase in cash and cash equivalents during the year</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents &#150; Beginning of year</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents &#150; End of year</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31,
2014 and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars,
tabular amounts in thousands) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Corporate information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. or the Company is a clinical stage
pharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. The Company has its registered office
located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. is
incorporated pursuant to the Business Corporations Act (Alberta). The Company&#146;s Common Shares are currently listed and traded on the NASDAQ Global Market (NASDAQ) under the symbol AUPH and on the Toronto Stock Exchange under the symbol AUP. The
Company&#146;s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma Corp. (formerly
Aurinia Pharmaceuticals Inc.), Aurinia Pharmaceuticals, Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Statement of compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (IFRS)
as issued by the International Accounting Standards Board (IASB). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements were authorized for issue by the
Board of Directors on March&nbsp;26, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basis of measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared on a going concern and historical cost basis, other than certain financial instruments
recognized at fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Functional and presentation currency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are presented in United States (US) dollars, which is the Company&#146;s functional currency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(1) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of significant accounting policies and change in accounting policies </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Functional currency and change in presentation currency </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;31, 2014, the
Company changed its functional currency from the Canadian dollar (CA$) to the United States dollar (US$). The change in functional currency, which has been accounted for prospectively, is to better reflect the Company&#146;s business activities
which are primarily denominated in US$ and to improve investors&#146; ability to compare the Company&#146;s financial results with other publicly traded entities in the biotech industry. In addition, the Company changed its presentation currency to
US$ and followed the guidance in IAS 21, The Effects of Changes in Foreign Exchange Rates. Accordingly, the Company has applied the change retrospectively as if the new presentation currency had always been the Company&#146;s presentation currency.
In accordance with IAS 21, the financial statements for all years and periods presented have been translated to the US$ presentation currency. For the 2013 comparative balances, assets and liabilities have been translated into US dollars at the rate
of exchange prevailing at the reporting date. The statement of comprehensive income (loss) was translated at the average exchange rates for the reporting period, or at the exchange rates prevailing at the date of significant transactions. Exchange
differences arising on translation were taken to cumulative translation adjustment in shareholders&#146; equity. The Company has presented a third statement of financial position as at January&nbsp;1, 2013 without the related notes except for the
disclosure requirements outlined in IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors. In addition, the Company adopted a policy of not reassessing classification of warrants after initial issuance and therefore there is no
effect to previously issued warrants exercisable in CA$. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Summary of significant accounting policies </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Consolidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Subsidiaries are all entities
over which the Company has the power to govern the financial and operating policies. The Company has a 100% voting interest in all of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a
subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability
resulting from a contingent consideration arrangement. Identifiable assets acquired, and liabilities and contingent liabilities assumed in a business combination, are measured initially at their fair values at the acquisition date. If any
unallocated portion is positive, it is recognized as goodwill and if negative, it is recognized as a gain in the statement of operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Acquisition-related costs are expensed as incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Any contingent consideration to be transferred by the Company is recognized at fair value at the acquisition date. Subsequent changes to the
fair value of the contingent consideration that is deemed to be an asset or liability are recognized in accordance with IAS 39 either in profit or loss or as a change to other comprehensive income. Contingent consideration that is classified as
equity is not re-measured, and its subsequent settlement is accounted for within equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Inter-company transactions, balances and unrealized gains on transactions between companies
are eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Translation of foreign currencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The monetary assets and liabilities of operations denominated in foreign currencies are translated into United States dollars at rates of
exchange in effect at the end of the period. Revenues and expenses related to monetary assets and liabilities are translated at average rates of exchange during the period. Exchange gains and losses arising on translation are included in the
statement of operations and comprehensive income (loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Payments received under collaboration agreements may include upfront payments, milestone payments, contract services, royalties and license
fees. Revenues for each unit of accounting are recorded as described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Licensing and research and development revenues </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company has agreements in specific regions
with strategic partners. Licensing agreements usually include one-time payments (upfront payments), payments for research and development services in the form of cost reimbursements, milestone payments and royalty receipts. Revenues associated with
those multiple-element arrangements are allocated to the various elements based on their relative fair value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Agreements containing
multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the
undelivered obligation(s). The consideration received is allocated among the separate units based on each unit&#146;s fair value, and the applicable revenue recognition criteria are applied to each of the separate units. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">License fees representing non-refundable payments received at the time of signature of license agreements are recognized as revenue upon
signature of the license agreements when the Company has no significant future performance obligations and collectability of the fees is assured. Upfront payments received at the beginning of licensing agreements are deferred and recognized as
revenue on a systematic basis over the period during which the related services are rendered and all obligations are performed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Milestone payments </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Milestone payments, which are generally based on developmental or
regulatory events, are recognized as revenue when the milestones are achieved, collectability is assured, and when the Company has no significant future performance obligations in connection with the milestones. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contract services </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Revenues from contract services are recognized as services are rendered, the
price is fixed or determinable and collection is reasonably assured. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Royalty payments </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Royalty income is recognized on the accrual basis in accordance with the
substance of the relevant agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand, deposits held with banks, and other short-term highly liquid investments with original
maturities of three months or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Property and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated amortization and accumulated impairment losses. Cost includes expenditures that are
directly attributable to the acquisition of the asset. The carrying amount of a replaced asset is derecognized when replaced. Repair and maintenance costs are charged to the statement of operations during the period in which they are incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The major categories of property and equipment are amortized on a straight-line basis as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Term&nbsp;of&nbsp;the&nbsp;lease</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment and furniture</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">External patent costs specifically associated with the preparation, filing and obtaining of patents are capitalized and amortized straight-line
over the shorter of the estimated useful life and the patent life, commencing in the year of the grant of the patent. Other intellectual property expenditures are recorded as research and development expenses on the statement of operations and
comprehensive loss as incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">An intangible asset arising from research will not be recognized as an intangible asset and such
expenditures will be recorded as research and development expenses on the statement of operations and comprehensive loss as incurred. Upon reaching the development stage, the Company will assess an intangible asset and only recognize it as such if
technical feasibility, intention to use or sell, ability to use or sell, probable future economic benefits, availability and ability to develop the intangible asset are demonstrated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Separately acquired intellectual property is shown at historical cost. The initial recognition of a reacquired right is recognized as an
intangible asset measured on the basis of the remaining contractual term of the related contract regardless of whether market participants should consider potential contractual renewals when measuring its fair value. If the terms of the contract
giving rise to a reacquired right are favourable or unfavourable relative to the terms of current market transactions for the same or similar items, the difference is recognized as a gain or loss in the statement of operations. Purchased
intellectual property and reacquired rights are capitalized and amortized on a straight-line basis in the statement of operations over the patent life, which is typically 20 years. The ALMS database (see note 5(b)) is being amortized over 10 years.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of non-financial assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment and intangible assets with a finite useful life are tested for impairment when events or changes in circumstances
indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#146;s carrying amount exceeds its recoverable amount. The Company evaluates impairment losses for potential reversals when
events or circumstances warrant such consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Share capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares are recognized as a deduction
from equity, net of any tax effects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Proceeds on the issue of common share purchase warrants (warrants) are recorded as a separate
component of equity. Costs incurred on the issue of warrants are netted against proceeds. Warrants issued with common shares are measured at fair value at the date of issue using the Black-Scholes pricing model, which incorporates certain input
assumptions including the warrant price, risk-free interest rate, expected warrant life and expected share price volatility. The fair value is included as a component of equity and is transferred from warrants to common shares on exercise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A provision
is recognized when the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present
value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company records stock-based compensation related to employee stock options granted using the fair value at the date of grant and it is
expensed as employee benefits over the period in which employees unconditionally become entitled to the award. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service conditions are expected to
be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related services and non-market performance conditions at the vesting date. The corresponding charge is to contributed surplus. Any
consideration paid on the exercise of stock options is credited to share capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Operating lease payments are recognized in net income (loss) on a straight-line basis over the term of the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Income tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Income tax comprises current and deferred tax. Income tax is recognized in the statement of operations and comprehensive loss except to the
extent that it relates to items recognized directly in shareholders&#146; equity, in which case the income tax is also recognized directly in shareholders&#146; equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at the end of the reporting period, and
any adjustments to tax payable in respect of previous years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In general, deferred tax is recognized in respect of temporary differences
arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or
substantively enacted at the balance sheet date and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable that the assets can be recovered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Deferred income tax assets and liabilities are presented as non-current. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Earnings (loss) per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per share (EPS) is calculated by dividing the net income (loss) for the period attributable to equity owners of the
Company by the weighted average number of common shares outstanding during the period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Diluted EPS is calculated by adjusting the weighted
average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method. The Company&#146;s potentially dilutive common
shares comprise stock options and warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Financial instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial
assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the
obligation specified in the contract is discharged, cancelled or expires. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A derivative is a financial instrument whose value changes in
response to a specified variable, requires little or no net investment and is settled at a future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(6) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At initial recognition, the Company classifies its financial instruments in the following
categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">Financial assets and liabilities at fair value through profit or loss: a financial asset or liability is classified in this category if acquired principally for the purpose of selling or repurchasing in the short-term.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Derivatives are also included in this category unless they are designated as hedges. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Financial instruments in this category are recognized initially and subsequently at fair value. Gains and losses arising from changes in fair
value are presented in the consolidated statement of operations and comprehensive loss within other income (expenses) in the period in which they arise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">Loans and receivables: Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. The Company&#146;s loans and receivables comprise trade and
other receivables, cash and cash equivalents and short-term investments and are included in current assets due to their short-term nature. Loans and receivables are initially recognized at the amount expected to be received, less, when material, a
discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest method less a provision for impairment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">Available for sale financial assets: Available for sale assets are non-derivative financial assets that are designated as available for sale and are not categorized into any of the other categories described above. They
are initially recognized at fair value including direct and incremental transaction costs. They are subsequently recognized at fair value. Gains and losses arising from changes in fair value are included as a separate component of equity until sale,
when the cumulative gain or loss is transferred to the statement of operations. Interest is determined using the effective interest method, and impairment losses and translation differences on monetary items are recognized in the statement of
operations. Prior to the acquisition of Aurinia Pharma Corp., the Company&#146;s 10% investment in Aurinia Pharma Corp. was classified as available for sale (see note 10). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv)</TD>
<TD ALIGN="left" VALIGN="top">Financial liabilities at amortized cost: Financial liabilities at amortized cost are composed of trade payables and accrued liabilities. Trade payables and accrued liabilities are initially recognized at the amount
required to be paid, less, when material, a discount to reduce payables to fair value. Subsequently, trade payables are measured at amortized cost using the effective interest method. These are classified as current liabilities if payment is due
within twelve months. Otherwise, they are presented as non-current liabilities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v)</TD>
<TD ALIGN="left" VALIGN="top">Financial liabilities at fair value: Contingent consideration provided to ILJIN (see note 14) is a financial liability recorded at fair value with subsequent changes in fair value recorded in the statement of
operations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of financial assets </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Financial assets carried at amortized cost </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">At each balance sheet date, the Company assesses
whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred if, and only if, there is objective evidence of
impairment as a result of one or more events that occurred after the initial recognition of the asset (a loss event), and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial
assets that can be reliably estimated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The amount of the loss is measured as the difference between the asset&#146;s carrying amount
and the present value of estimated future cash flows (excluding future credit losses) discounted at the financial asset&#146;s original effective interest rate. The asset&#146;s carrying amount is reduced and the amount of the loss is recognized in
the consolidated statement of operations. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. For practical reasons, the Company may
measure impairment on the basis of an instrument&#146;s fair value using an observable market price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>New standards, amendments and
interpretations adopted by the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following standards have been adopted by the Company for the first time for the financial
year beginning on or after January&nbsp;1, 2014 and could have an impact on the Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendment to IAS 32, Financial Instruments: Presentation on offsetting financial assets and financial liabilities. This amendment clarifies that the right of set-off must not be contingent on a future event. It must
also be legally enforceable for all counterparties in the normal course of business, as well as in the event of default, insolvency or bankruptcy. The amendment also considers settlement mechanisms. The amendment did not have a significant effect on
the Company&#146;s consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendments to IAS 36, Impairment of assets, on the recoverable amount disclosures for non-financial assets. This amendment removed certain disclosures of the recoverable amount of cash generating units (CGUs), which had
been included in IAS 36 by the issuance of IFRS 13. The Company has applied the amendment and there has been no significant impact on the Company&#146;s consolidated financial statements as a result. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendment to IAS 39, Financial Instruments: Recognition and measurement on the novation of derivatives and the continuation of hedge accounting. This amendment considers legislative changes to over-the-counter
derivatives and the establishment of central counterparties. Under IAS 39 novation of derivatives to central counterparties would result in discontinuance of hedge accounting. The amendment provides relief from discontinuing hedge accounting when
novation of a hedging instrument meets specified criteria. The amendment did not affect the Company&#146;s financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRIC 21, Levies, sets out the accounting for an obligation to pay a levy if that liability is within the scope of IAS 37, Provisions. The interpretation addresses the obligating event that gives rise to the payment of
a levy and when a liability should be recognized. The Company is not currently subjected to significant levies so the impact on the Company is not material. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Other standards, amendments and interpretations which are effective for the financial year beginning on January&nbsp;1, 2014 are not material
to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(8) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>New standards, amendments and interpretations not yet adopted </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in
IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortized cost, fair value
through other comprehensive income (OCI) and fair value through profit and loss (P&amp;L). The basis of classification depends on the entity&#146;s business model and the contractual cash flow characteristics of the financial asset. Investments in
equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in OCI not recycling. There is now a new expected credit losses model that replaces the
incurred loss impairment model used in IAS 39. For financial liabilities there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at
fair value through profit or loss. IFRS 9 relaxes the requirements for hedge effectiveness by replacing the bright line hedge effectiveness tests. It requires an economic relationship between the hedged item and hedging instrument and for the
&#145;hedged ratio&#146; to be the same as the one management actually use for risk management purposes. Contemporaneous documentation is still required but is different to that currently prepared under IAS 39. The standard is effective for
accounting periods beginning on or after January&nbsp;1, 2018. Early adoption is permitted. The Company is yet to assess IFRS 9&#146;s full impact. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRS 15, Revenue from Contracts with Customers, was issued in May 2014 by the IASB and supersedes IAS 18, Revenue, IAS 11, Construction Contracts and other interpretive guidance associated with revenue recognition. IFRS
15 provides a single model to determine how and when an entity should recognize revenue, as well as requiring entities to provide more informative, relevant disclosures in respect of its revenue recognition criteria. IFRS 15 is to be applied
retrospectively or through the recognition of the cumulative effect to opening retained earnings and is effective for annual periods beginning on or after January&nbsp;1, 2017, with earlier application permitted. We are currently in the process of
evaluating the impact that IFRS 15 may have on our consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 16, Property, Plant and Equipment, and IAS 38, Intangible Assets, address clarification of acceptable methods of depreciation and amortization. IAS 16 and IAS 38 are amended to: (i)&nbsp;clarify that the use of a
revenue-based depreciation and amortization method is not appropriate, and (ii)&nbsp;provide a rebuttable presumption for intangible assets. The standard is effective for accounting periods on or after January&nbsp;1, 2016. The Company is yet to
assess IAS 16&#146;s and IAS 38&#146;s full impact. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There are no other IFRS or IFRIC interpretations that are not yet
effective that would be expected to have a material impact on the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Critical accounting estimates and judgments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial
statements in accordance with IFRS often requires management to make estimates about, and apply assumptions or subjective judgment to, future events and other matters that affect the reported amounts of the Company&#146;s assets, liabilities,
revenues, expenses and related disclosures. Assumptions, estimates and judgments are based on historical experience, expectations, current trends and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(9) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
other factors that management believes to be relevant at the time at which the Company&#146;s consolidated financial statements are prepared. Management reviews, on a regular basis, the
Company&#146;s accounting policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment and are often applied to
matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management considers the following areas to be those where critical accounting policies affect the significant judgments and estimates used in
the preparation of the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Critical estimates in applying the Company&#146;s accounting
policies </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contingent consideration </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Contingent consideration is a financial liability recorded at fair
value (see note 14). The amount of contingent consideration to be paid is based on the occurrence of future events, such as the achievement of certain development, regulatory and sales milestones. Accordingly, the estimate of fair value contains
uncertainties as it involves judgment about the likelihood and timing of achieving these milestones as well as future foreign exchange rates and the discount rate used. Changes in fair value of the contingent consideration obligation result from
changes to the assumptions used to estimate the probability of success for each milestone, the anticipated timing of achieving the milestones, and the discount period and rate to be applied. A change in any of these assumptions could produce a
different fair value, which could have a material impact to the results from operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The key assumptions used by management include
the probability of success for each milestone (35% - 70%) and a discount rate of 10%. There has been no change made to the key assumptions except for a discount rate change to 10% as at March&nbsp;31, 2014 from 15% used in 2013, which reflects the
Company&#146;s reduced credit risk. If the probability for success were to increase by a factor of 10% for each milestone this would increase the obligation by approximately $677,000 at December&nbsp;31, 2014. If the probability for success were to
decrease by a factor of 10% for each milestone this would decrease the obligation by approximately $677,000 at December&nbsp;31, 2014. If the discount rate were to increase to 12%, this would decrease the obligation by approximately $212,000. If the
discount rate were to decrease to 8%, this would increase the obligation by approximately $232,000. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fair value of stock options </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Determining the fair value of stock options on the grant date,
including performance based options, requires judgment related to the choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to
determine fair value could result in a significant impact on the Company&#146;s reported operating results, liabilities or other components of shareholders&#146; equity. The key assumption used by management is the stock price volatility. If the
stock price volatility was higher by a factor of 10% on the option grant dates in 2014 this would have increased annual stock compensation expense by approximately $163,000. If the stock price volatility was lower by a factor of 10% on the grant
date this would have decreased annual stock compensation expense by approximately $178,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(10) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fair value of warrants </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Determining the fair value of warrants requires judgment related to the
choice of a pricing model, the estimation of stock price volatility, expected term of the underlying instruments and the probability factors of success in achieving the objectives for contingently issuable warrants (note 15(a)). Any changes in the
estimates or inputs utilized to determine fair value at the grant date could have a significant impact on the Company&#146;s operating results, liabilities or other components of shareholders&#146; equity. If the stock price volatility was higher by
a factor of 10% this would have increased the value of the warrants (equity component) by approximately $1,098,000. If the stock price volatility was lower by a factor of 10% this would have decreased the value of the warrants (equity component) by
approximately $1,189,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Critical judgments in applying the Company&#146;s accounting policies </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Revenue recognition </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Management&#146;s assessments related to the recognition of revenues for
arrangements containing multiple elements are based on estimates and assumptions. Judgment is necessary to identify separate units of accounting and to allocate related consideration to each separate unit of accounting. Where deferral of upfront
payments or license fees is deemed appropriate, subsequent revenue recognition is often determined based upon certain assumptions and estimates, the Company&#146;s continuing involvement in the arrangement, the benefits expected to be derived by the
customer and expected patent lives. To the extent that any of the key assumptions or estimates changes, future operating results could be affected. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Impairment of intangible assets </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company follows the guidance of IAS 36 to determine when
impairment indicators exist for its intangible assets. When impairment indicators exist, the Company is required to make a formal estimate of the recoverable amount of its intangible assets. This determination requires significant judgment. In
making this judgment, management evaluates external and internal factors, such as significant adverse changes in the technological, market, economic or legal environment in which the Company operates as well as the results of its ongoing development
programs. Management also considers the carrying amount of the Company&#146;s net assets in relation to its market capitalization, as a key indicator. In making a judgment as to whether impairment indicators exist at December&nbsp;31, 2014,
management concluded that there were none. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Plan of arrangement and acquisition of Aurinia Pharma Corp. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2013,
the Company announced that it had signed a binding term sheet (the Term Sheet) with Aurinia Pharma Corp. for the merger of the two companies, creating a clinical development stage pharmaceutical company focused on the global nephrology market. The
Term Sheet set forth the main criteria to be incorporated into a definitive merger agreement under which the Company would acquire 100% of the outstanding securities of Aurinia Pharma Corp. The merger was expected to be effected by the exchange of
shares in the Company for securities of Aurinia Pharma Corp. resulting in an estimated 65:35 post merger ownership split, on a warrant diluted basis, between the Company and Aurinia Pharma Corp. shareholders, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(11) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;3, 2013, the Company and Aurinia Pharma Corp. negotiated a tripartite
settlement agreement (the Settlement Agreement) with ILJIN Life Science Co., Ltd. (ILJIN) pursuant to which, upon the successful completion of the proposed merger, the combined company would re-acquire the license previously granted to ILJIN and
therefore obtain full rights to voclosporin for autoimmune indications including lupus, and transplantation in the United States, Europe and other regions of the world, outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. In return,
ILJIN would be entitled to receive certain predefined future milestone payments and would also own approximately 25% of the issued and outstanding shares of the merged company on a warrant diluted basis, which is calculated to give effect to the
dilution by the exercise of warrants but excluding the exercise of stock options. On June&nbsp;11, 2013, a draft arrangement agreement was prepared implementing the arrangement (the Arrangement Agreement), the terms of which were subsequently
negotiated by the parties. The Arrangement was intended to implement the terms of the Settlement Agreement, whereby ILJIN would receive a further ownership interest in the Company in exchange for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">returning to the Company and terminating: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">all of its rights, licenses and obligations under the DDLA (see note 13(b)); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">all other licenses and sublicenses between ILJIN and any of the Company, Aurinia Pharma Corp. or Vifor (International) AG (Vifor); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">suspending all of its current or contemplated legal or financial claims against the Company, Aurinia Pharma Corp. or Vifor. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the plan of arrangement on September&nbsp;20, 2013, the Company issued common shares to ILJIN. In addition ILJIN is entitled to
receive certain predefined future success based clinical and marketing milestone payments in the aggregate amount of up to $10,000,000, plus up to $1,600,000 upon the merged company reaching certain financing milestones (see note&nbsp;14). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company also acquired all of the issued and outstanding common shares of Aurinia Pharma Corp. at a ratio of approximately 19.83 common
shares for each Aurinia Pharma Corp. share held by an Aurinia Pharma Corp. shareholder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Settlement with ILJIN </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the contract settlement with ILJIN at
September&nbsp;20, 2013 was $8,403,000 and has been determined to represent reacquired license rights in the amount of $4,137,000 and a loss on contract settlement of $4,266,000. Consideration paid or payable to ILJIN is as follows: the
Company&#146;s 10% interest in Aurinia Pharma Corp. of $670,000, $3,671,000 in common shares, $2,690,000 in financial milestones payable and $1,600,000 in clinical and sales milestones payable based on the estimated fair value of the pre-defined
future milestone payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(12) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s tripartite settlement agreement with Aurinia Pharma Corp. and ILJIN
resulted in the recognition of a loss on contract settlement with ILJIN of $4,266,000. This is the result of a value allocated to the intangible property rights being reacquired from ILJIN as a result of the settlement. The value of these rights was
determined using a differential income approach; that is, the discounted cash flows that the Company is able to generate above and beyond what it was entitled to under the original licensing agreement. The cash flows used to determine the value of
these rights are derived from the same cash flows used to determine the reacquired right from Aurinia Pharma Corp. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Acquisition of Aurinia Pharma Corp. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company determined that the transaction with
Aurinia Pharma Corp. represented a business combination with the Company identified as the acquirer. The Company began consolidation of the operating results, cash flows and net assets of Aurinia Pharma Corp. on September&nbsp;20, 2013. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The table below presents the allocation of the purchase price to the assets and liabilities acquired, as well as the settlement of pre-existing
balances between the parties to the Arrangement Agreement prior to acquisition. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carrying<BR>value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Settle&nbsp;pre-<BR>existing<BR>items</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Fair&nbsp;value<BR>adjustments<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair&nbsp;value&nbsp;of<BR>acquisition</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets acquired</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Consideration provided by the Company for the acquisition of Aurinia Pharma Corp. was 3,682,000 common shares
of the Company with a fair value of $7,977,000, less $459,000 of deferred revenue that was effectively settled as a result of the business combination. The fair value of the shares issued was determined by the trading price on September&nbsp;20,
2013. The $3,501,000 difference between the fair value of net consideration of $7,518,000 and the fair value of net assets acquired of $10,729,000 is recorded as a gain in other income. Acquisition costs of $251,000 have been expensed (note 17).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(13) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s acquisition of Aurinia Pharma Corp. has resulted in the recognition of a
gain of $3,501,000. This is primarily as a result of the value allocated to the intangible property rights being reacquired from Aurinia Pharma Corp. as a result of the merger. The value of these rights was determined using a differential income
approach; that is, the discounted cash flows that the Company is able to generate above and beyond what it was entitled to from the Vifor License, determined over the contract life to 2029. The determination of these cash flows is subject to
significant estimates and assumptions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount and timing of projected future cash flows, adjusted for the probability of technical and marketing success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount and timing of projected costs to develop voclosporin into a commercially viable treatment for lupus nephritis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The discount rate selected to measure the risks inherent in the future cash flows; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An assessment of voclosporin&#146;s life-cycle and the competitive trends impacting the drug, including consideration of any technical, legal, regulatory, or economic barriers to entry. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cash and cash equivalents </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2014</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;1,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at bank and on hand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term bank deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The interest rate on the short-term bank deposits at December&nbsp;31, 2014 was 0.25% (2013 &#150; 1.00%). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Short-term investment </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The short-term investment, which is recorded initially at fair
value and subsequently at amortized cost, using the effective interest method, is a HSBC Bank US denominated discount note with amortized cost of $9,998,000 and initial cost of $9,991,000. The note is due February&nbsp;3, 2015 and has an effective
interest rate of 0.18%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(14) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property and equipment </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Leasehold<BR>improvements<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Scientific<BR>and office<BR>equipment<BR>and<BR>furniture<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Computer<BR>equipment<BR>and<BR>software</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2014, the Company disposed of fully depreciated equipment for proceeds of
$4,000, resulting in a gain of $4,000 (2013 &#150; $68,000 resulting in a gain of $68,000). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(15) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Intangible assets </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Patents<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchased<BR>Intellectual<BR>property&nbsp;and<BR>reacquired<BR>rights</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opening net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write off of patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opening net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of re-acquired rights from ILJIN (note 5(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of intangible assets acquired from Aurinia Pharma Corp. (note&nbsp;5(b))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization for the year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(581</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of patents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(822</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(16) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As a result of the Arrangement Agreement as described in note 5, the Company recognized
re-acquired rights from ILJIN and Aurinia Pharma Corp. in the total amount of $18,710,000. The re-acquired rights represent the value of discounted cash flows expected to arise from the return of the licenses granted under the ILJIN DDLA (note
13(b)) and the Vifor License and ILJIN License Back (note 13(a)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014, the Company signed a NICAMs Purchase and Sale
Agreement with Ciclofilin Pharmaceuticals Inc. (Ciclofilin) whereby it divested its early stage research and development NICAMs asset, consisting of intellectual property, including patent applications and know-how to Ciclofilin. Consideration will
consist of future contingent milestones and a royalty. Due to the early stage of development of this technology and the contingent nature of the consideration to be received by the Company, the Company recognized an impairment against the entire
capitalized cost of the NICAMs patent portfolio ($202,000) at December&nbsp;31, 2013. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Investment </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2014</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opening fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares received from Aurinia Pharma Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value to date of disposal (note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares provided to ILJIN (note 5(a))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing fair value</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s investment in Aurinia Pharma Corp. was carried at fair value, with changes in fair value
recognized in other comprehensive income (OCI). Since Aurinia Pharma Corp.&#146;s shares did not trade in a public market, the Company used a form of comparable company valuation approach to determine fair value, categorized as Level 3 in the fair
value hierarchy. Due to the unique nature of Aurinia Pharma Corp.&#146;s primary assets, being its license agreement with the Company and its intellectual property related to lupus nephrology research, management does not believe there are any
comparable companies that trade publicly for which an indicative value could be obtained. As a result, it compared the value of Aurinia Pharma Corp. to the value of the Company based on the planned merger of the entities and the relative valuation
formula agreed to by the parties and approved by the shareholders. Without providing for any adjustments for lack of liquidity or non-controlling interests, this approach resulted in a fair value of the investment of $670,000 at September&nbsp;20,
2013. Pursuant to the plan of arrangement as described in note 5 the Company transferred its ownership interest in Aurinia Pharma Corp. to ILJIN. The Company recorded a gain of $75,000 on the statement of operations in 2013 upon disposal of this
investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(17) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accounts payable and accrued liabilities </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2014</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;1,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated &#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee and director related accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued severance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Drug supply loan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2013, the Company had a drug supply loan in
the amount of $1,318,000 (CA$1,402,000) (January 1, 2013 - $1,707,000 (CA$1,698,000)) payable to Paladin Labs Inc. (Paladin). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The terms of
repayment were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">The Company was to pay Paladin CA$100,000 per month, commencing 15 days after the successful completion of the Company raising a minimum of CA$3,000,000 in financing which occurred on September&nbsp;20, 2013;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">Any outstanding balance was due on or before December&nbsp;31, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">Interest on the outstanding balance was at a rate of 10%, compounded monthly for the first 12 months, commencing upon first payment, and then payable at a rate of 18%, compounded monthly after the first 12 months. The
Company had the right to prepay the balance owing on the outstanding balances, plus accrued interest to the date of prepayment, at any time without penalty. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company repaid the loan in full during the first quarter ended March&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(18) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenue and deferred revenue </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue is composed of Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3SBio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aurinia Pharma Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lux</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue-Paladin</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensing and research and development fee revenues represent the amortization of deferred revenue from fee
payments received by the Company. The deferred revenue is recorded as revenue as the Company incurs the costs related to meeting its obligations under the terms of the applicable agreements. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Licensing and Collaboration Agreement with Aurinia Pharma Corp. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company signed a global
Licensing and Collaboration Agreement (LCA) effective December&nbsp;30, 2011 with Vifor. The agreement granted Vifor an exclusive license for voclosporin, for the treatment of lupus and all proteinuric nephrology indications (the Vifor License). The
Vifor License was for the United States and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong (the Vifor Territory). Under the terms of the Agreement, the Company was to receive milestone payments, as well as
royalties on commercial sales. On December&nbsp;13, 2012, the LCA was assigned by Vifor to Aurinia Development Corp, a subsidiary of Aurinia Pharma Corp. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In order for these rights to be licensed to Vifor, ILJIN had provided a License Back of certain rights especially for the field of lupus and
proteinuric kidney diseases for the Territory defined in the ILJIN DDLA, in return for certain milestones and royalties to be paid by Vifor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2012, pursuant to the LCA, the Company received as a milestone payment, an investment in Aurinia Pharma Corp. Aurinia
Pharma Corp. issued the Company a share certificate representing 10% of the common shares of Aurinia Pharma Corp. Aurinia Pharma Corp. had the option of granting the Company these shares or $595,000. The Company determined that the fair value of the
shares in Aurinia Pharma Corp. approximated $595,000 and therefore recorded the value of the investment in Aurinia Pharma Corp. shares at $595,000 (see note 10). The Company had recorded this milestone payment as deferred revenue upon receipt. Under
the LCA, the primary substantive obligations of the Company were to maintain the patent portfolio and pay for drug supply if costs exceeded a certain amount. Until September&nbsp;20, 2013, deferred revenue was being amortized into licensing revenue
as the Company incurred the costs related to meeting its obligations under the LCA. Effective with the acquisition of Aurinia Pharma Corp. (as described in note 5), the remaining balance of deferred revenue of $459,000 as at September&nbsp;20, 2013
was an adjustment to the purchase consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(19) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Effective
January&nbsp;28, 2011 (the Effective Date) the Company completed a Development, Distribution and License Agreement (the DDLA) with ILJIN for the further clinical and commercial development of voclosporin for use in transplant indications applicable
to voclosporin. The Company granted to ILJIN an exclusive license to voclosporin for transplant and autoimmune indications for the United States and other regions outside of Europe, Canada, Israel, South Africa, China, Taiwan and Hong Kong. The
Company retained the rights over voclosporin in Europe for future development and commercialization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the DDLA, the Company was
to receive a total license fee of $5,000,000. In addition, ILJIN was to purchase 90,700,000 common shares (pre-conversion) of the Company for gross proceeds of $19,875,000 in three tranches. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company was obligated under the terms of the agreement to complete a single Phase 3 clinical trial for the prevention of kidney transplant
rejection. A Joint Steering Committee (JSC) with equal membership from the Company and ILJIN was to have been formed to oversee the development and commercialization of voclosporin in the ILJIN territories. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company received $4,500,000 of the license fee and the first private placement tranche of $2,375,000 on January&nbsp;28, 2011, which was
the effective date of the Agreement. The Company issued 11,500,000 common shares (pre-conversion) at a price of $0.207 per share to ILJIN pursuant to the subscription agreement for securities. On or before January&nbsp;28, 2012 ILJIN was to pay
$500,000 to the Company as the Second Development Payment and purchase 39,600,000 common shares (pre-conversion) of the Company issued from treasury for an aggregate subscription price of $8,500,000. On or before January&nbsp;28, 2013, ILJIN was to
purchase the final tranche of 39,600,000 common shares (pre-conversion) of the Company issued from treasury for an aggregate subscription price of $9,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Prior to the January&nbsp;28, 2012 date, ILJIN verbally indicated their intent to alter the economics of the DDLA. Consequently, payment under
the DDLA was not received as required per the agreement. The Company on January&nbsp;30, 2012 notified ILJIN that it was terminating the DDLA. At that time the Company believed that the termination of the original DDLA was valid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company received notification in March 2012 that ILJIN submitted a request for arbitration to the International Chamber of Commerce (ICC)
Court of Arbitration relating to the Company&#146;s termination of the DDLA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In November 2012, the Company received notification from the
ICC that a Partial Award regarding its right to terminate the DDLA with ILJIN had been issued to the parties. In the result, the Partial Award provided that the DDLA had not been terminated and, therefore, the Company&#146;s contractual relationship
with ILJIN still existed. As such the Partial Award rejected the Company&#146;s interpretation of the DDLA&#146;s termination provision. In January of 2013, ILJIN formally notified the Company and the arbitral tribunal that ILJIN had withdrawn all
claims for damages in the parties&#146; pending arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2013, the Company, ILJIN and Aurinia Pharma Corp.
completed a plan of arrangement whereby the DDLA was terminated as more fully described in note 5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(20) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Development, Distribution and License Agreement with 3SBio, Inc. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2010, the
Company and 3SBio, Inc. (3SBio)&nbsp;completed a Development, Distribution and License Agreement for voclosporin for the territories of China, Hong Kong and Taiwan. The transaction with 3SBio included a non-refundable licensing fee of $1,500,000,
which was originally recorded as deferred revenue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the agreement, the primary substantive obligations of the Company are to grant
the license and transfer intellectual knowledge to 3SBio. Management believes it had fulfilled these obligations by December&nbsp;31, 2010. However, under the agreement, the Company is also required to maintain the patent portfolio in China, Taiwan
and Hong Kong, and to provide further support and cooperation to 3SBio over the life of the agreement, which coincides with the life of the patents. Any additional assistance which may be provided to 3SBio will be performed on a full cost recovery
basis. For accounting purposes, when services are to be performed by an indeterminate number of acts over a specific period of time, revenue is recognized on a straight-line basis over this future period. As a result, the balance in deferred revenue
is being amortized into licensing revenue on a straight-line basis to 2022. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Development, Distribution and License Agreement with Lux Biosciences, Inc. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon signing a
Distribution and License Agreement (DDLA) with Lux Biosciences, Inc. (Lux) in 2006, Isotechnika Inc. received an upfront payment of $3,000,000 which was recorded as deferred revenue. The balance of deferred revenue remaining as at January&nbsp;1,
2011 was being recorded as revenue on a straight-line basis as the Company incurred costs related to meeting its remaining obligation of maintaining the patent portfolio. In late December 2012, the Company received notice from Lux that its Phase 3
clinical trial using voclosporin for the treatment of non-infectious uveitis did not meet its primary endpoint. In December 2013, the Company received notice from Lux, that it would be ceasing operations and returning the license to the Company. As
a result, on December&nbsp;31, 2013, the Company determined it had no further obligations pursuant to the DDLA and recorded the remaining balance of deferred revenue associated with the Lux DDLA as licensing revenue in the statement of operations
and comprehensive loss. The Company and Lux signed the Termination, Assignment and Assumption Agreement on February&nbsp;27, 2014. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">Plan of Arrangement with Paladin Labs Inc. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Research and development revenues represent the
amortization of the deferred monthly research and development fee payments received by the Company from Paladin for the period from July&nbsp;1, 2009 to June&nbsp;30, 2010, pursuant to the terms of the Research and Development Agreement. Under the
agreement, the primary substantive obligations of the Company had been achieved by the Company by December&nbsp;31, 2010. However, under the agreement, the Company is also required to maintain the patent portfolio in Canada, South Africa and Israel
and to provide further support and cooperation to Paladin over the life of the agreement. As a result, the balance in deferred revenue at January&nbsp;1, 2011 is being amortized into research and development revenue on a straight-line basis over the
remaining life of the agreement, which ends in June 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(21) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Contingent consideration </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As described in note 5(a) the Company has recorded the
contingent consideration payable to ILJIN resulting from the Arrangement Agreement completed on September&nbsp;20, 2013 between the Company, Aurinia Pharma Corp., and ILJIN, at fair value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There were two categories of contingent consideration. The first was a financing milestone of $1,600,000 payable upon the Company completing a
financing of up to $10,000,000. The Company closed a $52,000,000 private placement on February&nbsp;14, 2014 and accordingly this financing milestone was paid to ILJIN by the Company in February 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The second category of contingent consideration relates to payments of up to $10,000,000 to be paid in five equal tranches according to the
achievement of pre-defined clinical and marketing milestones. If all milestones are met, the timing of these payments is expected to occur as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of this portion of contingent consideration as at December&nbsp;31, 2014 was estimated to be
$3,473,000 (December&nbsp;31, 2013 &#150; $2,690,000) and was determined by applying the income approach. The fair value estimates as at December&nbsp;31, 2014 were based on a discount rate of 10% and an assumed probability adjusted payment range
between 35% and 70%. This is a Level 3 recurring fair value measurement. The revaluation expense adjustment for the year ended December&nbsp;31, 2014 was $848,000 and was comprised of $315,000 to reflect the reduction in time until reaching the
milestone dates and $533,000 to reflect the reduction of the discount rate to 10% at March&nbsp;31, 2014 from 15% as at December&nbsp;31, 2013, with the probabilities for payments being the same. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of this portion of contingent consideration at December&nbsp;31, 2013 was estimated to be $2,690,000 and was determined by
applying the income approach. The fair value estimates at December&nbsp;31, 2013 were based on a discount rate of 15% and an assumed probability-adjusted payment range between 35% and 70%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(22) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share capital </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Common shares </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Authorized </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue an unlimited number of common shares without par value. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to February&nbsp;14, 2014 private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs related to private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to June&nbsp;26, 2013 private placement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued to ILJIN pursuant to plan of arrangement (note 5(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued on acquisition of Aurinia Pharma Corp. (note 5(b))</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to September&nbsp;20, 2013 private placement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014, the Company completed a $52,000,000 private placement (the Offering). Under the
terms of the Offering, the Company issued 18,919,404 units (the Units) at a subscription price per Unit of $2.7485, each Unit consisting of one common share and one-quarter (0.25) of a common share purchase warrant (a Warrant), exercisable for a
period of five years from the date of issuance at an exercise price of $3.2204. The warrant holder may elect, in lieu of exercising the warrants for cash, a cashless exercise option to receive common shares equal to the fair value of the warrants
based on the number of warrants to be exercised multiplied by a weighted average market price less the exercise price with the difference divided by the weighted average market price. In addition, the Company signed a Registration Rights Agreement
with subscribers to register its common shares with the Securities and Exchange Commission (SEC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(23) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Share issue costs included a 7.5% cash commission of $3,495,000 paid to the placement agents
and filing, legal and escrow fees of $198,000 directly related to the Offering of which $203,000 were allocated to the contingent warrants and expensed in the period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In addition, in the event that the Company would not be able to reduce the size of its Board of Directors to seven directors within 90 days
following closing of the Offering, an additional 0.1 Warrants would be issued for each Unit purchased by a subscriber for every additional 90-day period delay, up to a maximum of 0.35 Warrants per Unit. This represented a maximum of 6,621,791
additional Warrants (Board Warrants). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If the Company did not obtain approval to list its common shares on NASDAQ within 12 months
following the closing of the Offering, the Company agreed to issue an additional 0.1 Warrants for each Unit purchased by a subscriber for every 90-day period delay, up to a maximum of 0.35 Warrants per Unit. This represented a maximum of 6,621,791
additional Warrants (NASDAQ Warrants). All securities issued in connection with the Offering were subject to a four-month hold period from the date of issuance in accordance with applicable securities law, which expired on June&nbsp;15, 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Board Warrants and NASDAQ Warrants were contingently issuable and since the number of warrants to be issued was variable, they met the
definition of financial liabilities under IFRS, which needed to be measured at fair value at each reporting period. As such, the warrant liabilities were recurring fair value measures categorized in Level 3 of the fair value hierarchy. The value of
each warrant was calculated using the Black-Scholes method (with significant assumptions as disclosed in section (b)&nbsp;below) which resulted in an individual warrant value of $2.20. The number of warrants expected to be issued, which is dependent
on the probability of the expected outcomes and timing of those outcomes, was an unobservable input which was initially estimated at February&nbsp;14, 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As there was a degree of uncertainty in achieving the reduction of its Board to seven directors and obtaining a NASDAQ listing, the Company
recorded an initial warrant liability of $2,834,000 related to the contingently issuable warrants. Management used weighted average probability factors of 3% for Board Warrants and 16% for NASDAQ Warrants in determining the contingent settlement
liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;7, 2014, the Company held its Annual General and Special Shareholder Meeting at which the shareholders approved the
composition of the Board at seven directors, therefore extinguishing the Board Warrant liability relating to this condition. As a result, the Company recorded a gain on extinguishment of warrant liability of $438,000 in other expense (income) in the
second quarter ended June&nbsp;30, 2014. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;2, 2014, the Company obtained a listing on the NASDAQ Global Market, therefore
extinguishing the warrant liability relating to the condition of obtaining a NASDAQ listing. As a result the Company recorded a gain on extinguishment of warrant liability of $1,750,000 in other expense (income) in the third quarter ended
September&nbsp;30, 2014. The Company had previously recorded a gain on re-measurement of warrant liability of $646,000 in other expense (income) in the second quarter ended June&nbsp;30, 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2013, the Company closed a Second Unit Offering private placement, raising gross proceeds of $5,777,000 by the issuance
of 2,687,000 units at a price of CA$2.25 per unit. Each unit consisted of one common share and one half of a whole non-transferable Second Offering warrant. Each whole Second Unit warrant is exercisable at CA$2.50 for a period of three years from
the closing date. The fair value attributed to the warrants using the Black-Scholes option pricing model was $1,237,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(24) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company paid a cash commission of $236,000, issued 20,000 Second Offering units at a
deemed value of CA$2.25 per share and 102,067 broker warrants to the agents. The broker warrants are exercisable at a price of CA$2.25 and will expire three years from the closing date. The Company recorded share-based compensation of $43,000 and
$125,000 to the broker units and broker warrants respectively as share issue costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;26, 2013, the Company closed a First Unit
Offering private placement, raising gross proceeds of $996,000 by the issuance of 453,000 units at a price of CA$2.25 per unit. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at CA$2.50 for
a period of five years from the closing date. The issue of the warrants was subject to shareholder approval which was received at the August&nbsp;15, 2013 Special and Annual Shareholder meeting. No fair value was attributed to the warrants until
shareholder approval was received. Upon shareholder approval, the Company recorded an adjustment to attribute $458,000 as the fair value of these warrants. The Company paid a 7% cash commission of $605,000 on the private placement and issued 19,273
broker warrants. The broker warrants are exercisable at a price of CA$2.25 and will expire five years from the closing date. Related to this the Company recorded share-based compensation of $32,000 as a share issue cost and a fair value adjustment
to warrants. In addition the Company incurred legal and other advisory fees of $89,000 to complete the private placement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In order to help
fund its operations in the first half of 2013, the Company received loans in April 2013, from Dr.&nbsp;Richard Glickman, who was a major Aurinia Pharma Corp. shareholder, and ILJIN consisting of the issuance of zero-coupon promissory notes in the
principal amount of $195,500 each for a total of $391,000. Dr.&nbsp;Glickman and ILJIN subscribed for Units in the June&nbsp;26, 2013 private placement in the amount of $199,500 each and the promissory notes were cancelled. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to February&nbsp;14, 2014 private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs allocated to warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to June&nbsp;26, 2013 private placement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued on acquisition of Aurinia Pharma Corp. (note 5)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to September&nbsp;20, 2013 private placement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The warrants issued on acquisition of Aurinia Pharma Corp. are exercisable at CA$2.00 per share until
December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(25) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2008, pursuant to a debt financing, the Company issued 8,028 warrants to
purchase common shares at a price of CA$50.00 per common share. These warrants expire June&nbsp;18, 2015. The fair value attributed to the warrants using the Black-Scholes option pricing model was $172,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company uses the Black-Scholes warrant pricing model to estimate the fair value of the warrants. The following weighted average assumptions
were used to estimate the fair value of the warrants granted during the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annualized volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of warrants in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price on date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per common share warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Expiry date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>(in&nbsp;000s)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted<BR>average<BR>exercise<BR>price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable in CA$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;18, 2015 (CA$50)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;20, 2016 (CA$2.25 and CA$2.50)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;26, 2018 (CA$2.25 and CA$2.50)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2018 (CA$2.00)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable in US$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;14, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock options and compensation expense </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The maximum number of common shares issuable
under the 2012 Option Plan is equal to 10% of the issued and outstanding common shares at the time the common shares are reserved for issuance. As at December&nbsp;31, 2014 there were 31,818,000 common shares of the Company issued and outstanding,
resulting in a maximum of 3,181,800 options available for issuance under the 2012 Stock Option Plan. As at December&nbsp;31, 2014 an aggregate total of 1,376,000 options were outstanding, representing 4.3% of the issued and outstanding common shares
of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Stock Option Plan requires the exercise price of each option to be determined by the Board of Directors and not to be
less than the closing market price of the Company&#146;s stock on the day immediately prior to the date of grant. Any options which expire may be re-granted. The Board approves the vesting criteria and periods at its discretion. The options issued
under the plans are accounted for as equity-settled share-based payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(26) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A summary of the status of the Company&#146;s stock option plans as of December&nbsp;31, 2014
and 2013 and changes during the years ended on those dates is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted<BR>average<BR>exercise<BR>price&nbsp;in<BR>CA$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted<BR>average<BR>exercise<BR>price&nbsp;in<BR>CA$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#150; Beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#150; End of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable &#150; End of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;18, 2014, the Company granted 1,192,200 stock options to certain directors and officers of the
Company at a price of $3.19 (CA$3.50) per common share. The options are exercisable for a term of ten years and vest over specific time periods with the exception of 50,000 options which vested during the year upon the Company achieving a specific
milestone. On November&nbsp;18, 2014 the Company granted 20,000 stock options to a new director of the Company at a price of $3.44 (CA$3.91) per common share. The options are exercisable for a term of five years and vest over twelve months. For the
year ended December&nbsp;31, 2013, the Company did not grant any stock options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Application of the fair value method resulted in charges
to stock-based compensation expense of $2,186,000 for the year ended December&nbsp;31, 2014 (2013 &#150; $230,000) with corresponding credits to contributed surplus. For the year ended December&nbsp;31, 2014, stock compensation expense has been
allocated to research and development expense in the amounts of $nil (2013 &#150; $98,000) and corporate and administration expense in the amounts of $1,933,000 (2013 &#150; $135,000) and restructuring costs in the amount of $253,000 (2013 &#150;
$nil). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted in 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(27) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following weighted average assumptions were used to estimate the fair value of the
options granted during the year ended December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annualized volatility</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options in years</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated forfeiture rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price on date of grant</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per common share option</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company considers historical volatility of its common shares in estimating its future stock price
volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the
contractual term taking into account expected employee exercise and expected post-vesting employment termination behaviour. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following
table summarizes information on stock options outstanding at December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Range&nbsp;of<BR>exercise<BR>prices<BR>CA$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>life&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(28) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nature of expenses </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Study contracts, consulting and other outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wages and employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug supply and distribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent annuity and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent, utilities and other facility costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Government assistance (i)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">The Company has recognized Alberta refundable research and development tax credits for the year ended December&nbsp;31, 2014 in the amount of $38,000 (2013 &#150; $17,000). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Further, the Company had previously signed contribution agreements with National Research Council Canada (NRC) whereby the NRC provided
government assistance in the form of Industrial Research Assistance Program (IRAP) grants to cover specific salaries and contractor fees related to the development of the Company&#146;s Non-Immunosuppressive Cyclosporine Analogue Molecules (NICAMs)
program. The Company recorded funding of $nil for the year ended December&nbsp;31, 2014 (2013 &#150; $167,000) which was recognized as a reduction of research and development expenses. The rights and obligations under these contribution agreements
were transferred to Ciclofilin Pharmaceuticals Corp. upon the divestiture of the NICAMs as discussed in note 17). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wages and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee fees, filing fees and other public company costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel and promotion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent, utilities and other facility costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office, insurance, information technology costs and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(29) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Acquisition and restructuring costs </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance, moving costs and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for loss on sublease agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded restructuring costs related to the shutdown of the Edmonton lab facility in 2014 and the
transfer of the head office and all business operations except for the finance function to Victoria, British Columbia. The finance group also moved to smaller premises during the year. These restructuring costs included moving costs, retention
and/or severance costs and a provision for the estimated loss on the sublease agreement related to the Edmonton lab facility in the amount of $340,000. The remaining $271,000 provision for restructuring costs liability as at December&nbsp;31, 2014
is reflected on the balance sheet as $155,000 in current liabilities and $116,000 as a non-current liability as the term of the sublease extends to September&nbsp;30, 2016. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company recorded restructuring costs related to its divestiture of its early stage NICAMs assets. On February&nbsp;14, 2014,
the Company signed a NICAMs Purchase and Sale Agreement with Ciclofilin Pharmaceuticals Corp. (Ciclofilin), a company controlled by the former Chief Executive Officer and Chief Scientific Officer, whereby it divested its early stage research and
development Non-Immunosuppressive Cyclosporine Analogue Molecules (NICAMs) assets, consisting of intellectual property, including patent applications and know-how to Ciclofilin. There was no upfront consideration received by the Company and future
consideration will consist of milestones relating to the clinical and marketing success of NICAMs and a royalty. Due to NICAMs&#146; early stage of development, the Company estimated the fair value of the consideration to be $nil at the time of the
disposition and as at December&nbsp;31, 2014. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded $216,000 of restructuring costs related to the NICAMs in 2014. These
restructuring costs consisted of severances of $115,000 paid to the three employees working on the NICAMs and $101,000 of other NICAMs related expenses, including wage and patent costs incurred from January&nbsp;1, 2014 to the divestiture date. The
Company also recorded as restructuring costs in 2014, stock compensation expense of $253,000 related to stock options granted in February 2014 to the former Chief Executive Officer and Chief Scientific Officer pursuant to his termination agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded restructuring costs of $1,262,000 for the year ended December&nbsp;31, 2013 which consisted primarily of severance
provisions resulting from personnel changes upon completion of the plan of arrangement on September&nbsp;20, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(30) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other expense (income), net </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on drug supply loan</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on finance lease</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of warrant liability (note 15)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on re-measurement of warrant liability (note 15)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation adjustment on contingent consideration (note 14)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs allocated to warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on disposal of equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on contract settlement with ILJIN (note 5(a))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on acquisition of Aurinia Pharma Corp. (note 5(b))</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on disposal of investment in Aurinia Pharma Corp. (note&nbsp;10)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income taxes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2014, the Company has available Canadian
non-capital losses in the amount of $40,156,000 (2013 &#150; $24,732,000) to reduce Canadian taxable income in future years. The Company has unclaimed investment tax credits of $904,000 (2013 &#150; $675,000) available to reduce future Canadian
income taxes otherwise payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has available US net operating losses in the amount of $41,000 (2013 &#150; $97,000) to reduce
US taxable income in future years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(31) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The losses and credits will expire as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Net&nbsp;operating<BR>losses</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>carried<BR>forward</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-capital</FONT><BR>losses<BR>carried<BR>forward</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Federal<BR>investment<BR>tax credits</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2032</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2033</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2034</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2014 and December&nbsp;31, 2013, temporary differences for which no deferred tax asset
was recognized were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss carry-forwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potential tax assets not recognized</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Given the Company&#146;s past losses, management does not believe that it is more probable than not that the
Company can realize its deferred tax assets and therefore it has not recognized any amount in the statement of financial position. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
difference between the expected income tax recovery based on a 25.0% (2013 &#150; 25.0%) Canadian statutory tax rate and the actual income tax recovery is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected recovery at the statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-deductible expenses including stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-deductible portion of capital gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized deductible temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of substantively enacted rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax recovery</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(32) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Net loss per common share </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share is computed by
dividing net loss by the weighted average number of common shares outstanding for the year. In determining diluted net loss per common share, the weighted average number of common shares outstanding is adjusted for stock options and warrants
eligible for exercise where the average market price of common shares for the year ended December&nbsp;31, 2014 exceeds the exercise price. Common shares that could potentially dilute basic net loss per common share in the future that could be
issued from the exercise of stock options and warrants were not included in the computation of the diluted loss per common share for the years ended December&nbsp;31, 2014 and December&nbsp;31, 2013 because to do so would be anti-dilutive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The numerator and denominator used in the calculation of historical basic and diluted net loss amounts per common share are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR></B>(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share (expressed in $ per share)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The outstanding number and type of securities that would potentially dilute basic loss per common share in the
future and which were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive) for the years presented, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(33) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Segment disclosures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s operations comprise a single reporting segment
engaged in the research, development and commercialization of therapeutic drugs. As the operations comprise a single reporting segment, amounts disclosed in the financial statements represent those of the single reporting unit. In addition, all of
the Company&#146;s long-lived assets are located in Canada. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following geographic information reflects revenue based on customer
location. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Geographic information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Supplementary cash flow information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Net change in other operating assets and
liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug supply loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(34) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related parties </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Compensation of key management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Key management includes Directors and Officers of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Compensation awarded to key management was composed of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(restated&nbsp;&#150;<BR>note 3(a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses accrued or paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded $34,350 of legal fees for the period June&nbsp;16, 2014 to December&nbsp;31, 2014 in the
normal course of business to the law firm of which a partner is the Company&#146;s corporate secretary. The partner became the Company&#146;s corporate secretary on June&nbsp;16, 2014. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement, effective
June&nbsp;1, 2014, to sublease 4,418 square feet of office and storage space at its head office location in Victoria, British Columbia. The sublease is for a term of five years, with the Company having the right to terminate after the third year at
no cost. Therefore the estimated base rent plus operating costs on a monthly basis for the three-year period is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">June&nbsp;1, 2014 to May&nbsp;31, 2015 - $9,000 per month </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">June&nbsp;1, 2015 to May&nbsp;31, 2016 - $9,000 per month </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">June&nbsp;1, 2016 to May&nbsp;31, 2017 - $10,000 per month </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an
agreement on November&nbsp;14, 2014 to lease 1,247 square feet of office space for the Edmonton, Alberta registered office where the Company&#146;s finance group is located. The lease is for a term of two years commencing on January&nbsp;1, 2015 at
a cost of approximately $1,500 per month. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company also entered into a one year agreement to rent an office in a shared office facility
in Bellevue, Washington commencing November&nbsp;1, 2014 at a cost of approximately $2,000 per month. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(35) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, the Company reduced its leased lab premises cost in Edmonton,
Alberta by entering into a three-year sublease with the head lessee for approximately 9,000 square feet while vacating the remaining 16,318 square feet it had previously been leasing. The Sublease cost is approximately $19,000 monthly and includes
base rent, utilities and operating costs. The Company has paid the head lessee a deposit of $145,000 for the last 7.4 months of rent, which has not been deducted from operating lease obligation figures below. The Company in turn, effective
October&nbsp;15, 2014 has subleased out this 9,000 square feet space for approximately $7,000 per month for the remaining term of the sublease, which runs until September&nbsp;30, 2016. This sublease revenue has not been netted in the operating
lease obligations noted above (see note 17 &#150; provision for loss on sublease). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into contractual obligations
for services and materials required for the Phase IIb clinical trial and other operational activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments for
its premises and the minimum amount to exit the Company&#146;s contractual commitments are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Operating<BR>lease</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Purchase<BR>obligations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company sub-leased certain laboratory and office space in its premises and received sublease payments of
$124,000 for the year ended December&nbsp;31, 2014 (2013 &#150; $138,000) which has been netted against gross rent expense of $405,000 ($2013 &#150; $408,000). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contingencies </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes that the ultimate
resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">The Company entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these indemnification agreements is unlimited. However, the Company
does maintain liability insurance to limit the exposure of the Company </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(36) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into license and research and development agreements with third parties that include indemnification and obligation provisions that are customary in the industry. These guarantees generally
require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature
of the obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any payments under such agreements and no amount has been accrued in the
accompanying consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Capital management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective in managing capital is to ensure a
sufficient liquidity position to safeguard the Company&#146;s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company defines capital as net equity, comprised of issued common shares, warrants, contributed surplus and deficit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective with respect to its capital management is to ensure that it has sufficient cash resources to maintain its ongoing
operations and finance its research and development activities, corporate and administration expenses, working capital and overall capital expenditures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has primarily financed its liquidity needs through public offerings and private placements of common shares. The
Company has also met its liquidity needs through non-dilutive sources, such as debt financings, licensing fees from its partners and research and development fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There have been no changes to the Company&#146;s objectives and what it manages as capital since the prior fiscal year. The Company is not
subject to externally imposed capital requirements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>26</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments and fair values </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As explained in note 3, financial assets and
liabilities have been classified into categories that determine their basis of measurement and for items measured at fair value, whether changes in fair value are recognized in the statement of operations and comprehensive loss. Those categories are
fair value through profit or loss; loans and receivables; and, for most liabilities, amortized cost. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In establishing fair value, the
Company used a fair value hierarchy based on levels defined below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1: defined as observable inputs such as quoted prices in active markets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(37) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has determined that the carrying values of its short-term financial assets and
liabilities, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, drug supply payable, and financing milestones payable to ILJIN (note 14) approximate their fair value because of the relatively short
period to maturity of the instruments. Information on the fair value of long-term contingent consideration is included in note 14 and information on the fair value of investments is included in note 10. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Financial risk factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities can expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and other
price risk), credit risk and liquidity risk. Risk management is carried out by management under policies approved by the Board of Directors. Management identifies and evaluates the financial risks. The Company&#146;s overall risk management program
seeks to minimize adverse effects on the Company&#146;s financial performance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Liquidity risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk that the Company will not be able to meet its
financial obligations as they fall due. The Company manages its liquidity risk through the management of its capital structure and financial leverage as discussed in note 25. It also manages liquidity risk by continuously monitoring actual and
projected cash flows. The Board of Directors reviews and approves the Company&#146;s budget, as well as any material transactions out of the ordinary course of business. The Company invests its cash equivalents in bankers&#146; acceptances and/or
guaranteed investment certificates with 30 to 90 day maturities to ensure the Company&#146;s liquidity needs are met. The short-term investment consists of a discount bank note with a term of 180 days. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities have been financed through a combination of the cash flows from licensing and development fees and the issuance
of equity and/or debt. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s financial liabilities are due within one year except for the contingent consideration as
described in note 14. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest rate risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Interest rate risk is the risk that the fair value or future cash flows of
a financial instrument will fluctuate because of changes in market interest rates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Financial assets and financial liabilities with
variable interest rates expose the Company to cash flow interest rate risk. The Company&#146;s cash and cash equivalents are comprised of highly liquid investments that earn interest at market rates. Accounts receivable, accounts payable and accrued
liabilities bear no interest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company manages its interest rate risk by maximizing the interest income earned on excess funds while
maintaining the liquidity necessary to conduct operations on a day-to-day basis. The Company&#146;s policy limits the investing of excess funds to liquid guaranteed investment certificates and bankers&#146; acceptances. The Company&#146;s exposure
to interest rate risk at December&nbsp;31, 2014 is considered minimal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(38) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Foreign currency risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company is exposed to financial risk related to the fluctuation of
foreign currency exchange rates. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company&#146;s operating and financial
results. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s exposure to the Canadian dollar: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net exposure</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Reporting<BR>date rate<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CA$ &#150; US$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Based on the Company&#146;s foreign currency exposures noted above, varying the foreign exchange rates to
reflect a ten percent strengthening of the Canadian dollar would have increased the net loss by $66,000 assuming that all other variables remained constant. An assumed 10% weakening of the Canadian dollar would have had an equal but opposite effect
to the amounts shown above, on the basis that all other variables remain constant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following table presents, in Canadian dollars, the
Company&#146;s exposure to the US dollar for 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net exposure</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Reporting<BR>date rate<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$ &#150; CA$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(39) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2014
and 2013 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Based on the Company&#146;s foreign currency exposures noted above, varying the foreign
exchange rates to reflect a ten percent strengthening of the Canadian dollar would have decreased the net loss by CA$497,000, assuming that all other variables remained constant. An assumed ten percent weakening of the Canadian dollar would have had
an equal but opposite effect to the amounts shown above, on the basis that all other variables remain constant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Credit risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant
concentrations of credit risk consist principally of cash and cash equivalents. The Company&#146;s cash and cash equivalents were held at a major Canadian bank. The Company regularly monitors the credit risk exposure and takes steps to mitigate the
likelihood of these exposures resulting in actual loss. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>27</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent event </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock option grant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2015, the Company granted 960,000 stock options to directors, officers and employees of the Company at a price of CA$4.25
(US$3.61) per common share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock option and warrant exercise </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subsequent to year-end, the Company issued 143,000 common shares upon the exercise of 143,000 warrants for proceeds of CA$343,000 and issued
25,000 common shares upon the exercise of 25,000 stock options for proceeds of CA$87,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(40) </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d891272dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g891272ex2.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER 31, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following Management&#146;s Discussion and Analysis of Financial Condition or MD&amp;A and Results of Operations provides information on the activities
of Aurinia Pharmaceuticals Inc. (&#147;Aurinia&#148; or the &#147;Company&#148;) on a consolidated basis and should be read in conjunction with the Company&#146;s audited consolidated financial statements and accompanying notes for the year ended
December&nbsp;31, 2014. This MD&amp;A has been prepared with reference to National Instrument 51-102&#147;Continuous Disclosure Obligations&#148; of the Canadian Securities Administrators. All amounts are expressed in United States dollars unless
otherwise stated. Dollar amounts in tabular columns expressed in thousands of United States dollars. This document is current in all material respects as of March&nbsp;26, 2015. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial information contained in this MD&amp;A and in the Company&#146;s consolidated financial statements have been prepared in accordance with
International Financial Reporting Standards or IFRS as issued by the International Accounting Standards Board or IASB. The audited consolidated financial statements and MD&amp;A have been reviewed by the Company&#146;s Audit Committee and approved
by the Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement is forward-looking when it uses what we know and expect today to make a statement about the future. Forward-looking statements may include words
such as &#147;<I>anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;goal&#148;, &#147;may&#148;, &#147;outlook&#148;, &#147;plan&#148;, &#147;seek&#148;, &#147;should&#148;, &#147;strive&#148;, &#147;target&#148;,
&#147;could&#148;, &#147;continue&#148;, &#147;potential&#148; </I>and <I>&#147;estimated&#148;</I>, or the negative of such terms or comparable terminology. You should not place undue reliance on the forward-looking statements, particularly those
concerning anticipated events relating to the development, clinical trials, regulatory approval, and marketing of the Company&#146;s products and the timing or magnitude of those events, as they are inherently risky and uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities laws encourage companies to disclose forward-looking information so that investors can get a better understanding of the Company&#146;s future
prospects and make informed investment decisions. These statements may include, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund the Company&#146;s operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials, plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of completion of patient enrollment in the Company&#146;s AURA-LV and AURION studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek additional corporate alliances to support the commercialization of its products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation with first-in-class status for the treatment of LN outside
of Japan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to use the LN Phase 2b clinical trial program to gain a clearer understanding of voclosporin&#146;s time to onset of action in patients suffering from LN; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements are forward-looking because they are based on current expectations, estimates and assumptions.
It is important to know that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this MD&amp;A and represent the Company&#146;s expectations as of that date.
</I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Forward-looking statements in this MD&amp;A describe the Company&#146;s expectations as of March&nbsp;26, 2015; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Actual results could be materially different from what the Company expects if known or unknown risks affect its business, or if the Company&#146;s estimates or assumptions turn out to be inaccurate. As a
result, the Company cannot guarantee that any forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements; </I></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made may have on the Company&#146;s
business. For example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the forward-looking
statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Accordingly, the expected impact cannot be meaningfully
described in the abstract or presented in the same manner as known risks affecting the Company&#146;s business; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>The Company disclaims any intention and assume no obligation to update any forward-looking statements even if new information becomes available, as a result of future events or for any other reason.
</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company&#146;s
actual results, performance, or achievements to differ materially from any further results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause such differences include, among other
things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The need for additional capital in the longer term to fund the Company&#146;s development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays, or failures the Company may experience in the conduct of and reporting of results of its clinical trials for voclosporin, and in particular its current LN Phase 2b clinical trial.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties the Company may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties, delays, or failures in obtaining appropriate reimbursement of voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Difficulties that the Company may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of its products. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results,
levels of activity, performance or achievements. The forward-looking statements are made as of the date hereof and the Company disclaims any intention and have no obligation or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For additional information on risks and uncertainties
please see the &#147;Risks and Uncertainties&#148; section of this MD&amp;A. Although the Company believes that the expectations reflected in such forward-looking statements and information are reasonable, undue reliance should not be placed on
forward-looking statements or information because the Company can give no assurance that such expectations will prove to be correct. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional
information related to Aurinia, including its most recent Annual Information Form, is available by accessing the Canadian Securities Administrators&#146; System for Electronic Document Analysis and Retrieval (&#147;SEDAR&#148;) website at
<U>www.sedar.com </U>or the U.S. Securities and Exchange Commission&#146;s (&#147;SEC&#148;) Electronic Document Gathering and Retrieval System (&#147;EDGAR&#148;) website at <U>www.sec.gov/edgar</U>. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OVERVIEW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Structure
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Name, Address and Incorporation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia
Pharmaceuticals Inc. or the &#147;Company&#148; is a biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company
are conducted. The Company has its registered office located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. The office of the Chief Executive Officer is located in Bellevue, Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. is organized under the <I>Business Corporations Act </I>(Alberta). The Company&#146;s Common Shares are currently listed and
traded on the NASDAQ Global Market (&#147;NASDAQ&#148;) under the symbol &#147;AUPH&#148; and on the Toronto Stock Exchange (&#147;TSX&#148;) under the symbol &#147;AUP&#148;. The Company&#146;s primary business is the development of a therapeutic
drug to treat autoimmune diseases, in particular lupus nephritis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following wholly-owned subsidiaries: Aurinia Pharma Corp. (formerly
private Aurinia Pharmaceuticals Inc.), Aurinia Pharmaceuticals, Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary
Description of Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, which is a
next generation calcineurin inhibitor (&#147;CNI&#148;). It has been studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an ophthalmic disease). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has rebranded, restructured and refocused itself over the past year and modified its strategy to focus on the development of voclosporin for the
treatment of lupus nephritis (&#147;LN&#148;). The mechanism of action of voclosporin, a CNI, has been validated with certain first generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several
autoimmune indications, including dermatitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. The Company believes that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class
differentiation with first-in-class regulatory approved status for the treatment of LN outside of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>LN Clinical development program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June, 2014, AURINIA announced the initiation of its global 258 patient LN Phase 2b clinical trial to evaluate the efficacy of voclosporin as a
treatment for LN. LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The LN Phase 2b clinical trial, called &#147;<B>AURA&#150;LV&#148;</B> (Aurinia Urine protein Reduction in Active Lupus with voclosporin) or AURA, is being
conducted in approximately 22 countries and is a randomized, controlled, double-blind study comparing the efficacy of voclosporin against placebo in achieving remission in patients with active LN. The AURA-LV study is designed to demonstrate that
voclosporin can induce a rapid and sustained reduction of proteinuria in the presence of extremely low steroid exposure and fulfill specific regulatory requests. It will compare two dosage groups of voclosporin (23.7mg and 39.5mg) administered with
mycophenolate mofetil (MMF) vs. MMF alone. All patients will also receive oral corticosteroids as background therapy. There will be a primary analysis to determine complete remission at week 24 and various secondary analyses at week 48 which include
biomarkers and markers of non-renal SLE. Patient recruitment is scheduled for completion in the third quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In support of this large,
randomized, LN Phase 2b clinical trial, the Company announced on February&nbsp;9, 2015, the initiation of an open label, exploratory study to assess short term predictors of response using voclosporin in combination with MMF, in patients with active
LN. &#147;<B>AURION&#148;</B> (Aurinia early Urinary protein Reduction Predicts Response) will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks. Patient enrollment of this small pilot study
is scheduled to be completed by the end of the third quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from the AURION will contribute to the growing base of clinical data
derived from the entire ongoing LN Phase 2b clinical trial program. A more clear understanding of voclosporin&#146;s time to onset of action in patients suffering from LN may be gained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE DEVELOPMENTS IN 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on NASDAQ &#150; September&nbsp;2, 2014 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company received approval from the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ Global Market and commenced trading on September&nbsp;2, 2014 under the trading symbol &#147;AUPH&#148;. The common shares of the
Company also trade on the TSX under the trading symbol &#147;AUP&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement Financing &#150; February&nbsp;14, 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014 the Company completed a $52 million private placement (the &#147;Offering&#148;). The proceeds from the Offering are being used for
the LN Phase 2b clinical trial currently underway, general corporate and working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing was led by venBio, New Enterprise
Associates, Redmile Group, RA Capital Management, Great Point Partners, and Apple Tree Partners, with participation from various other institutional investors, including existing shareholders Lumira Capital, ILJIN Life Science Co., Ltd. and
Difference Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Offering, the Company issued 18.92&nbsp;million units (the &#147;Units&#148;) at a subscription price per Unit
of $2.7485, each Unit consisting of one common share and one-quarter (0.25) of a common share purchase warrant (a &#147;Warrant&#148;), exercisable for a period of five years from the date of issuance at an exercise price of $3.2204. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the event that the Company did not reduce the size of its Board of Directors to seven directors within 90 days following closing of the
Offering, an additional 0.1 Warrants would have been issued for each Unit purchased by a subscriber for every additional 90-day period delay, up to a maximum of 0.35 Warrants per Unit. This represented a maximum of 6.62&nbsp;million additional
Warrants. If the Company did not obtain approval to list its common shares on NASDAQ within 12 months following the closing of the Offering, the Company had agreed to issue an additional 0.1 Warrants for each Unit purchased by a subscriber for every
90-day period delay, up to a maximum of 0.35 Warrants per Unit. This represented a maximum of 6.62&nbsp;million additional Warrants. The Company reduced the Board to seven directors and obtained a NASDAQ listing within the required time limits and
therefore the Company has extinguished these contingent warrant liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All securities issued in connection with the Offering were subject to a
four-month hold period from the date of issuance in accordance with applicable securities law, which expired on June&nbsp;15, 2014 for the securities issued at closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC acted as lead placement agent and Canaccord Genuity Corp. acted as co-placement agent for the Offering. The placement agents were paid a
7.5% cash commission of $3.49 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functional currency and change in presentation currency &#150; January&nbsp;31, 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;31, 2014, the Company changed its functional currency from the Canadian dollar (&#147;CDN$&#148;) to the United States dollar
(&#147;US$&#148;). The change in functional currency, which has been accounted for prospectively, better reflects the Company&#146;s current business activities which are primarily denominated in US$ and to improve investors&#146; ability to compare
the Company&#146;s financial results with other publicly traded entities in the biotechnology industry. In addition, the Company changed its presentation currency to US$ and followed the guidance in IAS21-<I>The Effects of Changes in Foreign
Exchange Rates.</I> Accordingly, the Company has applied the change retrospectively as if the new presentation currency had always been the Company&#146;s presentation currency. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STRATEGY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s business
strategy is to optimize the clinical and commercial value of voclosporin, its late stage clinical candidate. In particular, the Company is focused on the development of voclosporin as an add-on therapy to the current standard of care, CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which was developed by the Aurinia Pharma Corp. management team during its tenure at Aspreva Pharmaceuticals Inc.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key elements of the Company&#146;s corporate strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Focusing the Company&#146;s resources on advancing voclosporin through a robust LN Phase 2b clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mitigate development risk by leveraging the ALMS database and management team&#146;s experience &#150; The Company has certain rights to utilize the ALMS database including its use in planning, designing and informing
the LN Phase 2b clinical trial.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate other voclosporin indications &#150; While the Company intends to deploy its operational and financial resources to develop voclosporin for LN, the Company believes that recent granted formulation patents
regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value. The Company will explore its strategic options to exploit shareholder value from this intellectual property.
The Company also believes that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection. Management will consider strategic opportunities for these other potential
indications on an ongoing basis. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Status of the Company&#146;s Development Program in LN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s clinical strategy involves layering voclosporin on top of the current standard of care
(CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF and steroids) as multi-targeted therapeutic (&#147;MTT&#148;) to induce and maintain remission in patients suffering from active LN. In 2012, the Company gained alignment with
both the Cardio-Renal and Pulmonary, Allergy, and Rheumatology Products divisions of the FDA on its proposed Phase 2b protocol. The Company has an active Investigational New Drug (&#147;IND&#148;) application and is currently recruiting patients for
the LN Phase 2b clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the existing evidence that supports the utility of CNIs in combination with MMF in treating LN, the robust safety
data base of voclosporin and the fact that CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF in combination with the other CNIs is the standard of care in transplant, it is reasonable to consider that voclosporin is a
risk-mitigated clinical asset for the treatment of LN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lupus Nephritis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lupus Foundation of America (&#147;LFA&#148;) estimates that approximately 1.5&nbsp;million people in the United States of America and up to
5.0&nbsp;million people worldwide suffer from systemic lupus erythematosus (&#147;SLE&#148;). Approximately 90% of patients suffering from SLE are women of child-bearing age. The disease causes severe impairments on quality of life and wellbeing. Of
the patients suffering from SLE, 40-60% experience renal manifestations of the disease resulting in inflammation of the kidney. These patients are considered to have LN and have a high probability of advancing to end stage renal disease and dialysis
if left untreated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the work performed by the former Aspreva team, the ALMS data has been reported in several respected journals, including, the
New England Journal of Medicine (<I>Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Solomons, N et al; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov
17;365(20):1886-95</I>) and the Journal of the American Society of Nephrology <I>(Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N et al; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus
cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103-12. Epub 2009 Apr 15.) </I>These publications and subsequent alterations in treatment strategies by physicians caring for patients suffering from LN
have established CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF as the standard of care for the treatment of LN. This shift in the treatment paradigm for LN and the establishment of CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> use as a relatively uniform treatment approach for these patients has, in the view of the Company, caused the LN market to evolve into an attractive and mature market opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> being the current standard of care for the treatment of LN, it remains far from
adequate with fewer than 20% of patients on therapy actually achieving disease remission after six months of therapy. Data suggests that a LN patient who does not achieve rapid disease remission upon treatment is more likely to experience renal
failure or require dialysis at 10 years <I>(Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; the Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46-53</I>.). Therefore,
it is critically important to achieve disease remission as quickly and as effectively as possible. The data suggests that the majority of patients in the United States suffering from lupus will not achieve complete remission and are not adequately
treated (BioTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Research Group In., ChartTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE, December 2010). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CNIs and Lupus Nephritis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia&#146;s lead drug,
voclosporin, belongs to a class of drugs called CNIs. There are only two other oral marketed CNIs available, cyclosporine and tacrolimus. Cyclosporine was introduced to the marketplace in the early 1980s while tacrolimus was first marketed in the
mid-1990s. Both cyclosporine and tacrolimus have lost key patent protection and have not been approved for the treatment of LN outside of Japan. For the past 20 years these products, in combination with CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF and steroids have been the cornerstone for the prevention of renal transplant rejection with greater than 90% of all renal transplant patients leaving hospital on lifelong CNI plus MMF
therapy (UNOS database). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2008, the Japanese Health Authority became the first major jurisdiction in 50 years to approve a pharmaceutical agent for the
treatment of LN. This product was the calcineurin inhibitor tacrolimus. In addition to this approval, a substantial amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recent data has been generated, primarily from investigator initiated trials, that support the use of either cyclosporine or tacrolimus for the treatment of various forms of lupus including LN.
The addition of tacrolimus, layered on top of MMF and steroids akin to the widely accepted and utilized transplantation regimen, appears to dramatically improve complete response/remission rates in LN (<I>Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li
LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct;19(10):2001-10. Epub 2008 Jul 2 and .Liu , Zhi-Hong et al., 2012 ASN Abstract SA-OR097)</I>. This approach to treatment can be considered a
MTT approach to treating LN as is routinely used in transplantation. Complete remission rates of up to 50% have been reported utilizing this approach. Long term follow-up studies in LN suggest that the early reduction in proteinuria as seen in
complete remission leads to improved renal outcome at ten years. <I>(Houssiau FA, Vasconcelos C, D&#146;Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus
nephritis. Lessons from long-term followup of patients in the Euro-lupus nephritis trial. Arthritis Rheum. 2004 Dec;50(12):3934-40).</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
plans to utilize this MTT approach to treating LN patients with voclosporin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About voclosporin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (&#147;CsA&#148;), but is chemically modified on the amino
acid-1 residue. This modification leads to a number of advantages the Company believes offer relevant clinical benefits as compared to the older off-patent CNIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voclosporin mechanism of action </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Voclosporin
reversibly inhibits immunocompetent lymphocytes, particularly T-Lymphocytes in the G0 and G1 phase of the cell-cycle, and also reversibly inhibits the production and release of lymphokines. Through a number of processes voclosporin inhibits and
prevents the activation of various transcription factors necessary for the induction of cytokine genes during T-cell activation. It is believed that the inhibition of activation of T-cells will have a positive modulatory effect in the treatment of
LN. In addition to these immunologic impacts recent data suggests that CNIs have another subtle but important impact on the structural integrity of the podocytes<B></B><I> (Faul C,&nbsp;et al. The actin cytoskeleton of kidney podocytes is a direct
target of the antiproteinuric effect of cyclosporine A. Nat Med.&nbsp;2008 Sep;14(9):931-8. doi: 10.1038/nm.1857).</I><B></B> This data suggests that inhibition of calcineurin in patients with autoimmune kidney diseases helps stabilize the cellular
actin-cytoskeleton of the podocytes thus having a structural impact on the podocyte and the subsequent leakage of protein into the urine, which is a key marker of patients suffering from LN.<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential voclosporin clinical benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
believes that voclosporin has shown a number of key clinical benefits over the existing commercially available CNIs (tacrolimus&nbsp;&amp; cyclosporine). Firstly, CNI assay results have indicated that voclosporin is approximately four times more
potent than its parent molecule cyclosporine, which would indicate an ability to give less drug and produce fewer potentially harmful metabolites. Secondly, cyclosporine inhibits the enterohepatic recirculation of mycophenolic acid
(&#147;MPA&#148;), the active metabolite of MMF. The net effect of co-administration of CsA with MMF is reduced MPA systemic exposure by as much as 50% (<I>D. Cattaneo et al. American Journal of Transplantation, 2005:12(5);2937-2944.</I>). This drug
interaction has not been observed with voclosporin and it is not expected that MPA blood exposure levels will be reduced with voclosporin co-administration. This is an extremely important fact to consider as most patients being treated with
voclosporin for LN will already be taking MMF. Furthermore, pharmacokinetic and pharmacodynamics (&#147;PK-PD&#148;) analysis indicate lower PK-PD variability for voclosporin versus tacrolimus or cyclosporine, to the extent that the Company believes
flat-dosing can be achieved for voclosporin. The currently available CNIs require extensive therapeutic drug monitoring which can often be costly, confusing and time consuming for treating physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a head-to-head study comparing voclosporin against cyclosporine in the treatment of psoriasis, cyclosporine was shown to cause significant increases in
lipid levels as compared to voclosporin. The difference was statistically significant. This is important considering the fact that most lupus patients die of cardiovascular disease. In another study comparing voclosporin against tacrolimus in
patients undergoing renal transplantation, the voclosporin group experienced a statistically significantly lower incidence of glucose intolerance and diabetes than tacrolimus treated patients. Additionally, in the Japanese tacrolimus study that led
to the approval of this drug in Japan, almost 15% of tacrolimus patients experienced glucose intolerance <I>(Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter
study. Mod Rheumatol. 2009;19(6):606-15. Epub 2009 Aug 18</I>). This is a major limitation for physicians wanting to use this agent in lupus and is a well described side effect of tacrolimus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that voclosporin can be differentiated from the older CNIs and thus possess a unique position with the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voclosporin development history </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More than 2,600 patients have been in voclosporin clinical trials including studies where voclosporin was compared to placebo or active control. The safety and
tolerability profile of the drug therefore is well characterized. Phase 2 or later clinical studies that have been completed include studies in the following indications: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Psoriasis:</B> To date, two Phase 3 studies in patients with moderate to severe psoriasis have been completed. The primary efficacy endpoint in both
studies was a reduction in Psoriasis Area and Severity Index (&#147;PASI&#148;), which is a common measure of psoriasis disease severity. The first study treatment with voclosporin resulted in statistically significantly greater success rates than
treatment with placebo by the twelfth week. In a second study comparing voclosporin against cyclosporine, the drug was not shown to be statistically non-inferior to cyclosporine in terms of efficacy; however voclosporin proved superior in terms of
limiting elevations in hyperlipidemia. Due to the evolving psoriasis market dynamics and the changing standard of care for the treatment of this disease the Company has decided not to pursue further Phase 3 development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Renal Transplantation:</B> A Phase 2b clinical trial in de novo renal transplant recipients was completed. Study ISA05-01, the PROMISE Study <I>(Busque S,
Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, et al; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011
Dec;11(12):2675-84</I>) was a six month study with a six month extension comparing voclosporin directly against tacrolimus on a background of MMF and corticosteroids. Voclosporin was shown to be equivalent in efficacy, but superior to tacrolimus
with respect to the incidence of new onset diabetes after transplantation (&#147;NODAT&#148;). In 2010, tacrolimus lost its exclusivity in most world markets and as a result, the competitive pricing environment for voclosporin for this indication
has come into question. Additionally, the more expensive development timelines for this indication has made it a less attractive business proposition as compared to the LN indication, even when considering the fact that a Special Protocol Assessment
has been agreed to by the FDA for this indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Uveitis:</B> Multiple studies in various forms of non-infectious uveitis have been completed over
the past several years by a licensee of the Company indicating mixed efficacy. In all but one of the studies, completed by the licensee, an impact on disease activity was shown in the voclosporin group. However achievement of the primary end-points
in multiple studies could not be shown. Uveitis is a notoriously difficult disease to study due to the heterogeneity of the patient population and the lack of validated clinical end-points. However in all of the uveitis studies completed, the safety
results were consistent and the drug was well tolerated as expected. The Company has now successfully terminated its Distribution&nbsp;&amp; License Agreement (&#147;DLA&#148;) with Lux BioSciences, Inc. (&#147;Lux&#148;). In conjunction with this
termination the Company has retained a portfolio of additional patents that Lux had been prosecuting that are focused on delivering effective concentrations of voclosporin to various ocular tissues. The Company will continue to evaluate these
patents and make strategic recommendations on how they fit into the ongoing strategic directives of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Rationale for Treatment of
LN with voclosporin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SLE including LN is a heterogeneous autoimmune disease with often multiple organ and immune system involvement. T-cell mediated
immune response is an important feature of the pathogenesis of LN while the podocyte injury that occurs in conjunction with the ongoing immune insult in the kidney is an important factor in the clinical presentation of the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of voclosporin in combination with the current standard of care for the treatment of LN provides a multi-targeted approach to treating this
heterogenous disease (similar to the standard approach in preventing kidney transplant rejection). Voclosporin has shown to have potent effects on T-cell activation leading to its immunomodulatory effects. Additionally, recent evidence suggests that
inhibition of calcineurin has direct physical impacts on the podocytes within the kidney. Inhibition of calcineurin within the podocytes can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin
cytoskeletion within the podocyte. This process is expected to have a direct impact on the levels of protein in the urine which is a key marker of LN disease activity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Current Collaboration Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paladin Labs Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2009, the Company
completed a plan of arrangement transaction with Paladin Labs Inc. (&#147;Paladin&#148;). Paladin has the rights to market, sell, and distribute voclosporin in the Paladin territories which include Canada, South Africa and Israel and is required to
make payments to the Company equal to: (i)&nbsp;20% of net sales, in the Paladin territories, less manufacturing costs until June&nbsp;18, 2016; and (ii)&nbsp;20% of net royalties received from third party sales, in the Paladin territories until
June&nbsp;18, 2016. In addition, Paladin will receive 2% of any milestone payments, development payments, royalties, and net profit splits paid to the Company, related to voclosporin outside the Paladin territories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3SBio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>, 2010, the Company and 3SBio Inc. (&#147;3SBio&#148;), a China-based biotechnology
company focused on researching, developing, manufacturing and marketing biopharmaceutical products, completed a Development and License Agreement (&#147;DDL&#148;) for voclosporin. Under the terms of the agreement the Company granted 3SBio exclusive
rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong, Taiwan, excluding ophthalmic indications which were previously licensed to Lux. 3SBio will be responsible, including costs, for the clinical
development, registration and commercialization of voclosporin in China. The Company will also receive ongoing royalties based on sales of voclosporin by 3SBio. The Company will also supply commercial supply to 3SBio on a cost-plus basis. 3SBio is
in the process of determining how to proceed with the development of voclosporin in this territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan of arrangement and acquisition of Aurinia
Pharma Corp. -September&nbsp;20, 2013 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2013, the Company announced that it had signed a binding term sheet (the Term Sheet) with
Aurinia Pharma Corp. for the merger of the two companies, creating a clinical development stage pharmaceutical company focused on the global nephrology market. The Term Sheet set forth the main criteria to be incorporated into a definitive merger
agreement under which the Company would acquire 100% of the outstanding securities of Aurinia Pharma Corp. The merger was expected to be effected by the exchange of shares in the Company for securities of Aurinia Pharma Corp. resulting in an
estimated 65:35 post merger ownership split, on a warrant diluted basis, between the Company and Aurinia Pharma Corp. shareholders, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;3, 2013, the Company and Aurinia Pharma Corp. negotiated a tripartite settlement agreement (the Settlement Agreement) with ILJIN Life Science Co., Ltd. (ILJIN) pursuant to which, upon the successful completion of the proposed merger, the
combined company would re-acquire the license previously granted to ILJIN and therefore obtain full rights to voclosporin for autoimmune indications including lupus, and transplantation in the United States, Europe and other regions of the world,
outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. In return, ILJIN would be entitled to receive certain predefined future milestone payments and would also own approximately 25% of the issued and outstanding shares of the merged
company on a warrant diluted basis, which was calculated to give effect to the dilution by the exercise of warrants but excluding the exercise of stock options. On June&nbsp;11, 2013, a draft arrangement agreement was prepared implementing the
arrangement (the Arrangement Agreement), the terms of which were subsequently negotiated by the parties. The Arrangement was intended to implement the terms of the Settlement Agreement, whereby ILJIN would receive a further ownership interest in the
Company in exchange for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">returning to the Company and terminating: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">all of its rights, licenses and obligations under the ILJIN Development, Distribution&nbsp;&amp; License Agreement (see note 13b to the audited consolidated financial statements for the year ended December 311 2014);
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">all other licenses and sublicenses between ILJIN and any of the Company, Aurinia Pharma Corp. or Vifor (International) AG (Vifor); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">suspending all of its current or contemplated legal or financial claims against the Company, Aurinia Pharma Corp. or Vifor. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon closing of the plan of arrangement on September&nbsp;20, 2013, the Company issued common shares to ILJIN. In addition ILJIN is entitled to receive
certain predefined future success based clinical and marketing milestone payments in the aggregate amount of up to $10 million, plus up to $1.60 million upon the merged company reaching certain financing milestones (see note 14 to the audited
consolidated financial statements ended December&nbsp;31, 2014). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also acquired all of the issued and outstanding common shares of Aurinia
Pharma Corp. at a ratio of approximately 19.83 common shares for each Aurinia Pharma Corp. share held by an Aurinia Pharma Corp. shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Settlement with ILJIN </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the
contract settlement with ILJIN at September&nbsp;20, 2013 was $8.40 million and has been determined to represent reacquired license rights in the amount of $4.14 million and a loss on contract settlement of $4.27 million. Consideration paid or
payable to ILJIN is as follows: the Company&#146;s 10% interest in Aurinia Pharma Corp. of $670,000, $3.67 million in common shares $2.69 million in financial milestones payable and $1.6 million in clinical and sales milestones payable based on the
estimated fair value of the pre-defined future milestone payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s tripartite settlement agreement with Aurinia Pharma Corp. and ILJIN
resulted in the recognition of a loss on contract settlement with ILJIN of $4.27 million. This is the result of a value allocated to the intangible property rights being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reacquired from ILJIN as a result of the settlement. The value of these rights was determined using a differential income approach; that is, the discounted cash flows that the Company is able to
generate above and beyond what it was entitled to under the original licensing agreement. The cash flows used to determine the value of these rights are derived from the same cash flows used to determine the reacquired right from Aurinia Pharma
Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition of Aurinia Pharma Corp. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company determined that the transaction with Aurinia Pharma Corp. represented a business combination with the Company identified as the acquirer. The Company began consolidation of the operating results, cash flows and net assets of Aurinia Pharma
Corp. on September&nbsp;20, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration provided by the Company for the acquisition of Aurinia Pharma Corp. was 3.68&nbsp;million common shares
of the Company with a fair value of $7.98 million, less $459,000 of deferred revenue that was effectively settled as a result of the business combination. The fair value of the shares issued was determined by the trading price on September&nbsp;20,
2013. The $3.50 million difference between the fair value of net consideration of $7.52 million and the fair value of net assets acquired of $10.73 million is recorded as a gain in other income. Acquisition costs of $251,000 were expensed in 2013.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s acquisition of Aurinia Pharma Corp. resulted in the recognition of a gain of $3.50 million in 2013. This is primarily as a result of
the value allocated to the intangible property rights being reacquired from Aurinia Pharma Corp. as a result of the merger. The value of these rights was determined using a differential income approach; that is, the discounted cash flows that the
Company is able to generate above and beyond what it was entitled to from the Vifor License, determined over the contract life to 2029. The determination of these cash flows is subject to significant estimates and assumptions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount and timing of projected future cash flows, adjusted for the probability of technical and marketing success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount and timing of projected costs to develop voclosporin into a commercially viable treatment for lupus nephritis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The discount rate selected to measure the risks inherent in the future cash flows; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An assessment of voclosporin&#146;s life-cycle and the competitive trends impacting the drug, including consideration of any technical, legal, regulatory, or economic barriers to entry. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2014, the Company reported a consolidated net loss of $16.65 million or $0.57 per common share, as compared to an adjusted consolidated net loss of $2.66 million or $0.42 per common share for the year ended December&nbsp;31, 2013.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activities in 2014 are significantly changed from those in 2013 as the Company completed a private placement on February&nbsp;14, 2014 which provided
funding for the Company to become fully engaged in its LN Phase 2b clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This process has increased the level of activity across all functions
of the Company and as a result the levels of expenditures are significantly higher when compared to the previous year, particularly in the research and development expenditures which are primarily related to the LN Phase 2b clinical trial
activities. As a result, the net loss for the year ended December&nbsp;31, 2014 is significantly higher than the comparable figure in 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue
and deferred revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded revenue of $278,000 for the year ended December&nbsp;31, 2014 compared to $969,000 for the year ended
December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded licensing and research and development revenue of $218,000 for the year ended December&nbsp;31, 2014
compared to $967,000 for the year ended December&nbsp;31, 2013. Licensing and R&amp;D fee revenues represent the amortization of deferred revenue from fee payments received by the Company in prior years. The deferred revenue is recorded as revenue
as the Company incurs the costs related to meeting its obligations under the terms of the applicable agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in revenue in 2014 was
primarily the result of the Company recording the unamortized deferred revenue balance of $698,000 related to the Lux DLA in 2013. In December, 2013 the Company received notice from Lux, that it would be ceasing operations and returning the license
to the Company. As a result, at December&nbsp;31, 2013 the Company determined it had no further obligations pursuant to the Lux DLA and therefore recorded the remaining balance of deferred revenue associated with the Lux DLA as licensing income. The
deferred revenue from the Aurinia Pharma Corp. license payment was amortized into revenue up to September&nbsp;20, 2013 until the completion of the plan of arrangement with Aurinia Pharma Corp and ILJIN on September&nbsp;20, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remaining deferred revenue relates to the 3SBio and Paladin fee payments and is being amortized on a straight
line basis over the life of the agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net research and development expenditures increased to $9.11 million for the year ended December&nbsp;31, 2014 compared to $1.99 million for the year ended
December&nbsp;31, 2013. The expenditures in 2014 reflect costs related to patient recruitment, enrollment and treatment activities for the LN Phase 2b clinical trial. These activities included site selections and initiations, site contract
approvals, Contract Research Organization (&#147;CRO&#148;) contract approvals and various other activities conducted by the Company in order to enroll patients. CRO and other third party clinical trial costs were $6.58 million for the year ended
December&nbsp;31, 2014 compared to $181,000 in 2013. There were nominal costs of this nature incurred in 2013 as the Company was only in the early start-up phase of the LN clinical trial in the latter part of 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurred drug supply costs, primarily for drug packaging, stability and distribution, of $894,000 for the year ended December&nbsp;31, 2014
compared to $373,000 in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salaries and employee benefits were $1.03 million for the year ended December&nbsp;31, 2014 compared to $856,000 in 2013.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travel expenses related to research and development also increased to $212,000 for the year ended December&nbsp;31, 2014 compared to $27,000 in 2013.
This increase is a reflection of the additional travel incurred in 2014 for the LN Phase 2b clinical trial by the Company&#146;s staff. Travel costs are significant as the trial is being conducted in 22 countries and at approximately 80 sites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate, administration and business development expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development expenditures were $6.89 million for the year ended December&nbsp;31, 2014 compared to $2.30 million in 2013.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The largest change related to non-cash stock option expense which increased to $1.93 million for the year ended December&nbsp;31, 2014 compared to
$135,000 for the comparable period in 2013. The stock compensation expense in 2014 resulted from the grant of options to the new Chief Executive Officer and the Board of Directors, including the Chairman, on February&nbsp;18, 2014. There were no
stock options granted in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salaries and employee benefits increased to $2.00 million for the year ended December&nbsp;31, 2014 compared to $1.04
million for the comparable period in 2013. The increase in 2014 reflected the increased salary paid to the new Chief Executive Officer, salary increases for the other corporate, administration and business development staff, the hiring of two
additional employees and bonuses, paid and accrued, to corporate and administration executives and staff in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trustee fees, filing fees and other
public company costs increased to $732,000 for the year ended December&nbsp;31, 2014 compared to $134,000 in 2013. The increase was primarily due to the Company incurring $279,000 of costs related to the process of obtaining its NASDAQ listing on
September&nbsp;2, 2014. The Company also incurred TSX listing fees of $182,000 upon the Company graduating to the TSX from the TSX-V exchange in the second quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professional and consulting fees increased to $952,000 for the year ended December&nbsp;31, 2014 compared to $392,000 in 2013. This increase was due to legal
and audit costs associated with the NASDAQ application process, higher audit and other advisory fees for the 2013 audit resulting from the Plan of Arrangement, the timing of audit fees incurred and higher legal fees related to the divestiture of the
NICAMs assets, termination of the Lux license agreement, public disclosure documents such as the Annual Information Form and general legal advice requirements. The Company also incurred consulting fees of $324,000 for the year ended
December&nbsp;31, 2014 for various business development activities. There were no similar expenses in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director fees increased to $455,000
respectively for the year ended December&nbsp;31, 2014 compared to $189,000 in 2013. Director fees in 2014 reflected changes to the compensation and composition of the Board during the year which resulted in an increase in director fee expense from
the previous year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travel and promotion expenses related to corporate, administration and business development increased to $295,000 for the year ended
December&nbsp;31, 2014 compared to $124,000 for fiscal 2013. This increase reflects additional travel incurred in 2014 related to investor relations and business development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-based Compensation expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For stock option plan information and outstanding stock option details refer to note 15 of the audited consolidated financial statements for the year ended
December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;18, 2014, the Company granted 1,192,200 stock options to certain directors and officers of the Company at a
price of $3.19 (CDN$3.50) per common share. The options are exercisable for a term of ten years and vest over specific time periods with the exception of 50,000 options which vested in 2014 upon the Company achieving a specific milestone. On
November&nbsp;18, 2014 the Company granted 20,000 stock options to a new director of the Company at a price of $3.44 (CDN $3.91) per common share. The options are exercisable for a term of five years and vest equally over a one year period. For the
year ended December&nbsp;31, 2013, the Company did not grant any stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application of the fair value method resulted in charges to stock-based
compensation expense of $2.19 million for the year ended December&nbsp;31, 2014 (2013 &#150; $230,000) with corresponding credits to contributed surplus. For the year ended December&nbsp;31, 2014, stock compensation expense has been allocated to
research and development expense in the amounts of $Nil (2013 &#150;$98,000) and corporate and administration expense in the amounts of $1.93 million (2013 &#150;$132,000) and restructuring costs in the amount of $253,000 (2013-$Nil). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amortization of intangible assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of
intangible assets was $1.48 million for the year ended December&nbsp;31, 2014 compared to $783,000 recorded in 2013. The increase in 2014 reflects the higher balance of intangible assets being amortized in 2014 compared to the same period in 2013 as
a result of the Company recording reacquired rights in the amount of $18.71 million upon completion of the Plan of Arrangement on September&nbsp;20, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restructuring and acquisition costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded
restructuring and acquisition costs of $1.07 million for the year ended December&nbsp;31, 2014 compared to $1.51 million for fiscal 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
recorded restructuring costs related to the shut-down of the Edmonton lab facility in 2014 and the transfer of the head office and all business operations, except for the finance function, to Victoria, British Columbia. The finance group also moved
to smaller premises in Edmonton during the year. Restructuring costs included moving costs, retention and/or severance costs of $259,000 and a provision for the estimated loss on the sublease agreement related to the Edmonton lab facility in the
amount of $340,000. In addition the Company recorded restructuring costs related to its divesture of its early stage NICAMs assets. On February&nbsp;14, 2014 the Company signed a NICAMs Purchase and Sale Agreement with Ciclofilin Pharmaceuticals
Corp. (&#147;Ciclofilin&#148;), a company controlled by the former Chief Executive Officer and Chief Scientific Officer, whereby it divested its early stage research and development Non-Immunosuppressive Cyclosporine Analogue Molecules
(&#147;NICAMs&#148;) assets, consisting of intellectual property, including patent applications and know-how to Ciclofilin. There was no upfront consideration received by the Company and future consideration will consist of milestones relating to
the clinical and marketing success of NICAMs and a royalty. Due to NICAMs&#146; early stage of development, the Company estimated the fair value of the consideration to be $nil at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded $216,000 of restructuring costs related to the NICAMs in 2014 which consisted of severances of $115,000 paid to the three employees
working on the NICAMs and $101,000 of other NICAMs related expenses, including wage and patent costs incurred from January&nbsp;1, 2014 to the divestiture date. The Company also recorded as restructuring costs in 2014, stock compensation expense of
$253,000 related to stock options granted in February 2014 to the former Chief Executive Officer and Chief Scientific Officer pursuant to his termination agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded restructuring and acquisition costs of $1.51 million for the year ended December&nbsp;31, 2013. This amount was composed of $1.26 million
in restructuring costs comprised primarily of severance provisions resulting from personnel changes upon completion of the Plan of Arrangement on September&nbsp;20, 2013 and $251,000 in acquisition costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other expense (income) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded other income
of $1.70 million for the year ended December&nbsp;31, 2014 compared to other expense of $906,000 recorded in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense (income) for the year
ended December&nbsp;31, 2014 reflected a gain on extinguishment of warrant liability of $2.19 million and a gain on re-measurement of warrant liability of $646,000. The warrant liability arose pursuant to the February&nbsp;14, 2014 private
placement. For a detailed discussion of the warrant liability and the related accounting treatment please refer to note 15(a) of the audited consolidated financial statements for the year ended December&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded an expense of $848,000 on revaluation adjustments on long term contingent consideration to
ILJIN in 2014. It also recorded as an expense of $203,000 related to share issue costs allocated to the warrant liability. There were no similar items for the comparable period in 2013. For further details refer to note 14 and note 15(a) of the
audited consolidated financial statements for the year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company recorded a foreign exchange loss of
$119,000 for the year ended December&nbsp;31, 2014 compared to a foreign exchange loss of $184,000 in 2013. Effective January&nbsp;31, 2014 the Company&#146;s functional currency is the United States dollar. It incurs foreign exchange gains or
losses depending on the fluctuations of the USD-Canadian dollar exchange rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense for the year ended December&nbsp;31, 2013 reflected a net
expense of $906,000. This amount was composed primarily of a loss on contract settlement with ILJIN of $4.27 million offset by a gain on acquisition of Aurinia Pharma Corp. of $3.50 million which are discussed in note 5 of the year ended
December&nbsp;31, 2014 audited consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Tax (Recovery) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition of Aurinia resulted in the recognition of a deferred tax liability of $3.91 million related to the fair values of the intangible assets. Since
the Company had tax losses available to off-set the liability, a deferred tax recovery of $3.91 million was recognized in the Statement of Operations and Comprehensive Loss for the year ended December&nbsp;31, 2013. There was no similar item in
2014. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIQUIDITY AND CAPITAL RESOURCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, the Company had cash, term deposits and a short term investment totalling $32.70 million compared to $1.82 million at
December&nbsp;31, 2013. The Company believes that its cash position will be sufficient to finance its operational and capital needs, including completion of the LN Phase 2b clinical trial until at least December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company completed a private placement on February&nbsp;14, 2014 for net proceeds of $48.31 million with the net proceeds to be used to advance the
development of its lead drug candidate, voclosporin, as a therapy for LN by conducting a LN Phase 2b clinical trial and for general corporate and working capital purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is in the development stage and is devoting substantially all of its financial and operational resources and efforts towards the development
activities for its drug, voclosporin. The recoverability of amounts expended on research and development to date, including capitalized intellectual property, is dependent on the ability of the Company to complete the required development
activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses of Cash: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign exchange rate on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities in fiscal 2014 was $16.90 million, an increase of $12.28 million from cash used in
operating activities of $4.62 million in fiscal 2013. Cash used in operating activities in 2014 and 2013 was composed of net loss, add-backs or adjustments not involving cash and net change in non-cash working items, which for 2014 included
repayment of the drug supply loan in the amount of $1.20 million. The increase in cash used was primarily a function of increased operating activities in 2014 which included the commencement of the LN Phase 2b clinical trial during the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities in fiscal 2014 was $10.08 million compared to $36,000 for fiscal 2013. The
increase in 2014 was primarily due to the 2014 purchase of a HSBC discount note with a six month maturity that was classified as a short-term investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for fiscal 2014 was $47.89 million compared to cash provided by financing activities in fiscal 2013 of $6.38 million. On
February&nbsp;14, 2014, the Company received net proceeds of $48.31 million from the private placement equity financing and in turn paid out the financing milestone to ILJIN (contingent consideration) of $1.6 million in the same period. The Company
also received $1.18 million from the exercise of warrants in fiscal 2014. In 2013, the Company received net proceeds of $6.41 million from two private placement equity financings, which included the conversion of $391,000 in promissory notes into
units in the first private placement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTRACTUAL OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into contractual obligations for services and materials required for the LN Phase 2b clinical trial and other operational activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments for its premises and the minimum amount to exit the company&#146;s contractual commitments are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:82.75pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands of dollars)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>one year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Two&nbsp;to&nbsp;three</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Greater&nbsp;than<BR>three years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations (consists of premise leases)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All related party transactions are recorded at the exchange amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded $34,000 of legal fees for the period June&nbsp;16, 2014 to December&nbsp;31, 2014 in the normal course of business to the law firm of
which a partner is the Company&#146;s corporate secretary. The partner became the Company&#146;s corporate secretary on June&nbsp;16, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key
management personnel of the Company consist of its directors and executive officers. In addition to the director fees and salaries to the directors and officers, the directors and officers participate in the Stock Option Plan. The compensation
related to key management personnel is disclosed in note 23 to the audited consolidated financial statements for the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFF-BALANCE SHEET ARRANGEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date
the Company has not had any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance or special purpose entities, which are established for the purpose of facilitating off-balance sheet
arrangements or other contractually narrow or limited purposes. The Company does have off-balance sheet financing arrangements consisting of various lease agreements which are entered into in the normal course of operations. All leases have been
treated as operating leases whereby the lease payments are included in Corporate, administration and business development expenses for the year ended December&nbsp;31, 2014. All of the lease agreement amounts have been reflected in the Contractual
Obligations table above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in accordance with IFRS often requires management to make estimates about, and apply assumptions or
subjective judgment to, future events and other matters that affect the reported amounts of the Company&#146;s assets, liabilities, revenues, expenses and related disclosures. Assumptions, estimates and judgments are based on historical experience,
expectations, current trends and other factors that management believes to be relevant at the time at which the Company&#146;s consolidated financial statements are prepared. Management reviews, on a regular basis, the Company&#146;s accounting
policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment
and are often applied to matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management considers the following areas to be those where critical accounting policies affect the significant judgments and estimates used in the preparation
of the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical estimates in applying the Company&#146;s accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contingent consideration
is a financial liability recorded at fair value. The amount of contingent consideration to be paid is based on the occurrence of future events, such as the achievement of certain development, regulatory and sales milestones. Accordingly, the
estimate of fair value contains uncertainties as it involves judgment about the likelihood and timing of achieving these milestones as well as future foreign exchange rates and the discount rate used. Changes in fair value of the contingent
consideration obligation result from changes to the assumptions used to estimate the probability of success for each milestone, the anticipated timing of achieving the milestones, and the discount period and rate to be applied. A change in any of
these assumptions could produce a different fair value, which could have a material impact to the results from operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key assumptions used by
management include the probability of success for each milestone (35% - 70%) and a discount rate of 10%. There has been no change made to the key assumptions except for a discount rate change to 10% as at March&nbsp;31, 2014 from 15% used in 2013
which reflects the Company&#146;s reduced credit risk. If the probability for success were to increase by a factor of 10% for each milestone this would increase the obligation by approximately $677,000 at December&nbsp;31, 2014. If the probability
for success were to decrease by a factor of 10% for each milestone this would decrease the obligation by approximately $677,000 at December&nbsp;31, 2014. If the discount rate were to increase to 12%, this would decrease the obligation by
approximately $212,000. If the discount rate were to decrease to 8%, this would increase the obligation by approximately $232,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value of
stock options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the fair value of stock options on the grant date, including performance based options, requires judgment related to the
choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to determine fair value could result in a significant impact on the
Company&#146;s reported operating results, liabilities or other components of shareholders&#146; equity. The key assumption used by management is the stock price volatility. If the stock price volatility was higher by a factor of 10% on the option
grant dates in 2014 this would have increased annual stock compensation expense by approximately $163,000. If the stock price volatility was lower by a factor of 10% on grant date this would have decreased annual stock compensation expense by
approximately $178,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value of warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the fair value of warrants requires judgment related to the choice of a pricing model, the estimation of stock price volatility, expected term of
the underlying instruments and the probability factors of success in achieving the objectives for contingently issuable warrants. Any changes in the estimates or inputs utilized to determine fair value at grant date could have a significant impact
on the Company&#146;s operating results, liabilities or other components of shareholders&#146; equity. If the stock price volatility was higher by a factor of 10% this would have increased the value of the warrants (equity component) by
approximately $1.1 million. If the stock price volatility was lower by a factor of 10% this would have decreased the value of the warrants (equity component) by approximately $1.19 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical judgments in applying the Company&#146;s accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management&#146;s assessments
related to the recognition of revenues for arrangements containing multiple elements are based on estimates and assumptions. Judgment is necessary to identify separate units of accounting and to allocate related consideration to each separate unit
of accounting. Where deferral of upfront payments or license fees is deemed appropriate, subsequent revenue recognition is often determined based upon certain assumptions and estimates, the Company&#146;s continuing involvement in the arrangement,
the benefits expected to be derived by the customer and expected patent lives. To the extent that any of the key assumptions or estimates changes, future operating results could be affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of intangible assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the guidance of IAS 36 to determine when impairment indicators exist for its intangible assets. When impairment indicators exist, the
Company is required to make a formal estimate of the recoverable amount of its intangible assets. This determination requires significant judgment. In making this judgment, management evaluates external and internal factors, such as significant
adverse changes in the technological, market, economic or legal environment in which the Company operates as well as the results of its ongoing development programs. Management also considers the carrying amount of the Company&#146;s net assets in
relation to its market capitalization, as a key indicator. In making a judgment as to whether impairment indicators exist at December&nbsp;31, 2014, management concluded that there were none. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISKS AND UNCERTAINTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
invested a significant portion of its time and financial resources in the development of voclosporin. The Company anticipates that its ability to generate revenues and meet expectations will depend primarily on the successful development and
commercialization of voclosporin. The successful development and commercialization of voclosporin will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of its clinical program in LN, including the LN Phase 2b clinical trial currently underway; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Timely completion of the LN Phase 2b clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and other regulatory authorities with a commercially viable label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing and maintaining partners with sufficient expertise and resources to help in the continuing development and eventual commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining suitable manufacturing and supply agreements to ensure commercial quantities of the product through validated processes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance and adoption of the product by the medical community and third-party payors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of the Company to raise future financial resources if and when required. Future additional sources of capital could include payments from potential new licensing partners, equity financings, debt financings
and/or the monetization of the Company&#146;s intangible assets. There is no assurance of obtaining additional future financing through these arrangements or any arrangements on acceptable terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A detailed list of the risks and uncertainties affecting the Company can be found in the Company&#146;s Annual Information Form which is filed on SEDAR and
EDGAR. Additional risks and uncertainties of which the Company is unaware, or that it currently deems to be immaterial, may also become important factors that affect the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital management </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective in
managing capital is to ensure a sufficient liquidity position to safeguard the Company&#146;s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company defines capital as net equity, comprised of issued common shares, warrants, contributed surplus and deficit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective with respect to its capital management is to ensure that it has sufficient cash resources to maintain its ongoing operations and
finance its research and development activities, corporate, administration and business development expenses, working capital and overall capital expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Company has primarily financed its liquidity needs through public offerings of common shares and private placements. The Company has also
met its liquidity needs through non-dilutive sources, such as debt financings, licensing fees from its partners and research and development fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There
have been no changes to the Company&#146;s objectives and what it manages as capital since the prior fiscal period. The Company is not subject to externally imposed capital requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial risk factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities
expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk. Risk management is carried out by management under policies approved by the board of
directors. Management identifies and evaluates the financial risks. The Company&#146;s overall risk management program seeks to minimize adverse effects on the Company&#146;s financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages its liquidity risk through
the management of its capital structure and financial leverage. The Company successfully completed a $52 million private placement on February&nbsp;14, 2014 which is expected to provide the Company with sufficient financial resources to conduct the
LN Phase 2b clinical trial and other corporate, administration and business development activities until at least December&nbsp;31, 2016. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of
Directors and/or the Audit Committee reviews and approves the Company&#146;s operating budgets, as well as any material transactions out of the ordinary course of business. The Company invests its cash in term deposits and bank discount notes with
30 to 180 day maturities to ensure the Company&#146;s liquidity needs are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate, credit and foreign exchange risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company invests in cash reserves in fixed rate, highly liquid and highly rated financial instruments such as treasury bills, term deposits and bank
discount notes which are all denominated in US dollars. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to its investment
portfolio, due to the relative short-term nature of the investments and current ability to hold the investments to maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to
financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United
State dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company&#146;s operating and financial results. The Company holds its cash reserves in US dollars and the majority of its expenses, including clinical trial
costs are also denominated in US dollars, which mitigates the risk of foreign exchange fluctuations. The Company has not entered into any forward currency contracts or other financial derivatives to hedge foreign exchange risk in 2014 or 2013. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENCIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes that the ultimate
resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">The Company entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these indemnification agreements is unlimited. However, the Company
does maintain liability insurance to limit the exposure of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into license and research and development agreements with third parties that include indemnification and obligation provisions that are customary in the industry. These guarantees generally
require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature
of the obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any payments under such agreements and no amount has been accrued in the
accompanying audited consolidated financial statements. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ADOPTED BY THE
COMPANY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards have been adopted by the Company for the first time for the financial year beginning on or after January&nbsp;1, 2014
and could have an impact on the Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendment to IAS 32, Financial Instruments: Presentation on offsetting financial assets and financial liabilities. This amendment clarifies that the right of set-off must not be contingent on a future event. It must
also be legally enforceable for all counterparties in the normal course of business, as well as in the event of default, insolvency or bankruptcy. The amendment also considers settlement mechanisms. The amendment did not have a significant effect on
the Company&#146;s consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendments to IAS 36, Impairment of assets, on the recoverable amount disclosures for non-financial assets. This amendment removed certain disclosures of the recoverable amount of cash generating units (CGUs), which had
been included in IAS 36 by the issuance of IFRS 13. The Company has applied the amendment and there has been no significant impact on the Company&#146;s consolidated financial statements as a result. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendment to IAS 39, Financial Instruments: Recognition and measurement on the novation of derivatives and the continuation of hedge accounting. This amendment considers legislative changes to over-the-counter
derivatives and the establishment of central counterparties. Under IAS 39 novation of derivatives to central counterparties would result in discontinuance of hedge accounting. The amendment provides relief from discontinuing hedge accounting when
novation of a hedging instrument meets specified criteria. The amendment did not affect Company&#146;s financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRIC 21, Levies, sets out the accounting for an obligation to pay a levy if that liability is within the scope of IAS 37, provisions. The interpretation addresses that the obligating event is that gives rise to the
payment of a levy and when a liability should be recognized. The Company is not currently subjected to significant levies so the impact on the Company is not material. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other standards, amendments and interpretations which are effective for the financial year beginning on January&nbsp;1, 2014 are not material to the Company.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS NOT YET ADOPTED </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in
IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortised cost, fair value
through other comprehensive income (OCI) and fair value through profit and loss (P&amp;L). The basis of classification depends on the entity&#146;s business model and the contractual cash flow characteristics of the financial asset. Investments in
equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in OCI not recycling. There is now a new expected credit losses model that replaces the
incurred loss impairment model used in IAS 39. For financial liabilities there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at
fair value through profit or loss. IFRS 9 relaxes the requirements for hedge effectiveness by replacing the bright line hedge effectiveness tests. It requires an economic relationship between the hedged item and hedging instrument and for the
&#145;hedged ratio&#146; to be the same as the one management actually use for risk management purposes. Contemporaneous documentation is still required but is different to that currently prepared under IAS 39. The standard is effective for
accounting periods beginning on or after January&nbsp;1, 2018. Early adoption is permitted. The Company is yet to assess IFRS 9&#146;s full impact. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRS 15, Revenue from Contracts with Customers, was issued in May 2014 by the IASB and supersedes IAS 18, Revenue, IAS 11, Construction Contracts&#146; and other interpretive guidance associated with revenue
recognition. IFRS 15 provides a single model to determine how and when an entity should recognize revenue, as well as requiring entities to provide more informative, relevant disclosures in respect of its revenue recognition criteria. IFRS 15 is to
be applied retrospectively or through the recognition of the cumulative effect to opening retained earnings and is effective for annual periods beginning on or after January&nbsp;1, 2017, with earlier application permitted. We are currently in the
process of evaluating the impact that IFRS 15 may have on our consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 16, Property, Plant and Equipment, and IAS 38, Intangible Assets, addresses clarification of acceptable methods of depreciation and amortization. IAS 16 and IAS 38 are amended to: (i)&nbsp;clarify that the use of a
revenue-based depreciation and amortization method is not appropriated, and (ii)&nbsp;provide a rebuttable presumption for intangible assets. The standard is effective for accounting periods on or after January&nbsp;1, 2016. The Company is yet to
assess IAS 16&#146;s and IAS 38&#146;s full impact. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no other IFRSs or IFRIC interpretations that are not yet effective that would
be expected to have a material impact on the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL CONTROL OVER FINANCIAL REPORTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting (&#147;ICFR&#148;) as defined in National Instrument 52-109 includes those policies and procedures that:
(1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company&#146;s assets, (2)&nbsp;provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with IFRS, and that the Company&#146;s receipts and expenditures are being made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only in accordance with authorizations of the Company&#146;s management and directors; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the Company&#146;s assets that could have a material effect on the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer
(&#147;CEO&#148;) and the Chief Financial Officer (&#147;CFO&#148;) are responsible for establishing and maintaining ICFR for Aurinia. They have, as at the financial year ended December&nbsp;31, 2014 designed ICFR or caused it to be designed under
their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of its inherent limitations, ICFR may not prevent or detect misstatements even when determined to be effective and can only provide reasonable
assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies and procedures may deteriorate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the supervision of the Company&#146;s Chief Executive Officer and Chief
Financial Officer, as of December 31, 2014, management evaluated the effectiveness of the Company&#146;s ICFR based on the framework set forth in Internal Control-Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the
Treadway Commission (&#147;COSO&#148;). Based on its evaluation under this framework, management concluded that the Company&#146;s ICFR was effective as of December 31, 2014. Management intends to assess the effectiveness of the Company&#146;s ICFR
as of December 31, 2015 based on the 2013 COSO framework. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in the Company&#146;s ICFR during the year ended December&nbsp;31, 2014
that materially affected, or are reasonably likely to materially affect, the Company&#146;s ICFR. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE CONTROLS AND PROCEDURES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disclosure controls and procedures (&#147;DC&amp;P&#148;) as defined in National Instrument 52-109 <I>Certification of Disclosure in Issuers&#146;
Annual and Interim Filings</I>, are designed to provide reasonable assurance that all material information required to be publicly disclosed in the Company&#146;s annual, interim filings and other reports filed or submitted by the Company under
securities legislation is recorded, processed , summarized and reported within the time periods specified under securities legislation and include controls and procedures designed to ensure that information required to be so disclosed is accumulated
and communicated to management including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
designing and evaluating the Company&#146;s disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control
objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chief Executive
Officer and the Chief Financial Officer, after evaluating the effectiveness of the Company&#146;s disclosure controls and procedures as at December&nbsp;31, 2014, have concluded that the disclosure controls and procedures were adequate and effective
to provide reasonable assurance that material information the Company is required to disclose on a continuous basis in interim and annual filings and other reports and news releases is recorded, processed, summarized and reported or disclosed on a
timely basis as necessary. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPDATED SHARE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at March&nbsp;26, 2015, the following class of shares and equity securities potentially convertible into common shares were outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible equity securities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,985,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,312,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,303,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2015 the Company granted 960,000 stock options with a term of five years at an exercise price of $4.25 CDN
per common share to directors, officers and employees of the Company. Subsequent to December&nbsp;31, 2014, the Company issued 143,000 common shares upon the exercise of warrants for proceeds of $343,000 CDN and issued 25,000 common shares upon the
exercise of 25,000 stock options for proceeds of $87,000 CDN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENTAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B>Selected Annual Information</B><I>(expressed in thousands of dollars, except per share data) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,896</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficiency)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total non-current financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholder&#146;s equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B>Quarterly Information </B><I>(expressed in thousands of dollars except per share data) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is unaudited consolidated financial data for each of the last eight quarters: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring and acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of tangible and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per common share ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3*&#094;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4*&#094;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring and acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of tangible and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (recovery)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per common share ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">These figures have been restated from those originally presented as more fully described in note 3a to the audited consolidated financial statements for the year ended December&nbsp;31, 2014. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top">On September&nbsp;30, 2013 the Company completed a plan of arrangement with ILJIN and Aurinia Pharma Corp. and acquired Aurinia Pharma Corp. The Company determined a preliminary fair value of the reacquired rights,
intellectual know-how and goodwill related to the plan of arrangement and acquisition of Aurinia Pharma Corp. However, at September&nbsp;30, 2013 management was still in the process of determining the fair value of the assets and liabilities
acquired and therefore the allocation between these asset categories was subject to change. Management completed the evaluation and made the final purchase price adjustments in the fourth quarter of 2013. As these adjustments related to the third
quarter ended September&nbsp;30, 2013 the Company restated the figures for the third and fourth quarters of 2013. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Quarterly
Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary factors affecting the magnitude of the Company&#146;s losses in the various quarters are noted below and include the amortization
of deferred revenue to revenues, the timing of research and development costs associated with the clinical development programs, timing of stock compensation expense and other specific one-time items including items noted below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense (income) reflected a gain on extinguishment of warrant liability of $1.75 million for the three months ended September&nbsp;30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs for the three months ended June&nbsp;30, 2014 reflected costs associated with the commencement of the recruitment and
enrollment phase of the LN Phase 2b clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense (income) reflected gains on extinguishment of warrant liability and re-measurement of
warrant liability of $438,000 and $646,000 respectively for the three months ended June&nbsp;30, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net loss for the three months ended
June&nbsp;30, 2014 included a non-cash stock option compensation expense of $435,000 while the net loss for the three months ended March&nbsp;31, 2014 included a non-cash stock option compensation expense of $1.30 million related to the issuance of
1.19&nbsp;million stock options in the first quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restated net income for the three months ended September&nbsp;30, 2013 included
acquisition and restructuring costs of $1.41 million, a gain on acquisition of Aurinia Pharma Corp. of $3.50 million, a loss on contract settlement with ILJIN of $4.27 million and a non-cash deferred income tax recovery of $3.91 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter Analysis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a
consolidated net loss of $4.92 million or $0.15 per common share for the fourth quarter ended December&nbsp;31, 2014, compared to a consolidated net loss of $1.70 million or $0.14 per common share for the fourth quarter ended
December&nbsp;31,&nbsp;2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activities in the fourth quarter of 2014 were significantly changed from those in the same period in 2013 as the
Company&#146;s LN Phase 2b clinical trial was in full progress in the fourth quarter of 2014 as reflected by a significant increase in research and development costs to $3.09 million compared to $691,000 for the fourth quarter of 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUTLOOK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. (the Company) was established on September&nbsp;20, 2013 through the merger of Isotechnika Pharma Inc. (a Canadian public
company) and Aurinia Pharma Corp. (a Canadian private company) as approved by shareholders on August&nbsp;15, 3013. The Company is a publically-traded entity, listed on both the Toronto Stock Exchange (AUP) and the NASDAQ (AUPH). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage pharmaceutical company operating in the field of nephrology and is specifically focused on the development of its lead
compound, voclosporin, to treat patients afflicted with LN. There is no compound approved in either North America or Europe to treat this devastating condition, and with the current standard of care, approximately 90% of patients still do not
achieve satisfactory clinical results. Further, longitudinal studies have shown that patients who do not achieve adequate clinical remission through available treatments will, in 90% of cases, develop end-stage renal disease (ESRD) within ten years.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia&#146;s clinical hypothesis is that by layering their lead compound, voclosporin, a calcineurin inhibitor, on top of the current standard of care
in patients suffering from LN, that patient outcomes can be significantly and rapidly improved. To this end, Aurinia initiated a 258-patient Phase 2b, randomized, placebo-controlled clinical trial in the summer of 2014, with the projection to
complete enrollment from 22 countries and approximately 85 sites in about one year. Following enrollment of the last clinical patient and six months of active treatment, the database will be un-blinded and the primary clinical objective evaluated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To fund this trial and Company operations, Aurinia raised $52 million on February&nbsp;14, 2014. At December&nbsp;31, 2014, the Company held US$
32.70&nbsp;million in cash and short term investments, and is financially stable and capitalized through and past the time of trial completion. The corporate focus is on the successful clinical development of voclosporin to treat patients afflicted
with lupus nephritis and execution against stated budgets, objectives, and tactical goals in order to accomplish this. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g891272new.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>d891272dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Stephen W. Zaruby, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report of Aurinia Pharmaceuticals Inc. on Form 40-F; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
issuer as of, and for, the period presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the issuer&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#146;s auditors and the audit committee of the
issuer&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen W. Zaruby</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Stephen W. Zaruby</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>d891272dex995.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Dennis Bourgeault, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report of Aurinia Pharmaceuticals Inc. on Form 40-F; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
issuer as of, and for, the period presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the issuer&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#146;s auditors and the audit committee of the
issuer&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Dennis Bourgeault</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>7
<FILENAME>d891272dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Aurinia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form 40-F for the fiscal year ended
December&nbsp;31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Stephen W. Zaruby, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March&nbsp;30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen W. Zaruby</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Stephen W. Zaruby</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>8
<FILENAME>d891272dex997.htm
<DESCRIPTION>EX-99.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Aurinia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form 40-F for the fiscal year ended
December&nbsp;31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Dennis Bourgeault, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March&nbsp;30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Dennis Bourgeault</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>9
<FILENAME>d891272dex998.htm
<DESCRIPTION>EX-99.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891272logo.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.8 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Consent of Independent Auditor </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion in this Annual Report on Form 40-F for the year ended December&nbsp;31, 2014 of Aurinia Pharmaceuticals
Inc. of our report dated March&nbsp;26, 2015, relating to the consolidated financial statements, which appears in the Annual Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We
also consent to reference to us under the heading &#147;Interests of Experts,&#148; which appears in the Annual Information Form incorporated by reference in this Annual Report on Form 40-F. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>&#147;PricewaterhouseCoopers LLP&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Chartered Accountants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Edmonton, Alberta </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;30, 2015 </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:5%">


<IMG SRC="g891272footer.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>PricewaterhouseCoopers LLP </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>TD Tower, 10088 102 Avenue NW, Suite 1501, Edmonton, Alberta, Canada T5J 3N5 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>T: +1 780 441 6700, F: +1 780 441 6776, www.pwc.com/ca </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:8pt; font-family:ARIAL">&#147;PwC&#148; refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g891272ex1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272ex1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#4@*1`P$1``(1`0,1`?_$`1H``0`"`@(#`0$`````
M```````#!`(%`08'"`D*"P$!``(#`0`#`0````````````0%`0(#!@<)"@@0
M``$!!@,$!`8)!P\3$`4)"0$`$0(#!`4&(3$'05$2"&%Q@0F1H;'!(A/PT>$R
M%!46EPI"4M47UU@:\6)RLB,D--0F-D8G-U<8@J+",T149'24)35%575VED>W
M.9)3A+1EA:6UQ59FAK9W.'C2<Y5GA^)#@].DQ-:X&3KR8Z.SQB@I>1$``@$"
M`P0$"`<*"@@$!00#``$"$0,A,01!$@4&47$RTF&!T2*2$Y,'\)%3TQ14E*'!
M0E)R,^,T%1;A(W,D=-0U51<(L6+B8T1DA"6"0X,8\;1%-C>R)C@)PL/D_]H`
M#`,!``(1`Q$`/P#]_"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`Z
MK=M]618%/A5:^[QM6RJ5,3+LG`J=VW#2+<I\:;?<?B.RL*=K$Y)RT29>APWG
M@X'B\7726,!0&YI-7I-?ILE6:%5*=6J/4H#DU3JK29V6J--GY:)_*YF2GI.+
M&E9J`^S!]Q]YT["@-B@"`(`@"`(`@"`],[:[PGDSO#FUNKD4MK7JU:MS9633
M9FK7/HQ`I]SN5ZER4E1*;<<X\]5IB@P;5FIB4H57EYJ)`@3\6.Y"B-><'"\'
M0/<B+%A0(42/'B0X,&##?BQHT5]V'"A0H;I?B1(D1\AQR&XX"220``TH#KMJ
MWK9M]2,:J63=MLWC3):;B2$Q4;5KU*N&1EYZ"ZX]&DXTW2)N;EX4W"=B.EZ&
M\\'W0\&C%`=F0!`?,?5#OF.[#T9YC9;E+U'YP],J#S`Q[II5D3%A2\M=UP"C
M7E6IN5D*?:US75;5M5BRK5K[\[.PH,64J51E8TK$>X8[L,@A`?3A`$`0!`$`
M0!`$`0'AW77F%T+Y8;`FM5>8G5W3S1/3B3J5.HT>]=3+KH]GVZ*Q5GXD.ETB
M%4JU-2D"8JE0>A/F#+PR_&B.PWW@Z77'B`.\V1?%FZEV?;.H6G=U6]?-B7I1
M*=<MHWC:=7D*_;-S6]6)6'.TNM4*MTN/,T^J4RH2D5V)!C08C\-]QX$%`=I0
M!`$`0'2[JU(T\L6+)P+WOVR[.CU"'%C2$&ZKIH=O19Z%`><<C19.'5YZ3?F8
M<%]]T//.!X.D@'-`4+=U=THN^J0Z):>IVGET5F-"C1H-(MV]+;K=4BP9=PQ)
MB+#D*;4IF;?A0(8+S[P<(==Q+`@/(:`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(#\!/TB>C
MZD][;WPW+3W2.A-?ARHT'T7U%U'O*=><>FZ32-4;KTXJ6JDS!KLO!C0G#ZJP
MK/MFGR41]X&#.7&^XP<9#P'O?]#CYOYS5#D<U;Y,[TG)B'?G)QJG./T*CU)^
M)#J,GI5J_.5FXI&0^"S+)D/T#4VEW+"CNCT9:'-2T,AUKH('N-SD_28N4'D7
MYSN8KDWURTGUD<N#0?3VV[GI%V6E!H%Q0M7;WO"V+`NJW-,;,MQR=E9RG5:H
MR%^!L_4YB5DH7Q=,E\@&#ZT#J'=M?2<M`.?3FVDN2W4'ELU;Y2]9KL^-X.FT
MIJ+6J=<-,NBKT:BS-S1;5KS*%:=9LJZJE;DG%FI&!'DYF4FO5F$)D1HDO#C@
M=^YW/I*?*'R`\ZNLO)MKYI;J_"J6D>E]`OF6OVTH-#N&4U`NF[;/MF\+7TVM
M6V8<U+U"7J]9E[G<EQ/5"8E)&!&@17HST."'8KP'B[N\?I0G+]SM\W]#Y+=2
MN676'E*U3OZ9G:;I='U'K-.KU-N.OP*5&K]/M>Z)44*U:S8UPW)1(#T2F.OR
M\[)S4?A@"9=B1I<1@/>>Y.^?TJMOO?[2[H"-HQJ+-:DW9;<*O0M88-8MARQ9
M&)'T>K6LT*4BT2),BX(T#XDHQDWHSK'Q.Q`R$80,1`2\Y/?-:5\FO>*<GG=U
M71HSJ'>=[\X`TZ>H&HMOUBV9*U+-=U+U1N#2JC&KTVI3#E7J9I]7MV+-3@@B
M'PRK[GJO6Q.*&`/%/>1=_'8O(AS$R'*#IER?\SW.ES,Q[&HNHM3L'0VUH\6C
MT&U[BCSL"BOS];D:7==Q3=0FQ(1(CSLE0YJ5@N%T1)AV(3#=`ZYW77TA/1+O
M&.8B[^3V].7K63D^YJ+6H57N&!I3J^8$Z*]+6VY+S%RT64J#])M:OTF\:%39
MEV>C4VI4:2>?D'8D:%$B>JB.N@?$3E/_`/VTCFX_P.U`_P#RX:5(#]H'.#_X
M2>:3_P`NFMO^;2YD!^.#Z'IJ93M%N[3[R'6*L4V?K-(TFU2K.IE4H]+?EX=3
MJM.L30*3NF>IM.?G(L&3<GY^6I3T*"]%?<AB(\[Q/!UI0'L95/IDO*E/Z.V]
M>.EG*%S#ZI:O33MV5J^M&Z3/TN5D=*K#M:H0Y)R\[UU)D:'7J>Y*UN#%]?!A
M2E-F'):$Z3.1I;C@>N`^D>@GTA'EMYC^[4UX[Q'2_1S62XYSEIJ]N6SJYRS4
M>6I%7U:I=PW3<EKT&BOT":DHSU(N"U:C*70*A!J;KL'\ZR$Z[$@0HTM$A@#\
M1/<*\PO*5<G>$:KP.;;D8NOF^U"YO.9O2*1THU`J5ITF^!RVW7?6L5WU>X+]
MO%RJNO1*5/SE?K](FYJI2I<FH4"C3;'BX_$<?`_85SM_2:M`^7/F>NODXY7^
M5_7OG^U^TYGJI2=2:%H5+/P[>MBNT%YV%<UN2-2IEO7S<MS5JT9E[U%7,G1G
MJ?(30>@/31CPXT.&!['=T_W^?+%WIU\7UH93-/\`47EOYGM.:=4JW<&AFK/Q
M?'GJG1*)4):D7%.VG<$DY)/5.=M6JSD*!5*=/2%,J4J8@?=@1(3D:)"`]%>8
M7Z6KRE<O>J7-[H76>7+6ZOZQ\M6L\_H?8MG4VJ6WZC76Y:#>-SVC<U7IM7E(
M54^0]NT2);0C\4S`GIV9=GY:'"EGHCT5V$!YZUF^DJ<N'+UHSW:FN.L6A.J=
MJ69WB%&N"Y)B;A5F@U)SE^MJT+JM&UKKKEWPG):!5KPEJ4;J^'.0J;)PYF9D
MI5_@A>O?AP"!ZA6Q],9Y.YWF`M.Q-0.5SF(TEY=;^K3LC9_,W>?Q8Y!G+<CU
M-ZDR^HD_IA)TV)4/D+"F1ZR;C4RK5:>EY</$2L2,Z8"`J7/],EY.K<UJHE!_
M@J\R$SRP7#<\[;U$YI9F'3J1+W'3Z158=(KMXVIIA4*:Y/7!;-(CQ!&BPW:Q
M"J[DN0'Y&',D2Q`^S7>7]\;H-W;FGN@=TU'3C5OF2O+FIC5B'R\Z<Z"T*7K]
M1U!@4*D6U7)^K&K3$=R%)4DTV[Z<_`^#0)^=F?A(,&6?<<BOPP/FQRS_`$HG
M3;4/FMTLY2.;SD6YFN0J^M;JY;]M:9UC6.%,1J7/5J\*H[0[.^4E+N&S=.+G
MH5$N:NON2$O4I>2J,G#FX@$=^%!=BQX8'Q9[^?OR^8/3[O4-"M-=#*ES?:%:
M>\G^KT&V]9[(MJ[ZK9%N<U<&BZBVK5ZG'MF@4B<A2%W4:OVS+3-)E35')B#'
MASCK(;KD1\/`?3;O+^\5Y&.\&[DB'S5<X/)[S8TG1:G\WUN6#0M)).Z:!I;K
M!3]2J#0Z]`I5^4^XIZ#4:''M&-;]PU*3?=BR<UZR/$B."$'X3L>&!]0K3[Q+
MD#[M'N;>43F<J,C>^EW+/4M!='930'2"<FI6]]:;EF+PLJ#<UMZ>2+\2J2].
MN*]/BUV9FJE/19N6IT&'`CS$2+!A!UU`?*ND?3`]-*%/6'=VO/=L<W^B/+AJ
M94H$K96OU0>EJU2;AILQ^:NUFATJJ6G9U`N>7EI!LU'A4BOU&,(#CQA.QB`'
M@/LCWD??1\OG=Z<G&@_.W+VG<7,CI!S%7M8]KZ;SVEE;H5+A5.BW[8%TZC4:
M\OAUS/RL-VF1*#:[[H@/0W9@3$=QR(["X8A<`^/>KOTR+E%L+4N6EK#Y3>8_
M57EN^4YM2-S+2S])LRD5RI2;D.+6SI_9]Q4[@N=VG07R^Y!GJQ19R,X[Q/0(
M3CSKQ`_63HUJ[8&OVDNFNN&E5>@W1IKJW8]L:B6+<$"'%@.U:UKNI$I6Z--Q
M):.ZY,R4R_)3C@C0(KKL:!%#T.(ZZ^Z\`!^`[Z4II/:FOO?H=U[H5?\`/5:0
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MG5%VG/UT6[#J<&B3]RVG6Z9$=E[CH]#KDU`D:B[&EJ?/R$U,078TJZY&A1'P
M/F/J_P#2^.4S2JM\Q>G<+EAUQNC6G137>JZ(V?II)5NVX7VU7;:KMX4.[;ZA
MW%(R=:AV?0*!,6I#'P>)*3\]-1:G+.P83SCDW%E@/:KF"^DJ\KW*[3>[TN36
MO1K56U;-Y\M`K:YA9BZ(4Y2*K!T.M*X84F8DG<E'D9=^O7C4:9&F'@\Y3I9Q
M^-#==>A.//O^K=`]/M-/IBW)S7]?K;TZUFY8N8+ETT0OI^',V7S"WZ](5.%&
MMFHO3,.@WS<FFU#I$6KR-G52++\+TW1JA<)A-:'(CKD0N`5Z7],<Y/XFOEI6
M5=7*OS$V#RW7Y<1I%I\S]V1*13X%2H0JXH<34+[69I_PF/8\E-GULW%DZU.5
M"6E029,S`,L@/V"2\Q+S<O`FY2/!F96:@PIB6F9>(Y&@3$O&<=B08\&+#+T.
M+!BPW@\Z\Z2'@01@@)D`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$`0!`=0U!ONU]+K"O?4R]ZG"HMEZ=6A<E]7=6
M8Y`@4FV+2HT[7Z]4HQ)='JI&E4^+%>Q&#J`_F)]U=S0=ZC=O._SM][/R@]W5
M,<Z->Y@+YU!T_GKGN&H3DG0M)X=SW+;NHLU8M`F9.X*(],U*DVA"MR0P]8)6
MFP84,$",\"!WGNL-=^8KN^OI%TK%YN>7N>Y-3WB]8N^BWAHI.S+YMR@0^8N\
MJA7],:I;$>8J%1A1Z"-=[;@4Z5BO1WC)RTQ-0&NAUYU`?0`6C:MY_3<:O3[O
MMNAW1(4J@R5TTV2K],DZM)R-RVOR"4>MVU7Y65GH4:!"J]OUF3@SDE,!WULK
M-08<:&78CCCP`W'>R4NG4CZ6_P!U=4:5)2U.G[BMCE=J%>G)*$Y+S%8GG-6]
M;+==G*C%A!UZ;F?B&ERTEQOM>,K`APV\#CH`&CU;M"U+W^FU:?T6\K;H=UT>
M7H%H7%`I5PTR4J].A5^T^0V?N>UJTY)3L*-+_&=NW)296?DHW#QRTY+0HSA#
M[CI`':.^OI-,IOTISN:JK3J?*2-2KT/E)C5N?E(#DO-5:-*<TVIM+EHU1C0@
MZ_.1H-,@N2SKSY>>]0X[#;P.N@`==YE[VM323Z:1H7>6I-P4BRK4JMFV32)6
MXKDJ$M1J+\.N[E&O*P;;A1:E4'X$G"^-[RF85.@EY\.OS41V&WB+$!U[OA=<
M=(-9/I1G='4K2C4:T]1)O22Z^4[3[4=ZT*O+5V2M*^'^:"\KL?M2I5*0?C4[
MX\E+?N61F)F7AQ7WY;X2[#BAR*'G'0/HISL][%W@FK/?'5CNBN[$I'+;HQJ/
M:]L4F/J9S&\P="CUZI5N+3]-9'5Z>E*')0I2HPS0+6MNZG8$K*?%-8G9R??F
M(KAE941(@`^2')+2^9.@_2\;.HG-SKGI+S$\P]'LB_*5J1J=HI0:=:]D3L_(
M<E5QRM-M[XCI=*HL&0KUH4.%*TRHPXDM#CNS4J\(@X@4![(\I_\`^VD<W'^!
MVH'_`.7#2I`?M`YP?_"3S1_^736W_-I<R`_#[]%^_P!"CWRO][M9O_RFSZ`]
MQ/H5=BV3.=W]S87--VC;<U<=S\U58L>XZ],T6GS%6KUETO1O2V>IMI5>>C0'
MYB?MR1G;FJ4:%)17GI=V)/QWN%L5YH'A'Z%?`A4ZO]ZS1Y%P2U+I^HO+]`DI
M"$UV6EH4M.\Q$K`<A0F\+HAR\)UP?C70$!%]#I>F#KYWR3L!\",_J!HL]#]8
M289F!>G,^(+\08M#KSYZ6$H#QS]#ONFQ;;YM>]&L_6"I4JD\U5<JEF1):6NZ
M:E96]JK1[=O[5IW6B2IOQA$<GX\60O6=HL:LPH;7C%^#/Q`?5`N@-.ZE:FJW
MTU&J77ROSU(KMG6M)7/,:S7#9$2!.6Q%J5!Y-IBR-39B=G:63(1XCFI,_)TN
M>BEXNOU[B#Q>C'$"UW'.FE@7Q])][W.Z+PM&AW+7]*[HYP+OTYJ=8DH<]'LR
MZZAS56W:4U<E!$</0Y*MOVS<$](NS+KOK8<O.1G7'G>-YH&[^F3TBEU/F+[H
MFAU"GRDY1JE<6M5,J%+CP''I&<IT_?G+K+3LE'EP`X_+34O&?<?=R>=>(0'D
M'Z;':-JT#E2Y`8-"MNA42!:NL&H-I6Q+4BE25,E;=M7[7%$=%MT25DH,"7I=
M"<<H4DZ[*P'7(#CLI"#KH#CH`'D#Z5_IU8%F=R+R746T+*M>UZ/8FON@=!LJ
MEV_1)"DR-J42;Y?=6X<W2*!+24"#"IE-FW9*#ZV#"#KD5Z"X\\"\XZ0!V/G;
M[W_F`Y&N6?N2N4CD_P!-](J]S3\V7*ARPR-KZN:[P(DU9^F$I>-E:6:949VE
MGX?28$*JW/<,_%^,9^=FC(TZ0E`]&E9KU[I@`?%;OI;0[Q>Q>\.[J.B]X]S2
M<MO,/J=$U3M:KV=0^7VS).RYG2ZW9[6O2AR=@77"%IVC6JI3[GJ<JVCS,W!>
M!-.G/5\)]8T#Z/?2E:I(T'O;>Y-KM9J$M1Z+1[XM&J5*L5&9<D:93)&F\R^F
M<Y4:A.3T=Z'+RDM(2D/UL:(\\Z[#AN\3Q`Q0'T-^E^5JC5SN?(TS1*M3*Q+R
MW-AHQ)3$>ES\K4(,"=@T>_7XTI&BRD6,Y"FH3D5TO0WB'W0\"1B$!^<7ORW*
MY![JOZ--4[A@5":T1E.620<O*!*NQC*1*X]IORW3#D"9]5Z'QA-6C+5-V3!]
M,NNS'!]6@/TQ_2:-7>4^J]Q%?;E%NW3*LT+4R-R]?P3Y:VJE0IB6K<_3]0++
MK5-GM-I62BL$A1M*I*JF,_*.AR7IABP7N$1.!X#\X?>24&]+<^B6]S_(7W!G
M9>KS/,>Y7:9!J#L1V9%EW/1^;6Y-/XP]:`\])3ED56GQY4CT3*1(7#Z+$!]K
M^^CT[L*V/HI6DU'MJR[7H%*MC1WN_P"Y+=IM&HE/ITE1+AN"K:5NU^O4Z7E8
M$*'+5JN?*JIF<FG1Z^:?J$R]%??>C1"\!]E?H_\`$B1>YI[OAZ+$?B/#0>2A
MAY]XO/"'!N:Y(,&&"6D.0H3CKKHR#H`&2`_*+]*8T>M[F%[\[NPM!+MJ5;HU
MJZUZ9<OFD]RU>VXLG`N*ET'4+FRU)M.KU"A1JC*3\A"K$G(5:)$EGH\"-"=C
M.NE]QYUKI`^_?(_]&^Y8^[)U6N[F?Y:=:N9Z]]8Y71?5.PK/HFIEUV!.VM\8
MWE0?42D[&D[5TYM2HS,]*STE!,N'IKU+D0A\N//.N$`?&KZ%!=FE5%IW>"V=
M=-3H='YCYR\-*JQ5)&Y9J4DKWJNGM'D;YE)]Z4AU)^'59N1MZ\YJ9-7$/B=E
MYB<E3,<+T2$2!UGN_JC:^J?TQ+FYO_EHG*97]'Z52=;JGJ#<%E1I>:M6?BP]
M*K*LN_*F]4*:7Z=4)>J<Q,VZ^],.OON3<\\8SKS[0\@,_HS6G=BW-WW_`'OM
M]W%:="K=X:<7EK8]8-PU20@3U2L^-=G,S=M,N.<MV+,.Q!2ZC5J7*.RL69A!
MV8^"OQ8(?$*-&<?`VOTI2V;=NKO@>YGLZY:'2J]:5R573>VK@MJJR4"<HE:M
MVL<T%L4NK4.I4Z*X9::I=2ILS$@1H+SI<B0GRZ0PH#<_31[2M:'6^ZBA0K=H
ML"$_=NO-I/.2U.E95WY+2\WR].RUNCX-#A<%%E79B((,LZR%"]8]P!WB+0/*
M7TTVR+-M'D4Y%Z1:MJ6[;=*LKF#J=G6=3:%1J?29"UK2=TAK$(6S;TG(P($O
M1Z"(=OR#HE)=V'``DX(X60W&`?L:Y=GGGN7[0MYYXO//:.:8O///$O///&R:
M(2\\\6DDG,H#S&@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@
M"`(`@"`(`@"`(`@"`(`@"`(#U_YJ>7"R.;WEVU>Y9-2JQ>E!T_UKLV?L2\JE
MI[7)>W+O<MRK/P?C64I%8G*96925^,Y2$]*S`BRL>'&E8T2&\X77R@/%/(!R
M"Z`=VORXT/E?Y;I6Z7-/J-<=SW=,52^*Q)7!>-Q7+=L\[-U2KW#5Z=2*#(3D
MU#EH$O)P/52<!V')RD&&PEPO/`>L7>(=RKR=]YCJUHCKEKS4=9;2U1T"D33+
M'NS1B^*/9-3CT^!<LM=](EJW,56T;IC3'R<N*%&F:?$EGI2++Q)R.>-XO.EP
M#M$EW0?*?(=YK.][%`G]6SS0S]%?HD>FQ+TI;VE(A1-)(&BL2;AVB+7=K#LV
M]9,N`PU4R_PPF.(7$P`#/F![H;E1YE.?OE_[Q_42?U:@\P7+=2[-I-@2%N7G
M2Z7IS.0+"N:Z[MMV+<MMS%KU"JU"/`J]XS9BF7J4HY'A"&X^Z0Z>(".I=T#R
MGU3O-J5WL<S/ZMCFAH]'AT:5IL*]*8YI0]#A:2SFBKDW'M$VN]6'YIVR9U\<
M(JKLN9L".87$T$"?F:[HKE3YL.>+EI[P/5"?U9E]=N51RQW--9*U+SI=(L"=
M&GE^5S4>VC=ENS=KU2HU,P;DN"8,;X-/R7PB7X8;[0ZT@>(>]&[A[D;[V2Y+
M*U#U\@:DV%JY8M!%HTW531JX:%;USUBS(=1FJM)VG=<K<]KW?;]=I5)J52FX
M\D^])PYR5?FXH=C^K?,-`>#M&_HQW==:"7YRFZHZ86SJ_;VHW*/J!*:H6]>+
MFH=/F:SJS>E-N.@W/2*AK1'FK3C.UZ1HL];T&')R-'%"DI>7BQW'838T1YX#
MO_>*?1[.1?O'==J9S/WY6=<-$.8&6IM%H];U-Y>[XH]GU:\9"W9/XKH<:Y92
MXK4NZ0?KE)HP<D8-1DW).=>DH4*!&B1H<&"[#`RY0OH[O=V<CW,YH_S;:!R6
MME)U;T>LRZK3E8UR:GNW/0[\J5[4:\:!=%_ZB2E1MTU*K7M5:5>LQ"+\C-TZ
MEPA+RWJY)SU1XP/8:PNZ`Y3M.>\CU"[TV@3^K<3F6U*I-3I%?IM1O*DS&ETO
M"K%H4"R)Z9I=K0K5EJS`F8E#MV"'1&JL>"Y&???$,>@'`/H_J!9-$U+L.]M.
M;E$X;<O^T;DLFX!3YDR<^:)=5&G:%51(S@<B&4G#(3\3U40.O>K?8\PL0'S)
MY'^YFY0N0#EIYB>5/0^H:PU+3+F>=N:'J9-:@7M2*Y=8@778<33JHP+<JU%M
M.VI*CNP;>BOF"\92-%=F'N-YY\!UT`>4.[5[L/EO[JK1F\-#.66>U,J5GWQJ
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M%S?).@RMK4NI4P1;HI$$P/A,_._!Y;BA.,!:@,.\1[G_`)3N\ZO?EUO_`)D)
M[5N2KG+'5J_5M/7--+SI5JR$]$N6K6=6:G*73`J5K7%%J$J].6/)>K,M$DH\
M-PQ`(GI`N@;OO,^Z?Y7N]?L/3+3SF@G]5*=0])KPJ=[6M'TJNVDVG4HE4J](
M%$GY:K1JS:]U2LY3XLDZ&.N0845Q\-=B`%X$#>=X'W7_`"V=Y1RV63RK\P<[
MJ;3---/[TM&^[=FM-;KIMMW3#K=EVM<5G4B'.52LVY<\C.R#]%NB:$:&_*%Y
M^+P/NO.EW$#P+SN]Q;R*<^_+QR[<O>L=*U%I$'E3L2@Z;Z&:KV-=DC2=6;6M
M"@VS0+6=HM2K55H%;M^YY"K25K2$:;ASU,BCX7`]=+F7??B%X#TULCZ*?W9%
MH3NF%V5&O\TE[ZLZ9:I6YJJ[K'=^LDA5+[O"?M*/29JW;2NGCLL6]\B*5,T>
M&_#@4^1D*@]Q/!^<?=$,0P/H-WH_<[\H?>VV9I];?,K`ORW[ETHGZY.:=:FZ
M65ZEV_>]N2UT0Z8Y<M!??KU!NBWZO;U<B422BQI>:D8K\.-*N/P(D$F)ZP#U
MVD/H\'(C+=W-+]V1-W#S`S^A(UI=Y@)^ZWK_`+:EM4ZEJ6)3XO>GXU:@V'\E
MH-(>ISKLN).'1W7`XX'VF,V*0/<'4_NIN3'6OD2TV[NS5ZP*GJ'R]Z0V/8EE
MZ=1J_78L/4:U(VFUO.VQ:5Z46]Z/+TN:IM[R-*]9#BS<O!A0)J%,1X$:`_*Q
MHL!\#XY:3?0^NZHTXU%H]ZW57N9W6RW+>JCE4I.E.J&IEJNZ?Q?5S@G79"MP
M[$T[LFYJM3'XK@]=`=J,O#F0UV,(CKSSI`^PW>']U9RL=YAR_:=\LVO,"^K0
MTMTKOBWK\L>G:*5NA6%,42?M>T+CL:BT:5A3EKW'18-LR=N7/,08<G#DG'87
M!"]6\X(8!`[+S.]VUR[<V7(M3^[TU.F=1)+02EVEI%9E/F[2NB1IFH$O2=$Y
MFV)FRHAN.IT&M2$>>X[2E1./Q9!]V8!B,=<+P+H'GGE.Y9--^33ESTDY7M((
MMR1]-=%[5A6A:,>\*K`KES1Z9"G)RH&-6JK*T^E2LY.Q9J>B///0I:!#`(==
M<==`"`]+N;KN=>4?G6YQ^6OGDUDGM78&L_*P_8+^G$G9E[4VA6/4!IKJ34=5
M;7<NRA35KU:H5%V%==4C&/\`!9Z1>F)8B$^2'04!]5T!^;GG/^BS=V5SC:V7
M7S`DZW<N^H>H%:J%R7^[R_WE;-`M.[+CK42+'K]PQ[6O"R+TD:)6+@F8[\:=
M>I;TC+3,>)$C1(+T:+$B/`?1;NW.Z2Y+.ZMLRY[8Y5[%J\O<-^/TY[4+56_Z
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MS2P-0'84`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0'H^_S)WPZ\0*;;18&M^!U%G_`!GDOC!\Y<42KN6?
MBEWC^C(^Z3EMXN]K*?E0^;-?%YG+]<)93;79_252.'_M0+A<YXXM#\"QZ,N^
M28^Y[EAYWM9Z=OYLJ1>:2_W&\-,M4L8TF2J3,>JJA1Y\^\8CE;T_HR[Y(M^Y
MCE>:J[VM].W\V48G-;J&[E2[2'Y*1J?A_LNM/W_XS\GI_1EWR5#W)<J-JM_7
M8_Z]OYHJ'FSU&`)%*M'#^@*I]F$?/_&?D]/Z,N^25[C>4FOS^O\`3M_-$/\`
M"XU(Q_K3:&6'YPJO;_;A1O\`$3C=?S>F]&??.G^!?*#_`//U_IV_FCC^%QJ1
M_<FT.OX!56?\<)_B+QOY/3>C/OF?\"N4/E]?Z=OYHP_A=ZD<3/BFT-G\P54>
M6L9A/\1>.?)Z;T9]\UE[B^44L+^O].W\T9_PN=1_[D6C_4-4^S"?XB\;^3TW
MHS[YI_@9RG\OKO3M_-$SG-MJ(]G2K2V?S#5/LNG^(G''E;TWHS[YG_`OE/Y?
M7>G;^:)7.;'49XL^*K19_2-4^RZZ_P"(/&J?F]/7\F7?,2]QO**5?7Z_T[?S
M1.[S6:B$XTNT_P"H:H/^5UE>\'C5/S>G]&7?(\_<ERHG17]=Z=OYHLN<T^H+
MS&TNU0TL_0-3^RQ6RY_XT_\`R]-Z,^^1Y^Y?E:*JK^M].W\T77.9Z_GAC3+6
M[)*I=6VJ+K;Y]XQ+!V]/Z,N^1I>YWEA97M;Z=OYLN0N9:^W\33;89AE)U+;_
M`+Z;U*CSMQ62KN6/1EWB+/W2<M1=/7:STK?S9<A<Q]\/YTZVNR3J/V36ZYUX
MI^)9KU2[QS?NEY<V7=7Z4/FR^YS"WH\&FGV[T_G2?[/[8K/[Z<3_`!+/Q2[Q
M&E[K>7HNGK=7Z4/FRRYS`7B__:^WAG_,L_\`9$K:'.7$Y.CA9^*7>./^%_`/
ME=5Z4.X6G->;O>SD;?9AE*SVUF^H+M^]W$_Q+/Q2[QRE[L^`K_S=3Z4.X6G=
M<KM>;^<:%A_0T[^GT_>[B?XEGXI=XB2]W7!$VO6:GTH]PL#6R["/T%0OZFG?
MT^H[YTXHFUN6?BEWB._=_P`&3IZS4>E#N'(ULNK;)4/LEIW]/K'[Z<5_$L?%
M+O&/W`X-\IJ/2CW"<ZT70P'X%1<V?H:<;_MY%SIQ5_@6/BEWC6?(7!DL+FHK
M^5'N`:T706-DZ*,1_,\YD3_3RTESMQ9+L6/BEWCE^XG"/E-1Z4>X9/:S70"0
M).BX;?@\YV_S<N#YZXNG3<L>C+O&?W$X/^/J/2CW3`:T722!\"HN(_G><_3R
MXOG[C*=/5Z?T9=\Q^XG!_E-1Z4>X<'6FZ0"R3HAQ9^AYQG^WMRX2]X?&HNGJ
M]-Z,^^97(G!_E-1Z4>X8/:UW2[_,5$._\[SGZ>46?O)X\EA;TWHS[YM#D/@T
MI4=S4>E'N&/V[;I8/SC1&X?S-.?I[-19^\_F"+HK6E]&??.CY`X*O_,U'I1[
MA&=;[J#?SE0\"S]#3GZ?V+A+WJ<Q)T5K2>C/YPS_`(?\&^4U'I0[A$=<[L'\
MPT+>SX-.Y?U>H4_>[S+&3BK6CS_$G\X=X>[O@<J-W-3C_K0[A`]KM=X;^<:`
MUH9^=9[`%G^Z"B3]\G-$945G1>A<^<)4/=KP&2J[FJ]*'<(7]>KP&4A;^1:?
M@L]V?VP4#4>^[FRU#?C8T.?XESYTZS]V/`(QJKNJK^5#N$1U^O+$BGV_AE^=
M9_+?_9'8JV?OXYQBJ^HX?Z%WYTS#W8<`DL;NJK^5#N%0\PMZ-PI]NL;F96?R
M&W^R*X2]_O.:_P#(X?[.[\\2/\+.7OE=7Z4.X<'F&O0`$T^W6G(?!)_SU')1
M;G^8/G:.6GX=A_N[OSQ(C[I^6Y)-W=7Z4/FR/^$1>S2VGVXP9_G2H;O[Y*+/
M_,7SNDZ:?AOL[OSQG_";ENE?6ZOTH?-D;_,5>X=XG:=;;6L`,I4,M^%2"X2_
MS'\]++3\,]G>^>,Q]TW+;='=UGI0^;(1S'WP6GXNMH`-SE*ACU?US7*?^9+G
MN*JM-PSV=[YXZ?X1\M?+:ROY4/FR(\R5\M8*;;6#1^@ZCOP_MGDHK_S,<_?5
MN%^SO?/C_"+EK;>UGIP^;.?X2%]L!^+K9_J.I?91/_<QS]2OT;A?L[WSYTC[
MH>6&L;VLK^7;^;./X2-]_P!SK9_J.H_918_]S//OU;A?L[WSYM_@_P`L?+:W
MT[?S9F[S'WT<33K99_2=1'EJB/\`S,\_4K]&X7[.]\^:3]T/+$5A>UE?R[?S
M9E_".OG^YMM]7P.HM'_":S'_`#,<^O/3<+K_`"=[Y\Y_X1\M/_SM9Z4/FS(\
MQM\!A^+K:8=OP2H,:-Y^,U+C_F2Y[>+TW#/9WOGC/^$7+67KM97\JW\V<?PC
M;Y:?ZW6V0QN$I4-VUM24NW_F+YXE%2>GX;7^3N_/$6Y[J>7(R<5=U?I0^;)'
M>8N]W@WXNMO^I*A]DEVA_F&YV>>GX;[.[\\<)^Z[EZ+HKNKK^5#YLE',1>SP
M)%.MSH_.D_OV_P!<5*A_F`YTEGI^'>SN_/$9^[3@"_\`-U7I0[AD.8>]20#3
M[=Q;_,D_F/\`?':I5OW]<XR>-CA_H7?GCG/W;<"CE<U/I0[A([S!WH6-I]NX
MY_G6?P/;459V_?9S;)5=G0>A<^=(K]WO!$Z>LU/I1[A*.8"\VL-/MYAP!^"S
M[6_^T<E.M>^3FB:3E9T7H7/G#A<Y!X-#*YJ/2CW"S!U[O"(WBD*`",F2L]X,
M:@K"U[VN9)M)VM'C_J3^<*^]R9PJVZ*=_P"./=.#KY>#2!(6_AOE9['>QE05
MC;]Y_,$VD[6EJ_\`5GWR#+E3ARK2=WXX]TD&O-W$L,C0!GC\%G?L@I]OWB\<
MGG;TWHS[Y%N<MZ""PE=^->0G&NMVL:9*@M9D):=_3ZL+7/?&)YV]/\4N\5=W
MA&FADY_&O(<C76[&$F2H/]33OV05I:YNXG<C5PL_%+O$*YH+,943E3Q>0C^W
MQ=K?T!0>D?!IUO7_`&05C;YCUTTJQM_$_*5]ZU&VO-J/M[W<T@R%!8/Z%GMO
M^^"L+7&=5-*JA\3\I6SOSBW2AB]KQ=P8R0H./]"SVS_?#>K"UKKUS-1^'C(5
MS7WH-I*/W?*5WM?KP=:RGV^2T`?G6>[?[8JPM7)3SH5]SC6JAE&'Q/RD;_,!
M>3HPI]O'_8L\S_C%3(6MYT;*^[S+KH/S8V_B?E(#S"7HPD4^W</Z$J'V24^S
MH;<WYS?P\17W>;^)0>$+/Q2[Q3B<QM[.M`IMM]!^"5`CQ5-3H\(TSVS^->0K
MKW//%[:=(6,/]67>*;_,I?3O$RFVQADV3J._HJBE0X#I)9RGCX5Y"KN^\?C<
M,K>FK^3/OE1_F;OQUK*;:_\`4=2^RH4A<NZ%K&5RO6NZ5USWH\PPRM:7T9]\
MHO\`-)J`Z"RF6HW'.2J?V5;BIMGE3AUR&]*=ZM>F/=.*]ZW,+5?4Z3T9_.%"
M)S6ZB.?VJM,_[!JF]G]UU,CR9PMYSO\`QQ[I$N^]WF6&5G1^A/YPHQ>;C4=S
MWM)M#MD*K]F`NT>2>$M5W[_QQ[A`G[Y^:(QKZG1>A<^<-=%YP=37&\-(LS`?
MW/J_V:7>'(?")9W-1\<>X1)^^[FN.5C0^A<^=*$3G+U0=RH]E;<33JOV95I2
M8^[_`(*UC<U'I0[A'E[\^;5E8T'H7/G2F_SJ:I.M_K-91+</ZW5C+_VVND?=
MWP22J[FI]*'<(T_?SSA'_A^'T_(N_.E6)SM:JN946R/XJG5G`=(^/%L_=WP3
MY34^E#N$6?\`F`YRBZ>HX?[.[\\5CSPZK!O]9+&P_P!SJS]G47N[X)6CN:GT
MH]PX2_S"<Z)8:?AWL[OSQ`_SRZL.Y4.QCAMIM9^SJZ?X<<"^4U/I0[AR_P#<
M-SO]7X=[.[\\1_PZ-6F-^([$S9_8RM8?\/+/^&_`OE-3Z4.X8_\`</SM]7X=
M[.[\\<N\]&K)+#0[$VL_K;6MG^_R?X;\"^4U/I0[@_\`</SM6GT?AWL[OSQ)
M_#DU8S^)+$9AC\6UK[/+*]V_`OE-3Z4.X=8_YA.=6L=/P[V=WYXR<YX]5WGN
M'XDL5NUE-K+`.G^OV"?X;<"K^<U7I0[AW_\`<#SE2OT?A_H7?GBZ.=O51H!H
MMD%K&$4ZLLZO[.+:?NUX%%55W4^E#N&(_P"8'G.7_#\.I_)W?GB]#YTM47\Z
M-96[^Q]7^S>Y0Y>[W@D?_,U/I0[A(C[^^<7G8X?Z%WYTNN<Y&I[S/ZSV7OPI
M]7R;_?I:?X?\%^4U'I1[A+A[].;I*OJ-!Z%SYTV4'F]U*B'&DV=LRI]6VY_V
MY*CW.1.$0RN:CTH]P[P]]_-DGC8T/H7/G38_PL-1_P"Y5H_U!5/LNN/[D<)_
M'O\`I1[AW_QLYI^0T7H7/G3IT6+9+2#+W?TLG*%TYMD5_&[EPU+%:GXX=T^W
M&%GF)/M:#T;W?-/'CV*'BV7O+$[)V@[.CX`H=VYPK*2U->NWW27&WS'EO</]
M"]WS6QX]A@$F7O7'#"=M[$G_`'OV*+.?"6\5JO2M]TFVK?,NR7#J?D7^^:J)
M&T_)!,O?!QR^'6YM;F#3LEKO\(KV=5\=ONDZU;YG64^&^A?^<*C\;3QA_.U]
M#JG[<Q_X.3?X1T:KTK?=)4;?-/X_#?0U'SA6>CZ>-/YVOO#,?#[:9_Q:JYSX
M-5X:STK7=)"L\U[)\,]#4?.$;TQITP-EK\SV3UM-SV_UMP`3>X/3+6>E:[IA
MV>;/Q^&>AJ/G#$3.G6/YVOMK&_H^VNO^YN2QO<'Z-9Z5KNFD[/-:7;X93\C4
M?.&3LUIRP_G:_".F>MH>#^MJ;W!^C6>E:[IR=OFK\?AGH7_G"6',Z=$X2M]]
M1G[:W?WN3>X-M6L]*UW3/JN:GG/AOH:CYPO.QM/MDM?`&?Z/MMG_`!<I:N\&
M:[.K]*WW1*'-'X_#/0U'SA8<BZ?EC)>]\,,9ZW,?^#EGUO!D^SJ_2M]TC3M<
MT?C\-]"_\X7X46PL`):]=S3/6Z=O13^E;1N<'D\%JO2M]T@7;?,S57/A_BA?
M[YL7(MB@%D"\\FC\^V]T;J?M7:%SA"?9U5/RK?=(<H<R;9</]"]WR_`C6/@R
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M_LRN6H^.'=($K?&%)K>TM:_BW.\3.QK5:SU-Q?U322?%*K'_`&WHU'QP[IKZ
MOC'XVE]&YWB?UUKY"'<3`S'X12OTJLI\-KEJ/CAW36=OB].UI?BN=XR$:UVN
M_F5P^^`_1%*WY_H5<IOAE,5J?CM]TXJSQ?\`&TWQ7.\2F);+/Y5<']4TKM'Z
M%424N%;S\W4_';[IGU?%_P`;2_%<[Q&(ML-9ZJXNR9I75G\&4>3X17LZJOY5
MONF/5<7?X6E^*YWCGUEL,/YE<+`]_/%*:2S=\%46Y+@ZEC'5U_*M]TSZKBW3
MI?BN=XAC1+78TP[BWM$S20SPRN*@3EP6F,=9G^-:[IM"WQ=/M:7+\6YWBOZ^
MULC#N3^J:5X?T(HDWP/>?FZWTK7=.WJ^+MUWM+Z-SO$;T6UB3^8W(S^F:3C_
M`/9-ZAN7`=YMQUU?RK/<&YQ=X;VEK^3<[Q"_$M5K/57*<`3^>J1MV?H0JMN2
MY>]8VXZ^M?QK/<)-N/&,*2TGHW>\01(MIC_YJYMQ9-4AN3</SGC@J^Y+EO>Q
MAQ"OY=CN$R"XTEA+1^C=[Q`\_:6+8-SY-/YZH_@_0BJ]3+ECU?G0XC2OX]CN
M$B:XWNUWM'3\F[WB!Z):(=/YA=`:/YZHV1Z?@;%578\K4QAQ/T]/\V;6H\<W
M526CS_%N]\I\5GDD>HNK^JJ+X/T&HC?*>V'%/3T_S9)4>.TKO:+T;O?((D6S
MFM,&ZV._T71,\?Z"P4.[^Z./F<4]/3?-DZ$>/JVDI:'T;W?(3$LX.G\QNOTV
M$_GRB8!F[X%T*!)\G;;?%O::;YLVW>/Y[VAI^1>[Y%%B6:S^478&#9-T3SR2
MC2_<U*KM\6I_*:;YLS&/,&>]H?0O=\@X[+87/47;@`T_"Z%^D6!<)ODO/U?%
MZ?RFF^:.J7,.>]H/0O=\B]998&,O=S3F?A=#;GFWX"J^Y^Y*?YOC'M-+\T''
MF%OM:#T;W?.?668P?F%WL(_GRA_I%84>2FNQQBG\II?FCO"/,-.UH/0O=\PX
MK+:WU-W_`-64)G^T5G=Y)^3XQ[32_-&V[S%^-H/1O=\D=>LTY0+N_JRA,[1\
M!R*Q)<DI8PXQ3^4TOS1I./,*CC+0>A>[Y((EEG#X/=H/]-T,8#9^@MBVM_N2
MW56^,4_E-+\T<-WF'/?T%/R+W?)"]9CHX3`NQAQ_1=#[6_G%6$7R6\?5\6]I
MIOFQN\PO'>T'HWN^9`V8`WU%VG!A'PNB,8T_T$IEN7)SBDK?%O::;YH@WEQ]
MW&G/0U_)O=\S#]F.<($&ZV%K`9NB;&?T$I=K]T'CZOBM/Y33?-D6XN.MU<M%
MZ-WOF<.)9H:!!NSMFZ)L.19)*=#]TZIJ'%/3T_S9#DN-N5=[1Y_BW>\2\5G8
M'U-UAI'\UT7#I_02GV7RG6BM\3]/3_-G*<>-5QEHZ_DW>\2B+9Q`/J;J8<#^
M>J*S#_82NK2Y:I10XCZ=CN%?<7&%*F]I:_DW.\3B):!#/473@!C\*HWA_0>8
M5IIURZHJD.(>G8[A&NKB^V6E]&YWBU"BVG_K-S@M_GJC8LVX2;-JM].N7\*0
MUU?RK/<*C4+B3DZO3_%/O'!BVCQ$F#=&S'X51\VLQ_.>"M;*X)O*D=97\JUW
M2LFM>JXV/BGY3(1;2=(!A71F`TS5&P;_`+#R5M9CPC9'5^E:[I"N_37F[/Q2
M\I8]?:;/Y3<V?\]4?+9C\$Q!5U8_96R.H^.WW2BO_2$Z2=OXI>4Y,>T@`/57
M-B-DU1VC;_.BN=/#0N"<5?SZ8>0K+JO;SJX9>$B=C6DW^4W.UK/T51LOZC5U
MIUHZX*[\<?(55_>IC0D]=:36>IN8G+&9H^7]1[%;VHZ?"BG3K7D*2_NTEG]P
MQ?C6E@3"N;+9-4=G^T]ZM+,;>:4ON%5=G92JU/[A0,>T&G\QNG;A\*HN9.?Z
M#V*ZL15,"FORTNWUOQQ\A"_'L\-;!NH-_HNBX?\`V+:K"$9K#"I57IZ&N*O?
M'#R%-Z8LW%L"Z_ZKH@_^Y%6EB%[-;GW2IOW.&NKIJ/CAW2A'CV7B3`NTL&R<
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MOS6E36?!-2VMS%3M$?\`)"[[G&OQM'Z-WOG%W^3OQ.+^TTWS9C\)TJ'\R:F8
MY_USM`[L/[$(X<9_&T7HW>\/7\G?B<7]IIOFS%Z:TJ=+I$IJ8W/^R=H;_P"]
M"QN<:Z='Z-WO&KO\F[Z6YQ?+Y33?-DKLUI6<!*ZEX''^N=H''';\4Y+*CQI;
M='Z-WO$B%_DZG8XMG^/IOFR5V:TK+P(E=2@6L_LE:+?^*5E0XUTZ/T;O>)7K
MN4%6L.*^GIOFS9NS6E^#)/49H8<:E:>(9T4E8N6^.)5<M'3\F[WC:%SE'9#B
MN/\`KZ?YLVL"9TR9A*ZB9[:C:K1_P7DH-RWQG\;28_ZMWO$R%SE)K"'%,/\`
M7T_S9MX,?38ETB5U`Q#,:A:^S_>Q1W#C">,M)Z-SO$VS=Y5Q:AQ.GY>G^;-Q
M+QM.CP\,M?N)&)J%L[^BF;%QG;XLUB]+7\FYWB;&YRNLH<2].Q\V;CU^G_\`
MK%]?^T+;^QRB^IXKTZ;T;G>.WK>6/Q.(^G8[AWB+)VD'GFW;4P<1^M)X_P#+
MX7\#RAP[*6HG['](?>*M3QU/'0V?M2^8-1&D;->/$]=U4^J/ZSWCD?\`"%0K
MEOAS>.IN>Q_2$NWJ./?4+-?Z5^@-;,2-E$,-X54`#_F8\?\`^XPHT[/#?K5S
MV/Z0FV=3Q]5_[?8^UKY@U\2GV.SB^6-6#-OR*?.(#/\`G(,%S]5PW/Z5<]A^
MD)D-5S#LX?8^UKY@H1)&QL0;TJV`/["'_P#\2YK'JN&?6KGL/TA,AJN8DL>'
M6/MB_JY7>IUC-9\M*NTX_K'?.P?])U!=GA3?ZW=]A^E)'TSF3+]G6/MB_JY3
MB2%B\9`O>L!NSY"Q#TG'Y3IZGA?UN[[#]*/I?,M:?L[3_;%_5SCXOL3!E[5A
MN`;\A7\>K]5">IX7];N^P_2G.YJN973_`+=8K_3%_5Q\7V&,[VK!_P"HL0^6
MZ%GU'"W_`,7=]A^E.?TKF7^[['VQ?U<F<D;$8#\M:N=GZQGPT?XS[%KZCA6W
M5W?8/YT?2>9?[NL?:U_5R]"D;&.'RUJY!P`-D1`!U?JE(4CU/"Z5^E7?8?I3
M:6IYC:PX=8K_`$Q?U<NNR-CGWMXU;A&'ZR7QC_C*L*SPOZW=]A^E(,M9S"L'
MP^Q7^EK^KER%(V4#Z-XU5N[Y%O\`5_SD72-KAB>.KN>P_2D6]J>/M8:"Q]K7
MS!LH<E9O#^NZJEG_`$.>&S_")2H6N&?6;GL?TA"N7^/)8:"S]J7S!=@R5H!C
M+MJ9Z[/>&S_"$J9;APU8?2;GL?TA$>IXX_\`@;/VK]";"%*6CD+JJ;6[;1>&
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M6_;?HS,P;=_N_.[!^MY[M_MMDH4K'#7)_P`XN>Q_2&/6<4^K6_;?HR/U%N`_
MV?G1A_S>>8P,:W^NRCNQPVM/I%SV/Z0SZWBGU:W[;]&'H%N@-^/YX`XC]3SV
M&&S^NVY1;NGX7O8ZFY7^0_2F'=XH\M-;]M^C('X%N/8/7!.GI^3KQSV_V7&3
M%!GI^$TJ]5<I_(?I3I"[Q3>_5K?MU\V8&7MH#]<,\<`S]3KW9_;<*+/3<(Q_
MG=W[._G3MZ[B?U6W[?\`1$?P:V@<;BGCCE\G'LSC_==0I:;@S=7K+OV?],8]
M=Q.GZM;K_+?HBJ]+VTWT;BGW<QA;;VS,_P!F567-+P3UCKK;V?U;],;PO\43
M7\UM^W_1$426MEOZXI\9,_4T]M&?]F5`N:3@6]CKKWV5_/DRWJ.+4?\`-;7M
M_P!$1O2ULL:;DJ&1:?DT]]F577M%R^XT>OO9_57\^2)ZCB^[1Z2U3^D+YH@^
M#6N\ZTW)4#N_4P]M.`_LUL"@7-!R[]?O_9'_`%@S;U/%TL-):K7ZPOFB(2=K
M`EMR5`M_Z,/9#/\`MTH4^'<N)T_:%_#_`)-_U@F+4\82QT=K[0OF2N_(VH]@
M;DJ`!#,+7?V]5;W!0I\/Y:JW^T;_`-C?]9)4-5QK=7\SM9?65\R1&1M1I/RE
MJ#'2&?J6>P`']_%#N<-Y7Q7[2U%7_P`D_P"LF_TGC67T*S]I7S)@_(6GPL^4
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M&U2'2;FJ)8T?K6>V_P"_BF6^'<LJG_<;]/Z&_P"LD6>IXO7]4M?:%\T9_`[4
M9Q"YJAN'ZEGFAC&_V[4J/#^7$TOVC?\`L;_K!!=_BV^U]%M_:%\T9&4M4O!T
M7/4<&$#Y+/$-S_NWM5CI]!RX\5K[[_Z1_P!8.=S4<6PKI;7M_P!$3B4M7A`%
MRU`-;^Q=_%G1\=JYLZ'@5?UZ\U_17\^09WN*;V.FM^W7S9F92V!Q<-RU`8#*
MV'_K?[]]"M;6CX$J4UM[/ZM^F(EZ]Q/;IK=?Y;]&2.2UL,#+EJ!.+?U,/AHR
M;_9O)6VGT?!OP=7=^S_IBHOWM?O.MB"_]7]&2"5MG$&Y*@\S/]3+S<<O[=*W
ML:/A*:IJ;E7_`+C]*5=R[K,?XF-?Y3_8.3*6N7A^J.?PQ'ZF7OLTK>UIN%[-
M1<]C^D(5ZYJZ8VHY?C_[),)6V"X/U13X9_T:>Q'2/CI7%G3:!97I^R_VRBOS
MO[8+TO\`9./@ML$D?*.>&7[&GOLTKK2V=&K:_C9-5^3_`-LKKLKC;\U9=/\`
M`<_!;6`#+BGP22"?DT]FS%O]><%<Z>SIJX3;_P#!_M%1J&Z.JIXS`R]L8_JD
MGP=A^3+V'_#2M[-FU54D_1_A*2_N*$JO[A7?@6SA^J:H#;^MAX])_MT&-5K:
MA!.BK\7\)27O44=9M?\`A_A*QEK6VW+4!B?V+O;3_?Q7-B%%5+`IKRT]:.[*
MOY'^T5XLI:I/ZYZ@S#]BSQ;V_'BG04]B5>O^`JKWT'>QO2R^3_VRG&E;3867
M141TBU'L/^'5:Z?UR_`7I?P%1?AH&OUB:_\`2_VS4Q):TB7G3=M4+,"/DB]_
M^(`K>WZ_"EJ/I_[)3:BWPU1>]J;BP^1_2%&)(V<PCY651N\V@\?+<*F1GJZT
M5J/I_P"R4MVWPBF.KNU_D'\Z:R))V:T@W?5<'BW]1KY'_:)BE0EK/D84_E/]
M@IM18X/]<NK_`*?],:V-*66]C\LJJ!DSY%/G+_K*&JUL3UT84]1#/Y7_`&"M
MG9X$GCKKR_Z;],:J-(V01C>E7`#2/U$/G;_A,Q3K<^(Y+3PK_*_HRLU5K@"P
M^GWD_P"BM_\`^\T\:GV*TGY;U@8M_6)$.1;A^JE3XW.(I4^C6_;?HRGGI^7<
M6^(7\OJG_P#T&LC2%A-QOJLMQ_8$^?+=0R72-WB>2TUOVWZ,AW+'+=/[2U&'
M_)O^L&OBR&GQ:V^ZUUBP(FW_`*UJ5;O<4^JVZ?R_Z,@W-/RU7^TM13^AO^L&
MKCT[3P'TK^K8P9AI[$/3_P`[0ID;O%J?JEKVZ^:(=W3<L;V/$]1]B?\`62B]
M3=.#@;_K;?\`N[?;_P!KEGUO%?JEK[0OFB%=TW*^?[4U"_Z)_P!9-=%IFFX(
M'VP:YN+=.(G7A^K`8K:-[BM5_-+>?UA?-$*>DY6K_:NII_07_62L_2M.,6ZB
M5YW!O[G$0X?XX-4CUO%OJ=K[1^B.;TO*G]ZZBO\`07_63$4O39@'VPZ[T?M;
MQ-V?Z\$];Q;9H[7VC]$8^C<J/_ZKJ?L+_K1P]2]-3GJ'7<OWMXF+?^N">MXO
M]3M?:%\T8>DY4;JN*ZFO]!?]:)7*3IL#^Z%7<QGIQ$W9?KQ3UO%OJ=K[1^B.
M]O3<JUI^U=3]A?\`62=RE::M!&H-=)#6?M=1!XOE?L3UO%U_PEK[1^B)D=-R
MN_\`ZIJ:?T%_UDV,*G:<G*_ZYC_[NX@P_P`;B$G>XQ2CTEK[1^B),='RPG1<
M3U%/Z$_ZR;&%3=/77@1?]<8T_P"3U_+=^NTJ%=N<6:_5+55_O_T1,MZ3EG^\
MM1]B?]8-O`I]A8,ORM'=^H!\9G']E?F465SBGX6EM^W_`$1-M:3ENCW>(W_L
M;_K!OI2GV(3A?%8>`PQL5]T-'_6@[5'E=XIMTUOVWZ,G0TW+K6'$+_V1_P!8
M-S\!LC_GI5_\1WO_`,3+CZWB/U:W[;]&=OHO+O\`>%_[(_GS:S!82!N\H'M+
MZYY2KC(^^F*JS317L.LO#RJ%-YD^U'#$U$R\`WHP[2,/&H=RY+`F6<:FMBO@
M##V\ERWY$^U%52>1J(T0`'$-.+-O65G>D3X0316>C8XD8C/IZ.I5SG*K.VY*
MN"P*C\3%ONM&S;FF\QN/H)`^#F6=1'@W+&_)&DX32R#7&8XY])/5L";\^DY[
MK,X;[N3<&G#`'`)O2,X]!=AQ0Z<\-V'LP4A3F\Z&6E0V<)]N\.[.DIO//:0;
ML(UJEB7H9R(:UN+<&[AL72W.3?20;Z22H;.&\2#B<LQXRIEJ5<-I!N)T=#80
M7PT8DGP'V,4V+9`E$V,)[,EN)SZS[2D1=3BU@;&$\.(!I#0,SOV]>"V9#O1Q
MHC;P7Q@WBZV[3TMW+:VW4ARC'QFRA1"QGI8-+>@+L\<2+<CTYEMR(T#WS3Y.
MG(K%60YI-X9HV;D1H`]+(-W>52%D5LK<=YUZ2VY$=`RV[3U=*V'JH^$Y,8NE
MKF!.!Q;GNQZ%M&M<MASNVTH^;6M25R.\W,L>(#=H7&[5I$=IO(S+XQ+<LV>[
M[2AR7G,4?08@M(WY>`LWYM4=YLS1F3[PRW=.#6,#%"N=K`UI)Y(K1<,<SF6>
M10;F7C.UJ*WL>@P#XX6@AN73V]2@W&]Y]!W<(H@XB"<MN/3[:A3[1GU<,V5W
MR]Q''WWB=W*JN_G)+PG)45Q=9@\0,6C#!O0/Q%77,9$NUMKTD$5YKO0P-Z,\
M.U5UQ)K'I)4WYI6!!#=AZ?`.U1+J2=#%O),PX@26;,!YU`FL<<F3Z.A@\06=
M3`3NW]95?<5),E6^RFR#,/'82QT><X]"AW$CJJKQG+<&DX'#+,#/H`4*XJ2P
M,I>=1%5]KQPPQ;DW#;X@N$TJ49VR7A#S#EX>GPYD[%!G%;3"725WP\TL!\&U
M:I.F&1(@XTQ(^%YN1:FZ\SI6-/`2.A]N+>IB23:QR.<W'=P)72-N>7@6]N*S
M1&:#F#&C:WJ/XJG1BJ462-L^LG+"UXG%@(.Y@Q!ZU/LK"KR*Z_A=:,@2QUF0
M:IMN*22Z2)-8G+A]^,W7CXV]/2IMN.'A(,^T^E,Q)`>&.(\BLM-%'&YB3%[(
M]HZ]OB5WI\L2ON=HF#[&?6G+SA7%B"VY$6]BR9T@Y$899Y;0KBQ%*CZ2EU/:
M?6<@G''(=;0<NMBO-.E@WF5-Q8MF7&>(!HZV;?*K>Q%;2!?R)'G^EN]T-V9=
M2N[%%D>>U&7C,?6`$G,8=BO-)V$GTE7>[3ZCCU@`=Q;CGT,RZ5?Z>*2P*?4X
MJK(C$#SSV+=[/8Q7%BM8GG]3^;F0QG@&%ON,5O8C6:KD>9OSP?2BL7PQC6-+
M<=A.78KVS'S2DOR:\XK18@)8#LV]76I]N#6S$IK[\XUL>(0"2&#KP`R5QIHJ
M5/AM*G4S5,,S41GPT/#/%I!\95U;BDD4.IE6$J]!1BQ`3F3AL\^:EVU5Y8E%
M>:H:B.^/2SW].>0"G6X[-A1:B;Q^&TU49_/-F.'7VJVT\8NWXRIO-)XFGCQ2
M<@>LX9CK;FK*S%9O,I-3-N57\,#4QW^$%K3U-9N4M*N)3W;CJT\C3Q7B6DMZ
M_*QJD6XXD"[<PHLC51HCOI!I;TD]AW*;:A7+(@SFTZ[#3QWQQ8EN&.>S;B5.
MA%-8D.]<K+!UP*3[X.!)R+%EPBBMO3V1R*$1X',C+P>/:BBMY4(4YNCZBH_$
M#6-;CM/5TKN1?62*QC`$ANUG8-O4$,^LD8O1O2=:<@P#MZ]K%D.Y,LPXQ(`;
MM':<^QA"$J$V6G(K'FC$G`CPGJP0F6IO!>$V,"*"1L(.(VM&['I22PQS+.#Q
M-M!?;Q`[\/(5$N)?&3826%#>RKS2Z#D`/*SMQ4.:QIL)MJ32P.Q298,#M:WK
M.![&*'=C159/M2:=$;'UA^N\BX41,WETGE..^.-YI+-G9XE]:DX+=/T$VY/[
MIH9F-Z3,@">W,E0KD4G@6UF"DS3S,9O$PY$$G%1+EM8$V%I0=4:R-%`=)).'
MXFU<)I1P)=I-R5#5O%U]TO//$$[CL4:5UQRH3U1(I/OATD-.!Q)V#:N6XGB6
M-%3PE6)&8\P-+,F[0W$]2>K6T*$4/A&&+?'B?Q%EVXHUE;4AZ_#,L9OR[%KN
M1-?H\-K9-#B@!N7NY8#:GJ_B'T>'AH;"`7"6-.PXX>-=U!(XRMQR-C"C.C!I
M;BQCRV<%TD2[:BU7:7H4=W:\]V[>I945'%%=.RI*AL(<9T!H>>&&_#P;%WM/
M/:1YV(XUR+\*,&ND\6\$=/N*=!X$*>GM]+Q-C"C!N!?8=Y[.O-283JZ/(A7+
M26!M844'/B)]GG4B$4U5D*=N+Q9M8<8.N@@O%I8QG0<6]:WE"-O&)$E:BG38
M;"%'!&)>&&.&]N"Y.;V$6[:CCG@7H<5P#WQPR13EF096T7X<<``$O*0INF!&
MEIXXO&M2S#F,#GF=@Z%LINE2+*%%5$SD?TL<?`SQ-65<9PN4W2SZ\$'#8U:.
M3>!',#'P\PSZNDA<W"KJS*JS-R,&ACV+/9U8EJCRMQJS&;H<O1!O)9TYEG6H
M<X*N!ENF",'WW7VNEYX8$DC8<,#T`*).Q&M&;1>YYQ'Q.NNNC%AW9LWG:H=W
M3PJWC@;>LEFRN\^,>%XL#6X[>C)0;EB"QQJS/K);:$'%Q%H>+"`#CV;E1WXT
MNR\#9,AIX2BKKK5XAXNG!I9Q>$,5=>@EYRS.JMQCD8Q^#A#H):<RW?YE7SAA
MO'>-N-SS7D52'77,"3BP>91)Q3\YG2-F*=.@K%X.O$`DM:T$]+/`%`O+HR)#
M7FD3T4DD-.3`W+,M/0Q0+D4V2(+S$B)Z)PX!I#S!CFUG8H5U4K0V3K+P'!BG
MA9C]5EU-+%!DOPF=8/SB(Q&#$EK!CY6=2X-5=-IOFS-TY$MQ)([!GX5RE8A2
MC#Z#DEW%I/%XFK564L-AM%NE-A@WJ\?MK;U4>DVWF9<0`;CQ=K,^M:NRGU&D
MY/=(7XA&/2T]+>W$8+I:T\7AL.49MG+L0O.C86,VYX9JPM:>$LZAS:9((AQ:
M#LWAH8&]:EQLQBE%9$&_+>FQ#B'$8AC3M#1YU*A:3\1'NHF=>'%PDEA86CL:
MUO2IUNVL.HKINDFUTG,3A$1PM..!'2&^96=BS&N!&N2=?$9$NAT8G`-\.8VJ
M\L68[M/"09SK*I8<+O"STO18?859651(A7[CJ^DS<X0<R&M+=A\2N-.MY*I2
M7[C=6\S@O#$M>V8-R+6M[5=:>*32*F[<:JT'GPT%IP9V@9*VL9TV%7?U$]VN
M!D8@+HQ.YHV8X-9UJ\LQPWEF4-Z])X/I(C$82`3Q,`Q.SI5]I4MQ/PE?=N-X
MF/K!@&D%N_#)7NG56EL*B_-XK88E]T$O<1!&QN:NK"I)+846J[,EL9!%C.M`
M)+#D=N'0K:QG@><U$$JE4QW3MZ`W:KNPG3PE)?@FJ%1^,[D2<M[/:5G;6/@/
M/ZIN$W%94-?%C./$@DX9=H5MIL*)%'J+C69JIB(XYAQ%C#[>:NK$-]I,I-3>
M:C+J-5$F7?28\]GN9^*K.W8C&2H4%ZX\Z&MBQ7,3Q/9GI+#[JG6[:I0I-1<=
M:&GF(SH)])[+;[#BIUE;L:+I*?476S41H[N7$]T8[%9V\REO3JC3QY@,(!>P
M\99TYXJ5%9(I-1<DEO8&EC3>>+V\^52+:2E1%9*]*E70U468=Q)>/G'8IUM.
ME"!<O2HZ4-3,1@W!XG#:6;6X,WJ9%;JH0IWI5\1JGILB(\,P`T'''HS6R3:(
M%R_+*B*<2:((.8).6#.CI"*+JB([KR="!^9:TMW9[=^+<UT:>5#7>Q\!!ZUP
MEI>(XCOPZ>Q*/H-=YMX&0+A9Z3S6,QRS[5BDAOT="1V,`\`"\<0S=D<>M9H_
M&=K=R5*>$N08N6):6D]>*4:QZ"PC/===J-I"B`$/`G9X1FM9S='TDN.JG79@
M;B#$'$<3M/7LZBH5R<JDVWJ)O8L3L$G$!`):,!CEMZUS45+,LK%Z4HNM,SL$
ME%XRP[&,9N!*C7HIHL+=V69MF=)\)4$D>LD>3YI\-..3&#>OK2E*KKX#]#%I
M4D:*.>(DDYD@=#,/(H4G@7.FC7,T\<9X[B>PL4>4][`L:8)&JF'O1..TCW!V
MJ+==4R18Z$:UY]@P/61T*ODZLL(VU)8E!^(.(M._'9U+?UCV(GJ-%4K/%K'C
MF"6-S8"PK#N/894:]1P\0&G<SRM\J*;>PRXT,022PX8X]/2P=2>M2R6)C<;)
MG#UY,!P!8$5QL;AL(+[,&GK/NM4CUF"P(\X[<*FQ<V'>/J?9T)ZUO!HAW(T>
MZ67'L0`=O@6'+I(L[=6Y&R@/;GBT;#[.A=K5RKI1$2Y6E&;>">+A))!&X>`>
M-3H2PIL1#G!-EUQYC1F!U;UWBZOH*^::J;:!$:STB#ELV>'-JFV9.E-A`G%9
M/(V;KWHACQS&#!N:=B[79N45@1W!-%^#$(9NWL\&"CT6W,BW88.+R-E#>:QI
MRQRP6*]!72@JT+;C^TD]"D1R.,HUJBR[$/"UISR85LJY(BW(O,E<BMP)P(W=
M*4>TA7(I^:6`]PNL!P(:"<,=H'02AIZE=)@TM;MZ/%BCH':2S9RZ^01X/%DS
MH"X2[3"M(E+S!TX=@]U0ITQ?A,>J729.D/%K6>B>G'`*-<=)8CU=,6\#`D'T
M<BUA+0<&X]&:B77C4PK>\Z["!_$O.E@V@[]_5BH-QY/:;>KQ(0.!C.P[<=JH
M=1'^-EUEE:7\4D]B,8CQ#,=P`PZE`G$V5'@8OO!YS/:&=3OFP4"[&F1TL87/
M$1<0X>+9F.LJ#..PE4QH4R6<3YS>P'N=JAW(UKT&V;\"(B\#P]`QVJMNPW6Z
M[3M%5BNDX?.9V!G"=I+PW;,"H5Q8]1FE/-1P`'0&XX$'<-IZU"N13P.L<Z(B
M>=:>W$=&X]?0N.Y1>$Z9')>9GFS+H'4,$5M=.)A8G+"0#P@AC=@9V'%<Y15<
M6;51&S%K!U8,6*0,U,^$D-#K&[01O1)9Q9K-K=.&8L>S'LP\*DP@<7ABCAT,
M83D<689>YL4Z"PKM#I(S?+02!EV-P]+Q+O&.52'<7\8S)S)TC8"6[6=/4I5F
M&)&F\3-PXEW:"2/<Z"K&W;555E=<PD^L/EI8W/+K'G5A83V9HB771KJ,FY-.
M6/8?9X5>:>*:(%S"1,X\P/8X,QZ-O@5A:Q9"U&->FGWC`Q6C`L9CU[&L5OIU
MNM(I;RS`>)8&M9FW=LZRKJQ&M&5-Y>:V9DXAT9Y@^8JWL6T\2FOOS'T5."^Q
MN&P@]!VJ\L5H45[(KE]KSQ.X$$8XJ]TUM;B2Z2!>;BSAU]N.PY^WO5YIH;M'
MM*C4RI5>#[Q&7P=K6A7=E5H^@H]0ZP?@*<6*&[F9XG`;O"K?3VZO,H=1-[K?
M05'HN!802UH\YPWA7ME/!>`H[TZ/>H5(D0.AI:\3AGY\U/MIT/.:Z7\:VGL-
M>^^"20UK.@A6VGC5]!Y[4RWE3H-5,Q/?`EC`2!UA76G34H]92:AUC+J-5$?R
MS](8Y9[,%=6XHH+\Z+`H17V8-V?B=1*EQ6&917VJLTTU$82PM+!CAV]:G:>.
M%:E5?>ZZLTT5[,E['S[/$I]O*A3:B;6"-1,/X/,).!Z.D>-2XQK1[2DO/!IF
MCC/D[<]NT,8T*1!*M7L*FY+[AK(I`VMWM\ZL;*;52#=F\35S#SNPM\19CXE)
MBWM(5R;;Q-2T<9+SQ#`>K`C8`ML:8$"Y-OSD5(SS3F<&O=!PQ![5F-:JM2'*
M>*3R11,;8<-K#B/$I+Z3*N[4B,1<2W?ALV^19,>M:=:8$PC=?"QAWY]6]8IC
M1&-^LM[:2PXK"S,DX8_4AN2Q1^(DQ::+L-YCV;6XCK9YPL;&3H2JMXW$!]KK
MK3B"`=N[AZP5&DJG:.:-U+/<0(.&&3>D*)<C]TG6Y4\1V"6?`==&09XV>8KC
M"JKUEEII53?A-](1/38.EA]G2N%W*I:6WL-SZY[I\)4`D;S/*,?^6/>D,`1V
M[\U]9$Y;3]$MF-'0T4P\QCK<GCCDW$GRJ)<EL+K3QJDS23<7AXF'-W(="ARE
MM+-0P7@-1&C>B!BTEO4&%1;MRJ)-N-7UFO>B,=+2!AAV-]I0FZR)L%BO`4X@
M))/&,#N_$6SG0G*#95+[&`O`L):SKPP"PIXF7#H9@]%X?JL\#U`M8%ES3V&%
M;HLSAU\L'I,:<.H;SFU-]9T'JWTDSKS/J@`S>S'?TIOU&Y7:67(Y:UH8"S8Q
MF&&6*[JXLFCC*'QFQ<CO%GI=#1DWSK._'.E"'.#:H7H44G#U@9O(QW8,6DI;
MR(LE7(V,&(>)T^L=..(ZL@NMIX]1&NP31MX4=C/2!QR&P[<%80=5U$"4*OPH
MV,*(<Q$=_(L:<\,,,5(C--T1`FG5I])L7)@.%CSPR!]A4FW-IU(%RVFO#4V,
M.9X@&/N]._>=ZF2FGL(KC4V$*8(Q+[N&.W8<L1M7/J.%R.'A1==G,AQ`';AD
M%E89D&Y;WG6I>=CD@>F`&`]/XJDIJA%G;2PVER#,L=9QNX$XG;DM98LB7(.M
M<"5R8!>9QNX!K1FLI(ASB\BT(V&+PZ#YEG'9D<]Q])QZX;^@^P;"L4H8W#@/
MDO<1>!;ET#JZ"N$NT9W7L.7XO#@7P=I'3ECX%$EMZPK9D(W"&MQ(([,,%#N)
MM^(PX-O'(P,?L'$QO:S-1KBH_$8W'4XXP0?2#'CB>@'SJ#=PH;NW19F)?(8\
M'@00&`=?3E@%47H5E)DNWA!+P$#\4/LX7@`Z6,.]GNJ!<CTFZ6!$8C3P\3``
M6G>6>=0KL:1KX3I:[=48&)P@`D'B(ZO8&XJ!.#H2NHB??Q:"#B71ATXGHQ4*
M43"Z`Z[Q.CTA[UO:TYJ!>A5R>P[PRJ<L)>=<#P9OZ>'%JKIK:;M?A,X>!#K0
M1@6=F:BSMX=9O#!T(2\QW,`@`#QXKAZJK;J=*5(W'"\6O/9EN6UGMK/JZ&7A
M@2D,'OOXI1I6_/>TUQ,&C_7!X`L>J\#&)FZ=H>;BQK,NQ%!1E4UED</.L.;1
M["IUM?$:5."]Q!C=F>SKZE+A&G4PE1U."P%C0?$T,'E"E1MU:Q(MY^>Z'#C_
M``EF#"WP;U,A'#J(MS'K.78O"^SM9OW[U.A!M)E;<Q;7A.7GFO@@@`EH[,\E
M8V%C4B7EBGX#*(_D6C'9LQ]U7=BWXB#/M4'K6PSBPY;LMG2K*W&F+R9"U"HW
MU'$)[WQ+P&WQ#PJUTJK1%+J#%UX^M/I,&79^(KRS'SDBHNOS&2/QP",0QI!V
MY%GC5I9MTQ\)3WEYCITD;T</=>PY>%7NG6%"ANXD+T5A/I`X!H9GYL%Z#36Z
MVUCM*K52I+PF`B%CK'@6MPVJZTZIF4VHG@T0OQ@"\6@%C"WLV]*NK"K2A1:F
M?F./@*46*7?JF[?:"N+%M2=2@O32PH5R^26\0)83AEU=:N[&"Q*743QJ48S[
M<H@\?A5G"%,-IYK62_C6WT&O>?/ICC!(&W%OD5I8MO!UP*#4R<E7X9&JCQ2P
ML>8=K<>S-7-B/G)NA2:ATA+PHU<2*<3Q@>S8KFW!)=90WY)8&KC3`Q'K`3B&
M#>%+MQIB4=_:S4QXQ))XPQGXH5C9A1593ZB7G5\!J(\4NXF("W#H;L\(4R$:
MLI]3<JFC33,P0Z]Z8&!8//V*;;CM**]+S7U&BBS&TOCJ9D?:4J%NK3V%9.6%
M<VC619AC7FM'2`P%K,<5/C6E"#=ELVLUL>8,1TL(W,V];O0N]M416W6W+Q&J
M?C,+>(,.&.+?*Q=4DLB+<E2KH57XIQ'$-H;AT]"+M+PD"4\%4J/-+/3&P@L\
MO6I#5,3926PP+S/JP6$C+(-V]#42VH;P$?I'O>$CMQ/2E,*&*TP19AQ6O!CP
MP9CTL/E6'2I(LRJJ%V'%X2"W-HZ\R"MFJJA-B\I&VEIAN/XUGM=JAW8M8=!)
M4ZLW\"-P@/DMZ,LSX,U#G&N!,MRP3-]+1Q$X7LL"&=;WF4:E&T6NDG6,O`S?
M2#WYH?2'M8^!0[C\UEC;G5&Y];^.\7N*#0D^M\!Y;FGL<"&;]I[>Q?6#*5%B
M?HW@EO'7)E_/+,C:QN>'1@H=R6S:7.GAO4H:*9>XFAN0#>W#IW*%.6+>PLLD
M:>*3CC[`HLY8DBU"AKWWB3T8M\.2AW)[N1,@L*E:*]B6;,<]NW%*UQV%HDE%
M&O??Q...+?"&LVK"KF;466TC>>+S,\`T`-8WVTJV*+P$KK2P-8,FMW>1K5FK
MV&-U5)G23ABW`#L"5DMIE**Z"=W`,:&DMPQ9X"5W3:(DHUP1>@%X@EH+/9F2
M0LL@W$;"$TDY9=3,>DK"PS;(U-[!%^%Q-(P.X^ZNT)TH\2/<A]PV<$D$-V##
M/'#;O4^$]Z.!`N+.AM8#YVYG(@%=H2=:;2!<CL69L''O2#<?9EB%-@^@A7(U
MQ+\$O`X,V-P;UJ7!IJC(<HT=#:./>CV'Q="WRZB/.-,RQ"(V`->W8$>)JSB0
MKL?NFTA^D`QC`!L7=/`BRC3,E=>9AX&,'MK?#H(<TZU61,Z\2?J1U;O`%K@B
M'.$FBRZ_L:WI.78U9JCEZJ3S9CQG)N(PP(.>TE#.XR:&^00W<QN;3EAED%'E
M2KJ8]7,Y?.+6D[FY89Y="B3#@TO""20#CD>P'SJ+<S"A)]1'Q-X<3@0P-SWD
MYM46YF^FAE6Y9X')B%I(/HY.CIQ4&Y1T#MNN.1CZUO"Z&C!GF5?<CBWL.BPP
M("^`7F;#@S+)G:6!0+L'GL-XNIP'AZQUTXX$GREI*@W%2-6;VJ[]3%XX\1WX
M#H&X=:AW8DI=!PUI.T.M\.Y5\EM#Z>DR=B,8,F=@.>6]BA7;;JWL.T:T2.'G
MF8M82=^TA5UV&-?P3JG5T,S$'`,V[?9U*'*+K4S%><5'CQ%FS;U^=BS1>([9
M(FXF#=N;L'X[I*U2WGX#7-D+SWY+/;EV*-<@W-[M#>A@U:;D_`*&;AQ;Z79T
M;UM&#WO.H:R7FDO'OQV89,V$8^^"D0MM9'!KH(7'BZ0,>L]&PXJ?"*<<,S9X
MHYBO,RP+1U##PC%2;4,<<F0Y]MF+A#P&_IW'9UM4N$'O8TP^Z19YG#<SBT%G
M2P[]JG6DDTMA73PF^LD:6@YL#6;]K1TJQL12=-A%NX]1&^UCH&36];=BO-/!
MYD"Y^,<//M`(P+""SV8%6-M8T>1!OYOJ,1$8QT[F]8\3<5;:=*N&!2ZC%.G0
M8F(0<SBSBZ-WA5UIXUEN[2HO+S61Q'VEI.673T8;"KBTJ-%1>=(/K`>/#B&$
MD^'W6JZL)+XBAO9X&#[Q#[Q:PD.X;#A@O0Z2/\5795E)JY4NXY4(G7L#B1GA
MDSM:KG3JK11ZJ551>$JO/O///9X>QN&"N;,<53(HM0_,?25(T3%T![PG?[JN
M-/;DG7845^:R9`8A#N;3O"O=.E7'(H=0UX2C%?QQ)R#6-/2K"$=FT\]K))7&
MZX4*$1\YC/I;EUJWTT*/&AY_4NK\!J9B(2'F8,&?C/0KJPDY1ZRCU,J*74:B
M(\6L+QQ;M\S%;1B\E0HK\UNT-3%?]]CM/A4VW'#$H]1GF:N,7][!FQN&"GVU
M2/A*>_);U=E#4S3Y(#7L&LPWLWGH4VW!Y;2FU4JK`TTP]@3N:>L[NE3H1*6_
M)Q3;>%#2QGMC/(I5N.%2GG*NUFLCO,&.33ADT=.\*7&.TA799O&E36%[T7MC
M2<6Y*7&*2Q(5V6]+>70:J._PM)8<68#;CTKHDMI7W)-XXT*#T1A!:<.D8GIQ
MQ8LI8[*$.4ZO>V#UHPS8<2S8QG3@%WW4\J&?6QV5J8OO\0)&P^$9MSWA%]TR
MKJ(W8@:T?6M;TM.!*S1,UG*KPJ6(<1CH.UOMX':L41(M2KBC90'FNDG<>O+;
MOS6*;-I-A*N*R-E+%G"6LXB!T>11YI4:>9)C)5JMAOH,3/+-C-F`Q+.DJON1
MIB3+<JKP&\DW\&=N.\[.PJ)<5&NHM--+S'3I.SR+[7F[?.S%O6J^X6=IU?@-
MYZP_6_QI]M0*DG>CT'EF:)XWA@S$`;LLO"OJ]N3CNGZ1[5EUQ6)UJ;XB0QC.
M([>EBK[D_C+O369QV&EF>(-RQ`\X'2HDYJF!,=J:S-3&?X0"=YW;0W'J4><E
M6I*MKS?":M^,.$XE@./L[%`F]YX9$J,:T2*3\8/$L\&6&'D71S5*%BFF5(A>
M>>:`,WF8[NS8GK(T\`S=3`/O.Y@#(9M.)P6'=BECM,YDL.(<-OAS.:QZ^WTX
M&'5$HBX\0Z0,6##`]:>NMUVF43PXA;@PXAN.`;D5,6,4Z8'.5J2571%R'%>#
M'2!B3@&]:S6I"N6I4K19FP@Q'PPL#"QC2268>!:R4MA%=MIU+T.(\'CZ+N+-
MN?D76"KAM(URW)MM,V$.*\,_JL<2W!3;:ENT6P@W+4MAM(4<E@9D-AQRWKM&
M5'X2!.#3;>1LX44EA(=RP]F(8IUJ2:PS(4K4VMF9L(44A[ZDC`9GS;2I<+D8
M]HA7+<JU-HY$/"20[DTX^!=%<B\F1)Y$SD4CZD98DG9T8E=%YRKL(EQ5-E"F
M00Z[@`SS+O1T(LXX5+'K7CBX'6,9FS'SX(JM$&[%9(S$2(&EYUUC-[=H1D6>
M"+#L8XL8<,MC.T!9.;27@`BD$`,ZMK=V&Q/'B*;5F2.QB'VO%C!@`HDKD5)K
MPFN^LMIF8_&0`6X]1WLZE'DZK`;\?&9^L>8QH.&'7O[5'E%MU1F$MYT1CQ/#
MR]0W=2C78R6!T::S(S$)R8QXL`!V[U7SA+(;KKX2)Z*<-A<=#>EOGQ4:<'1K
M:8<&\4"^3PX`-+I/7PC'K4&[:DS*C+$P$4!\O':'PWH8/$H%RW+=HCK!-/'H
M,C&!):PY!WPY#M4.Y:DXT6=3LG@9%XNEA'00#M;GTJ!.VVW3(SF1O//%Y@P9
MCU8X`#'-0[EFYC7:=8811F\2\\'=@P[=I\*@ST]S-Y'6-4CEYH<\6>>*@SLW
M(Q;>UG2#2(@2!Q'!@&/GRS4:C?4C+DF!%#Q[<L<=N*RH-]1LFD9$//8X'=BN
M4TTW3,P[D48\#^X>%:5ET#UD21P/`XL9NSSP6T:MXYFL[D=TP>:Z\P,VX-S&
M!SWJ1"$F\,CCZR+,<PT,R#VW''$]&&:G6[<JTIB8]8D1ODO$])`SV,&'3O4R
M-F;I*A'NS3E5',(D-!QW>0A3+=F;V8$2<XY[3(ECP)V@-/:`#V*9;TUW.B*^
M[).IEZUUUX',-9[/"K*S9ENY8D*Y<C0@>?X@77<2"2`W8W85=68M+P$&Y<BL
M'M(GHC,#@2SL:.IF:L+-FY-*42%?G'=\)@'W@P/#$-X2#FS,'K:KK2V)I^$I
M;\XT(C$)!>V/.L..(QP.0R5S8L3C).F147IQHX[2-]]XD`,8&`8YEF.QK5:V
M;4Y.J*>]<C1US,_6X,>W8=+WN*^LVZ+!8E%>E&M41OQ'GCG@P8M;BSRJ[TJI
M;735E%K)+UK:RHB)Z,\Z-C,ACFS(9;E=:6+I4H;\H[,RF],,;B<6@')I]M7-
ME>=$I=3YT7NE)^(7WFC$@D%IPZLE<673!%#?C*,?.S*L2,\,&\(Q:SHP\:O-
M.DH8XLH=1>BG1YE&)'>Z"-^+=O0K"W1NIY[5UN3WX]DI/QB73LP.)+"?;5M9
MSZV>?U3W:FGCQ7\0"QX@L:<#YU>:=4:JLB@U%V*@][.AJHD9]PDO`'8>C\56
M49*M<D4.HNQ:-5&F#Q$!F+2?,>M3[3CA4I-1=C6M<#618[WU0:<<6^##L4^V
MMY5CD4UZXJTV4-3,Q7^'$.L#S0&[58VZ9])3ZBY&F9IHT9YCQ+,?>X]?1FIL
M8XT2P12ZF[&46EG3$TT69X2>(>EM9[,U)2Z,BFN22CG@:N9CM&1:02#GAM)Z
MPI5E4=&0YW(M43-=Z[\S+&$XD-;CT99*8HMH@W[D5ADS5S$9YF0!XLRUGDQ6
MVY(@3N13W77(UK[[Y:<,.GKQ8ME%J2(>_&M"/UI`Z#TX=.Q26E7`VPJ'XKX`
M8=I86G+=E[243QIB'**PVG#L3![K!8TM&/F8CW3#G&-*ER$^W`D-:.WQ;0M7
M38=;=Q+"IM(#Q``SSV]"Q6/C)]NXDZ,VL)XN@-``S\#&+C./QDR#HZ,VT*(6
M%X9]>\CS!0+MMMX$RVUDCL$D\2S;U[B5!N0E)T++3W(PB][I.RT]_-N0)Z^@
MJ#=LW*%G:FGEF;SUKWL)]M0_HMWP?&3-V1Y@FR.)YF[P[>Q?5;<[)^E.':.M
MQWL.UX=3"UG:H5W-]1?:?I-%-/XO-V,+.A1'DR3)FDF'FD#>6`>-1KFPWM+#
M$U,1H!QS!'4?.U1-KZR?:CA5FO+Q#QZV,ZEI0L?5QH8O/,8S8WQ]J;4D-R*V
M$,1\C-F&/;FW:M)T6`4(T.7(C>'BP!W[69`>%<S*MP9('V;?>X;&8L8L;!ZJ
M'067'V!K6MRV>9I5E"4J(Q)/*E"Q#C8LSZ`-_6M]Z:QJ1;L5+-8&RA/[F89N
MMQ8M[<G-D/+!EZ&\6=>(Q]C%(AVB/<2KAD7W'GP0T'R[@T*=:I1])`G%[SKD
MS80GWAO!ZF]K%A).177(T='D;:"^<,\LF;^D*;8(,Z&P@O/!F#&G'/9[2[SV
M=9$N+S:,V#K[P&UC&L(SPWKK#$KIQI)I9$\.(<V=?I-\I4N/91'FJU3R+CCY
MS8/#BI";:H0I*57^*6W(CQ`+,&[_`&ULB%<C1Y4)A$>:,O#L6/$0I1EMR+(B
MGAZ`UAV9^=.I&-U`13BPM;@0&#Q[5FG2'%/`R#Y8"UF`._9BJZY%>L?61)0D
MYMK*IP[%(;L).&TXLQ[5C=04&6A&:T/%F':<<?`M9))>$Z68M2\Y;#D1"QIP
M#S`.@`J+=BWGD2O])B7\^'(8CIWG'8%`G%Y_&:]97>?Q8[]4&DXX;V>%1IQ_
M"";.0^2YAGQ`=0#`-BB33R,K#,X)Q+=V'2<O$H%V.%$C=&(;Z).&(;VG+I4*
M>.65#I%5QV(MA\$DY@!O1Q-P4"<&EX1X"-V)Z;6]':6X]BXSBMWPG=+S42@[
M6YD$#=@T;]B@35538;F8+0TG?AO_`!5"U$4[>)LWL(7BUNX^SQ-4'<BEB91P
MX!@W:UG3O*.,:8Y&&RP'@'0"^`T9,;@HLX^=@C6C9'QN\3&X?7>XL49G=="8
M/`Y/AYFQC%F,?.J<[B:CB8O'`]'\:=AZ05*MP;Q69PVE9UXN];/",C@K.,:K
M_6-GB</8$GJ[,`>U3K*;BHO,C2S:.''G7A@<O'VJ;:BZMD2XZ/$P>?:'@2P@
MX'/!K&=BL(+*A"NYLB>B'T6G`8'PJ=:@J[K*ZYT&)B,#I['BW)N04ZVG3=>9
M!O8R\1&\^'B2'L<,>QFU7>BC_%)K.OWR'?;HF1/OECN\%[#H('M*[T\:R361
M3ZBFW:1E_#$X`8]./1DK:">5"EO+%KK(S$`(:"7<7AT,S#5::=?&4VH;IX2-
MZ*6=()9TX^575A2K7\&A2WUM1CZ[,#`AT#JV>`JXL1I%4R*+68S*ST0EUT$X
M@D'HV!7.G5,$4-]]&92BQ"<.(-&)P\'B5UIX.J=,2KN]EO85WXAWC#9@T%NU
M7%F*R:*35./BVFOB1,'A^.R'7OV*[L+S:GE-7)*3>PIO1'@"6$=+5/MI]E%/
M<=*U*+\4D9%G7T'VU<:>/G)L\[K))UKG_`:J8?)(Q:QN.YN&*N[2VH\SJFMV
M5#43,3!_$M8`!U9J;&K="@O-T?0:F(\1BPDC!NSIW*=;[..91ZF6-&S7QGBW
ML]O!6>F3]73PE1>ECX34S+Q(:"6-[&!65E-*DEB4U^4G6IIX[Q81A@&@]._I
M8I\4J5_"*:ZZ)]1I)I\G#-N6/4WL76">TJ+C5&OB-9&?(`:0,,>AFQO6IUI*
ME:8D*XTNHUCT3A!8<V[E+A%I9%=<FVZR-='BX#BQ!.`]U=51Y$&;;ZRF7P.@
M,8=V.6S!8Q7A1&G+&K(@^UFQK70,"&!BZU3-7.5,1Q88;V'IVEF[)8Q74;*3
MSVG+I8"S/-N[$X'9B%J\35RJZ/,LPG\`6L.';M:"L.F9WBS:P8O$\ZTL]SVU
MA9T)MN6]3IJ;B&^T#:,F=JQ/:6=N5:-YFUEWP76-:&^'VLE"NYHF6Y4?A9V*
M1>]$,.SQ*$WYW@)D)'9I(AIV;_QP\Q"XW7@7&F:=&N@W7K(?UH\?M*,6&\SS
M+-/@O/!N3IQ;@<-_:OJ<GD?I4AVCK,>(&`-9Z1;CB0W`]6*A7>T^HO[&#-#-
MO,XB,3OV8D^THFPE[N]@S31GFD'-I.'8?:8HL\SM;AC1Y&N?+0]@1N.[:>U1
M)/%D]+(UIB-?(9E@L8)>$LMS!$3SX==S])I/1FS:F6*#@O&5GXH(!S+0<,@T
M[<5I.B&Y$Q$7?F"6G</-@N6-#=0BD9>O:S:,F=`P!S6*+QF=Q%F'%+6,;DS#
M#MQR4Q2E14.4X.E2VY$8<`]B688#PM3UC(DUCX#9RT0`DOCA'"&9=C23C@N]
MB3;?21)P5:XFRAQ@.K!F"FVZ[RZR)<@JX9%V'%:!AU=O:IUO`BS@JE^%&+?>
MG([CX,5B/;*^Y;C)XU-G!C-(/"\,&,V=G2IUGH16W(..#R-E#C!@]]X_"NLL
MUUD2XFTJEUV."X&%I9[;-J[QS;>1`O0=:T>)8AQB0,F[F>P*3%^;780I1HZ8
MEMR,\!DI44MTXRBGF7G(PX6L>+"W?L&6+%BF)!NPK@ZG/P@Y!U['J]M;4J0W
M;7X3P)W8[`&XG+`>VE.@YN$:^`R=C-()!9F!TX].U*8!11/ZW`,!:0`6C+VE
M%E!.3?A(TD]YTR(WHC".'B)&;<AO/8L;D6Z/(Q2702^O!#2W(]&YNW)<YP27
MA-E5=9F(V#"W9D.GKW*/.*?4=(M,"-X,AM)V^#%0;D,?")*J,"\6@@'#WQW8
M,9X2HLX[%D:JN9DZ_@QC&O8-PR#6YM4*Y&F9TPH9E\8-RQ+1LP8SH9V*'=A2
M%5VJF%F`^&$D](]C<U7W(T=-AW7XIR(AR+0"2W>W8SL42Y"N*#SJ<O/8X#(;
MMC<<O9FHTK:HUMH=8/!-D_K`P.C`X-.&.#6;V-\2@2ABV^RCK%;62//@.@-Q
MQ\`.S',E19VXS7G&5B1ND$<1Z^L[AT*.]/';4-[`"2W!ARR8`.CI:BTT7G6@
MS)01PC!IWGV-7*=B.\Z)F:M'!>`S#H]G6N?J%T,SO,Y#[H!;@<FC`,._%;1L
MQ3Q3-)U<<3CU@X@TAN_!A&#&]):I$;&ZL$\R*\")]HQ='4W?M4^W:B\<3*\)
M@\\2Z0P\1#!A@,,MA:&J5;MT:6-2/=7GU61%")=P>!&YNW>Q3HP7C(EZE2.(
M^`2W$/><CIR4RTJM.A`N9,B>?8]EAD,,,-I5A;@JU*ZYC&NU,@>>>(X6%C`?
M]3VL4Z"7:(ES.J'$UP8,>PZ-FU7NDBE;5,F0;[P\!C%B8.EA:QYK,68!7.FB
M\$\BGU*S>TK//ED1K6$`AG6.G/%6]N%<=J*:^Z-])#ZX-(Q8"&>)JL]/;6%5
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MQ%=`.8QZ-V2LK,:XM%-J+C2V&HBQ76/9G`M&'8.U35%/,I;]S!XJB1HIF(1]
M20?)T9KM"+J5$YMTRJ:V-%:Z`!AD6#RXY,5A:MK=(=R571M&ICQ@&\(.`P]L
M8L4F$6UBB!>FJT=*&MB1"<SB#AV8]2VW%X:D"<Z8O,J&,6/.EK<3AENWY(H5
M>1"E-;V>1'ZUA8\/K6'<UO3FNZM+.C3,[_0/7#9L+&X9#>LNRO#0R[LB:%$&
M()PZPT8M"XW+='A6IHYNM<*DSKVS%K0?+BM=PEVY;-AL)>(\",&]C<,EA0)=
MN6[BLS=./EWA8UA9XLURG1IEC;G3QFXEWV8XYGL.'F4&Y7`G1EA7:CL<@_@&
MMW^`J'//`F6IN2Q.SR+[>QG7M7&[2E2XTLZ+!FZ];TN^SM4<LJGF&,2U_P`#
M%]3=SLGZ68=I'69I[TF9-/@PRV,#5#NYOJ+^PO.---/,!QV!O6UO:U0WD3H*
MKKT&CBO$$8[SXO=4>X\5T$ZU%-)%*(^0'NGQ88J#+.A*A;4TS3/1#QO/-Q)V
MG#'W%E)%DH8)%6)$>..\EN/2/,G0AND0>:7M@==\;=F]BTN84&Z&DN$M(:/"
M=Y7%OXC;=V/,RA%C`2W8W:21EU`HG4PU1%MR(76L);F,V=1.3%TWY>"AG'=Q
M+D"(\P-)Q)WX>!8=QI^`A7+=53'=+PBO,=Q:PX@DL8/;"E:5[TGLP(4HX8UH
M;"#&+P&.\L:2K&UA(X7(U3SJB_#?(PP()Z</$I]O(A3C7IJ;"&^]AGV$X'?T
MA8@_/(,EBT\JE^'%>9F]F-_AR4ZP0;\*^<7W8SY`:=K-K`U=I[.L@7H55'4M
M0HKPR).6W#I9O72)#N1+D.,\"<\68["QNU2X]E8E?>AM++L5YK27LLBUF*E+
M&-%0CM*E"[#C/<+.(NCH\V"S1;<R+<BGBL66'(KS2PO9>S-8R($X-NCR)/6/
MDC$YCV8)4T]4BPZ^0,SUDL8>CK1NIC<2.?7EW`%O6<F=*UW$\6<G!5JV/7$@
MD'KQ.&368-:L;BZ3&[C5F!BMPXC@,3O]W)8E"F*S-6J8]),Y&+PS+3OW98J)
M<MI1J<U@Z'(B$;3AB,SO4.Y&N>;-UE3:2NQR'G73OQSW$A1I6TE5&FUT#T4M
MXMCK6*#>CCX3==!B_%/"P$XCIV_B*'<CA7PF4O.\!RX^2`&^]`:6_6YJ!?A5
M5VFZSJ6'7\R\=OHYX*`T]AMX"1QXD\1RP`&)#`WA\BXS@L:'5/!(E!(]+/'#
M'/K\JA78_=.SZ`27G@&X`%I\9(Z=@4/<Z1DB0'=Z.6W!T#SE:[C>+-0[$:]B
M6!I[<,RL[K>"-E@676<+=GNKG*&+J8;Q(HC'F,.3=_0M5%>$)T,'G7PX3@1A
MF>D+96HR=*F)OS:%8O>`]?HD*1"VTZ'!HM%]KHQV-SS#1CV*5;MU5-IHR$Q#
MCL80W'868]84GU?G-;32:S,8KY+KC"!@]UC)2+4:NG0R!/M%)Y_C&&!!8S8Q
MK1TJ;8CNW*+)D"]A5[#!YXO`.[MNUNP=A5A&.[@LB#.E&8&(2Z"W'#;DS,*7
M;6/A(4L'X"%^*02=@8S',$>)7NCC2"IG7[Y"OY-;3!Z(SA+<'N+PAAP5[IUO
M9X,I]1BBO$BD@AK`]AAUMP\2NK4:)%+?Z>@IO1"TNDD8EAWEN>6Y6%E8IE)J
M/N?PF,2(>$>EB,&YY9,5WIHTC4IKV.*('HQ&!.(9ALPRQ9@K>Q;3@NLH]8O/
M;\!3>CO9DG$D[?9FKC3QI@B@U'@*C\9XO$-9T;&':-ZNK"R>U%-J?S4GX#`Q
MGFYM)RQ.(&TG82K>Q!//,\UJ984V,UKT4@O8$`DM.W/+%F"O;"=#RVKEL-;$
MC/-.+W@5E"-,*%)>FWC@:V+%+VUX]A&?3TJUTL:JN1YW63K7++[QJX\8M8P@
M@]@[1T*XM*F1YC5X0;J48D0_7'+%G1Y586[:WEG4H[UQ[N"-4_$>#0U[WQ8U
MK!L;UJ<HMYE'J77%E"+%>;B0.L[MNQ6>D24,*UJ4U]I2J:B;B^C[\^^.W///
M<K2$&BGU,VU0T[\8L(!P'E4F,,I,H[[HGM=#4S$5]N!+=^.7@P*DPA%M.N)5
MSFJ>$U,>.\'2PE@SQ.).'2T8J=`K[LDZLUKT5XAK#M#&GM\JE1CA@0;GG3QZ
M#7S,4\.9#'@QA/2/.MFJ]9"N3IB4N)XO8EO62,SY"MHYTQJ0'*KWMIC$>;]4
M6$AA/B!4C'*AOOMNI&7BZ'MOG'MHJY,SO,S#Y=9Z3?1!PVAN&"XS3WE@<Y2W
MG4N0HIP&QHZ,/;6C3S)5JX\F;:!$](!NW;X_"%JTZ,FPE6C\)N8<1H=+<F,Z
MF^=0KE*,GPDV\3;R[^_:\H5Q9%C9FVL=AV*4>(#N)V[>DGPJ%+,F698[IV:0
MSP)8T-W[_.N%YX%MIG1F[7`M/6OH/-,PT$MQ.S8T>Z5]3=S(_3!!^<=7FSZ9
M).&);L!R/05#NYLO]/G@:2:>Q;EEX,@?*H3R+.Q&N/0:.9>Q=(.9/D*X2V$Z
MWM-;$?!<(Z,>LXM[5"?:;)\%@F:E[%YC6%C?(E=A8*W5$3&NC':2S+(K.\9=
MOPD)8"<<7@`>@-R\"Y7'6ACU=-IR]$'"W)GU.YF]<<^H>K,8;[<\-I)ZLLL,
M5EMTP'JM[:6>,!TAK6<.&36])!7/>-[F$.HNP(CH&8Q;Z/G:QJRI8T(5RC99
M,5UCIWGI\?6INBEO3:?01+GGQ6PO2SXXW,&`/8''R,5K;:KABB)*62S-VZ\Y
MQ,X@<-V14ZVE1D*Y3SED77'PP8C<S%:P?GE?.N*1>@Q0`&MZ\<0I]C/!D.[%
MRP+HC.L'I;1@S9X%VGLZROO1K#QER'$=8/2ZL-^Q=8YL@2PR++D1WK'7O\BE
M1;W41KK\UU+;L1QC#E@PM*E+)$-T:I4MPHH+N#X&.3&GPE9ITHBW*;U"U#B^
MD6/;-S5BE"!/+$G];DU\,:-C-JP<>HD$4-!V>TF.W`URS('HHXR&[6Y;-V3<
M5U4,*G)M5=!ZP8XL#<M^&?4MMSPXF*_&<>MQ:W8P=NU:R@DL\3265"9R*&,Z
MB?"WR*'<CLV'-8DSL4%IWM9AEXE!?:H&G2A$]%X7V@XDL[%Q:JWT&%]PD,48
M`9#A;XBS)0+L:UEX399>$X,4,+QZ6#L&X;5"N1:=$;>`S<B8`'-H#?QN&0Z5
M#N+%K90Z1Z.@N<0:QN9/9M5;)?A/-F4\&R9V(&@##?U+@XXG6&2D6'W@QF\C
MW!VJ)/:SM$.,82=K6>VHC;]8NB@;Q!?#W5B?R1V9,8`MTJOP&R5"*&]CTM/D
M66]W`PV70\`Z-[,E$FFYMFC,G7@6M'C6NZ:MT.7N$ND9$]9VK:,7O8&C;H5'
M@PXYY>#VU/M.N>9SKL(#%:!L&.&XM!;EM4V,%3#,RU@<//M!_B3VX8]JR\7X
M2/)TDUL(Q$:'1U^9HZUWA'>6]T$.]A)$)>#2WL\1;YU-M)JDB%>[#9`8G"]C
M[UN77GCGTJ?&.^5\L8>$P+_#M8#CCBSQ=*G0BVJO,A7.U19E=^(`\\,O1#,R
M,O:5UHXOU49/I^^0;_25GXK770<6$EO8,,!M5]96*Z"FOM9["#UO&0"6'T6'
MQMP`S5O:5(]**:_@V1OQ`2QK"#GU'<P9A6=A8IK*A2ZC:R%Z(.%C>GJ()QRR
M5S:3P>PIKZHZK)E4Q@&](#>T,W;U<6(4@EB46L[6\N@I/1@UA.3>QH;NZ5=:
M6+3JBBU&6]M*;\;$#81TE@\"N;.<:E)JG6U/J('XQ`SPR&WIW*WL)*5%M/*Z
MQI1?PVD,5]H##L&6]N;6%7NFRQR/)ZN3RH:V/$(Q!V##P]"GP2^Z4TW5-,U[
M\7`AXXL/H[L.@8JVTJ3RR7E//:S;3/\`@-7%BN@DG`,P!VD-;L5U:BU1L\MJ
MJM-%%^.#BT8$@9^TI]M5Q*._+=P>)KHT1W$O/-W[.Q3+=$\"CU%=[`TDW$<X
M\"ST?$WM5MI.QO;:E5J&U-/P9&CFXKC.LX,;N*L+;;H4NK;[)JWH@8T%@`P#
M-N*G0BLWB4E]Y]1JYB(`W'TCABW#>>U2(1QWN@J+D]G0:J/$X70Q[!F[=LR4
MZTU7(@W6F_`:\QCB>+#J9YMBEP=$0KO:HN@I3$0$`9@/X>/H!6]*K#,K[C3R
M*)B,>(S!9T;<LEF-:X])$DTI^%"(^ZPAN1:WZTAC-BDK%T,^M2V8G'&!TXEH
M_&[]R+'#88]<GA0Q+W`72"T`>(DL'8Q<Y]JAK*>]BT7(3X9N+1Y,%P_"IL),
M,75&TEGQQ!IPR;U!8?9?43H/>DGL;-]!?`#I;FQFQFYO4JJ>TGQ[:Z:FX@%C
M<68M[<FJ'<)]J5'5'8I,M+IWNMZE">;ZR=;^X=JI[P)..XD]>&SJ4>]V2UT\
MMUU-YQN?7#QJ/4M-]]!YGCOXO$'>,5]3MRE#]-T,_&=9G"UX[VD=>..'65"N
M=I]1Z#3T1HYCWK_GV$-*@77A@65NF\:.*]D,#B?(?&H-QO`G6E@S51'L7\MI
M\/XJAS>!-I@B@\?2:0,6X;1UK"J6*[-/`0/O%F>&/E]Q8J*?&5"_B0-P:=^+
M3X"L29EHP+[!ABTL'7M)6*U==AH2PX@8,B0"QFT9M[5JZOJ-XNIR[$(>)PQ9
MGMQV8Y+6.*\9!N5=5M+$%\LS`&/0<\^U2HI.7B(MS/PEQV(UT8#`;=C,-ZZI
MI98$%Y[39P(A+``Z,0>O#8>Q=K;?2R/=5<>@V+D1Y@Q=P\RG0;HL\B'+#''$
MN.12UWIW#:N\'+>K4XM4-E!B'IP.[9X5,M.6[@UF0YY;#9.Q#@QF#""1@I<:
MUQ*^:I@RX(IX?J""W!@:U2X5Q(=Q9DSD4L][XO=4J%-U9$&2Q+#D7#!K=Q'D
MQ6=IQN1>:I@2PXV.6..SV;%-CT8%=<K39F6'(Q!Z6;C[:D0BJ5>1P4:XNE#(
MQR,#NZO*<5LU'P&MR*IA0S<CD#`XG:<@=A.+&+&[':0KL72O09>O(.PO%F7X
MJTICT(A>KDY5J2.QO1;@6O-&&672L?<1G==<S-R-B,B]PEK1EECFM+E=WH53
M>TO/QRH9/1@`2,R=G0&#:H5Q.E5D2J)G$*-BQH:/2.63!@`W:H<T:M*N1((S
M7B2`S$#)K<.G:E$H4VG!TWJ$HBD=;1EU,WJ)>5<%E0.E3(Q&L`&&\Y,#.E1E
M%4JT:>':3./MQP]$`'=L\2A7XI*E%6INL(^%D[CS6EN1/;O\:B3C%^:D@W14
M,X<3TBUN0`\>:BW8+P8&CJD63%:1UAF[8TY^!09P6;I0WBVEX27UAPZGO!CT
MYJ)**:JTC:IFX\T=@[!CXUQDTL$8<F20WL<,FEI[-^Y845FS6K#\4#`8EFPM
M':N,J;S-E4B]<_T>!:FU"5V*"0#ATDX))55#2::B<1'PT#9L/@VM6T$][`X+
M,B?+`#AYB&A6$$U@\S?>J1\8Q&&#&=19AUXKJHXIG"]V6_`0OGWK.EI'9C@I
MUF*:IM*]NI5C/D,>=V,!9CM:T;U-MX4(%QNK3RJ5GW^(-VC-F_HQV^56%BU1
MU61"N5W:>$@]82Z&YL8S>S/PA7UB$5L1"DVI,JOQ3@3]20WI9AY"K?31BX))
M(KG6K3(3%):>O`[&=JO-+&*2BTBJU#P:9`]$9Z0Q8`-AQ!9X%;VX1Z%1%/?>
MSI(HD=G"1L.+&88]:L+%M5HJ8E)?K6C('X[0W:`\`,.C8U7MB"6Q4*:_58>$
MU\6,T%F8+&;2,<1CB%/@E7`I;R>.]BJ%01RTDAN.[,[L\U;Z6%6>>U7X1%$B
MM<+&`NC=[,5=V(/>66)YW4;RS;:Q*,2.6!G8SR@-Q5O9BD]A1ZK%,A?C$AA+
M,R<=^SK5U92W:X'EM;1+"F9K8L8M(.&`\6W-3-U.?@H5-VBQ*0C@E[+`9G;X
M3T*UTT=R)Y[6-4:6?\!KX\88D,:PY>'`9*WM1;29Y?52P:Z#5Q8YV9[<,M_1
MBI]M4\90WE6K-7%BO/-R`#3CMZ5,MJO65%ZB7A*$Q%PR#Q.U@R\*L+,6H9X5
M//ZEUGXC13$5XM8-O9V*=;@TL64>HHU6IK8KY`>!+N673CCFIL'YJ12:IUBZ
M9&DF(H>)81N'6.W)2K=5GM*=MY;#53$3'A:&#/%FSK4V$L")==<MAKGWWFL=
M(Q\/L8K/24=MUZ2#>E1^(A$3TRT9M:6-'7FI.[CX"NFL,\2I&BXGA9BW=AOR
M.\K,4J-;2%GF4GGWL1M+&+",T69*Y%(`)S#72-_3U(JIT,M+(LPWSM#0,<MA
MQ3;X`7'7B76L`8^ZS#$AA\142ZZ1P.]I].TVDN_NV?R08H"DZYLFP?FTZS;0
MWB0YCCG[&=27.T^@D6*N*>TWL!XD`9X'S$*).E$7.GS1V.2>]X6;#Y6^`*+<
M2)\3M$@2,6YLRV#'VU%NEUI<54[`N%$6)YCF'@7GF':?*%]2D\C]-T/OG7YD
MX8L]\6';F=O8H5SM/HH7]@TLT0R(>@`^S?FJ^YV2QM=HT,7-T[&_R)4&[A0L
M+>1J(A;QLZ?!GXE#N,F["@^]Z6QK.S\58K14+".14B%@S.!.`RS0R52]F`=@
MQZCYR5JP1%YNU@R&.P#$]JQ5&&F90WCE@,,R?J6?^BL/'$S&++A(Z"</`6>1
M:6W@^LTE!-;*DL,L+,"TX#'#H&Y2H8UJ0+D*JJR+CKN(>;@<7@W#L'D76JV+
M`B3M[R\PV,(@%T`G`LP)80NMMX/H(\X.G47'<#B2&XX'R]*G6W@B!<BZM%F&
M_A[\AAW^S:I$.T1I1EE15-G!B'A!XNC/V%3;61$N1V[#8PXCV3<L5,5$T0;T
M52I;#[7#B0&';EO4J+HZ$&::P,W(F`'&6@8%JDQR61!FFGE@67(A/U>73C[2
MVHCA-5BTLR81",W@&=)\RF6GCCT%?<A\1*Y%!>)XL&=._K4J.6TY6X-X4,WH
MHWGQK9>"E3$X/Q$CD8$-)8W`,SPRZUBGQD&<=UNID(F+`6G><V9%:N+VD5P=
M6]E281!B`2<69MS";KS-7"3Q.?6!S%NQA;O[%AQJL<C:W;DI5>5#$1FD-.):
M=N&X#<HMV*QZ#L_!D'8I!(;B>O!@'2H$X[KQR,%AV(>+-H#,R<]A\2./FIK(
MC2PF^FI.[$8.-YXM:6#8QC5'N1K@9?0B</X-;F#AX,.K%0I1;>&1RS?@)G3@
M'0?R726^V%%N1Q.L<JD[KQ:''2<3M.):<CT*$X8T,/I9SQ<+[_I9#/;XMZY.
M&^LCG6I9AOX`G-KK/%Y%$O6VWNI*AOGD2&(W^.9TGIZ%!E"BQ1ND30WSPY[`
M2<MZX^K6;2,.E0Z^>+`D#':0W#%J;B>Q&4D9%\;&=H*Y2LMR>",]1CQ=/E3U
M/@1C$R#XV]C`5J[#Z$8EEB8O/EUX`XNGM9@,O"MH6Z/)')I/K$2(UP`'9@>T
M8*?:MUEC0U697XL\=S>@X,*[QM4DE14J<KW9?4`>)TD%C&^SM4NU:DG@5DJI
MHJ//-:TL&+&9'H(Z#DID;3WDTB->5:E=][A>(:QK/"U6MBTVU)4H5L\8LJQ'
MN$@MS]UGLWJ[L6ZK&E2'<S\11BO\#Q:20>$XX[AY%:68>:HJBDBOF_.JN@@]
M9PDXECV#.CVPKG3PEAO4P*K44=5M*S\5G$06`[&EC6AO8KFW'>2<2FO8Q\**
M\2*&L;@0&G(^^V*QL0>7X137TFVF58L;A80<VAG3@SRJYT\)4H4M_'!YE4Q'
M2X3BWA\F&':K&W&CJU@4MZJK4K"(<<<,]N>]7.FBFZ1S//:M*LEX"*+%:Z\1
M@3F/:*N+,'O+'`\[J$T:]^(\,0QF6W\56]F*WDRDU;CNLKQ7Q@U\Y->+3Y=R
MO+*262/+:MJF)K8K[,2\,<`PDCMQZ%*<:R\)2WY111,1A>QP`R!+>W85:Z>+
M5,/A4\YK))UW?A@:^/%`:SWQ#<,/.KJU"J5<CRVJ>$G4U;\1[$<7I':WP[<U
M-@E7#,H[TX[N)K7WSQ'B>P#<&MR4RW%O)8%+J9/*-?@RE%B$@D8C(`^UA@K&
MS%QCB4&IN1]91YT-',OO$@`L82W';X=BF03;H4FHE&E*XFLB/,#Q+Y)#6XJ=
M:AM>12WYNDJ]&!IXKSK>K+!F>_P*1"#JF4]R32:6;-9'+H:&M;BW,L'XBFP6
MW8B#<FT4GVCTF]0V=&&Q6-E>9XR#>FJ^<5'HF)V,PZ#OZLE(C]T@795=(U*<
M1]CS-CV':=O:W-8J]XAN2KXR-\98XC$$^,%'3-'3?C4Q#Q#<<<0<?'X<D>28
MWX_$6H3[`&'':#DQN'8LO%'*4ZR\U["ZX]Z(+3[X8;,&L4.[DUX23":SV&TE
MWL>C(^`L5>L)$V+Z,S=0?J<MF.U9G@W4FV,J&^EC@W,>=K&*)<Z&7.FQIT'9
M)''AR:PCJ`*C7,UU%A$[5(9X9[?9U!1+A<Z0[`N!8GF&8+A):`"TX>#S+ZE+
MG9/TW0^^=9G'G@\0WT>(L&P8XE0KF#?47]@T4R^]Z0:6;.IIP[6JONY>`L;7
M:\9IXI.>X9=8*A7=A8V]II8CQ`>&#3AXF*%<SKX28J[OB-<^^]QD["<&]`Q\
MBQA3PHGQK1=10BQ'@]P@[3AL]C`LK*HJZF!>#3M#!VL/MK66*)%F*DVF8O%U
MN6?B`!P"YG?U<.@.O#`<(P&/1M'B2E0[<%D6(;X+0<3OW#8,EK!NGC.$XT?@
M+`>!(X0P`X'?OP(P:I=MXX]!"N05<<BP[$=8&C+`]F!V+K1O817&F%#8.12S
M!UC,<\@S\BM[=%6KH1;MO:7X#W$&G'!F...'1L4ZWA3#$@7(I["Y#(:6N`]&
M7F4F#\[H(\K:2JT6X;PX6%UA!R!.6]H"FVW1>,@W8-/_`%2Y#B$8M]\,/8S%
M2T\5UD&Y;HO.6!<A1272Z6?B[,E*3(-Z"K5+`M./#ZP89L+/$I,>RL2'*$6\
M29U\'*'C^2]Q;X;"+*$E5_@DSL1PAA<#?/X&J7;P>>-")."RP,P^X/J0/#_Z
M*EQRQ=3A"W)/`R]8Z6#@!QW^V%G`YW(])SZPC(,&P#V%,=A#N0J_-6)(Y%#V
M.0`[2,&E=E%43>9"G&2;6TG<BNL8`QI:3CT'<,V++BF%"257F2F(Z<``3T^/
M9D%I*":HD9HUB\B,Q'76!G03[`H\H)K$U>)SZP.XC/-OBW="@W(=.1JGC4D<
MB@!WI#.T8MR3=3A@L6CBUYSD2NQ_2(;@#OV,:-FX*'*+B\5B8_!++D8G%OU+
M!XF'+I4><**B7G&CR+CD5K7AEPAA\&74HEV&&[M1TR5#)R,]Q#';T9X'=CFH
M-VW^+TFLNS7:9O1"7B0?J<]^\K:%E[J;6!A42Q+3D5H(/XT=36=&+5$N6J-X
M&8$[CQP9N+/"HMRS%846)NV6'7O1.P``]>?0N2TZ>:-<#AQ\DM.`!RSV=2V6
MFA'8;JA(7QO\1]I1+MJ>^U%8!UV''&-_B/M+EZF[T&/.,G7PW\7VEGU<TO.1
MB5=W$BBO,?!&6WIR76W94HUIB<S)]X<(QP+6>$=&]38V4E6F)SQ*T1XL>QPP
M[1@I%NTI9K$YW'@^FA`Y%+"`<&%G2[M'85,A:I1M%;<63*T2(0\,<"!Y0P]B
MFVK.VA%EBGUD$5\YMQ!&'7YBK*Q;5<$5L\'3PE6)$+P'0Z>WI8S!7=BU39B0
M[N$JFOBO\0./I!GD5A&VXS6!7W<&Z9%4QB0QN./C#-W0K73Q<<)+`JM1@Z["
M#UH+P=Z#X!EL5S:@L''(I;^%2O$B!TL_'9=&>Y6-F#>-"FU'3M16C1'6-V$'
M9MV[-C%<6(U5/PBEOXNG@*7K!BS+A&'3@UF"LK<&G1Y%->>&)"8X=>!(SPZ]
MFY7.GMY4//:I)N5,_P"`KQ(P(>#,6'V9*ZLPRJCSNH36%36OQCQ,`!=\&/:%
M;:>$:XYE'J]W<;^&9!%>:,,F9[O%BKS3Q=*4P/+:QX%%]X,(>&)]FP="F;CW
MJI'GM5)J;5<*&O?BNN$L#2WP;MFQ6>GBZ^<CS6LFZ/''^`U\6*Z7@7G02]TY
MYY8*YM0P5#S.IEYLG6N&)KXSSHXB,"#@WQC(*7;BDUAB4%Z=>HU4>(Z`=Y:T
MM..\Y=*LK5MM4>92ZBY+$US\5X@LR9GT^#)3;248TFL:E%JY>?X:&IB/M>?)
MQ&)'7X%-MQ;=$L2BU$Z*K-5$?#"PMP+1Y-FY6$;>"36)37KJDG7.AJ8T1U[`
M!C,-N.?0NT;<EUE/<D\EXBC%B#A(&;2S/+P*7;AE58;2%<N*,O.9KWHA.!.+
M,!AEX%86THQI0K[MQ.7GE=Z(Z#BZ&'+<WP8(U3%$&Y/H>)1??8\S,`X$["22
M?`U;9QKM(LI;?"9//M!=9B0"[CM&:1IM#D\R$/-(.QIQZ2-VQ,'5=!BLBU"+
M0271D7?9V)%X4,-T=-I;@OO-8]]<"1O&(*A7.R^LDP?Q&R@OO<086#9CXE"H
MFR9;FZ*KQ-_!?)#OC\"Q/M-EK8R.R2Q'!EMQZ2T*+/,N=/LH=CDW@.!F&!+W
MA+5%N9HL8G:)!_$L\/A42XBXTF'PZC?\;V_Q!1:LLSS#,O#C.(S>\8"^I>YV
M3]-UO[YUR:;Q='$]Y5"NYLO[.PT<SD\,2"S'I9XE`N+S:^`L+6,O&:F)EO+<
M>E@*@W<T6-O-FDC`#B8"WTL3LW>109[28NSXC5Q/?GJ)[?Q$QW<<R<OO&MB>
M_8\6,:6>[O6>HS_H,22Z"P@,`PWLV>%:S)FE2;:?08AXM=9BPM9F20,SVE:4
MR1+W8DKN`_'$M66EEL-*)]1PX\0\0T;6GP;5SAMZSC<5<2\X]Q@-(P:SLSRS
M:I<-Y,@W$JT1.Z]EA[0/2>A=6F\R-**>+I4NPG0!B\&Y'I72VWB1;E7AL-A!
M+H#!CN`/:>E3H5HB%-*I;AO'%F'0>C)=X=HY22:H\46X;SX=P(S*FV^SX"ON
M)-XY%AV(^`.+JP&Q38YX/`@7XUBJ])9AQ"'MH:P9*7%MYM$&XJIEMR(6L#PQ
M4J#=%7(B2CTK`L.1'@??!A67X41YQ3P:P)0^^#F`ID*8=-"ON17A!B1#]4%*
M@DU5G!44MN1R(CY+O$\,QY5FB.<TME25Y]@:`3V+"Z"-*JVXDCCQX07BS#JS
MR4Z$(.*>VA#E#SFZ8G+T5YWA`RS`8,VGI6SA!C<Z3.'%+6<6+,6]C5I.,5'P
M'*XO-\!D8@:P9DYX8#?VJ'*.U=DX&0B,P:W,?Q6QO4H=Y1\82JZ["7C8`P@D
M@-(V#:SI65%;F&=#D\9>`"(0P-Q)P&;`SVE#O05:KM&C^X3B)PNX'-K68[F[
M>A16NC,UK5XE]R,P%W\:&=&33[2CW4L]IM3&IFX^``T_5$YY]`Z5!N12KX##
MJRPY$!9O9CXM^P+M&+=M88&LL"=R)[X_CQVG+#H4>Y:44VS>"P+SC^`Q&1;U
M>90)PQW@R4/@C<`!FFZD92H<PRTM.32SP+1JIFM"4G<N;MJN)JY[$<-*>KB:
M[\C-PAN*YW+2<<!*=8T>9#$/"^W8T^9+<*+PFI$\^P`_4G/HQ'D4^$4T&C!Y
MX,(WL9U+K"WC4C7-O44R\P#'?V9*QMPC*F&17S=2L^\T@[6>/W5*LP2GNO)D
M23S*S\4@LV-'XBL[-J-:JM2MO8)OPE-Z-F&YNG=XAU*ZLPWJ8$6ZL*^`JO/L
M<Q(8>G9^+DI;C6=%L*Z7G=93>)](C9LVM9[BM=-%U295WW@X[2J\_P`1!<(`
M#<V;.G%7%J,51=)27\F01(HX@T@'ZK)G1U%3[%44VHZ5M*4:*1@3D,,O#TJ[
MLQ3C6F)3:A=&91]872UK6NCL/2K*$5.6.12WFGB0Q(PX0W(-PPRQRQ5MIXI/
M#(\]J\W38OO%>)$!8`<6,'F\:N[%:I4/.WZKJ*D7#%N+.C$^VKBQ%/,I-6U1
ME5Y]CI:]UXC`*ZT[>2R/+:W*I4?BEA)QS`RV]N:FRC+?I'(\UK&W<:KA0U[S
M[270W`=!QZVM5CIK>-99_P`)Y?6.L77/^`UT:(2\!TXEBN;4:--'F-4Z1D^D
MI1R[@&[&G':IT%5UIB4%Z4J.AJ9AX%H/;XCY%8VHMJNTI-1O.57F:U]X\+Q&
M0)`!9BIMJ,6O.SJ4>LEYWB-9$W-QR>Q9[&*?:ZL2AU$W3',U48N\3P&:EQ<J
M5>92WVTI)&NBET8C%F#,&M7:"E)^$J9R=/":R([Q%XG:<\F`=2FVX2P1!N.F
M)KHSY=+`0S#I9V[`5*6&!`O-3EAG0A>?!#&]#,&[6]:V\*(,JIU92+S7N%HP
M+#N;UK"P(TY^=YN2.7BUGUSODWL1X.O2-]_&<-])X=)(QP+<F=36+&3,;[H6
MH)]%K#B,MH(/6F3\`<W6I<@L)P#6EAQQ`_%4*Y55),)8&SA8/AG5X6J$L6NF
MI+MXT-_`'O0QG3Y0LW,V7=@[!+/L=(ZQX\U$N/%%SILD=AE'FEP;.'^2)46Y
MFBQ63.T4]_-GLS46[F7&E6%?AL-_Q/;_`!!1J(LCS/,.#C>S]@7U(7+DMT_3
MM9M1DDSKTT>$\.P//8[??;]R@7+KKLQ+NS!51H9Q_@(`&#S6^-192<HNI96;
M:K0T4Q%>=<)[-K6GS8J'<Q:+"W!8FD?C%CQ9O;V^ZH,]J)L(*6#-?$?],[<&
M=9P]I:[S2ZB4L&4(N+S<26M/0"?=3>:),;49*KZ3$@$G'(#+;BTKG<N-)$NW
M:5IU6;(\'7@02PEOBPZFE<_62KX3IF2AXC'V-9Y`%GUC;H:/.FPR=<!)](Y@
MG=L:,\O.MUYJPS9$E<DBRZ>#`9!IQ\&/6ND;DEU$>2WB4/<18TA@V8>'%=[=
MQS=#E*$8JN;+D.('1B23VGSJ5!/&A"N+[I>@1"3U#I!Q[5,A'!8XD.Y#!LN^
MN=`S*D6T]XC498$3)CQQW'#KS4VUV?&1;D:.C+?%@Z.)[8&M\>:EQK780+L5
M)59,[$(+N>SV9J9$K9),G$4`[<]Q4J*>ZB.X[&6_6`._5>,^==%;;VD*[-JO
M@,Q%#`2\]B,FG?LQ4^W:VE9<G.CHMIEZQT_5/#M9YU)E'<C@<K3<Y^=T`1`'
MAZ3QQ&9;YUB"<LS>XL'0E>C-'"Z20-N/MJ1'3QE3>J0IQVO,S]=PNNDDDX8-
M:/`U=:*."R1P:;=-@,<OETC,=8#!CO:AHU3,Y,7@:027B.P-[<UK<2IB<[BK
M'P5.1'>VG$EW?L9TJ.XJ2IDB-N)LLN/@<1)(S/@`RQ7&5B$UU&^Y')&;L4'/
M)F'4T8,WK>6GBHJCPH<9VU7:'7VO-:??,&);L8W%1+EB#=*NII**:H6G".%K
M6XG#8,!TX!1)Z>,94C4>JC0MPXC2T?6CV=BA7;*4?]:IL[4:$H?Q&>#2!NZ3
MTE19V(XUJ:;B+#K^`8<2[X/=2-5'<_`1QEVJ;"=R(1ED7AYL5!OS;?@.BP7A
M+CD4DAWH+3VY-ZE$3<G26",+$L.1&AG1ATL\Z.VGTFU*$D**2<AF?(GJD:/$
ME>C`9CP+E))2H<FTG0Q=C//-P&'7[:TH:[Q,(@PW^+I6:)ARP.'O3Q/L]C%O
M"VGCM-%-IFO?BD`;1CAVC'-3X:>--M3??(3'(X@<B76'<UBZJ%)4(MZ<L4N@
MKO12<&#:#VJ9;CNOK*RY=:297=B-S)P`(Z069](:IENVFZD>3>?25([Y!:TL
MXO",&=JL=/&B\)#O=CPU*SY=>`+2WA./5XVJRMW9P>RA#D]C*1B-=8=A#?-M
MRP5K8MQN)3E6K*R2<9.G051%])]TX`8#P;<5>:?3)T=65>I33="H^^''@PG$
M8CP=.>"M;>GB\ZIK(IK^-44X\5I:-^W=X>A6-C2QVOX4*:]MB\RB_'+[,C[X
M;<-VW>KNQIU3&M"EU&#KL*9B$.G$G$=)SV8J=&S"M,50H]1))M;"O$BY#$X[
M>GMQ5KI;,<)5=3S>LDTW3X8%5^(.(-)8,/9BKBS"C4EF><U%R:JL*&,6(WZI
MX9;3NZU96MYO(H-5?G1JBJ4XD0'`$Y$'/VU?:>&5#RVLOW&]A2>BN\!#268X
MM;Y5.A!M[SS/.ZFY*3<\*TH:]^-PDL:6G'>S$[U96H[K/,ZUTK7;Y#5Q([ST
M7'`$LS+1XU8VY8I;3S.IE@U@59AX<1Q(R.?0S>I\)R366!2ZCLX&NB/NO$C'
M%N.T].:GPG)+$\YJKKBZFLF(IAO%T$L8#M9Y5::>"E;WMM2HN4N5<C5&*2^>
M)N.+<=IRS5A;C15VLJ=1"*57F4(K.(EK.AK,FG)JE0BFJ%#JTE;;6=#7QGG<
MP7LFGV-4BTDG4HISE&+\!K8CQ>!87AB1F0=NXY*?;H5\YMYFLC/<+_`22UUI
M;GF<,]BZN"DJJI#G+'H95>(S!>:3AX#_`!RPDXX,@W+CC$J//!T@M+1GT[?9
MTK9P2(6\T_`'HN/%O#`SP^`@K&XG$QOO(X$5KVS-X%N79O1P351ZQ[2]`?)=
M.):#Y3[J2BL_`=%*JJ6Y=]CW2T>+VRHURVJ8YU)D(I*FPVD%YKP>ZO.%!E;C
M&5"9#"B1OH44D.^$,]G0N-SM,M;-V54MAV.58723F<F9*)<61>:>;^([%*`>
M@`3B[YR?.HUQ8EA;FW%MG:)%CN_%GG\RB7<RWTEV3P-WZYWI\'NKC0MZL\VS
M#_IO8;3Y!YE]1-SLGZ>[&21UR<():-Y_+*ON=KX=!<V<S03?I8;0,.II7!]E
M]19V>TC2S>,,X?BC#S*)/,L+>3-&\/1>#>D>5GA4*6;)MK8S71!B2UC,`.QI
M\"TV^,D4Q\94?!V-`:6G>UJPB;;R1'@.(C8!V9X+E=V$MD>/$!GCGT`9+B8V
M&7$P-WX,Z<O$5E9'/;X"1TL+,F,)\H4E=+(,R1X^EQ$,<P(Z=QPQQ)3/J-<L
M%F20WN)I(RPXMOD7:RO.9SN81\)9AO;'0W`=#,]ZL()].!!G5TJ7H,1YK&,W
M]>[)2HX)5Q(ESLMEL//!K0#UL4BWN[RIF1:HMPGM[@8WKQW;U-M+S?&1KF>'
M070\&AKN#?9L4J-:D"5=TF#X)]Z`S:/Q%,C59E9.JI4D#YXLF^!3(TW$1)4W
MF7.-XN@,V#:/.%V3@0II-M>$X??8SB`:!X0TXX`A3H/#!X$*Y%YHX$3>Z&;_
M`&!=[E=WPG"U%JXUMH.,-P='L[%M94JIFUQ/'H).-YA8Z!X%9)*E<V0+C6!S
MZWT6$#+M\BP[3;J1WO-G#L4L.#&'$CH8T9+#M)9LPUTDKT7A`+&DEA.3&[,E
MI.U5>`UN1K`X<B-/$=A]$=`+2<L%R=M+"N)Q2)G9@O$[L6>+SH[22Q9M1+K)
M!&XBZPX,&/;B,EEQI!UZ"//S:DCL7B>`&1>8W>T99*#.-,$<TJ8LN^MX889M
M+,\PP-V9*/)55#HE4MPXC`TG$@,#-Q'0HMRVMY]1K+'!$SD0@DYDDCP`*%<M
MMTZ##Z"P[$XN%A:.%IZ2T8=BY2CYN[L([5),O![!FTO##<"Q0+L,&N@Q7$S#
M^(`+`&X[SCXE&]6;K#$MPW^E@\A6?5F&ZDKCQ)8"P-/;@M=PT;)<@T[%PE:\
M[:<9/SC#UKCOU3&_C2<NQ8]2S&)F8N#>+##9O[$C;\ZAAIT.'9C826'H.'B4
MJW;I(TH0Q#Z(.P^V%8VUM%:%%]_$@Y%C/%Y2MI6Z3J<KBQ9#QX@;<>T+O:AO
M+$J;_E*I?+N'4SH.'G4^W;R1PBZX%68?XG3CB'@2&9'#%3[4*R741KN$7T5*
MCT8NEFQAPS8=A4V-NL:LA3Q90BQ&,+6`LQ[&-RVJZTD-ZVDL_P"$K;E<>HJ/
MOEKY!]A&>6U7NE3@D5FH>#J5(D;B=QP(=\3>I75I)T*748+>1KH\<N'>TCP,
M'0<E.LQK*A3ZC%U*A?820P`AFW![/=M5[834*/I*74.G40/OD,:&;3Y\@I22
M<J[2@U*5:%=^,#B]D-O0>S8K33)8(\QKDU+#/^`J%\//8;FD=([`KJW6,<<C
MSFHJMY[""+$R#6M#1ALVC)BGV6VU3,H-3M;R_A*D2*Z,\,,\<]^`5W8JE@>5
MUF]O%-^.&-+&EK2S/Q*PA%M'G[\99;"B]%!)9D6`''P9*?9A*6+/-Z]-UK\,
M#717B(A(QQP&76,BI]N"4DV>7U%%6I1CQ"6'P=N8R4^+5:E5J72.12??P#`T
MY=G@4^U%OSI'EM76KK\,2A,/$XD8@8,_$5MI_P`W195*J?FK>-3%>(!;X=W3
MDIL&FE0J-1)4Q9K(CS[3BW?D.HJ5!XT*344W9/;3[Q3B/DL`.>09XL0I%IYE
M#-MIU-;%?+I+2QAQ&8(V'`*=!8(B22H:V.>)YK`"1ATL)\"D1PP*RYVL,BN7
MB.D-;GT>4))552%<6]'PE9\^F=O%Y46*\*(S6S:8'%HW9>SK68LY^$#ZH98\
M0&QN&">`4H;"![W%U@()WXC(X9+7-'6WV?&7H/O@,V@CP8^-JX7%@6$?";6#
MFT=/9M"A3[7Q$E8.B-Y+AK&%AV[VM;Y%$N=IEA:PE'K.Q2SP#O5AVM46YL+V
MQD=CE'@!#&WA\KQ4:YF65KLL[/(EN)W^8J)>S\1:Z3/X>`VJYEX>=YESTWL=
MI\8`7U#W.R?IZL+!'6IMTA\X[3^6]M0+O:IX"ZLFDF?1+<V@>4GSJ.^PRRM*
MDD:.:/HGH+>QI:H<RRAE4TKY8Z?#X`%#EFR9:S74:E^*!$>:.CJP]I<\SOEB
M5'XG$1L=!>/:"L9,F6U@NLC?BAUN!.6[8\Q<[KR9,9@,N('=ANSP:N)JS$/;
M>O'8=@[$J:2SH<A]O807CV-Q4E8XD*>9,WC/$U@#?)B3TXK8TRZR1QX_4D#T
M<F-):Q=K*2D^DYW.SB686#0"`\2&[>KRJ;!*KJ0;F*1L(+CY9Z;HP)Q"F0R1
M#NI;K+/"\`>)]PY99YJ1#M8D14J7(3[W#[X9]:F6HIK/:1;DEO%T1"``T>+M
MV*9%*M$R)->:2B(`!B/"%+@FMI7R1DZ\&DEX`[E.A7=1"G539*[%:S$%F#6C
M9Y&KO5T(EQ.M.DD>?>?/OW0P,Q8I<755(EQ+,A>>>=#>-TM+&!G3UJ6G5T.,
M8I2IX#@17O1Q&)9LPQ4BW!;V+K0TN4QZB8OO?7N^`>VK&VL*E=-)$9B<.T,P
M#6]':L.,JYHC-NKH<.1SQ#A(87ACAAET+7U:S>872RR]$#KN8QQS`:5K*$FA
M=K*-`[$:ZTG$``>`;%Q<-W;B<<LC@16M#=_4#@.TIZMO%O`5IBR=V-[T;@,.
MEN96SC54V$6;;DWL)X<3%K0T/,\6!Z`H5V&#2"57X"Z[$PWMQ\GB4-+$V;V$
M[LPTN[0>$-P9L6SM^;O/,U>&)>$5C7=I:T[FL4&Y:JL\C5+:6X,3`8?4L\84
M>=K=C5LX27G-EOUF3"TE[$^)B@7+=?&92J6''N+T1L:WK:N/J6MH:?B+3I:&
M-W'KZ5J[>PPD9NS+H+`,6G<P89=:S&PWB\C5QJ9&,TM(+5K*U25*G*2Q,'G^
M)F&2U]4^DQ0Q!.S`[\_$MHVJO%F)8(R]:`>$Y]&1ZET5AIUK@<UBC)YY@83@
MSP8CRJ;;A1^`,IQ?JNEC/`%TW*S\9'F_.:*?&SA;F&L*DPLNKH5^I6"96BQ`
MZZ\^<6,:.T>VI]J&\U%9D.+H_`4(D=K1D2<,<"".K$J=&TU)-=!RO*L7T%./
M'`80,6=&#=_0K"W9JMVI7/M4*#\7B<!V@NX-Q##Y"59V;;BET5(-U8LI>O8\
M]TDX88'#$="NM,BJU"K%E.-$P)!V#M+6=BN(+!/H*6YDXLHQ#ZST6@$EI/CR
MZE8:>#3J4U_!T*[SQ=+6@L!`\N:N[*JJ%-?I7=96B1P!PDXX'P]'0"I>Y2YO
M'G]3'857XP8'6M..W>K2Q'%4V'F-;52>S_X%1Z)PG`C%WHW*YM-*-#SNH?::
M*<2(220<`>@[/;4^RTY%#J7@Z?#$CBN^BT/!I!]GC5YIUYN)Y/5R>^Z?#$I/
ML#OO@2,>UONJQMQ=,R@OOHS*)B\#Q;MZLFJP@G2BV'F]<JR=?A@5HCY>#01T
M=74&*7;MNJDW@>8U&WI-?$!?XAQ.AAR[/=5C"$:IE1J6DNET*$;\S:UX''/>
M5.@_N'E]36KH4WXK02"W/L9TL5A8CO6Z^$H[KW6:R._FT@/'>S+J4RW%.*Z*
ME/J957A-/%?>!&(.8P9L*FVXI-T*6]DZ[2K&?>W@9'%FT*3:CF5%RE)&O?+3
MF&XM(9M;L4Z"P1`G5.I0C.%O$'@WA9VM*WR(3=<&5R]TM;ET9M!ZD3(-Q452
MJ^^,3D<3V@>1@!182H1I=HQX_2!9F,.LY]:SDS7=JB1W$CK(;VM6<F:4-C+D
MNNXL.8\:U:\[Q'6&1<EWO2_BPSM!P7&?9)\<UU&V@O#C;F&C\JH5SM/J)=?/
M^'2;V"6,Z&GQ.A0[F986^U%&\ES@SI:HMS-%YI\OB.RR0XBYT.^0L4:YF6=K
M)]9VN2'"!BW$>0J'>>/B+32=/PV&WX>E<ZEUO'GB8]^_[-R^HFYV3]/MC)>,
MZS.^^/6?RZK[O;\1<6<S031;AN8N#[+ZBTM]LT4QB`-[6^`GS*%/`L;;JC4/
MNDNO;PUO2S!0Y9OK)=K-(TD8,>)PP;X5ILIX#O39X2C$+"!N/5F2M=E2=;[)
M&\6DLQ8/*\?,N5W)(ELS8P-&UN'B!`ZES-?`1;&;#NV8%K5C8:/%U#K<`&XX
MEN;`P^,E2O`0IO$G'1[T-:=[/:6SP7A.?AVF;I+7F;L]OA76RJ/PFERF[5EF
M$>''-I#!F\3OS4VVL2!<QIT&PA$[2\,,<3@-@SP4R"RJ1+C6ZRP&C%KYZ\05
M(AN[Q%JB=QYYFT!O3[:FVE'=\9#N4WO$6W7B/KCCMQ9XU*\VN3(<I)HF#WUW
M%T,\[5,BETD&7@.00\3B^.LL\&:F0?FHB33WFP'RZ2'23B=N.>UA4F.7B.4X
M)8O:2@DL])_)N94N'9(<NG"@>/"[M>:1GCO4Z&[*5".TLS`/M(#",1CEMWMP
M4^U!++,X7$J/J)#C]6]_JE,A'80)X[",O.G`^L/@/E66DGC0BN.+V&'K>`AU
MF9S.8!+,VA'NA)(L&*.$-).`Q:WRE<Y+`TN/S<`(QX<#B-V60SQS6*16S$X=
M8<C,:WIRSV98X)1/%FLG5T1.Y%:0<@SSCISP6LEO+=1'E@Z%J'$);BP<0Z\M
MN.2B7(J.+S.D518YESUV&!V'R#WN.:CVK=+M9TR"729PXA#"6YNLW!C,3BM[
MMNJV&D\67_7<1SPR);MV;<E#E:<6VZ!89FPAQF..G!K,&>=1=W>SI0XR[31.
MY&PX6[0T[0W'-N:CW;5754H9+L&(6X'';[.E091I*FPU;V%OUP='"Z6%F>&`
M.8:W-;1@GBTJ&A'#?WLQ./F*ZT7@!,8[,`QO3^*HLTMYTR.<JU,?7O?C/'[:
MUH:XF0CMP/""<,.GK*VC&K,2R(GG\B"W'#'=M:I4+>&PU6!F8W%@3D,]_1UJ
M8K22R0:H4XL8M+7L@S`^%N*1BMZC2(URF\RC$C$D8X!I&\J;:MU:6%2!J5YJ
M*\2-QN/AN)]]X0QF*E6[+C=35*$!JCJ48D3T@,AXP0`.Q65N-,'2ISG3<\92
MC/\`$W+!T]1Z<U-A:<98%?=P=?`4/6L<:3@W/;GMQR5A:C1$">**#[_IO!NT
M[?)BK?315$5-][K:V%:)%(=.6('4TGKSP5I;B\UDBFU.3:*;\7$$%A:-N>`P
MSQ"L].GM*74MYE9^/B6[GF`=>+0U7NG4:*A3ZB.\JK,JQ'P]Z6W!K-WA:I6[
M25#SVI;SVE&(2""#B&[59Z:";/.:V57X?X"G$B%N)>9FP$X,S#&Y*YM05$L*
ML\WJ%A)[2)^,<AX-X/4]F%/LQC%T//:O[O\`"11(CS,SX3@?"KNQ&JKL/*ZI
MI2Q*;[[P:W:,L>UC2K:W&.907VJ8FO>B`O>D2=@+<=^TY!3(I;#SFORP^&!!
M$B$![A;PLV-)RZV*996*;VGF+\:U*1?:"SC!/LQ86JSMV]LJ%/J-W=-=%>+'
MG3O.)V'9BI<(*N]L/,:MTDTOAB5>(.N$C,$M!Q\`:ID5NJFP\]J727B-;,Q7
M7@"00PX%@#>@M.*DV\%0HM2W7>V&IB/.EXXEF&T8'HQ4NVZ%+>;;:Q*T5X%F
M9#&#:T*1;EF0)II,H1,"6-\XW-R4ZW/I(DGL95B/8L+6D?Q)'MKM2J*^?:P-
M>\6/-QSQ9TMQW%A"Q'H(5UUAXRN_[\MR.P-PP\1P(1])$>8.SH/;CN\"R^DR
MB1U[$`9<7:%FN1S?WB_!?+&'+#'K*P\Z^`W@\"W+O,>`W/`^5<)]DL(YFX@G
MTAV>,>XH4^T2OPC?03Z+OLV*'<[3+&T_.CUF\ES@\S:6#Q>THMW87FGR.T2)
M9ZO\B1_'%1KA96<F=KD<NT>0J)?S1:Z3[_D-TN)<'G:9P+SVPY>)?43<?FGZ
M?[&2.LSOONTGPO-4"[VO$7%G,Z],GTF;V>=<'V7U%I:[1HXY`83D#CX"5"N%
MA:R?6:N(\[Z3#O\`(H<MI+M)[R--$9QO8>BUOB'G*YU7W"6H-O`UDR'N,#>?
M(0/.L?Z"=;@]VFTB)#A>XL&\+/#BN=W%5),DXYD@B.<((..`.>.97+$YR3\5
M"OZQUF&UTGMVC+;BBSKT&*4>)(ZTDO#<Z!VC#QKJKL,JXD>6FNO&F%21XL(<
MW8GJ&3.U=4U+SMB.3M23Q,P^0"!M#6[0=S%VLIIMLY2@Y1WB>&>`\1+&D`'/
ML[5,AC5(@7(2P21?AQ0\&-)VG!F1ZE.MQEA7H(L[,VFEF66Q`[AE@P-WGJ7:
M$EOY8D96IUI1$KK[_P!=M]FQ3[;AND&Y!U\18=CDGT0,,3U=JEJ+DZ$%VVU@
M3B-@U[<6AGG`4N%MO(B3L7#(1>+$9;_<8I<(2HD1)6[BDT.(@M!VG'V#I4N-
MJ3HEF;2B]U)KSJ')BO#:=WLP4V%J5*4*Z['H2.'HCY&9&/MJ=;@[<JS22(DT
MVJ;3$/OM'I',*9:G%NB9&N1:CB2>L.+3U>QBG6W%+SLR%-2HJ'!CND9X]OD8
ML.#E*NPCNS<[1`_$>+P(#70S$EG3DQ94'LS-7!Q6(>BGA'$=WA[$=J<L$<IY
M41EZYCC!E@.+L&068Z>YT8G#<DQ"BM)):W'MR\".Q=Z$D8=N>PLNQ@T#<S#=
MEBU:NU)+#,Y>JE5U+\**&$MPXACX-BBRTUUU>T;LF67(@+.HX>=<_43MRWYK
MS*4$ZQZR<1`P`':.(]F23W,_P3DJO%YEJ&_@&X,:`-^T>)5=V:<J_@C-X%^'
M$+KCNUH:.S/RKF]UI;IQDO.9:<)&69>Q[6*/<6Q9BM"ZZ_P@$G'''=L!ZU$=
ME[V\UYIKM)1$`=:3A@S!=*1ID;-)XF,.(\\<\,0SL6KC%[#!.TKA.,=XY22J
M&E:[L36B#=^2**KAF8DENF#T1X>]Q!V>#)JF6H[=AR7W`_$=(!=+=NT8Y=>"
MFQ53>NTKOO\`%Q[\.UH`:M)P2E@1+G:90B/$EW8<?,IEA5PVD*^ZQ*;T3PNX
MG/')I\"L[:3:6T@,@?BNM;TXCIP4B,6G3:1Y/!K94I18@=&.&!8?`P*SMQ=*
M;2+=54Z=!KWXSH=X"?2:,-ZGVM-=E%.*PJ53;WG3(UD6.''R6^CQ>!C,L.E6
MVFL7(JDD5VJ54WM*T2.'H;V/U(9TX]6"M;-MN2C3,I+V5"@]&86-;C@-Q83@
M6*UM6)5IM*>_M3^&)!$BM.!Q8]XV="L[%N45B4NH;@\L"#C/""#B,]F!.*L8
MVIRE6F!Y_5T3P*[T0EO#Z6)QW#)6>GLR3H\&>:UU-ZJ*3T0M:<"QIV@]/:K.
MW;DY**/.:A82:*L2.Z-P(.'OL/`,%8V;$T\3SVK55B81)DD<1`(8?$QFQ7=F
M4(K=/*ZN*4L?AB48DT#@<2,L]IZE86O/C5'G[RJL,2B^^>)TG`<08S%N*GV8
MXUV,\]KFJ.OPP,'XF#^YF?9U*PM1\Y="/*ZENC=<"D]'==VLZ@3YE913;13:
MA^;1&OCQ'R"6`@M.>>XX;5+M1>W(\SK)14J;?X2EQ>B6EA#2&;!N4E1E)561
MY[4N.]5=FAK(I>B#AW/'#PX]BDVX3Z"AORK4US[KSI)8,M^YJEPMSSI@5%Z3
M2J]A4BOD``%G4,FJ1;M2Q*Z=Z$D^DI/Q<6G/)N\MVX;5.A:DU59$*<DF5XKS
M02-@;U%I7:$6L&5TIK>H]I1>?!P'6>@XM1VY1=2#=FDO&0//$D/?5-/;L\!(
M6WJVU0B^N@I,EX2\2,,AMVXK7<E2FTRKL3$![B(&][PC\1-R1AW(%R&\Q@>P
M)`/\<1YEAIU\1O"2+LJ2^\P9AA\!4>>"\9.C<@S=P@\W<6`[\`#YE!GVB9&2
M>.PW<$^BXW8&GM#JB7.TRSL]N/6;^5!+H9]<3[/"HMTO-/D=HD@?S/H&/7Q%
M1KG065KLOK.UR)V;6@]F*AWLRUTGW_(;M<BX/.\W_*QVKZB;G9/T^V/OG6)W
M,=0\H4"[V_$75G,ZY-X/#K=\I7!]E]1:6^T:*9R/;Y%#GGXB?:R9IHF1[?(5
M"GM)MK-=7WC5D^D\.IG:SVER1/M/SBA,'\V_BF?QP"RNR3H;.LAB#B..+&EG
M42?$Q<)Y4.]W(B+I`PPS["P+1;#EUD!`+IQ9L'M=.#4V>`T;=2TX1CC@"X&[
M,@/*N,>W\9*G^:74<O/<45NP!K-^P#QJ=:RH0YK'Q$CH8Z'MN[\<T^=2XYLB
M/*FPD#7BZTX@Y].W=DI%J5*D.ZZ42+CCP9FW<.A3H*323R(SJVZEWB]'+8-J
M[V^T<-W$.OD9#V>!388I%9=C21-#?'U^8R9EOV*QMU<L"#0F#X((&.&?6IT*
MIXG*:Q;.000/2Q9DQ3+<G54(4F]XS=+`>%[Q=6]6$)><JHYS=6C"(\^3[[^-
M&\J;;=5@0)[KK4X:^P>G_&CIZ%(G6GC(DXQWL#@E\#W_`/&CVEO:BZUVD>]%
M;I"]%?\`KO$/:4V$6RNFTE@8F*2/2.'8/(%,BDDNDRW_`!?B.7(P=<)!VY#L
MWA&ZLA7*MD;T8DX8;]K?$MX8LXX+,E=B`.M)Q./2<`NU:&*O820HK6@8-;AO
MRZ,%J\3>*2Q>9.[%#N&T;-X.WL7"6;(\W63+,*.T,XFD'`X,'BQ:M5CF%D7H
M<<8M+`1B>G:,MJUO).%/"1Y^#'$G<BM(W88;QL59=BGLP-*T+KD<#WV>P;BJ
MR=EN5*8"*>S(OPHS0#M9ET>XN,HN&"1RGA)FPA10!GBW#KP9V+GN3;R.>)9$
M4!TO'':=F/NK,H/=Q6`#L3B/%T``?C=BY;BZ!4LPWQU>W[JPX+H,5H6?6?C?
M'[BX3AYV1QE+SCCC_&^/W%IZOP&M3AZ(P%H\?N+*@UL,2E@1^L;L\?N*9".Q
M&F!4>B\#S3VCHV>-2K<'2M#.+P1B]%XAQ.]'A8NDK>-4B/=P;*L2("S!C&MV
M[O*N]JVXX[2!>[)KX\0NNO$>^8T='MX*PM1JTUF0\RB8P(!&88UWMQ[%.A!O
M9B1+F'54KS$5KK1X/#@I\(TQ?:(S>-?`::)%Q+1@>'LQ5[I$_4I]96756K*<
M9YN+<R]CX%9V://(K;[JJ,H>L('""QH&&_Q8*QLP_C4]B*2]M*\5\'HQ&'9O
M5G!-2KL*74U3KL*C\0X!N`#V'5TJPMJB705&H:>&VA`9@AW$L`9@0,F[V*VL
M1K"M,#S^I5'1D0CL>./""6MP(Q[-H4^"=$T>8UR=?!7[Q4B172<P<,_8%-TZ
MEOJO2><U*[315B/-;AOV]H*NK:DD>?U+3P(GXA#H&>[+Q8*9;@VZ^`\MK$]Z
MKR-=%?:]@"&LZ_(K?30I;QSJ>?NXU2*L2(`71MXA[,E8VXNE-IYS71I6GPP(
M222\>+J#-ZG6\*(\MJJ*+;S*48M;Q;"1V':K"V\446I=:4Z"*(^`X`'AD&8;
M<,,E.M)X]9Y75X2P^&)K7XC6M!(W>5N"EVUYN'24EZ#VLHOOCB/HEK-XR]M2
M[,<"DU&&90BO`@^BS,CKVJ=%>:4M^-=ZG04WG@0QN.T>S<NENN)421KXC03M
M:26=+3@K"R_-(\\UTT,"6MQV-&\^9H*25&5UU*I0&+S&L71XK`A7E6-2,X/$
M=HZF8>%:Q*V2R9,Z\1@/QOC;[2S^$S,=J,@^`^?_`%CP/C6#/D)V-81N)_CG
MB%RE@T=89&QDW>&(UF!:/$WQ*+<?FKK)EO,W4(GC.[@_D%"GVBPM]E=9N():
MZZ?QH\@4.?;?7]XM[7;CUG9)+WKO5YQ[2BW2\T^T[/)>U^64>[FBRLY/K.T2
M/OA^1=\ZA7LRTTGW_(;Q<BY/.\W_`"L=J^HFYV3]/MC[YUB=S'4/*%`N]OQ%
MU9S.N38)>'6[Y2N#[+ZBTM]HT4R"PX>QBA3S1/M[32Q,C[-A4.>TFVLUU?>-
M6\#Q/%FT>SQKEL)]KM&NF`?6NEA#7R>QK5E94)L,O&8/9O9X`>-XM\2X7<B1
M=R0!'"ZW'`>-K6^!:;3A*NPK\)&!!8TO9;!O[4Z#7/$X=;ECF#T,P\BXQS9+
MG^;^(G=XB1ABW=Y>H*=9RJ1)Y^(E+V#O8`T=32I=O%LB/L^&A*WWH&36=).U
M2;5,6R'/8RU"'0P;6]&0W*="3=*94(K;JRX]$AN@#`X#)A\Z[6^T1\:@189&
M1.)V#VU,MY(@74ZF4&*YZ7O1A]4P>#%65MT>!7.NTG]:Z'2&N9':&[<L5-MM
M[V1RN9LQXP!EBS;^*IUJ2JBODWOOHJ9"(>$GT6_B=*L(.LET&DGBCA]\L;B<
M-F6?6IMIJF6TAS:`?:-OL[5)S=,R--I,QB$\!SR/D4BW';M(UYK=-<\^?Q_L
M[5,M0*VY@E4X]8^0QF'2WVV*6K<*5;Q,O\W7P'+D1@((.>SLZ4<8$&ZS$Q0P
MXCL./ES6UNW65%4CXDCL5T@>D,AF<<NO>N_JDLSI%8%B%$=#?2`SQ)ZLL5JX
MUR6`KT&/K7B^0&L)]\6M9D<6Y,7"4%4CRPDVRU"?X`>)K"<MIZ@3O**$3G)M
MX+(M.Q'B02689`X>!:SMIQP-942+[D3`'IP9FP]JA7+*RQH<4JLM.Q&M)Q+&
M=HRVM8H<[='M.J5%0V,"(`ZZTM+,FX[F9J%*U63P9&N/SF7X;X#23AEGLZ,=
MZ>JITFE:DCT4O$/`L`8P-\9#6+6=M..3%'D67(N&8Z-GG7!VET,U>!:A1&[1
MT^9:^J7A-2QZP_7>/W5QE;\YYG*251ZP_7>/W5KZOK,41B\^2Z?2W;>GK3U;
M\)K))(CXV?5>/W5*MVO.R9R3Q*S[V#3[&*?;M84HSI%KQE;UG`TM!;GCY,1B
MMW:HZ*M#C=Q;((D3TG7@\&8Y'#!2;=E..TKKV5"A,1>)PD$-P.>+6CS*7:LT
MDLR&\#5Q(A#S06$8#JS+>M6-NUA2CJ1KG9\9%$B\;F;'@"T`XM'0TEBG1M)K
M)D.>#\%#6//%A)S+"1VC8KG36Z6HQH0)T=2E$B,(V@DM&T99#8586[>-'6B*
MG49M%**\.%H/U(;O&/B5AIL+B7X-2EOX)LIO1@"`2".OTLCT[U;P@GD4U_&O
M3_"58D8,+"/JL'L]G2I\()JA2ZA-2\1"7W2ZQK,1FS?UJTTL?XNCRQ//ZEU9
M5X\<R0'MAV-/2K&W%4HCS6MGG7/^`KE\A\#!C!GV]*L-/"+FCSFH;6]0BB/L
M('$!V[&$[U<1RP//ZIU3K\,2*(]N>&()SVCMVJ5;J\*8'E=6VI88E*(\2]L&
M`Q&'C:K6PFX5VU*"\\,2"*^ZZ'<'22>@GMQ5E8MM^<TZGF]<G7#X8%8Q1N(:
MW+H[581MQ23VGE]5%XMY%&-%+2QA#6>ECF.@J7;2JJE#J<E3H((SWH-PQ#<-
MA8WP*;"22IX3S&KHIXY_PFO?+<FC`J3":W2BOM-E%XXD-.W;N4FW)-8%)?*4
M0LX@TY;]N(P4R#\TJ-0U22\'WB@^^!GO#"-QWX[%*MLIG+#$KOO`DM8UA9TL
M\ZFVL%@1;N$D1O/.EWB=9@-F_:"MI>$@2=9%+`/;#M\JW6,:$&YC%F)S)PQ!
M\30/(M5G0K7D8NO,#YVCA8/9L66_.ZPF<NNGB)86>L);T%H\J(V+\#A/HO?C
MF8LVKC<^Z=[>1L98AN!#>)GA!42YEXR9#%^(VT'W_P#]'_(!0I=KX>$GPR76
M;>![R'U#R*)<[;ZRWM=J/6=GDLAU>=1;N1=Z?:=GDL&=.78\H]W,LK/9?6=H
MD??`]#OG4*]F6FD^_P"0WBY%R>=YO^5CM7U$W.R?I]L??.L3N8ZAY0H%WM^(
MNK.9H)@->/0`?&5P?99:6NV:2<][X?RJA2+&W]XZ_%]Z]U'\J5#EM)5K-=11
M)],]+Q\@*Y;2QM9FNF?Y9#ZRFUDV&?C\A`_]5V>5<+N2.]S)&`R<ZAYUI+,X
M2^'W"(O8#I=Q\0:MTL3!QQ>^[!UM8SRJ.NU\9+G^;1.Z]Z98<P]XS[2FVL($
M*>1E[YUP=)\#2/&I=OH\!$DW1G+I]-T['3Y<%(MXU1$N812+KKXP!.;2!U%6
M$%@EMH1=K.#Q#%@9U^4,7>&,J''"M"6$X_P8LS*F0\!777YQSP/8Y>'W%8VN
MT5^(#KS-GA]Q3HRH\CE<>+,VOL]]L\W4IMIPP*Z;6^^L.Q2`0<<=O8K&U1R5
M.@YS2;)78QX'O1&W;T*;#!$*2Q(O7O`E@W[3O4R':\1PFL3%Z8?8<,ND[E)@
MJ^,CW8^:53%+V)`:K&W;I':5UZ*:0,4LR&2[JRGC4RXKU=/`1<9.T^SL6_JX
MHA75%+`P>P#5O!4=5T$=$7K`"&!OB71MLV1-"?))!+3CANR*SNLWR+;L8.X;
M0`.@-4>4%O,A7'YS)A'+<<7FM`V,S8BM)[31%R#&'U6T$CVNC%9=M169I<6%
M2\Y&X<3CB`SR>`*/<MU\ZII!5D6X<3%N>[VE7W+?6=&7X<08'HQZ![`HSM8D
M.>,F6G)@O!F3#EO9BT^!:^K72%&G66W8H8&[<O.M)VTHB3W54LPWM_0#U;"N
M'J^LXMUS+D-X#(]+?*/`GJ^L5)_6N[//[2XRL^<SE)XF/K/QWB]Q/5+PFM0_
M%=X3GL\O4%F%GSC$G@8NO.D-;XBI5NTDZMXG.I!%?;YNH;>U6$+>/B"\W%&O
MBQ`26;&$]>P+#AY]#6<MYOIH4GHW"P;&XXY=*E6;6-"!?6!5BO@<1\`WLR5A
M;M+>2(6>!KGW_2:3U]NSP*PA;3>!&NND:>$I/Q=KI(/FV^%BEPMT7C(4B%^.
M'LL"S$8]6'0K*S'"A7W%1OHH:R9BL8P^DTY=2LK$4U1E5J<VRB]'#SI&3Q#`
MS(AK5,MV_P",BMA2ZC%,U\9YF>&(Q[.I6]N%,2DU&$L"&(6L_(O8J5!;"JO2
MZ2N8CP!)QPR/6%;Z>*]4NMGG=3F5?7$D_4L.QN*L+<:>,\WKHU?PZ"J]'/&/
M3.0]G@5CIH>>ET'F]0FMZN1Q$BM+I8W(-WL=*M(0S;S*#513BW\,R$Q2&X#,
MJRL6DE4\GJL)T^&9"_&+<0,O.K73VUN5\)Y^_BL2E&B$\+#]4K2VE3J/.Z]K
M9\,"`%]N)PQ]F2D55*GEM57=D5HI(;AF69Y$=BV@ZM%#JG1+J(8I/`&L#'6G
M;@SJ4RWEXSRVJQN?#I-:]$`;Z19EECBI<(O<\!27DBF\\2277MX(W'VBQ2K*
M>TH]36F!5BEK<,=^_?L4V/912ZBKWNHHQ`T-V,9U;BN]ME/*JS-?%)&!S^I]
MKP*QL]DC7<TS!T\,)\=/$.G`-!\"Z/%E>WYQ7+V(Z,/+[:1>PB3>#,2]@&'>
M/`""%A]HKZ9F#6E_<`/.LO-&E,C8-]`CI!_C@L;4;AS`C^*\9*YSS1WAV?&;
M&3]\.OS%1+O9\9*M9O\`)^^;R#[_`/\`H_Y`*#+M?#PEC#)=9N)<>@[U`^(*
M)<[3+:SVH]9V>2]Z[[-RBW?O%YI]IV:3#7G.I[\LH]W,L[/9\9VJ0!8QGU0\
MZAWLRTTGP^X;W@>Z%P+@\[3CK(8.Q?45<[)^GW3Y(ZM.YCJ'E"@7>UXBZLFC
MF`SBZ0[YUP?9+2UVT:.<_E;WLV%0I9EA;.O1,CVCQ%0Y[29:7G+J^\42/3/6
M3U8`+DBQMJC-;,_RQSM3:R9#[_D*[_U74/*N%SLH[W<D8.O`AT;L.M@)\ZT>
M.)PD5SM_(CS+;::F/$/2Z2X/`QJX17G^(F3PMKQ$KKQ#SQW<0'@#/*IMI5P\
M)#F2N'T!U`#HQ+5+@ZR9$>TE:'`#F=@WG;X%)M85(=S$RA'%IS+2?"I]O8_`
M1I.F!;>X>$<71[,%TMU<R-M.77G0,`T-.+2IUJ.&/20)KSAQ#'T?'[BL;</.
M(=$<NO.XX,W9E3K<4FSE<2JSDQ!]=LW>XI]I1P*R:6^^L@X_?',<1Z-JG0C6
M2H1Y]HR$1CKPX=^WW%/M1I$@R54V0O16?4[=_2>A6%O"3?@(TGYWB,?6>B?1
MV;^OH4RW@TSC==45S$Z/'[BL+4LR!<R1SZW!G#LW]'4N]-IEK^+KX"+UI#?2
M8>H>TF[)D.ZB'UN)8&]+?<76U;QJWL.5,#`ODD`EN(PP\P4A[L>L8(M0GCCL
M#"WQ-\2QO-FDF\C'U_I\+NPY]&[$;%'=NLFV1Y9T+,*(<6EI;GN/5TK:E,$:
M-E]R+P$'-H;P]?2L*%73::M.2+CCY+'F[AV;.I<I(QA%&PA/^WU$*+<ALZ##
MQ+;L;B`&P9GZX>XH4H5=2.\),N0XG",3C]3UAC%CU9ANA9=B/8%N9:0P8[/,
ML3MK=.>9><?8&@[,.D%<=QLU)X;Y>]F1'@V+=1H8)^-[?X@H\\),YRS'&]O\
M0]I:&#@OO,S\06T>T:3[)AZQX'`^12(+:<D<O/M=:>WLV=JL(+:&:R/$(>)Z
M0!T-'C8M7'>N5Z"/.N\Z=!KXC_$0S+T@5+MQHJ])'NNL2B_'+H+N8/5Z(;U*
M99C61%:KB5XS[,NSMVJSM1_"(5W"+?A-8_$8ZUN)\2FPCO.A"EB\.@J&+Q$M
MP>!#!Y/`ID8NBID09O\`T%&9BDX$[PW?DIEBBS*C55:->]$S;M9V#9XU96,;
MD4RENRS16BQ#L+0#EAN;U[5<0I4J-0E)D,2*!CD6/#?AX,5+M1WE0I-1%IU6
M1#QG@Q#>G+;U*TM*D53I//ZG'X>`J<0:]BPDGRE6<(K#PGF=;5/#I^\4R^/6
M.^EN\_0I]A;MR-.D\[J)54JF$;;U^97%MXU//ZK)_#:1^L8#Z.T[>KH4V/3X
M#RFKE6?PZ2&)$;L9EM]Q66E7F;Q07L45WHCI9Z0P(9X^A65M2W5@>=UR5?AT
M&''B?2\7N*1N5BWT(\OJE@Z9%"*P$X-Q9N;M6\%5HH]1@EU&,3W@PP8".L`8
M*9;6#ZSRNKG_`!CP^%2B\!BP;V[5,MX0*&\ZLIO.AIW[^I2K%"EOY%5_!NXX
M^8J=%)Q*G4)/>?@*AP!;EM6T%0I;BJBC,@#$;\.H%I4^P\*$.>.!6)'`]PY,
M;X6^TNVTK9U4Z%0/-).9P;UXHEYU")/)]9P3@Z=GI'\LL/M$+I.`6<9Z'?.F
MU&CV%QTL<=/1YPLO,+)]9,YF.W\LN4LT28=GQFRD_?#K\Q42[V?&2K6;_)^^
M;R#[_P#^C_D`H,NU\/"6,,EUFZEPUQP?C!Y`HESM/X;"WM=N/6=FD_>=1]Q1
M;I=:;)G9I'-WJ>_+*/=S^(M+.7C.XR.7:YY5"O9EII/OFZ7(N#S=.$M>Q.9\
MR^HF61^G.TW]TZY-.@O$[1Q,_P!4H%S,OM.W3QG79K/P>4KC+L,MM._.-#-`
M\('7X@5!GF6L.R:2*,#AM/D*A2VDVUFNK[QIWB>,XG8M-GC.R;5"G&S'6?,F
MTFVV\"M$)`?_`(D>$KC<6");Q(6D!TC?Y@N2Q1J\C![,>SZE;;30A!](?DO:
M7*':?4;5="0%KV.TDL[-W0IMC*INDJE@%H=Z'?&3[2DVMK-9);M27B:\=H!`
M'B4FWFR%-)5+`?#KK&>D0WJQ&)4^WC1%<U6;?A)FY-QP4B#29QE0SAG`X;?:
M4N$W3#(B7:;N1F3T!6>FDW)UZ"NO.BPZ3@G#9D596L6ZD*;>)7.:GVTJ(KYN
MLF8QO>AF&>6&PJVLQ6&"R,SHTNHKA[T7L]JLK$8TQ2*^XUN^,IODM..W>N]%
M7`CRW?`<<3'3CLW]:F6X9+#`CW*..PB=>SQ\:G+=HLBOE0JO1/3>Q>S.WW5U
M3CNY&V]'<R!B-&#>W\52[?2LB+<:;5#D1`"QYX!F\^ZN\HO=R(E3CU[N#,VC
M-C,^M85O'$`Q&M)?[&^9JW2BC7`DAOC`M&6;=N8:CH]A!N.LW3I)S&&`=..U
MA\+&'-:;JJ:I=):@Q&EA>Q`WYC9M6LX^;4V;2B;.$_DTX8;<B.U<*(Y/$NNQ
M6X`X-/;L+,<5JU%[$"VY%=<9CT8>S+!5-ZVW=E2E*D>?:9.[%:PM+6M8WW5I
MZIG*C+\*(#@W8T-/N[UI.V]TP\$;"$]L;T=3/;7+U;-*EJ$^!X?8WP)N,Q4F
M,0-]]X_=6/5-]!SEF<>L'UWC]U/5=1K1CC!^J\?NK#M[JK@8DL#AHWCPK:"V
MG,IQHIR#QW#'/?MR5E;CMV&%TE)^(W:W(G%OL)67%.=5L.5RC;Z2C&?X6,.(
M;YEVA&OC(MY>:4(CX(>>;LW^16&GCYZ\!&*;\8@,>+0UIZ-@`Q5K:2IE@0[T
M4TZ9U*C\1HP+1B!U[?`K*$57>5"LN8/PFMBQ,<#NV^165I1<,D0I4?70@]<!
MQ!XMR9M9U]"DV[2=&DBMU*S*\1\<#QP8P#!F..Q3+<-UY8E%J5@^DU<5_$8L
MQVG\;UJ;;R;VU*:]3'I_A((S^&+<B0Q6=G\9Y%3?Q9`'B'`6G-N?XY6NGW96
M_&>=U**T2,^3F/?'8K&W'[AYK6)-OX;#$Q`1B"UG9EUJ7;6*9YK40QET&'&,
MRTXGV9JRMQKATE%JL,?AF0>L!)&.W=OZU-BJ(\MJVMZI#$+3V>VK#3]A=9Y?
M5.L\,J$3[`!UJVMR53S&L;W:OX8$/$6>SI4BN)YG43E4K1GRT8C9Y"I5NF'4
M5&JE*B^&TBB/N\.+SNW:/K>M3(+!]9Y?55WJOX8E9U\<+W"0<#M:SP%=V>=U
M7:*?K/2+1@W9U])4JPE0H=1)IOX;"K%>Q>8=F7A5A;6"*74R:BVGL*41YC#L
M(8?&N[296SEYC94B/-PW-(/06[5HL&0)MXLK`ACW6\!Y5*AV2MU-=[#H(@1Q
MO,8S'#KZ%F3Q3VG!9&+WO.TCQ%;/,32H^HY&8Z@CR\9!V>,G/O?#^6"U>9OT
M]98A9CM_+%<9YHE6<O&;&6]\.L^4J+/L^,M()?Z#=R_O_P")+?`H<^T2:)/#
MI1O8`P<ZO,/;4.YVGUEE:[4>L[/(C,=/E8HMW+XR\TVWQ'99)UA&&#'F?ZHJ
M-=S7B+6PO,?6=LE&\.&]Q0[V?B+S1I?Z?O&_X3]:?`N)941YNG7,7F=.?85]
M14LO&?INM;.LZW-`M.!S>_+*!<S+ZQDCKTPYB">C#?B5QEV&6VF[1HID8-W-
M\8>4&9;0[)I(CI#IZ`\?"Z6>5099OK)=IXKJ-(\Z>,[L/$&GRK782$L45(X]
M+HXV>,+"V,FV]A5?&$3J'E7*[DNLEL@^I'7Y@N<3#R(WOJ>S\JCR.>P@;Z1W
M!X'V>!<X]ILV,Q[YWJ?\RF6>PS<G=>P)W.G^-P\REV\%XC6>21)#R'6#X@5(
MM[2%>[31(X\T%X[1YQAV*=;S1`EA)]99X@ZPG:NT$W(C/%AR(2Z0,,=AQV*?
M;BDD1KJ6Z<EY[ZX^$JUTJCOO+(K[RP\9B\\\SWQR.TJRMTJ\B%-9E<O/-]\]
MX2IT*;J($EYS.(D1X#$DM#,2=Q5K9>75]X22:740^M/"]@,BK"R\"ONP2B^L
MI/1BT^B,]ZE6\9$2<50Q,4L/HCPJ=:BZG"XEND'KCL'C*F1A4KI116>BGC.`
MS*ZQMM9Y&S2W##B>^N>\)5EI[>%6E0BW,\"-Z*&$XD]/MJ4XT6.1$:H8",21
MZ(&(\JU:5#5DST4#9BS#'W%S>Z:F;D0O`;-X&W<LX=!#G^<?63B)BS;O\NY9
M4%T&4B]!B,(;DPX[0,^U:W8QW1/LFQ<B$L9DUG7C@5$:3ZCB7G8H=`.W,#IV
MCJ113V`GAQ>+$YG,=&QG4H-VVO6/K(TT]ZI<=B`$;]^.*T]7X$:.J+\&(&C<
M6[\-_C6EVTW"BS.;J;.'$P)W#'/L*B^HN>`P')@#$DC8QJ>HN>`S2I(9EXXN
MN@C82UJ>IGX#1I5Q,/6OYM/^J+/!N6/4W/`,"5V8+?2=#.AJ2M3IC2AI-+=P
M)Q%!&`&_/W%M;M.FPX.I2B/$AN_#J&U3XVWLR%2D^^P$]/AW-[5LK;WGE4CW
M'YS*45]K!MQ:>G:I=JUE@B-=EO(UL9_A:1V=3?.I]FT]]-I4(Q2B1&M&T9C?
MN[`K"W;;>&1'N9-^$I/1"[U'9Y6;BK"VMNPKKJ4NNA1B/M)(P&'N>-3[<:Q3
M615SPKU%-Z*PO`[=O3V;E/LQV["MORSJ5WHNP%HV#8P9J=&%9+H*C4)-,IQ7
MP<\#Q,\2F6[5984H4>HC1^`ABO'>WT7MJL(P5,L"EO2:9'#?;"]+L_U2L]/#
MS$UD46I=648CV)#3[X[^E64(41Y;6U3\?WC!I9F6LWE2[5M[Z?X)YO4-^<9!
MX8`D-Z^A6<+<JUV%'JGYOPZ2`$!XEHV[1O"F0B\VL#RFLQ=/AF018F0:S!K0
M>M3[<=W"FT\OJJJ=%T%=]\L'I'/Z[W5/MYGF-97=^'08![T??>/K4AYGG+ZZ
M2E'C.!YA)+&=.PJ7;V=15:K)?#:01'W2Z`WQ'<5.A]\\QK'5T^&95!(=>82,
M#D2%VVGFM7FRJ(I!8]B&G'$G,J99P*'4JK9%$>87B,0P]N)4^WDBAU.3ZBI%
M.72`SQKNBL;\QHJOO-`W@O.GL!8M)*C(<\F5\P>L'QD*1:Q@0+__`/B1C^6>
M#^26TB-L0/O#^2>\ZR^TC:>3ZCD>^_B1Y2LO[Y!>7C+/U/A_+!:O,VZ>LL0@
MU[L>/@)7&>:)=C+QFRE??C^*\ZBR[)9Q-[!'I=CWG4*YVWU$E]I>(WD`-==9
ML]H*)<[3+*UVH]9V>3&`/2SQA1;OE+O3':9$`\#=SWY91KF:+;3]E]9VR3`X
M26;7/&U0[N9>:0WZX%D>9YLO<9!Z6^`;E]1<^R?IOM??.NS3SS2&_7#9]<H-
MS,O;&PZY-O/-SW?EBP+A+LLMM+C(T4PT`#:7L?`\H,RUMOI-1%&#_P"19_&J
M%/[Y+M=I(TT5WAB$`;R.KA`6CRPZ"4LS7Q6MW^FWQK!+MY+K("!Q/AF8'Y9<
M[N2\9,97B`!S#,9+DC5]I=!"/2=/%BS#^-3K-'@1AQWTL/J1YUHNTSHEGUF;
M'>(!F0>;GM9[2EVJ[IGRDH#IADL8T?EGL1X%*AG3P&LLTC-CH=8-KP&W)@:I
M-LA3QFV3.!T.M9@'>G>%.M[*9E=/&XUX3EP\;PXLL,-P:I4$DSDTE7K,R0,'
M0P>ZI,)NF'20KLJQ\8=`)+59Z7M-^`KKV7C.'C#`9T'>K*W%XD.:>)7;";_^
M\IUN,J(@23WF<1?5ET,\^XJZLX)=7WA+)=17>P#PZ"I]G(A76]WQE!X@$MWJ
M=IXN<Z+H(LZM8$;SQ8^PX!TD8="M(0HE58D>ZJ116<)+6G=YU,C!8%===*4*
M,2(]QO-.`>.P>TI4;:IBL0WYAAZP[_%[BEPW4O`1+K55U&+KQ>+#B&+MB]A&
M;1F!B.L>5:N#:Q-20ET=)W8^5%9?094*]0=?](;&#`9XCI6RLM$24:3?66@^
MZT%NT>58<&MF)J7'']K<0&+A.VVL4:3JT6W)@.@#B:<.S>U<U:\!S2;+4.+B
MTO-+<>I@#<EMZOP&U&7W(C-NSQJ'<M?QCP(UQI-U+T-\/$-.+0L>J\!'K4V#
MCX=`(+#X5K.UYN0+3LR71PM:6,.&6&1PQS7#U?@,J*9##B$EI+23XF,W)ZOP
M&]$6Q%(`'%XO<6/5>`XR2WC(1'CD]XA[2>J\!C`Y]8^,SXA[2Q*S54H:RING
M(C$%O$SL]Q9MVL:)8'(A?F>/`%F[:#M.S8%.MVE151HU0I18SWUV&![-ZZNP
ME)T1%N9LU[\9\8MWL\ZD6K6&6)"NMI5*<2(7FEN3/9DI]NTE1T.*DGEF:Z+$
M+6MQ;@IUJWA1+$X7>SXR!Z*'@PYC#K/F."E>KIED0;BIET%&*]PDL.)`\&>W
MJ4RS!I494W<WU%-Z(#B<VY;^WI5A"-%0JM1M*I+'BS9GXU,M)U705%U["M%?
M!.YN._8Q6=JBV4*F^T4WGWFECV!PV9*?;@FJ["EU-'(B>F'X;',QUC;CN*MM
M/:\S$\[JB!^*Z6%[`\66)[6@*?"VV>;UKQ?PV$;T1QA8=F&!]I3;4$I),\WJ
M$VI4(#%=P]+'J/M*P@MAY_4QE1_#:8%X9M4VVH[<CRVJB]ZGPS,6N'/,=:D-
MT=-IYG4M*='T$;X<8.OI4FWVCS6LE'=^'01,<X?Q5)KB>9U,HE6*ZZT8;O(5
M+MO+J*?4Y(PB.N\.6_R*=;:IXSR^K[7PZ2J'1PGM7=YGG]5B5?1;B-OG.Y2[
M#JBAU*Q="(\(+P(P(\>/E4^WDBCU:K!O;0@?`W9,_DO:4@I9]EE-[A:0S:7F
M^%)K!,B3R96?`!+,L?*5TL]D@WL_$1C^6>S9Q+I(C;#AOH,Z2?*LO-&9=GQ&
M;OOOXEWRK+R\9"V>,FADO1"Z3@U[#M6'VC?RE]QT![##T3Y?=7"YFB3I\GUE
MZ7P).1!'C)4:79\9:1-U`)#V;6CR@J#/M>(D[3L4N,'>HCQ.J+<[190[46=D
ME&@$;&[ND*+<S+S3Y':)(/#U;"WT<>U[%1;G:+2QV7UG;)$/$%I8,//YE#NY
ME[I,O&;YCWUWB"C;Q9GFZ;`+SP.TEOB7U&S[)^FVULZSK<TX,<_JORR@W>UX
MR_L;#KLT`#AM9Y2N$NRRUTW:-%,#WO2WR*#/,M(9,U$0,#WY'S%0Y??)=OMH
MT\8'UG9[/*N>TE;36Q1[W>7GO$2FQDRWDNLJ1"PG8T9_Q17&]6A,>1"\\'@&
M^S`KD]IJ\B!S)[K_`)%;&K,1]4/QH\A7+\-^/[QNL_&<C^6'J/D4RWV%UFR^
M^9_4.]GD*DP[;-9$A/O1TM\@\RE0(,LVR3B8X!O&/4T*?;S17->>WX0X?2'9
MY0NZ[1'N/'QDC[P!9M9X.M2K:KU5(=Q^;3PD3222KC1KSGU$&[B</$`8X8%6
M=O-D2>TK\0;F/"%.MM41`GVF<Q7G>`>D[EO&XJTM;#62>!3?>=]+TG?>G:%.
MM5I@0KB>[XS7O/.M/I#/>%8:.OK'GD1I(XXG>%[TAEO&XJUA&3Z3A<3H0.O.
M_7#PA380:Z2MN;"A%>=]8]Z0]\=H4NW%TJZFK3W<B$Q`!EM]I2[=NKHR-<@Z
MKJ,7HK`W+QJ9ZND:O,C*/21^M:\#CF.CSK%$C9)(D,1T;_%[:PY)"IRY$:<&
M@'R[%JY-Y9$&X_/?66W8@:"2S?D!TC-8-"<Q\.$?ZKH+,EK->:)+`L0G\FM.
M(\."Y&ALX<1C-IW=&[L1(UE*G63NQ\<\M_DSP6CA&M2!/&;;-C!CX9XD]'DZ
M%KZN)K0N":`V@G>&8,S;BM+D([N!E1VDD.*T8EN9]FUK5'W(FQ+#B]/1L]A3
M<B"V(CC,_&/;6-R)QD_.)H;[I!8TY;O;3<B8.7WW0Z3C[#UK64%3#,UED0>M
M=.WR>VNMNVJU.92B1F#`[=FY2X0V#,B$QQAA..\LQZNE=7%;V&9$O1HVR!][
M'I\04FS!-/I*^]D:^-$8"6X#`,[,5.5N-%7,C+`HQ8C06G';T[@.E2;269RE
M*JH\ZE2)$8,,-WG."F0C5^`BSS\12?C[#T!O0IUJW5;VPJKL*MM=!3?B8EF.
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MOGTCTA\#L:?(%F6,"%+LLK/>;VUO9R9"O9^(C'\M[#YUO(C;`ST&]8\JV>:,
MOL^(D`Q!_&@>-)9>,A>4G@#TWC^.(\:/M>(W\K-@X&O'J9X2N%S-=9)T^3ZR
M[`#3UEW\LHT^SXRTB;J7'I?ZD>`%0IKSF2OPCLL`8.])!\("ASQ;+&WG$[%*
MN\0/03CVJ-<S+O39':9($>KZA^746YVBUL9/K.W2()!PS(\ZA7,R]TF2-[ZL
M]"CT+,\V37I/'`#$Y=B^I*Y;6Z?IHA<>\ELJ=:F@]CEF1_',4&[;574O[%QG
M7)ST6;_1'1F5$FO-;+*U>E%MHT,<EYA8,"?(25!N(LK-Z4LTL34Q26/9;?`!
MBH4LBXLQ36]M1I8S[QB/`,]GXBYDBN)K8KQ8/R;P\:U;?QDRV\NLI1B2'ADP
M-\9)7.YLZR6R'8[UCRO+D:O(PA[>L?E5EY,U9B??/]7MKFNTS:.0'OS^1/D4
MRWV%UFRR\9R2QQSIP4FWVV8D2AA+WXT`=JE6\R#<PJ<MQSR=\&(4^UFBO>$G
MUF3A9Z1Z/&I5N&].A$FZLS+H/I$JQLVHO`AW,B!Y]K>')F>1]Q3[/F2PVD2:
MJZ$3SQ(82W/,DJSLQWFZD:<4FT1`-:K.U8BXIU(D[<:UQQ(XWO?9N*G6U1I'
M*=*I%7AXG7B>D>=6VFM*4MUY$*[V?&4WW`TXG-7%G30MRK%NM"-2N96>+&CK
M\ZL;<4J>$YW(*E"L_$+@)#,AY6*="">!!N68HH//DO$D9DE;.3CYJV!6HN-#
M'UC<,%)A.F)#N0CO9F#T4O8,&?2IL)>L>Z^@@RBHY&'$6M6[LI[6<S+UAW!:
M_1X]+,4,Q$#K'MI#6#H6?H\3A*VG)F3L9Y]A+`P[,!LS6?41\(]7$NNOM=ZL
MUB6GBU2K-+D$HU+<.+@P,;@?;[5A:2'2R-)K)9ER%&.UF9\8]M;?1;?2SG0M
MN%I:<&AI[%!N6]V;BJT3.,K:;J7'8NQP[<3NZEINF59B673@-_XJTE"L<1."
M4:HNPGL,PU@Q\O@7+U:.5"6$\S/?X&A/5(4+@R"XR5)4.$NTR5R(7&@`%JU-
M1$C%YPA@&7E6\([TJ&)9%;C/1[.U2%"BIB<RM&(8QN0\JZQ<HNJ0Q*;S_"&#
ML["U=HQWFI/,CW,V1.S)/OV`[#OZ\<U/L6TI;2NOJBP*L5\XY;/,IJMID.IK
M8L4DX,S\+&+K;M).A&NX1KX2L_%)#,&C!O7X<5/MP5*8D=RKGT&OC/D$Y;/;
M5A;MI)1V$"?WBF(CS7CF/9CFID+,6^HJM3%.I`_$':!EL4VW9Q7046HBTF0O
M>GCY.I2X656C*/49E;A8??'J;AGN4^W;6[0I[[9&_%>=+`!LW^VIT$H+<610
MZEU(XD;WN6?2IEF;2H>9URJ_AT$1BM!!W;BI]J;=%M/-7XOSB)U\$^W@K"VW
M%HH=7%I?#I)"1FWQ]2FVYR:R/)ZNN_\`#I,7GW!@3CT8J9;TZN><SS>I?\8^
MHQ+\-Y@:<P,F9[U.M:6.=3S6K?FOX;#DNN@%AR&\;BI/T:'A/,:J347+:0/0
MW7\6Y,R[5VA:54MAY[4ZF;5*(BB.`.YG(Y8;%,A%4\9YW4R;E7X9E<$,(.9P
M!]M2'910ZEU93?`<?+-Y4FS:BBBU#I*I4>/I]#P(\94Z,4D56H[+ZB%\\(+,
MW3[8\RZ)X%-=6#ZBN^6O#K?\;KRVEV"N>3(>$/`$[P/`2LVG1>,CNVIK>>="
M,AD1O0?.N\EA4A36[&J.0&N=KWG6)8-'%7'*BZ2?WC&8\0`Q]G2CV&59B\2P
MZ`Z"\/KB?&`FVO2'!(N0L6'H'C>*XW.TB5I[<=QO;4OR[N(.QKH_+'S*-/L%
MC"*;H;R7<Q!&P-_C/;*@S?G,G*VFZF_EWBQPL#</(HL\V6-JVG0[++-](@#;
M[`HDW6A=:>VOC.TR3Q;#!`R;X'E"O2W6J%OI[*HUCF=MD7BS`;1X,?;4*[<>
M9=Z2VMTW?K3N4?ULN@M/4QZ3SC,N`O%F#.+S+ZF;G9/TO0[53K4TZ6D#'$_E
MO=4*[F^HOK&9UN><QQV$8=I*@3PAXBPAM-%'=Q`&`S/:Z5!N%CI]AIXKN#W4
M0/`Q0I9,]!I^P:2,XR*3O\@&?:N>RIWI5FMBC9^.>_+!87WB7;54BG%&)W$#
MSKG=R3)CR('G6!W<T>?VUQV&KR,((]\=W_H$+;::LP(]^=^'@_%7*/:9M'+X
MC$AKY`W%3;7976;;/&</90_9M4BWVF8EV2=S.)UCR!2;>9!N;3$?5]OY8*?;
MS173S9F#BZ.AT^,*?9[52)+.@C/-]$9#/K]Q6-G,BR7FU(=G85+AVB)+M&#Q
MP/45;:98OQ$2[+%T^&!""<<=JN;26X0[DI88D<7+P^0J1#,C2[2*[OO'NWR*
MWTO:741+N7C*K^9ZU=1S\1'692B9GM\I4NW^#UFL\EUE2-[T]0_+*=;S9$N[
M2AM/6B7G-^$PNRNH@??X#GTY=/45*A&KH0[G:(#'==+"^P_D2?(%.LQ\ZJZ"
M#-.A@9H`X%HWL9_(J5NLYT(C,/%OIG'8SW%FAM1$SL7T1Z6S=[B49QEF6(43
M><&XX='4E&:MI9EQV*<FLV=?6LI$>])N.&1<AOX;MO4=RS1D4N0W]I.6?5O[
M$!G\*:>$%KNT[QAT-4"[VWUFM*/PER#&P:W$Y#KRV+F9-@[&:-P'L(R;M6DU
M6)I/LEN'&:&-8W;T;-G2N&Z<"2%&]H=?@VM3=!<$;`8^+W%QE;3DW4XR7G,Y
M]=T^+W%KZI=)K0>N;M\7N+K9MTN)F)+`X];^.\7N*=1G,H1(_B\F/0L`B+[7
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M%F#%M#M(\OJ,SE^+Z(#VY[TNPLP`4F*P?64VHC5X?#$K/Y*7$H-3FRJ^>+';
MMZ_=4B"HRAU&+*1/I`[F^4J4LBJO/S'U$<3ZOL\KRRBIN]DKQ#[TC>?&"M_P
M65DLF8N^\_BO.5FW]\T78?41D-?[2/#Q*1++QE?/L>,Y=#''AN+X\96LMA$C
MFB5_ZCL1["7')EIT>B>LK.U&KS+D!WT7>E@[.+-<)]I$FQV'ULVDLZW9AQ.L
M\#RC3[)/M9F\@.^DS\:?RI8H$^TRP67C-W`=PAGI8>S:HUS-EE9V,[-+.LXF
M;_.%$GL9<Z?8=JDG03#:/J?Y(J!J,UU%UIMO6=MD0S(;E!N]GQEQI.QXS<>K
M?W>,>VN547%4>=YIP%YYF9XBW=DOJ9N=D_2O#M(ZU,N9XC%X^50KN;ZB_L9G
M69]UA;FTA0;G8\180VF@CD'+(>T?,H%S)%CI\T:>*0PEFQ@\#%"EM+[3XQ-'
M%B`OG`X%GB7/90D>`U\7$@;GF]>*(EV\D4XKF!.W!GA8N5[)(F,KGWH;T^0+
MBLD8>1"Z^`Z0PX>3$>=;9_$:,AXP6AA])XCPL"XQ[3\*-DZ+XCD8O![>'O$I
MMI^;3PFR^^</#T89]F]2K?:9B65"9S.)UCR!2;>9!N[3`%H)WM/A*GVLUU%;
M=S\9DZ?2..`X.QF:GV<UU$1]HP>+6G>586,SA<[)CL["ID.T0)NLB-[(]15K
MILWXB)=S?PV%;UKH)&?2,E<VGYA%FL$118P9[T[=VXKO#,CR5&BB9AX!Y@PQ
M9X%<:7M+J(=W+QE)^9?:<L]RNHYG!9E*),OM.6W9TE2[>SK-)["K%F7^$Y9#
M9TE3;>;(UQ)U*CT1XNY^^Z,=Z[J.-1&*HF:^(.,C%F"E6X;"+<[1B\XS%OB5
MG9AYV/05T\C%BE;B.1Q@$W##DD2!]@#!L6?5HCRDV\"2'$X3EF?*L^K.339=
M]<.`%AP9D5G<-)KS2PY,NAUI'3F-VP)NG%&;LWQD8%@)9B-VW?BL;INE0M0W
MFEHP!#?(JZZJ7'UG&6;-G".3/KO*Q<S!?=]Z$W-_S4:3[);A'#L!3Z,^E'`E
M<]'/'-/H[Z4"</-Q8HMRTU-JISDL3EO0M?5/I,4.0_PEI"WMPW9U9K->:9>O
M'UI\2DT1Q*,8L'3[;`@(#&#K@=86AFWI7>W';TD:XL657IAUK2#MW*9;5%3H
M(-[(UT6.'FNL.'2I<(T57M(J*K\QPG)KI.SJ&2DVX8D6YE7PF$2.Z71PXD9L
M+<\FJ=%;2)//Q%%]YH.QK!GTJ;:A5)^$K;FWJ*9>X2^W\1BL(1HDBKU!4B1&
MX9M#?9X%,MQ>^GL*>^W1D).1W*TM6ZO84FIQ?PZ2N3CXU/@L*E+?S(WGF8,7
M:,:XGG]48//M`P8PJ;9AC4\UK5B_AL,6[.M3[<?.3/-WUV@,P%-MQWG4H-5D
M_AM,MI[?*%8VUA4\IJ^U\.DY!(=#-Z[QS\1YO5).Z^HS!)(ZPI-MNB/,ZQ+<
M?C_T'+V3W4?(5*3Z3RVK_-OJ(/:"Z0:<CRVHS(WSQ,&6>/80I4<F5-[.I#D"
M[VJ4LR@U:Q;*[&OD;V^0E2H*K//:@K/.,)QR:?&5(CD5-WLR7@((F))WN^=9
M6957>PRO$R<Z_,M_P7U%;/)ASWA[?*5M:5:G+\#Q&'U?\7_Z2[2R(-S\WXS)
MW!OY(GSE'L(:S1)$82ZP,`\S/*U8>9+6"+CH!AX8-)\:R\_$:O,N0BP.#H\Y
M7"?:)5CL>,V4N\,,/JG?$"/.HL^R3K7:H;V`1Q$L.3/$?:4&?:+"*J;V6>P<
M+,,SV!1KF;+*SDCLTL&!N;3EX%$GL+G3XT.T2#[KQ<:[D".G`E0-1VEU%SIL
MGUG;I%X')W=Y5!N81+G2OS:>$W?%^->\"X%MB><YIA>.8`!;L:5]3<^R?I9A
MVCK$ST$XDD-RS9X5#NYOJ+ZQF=<G@W`[W57S[#+&&TT$=UI'4T^!0;BP+'3[
M#31G<#V@=.&:A/;T%]8[)H8COIO])9VC/RKF2,4S6QL(@&_!FP-!:B)=MX+K
M((A:#T,\;ZY75@NLF,K1'?0!&T>;W%RVF-I3=R>)P`!))P``Q+3LP65]XUI5
MTV_P$+77GVN%UYWB&+I!#?1;B,,URA1RPZ!1K"69([]3U/\`F4NSC$W2_P!(
M>][#ZPI<.TS$C.&\Z^8O"\Z\QX`\)!869%F2D6FFW0A7HR6::,7/>CJ\X4^U
MLZBLN]KQAK`^WH':2Q6-O-=1$_#\9P<E/L9D>[A$Q&2F1[1`EVBI&B-!`+'0
M"TY-]Q6FGS9PFL7\-A5`()!!!P+'@06'(L(!85<VNP1+FPCC9>'R%2(9D>>:
M*#V1ZBKC2]I=1!NY>,I/YGK5U'/Q$=9E*)F>WRE2[?X/6:SV=95B^]/4/RQ4
MV&;(]QX,I/Q``SH\04V$'@WD:J:44BL(NX9>S>I]FVUBZ$*Y-;VTPB1RS`#/
M;^*K"S:EO>(KKDGLR(#&>.SP?BJ5ZJ1P;DSCUIW>SPIZN1K1DP?)`RRZ?;6=
MR1S>9D'RT-8/9UIN,P3/1PZZ68G##8#X<&IN,UFO-.'(CSV9;M`;AU,;L6-R
M1QP+<-X^/'HW%-QF:FRA/G#80,//M4&Y%;[KG4Y/,V#D4AAV;/=Q6E%T`MPI
MEU]H=?#W#@\'7@2&[V$L9V+>W%.5,#2ZFH%^''#,,VLV^WAFN^YU$:C)O7/>
MQOMIZOJ%&3NQGN$>SSKA.S63P1RDG4R]:\T`-))8``22=P`+25CU/@1BC`BD
MGPC'>,",\PM7:W56B-9]DRXST>SM6M$<2C$C>%K/=S6*(%9Y_!O6SP]>;%)@
MENHCW,V4GXC6[O&Q2;<2%>R12>?+3O.:FPC@1"G%?:<.P>52K<:+PD:YV?&4
MWXKSI:#TD;#N!#<5+MQ^(AS,!,AX!N#V.66\[6C!6-J#4<2MN9LKOQ/?;NC:
M%,MQR*O4+,I/Q"W!C=JGV8T>.137\F8\99L5C;C0I-1F0%\\6S)2[:>>PI[Y
M@22`3[,U,BFFZI'GM5M^&PX]OVU,MM)(\WK<W\-@V^S<I5IK>3V'F]1E(Y!#
M0K.W3+I//ZI8/X;3EX[5,A*)Y75+SOATG((+HZ_;71-;WB/-:EIW'U&3N?:%
M)MY(\UK.P_'_`*#-[)[J/D*D'E=7^;?40>T%O#M'E]1F0_5#M4N#P:\)47LR
M*(6-(V*9M11ZI5;1`UCXZV>'#SJ9;S9YR_M(8F9ZC^6*[1R*>[E+J*C^9_(^
M=9167>PR$_4_Q7Y0K9]DK)9,Y=#'?"NEG)G)]DP^J/6/*5UGL(<_S?PZ#)GH
M`])'C>6'G0@K-&3^SV;`FWQ$K8BS#/HXM8,`.O`+-<6S$L\#8076LS+`?%AA
MVE<9X2742K'8\9LI=S#9[\>THL^R3[*\[Q>4WT!S''/_`.2\H,\9>(L(F^EW
M<'<.OK]@46YFRPM+!':)=PAW#$>/,*'<R1=Z;-'9J>[B[AO;AL:?,H&H[2ZB
MXTV3ZSN$@ZUK!]:?*H5WLESI,O&;S@/1X_:7`MCSA-PWN(M=R!]Q?4].W-QP
M/TKVYQWCJ\TXS/`M\Y'G4*["57U%]IYQEBLCKTVXTO;6`,\)4"<);I8VY(T<
M=W+8,OXU0;D)(GV+D52K/H5RU:*:83&F%-O#5*WJ/59Z^+G-.MHUIV+$#LK%
MC?%5)DI.&Z^ZZ['JD]+1XH+&O./.8L`7S)R)RIP&?`(<2Y@LVKEW5ZC=M;]<
MJ[D(I=,I*3ZJ;#^8O>_[R.<;7.%W@/).KU%C2\.T>_J/5459I>LN3DVFZ6X2
MA&FQJ6%6>FG,IIM+:7:NW';],E/@5OSPE:_;<!WUAA0:3581XI2`]%>??>A4
M^HP(\!UKQ(<AAI7QKSQP*'`>8[^BT\=W12I<M+8H2_!5=D9*45X$CY[]TG.-
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MK-;I]/CS5.IK_JX<7@FH\)TAQ\0HSCQ`!(=>!.!"CV.$<4U>DN:_2V+MS16G
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M5V(Y#]9QOPW@\`0053:/E;F/47[NDLZ+42U%JBFMVFZVJI2;HDVFFE6K6)[C
M6^\?D/AVAL<2UO%M##1:E-VI>L4O6*,G&3A&-9.*DG%O=HFFFZHZ=4*+6+/N
M67H]U6Y49&J4BIT]^I6W6)2/(SDQ"=F(,<R46#$<]9ZJI0!P.ONAYU]U]KI(
M49Z;4\/U_P!'U]F<+\)QWK<TXMXI[K3V26":SK@7=GBO#N.\(EKN"ZNU<TEZ
MS-6[]J2G%/=:WTTZ5@\6G1IJCH>V/-U=-/N&+8$&5T+KFC4>4E*P^]%KM`I-
M`CU^!&%+<AR<G`I#I<F96C1(9+8CP?<,P`''&EOR%SUK;6KGI8V^%W>'2C&>
M,X1@YI[M$E#-0\.*WLEM^#/<IPK4<*M\3G?YCT_'K=RY:25F]=O*RUZQN<G=
MQC*ZGDE1J#;DZ*G@^B\O>N5>IL.JTK2F])FGQH0C0)B+2C(&8A/>D[$EX%1B
M2DU,./C%TN./![8J?2<K\Q:BTK]G1:AVFJIN-*KP*5&_$CVG$?>7[O\`0:MZ
M35\8T,=3&332N;]'T2<%**?6U0\6UFCU>WZC.T:O4NH46KT^.[`GJ95)./(3
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M`:?A'$-/?T=?HEZ[%;K==UJ2>#>+BT]M:4SQ/9^[SWC\4YTY;XOH>.*/[8T6
MBN2];%*'K(2MW(UE&-%&Y"257%)--8)IM]_Y\=.;OOK5;3RDV!9U5N.H0[%J
M4>;@4&F^L$O`%=]7"C3\RZ(4K*0FM=<,:(X"6AW:KKF727]3KK4-+;<Y>J==
MU?ZVUY+QGF/<CS#PK@G*VOU7'=7:T]AZZ*B[D\WZJK45C*3VO=3\)\V;SLN[
M["JGQ'>MMUBUZOZD3#LC69.)*Q(TL^7G'9F6B'B@3<L\^Z7?60GWW.($-:&+
MS<M%J=//=OP<)]#/GWAW&>%<<TRUO!]1:U.EK3>MR4DGT-9Q?@:3.QVKH1K/
M?5-<K%I:97?6Z3'=>>EZI!ICTK3YIT?52<Y48DG+SKG3">?!5SH]#JYTG"W)
MPIG3`\[Q?G'E7A%]Z7B7$-+:U2>,'.LE^5&*DX^.AX\NZSKLL6JQ*)>EMUFU
M:O#A.S)I]=D(]/F'Y9_B#DS`]<ZZY,RKY=($6&\_#)!#6A6:MW(3W9IQE3)X
M$[AW%.&\6TZU?"[]K4:9NF];DI*O0Z9/P.C\!V2#H9K+.5&WZ7+:87I$G[LD
M)BK6W+FB3$/XXI<K#EHTS49:-%]7+N24O"GX#S\6(^XXZ(SC3Z;K9MO3WO-\
MUU957N;>6(6+VHEK]*K.FFH77OKS).J46ECO-QE1)-NCZ&:2'I%JE.U.[:')
M:?W5.U>Q(8?O.GRE*C3,Q;+AAQ8[K]6$'C<EW(D"`^^X07@^XZ7G6NAJF0M7
M$W@ZFM_F'@,-/I]5<UFGCIM7^9DYI*[DO,KG1M)]#='B32>@6MU5M,7S3=*K
MWG;2?E#48=9@428>A3%.=AF*:C*R994IN0]4Z7Q&A07X9<'$"1BK&W;=%7*A
M%N\V\L:?7?LJ_K]-'B"ENN#FJJ66ZWV5*N%&TZX&KLW0K6;4.B1;ELC3&\+G
MH$-^*Z*O3*4^_(S#\`\,:'3XL=^!\:1(+WHO.RPC%U[T2&X*;%;JI)I,C\4Y
MFY=X5JEI.):W3V=4_P`"4O.5<MY*N[79O4/&3],J?Q@:-\6U`UD3QIIHXDIH
MU45%V,9=ZGFG"%\,^'NS`,,P>#U@?]%C<%8Q_B_/GA$FW)VXV/I+E#Z,X[V_
MO+=W:5WMZM-VF-:TIM/-3G*KS)/TWXW=T2U!^!>K]=Z5&X)TPN'CXA27XSM7
M/HXL$#BZ%M])LUIO(\L^<^4U>]0^(Z7UE:=O#TJ;OW3P-,0(\I'CRLW`C2LU
M*QHDO,RTS"B2\S+3$%\PHTO,0(SKD6!'@Q72Z^X\`\Z\""`5V34LLCTD91G%
M3@U*$E5-.J:>336#3Z3SA*<MG,'.6^[<TIHSJ#'HKTL)R'-.T"8=CQI0N>M=
MF8-+B%RL1X#T+T@\Y+O`NXAH7-W;2EN[T=[K/-7.;.6+>J>DGK]*M1O4IOJB
M?0Y=E/KD>)J%0;CNBM2MN6W0JQ7:_/1HDM*T*D4Z;GZM,1H;1&AN2$O!?F08
M##ZQKH$-AXB&%;R\U;TJ*)=:C5:31V'J]5<MV]+%5<Y22BELQ>&.SIV'DN\]
M`=;M/:*;BO72V\K=H4+U9F*Q.4SU]/D_6$.PS4)F0BSCE.#SQ8V8]6&EF:YQ
MN6[CW823D5&DYGY>XI=^B\/UEB[J7E%2I)T_%32WO%4Z_9>FVH>H4K5YNQ;)
MN:[I:@.08E;CT"ES%1A4IR8AQXLO\,>@NGU3T>'*Q7G'<7G@X\0,"MYM0HIM
M)O*K.NNXMPOADH0XCJ+-B=RNXIR47*E$Z5Z*JO60V79]VW_5_B"R+;K-UUH2
MD>=-+H<E%GIP24L]"=CS3\*&/0EX+\9QUYYX@!Y\#,A9DMQ;TVDO"===K]%P
MRQ])XC=MV=/5+>FZ*KR76Z/`]BN7#EVK>K6KCMB790+UHMN4&<JM.O\`JE,I
MWP:;M*JR=*J4U(4JK3,_)S4I2IR>J$B((=BPWGCCPAK"H%^D:SPQR\)Y?FKF
MK3\$X(^(Z*[I[FJN1C*S&4JJY%RBI2BDTY)1=<&9<R7+U<&BEZW3"I=NWG,:
M74J<I$I2+XKU.>^+IV)4Z7)3+TM$K,I*2M/BQ(=1C19=TN..$F&QG$U:VDKJ
MV;W09Y4YITW,&@LRO7=.N,3C)RLPEYRW9-5W6W)>:E)U;SZ#S%S7WI2;BT_T
MKDZ?RZU[1MZ%%^$R]P5FW:319:L2;M%=A/4>CS5-=$:IRKQC0YDO3`AO\+CK
MW`UYXA9MN,VZIT*'DW07]+Q'6SN\5MZ]/!PC.4W%[_:DI81>#CYM5BU7!'K3
M8^C>K6HLA$JMCZ>73<M+A/OP7JI3Z<7*8]&A81H$"?G(DM*34:$<'G(3[[SI
MP(!7>5R$72329ZO7\>X+PNXK/$=59LWFJ[LI>=1[6E5I>%I'7IZSKRIER&SJ
MA:MQ2=VB/#EA;,:C3XKK\>*[QPG(-,=EWIN/ZUSTG'G'7G7G<02,5E2BUO)K
M=)EO7Z&]I?IUJ]:EHJ5]8I1W*+.LJT5-M3RA,<MW,#(TQZK36D-\PI&%!>CQ
M7A2/734*"XZ7WXD2FR\6+4W`XX"2#!:!L7%W+;>#121YKY:N7O4PUVG=QNB\
MZBK^4TH_=/+?(;"<C\R-OPYB$Y%=<MF[WO5QH3KW!%<I\,![@?=/!$<+1D",
M0M+Z:M^,I/>/*4>5;KBVGZZUEUG2^9&BU*L<SVJ%!MRCSE4J4]=[DO3J-19"
M+-SDU'?HU,B/0Y61DH3\2(\3Q/O,=WO/;2LVXUM*N5"=ROJ+5CE#1ZC53C"U
M&Q64I.B2WI9M_%]PZ1=>B&L5C4=^X+NTUNR@T.$(9F*M-TYV))28BONPX9GX
MTG%F13P_$?#H,?U8XB!F0D8VYO=C1LF:/F#@7$+_`-&T6JLW-0\HJ6+IT)I5
M\53PK&C``GBV'W-BZ^H?07-#Z.ZPZ1:9V_R3Z8ZBT:SZ33KVJ\MIY%J5RR[L
MP*E/1*W)Q(E4>F(C\=]R()Q_$NEWA=/O0ZP+A:4WJ';62KAU'Q5PGC/%-1SS
MJ^&W[TY:&#O4@Z;JW7YM,-G_`,3T2<TQU)CTBW;@@6%=LS1;OGH=,M6IRM#G
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M72_`C;:@:1:HZ7PY2+J#8-S6G+3SY@R4[5:>13IJ8#AB?!H-2EGYBGO30A@O
M>J]:(G"">%@*DZ2[9OU5J49-;$\?B*S3\2T&O;6CO0N-+%)XI=-'1T\-#Q47
MQP''V$JV@FJ'.>;*PC\+V):[EPD^0J9:3KCD5>HVD;T8/`E[!A+<SU'`*?;7
MG)_@HIK^1RT%T,]F2FQE'>P*349D!SP4RS*.TI[^9(Z\`X!TM\94E3C4\_JL
MSDON[]JE1:>"/-:W-_#8.-UN?BZ%+M-;R3/-ZC\(XX@W-6<)*M=A0:K)_#:2
M')2H9'E=5V_ATD>#`NN[6?FY4/)ZG\X^HY!(81O&/A4FW"5$>;U?9?C_`-!G
MZP@%N+=O0SJV*8H2/,:MOU;ZC@$'+<MXPDI5/,Z@A.;=Q*EPMS*>\81'202Q
M2Z-252CU+Q*Q]%X$[&>)2[2//:A8L@B$-)V<)/8TKM'(I;NWJ*SV)PVNX>%J
MRBONQEN$;P(+H_)?E'@MGV65LX2Q\)PZ0QAWX]2WM226)PDFHT9P"`\WI/G8
MMY3BVDB-*W.4*(R=+IX73^.)W,Q\>*QOQK5$1:>[7!$C[@`!:W`EG@6=^->H
M[^JED3.NDC<![;1X@F_&G6S#LW.@V,J`&-):72?"<`N<Y1<JK(DV+<U%IYU-
MO+,PR]\/.2H<YQH3[<)+$WD%A>;^-\#'?.U07<B3HQ=:;:F_EN$NPSL(#?9M
MS4:Y)59:6K4\$\T=IEBZ7<#OP[0HDYQJ76GM3PP.SR#I:[U'QDJ!>N1;5"VL
MQ=OM;3N%/'$WL\35`N3BEXRVTLDEN[:F^]7U^)<-^/26U3S=,@\3V(.&/1T]
MJ^JMY'Z4;?:.JSN;2-I`\."K[FU^`OM)V5UG7IE@XF=IZ=RK[F52SCX"I2Z+
M/7)6J/;]-=+]1KM5DJ/)0P&GX149F'*P7B/K7'HG$]N=!*XVM+=UNKM:*PJW
MKLXPCUR:2^*M3&MU^GX3H+W%-6Z:7369W9O_`%81<G\=*+PL^F?,'ISJC&M_
M2*SM';=C3]*T]F*?6WIIRJ4>F."IVU!E)2W(3T.>GI2)$B`"/%B/.@N\3XQ:
MU?.7.7!./STG#>&\M6'/3Z.4;E=^$?/M)*VJ2DF_PFWEB?R+[L>:N3X<2XYQ
MWGK51MZWBD9VMUV[MQ^KON4K[K"$DEV(Q3:=$\*'1>>VRIBL6/8^IAI[TE4Z
M''A46X)8ER-%E)"XH4./`A1XL!Z)!?=IE:@>IXG7BZ7IDD$@JJ][/"YZGA6E
MX[N;M^TU"XLVHW%5)M8>;-;N#IYQZ;_+?S!:T/,7$>4/6JYI-3%W;,L4I3L-
MIM)T:]9:>]1I.EM5.K7B&]WI;`_P>\5_Q%$U_P#^'M/_`.G_`/,,O.!?_P`I
MM9UW_P#Y)#E4#.5+7[I-_?YNZ?YDY`_^P.+_`/K_`/R\3/OO_P#S7RSU:/\`
M^>N&SY&:O"H.@NK5>C2;E1AT"N56MF1B%UUR;-'LZEU)V`7GW(CL,Q'Y8`/<
M)X2PLP77W5:A:/E/B.KG%35F].>[T[EF,J;<Z9["N_S%Z*?$O>3P/AMNX[4]
M3IK=G?6<?6ZJY"N#5:*6557(]9[2U]U'UOUTT.^7,Y2XLG1M3Z=4:+(TREP:
M>Y3A5IJ4<B2GKW'GH\Y`EX,LXXX]&>>B9EYXMP\7P_FWC/-'-7"UQ65MV[>N
MC*$8Q4=W>:JJYM)))-U>=6?*W&?=IRM[OO=US$^787E?O\(G"[.Y<<W/U<9-
M2H\(MN3;44HY))4Q]AM9,>?W1CHIMK?_`-2\%[;F/_\`*W#?R+7^F\?%O(G_
M`/&SCW\MJ/\`1IC/FDYG]3-+=:J195CQ:/2*'3X-O5NMN/TJ3G9FZ8]8BER:
MEJC'F8+[\K+.2,N["<,N8<?B/$8GHN.N[<\<Z\:X'S);X;PQV[>EA&W.?FIN
MZYO%2;6"HJ+=H]M<DM?<_P"Z+E/G#D*]Q[F!7[_$+LK]JTU<E&.G5I>;*"BZ
M2DYMR>_6-,%'%M]?[PZER,.]-%JY#@..5&?AU2G34PZZ!$C2E.K-OS,E#B/#
M%\2T6IQRZW+UA47WLV+2XGPW4Q5+TXSBWTJ,[;C\3E+XRT_RPZO43X!Q_ATY
M-Z6V[<XQV*4[5Z,VORE;A7\E&U[P=ZHN7CH1$H\L_.U>%,W!%I,E#EWIM^;J
M<*K6E$I\JY*.@O33TQ-NN.>K'OVLVJ7[U'=7$>&.Q'>OISW52M9;]K=5-M71
M4VE;_EJ6EEP/F*.MFK>B<;*N2<MU1MNWJ5.6]^#2-7O;,SM$A1N=6<N:WKMO
M?5?3[3Z2CU6GS`L:>JLA)RLQ3A-R[TU2/B^5H]0AS<Q&E7GH7I3T:,'WA^:.
MEA%E:L>\&YJ[6NXEK=+I8.<7ZERBDXU58[JC*K:P[;==J*;4Z[W$6.%ZG@W`
M.#\2XE?C9G'Z7"W.4E/=>[<WY7(.,5)*6%J,6EV6L#PIWCDC*0-2M/Y^#+PH
M4W4;,G(4]'<<==?FG*?6WO@?KG@`8CT!V<B`$M/"0,@%5^\RW"/%]-<BDIRT
M[3?326%>JK/;?Y9-1>N<K\1T\Y-V;>NBXIO"+G:\ZG17=3?AQVGK+RS_`/B!
MTA_PSDO]K3B\]RG_`&_I/Y9?Z&?)GO5__'?&/Z%+_P#5$^D',9I1R_7-JY3;
MRU<UCD[3F:;0:'#FK&BSU)DH]4I5/GZE,R\9Z)&]=579:HQ8L2$_ZF%Q/.PR
M''@]B/E#F#A?`=3Q>.LXKK%:G&W&MNL4W%-M9^=1NJP74?R_[N>;/>#PSE"Y
MP;E'@T]7:N:BZXZI1N24+DXPBU14MU@DI+>=$VFTU@>L7,AS$6UK1JMH_;EB
M>NF;/LN]J%,.UF-+1I(5NKS]=H\L8LC*3+L*9ATR0DY?@AOQ'(;\5^*^>$.N
MNEZIXQQW3\6XEI[&BJ]+9NQ\ZE-Z3DE@GC1)85I6KV'R1[N_=YQ/DOE7C'$.
M.TCQC6Z*XO5J2EZNW&U<E24E5.<I.K2;45%8U;2]A^>'F.U*T;JUF6UIU.4^
MAQJU2YRX*G6X].DZK.QG)">$K+4J%+U&!'DX,F^^7GXSW`]%?!#KKS@XB]Z?
MF+BVKT%RW9TK47*+DW1-X.E,<*=/WCXT]S7N_P"7N;=)J^(\?A<O0LW8VH6U
M.4(K>CO.;<&I.62BJT6;3PIT'GTCP;MY?=#;^J4I+PJ[59JC3,6-`=+HEX-U
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M3H<:"&`<(=+`IVO3=JW*5'/I75C3P$'W(WE#F7BFDTJN0T#@I1A/M1W;V[#>
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MJ9*2L*V7J!5Z;)R4&4J$."[4)YR-)3C[L<S#[X?B`/."&!P*71>K4MI#]X7(
M/`N6^5+&OT"N/B$;T(SN2DV[N_"3DW&N[&DDG'=2HL'7,UM&YL-3#SORFB-/
M%`I&E5.O&KZ<PK1I]'D(4-^#(4R>BPZX:B[+NST"H_&$J[$=A0GG)9R%^9^K
M>),0R/50]1O_`(>9MJ.0^"_X:2YEN^MN<<GIX:AW93D\92BMS=KNN.ZZ5:<F
M\:K(\#\R4*]+6[P*!/Z+6U*UK4.;A6O6Z-17Y&',2,[7)^U)JG5*>GX)CR,&
M'`=IT-^8F([\:$[#+CT5]\,)7:+4M&E-X5/1<J2T&M]T_JN8+TK?"XRN0G.K
M34(W%*,8NC==YJ,8I.M=U(]N](+7YSZ/K!:]9UEUVTZC4>I19LU_2QVMR#U1
MG)&:ITY\'A4*C25LR$O#FY&<=A1'7X,P6N0WFOOAH,63M.+W8OK/CWCFLY`O
M\"O:?@/#=4K\$MS4;DMU-257.;N2=&JJCCFU@CPW/:;6K=/>D5"GU*DR<6ET
MNW*9J-,4Y^%#,I/W%(6C2796;F)<N^KC/NU6:A3;[00_&@\3S6E2E*4=!O+.
MM/NE];XOK='[G(W+4Y*].[*PI5Q4'=E5)_DIQ70G0\<<SG._KQ8/,E=]O65<
M,G2;3L"JR-%E[7FZ+2YZG5SU=,I\Y4IFM1X\M\:Q#/S$V^ZX8$Q`,&$'>`A_
MB>>[Z?16YZ=2DFY26?D+'E+W?<N<2Y4L:GB%J4];J8.;N*<E*'G-14$GNX)8
MUBZNM<,#S7R`TEZKZ;<P6ODN];%(U)O:[[REI.N5ETP+?MDPJ;`N5UV8C/\`
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MZ,FZ:W1AT_&]M>%2.(IK3X_C+[YZOWL__:T?Z7;_`/TS/.6A6HMWT+G^U6T[
MI=4=E[1OG4S42>N>EO24E',_-6]1:_-4F-#G(T!^=DGI>,Z"\(,1P1``'@0H
MMZVGI(W&L5%4\9YWF+A>AU'NVT7$[T*ZW3Z2PK<JM44Y04E1.CJNE.FP\2\^
MVM^I=0U,U)T6FZ_#?TXI<[;,[)T)RE4J%%<F(=NTBL./1*K#DW:I&<=J4T_$
MX7HQ=:P,8`%TTEF.Y&ZEY[J7GNVY?X3:X3I./0M/]JSC<3GO2R<Y1[-=U>:D
MLCV*Y[J>:SIWRL48Q#!%;N"ETAZ,"`80JE`HLB]%!.`,-V8+P.\*/IZJ5Q]'
ME/+>[N[]'XEQG44J[=N4J=.[.;^\=@YUM9;QY=:3I)IIHQ-0K(ID6D5"-$FY
M&G4Z:C0Z9;[U,I]-I,J*A*3<M!<??F'XLR^(9BQ7@ZUX-?XM=/;5[>G/%D3D
M+@>AYGOZWBW'HO47M^*HY22WI[TI2>ZTWDE%5HL<,J>G5EZW\PVKFO%JWA9=
M'H-<U:D[+F;/E(KE)@R]*>I3D.?$[<=8A1YV#3Y"/`-4+[\4/0I8/\#CL(\?
MJWN\K4+=IQE50K4]YK^`<K\$Y<O:'7SN6^"RU"NM;S<M["D(M)R:>[@L94JV
M\*KZ+:%6YS0V_J?"BZQZTV/<U,J%+J0JE@2M8E9FN2TV_`=F:?.4NFP+=I3D
MJ[*17?S3U;XA^H>>P>P*B7':</,BUX3XLYBU?*&JX2UP+0:BS=C..[><6H-5
MHU*3G*M5E7&M,CUYTLD)2D]X]?M/D($.6E`_><V[!@N.PX3D:IVY2:I-EQQT
M!UT19R<B/EF#7BNLZO2I_#,]-QB]._[K=-<NMN=+2J^B,Y17W$D;?3S4*PK!
MY[M=7[ZGZ=1'K@>%$MRO59^%`D)"IOP+>F(\G'GX_#!IIJTM"#KL9]YQPO0O
M5EX<8!2MW)Z>.XFSAQ3AO$>(^[OARX?&5Q6O/G".+<:S2:2QENMY*KQKL-/S
M)Z?<V%J6KJ+7I35:)JOHY=$M4)BNR!AR,2?HELS<V[.N18%,?E8L"!(4Z%PN
MO3%,F`R`X8C\)USB+O2Q+3SE&.[NW5]U_#I.G*_$^3M9J]+IYZ-:/C=EQ4'C
M2=Q*F,JU;E^+<6;HG4^449YH/5XM@[58[LN@^73ZW:^O</=W:/O9?G+28_\`
MV!]0=*JZ^2\,CX6X'_\`D;6_E:C_`$G<I'56O:.=WWIS?MJRM,C7+*T6CTJC
M3=4EG9R!2)BNUZ>ID6JPI=X<,>8E96/$X''B(;Q+'^)SB=>RK$;_`!*5J5=R
MKRVT615ZCAMCBW/FIT6I<EIW.4I).F\HQ3I7H;77T8XE33C4FYN87D;UOJ.J
M,>5KU9H=.O\`ISM3=I\G(O38M^W)&Z*'.QI61@R\G#GZ?/1G`[$A0W&^I<>9
MQ-)Z7[$-)Q&U&Q51>[AUNC^,UU^@T_`N<='#AJ<+4Y6G2K=-Z3A)5=71KI;S
M9U;E[G_M#\A5Z:UVI)2,2^:XY6ZL:C,RSDP79F#<OR*H$.8=/\OD:(&S3L!X
M^K,1^(T>F\M]1!ZKBD=+<KZM-*GBJ_C.G'H_MCG*WPK4-_1(;L:)TPW?62IX
M995Z$N@^>&H'-9K-JAI[.Z;ZAU^2NNDS=?I5PP:G.TB0DJY(3-*>F7G)26F:
M3!I\G$D9A^8:\[%@/Q'>%CC[KI(7I=-PW2Z>\M19BXSW6J5PQZZX^,]3IN`<
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M,K,6>9O]!R<SUGRJPMY^(J+YR][P]JWEVD46HS*3^WK/E*EVB@U.97B>]/\`
MZL^==D4UQ8ME8#$'<Z!X6^TLD*[V:'+[K7A_%>=WSK,NR0+BR(&9^/L)65A$
MA7M@80#_`.L![&/+5&'G4RANM)>Z"&>%%]\UCE4LOND@8;&>$!*XMF$JOP%D
M.,=(Z<>P)T&Y?EG<CT`]C2N<S>UVF;.5=PQ&/'XF%1+N3)T,CL$!STC^0+>Q
MWVE7DN'YR/6C>RCAX8?0!VX8>-<KNTNK/;9VB7=:W!A]T>TH$\D7>GV';)%S
M%S'9YU7SPQ)\JT5.@[;3G>$$GZX9=94.YD3]+%N6.5#L37/K3X?=4<ML3S1,
MN^D<'LGL]K,>U?5D\C]*=OM'59QUXG+:69[_`"JON9OJ+W2Y+H.O33KWIX,&
M'G5?=R+.&T\K<O->L6T]4:;=.H%3--I=`D*A.4Q_XOGJBY&KD:$Y(RCCT.0E
MYF-"]1+34:,Z^7>$1(;N+6+T')^LX3P[CUOB/&+GJ[%FW)Q\V4JW'YJPBFU1
M.3K3-(\+[TN&<Q\;Y/N\&Y9L^NUFINPC<6_"%+*;G*CG**=91A%JM:-[#/5?
MF/U&K]_W15;,OVZZ):D6H&7M^0IU0FJ;+.TR3@0I2!-_`V./08U0,$S#X>`>
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MNGYNY(X;P'7<`X2[ENSZBY&$Y1FW?N7+<HN5=VJH]U5GNX9)114<0]V?O?X_
MSEP?G7FA6+VK^EV97;5NY;C'1V+-Z$XP2WZ.J=R6[;]8Z]J4IR=/"_+CK1IU
MI]H3J]9EV5N-3KDNAVX?B.0<I54G'9XU&SH%'E779J3E(\I`>>GX9=/K7X?"
M/2.&*\WR9S-P;A'*O$N&<0NN&MO^LW([LI;V]94%C%-+SE3%KIR/;^]3D#FK
MFCWB\#X_P73QN\*T;L^NF[EN&YN:IW9>;*2D_,=5NIU>&>!ZKZ,U^EVAJCIS
M<U>CORE&MZ[:%5*M,N0(TR_+R,G,N/S$9V7EW(D>/ZMT$\+CKSQV`E>#Y;U=
MCAW'M%KM6]W36=1"4W1NB35715;IX#YCY[X9K..<G<5X1PV*GK]5HKUNW%M1
M4IRC2*WI-)5Z6TNEGM=J9KCIG7N;G3;5.E5^+-61;DI;\O5JQ\4U6"]`?DW[
MB>F3#I\>3A5*8<@BI0FER$6M+`6%?(O&N9^"ZOW@:+CNGNN7#+,8*<]R2I3U
ME?-:4G3>62ZLCX5Y4]WG-O#/<EQ7D[6Z:,.8=5<O2MVO66W525C=K-2<(M^K
MEG);*TJ>&N:G46T-2]<(]XV94XE6MX4>UY5V>,E.R)?F*88KTX[#EI^!+31=
MAB(`"7`'CDW->?YZXSP_C/,W[1X=-W-'ZNW'>W91QCGA))X=1[KW.<K<;Y4Y
M`CP+CUI6>)^NU$MS?A.BN4W:R@Y1QIE7#:>6.<C6[3;5JJ:4S5A5R/6H-L/U
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M6,?-Q?G4DD^G:4G)_`??7RIP74\B<.X9HK>DU-VY76SN0<81NQ5N<ENW/XQ;
MJ\S>MRG&O9>"7@CG0U?L/6*Z+$J]AU:+596DVS.R=4,6GU"GO2<].5*#-0Y4
MBH2LJ8[[D-P\3T,/.#?BJ?G;C?#N.:W37^'3<X0LM2K&4:-NM/.2KXL#WON-
MY+Y@Y*X5Q#1<PV59O7M7&5NDX3WHQ@XN7F2E1-Y)T?@/`^B-ST:R]7M.KLN*
M9?DZ%0+FE*A59N'+QYM^7E'(4Q#?C"6EG(LQ&#CT4$AQUYYC6`JJY=U-G1<7
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MSE\T3LNTJW$J=UV=%LZ/7*7'I%6DX4D]0[-F*3..19N<DX$G,.BHONN`07XG
M&X2\,,5;:S7Z;4<-L6;,JW8*-51X4C1YKI*?D/DKF'@G/7&.+\5LJWPS5J^K
M<U.$G+UE]3BU&,G)>95^<E1X9GE;5[5/E)YG;6L>M:CZDW1851M*#.1ZA9DA
M3)Z/.S,2I0)+XTID!P42JT^:B&+(AR5G)=_B$-X\0=XF.V5[4\-XA"$[TY0E
M%=FG32JR:ZFCR'+?+GO+]WO$-9H^!Z#3ZS3ZF45&_*<5%*#EN2?\9"25)5G"
M2I58-TJ_"_-]S`Z/ZKZ,Z6VEIA.5&'-6O581B6Y5:;49:;H=%D+:GJ'(09R?
MF''Y":F`'H+OYC,1R022\6$KI?U6GOV(0L5PV/8DJ'H?=QR;S-RYS1Q#B7,$
M;;MZB'YV$HN-R<KL;DG&*\Y+/.,>BAJN;K7S2[5'1;1*T+(N&/5;AM(TV)<,
MB_2*O3A3Q*V@*1&=>F:A)RTK,1!/GA`@OQ&@%YK&$R[EZW<MP4'5JG^@V]W?
M*''N`<S\5XEQ6RK>BU.^K<M^$MZM[?6$9-KS<<4N@H<A>O>E^AT_JC&U-N&/
M08=QR%JNT9^'2*Q5Q-Q*3%N!Z=A,I,G.O0(C@J$+A]8'0^TL.!7>Q.,*[V6!
MO[V^4N.\TVM!'@=E778G=WZSA"F_ZO=?GRC7LO*M#Q=R9:N6'I%KU4+VU`K,
M6B6W-VU==-A5%VFU&I$3E4JE+G)&'%E:9+3DW#=BP)1_TN`NNO``D-5A%-V8
MI=")_O*X!Q3C_+$>&\*MJYK(W[4G'>C'",9*6,FE@VMIKJ1JW8DKSPOZT1ZM
M'<T[>U;KESBM_%E1>C"B3TK49>7G32W98U0!Y^8<)<]5ZUUTM+N#%,46[&XN
MU0SJ.`<4G[LURY"VGQ=:"%O<WHTWXN+:WJ[NQXUIX3SC<7-?I?2.>N5UUHTS
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ME)VDQZQ1HELP:)<,O*0*M`DH\*;E(A];+O17'(;\>`ZT\!+RL+6EE/1^HN83
MQ?CK@>DX5R9K-1[O/W7XHE8U[G.<<5)1EZQS@VXMJCRE1U2;VX'L'J/=W=K:
ML7?]O"\+KN>)<<U`ITS6['DI"[:>+BFZ9+PI:6@UNBRU$>=B3AE9>'`BO2U0
M@2\9V&.-][%X\[4.)VH>HA%;NQX8=6/WCRW"]%[UN"Z']WM#9LK2Q<E"ZY6W
MN*3J]R3GE5MK>@Y*N"61X4Y6N;'2?3NHZT::W_0)ZG:&:KW-<M5H4O+242==
MM6FU\3%)C4&JTNGOQYSXJG+;^#02_*F,_+18!`=>=?XW.^JT=ZXH7;;_`(^"
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M`\0%(GI[DM(K+PGNKXT>XU7+NLUO(D.7I[L.(QTMJ-&U17+;C+=;551M4JJI
M5J>6N<RX>4S465KVINFU[5BX=7[KF;<@1*3`A5N4H4O(R$K`I\_.SDE5*'(N
M2LV]2I5R&09AXF*Z"[##7R>6DAJ[;5NY&EI?'_I*?D/3\Y\+G:X3Q73V[7`[
M*F]YN#FVVY))QFZK>;?9RS>2+?.#S"::ZH:>:'4O3:YH]2N"R)F%/U5QZCU>
MG&E3$M0J?*R[QBU&3E($Q&AU&6P$)Z(/0:UC"=+&GNVI3=Q4C+RG/DKEGBW!
M^(\1O<5M*&FU"I'SHRWDYR;PBVTMU[:9GFJX=>.4'FIL:T/M]5NM:>7M:KC\
M2.[3X-7@1H<Y-P)>%6(='JE/HU<D*C0JK%E8<5V%&ANS$(N.ACKP+SW"-G4V
M)/U2WHL\]I>7N=>4.(7_`-W;=O4Z"\\*[K5$VX[T7*#C.-6JIT=7FLO&FF_,
M-RX:-\QL&K:=42JT[2*/IK`T_J=??D:A&JD:O.5OXYB7?'DYR)%K$_+30EX,
MO,/%QR.77>-R#PN.NG>=B_<LTG^<WJ^+H+?BO+7-''>5W8XI<A/C2U;O1A6*
MBH;F[ZM->:FJN2Q:V.574\BVU?O)7I3K=/:STS5&Z[XN2\*S7([G#3*G,4BR
M(-S"9CUJH3\5ZBR-1GX1]89>!")F8T*'$`]6>'UCNDK>JN6O5N-$E\="JU?#
M^>^,<`CP*]I+.GTMB$%VHJ5UVZ*"7G.*Z6_-3:SV/Q+9FO>F%*YW[MUBGKAB
MP=.JJ[7(4C7?BBKQ'HAF[9I--EWWJ9"DWZI"AQ9R2B.@O000&$@`M725BZ],
MK27GKREQKN7N+7N0+/`[=I/B<-RL-Z.RY*3\YO=R:VG59VZ.6;5#F$UKK&JE
M;N*2L6\YB5CV)>5%EJM*Q:74)>%(0)F<G*>[(S<R[+SD*`771,R4:'PNGB=<
M+P>&\(:FW;BK23FLT2XZ7FKA/+.@L<)A:>OL)J]:DXM2BVVDG5*J;_!DGT-T
MH>=)K7+EWT`T"O;2O2+4&YM7:U><I7I61=JD"=^+*&_<5+=HT>,]%CTJCTVG
M4R2E6QA+2[L6+'F&\0`?+SNJL:F_?C<NQ4(QI]S$\Y'@/,G,7,5CB_&=-:T=
MBQ*#>ZUO3W);RRE*4I-X;SHDNJC^4[[SKK@=#P(==`S:U@`#59T9\MYNI]"M
M8.8#2RZ^3+3;26A7#'G+^H,"P(-6HK]&K$NY)OV]*1(54+U1F)*'3(L.%$P<
M,.,_ZQH8,V1-/IKT-;*])4MNN-5M/C#A?+_%=)SIJN+W[:6@N.ZXRWHNN^ZQ
MP3WLLZI4-7>NO>EU9Y&;)T8I]PQH^HU)?MIRH4(T>KPG)?XKN&9J$Y$-4BR3
ME*B0G95X%TN1GB\2``UK)&GTEY<2EJ&OXG'&JVKHS.-C@?$[/.E_C%RVEP^>
M_26]'&L4EA7>S\!ER]<P&E5A<J6M>F-TW%'I][7;\O/D_2(=&J\X[4/C^RJ=
M1J9PU"4DXU/E_65"7?<?]=%A^K='$<"NVMT.INZZU?MQK:CNU=5A23?6<..<
M%XEK>9='Q#3VU+26O5[TMZ*INW')X-URZ$ZEWE4YG-)*/I)<?+IS`N3,M9%8
M>J[E,KD.4J$](.TROGX14J14A28<>J4V8E*F\_,RDU"AO@/1,3#>ANE_76</
MU4[\=;HOSJV8)U635<'A@T1N9>`<1N<2AQS@[3U4=VL:I.L<%)5P=5@TWLVU
M=/$W,!"Y+[5TUGK8T"J-P7UJ%6*[29[Y85EVJ1X="HL@],1)RG2T]4:;0I2'
M\-XW7."!*Q8D3.+$8XZK/0+B]W4*YK5&%A1?FJF+Z<&_NOJ.W"GS-J-:K_%U
M"UI(P:W(T\YO)M)R>'A?4L2[S-W9RB5K1O32G:&46ER.HLI.4A^X(U/MRJ4>
MHRU)AT";@UB5N2I3LK+P*O/1JR_`>=>$29>+[CS[KX=)XMN&6.*QU=R>M;>G
MHZ5::K7"BV*E>@K^%6..V]?>GQ*4GI6GNUDFFZJCBEDJ5Z#T`?+S3F`,!L7J
MK,%GM+'4;2-XGA8TX@;3T*:H)JKS*:_DR)KV6/C7:$2FU&=27BRQ"FVH;-A3
M7Z5.6A@Q&?G*E1C5NIY[59OX;`2!M&>_K4JW')'FM;G\.@`C>%-MQ2/-ZC\(
MR#SP(82.HD;%*ADR@U63^&TM<;P8>(]I)':I\$J'E=3VS(1,VC!FSW2NT%B>
M9U4//PZ"=T@N@C?[:F6]AY;6*B=?A@8GWOA\ZEK)GE]9^;EU?>(06/-]FU91
MYC4$N>._W%86\UU%3?#Q'`<1M6[[11:C,IOX^$^4J7:*#4YD$3WCWY`_R2[(
MI[GX17^J_P!3_)K9$"[D<O>^_P!5^66)=GQD*YLZB$#%[I!\I]M9_!(-W%I'
M)`8[TO,\3P2/28EMZC*&P$XAGI!K>@X(OOF%V:%M\MX6$;%KL$?*60`PC>\6
M^3P+/1U&&\?$7Y<!F8Z`W<3AUXKG(ZV<ZFVE'>D'TV]BB7>R3K:.PP76DX?4
M'R%BKU]\F0[:ZT;Z5AX.=0\_F7&YM+JRO..T2KA#6AK3AATJ%/"B+G3[#M4E
M##7,\CX.+/M8H%S/P%HHU2?0CMTBX>%C&L>=9AN:H%S+QEEI8XXY&ZX7_K1X
M/_DK@6NXCS=,M+Q:-A8TY?B+ZLGD?I-M]HZQ-L8#DQX]I:J^YF^HOM+DD=<G
M0PO;<CT;V*ONX)4+2-*,Z_&&UC`2S^-*A7=A*MYHT\?%U\;!B3M/5V!063EV
M?$::)B^>MI&YH8Q1GM+F.27@1IYCWPZ'B&G;T^%;+I+"WDNLH3`X@\S-@9VE
MF:YO(ZWMG65'W?1=/A\!]I:'*.1"/>GV?5(9V%"(Z222,.)A\2[K)&7]XQ<=
M\)#WB1Y+K$<S)C'6[W#XL%O;VHS+(P?R=_)^8+O:(EPP`](]3?&K"&SJ(CR?
M69/!CIZX9\):I]K-')=H')6-@B7LBI$]\>KS*7'M$5YD)S"M=-F_$1+W:?40
M1L_!YU<V>P09["O'>#L,$[L.D\)5U:["ZCA)5:-3$)>#Q):6%3;6?B(=S+QF
MLB;?R7MJRTV9&N&LB^_[3Y5:6NRNLTV%:-EV#RJ:LC4I1,NWS%7-K\W'J(4^
MV^LI%YCK.T]2GV^R:HIQ'QMVD8*5*.\J$;5?F_&0EYT@XY@[]W4NMJ&ZBO("
M^Z-OE]I381PH*5.>)T[?$5(4%0XO,<3N_P`1]I9W$*G!?=`S\1]I9]6GM.=S
M&)9@Q&$=8!\RSZI=)QH7O6.^QOM+'JETBA/"C#8-C/.N,H*K.4EB7/7!XC>.
MOVNA8W$8H78,0%@.3#[JTN1I$YW%YI9XG=_B/M*/1D<L<3N_Q'VDHP8EYUN?
MB/M+-&:/,FA1770\,\1O]I*,P9O1@!EY?:6\%61K+LD?P@;AX_:7?<.5"GZQ
MWV-]I-Q"AD7VNAF7E+<%NEL(US!LJOO`99X^QJF685="!>R*?&/6-WM8.PJ9
M->90B["&*^PX[\>W8LPCL(USLT\)1#SN;?$5+A':0YY^(A>>=;GXBI2MK>*V
MYMZB*(^[AT^T%.M1^X56HVD7&[OR4I1VE/?R8#SK<]IV%=H1VE+J"(YGM/C5
MC:A15*:_F-G8N\5M//:KX?$<-P9[-JE6X8UZ3S>MS?7]XR=S':ID8^;7H/-:
MC\(G&872WDR@U63^&TL[`IT,CRVH[8]I=K?:/-ZK\X^HS<>X0-S<1X5-M[#S
M&M58OI_@)GO>]A\BE+)GDM7^;EU$`]][.E91YC49$CN+O:?*I]K9U%1>,(F3
MWLV+H^T4>HS*[N8_)?R14JWM//ZG-_#811<G_P`B]Y7EVCD5%S)D`&(/2/$#
M[:W617W<O$9$!AZSY'CY5K/81+NSJ(`/?'=YR?:6[R(%SMHY?=P8=KS1U8K1
M/`UD<0AZ(!^N/G6VSQ#)>(NONCT6#%H'B"QL067B+`=P9O;^6!3I,-T9?E7#
MGLQ\'$/:7.6:.UG.INY%UF/XYWP^EAXU$O=DG6_OG9)?;AFZ?`6M5=F2X=N-
M>E&^DO2#I9@`&>+S%<[FTN[+K([7*@<+6X-]W=O4&YFBYT^%#LDB7FNX8L!\
M))\Z@7'YQ<65O*C.Z2```Z6-Z,_;4"YD^LM]-!-5-SZ/UWB*XT+'<1YDF@`\
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MPU\T\"`!L#.UGF5S:["ZCD]A0?\`>GJ*FVLUU$&YEXS6Q-OY+VU9Z;,C7#61
M??\`:?*K2UV5UFFPK1LNP>535D:E*)EV^8JYM?FX]1"GVWUFLBEG@:1U*?;R
M-$:^,^=F;03[2FQ561]3^;\9!QO,..P[`I4,RO96+SS<_$/:4J"JDC*R,@\\
MS/Q!=TJ*APEFSGC>W^(>TLF#@OG:<&[@BS-)]DLPGLF=`[#DMCD6^-[?XA[2
M`.Q3Q%NSV-7"7:9REF;"$^<.MG;FW+>M3!L83QP9AAX\EB61I<[)/QO;_$%H
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M=@D@S@P&(#5SN;2ZLTJ=LE@2#@WJPW>=09["ZT^QG9I)STG0`68X]K%`GF7V
MF[#.X2`(&#N1=:H-S+QEOIU54-[C]:5PJ6?J_">:YIUKQR:?/D3U+ZM<#]'=
MF:B\3K<V`P@C:]EUGQ*%<6++G32J\#K$X&<30=G7[,5"N)41=:?%LZ_&&+N6
M9V#'`X*#=2HV6%JFZ:6,`QXD;3GL;N4%K%HGPPSZ#2Q`"\<,2"SJV8;UF<8I
MTHLBPC*C5>@U<4`LPR>)/L[%"N$Z#R*4S@Z!D3NP+.)I)\*XI5;.UUFLBGT6
M`EHZ^GQK*H<JOIQ*8:PM)\+/9FL41M%NF)%$&!9LX>O-97WC+VD3KK&#\GY0
MCQ3.=7F&'A!:=Y;N+S`Q=K':\1UBW1UZ#GA'#%Z#AX&J?:2WCC=_!(@,`>@C
MPEJG6Z49$?::\)'B7F-P(9XV>=3K*5?$19NCKX0ZUG:5864J>$K[K=<RJ^WB
M:W,#Q*QTR3FZ]!'MMLKO_5=7F5I:2KXSG=[3ZB!W:K"&1"N;#7QV%UXLS>/G
M5I:R74<I]I&O>]Z>HJ^L)4R(5W+QFNB[?R7MJPHEDB.S6Q<SV^4J78-)Y&OC
M$L.)R'E5U8BFHX$6XZ5*3Y/",3GOZ"K2*6ZNHB&O>R>ZBIEM+=,E1[WQ[/,I
ME$1M3^;\93B-!+,/?+K;6-2`0!389F3EHWCPK+BVZU.#S#1]</"L;CZ09.D-
MS'A72U%J>)SN=DE#P!&(S&U2J(XECC_'>/W4H@2./!N8.#"?9U+6BZ#C+,NA
MX,S9OQ8E%T&IF[$(.#_\<BBN@UGV2W"B%F)/AR/NK;=CT(XD_'^/_CO=3=CT
M($[KS71Z7C42Y;K-T,$CKX=:U[-FWW5IZM^`8'+T0$,;XQ[:Z6H4GC2AK*E#
M#B&\>%2=V/0CF5^(?7#PK-$")Y\M(X_X[H7.E9^`X7$L2%Y[+TM^U2X*F+(-
MQ+`@>>S]+QKO2J(<TL2-YX'ZIO65FWVBNN9%4$-&(]A5A:541)D#Y''F-FU2
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M"^/$'?/[2[["CEBWUD;S0YF6^EM.UI7/.9%N]HB8=^X^`D,71Y$:-*OI,BTE
MXXD-`/A*8**"6).X[DP_4D^58?9-+BJF6>%CH8221XSN7-OSB-:;QJ7(;IX#
MB??%N/2!@M:X$VTENFRE73T[CT,W+G=P?B,37GIKH-S*AF)R:,/9M5?=;W?&
M3K'WS?2H!?XF8,/M#P-45Y%U""2I38=@@.L8S#`8=?M*+*3<3O85:>!G:)(#
MA(])K<SV*'<;JB]T^43MTF,8>67G:J^Y52+6RI9+-G;I%T<+<??`=J@7&Z;<
MR\TT9)U;-YPC>?#[B@[S+$\SS6;QR\S"OK%H?HYA-;QUJ9#<6EC7O"W/;M4.
MXJ-ES8EE0ZU/.DEYA(P\&/DP4*YD7NFFL:YG7HXQ&&1V]1WJ#<QJ3[4Z/P&D
MCNX/,QP;C[-R@_A,GQFJ8FEBCTB>AG;M/0MKF?B)\9*BJ:F*TO,&0)'7B%`N
M=FOA+"$EXBC,EH;T>X?&N*[3.S;;-:]FZUN>!WMR;X%GP(UVD+KOHO`C')O4
M[[86*G380Q`QH'3XW0?.LHPR$.L/:]X$I_H-*#A]##8P=@>;YEVT_:?4=(_>
M,F#TL,P&].:L+7:.-W)=96=#7.K'S>=3K69%EVV1CWP_)>=3;/:\1%N??,0"
M&@['BK"UD5]S$K1,QU*RTO;?41[6TK1/JNKS*TM9^,YWLV0.[5/CDR%<V&NC
M>\/7YE:6LEU?>.4^TB@][U[J*O\`3]DAW<O&:Z+M_)>8JP([-;&V]OE*E6#2
M>1KH^1ZAY5=V,HD.YM*;_O1UCR%6BR1%-><GNU2[79,E1[WQ[/,IJ561M3^;
M\92C'%G25*A'XB`NDAR4VW`R5WH@!(9D?9L6TK<JX9'&2\YF/K!N\?N+'JY&
MM&9.Q,<O'[BWMVY;QI<[)*'RT8;1M]Q=]R1P)^/H\?N)N2!+#B!OE'G3U<CE
M)8EP1.WV=2QZN1BC,G8@)&'L\"RK<JFD^R7H;QZ]^.>XK.Y(XU)>/H\?N)N2
M!8<B>B,/'[BCSMRWF8!C`9CV>!:^KD*`1@\6`>SP+>%N6\:RP1EQG=X_<7;<
MD<ROQ]'C]Q-R0(GXF)P\?1U+50>]X3A<VD#S^6&_;[BE0BZ);2#<V$+S^!P\
M?N*5ZOS/"0I[2$Q&G+QI;@_&0+N$?&0<>.7C]Q6-N%%3:0IE=^)Z1+-VWW%(
MC!IXE?/[QP8F>&[;[BE6XE5J-IR'VL#,^GH4V$4L2EOY,DV>SH7:':*749G)
M]][-ZDPR\93:C,PW>S:IBS*#59/X;"5S,^S:IEO:>9UN;^&PG=]\/9L4K\`\
MUJ<IDBS;R9YK5=E]?WRT[E[.A3(9'E-3F/:6?P_$4>H[7B,AD.OVU*M[#S>L
MR?PV`9CM\A4Q9,\MKOS4NHY'OO9TK"/):C(S=][VO>53[.SJ*B]D<1,SU#RJ
MPM]DJ+V3^&PP='I/'I\ZV//W^S4P>#7W@,V`#M)6$5UZBA+HI]XAB!I/7Y&^
MVNZR*)+,CB!@`Z?(T>9<XXR(MW,C`8S>T>,D^);RR(\<F3<(["^,.IOB26PQ
M$L..`M/Y(=6?MI+)&K58OJ99+N#H'1CX6KEM9%M9,N.N#A]F)X@L+LDVWA$V
M4LXP=+'CAUE:7,_$9HY2\!MH3A==!WONL[20%7W.SXRQTT:82S_^!O)4;_!U
M`X>$J&V748UPVG8(`+'<\PP[=C05%ED2+$<O"=FDP</K2\W'>%#F7FFC18YG
M<)(>\PV,\;%`N]HN+$</"=OIP]$@_7`X>/R*ON9%S8@S>>AO/@'M*"6FY'H/
M929H5KM>_5O*.X%OZF[C.8WB67UKO2Z&GZW'V5SR'Z#[7$N+IX\.G7^7L=XZ
MW,T*U<OE_)NXG`VO<IVM9A*J)<TO#ZNNLCE\E=\A<6.*<9RCPRXZ?\QI^\:"
M9H%I/<7%J))#`?L3ND]N$HH4])PZB_GD?97?(7&FXMQM5KPJXW_2=-WC11K<
MLXYZCR.W]B-U]+<I11)Z/AM7_/8>QO=TGPXMQW^Z;M/Z5IN\:B-;5ED$'4N0
M`QP^1]W;NB34)Z+A=7_/H>QO=TF1XQQ]1\[A%W[5I>\:B+;5D-QU.D!O_49>
M!V=$DLST7#/KT,OD;WD)L>,<Q?W/=^U:7OFMBVO8H`/VT:>,3^PN\M_]([BH
M5S0\+:I]/A["]Y"=:XSS%2G[&N_:]+WS71;6L5]H.JE.V?L)O/>/Z"VM7%:'
MA57_`-PA["]W23#C/,;_`/HMU_\`5Z3OE-ZU;"8/VU:<&,839%ZYAO\`0.QJ
MS]!X5G^T(>PO=TZKB_,=/[$N_:])WR'Y+6&'3Q:KT[:S]0]ZYG_8.XI]`X5E
M^T(>PO=TS^V.8_[EN_:])WRO%M:PF_NL4T'T3^L:]CT?SCM"?0>%?WA#V%_N
MFKXQS(U7]BW?M>D[Y5-K6(/\K=-Q#W[!;VV'^D5GZ#PEO]?A["_W35<8YC_N
M6[]KTG?,/DO8C"/MMTW$9?(2]\S_`+!VM7:SH>%*3IKX5_D+W=.L>,<R4_L6
M[]KTG?,A:]A_OMTW<?U"WOL_V`IMK1<,K^O0]C>[IRN<8YC>?!;OVO2=\P%J
M6$QX#5JF[?V"WOAC_2.Q2X:/AJ?Z[#/Y&[Y"++B_,5?[&N_:]+WR(6K833^V
MY3<6']8E\;#_`$@IT-)P_?3^F1R^2N^0CSXMS%C_`-FN_:]+WP]:EA`G]MNF
MXX_K%O?JV2'0IUK2Z"GZW'V5WR$"?%>8/[GN_:M+WRJ]:E@D-.KM-`'_`$#O
MDY_[`5CI]-H5)TU47A\G<\A&M<5X_7#A%W[5IN\5G[4T^]+]M^FY?\PKZW?W
MO5C:T^CK^L1S^3GY#%WBG'ZNO"+GVK3=X@=M33[']M^F_P"(-]?8]38V-+1_
MSB/H3\A#N<4X[A_VFY]JTW>-<_:FGI:#K'3,SA]K^_-_][U96[.GP_CEE^++
MHZCE/B?'=Y?]JN?:=-WBE&M+3L`C[<E,=]%O[GU^G?C_`&/5Y8MVJ87%Z,B)
M<XEQRG]EW,_K.G[QKGK2T[)+=:*5GE]KV_\`['*=N6_Q_N,X?M+C?]UW/M.G
M[Q2BVAIQC^W32AG_`).]0#OW4Y2K$8;)5\3-)<2XW3'A=S[3I^\4(UGZ;L+=
M:Z4,!_DZU!W_`-[E<6<%&F)%N<1XSC_VRY]HT_>*;UG:;,QUMI(_^'.H6[^]
MRL4W18$;]H\8_NVY]HL=XUS]G::AH^WA21@?\FVHAW_[F*7;E+=[+^-&?VAQ
MG^[;GVC3]XI/V?IH"?V\Z3\VNHI_Y,4ZU*;EV'E^,B/J-?QAV\>&SS^L6.\4
MXEFZ9%YIUUI`Q/\`DTU'^QC%,@[NRT_2CY2%]/XO_=T_;V.\1FS=,F_N[4CY
ML]1_L6I]IWDJNR_3CY1]/XO_`'=/V]CO$#UE:8$D_;UI&?[V>I'V,67+45_-
M/TH^4Y/7\6K_`&?/V]CO''R*TP_?UI'S9ZD?8Q8WM1\D_2CY3'T_BW]WS]O8
M[QDY96F`>_=UI'S::CC_`),6T):BOYE^E'RFES7\6<?[/G[>QWB869I@T?MZ
M4C,?Y-=1_L8NN_J?D7Z4?*1_IW%?[OG[>SWB;Y&:8_OYTCYM=1OL:L;^I^1?
MIQ\IGZ;Q7ZA/V]GO''R,TR!:-<Z3\VNHWV,6=_4_(OTX^4T>NXK7]0G[>SWB
MS"L[31X%NN=)>Q_>UU%'_)@3UFI^1?IP\ICZ=Q3ZA/V]GO%ARS-,^+]W&DY?
MO;:B_8U/6:CY%^G'RFES7<4W?U"?MK/>+`L_39W+7*DC_P"&VH9\M-3UFI^1
M?IQ(_P!-XG]1G[:SY3GY(Z;_`+^5)^;74/[&IZS4_(OTXCZ;Q/ZC/VUGRDCM
MI:<,'[>-)^;;4+[&KE*>HK^9?I1\IGZ=Q/ZC/VUGO`VAIN<]<*3\V^H7V-6-
M_4?(OTH^4S].XG]1G[:SW@[:&FX+?MX4D?\`PWU#^QJS&>HK^9?I1\IK+6\3
M<?U&?MK/E)/DGIO^_C2?FVU#^QBZ[^I^1?IQ\IR^F<3^HS]M9\IC\D=-?W\:
M3\VVH?V-6-_4_(OTX^4Q],XG]1G[:SY2%^S]-B\?V\:3\VVH>X?[FHI:A.OJ
M77\N/E.<]9Q*C_F,\OEK7E,#9VFAP.N-)^;;43[&J1">IS]0_3CY2%+5\1VZ
M*?MK7E,7K-TS`/[>%(^;?43[&J5ZS5;F%A^G#RD.>JU[;_F<O:VO*0FS--!C
M]O&D9_O;:B_8U;6KFIS>G;_\</*0KNJUK7ZK+VEORD`LS3(?Y<J1U_:UU&^Q
MJG1NZOZM*O\`*0\I#GJ=:W^JRR^4M^4Q^1.F)#3KE2&_]VNHWV-797]7]6E7
M^4M^4KYZC5U?\WE[2'E,'K*TP`_=SI`;_P"[748_\FJ3;O:VJII9>TM^4K=1
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M_?PI'S;:B_8U9MZSB5'313]M:\IYW4V-)NNNHBL?DY]/467;.TT9^[=2C_\`
M#?43H_W-4N&LXG3]1G[:SWCS.HTN@;QU<5_Z5WR'/R-TT_?NI.7[W&H?V-6?
MIO$]_P#49Y?+6>\4U_1\-WL=;!8?(WNZ<_(W35@_;NI.?[W&H?3_`+FJ1;UW
M%,/YA/VUGO'GM5H>%-.O$(+_`-"]T?DF4.S--"^Z/MVTDYX?:XU##?\`@U2U
MKN*T?_;Y^WL]X\UK>'\&=J5>)VU_T^H[I)$LS30/8:V4D8_O<:A[6_[FK"UW
M%?[OG[>SWCS&HX7P&F/%K?V;4]TX-FZ:@,^W=2?FXU#Z/]S5.MZ_BZ:_[=/+
MY>QWBKO\*Y?_`+WM?9=3W#@V;IKQ?NW4GWI_R<:B?8U3X<0XQN_V;<S^L:?O
M%1?X3R[NNO&;2_Z35=PB^1VFH_RWTD-?_>WU#\']C4?$>,I?V;/[18[Q2WN#
M<M../&[5/Z'J^X1_([38Q"/MX4G,X?:WU#R'3\6HN(<9_NV?VBQWBNU'!>6/
M5RKQVRL/J>L[@?LO3,_Y;Z2"2/\`)QJ(=_\`N;M7;]H\9I_9MS+ZQI^\4RX)
MRM1_]^L_8M9W#!^R]-"0/MX4D9_Y-]1#FT?W-&]:QXAQG/\`9MS[18[Q%N<#
MY5;_`+?L_8=;W"-ZS--72?V\:2/1_>VU$WO8_P!C%E\1XS5+]FW/M%CO'!\"
MY4I_]P6?L.M[A-"LS31K'];Z2\&\0_:WU#&../\`8U9EQ'C-?[-N?:+'>,+@
M?*B3_P#W!9^PZWN$PLS33BPUOI(=+V7VN-0^W'XMZ%A\1XSE^S9UI]8T_>-7
MP+E3=?\`^X+.7U'6]PN&S--'BZS6RE``Y?:YU"V?[W+G^T>,X_\`;9_:+'>(
MUO@/*>SF&Q]AUOS9<%G:;,'[=5*RP_:ZU!WM;_8[<BXAQBG]FS^T6.\2X\"Y
M4IAS!9^PZWYLO0;.TY=+O[=-+]ZQGVO+_P`<6DXT[<N5SB'&*T_9LZ_TBQWC
MO;X#RJW7]OV:?T'6]PVT"S].RZ/VY:6\Q\?Y/K^&60QI_2H-S7\6I3]GS]O8
M[Q:6.!<K5JN.V6_Z%K.X;R7L_3WB'#K!3#D!^H&^QGUT]1?IW%:/_M\_;V>\
M6UO@?+*C5\;LY?4]7W#?R]H:?AG[;5,.1`^0E\8]39#H4:6NXI3]0G[:SWCM
M;X)RTFMWC=K#_D]7W#L,K:EA@8:JTT]/R(O49GID=RB7-;Q/#^8S]M9\I<V.
M#<N47_>;7V35=P[))6S8X+K-4)!X#_H7>0VXG&14*YK.)5_4I^VL^4M;'!N7
MZ8<7M-_T75=T[9(VW9CN6I,@]B,K/NT-\,FH-S5\0H_YG+/Y6UY2WL<(X%7^
MUK3_`.FU/=-W\F[0_?&D?\4KJ_2B@_2]?]4G[2WY2P_9G`O[TM_9M3W3RW-6
MD^7C^J2RQNXKEE1X?S-?73^SW\OI?:KR'WR6^-QK5Z3B'V>7E.M3=G1"?UT6
M(`TYW3*#:W_6L%#N<-E5_P`?I,OE5Y"WL<>47AH^)?9I>4T,S9<4E_\`57I^
M,![Z[),;<S^9*%<X9)T_G.C]M'R%OI^884==%Q-O^C2\IHXUCQ'B[^J[3QF/
M[,),%I!9_P#,J+/A4L?YSHO;1\A86^8U3]1XIA_RL_*:6+8D5CS;QTY!](8W
ME)##+_6<\%!?"9[WZSH?;Q\A,CS)!K'0<5^RS\IIXM@Q>(GY9Z:C`L!O62;B
MW'^4+:7"95_6=#[>/D)UOF>+=/H'%LOJD_*:^/I_%9A>NF883G>\B!M__@;%
M"EPATQU6@S^7CY";:YHM[>'\7Q_Y2?>-9$T^B^E^K?2\>B/V<2`9_P#R.E<E
MP:57_.M![>/D)UKFB";7[.XQ]CGY2I$T]BEGZN=+L/\`IU(!N&#/S#/!/V-+
MZUH/;Q\AW7-,/[NXS]CGY2J=/(S#^KK2Q[_KW(=(_P!86/V//ZUH/;Q\AG]Z
M8?W=QG['/RE=_3N*2>&^M+,0S&_*?N!_UC82BX-/ZUH/;Q\AA\TV_P"[N,_8
MY^4A^UQ%./R[TJQ+S/U>T_:,1^AUE<&E]:T'MX^0T_>B']W<9^QS\IA]KB,`
M/U=Z5-8&_J]I^;6?ZPN]G@\M]OZ5H?;Q\ATCS3"C7[.XS]CGY3D:<1F/CY=Z
M5'T@?U^4_P#^HZ5.M<)DI?K.B]M'R'*[S3!N/_;N,_8Y^4X&G$9OZ^]*F$?\
M_*?U?ZPI<>%2H_YSH\_EH^0BOF>']W<8S^J3\I7&F\;C/ZO-*=H_7[3]_P#Z
MA38\,E5/Z1H_;+R'&?,T/[OXO]DGY3E_3B+@?EYI3M'Z_:>/+`Z5-M<.:7Y_
M2>U7D($N9(5_L_BWV2?E*CVF\;A>`OS2C9^SZG;"T_\`S"L=-H&I/^.TN7RJ
M\A%M\QP4OU#BWV6?E*C^FT<A[]7NDV6W4"G[OZ75E;T+37\=I\_E%Y!<YC@Z
M_P`PXM]EGY2`::QQ^S[23YP:=^EE-CHW3\[8]-$*?,4'3^8\5^RR\IKHFF4=
MKS-0-(O?/,;J%3@<]OYVP*L[>FI3^,LY?CHXSYB@VOYCQ3+ZK/RE&8TQCEO[
M86D`]';J)31M/]#*[L6:+MV_2(MSF"#_`.!XIG]6EY36O:7QVG]L31W/]\:F
M?I=3_5?ZT/C.#X]'ZEQ/[-/RE2+I='Q_;%T<&>>H],Z?Z&4FS"GX4?C-)\>C
M3]2XG]FEY2A%TLC$?NCZ-#`9ZD4P;?Z65O9P42)<X]#'^9<2^S2\I4?TJCL'
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MX#W[9>B1QV:GTH__`'5/I#^3O>@S'[8C]5UWL)>4LN:51P?W2M$\OWSJ5^E4
M]>_D[WH,TN<7CN_JNN]A+RDGVJXW[Y6B?SG4O]*IZ_\`W5[T'Y2/^UX_5==[
M"7E'VJXW[Y6B?SG4O]*IZ_\`W5[T'Y1^UX_5==["7E)7=*X[!^V3HJ?_`(FT
MO]*K1ZC'\W>]!^4S^UH_5M;[&7E.?M5Q_P!\G17YS:7^E5CZ0OD[WH/RF?VM
M'ZMK?8R\H^U7'_?)T5^<VE_I5;1U&/YN]Z#\IJ^+1I^K:WV,O*<?:KC_`+Y.
MBOSFTO\`2JZ>O_W=[T'Y33]K1^K:WV,O*/M5Q_WR=%?G-I?Z53U_^[O>@_*/
MVM'ZMK?8R\I&]I7':?VRM%!_\3:7N_I58^D*M';O>@_*<9\5BZ_S;6^QEY3@
M:51\?VRM%/G-I?Z54J&HBO\`RK_H/RD.?$XX?S?6>Q?E,7M*HY!_;*T3^<ZE
M_I52?I45"BM:CV;(4^)1Q_F^K]D_*8'2F.S]TK13YSJ3^EUO;U44Z>JU'LV0
M+G$53\QJO9,K?:IC_OF:)9_OGTIO^U5+CK%2OJ=37^3?E(LM?&OYG4Y?)ORC
M[5,?]\S1'YSZ3^EUVCJXTJ[.IK_)L@3UL<?XK4>S9E]J>.?\IFB6#/\`*=2O
MTLIEG6Q6/J-57^395W]6G7^*O^@SG[4T?']LS1+YSJ7^E5WEQ".Y^8U5?Y)^
M4JKVHJOS=WT6/M31V?NF:)?.=2^C^A5QAQ!;WYC5>R93W[M7V9^B9'268;^Z
M7HE\YU+W_P!*J1#B,:?F-5G\D_*5%^:;RE\1DYI-,,=_;+T3[-3:7O/]"J6N
M)1^KZOV3\I2:E53)W-)X[3^V7HI\YM+_`$LI=OBD<?YOK/8ORGG=7:<GVH+K
M?@)AI1'XOW2M%/G,I>[^EE)_:BW/U;6^QEY3SNHTS:E_&6?31G]JB/\`OE:*
M_.92_P!++,.**C_FVM]C+RGG]3HFXO\`CM.L?E%TEIW2F89^Z1HM\Y=,Z/Z%
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M'$\?MCZ,>](_=)IFUO\`0RFPXY'=_4^(Y_5Y>4J-1RS-JG[1X.O^KAY")[2F
M8]']LC1?WQ/[I5,VM_H7I6SXW&GZGQ'[/+RE-=Y5FU_:7!?MD.CJ(QI1,>L_
M=(T6R/\`E+IC<26?S*D>-Q^I\1^SR\I5ZGE2;A)?M/@F7UV'=,WM*(Y>/[9&
MBS1E^V73-AP_F7I75\=C3]3XE]GEY2I_=":@_P#NG`OMUONF'VIXY>!.I.BV
M;W^4NF-;B1_,JPN.12_4^(_9Y>4B7.3KF'_=.!?;K?=(WM)YAKW[9.BK"ZP_
MMF4L;7OZ&Z5E<<A7]3XC]GEY2/+DZYA_W7@/VZWW25W2>8=8W4G1;(?Y2Z9^
ME5C]N0;K]#XE]GEY0^3KE/[5X#G]>M]TD=TJC!]T_;(T69_WETMN..7P9'QR
M./\`,^(_9Y>4Q+DVYN-+BO`:T^O6^Z6QI9':"=1]&-K`-2:9GD/YGZ%R_;<:
M?J?$?L\O*1K?)MRO]J\`^WV^Z77=+8^7VQM&LS_E(IG5_.W2L_MR.'\SXC]G
MEY27#DZ[3^U>`Y?7K?=+\/3",T$:BZ.$<+`S4:FG([/SMT+C/C<6Z_0^(Y?5
MY>4EVN3[F[_:G`OMUONFV@:8QAP@:A:0/->=.&HE-/\`]W4*?&8O_A.(?9Y>
M4M;'*$X8_M/@GVV'=.P2NFD8%IO_`$E.&'#J!3CF,/YGZ5%?&8T_5=?["7E+
M>WRG-JCXEP7!?7(=T[!`TXC`.?J[TI:"!^OVGG`;OSNHLN,1:_5==["7E.MK
ME2[6JXEP;[9#NF_E]/(H#/EQI<0WZF^I`L/]3J+<XM%T_FVM]C+RES8Y5DDJ
M\0X17^EP\AV&2T_BAC;TTT)9CPWM(O>#\P4.YQ2.]7Z-K/8R\I<6.6IK%:_A
M+I_S</(=PDK%BN@?JPTZ>#1[V\9(LWY0>A0;G$XT_5]7G\D_*6FGY<G7'7<+
MI_2H>0W7R(B_\[M/?\;Y3_ZE0/V@OD-5[)^4L?W<?UWAOVF'D/,DSIU?;Q)=
MLRZSGE0:D?)+KZ[_`-A\5I^K:CV<O(?>Q#F?EE/^T=%3^6M]XZY-Z9Z@O$\%
MBW<]B3^MZJ':UOZ&S46?`.+RQ^BZG'_=R\A<V.:^5$JOB>A3_E[?>.OS&ENI
M#S66!>)RP%N58MQ+?YE*B3Y=XPW3Z)JJ+_=R\A::?F_E&+=>*</]O:[QHX^E
M&IF!&GEZMVAVV:N1D?Z%WJ+/EKC3K32:KV<_(65KG+DU+'BW#OM%KO&FCZ1Z
MHD%FG-\/8DM%L5AI;_L3I42?+/&ZX:/5^RGY"6N=>3$L>+<-^T6N\:B-H]JJ
M7L--;[/2+6K)'^T]JYRY:X\_^"U?LI^0G0YXY(C_`/6.&U_I-KO&MC:.:L'#
M[65^D<3Q;\E*V6X_TFH<^5^8*8:'5^RGW2;;YYY&27_>>&9_6;/?-=$T9U;>
M#S-+[_)8`SY)5O?_`$FN7[K<P)U^@ZSV,^Z3K//G(=7O<9X6L/K5GOE)_1;5
MYCK-+=0"S=:-<Z<_SDG[K\P_4=97^1GW23^_W(-/[:X7]JL]\IC136`!YFEF
MH71^I"N]?\Y8XK/[K\P_4=9[&?='[_\`(-/[:X5]JL]\K'176,O$?:HU#9AB
M+.KVS#/X#N3]UN8?J.L]E/NG%^\+D7+]L\+^TV>^1G1/61S`:4:AO!A9^H^O
M'%O](K/[K\P?4=9[*?=-'[P>1O[YX7]IL]\B^TKK,S'2;43#']9M>WM9^@5T
MM\L<P1;_`)CJ_93[IM#WA\C*J?&>%TI]9L]\Y^TIK-Z3-)]1?29G9U?SQ'\X
MY8*5;Y<Y@3QT.K]E/R'.?O"Y'E3_`+QPO#_F;7>,#HIK,P,TGU%R(_6=7L,6
MY?`5,AP#CM&GHM57^2GY"-/G_DC&G&.%_:;7?,!HCK-QM^U/J,/>G]9M>9BQ
MO\PJ9#@7&]U5T>IK_)S\AI^_G)#C7]L<,K_2;/?,8VB.LP!X=)]1GF'#]1M?
M/DD5-M<$XTHXZ34^SGY"!/GGDJO]K\,^TVN\4QHAK3Z0^U)J/B/^9EP9_P!0
MJQTO!^+*3WM-?6'R<O(1/WXY,B\.+<-?_46N\57M#=:2'OVI-2&L/[#*_N_I
M!6$.%<43_5[V?XDO(:W.>.3FW3BO#?M%KO%?[1NM8RTBU)/_`%+N#](J?#AO
M$:8V+WH2\A`ESORBW3]J<.HO^8M=XH1="-;2\\1I!J607B<+*N`YL/\`."L;
M>@UJI6S=R_%?D,2YTY/=/^Z\/R^L6N\4XV@FM[S6:/ZF^]9A9-PG?_0"NK&E
MU*6-N:\3(MSG+E%K#BG#_;VN\:Y_0'7)I(T<U/./_,>XOL>I_J+_`.)+XF1Y
M<X\IK+B>@]O;[Q2B:`:ZDG]IK5%F/[!KCZ?]SU)LVKJSC)>(Y3YRY5W<.)Z"
MO\O;[Q2B\OFNYP^TSJED,K%N/?\`WO5Q9P4:D.?./+#RXCH<?]_;[Q1?Y?->
MLAHMJH0#F+#N7<<?['*T@[;2K)+QHT?-G*^[7]I:&O\`+V^\:V+R[Z^XLT3U
M6+0<K"N7I_W.4NW.REC-?&CE+G#EE9<0T/MK?>*;_+KS`-+-$=5SE^P&YMW]
M[E.M:C3PE7?CETHC3YOY;N+=?$-%3^6M]XI1>7+F"):-#]63B<K`N<_\FJRM
MZ[2K!W+>'^LO*<ES3RS_`'AHO;6^\0/<NG,([EH;JT?_`(?W1]C5+CK]'\K;
M])>4?O1RS_>&B]M;[Q&>7/F%8W[1FK33L^U_=&'_``:CU^CK^=M^DO*<9<S\
MM5_M#1>VM]X@>Y<>86(PG0S5L,P_<^NC[&+K#6Z%K&]:7_BCY1^\W+?]X:/V
MUOO'`Y;N809:&ZMD_P#=]='V,71ZWA\%O1OVF_RH^4TGS-RWN_K^C]M;[QS_
M``<.8;]XO5OYOKH^QBU_:>B^5M>E'RG']Y>7/K^C]M#O&7\'/F'_`'B]6_F]
MNG[&I^T]%\K:]*/E'[R\N?7]'[:'>)G>7'F$(#=#=6FL_>^NC[&K;]HZ#Y:U
MZ4?*<9<R\NU_7]'[6'>)X?+GS!N@_M':LXG;I_<_V-3]HZ#Y:UZ4?*8_>3EW
MZ_I/:P[Q*.7;F#;^X=JQ\W]S_8Y97$=!7\]:]*/E-9<R<O;OZ]I/:P[QE_!V
MY@_WCM6/\0+G^QRV_:.@^6M>E'RG+]X^7_KVD]K#RDG\'3F`_>0U8_Q!N;[&
MI^T>'_+VO27E'[Q\O_7M)[6'E)!R\<P(`'VC]5\/^@-S_8U:/6\.;KZ^UZ43
M'[Q<O_7M)[6'>.?X//,#^\?JO_B#<_V-6/IG#OE[7I1'[Q<O_7M)[6'>.7>7
MCF!)8=$-5P/\`;G^QJRM=P].JOVO21K+F+E^GZ]I/:P[QG_!VU__`'DM5_\`
M$*YOL<M_VAH/EK7I+RG/]XN`?7=)[6'E(_X/',#^\AJM_B#<_P!CEC]HZ#Y>
MUZ2\IG]XN`?7=+[6'E,3R[<P!..B&J^/_0&YOL:MEK.'/SO7VJ_E+RD:YS'P
M.K2UFE:_E8>4P/+MS``8:(:L%K?V`7/]C5VCQ'A\:?Q]G#_77E(5SF'@VS5Z
M5_\`J0\IA_!VY@3A]H_5C_$"Y_L:N\>*</DZ._92_+CY2++CO!W7^=Z;'_>0
M\IP>77F!_>0U8_Q`N?[&KM'B/"XNOTFSZ<?*0[G&>#M8:K3Y_*1\I'_!PY@,
M_M(ZL_X@7/\`8U=5Q;AJ_P"(L>G'RD67%^%5_6;'M(^4C/+ES`@X:'ZLG_J!
M<_V-5A:XKP>4%*>JTZE_*1\I7SXKPS&FHL^G'RF0Y=>8,?Y#M62UG[`+G^QJ
M[QXOP:/_`!>G]I#RE;J.(\/==V]:?_CCY3+^#MS"8_M&ZL_-_<_V-6[XUP9K
M=^EZ;VD/*4^HUVDW&XW;;?Y2\IQ_!VYA&?N&ZL_-_<_V.6L>+\%3K]+T_M(>
M4IKNKLR?:C\:)?X.G,"W]P_5C+_F#<WV.4J'%^!Y/6:;VD/*5-Z\GBFF9N<N
MO,``&Z(:L8-_8!<V_P#O:NSXWP1/#6::G\I#RE+J?62[*;1.YRZZ_P"9T1U7
M_P`0;F^QRDPX]P--UUFE]K#RGG=99U,J[MN3\3Z"8<NVOS0?M):K_P"(5R_8
MY25S!P'<I]-TOM8>4\_?T>ODI4LW<?\`5EY#/^#QK[^\GJM_B%<OV.2','`4
ML=;I?:P\I0ZGA?$Y1:CI[S=?Q)=/467>7G7QG[B>JN0_8%<OV.4N',7+ZCCK
MM)[6'E/-:C@?&9/#2:E_^G/P^`D=Y>->B&G1754''#Y!W(/^3EU7,/+K>\]?
MI*_RL.\4M_E_CSFZ:+59?)3[H/+SKT`&:*:JG'']0ER?8Y=5S)R['+7Z/VL.
M\4&JY9YDE%[N@UC_`/1N='Y)G#Y>]>G<?M*ZJ`MVV)<FP?WNWE=ES1R\W1Z[
M1T?^^AWCS.MY2YKG!J/#=<\-EBYW25WE[UZ>?!.BVJ8&?ZQ+DW$;:=TKJN9>
M6E_]0T?MK?>/-WN2N<7EPKB+_P"GN]TP_@]Z]<1_:5U48T_L#N7['*1#FSER
M+JM?HO;6^\5E[D?G2N'".)?9[O=`Y>]>F/'[2NJC2"/UB7+]CNE3[7-O++A6
M7$="G7Y:WWBFU'(7/,G2/!N*-?T:]W"-_EYU[;AHKJH0#_S#N7+_`-G+?][.
M5Z?VCH?;6^\55WW?<^-8<%XK]EO=PP=Y>=>P^W[2NJG;8=RL8,?[G;5LN;.5
MTO[1T/MK?>*F_P"[KW@3K']A\6HU]5O=PR/+WKWZ1&BFJFQGZ@[EVM;_`&N6
M9<W<L4HN(Z'VUOO%=<]VGO!4*+@7%W_TE_N&`Y>]?`?W$]5,GC^L.Y<]G]KM
MK$7-O*]/[1T/MK?>(LO=C[PY4_[%QC[)?[AB.7C7MX'BT4U5](!OZ@[E&TM_
MM<BYMY8K7]HZ'VUOO$9^[#WC;W]@<8HO^4O]PF_@\Z]-;]I751F'[`[EZ<_Z
MW+*YNY7KCQ'0^VM]X?X8>\;"O`>,?9+_`'`>7G7H/$C1351N'[`[EW#_`'.W
MK#YNY8W7_P!QT.W_`,ZWWC$_=A[QG'#@'&*4?_"7^X6?X/FO;1^TMJGA_P!!
M+EV#^]RB_OARW]?T7MK?>(L/==[R$ZO@'&<?^3O]PV4/E]UU+OI:,ZH@G?8U
MQAF+6L-/6'SARY7]?T7MK?>)4/=C[Q:T?`>,4_HE_N&RE^7[7%KO%H[J<Z`&
M8V1<(S)WT]:2YNY<:JM?HJ_RUOO$RW[L_>&DU^P>,9_5+_<-K`T#UM<+I.C^
MI@](?L*N`88M/Z`PS45\U<NM4^GZ/VUOO%G:]W/O"BO["XO]DO\`<-]+:%ZT
MNOANDFHX#,6V9<#,LV_`5%?-'+U'_/M'[:WWB?#D'WA+#]A\6I_1;W<.P0-$
M-8@'6Z4ZBAF^SZZ/+(J-+F?@&Z_Y]H_:P[Q86/=_SY%JO!>*K_I;W<.P2^BN
MKKN>EVH#K3BVTJV/+)*)<YEX$U5:W257^]AY2WL\A\\)JO!^)K_IKW<.R2&C
MFJ\,@OZ:7V`/K[5K(V],FH=SF+@C:_GFE]I#REM8Y'YSCGPGB7V:[W3M<EI+
MJ>Z&/:<WL[B#Z5L5AWRR@4&YS!P9ITU>FK7Y2'E+6QR7S?%8\*X@O^GN]TV_
MVJM3/WO+R_Q:JWZ44/\`;G!_K6G]I'REE^Y_-O\`=FO]A<[I]JU_.Y_?80!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0'YKN='GD[W&L][!<'=V=W%(<D,*
M2M/DZM+FCK57YK*'JL(\2!4M0YBP:Y)4^O:>7$^(T43M2IKTO+/4MP"&([[T
MP2'7"!]/^[Z=[TEVBZG?_J<Q.3F)7_C6V/M0_P`$-S4YVF"C?!*S\K_EQ]LH
M^O,^9[X!\!^">AZL1O68\*`^B2`(`@/4FT>=;0^]N<C5GD3H<W=+^OFBVE=H
MZQWO)S5M3<M:4&R[WF*;*T*-3+I?BF4J-2B1:M"$27=<!<]/$\#S`/2KN-^=
M77/GWY**KKIS"SUK5"_Y/F'USTU@Q[0MR':U)%LV!<\*D6_#>ID.<G73.N2S
MQ];%XVQ"0T-#2!]BT`0!`$`0!`$`0!`$`0!`$`0'QV[CGG4URY]>2FK:Y\PD
M]:]0OZ3YB-=--8,>T;<AVM21;.G]TPZ/;\-ZF0YN==>G7)4GUL7C;$)#0T-(
M'V)0!`?'/FGYUM=-)>]^[L/DPLZ>M:#HAS5V!S6W'JY)5&VX<_<\W4=(--JA
M<]G&WKB,Y"B4.%"J\"&],.B%%$>&"X6-!=`^QB`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`_'-S<\GMQ<ZOTE3433&V.;'F9Y/:A0.ZKL.]W]1N5B^#8-
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MGGHLS'>>B/DO/%`?D!Y9N[8T5E_I,W-M2G-2^99Z#H?H]H;S>VQ&B:WW`]-U
MW4.Y-0[7NR=L^^)D2KL:ZM(9:?J3T&7MV.\)6'*.NP2\\X$!Z(<B'=P:><QG
M<A\[W-9JOK!S!Q;WT!NWGOU"Y6K;L75R[-/+`T'NO2F3JU\_*JE6?:<[3*5=
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M7P"T$'%`?B3UXYU>:[N(*?S@]VU4']8->(',52JE<_<N:PUF>KM_W=*W)K7=
M].L*X-!KNNNKS4[/5&Y=#[AO`5NEF:C/Q)M^7=];P.5>1@00/(_>24'FQ[OG
MD)[I?NNM%;LUUO[4/FPU,G[&YH=1---8:?;&ONJM7IM,H]]ZJ:8:9:WZL5:+
M2K(J&J=TWK.25&FIN9XH5*I$&0APXT&)%EHP'BSE3Y7N\-Y1N=#E7U&Y)N[?
MYZN5[1BL:ET&RN=73K7OGHT3YB=(=3-&[EGI*DU_46#:\[?\6Y:-JAIY`FH]
M7EYRGF-ZSX.(,*!#AO1X,V![,5[0.'WTO?.]X!H)S>:V:NVMRT=V_2=$[6T9
MY4M+=2*YI:Y?==U3M6+<5=UJO&;MZ8E:K5W96>E'A"F9<PYEV!4:;!$Q!@PG
MX<X!Y8[OO22\^5_Z0+S0<LCW-1K1S$:3VCW9^GUSZ<4#6'42?OFXM)J14M:;
M-I])T^NBH/Q8,*XZ_;LA+OQ:=5I^6-9?MVI2<&8CQ^$QHP'KU]'LY)I?FILB
M6YW^9;F"YBM6;EY<>=_F1D.7'2BL:HUO[4NG;]'K3DO4[@K=`CF:J-[W/6:I
M51$=BSTX9>3EJ=(P8,)T0XOK0/TM=X7K]>/*MR+\W',AI[2):NWWHER]ZJ:D
M6?3IZ7?FZ<]<EKVC5*E1YRJRCC'YJCTN>@N34Y#!=,26@Q'>)UO$`/PE:7<H
M?/+KKRSVAS76[R6]Z)J#SY:J612]<[%[QFWN\DT(HUO1[PNBGP[QM.IT'2>+
M?$A0:3HJZ)N!+/T./"@5&!2O60?6RKX$&$!].N;B'SK<RG.#]''T2YF]1=9^
M4#7+732+F[H7-Y2=$-0X-GUZH52SM-+:^7LO(3]@UJJ6M2)[4JWZ1.N2D[(Q
M(\>W7*\]%D8D&9EX3S@'DGE@M=WNK^]Y[QCEGY9J[JQ<7+5;?=637.[0>7[4
M+4F\]3J5+:W6C<U/ID&);-3O"J5JY)6+<DK#FH,R^9F+,S3T\'8D1]R7E'8(
M'7>Z/[LNUN\/Y3;'[U#F%YTN:RXN>WF$K%^ZA4C7#2[76NV?2N6RK6]?-R6W
M0;&LG3^1CQ[(F:':[E`<-0H5:DINCQ($5^0<E(<F!ZP#T4T+YIN8/DG^C2:G
M5KELOB#/:PZ@]X]JSRX4O7&RXM*HT.BRFHFJTQ2ZWJC9=2J$U*4"V(]QRE)>
MEJ14(\Q`EZ5&J\"9=BPWX,.(Z!5')-WD/+C4=--;.[W[MCO*-%^;6P;SM:MW
MMJ=KGWBF@.L^G_,Q;\.H0!?5I:^:=SU^2-(JL*]99^(8;]*=DQ+3,3B<AF*(
M,:`!]5>\'I-W=Y-WSO+GW5^M.K.IV@7*-;G)3&YQK^TLTVOB/8=U\Q^ILW>5
M3MB'IS5;KH\01:G0[+D)$S3TO+&/P0J?4XT+U<9Z#-2@'B^XN2.S>1?O]NY8
MTTTJUQU2O?1VH:<<]D[I_H;J[?\`/:HU_002VA%:A5V+:5Y7)$F[X&F6H4T_
M"?D:74IJ;@T^J4NHORD00YF)!@@?L)0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0'I)2^0_2>D]X)<W>/2]Q7Z_K3=7+/3^5B?M:-4J$=-H-A4Z^9"_H-8
ME:4Y;SEQ.W6_5Z<Y#>C/U1^5^#EX"7#YXT!Y8YIN5K0WG0T(O_ENYC;&D=0M
M)=2*9#I]PT&;C3$E-2\S)S4&HT:O4&KR42#4:%<EO5:5@S<A.RT1R-+S$)UX
M$N\3KP'QRT)^CH\LNF.L6E.IVLO,[SL<Y]K<O%<E;CY<]#>:W6L:BZ-Z15JE
M/A^W:I3K2@4*E2]5F[7]5!^`PWS!D71`AB-+1G7'70!],3R%:2'O#!WDWRBO
M_P"W:.5[^"=\EOC*A?:T^U]\OWM1OCGXI^3ORC^5OQR]ZKUWQI\$^#>C\'X_
M30'N^@/22R.0_2>PN?'6SO"*3<5^S.L&NVC-CZ(77;,_4J'$T\IUKV%-4F;I
M-0H-,@6_+W!+UR9B4>$)B)'J4Q`>!>X(3A+0!XIY>^ZPT$Y;N1G6WD#LN\-5
MJKI%KQ"U^@W9<ERUFV)K4&G.<Q5-J=+O+X@J=-M*ET*6>I<M5'S3C'ITQZI]
MUTQO78@@>)=5NY%Y2-6N4#E8Y3:G<VMEJ5+DGHE+IO*_S-Z?7S)67S,:4U*E
MT^7I[]<HM]4.@2M(>BUN%(RQJ,J:8).8?EH,5R'"CP($:$!M>2SN@-..4W7J
MH<UE_P#-#SA<YW,M&LJH::T#5/FIUEGKS^0^GU5CR4S4[7M"UJ/)4.A2LK4Y
MJ0AQ8[\ZY//.Q07X'J'WXA?`^NR`_-)$I\SWG7?VP9V<D)BH\I7<KVN\*;'F
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ME;=OZ5G:-5Y.M/T^4APH$":=$&*9>!`@S'PF%+2KD`#M7)?W.G+/R,\S=]<V
M>EM]:_7GJ[JAHG(Z-:F5W6?4H:FU'4.9A791[RK.JUY7)6J*[=M9U.N6K4.7
M<FHYGW*7`E(;LO*2,M!APG'`/8KD(Y$-*.[PT6KVA>CEQ7[<]JW#JUJ+K%.5
M'46I4.J5V%<FI=2EZG6I&7F+?M^VI%VC2<:6==EG'I=Z,ZZWCBQ"6H#W#N"W
MZ'=E`K=JW/2*=<%M7+2*E;]PT&L2<"H4BMT.LR4:G5:D520FG(LM/4ZI2$S$
M@QX,1UZ'%A/O.O`@D(#\[LS]&OY>($I7-*+1YU^\5T^Y+;EKT]6ZQR+VAS(3
M,EH`]*52<?J%4LR0@3=`G;FDK#J4V^3'D7IR+,Q02\]-&*?6`#Z9WSW;&@-Z
M\R'(?S*PZEJ#;%P]W?:>H]DZ#V90KADYJRYRV]2;`I^F\_(WR]<M)N"[[@B4
M2W*7!^!1G*M+QS'!B3+\P24!VFE<AFD=)Y_+W[Q.'7KYFM8;]Y:J7RMUFT9R
M?H,;3-RP*5>-/O6%4Y6CBWG*_P#*6/4J:Y"B1(M2B2AEWGG1+AX\0`^8]`^C
MB\JEB:J7Y6-)^9+G=T9Y8M6+NF;UU4Y$]*-?JI8W+#?<_/Q2_5[;JE#H5.E+
MI@6!78($M.TN#4G(D20`DW)F%*.PX#@'M[HAW.')IHUR%:C]V]/4*Y]5^6/5
M&Y[\NFXK?U'J5)>K4I/7S79.Y(;ENU6SJ':3MOO696J;*S-#F):$Y.4^/*PH
M@C//N!Y`>IVF7T>G1VU[XTDJ6KO/-WBW,]H_R^7A0KYT-Y;];N8^;J.D5D7%
M:,_`G[)G)R2MFAVY6:X++?EH;E.<$U*0X<)SU+[L2`]$@O@>WG>-=TIR^=X[
M4M)=0KMO/5_0+F+T#GIF;T9YFN76[H5B:P65*S\=R9J%`%9BTZI2]3M^9F`]
M%APGX;DS)QHD5Z5CP!,33L<#P]H)W%_+=H=S0\O/.G4=<>:_7#FDT'D=4)6I
MZQ:]:MPM2[IUD.I]E3EAORVHTY6[>B3,I;M@T"I3+EMTF@Q*/3Z?$F8T6+#F
M8T:/%B@?:Y`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!
M`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!
M`$!@Y#AP^+U;CCG&^7W^!T.\3[WOGWN$#B?>9B3B4!F@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(#\M//E>7>-\P/?@6]W
M?G*3W@UR\DNG#O=V4OF;GYFE:,:<:P252O"F:VW58=2AO4RZY>FU67CUFF3\
MCQ17:GZB$[3@'8!>BO/H"G-<XW>H]SOKIH#:W>B:NZ7\[O(=S%:BT7162YRK
M*TUIVC^IN@.IUR&9%JC5BS[<EY6V)BSJJ($2+&C#X;&$I+S$=R==C2SLC.`?
MI.U9UTT2T$H4K=&N>L.ENC-M3\Y\7R-PZK:@6GIY1)V?X/6?`9.JW=5J1(S4
MYZL\7JG'WGV8L0'<;0O&T=0;:H]YV%=5MWO9]PR@GZ!==H5RF7+;5<D7GWX;
ML[1Z[1IJ=I=2E'HD-YT1(,5]PETAK04!XGB\U?*_`U1&A\;F0T%@ZTF<%.&D
M,75_3Z'J?\8/$!V0^03]PBZOASQ>#(/P3UAW(#9:M<R7+MH$_1(>NNO>B^BT
M2Y8C\*W(>K.J-CZ=1*_$AONPXCE%<N^N4=ZJ/0XCX#P@")PDXL0'>ZKJ!8="
MLY[42MWM:-'T_<ITC6'KZJMR4:GV<[2*F]+NTVJ/7/-SL&B"G5!Z<@B!',?U
M44Q7.%X\3K0.CT?F.Y>KAU&J&CU`UWT:KFK=)I#EP532ZCZGV34]1:;08DC`
MJ<.MS]E25<C7+*4E^FS4*8$S$EG8/J(KD3BX'G20+&FVO6B&N--NB>T0UGTJ
MU@E[1G(M&N>;TLU#M'4"!;-;$*.\Y2:]&M.KU>'1JH?@[Y$"8,.*0X3PX%`?
M"WN+N\*D;A[L+2O6'GZYO;*DM0KXUNYA+4HM]\Q>JMCV/5[MD[2U1K%$I-&H
M\Y=-2MV!6/B6GN0H(ARSKYA.L!`#$!^B2GU"GU>GR-6I,])U.EU.3EJA3:E3
MYF#.T^H4^=@N3,G/2,Y+/Q9>;DYN7BNQ(46&\\Y$<>#SI((*`\*69S3<L>H^
MH%4TGT]YB]";[U2H9G16M-;-U<L"Y[^I!IO'\8BIV?1+@GKAD33_`%;WK_6R
M[OJ6'C8@.^W+JCIG9E4<HEX:B6+:E:BV_6KMATBY;NH%"JD2U;;E8\[<5S.2
M%4J$K-OV_0)*5BQIV=#GP:5A0WGXK[KKI(`M6#J%8.JMHT74#2^][1U'L.Y(
M,>9MV]K#N2CW=:5>EY6<F:=,QZ-<=OSE0H]4@R]0DXT!]^!&?=<C0GW"0\Z0
M`/C!S>\H?>@<Y_.Q.6S3.<6^.1?NY=/M-*;'M:M<J5WTFD\R>M>L-0ATN/5H
MMV5BH4":FK+M6AQ9V;EH,)V-,RT6#3H;WP9^+//1I0#Q3W+',US2U+F@[RKN
M\.8?7:+SB4#D+U`TPINEW-C/4VF2MV7-0]3Z/<%7FM--2ZC0W32JY?%@Q*2[
M*S4=Y^)/.3\&?@QWWH<.7=A@>.>\FU`[P7E;[T'NY[KM3GKKC_*MSG<ZVE&A
M,_RBTW1K3VF4.T+-IM%MAV[!-ZGU%VX;PNB8OBHPYR8F'G'*:_*_#/5P'P["
M=0'Z:T`0'Q![Q:P>]#YJN:71_E*Y3M2KNY*N3X:95;5#F0YWK*D[6J^HE=ND
M5V8HUNZ`:4RTY7Y:XK<K0DY>%4IRJ0H$LX8,VT33PE'Y*=`]9>2[47G6Y`N]
M.H/=;\T/-1=7/1H=S*\O=W<P7+/K9JG)2T'773FX].JA,2]Z:>:@567C3<>Y
M:!/TRFS4>!-S,>.!%$J)82_'-R[H'@&VYGO$._.YC>;^[M".?C5#N\>0[E+U
MKN[E@T1BZ!T1R8U!U[U9T\<E8=^:D7E<$.X+6J$S9L"9G)6-*R0FS*Q)2<@R
M[D&%,P9R:C`>[7<H<Y_-/?5[\Y_=S<_%RTN_^;SN][_MF@3FL5+IT"CPM==%
M=0J?.5+374*;ITK*R4#X\>ITC#C3,<08$2-)5.0,PX].B:C10/"&H6HG>!<N
M??\`')+HC>G//7-6>5;G;/-]?TIRY0='=/K)MS2JV-*]*;DJ]C60Y=LNY7KR
MO`TRH1Y*9?J+TW3XL>9DGGGX1AQC#=`_36@/S=]\7WRM1Y8]<>7CD:Y77)VO
MZY:D<P'++0>9+4>BT\U:@\M&D6JNJUM4FFV_7:C\'FJ32=5=;*09J7I$I-'U
M\I1?A$\ZX[$B2,5`?I$0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!^96\KK
MM:S?I5U(K5X7-;UIT=SN7(T!ZJW-6Z90*;\(B<TM0?<EQ.U::E)9Z8?APGWP
MX'B^7''GF,=>(`\'?2`N:;1KO`;)T<[GCDSO>T>8WFGYG-?]*YVZG-*:Q3;Z
MM_E[TNT]K\*[+LU)U!NRW)BHT:VIJEP92&^_*&/\+ATIV<C178;99R9`]']?
MM%.9KG1[^'GATZG](^03F7K'+'IMH?97+9R_=Y#?VL=,M2C:*7-I]1[@KVI6
MB>FUAT"M6YJ/4*]=#T2/<E4GH<>+3)N;@PW'76N^H`[YR]:.\^O=Z\J??GW#
MHOJ-R646WJ/HI5[PL_E=Y$-?-2=:CR:<QDO;8>OJX+>MG4.W8%Q:7QZSIU/3
MMPB1?G(_JIZD2D.7@.PI7U<,#W8[M?NT^XQG>1?DGYEYFC:-7SJ-6(NA.J<U
MS0WSJM.2&KM8YMIJMVU<LS2:A<[]W4^=D[PEM8WC37+2X7H;\:&[*19:9BOO
MOQ0/DEHQRZ<V7/YW@/>MZ@W9R\=U[S9ZT6!S7:D:+SE@=XOJ'KPYJ%H;H58]
M1FZ?I/*:3:6V9;M8M.@Z4U6VHKL21N6`!/3D[!F(GK(1>>B3('DBY-`]=>7+
MZ.=WP6F6H.M'*GJOHA3]2*3-\OMG<J.NUX<PED<NH>UTT_=U-T"-VWU1*?<5
M)IUCW-+RD:0ITW,STW"B3<S'C1"_'$2*!N>>'NRN2_3)SZ.=;^FFCU+T[J_,
M/KOI;I7S!ZCV1/U2U]5=<K)U5TSLZ9U4I>J6HE&G9.ZKLB:A0*O4I2>C3,T]
M$A2%4FY26,&6BF"@/H;RNZ#:,\IWTESF`T;Y9]-+/T)TDNSNE+7O^XM,=+J+
M*6?8-3O62UWMVWY6YXEI4=R6H4"L0:3!,(1H4"&\3&CQ"V),1WX@'IA]'G[O
MSNF>:7NW+EO_`)D;)TAYA-8J??VN=OZX0M9KE%4G>7"V)346[IRVK=LF4J%:
MDSHS;%7M.;AW*]6*6*?'G:G5IN,_.//0`Y+@>GMB:\<P>EGT>CO<+4Y3-4;_
M`+DY8]%.?>Z>7?E0UUBSU:G*[1N3&Z-2+"H]X1[8N&1EXM3B6=!HESEV)4).
M&\9:!7YY^"()A.NP0-AJ9W4_,/1N5OE^O?26Q^X6Y*1;=Q:25SEI[P#2/FSY
MC[-U8GKU>JM(%HU.!K#<]G35*U7JU_/13`?EJL)^$_$FS$@PX#T)TPP/IYWA
MO+%;?-WWZ/=!Z&\V<C"N*D7#R.ZYU77.T;)N"N4.T=0:Y:=)K5Q5JSYNI4QZ
MAUNHZ9U:])!U^8DGO@[M2I\/X/'<$*-%AD#]4ND>D6F>@NFUGZ/:-V50=.=,
M-/Z1#H-F63;$F)"@V[2(46-,.R-.E0\^8<,S$Q$B/$O///Q'WGGB7B2@/3B\
MN8#DTYV-0.;;NNYW56XI;6>T]-Y>D:Y:;T87OI=J%2;$U)H,C,RMS:>WE.TB
ME2M>EQ2J])OOU&@S,\Y(O3D`1RX8KKI`^.?<>6S+\D7>#]Y5W3.CUV4[6#E5
MT!DM-M?+&U&F:3:K^I6GFH&KD"2-V:-:OWY:-*I<&_[G@/18AE(]1=-0E)>C
MQ(1$,%Z6E@/+W?E_^,;N!O\`_J#9_P#Q?1T!^A:\[SM+3FT+HU`OZY:)9MCV
M3;]8NN\+MN6I2E&MZV;9M^0F*K7*]7*M/Q8$E3:32:;*Q(\Q'BONPX4)QYYX
M@!`1V5?-E:E6K1;ZTZN^U[^LFY)-VH6[>%EU^E71:]>D'GWX;L[1J_0YN>I5
M3E#$AO.^L@17W.)TAK04!Z7=X[WB^@?=F\NM8UYUNGIBJ5.=F3;&D>DMOQH+
MVH&MFI<[!)H=AV73WG8T4Q)B,\Z_/S[T*)+TN3XHT0/O>J@Q0/G)W3/*KJE=
M^NE]=Z#WA&H=D73W@.O]D/VC8&A%I771JS:?)7RW1*C#K=,T7M*ER54J#T2[
M)AXPHUPSP,1Z%'?BPC%B3$Q49F;`\.?1S-1;/T0M3G^[OC4^X*/9W,9RL\]_
M,)<US6A<E2D:16KDTIU!GZ36+-U8I$">F($Q6;8K$*2CO/3D)U^'`E7Y.+%>
M<<FY<O@4^Z9NRD\V7?9=])SQ:3S$O7N7>4D^7KE0LO4.DQ7)NU]1KXTNLVBT
M^_)^VZM+E^1KDG19FSH45R9@/Q(460JLG&AO/0X[A('D/GW_`/VBCN+O^ZCG
M_P#\RM00'TA[TSFJYB^5#E5NJZN43EEU7YIN9B[OA%GZ167IMI[7[[HMJW!/
M2,>(]J-J9\22\5V0LVT8+OKW99YYV-5YXP).'ZN'%CS,L!^)C7?56[N7ODMY
M9=/[T[MCO-*/S#7SWFG*?S3<TG-7S%Z0VW0:QS5\PM)NFMUNJ65;M3@774IR
M)5ZS,3LQ3;&H+T.%+2\K">+_``S$::BQ@/Z*6FUW3FH&G5@WY4;/NG3VH7M9
M5K7=/6!?,G`IUZV/.7)0Y"LS-GWA3Y69G):0NFV8TZ])5"##C18<*;@1'77W
M@`\0.ZH`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@/F/SC=SAW<'/[JI2]:^;;
MEOD-6]3:-9=)T\IUSS.H>K-J1)>SZ'5Z]7:71OBVQK[MFD17)6JW-/11%?EW
MH[WKRZ\^7770Z!YKY2>[OY(^1&0J\ERD<M6F.B,:X)>')W!7K9I$>=O.OR,&
M,Y,0:=7+\N*;K5ZUBF0)B&(D.6F9^+`<B#B=<#V*`\;\\/=1<AW>)U"TKAYJ
M=#9*\;YL25?IUH:EVS<]WZ;ZE42D1(\::?H3EZZ?URW:Y4:`)F9C1(<C.Q9F
M5@18\6)"APWXL1YX#RMR?<A'*)R$Z9U'2/E/T/M32>S:]-NU&[!)/5.X+CO>
MINRKTF[4;YO*ZY^N79>$U#EHC\.%\83L>'+PXC[D%V&X\72!Z0V[]'S[HRT>
M9"D<U%K\HMOT#5"WKUIVI-NR-(O;4FG::V_?](JLO7*7=5$TJE+O@V!3)RG5
M:5AS$"6@R#M/@1''2Y+NL#`/)G.;W*_=O<_&I$MK'S'<OD&L:LN4N6H53U&L
M2^=0-*+LNJ@RDN[)2U&O2I:;W-;)N^5EY!QR6A1*@[,3,&5AN08<5R$XZX`/
M-$GW:/(Q2^3VX>0>A\NMFVURF7;*09:Z=);7F[CMR7N2+!K=(N+XUKUV46MR
M5]UFXIBL4&3BQZG,U2+4)@2T-R)&?ANAQ`>0-1.2?ECU6F>6";O[3&7K\QR:
M7;;M]<MK[]R7A(?:VNFTZ5(42WZI`<IEP23EQ&G4VF0(8A5<3\!_U8>?<>>)
M)`W<ORD\ODKS25?G1@:>P'.9:NZ.0-`*IJ7\?70],36DDO<<"[8-H_)QZMFT
M84-VX)6',?"W)!V>)=#AC%ST4!\UK_\`HZ?<\ZC6-9FGU6Y0:11Z/8<S<,2A
MU2T=1]6K6O"9IUU7)/7;7K=N:]*3?4"Z+RMF:N&IQYF!(U::G(%.?C/B2$L'
MW@0/I]IQRO<O&D>@5.Y6=.]&[!MKEVIEHU*Q(.C\"@2D]9$W:E;A3<*OTBMT
MFJNSSEQ.7)\83#]3BU`S,>I1IB+%F7XL2*^^\!\R-+_H[G=`:0ZNTK6>T^46
MC3=Q6W7GKHM"V;QU`U1OW3"S[A?G8-1^-;>TMO*\ZW8L"/"G8#D2"Y'D8\&7
M?==>@N0RZX70/I+=7*;R_P!Z\R>E?-Y<VG\"I\P^BEF7=I[IEJ&:[<\M&MFT
M+Z@S<O=-(AV_)UJ7M6I.U.#/QG?73DC,1X(B'U3[F#`/8M`?,_G9[HGD3Y_;
MRMC5+7W2RK2^L]FTQRAVWK=I5?=XZ1ZL2-`AF=,.@3=VV+5Z1&KU'@&HQ_40
M:C#FW97UT3U'JA$B<0'FWDLY">53N^=,ZAI3RIZ5T_3JWJ_6XESWC5X]2K%T
M7O?USQ89A/W#?5\7-/56Y[GJ+D-YYV")B9>@2KC[SLO#A.//.D#O.M_*=H!S
M'7AH+?NLU@0;SNSECU.D]8]#ZM%KMST=ZR-1Y"'!AREQPI6@5JE2-;?@NR[C
M):HPIR4)=!,(E`>@_?I:'<W'-#W=^HW+'R:VK*W'J'S!WKIEI;?-3F[GH5L0
MK'T7K-WR$[J5>$6)7:C3169"!3*9#D)^1E'HL]%IL_,OP841Z'P$#Z`<J7+;
MIUR?<MVBO+#I/(NR-@Z):>V]8=#>]1"@356?I,FZ*O<U5=@_F<2OW=7(DS5*
MC%#3&GIR+$.+Q0'JOSE=T-W??>!W]0=3.<#0V?UHNRU;=%J6M%JVKFM5OT6V
MJ$9J)/3,I0;5LW42W;7I<:I3L3ULY,PI-V:G'G(?KHCXA0@X!USE'[E;NSN1
M35^!KSRK\LTAI7JO*VY7+3@77`U)U@NF)#H%QB5=K,@*5>VH%R40_#'9.&/6
M&6]:X'?0>=:6@:KGP[DGNYN\=OVB:K<S.B4Q4=5*-2I>WHNH]@7C<^FUV7%;
M4H'X<M;UX3MJ5&1E[KD):7B/0($2=@QIN6EGC!@QH<+T$![T\M/+#H+R>:.6
MIH#RUZ9V[I-I-9D*8=HEIVY"F##,W.QC,5*L5BJ5"8G:S<5PU:9>,6;J$_,3
M,[-1,8D5Y@8!K;\Y3>7_`%,YA=#^:J]]/H%<UZY;Z5?U%T8OU^NW/)QK+INI
M]%B6[?$M!H5.K4I;-8^/*/&>@E^H24V_`#Q>@F&]Z2`]BT!X`YA^5W0OFLM^
MPK6U[L6#?M"TRU:L77.QY&-6[DH0H>J>FLS.3EE72Y'MFL4:9G8E%F)^,1*S
M#\:2CA\B-!B```#S^@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@,7WW(8#S[[K@+SK@+[P=!>?>#CCH)(!>
M??(`&9)8L-I8O(S&,I.D4VZ5P\&9DLF#URYB=?931&B4MZ3IPK]T5J=@B1HH
M>>==<I<O&<>J=0FWH?IP8?J084'Z^,\,PZ\OY4_S3_YF-'_EWY=T=W0Z/]J<
MX<1U$59TB;26GA)/47[KC5QBHUMVG3SKLEFH2/F'W0^ZF_[R^)WXZF]]$X'I
MK;W[U,[LD_5VXIX-UI*?1!=+1Y@L6]*+J%:E&N^@17HE.K,HY,.0XHX9F3CL
MX9F1FX><*;DXX>AOC>&AH(*^=/=SS_P#WH<EZ#GGEF;EPK7V%-1EA<M3RN6;
ML?P;EJ=8372JJJ:;^/>:.6^)<I<=U/+_`!6*6LT]QQ;6,9Q_!G![8S5)1?0\
M<:G:WGG7'2\^\ZZZ,WGB'70TL#26`8E>X2;P69YZ4HPCO3:4>EX(R6#8(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@/CQWX=\UFT>2*?I%`G)ZG52]]1['M]R?I\W,R,S+2\G.1[@CF',RC[D>
M$]$-(<=!=(S7\_\`^9/BFHX=[N)6=*YQO:C668;T6TTDW-XKIW4C^X/_`.OW
ME[0\:]_UO6\2A;NZ3A_"M7><)QC.,I2BK*K&54Z>L;Q1\6^2/O5>:'0&<I%N
M:K5JJ:ZZ2F)*RTS2[KFS,WQ;LD.&&]%M6[)ALW-NR\(#ADZ@]&@O`<+CT(XK
M^=/=M[\>=^6=19X?QB<^*<$E*,-RXZWX)M)>JNO%TV0FY+8G$_O3W^?Y.?='
M[R=-?XORA8L\N\XJ,IQNZ>.[I+TL734::/FQJ\[ME1DLY*9]OOEO8W-7#AZT
MV+<$M<MI7!Q2%'C0GWG)BD0Z2\9>8H%6DAQO4VMTV9+PFH#V(B/<0+SI=>,?
M_,_[@.?X^^7B6G]ZFBO\+YAMV[/J=-J(XPT<H*>FE;E%RMSA<C)S<[<I1]8Y
MQ;WHR1_`'*^HN>[_`(1#EC=2U-F3E=E'&-RY)XW(MI.4)))0;2\U+!9%R1YH
M[-Y6WI_36-,P+BORZZ5,W9:%@0)KAF8;DF]#DYZMU>*<:71(H+I#1ZR8>A/>
MK!])X?T__DA]P/O!T_*_&N)6;%Q>Z;3ZVU&>L<6K5O77%25BSO4]9.Y;497-
MVL;;47-IS2?\:_Y]_?3/W/\`NC?OFL<)O\3U^GU-O01C%J%KUE_>=B6HN9QM
M0FFI.*<GOQ@J-U7SAUZYE-=]1JS2*O<UVU.6D*?<M,JDC;5OQH])MR1$E,_"
MH#KLC+Q`9YZ&_!'YI,/QGW@&DLP'V0</Y5X!P;1NSHK,'=E%Q<YTE.54UBWE
MU))'Y=?>!_F<]^WO;YKM<6YNXOJX</T^JMWK>BTDI6-'9W+L91W;4&O6-47\
M9=E<FZ5<J*B_350:@*M0Z-50UE3I5.J`;FR=DX,R&Y8LB+^6+]OU5^=K\6;7
MQ.A^FS@FN7$^#:3B2K34:6U=QS_C(1E]\VJY%F$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!\T>]KTOC:E<E.H<
M>1DGYZIZ?5"WM0I6%"<,2/\`!J%4H<*L&&X,2ZY1YV,^^=D-PG8OBGWS\O6^
M8N1-19G&3EI[D+RW71^8_.V/\%NO@/ZI_P`FG.2Y/]^W#?635O3\1M7M')R[
M.]=@W;KX7<A%+I;2VGY9:+IS%G;>FIR2E'HH>I<Q,0C"AO/']#//N!ST7B'@
M7@P@9Y%?RK[H^`:1^]3EK3<2BGHOWBX<KJ:3CZOZ99W]ZJHXN-:U5*'VW\X<
MVSM<.UD8S:N_1KJ571U]7*F3Z3R-W9?,;4.5+6:[*'?<Q-Q]%=0[9N"HUREO
MQWX3M%OFUJ'.UFV:I2X,0&%+SMP_`32(_HCUOKX)>:]#=(_53_G[_P`M?"?\
MSWNVX9Q#ER%JW[S^":ZQ;T]]))W=#JKT+6JLW)*KE"PIK5VTZ[KMW%&BN2K]
M8_.NAEQOA5N]H*+B]FY!)TKO6YR49I[7N;V^L<*/80\L-3U)UUYP*OK)?/PJ
M=N"]A>->K,&+%??EJ'0XU.BP*1;<@22["IM"DS!E)=P%T,=XBUYYXJU]]'*W
M(ON?_P`K^E]T_)D(6N!\)6BT]EI+?O7HW8RO:J[2F]>U$]^]=ECC*B2BDC^+
M?_[(^&Z#4_Y.N-<N::,6OIO#(VLJRNK66Y.Y1T\["4GT=2/I#=FG$>X;UL:T
M:=*1HTS<-U46C.2[CL-Z*^].S\.#--<`_F:4BOQ2^P@N@[E]<&IXKZK27+]R
M2W+=N4F_`EA\;PZS\S'+WNQU/$^:M!R_8M2GK=?Q"QI[<5%/&Y<BIR<5MC%N
M55ANIL_2[(RD*0DI.0EW0Y`DI67E(+CH8'84M"<@PW0-@=<<`7\QW)NY.4WG
M)M_&?I/T.EMZ'16=%925JS:A"*624(J*^XBTM"4$`0!`$`0!`$`0!`$`0!`$
M`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$
M`0!`$`0!`$`0!`$`0!`$`0!`$`0!`>L/.ES+VQR<<J',#S/W?$@"CZ*Z6W;?
M#DK'>`=JU:I=+CFVZ##=,2$]%CUZX8DK)N..GC>>C`.@E@0'\WNR?IB?>GRE
M]V?4[_H_+I4=-A=U(F+MH]'TAJDA5ZC9T&KRS]Q4NBUF)>T1V!57J.8D.!'+
MCW!&+KSSIQ!`_ISZ7ZCVGK#IM8&K%AU.#6K)U+LRVK\M*K2[P?@U&W;LH\G7
M*/../#!D>0GH;Q&PEB`[V@"`(`@"`(`@-;6:13;@I%4H-9DX%1H]:IT[2:K3
MYEP1):>IU1EHDG.RD>&\T/P9F6C/./`Y@KG>LV]19E8O14K,XN,D\FFJ-/K1
M*T6MU7#M99XAH9RM:VQ=C<MSBZ2C.$E*,D]CC))KPH^`-X<EU0T'OF?M9R5C
MU+3NH3LS-Z?5Q]UZ8<^*HL1Z([;U5B%U@K-(<>$,\6$:&'8@S('\U\9Y%O<O
M<8C>TJ?J8W%.S->"2E%-K\.#2Q>Q)H^R#@'OUT_O#Y;AQ"Y.-OF&%M0UEG+S
MZ4=VVJ_FKO:P[+;B\L?7FX^2"GU*I1)B3IL-V`]%C18;S\*,_P"MA1HIC.._
MF4'A9#XBZ2TDEN*^]OW:?YG;G,/)6@XO=NR6JNZ:"NQ37F7H14+L<_QTVO\`
M5:=,3X`UO-%_A6LNZ*[)/<E@\JQV/'I5/&>WG+)RMTO39VNW?-2#DL\9#XGI
M4)CSKP==+D6HQW'C#A/\),.'#!+3@]V_$WOP][NHYLAIN7;-R4HJYZZZ_C5N
M.;6V4GE^"?PA_G0YO?,7+FBY0<]ZQ&Z]9>ID]R,HV8-U>;<IM46477$]Z.7O
ME^B.WU%UBNV2]29!V8@V+38[C(CL2=EQ+SEP3$)]W\S9+$PY4'TO3>B8>@W^
M5N:>/QEIWPC22KO->LDO!E%/KQEXETG\H?Y:?<1J-/S'_BOS78=IVHSCPZS)
M4E_&+=GJIQ>2W/-LIX^=*YAYI[Y+X^/[S"`(#I&IM?G[3TWU!NFE&"*I;5D7
M77Z:9F'ZZ7$_1J#/U&3,Q!#SABP?A$L[QNM'$ZT-"`_%-]'^^D$\_P#WDO>%
MO<L_,>_HD]IH-&M3KY'R!TXF[7KYKEI3MM0*215HUT5:&9/U=5B^LA^I]/`M
M#,0/W((`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`_$I]-`YW?
MM?<M>AO(K:M1$.OZ_72=6-384"+PQH.FFF<Y#AVO2YEQQYOP>Y;^F'9D<0']
M@V8AXH#X5\U'=%5'3?Z-=R=<YOR5?E-7*/JW7-9-3'Q3G7*P-#.8Z;DK;L.)
M4XX`F'Z=17[=MR>@0V'U3EPQWWV!U[A`_3O]$-YZ/X1W=Y5+EBNJKQ)[43DT
MNCY)R+DW'<B3<UH]?,>I7#I]%A@O/3#\M0:C#JE*<+V$*7E($-UCKH"`_60@
M-+<=QV_9]`K%U797*3;5LV[39RL5^X:]4)6DT6BTFGP'YF>J=5J<]%@2<A(2
M<O#>?BQ8K[L.&X"7B`$!XXTSYA=!M:)ZJTS2#6?2W5&HT.4EY^M2.GU^6Q=\
MW29*;C1)>5FZC+T"IS\62EIF/"><<?B!UUYYT@%H0'F%`>,]3-:-(=%Y"EU3
M5_5'3_2ZF5N=BTZCU#4"[Z#:$E5:A`EWIJ-)4^9KT_(09R;A2SAB/0X;SSP<
M#2&(#=V'J'86J5LR5Z::7I:VH%H5&+.0*?=%F5ZF7+;\[&I\U%D9^%*5>CS,
MY(3$22G8#\**ZY$)AQ'"Z\P@A`=>U-UPT9T5EZ5-ZP:KZ=:6RM=C3,O19G4&
M\K?L^!5H\G#<C3<&FQ:_4)!R=BRL**Z]$=AEXN.O`EC0@/'^L_.)RK<N^E=+
MUOUOY@M)M,M)*]"EXMNW_=5ZT20MVYG9R`[,RCMKS@FHAN:--2[P?APY!V8?
M?<(+H((0'0^7[GCY%^>:GU6E\NO,?HEK^[3W'(U8MZT+PI%5K],<XGO4S<];
M$:++W%3G`\Z2Y&?EG`#D\N5^Q9U-MVK\5.V]CQ)>BUVLX=J%JM#<G:U$<I1=
M'1YKPI[4\'M)=1KWY6-$:W`MG4C7+2'3"L3TBY69.W=1M0[5MBL1J9&F(LN*
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MZ*C.P:=3:3.:BTVWHE3GIB)ZF!*4R8N44>3J,Q&B8..P(D0O-#,P@/IM`CP)
MJ!!FI6-"F9:9A0X\O,0(CD:!'@1G!$@QH,:&7H<6%%AO!YUYTD/`M&"`HUN#
M2)BC5:7K[DE$H,>F3\&MPZEZKXN?I$65BN5)R?\`7D0?@3TF\^(O'Z/JVMP0
M'SAY4](.Z3LK5GX\Y,K1Y**-K5\G:U*_#M!GM+GK_P#DO,19,U^$?DC,Q:Q\
M3Q(SD#X3AZKB#G%L0'TQ0'1]0M3=.=);:G+SU2ORSM.;2ISI>GKFOBY*1:U"
ME0'2\R-5*W.24DX]P@D`OM+,D!\U*[WZ_<_6[4XE(J7>&<M+\Y">X(CU)OAR
MX)$/>M>@D"JT"4J=+>8^X6LC%COI'T2"@/<KE^YT.4GFNEIJ:Y:^9'1;7%V1
M=+T_+Z::B6S=51D'0&O&?I5+J,>IR(=&?K8+C&AN80'LR@"`(`@"`(`@"`(`
M@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`
M@"`(`@"`(`@"`(`@"`(`@."0Z"\\0``222P`#$DDX``(#^2ESMWC6^_/^D('
M3>SIN:J6F]Y:^6YRZV).29F7H%.T)TGJ<:F7;>4L_`<??EY2J4NE5JOB*''2
MZ[-N\6+J`_J%<PO*GIUKSR?:H<G,_2Y*1TYOS1"KZ+TR1>A?G2@TQZUC;]KS
M4"'!<=+AMR/+RLQ"X`"Z]+NEUA`0'\O+N!>9FZ>ZT[Z&EZ-:NS4W;5LW[?5V
M\FNN5+FXOP21IUQ3%U/4"T:]4($5XPG3;FI=)DSZW%^'(S4R'#^:%H'];%`?
M-'OF?]$QWC__`)+^8?\`S9W"@/Q@?0@O_$ISV?\`<=I7_P!O:V@/Z-J`_$;]
M-V'_`/B7R3G;_"*O<-Z]-([?"Q`?3GZ*'_H2.6O_``[YB?\`/M?J`^07TX$#
M[4G(.68C4;68`[6&V;.:&]+$!\&^4+D7[PSZ1Q6K#IU(NFV=)N6/DDT=TZY=
MK6NR\XE<FK`LV%;MMR;IH5JV_28#\W=6H]WO0/C6L17?4.084:7=CQG(8E7'
M@/TT=RE]&8U>[M#O!YKF9ULU9TTU>L:Q]*;@I^D54L9VXJ-5WM1+QC.4&J/7
M+:]:E'7923H]H1)LP8L.<FG(LQ,N^BZ8;4!\-_IH@'_ZF.BY8&GE'LT$LQ(&
MI&IS`3M8U`?T5N1L`<E')\`&`<K7+\`!@`!I-:3``@/YO?TMRXW[,[ZBS+Q@
MR<&?CVKH-R^W(Y)1GWH4*>?H-SW;5(<G'BN`ON0IAZ6X"0"70\2$![.<I?<S
M\^?TBRO3?>,]X'S&UC1O174"<JD#1BWZ91HEQ7!-6;3ZA'DY:GZ5V;49VGVO
M8>FE-CRC\I!G(QBS=2CPGYAZ#&)>C1`.P=Y)]#PG^7CEXO\`UZY-N8BZ]9*M
MI7;%7O2Z=(=3;5H],N"XK9MZ2?J-<BV/<EL17)*9KLG3H$:8<D9N3A.QW()<
M<C^L>==('EGZ';WGFL-T:FZA]W%K%>E;OBQX>G54U7Y?YFYJA,U6J61.6I4J
M9*7G8--J$]'C39MBJ4FLN5&3DR3#D8LC']5PN1N$`?O!UR_<4UA_[K=0?^R5
M70'\P'Z($`.^.B```.\M6NH``8`RIV0`P;,$!_3<YF^8"Q^53EZUFYD-29DR
MUCZ*Z=73J)</`\Z['FI2VZ7'GH=,D^+!^H5>;APY67<`+S\>,XZ`20$!_*YT
MDMOO"OI1_>'5RA7OJS.V_8E%=J5^UXU"/5)W27EKTEA5-^1H]&LRR)68@2E0
MN.<?GW)"4+QAS=3FGXL>:F'8;L5YT#]-TA]"9Y(H5L?`:GS:<S<[=OP7@-Q2
M=+TSI]%^&<+H,P[:\6WJC,B7XP2(1J1>80/6%C2!^5SO7NZFYG^X$YD-']1=
M*M?*]6+2O2:JM;T+U^L45*P+UHU>M&9I\>K6M=U.DIR;E:?6H$&<EI@.09J:
MD:C*/O!YWT(L(`?TR.Z%YS:US_=W3RQ\TEV09.!?-^65,4O4(4Z&Y!D(]_6-
M7*I9%W3\G`<]"6@56M6_%FA"`#L'UW```Z$!])T`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`?'?OY>=B%R']V!S):L4VHFGZ@WE;,3132<PGW7)PZ@:J2\W
M;LG4),>LAO\`K;;HD2>JI><(?<=D2\,0$!_/?^C2\W_(-R&\U6K'-9SN:EU.
MTKDH6FL2Q-$:=3K(N:\YF/6+ZGS\O+JC1Z')3;M-F*?;U,<I\(Q#Q1X=5F,N
M'$#]NOX5?W+GWPEZ_,SJ)]AD!_/N[^37_D^YC.\>O'FPY#M0*A7;.U?I%H7Y
M=4?Y,W#9%5MG6>C07:1<,]*RU8E9*/Q5@4:2J@F8&<['C/%CWI/`?U">YPYV
M9'O`N[EY:>8QZ=AS5YU"RI:QM6I=U_CC4_5G3P.VK>[LP,3#%8GI!VJRX)XC
M)U""\6$D`"[WS/\`HF.\?_\`)?S#_P";*X4!^,#Z$%_XE.>S_N.TK_[>UM`?
MT;4!^(WZ;M_X2^2?_P`Q5[_YM(Z`^G/T4/\`T)'+7_AWS$_Y]K]0'R"^G`_N
M2<@__>-K-_V9L]`?8+Z*GIA1].>YFT#J-/EI6'4M3KQU8U(N*<@.`1JC4:E>
MU1H4E$G'PXX7XTE0+>DY4-:QR`Z&H#]&B`_F#?31?])AHM_Y2+._SD:FH#^B
MKR.?^"GD^_\`*WR_?YIK20'\U?Z8B&][K`&_EAT;'AJ=[H#^EUR;V!0=*N4?
MEATUMB6@REOV-R_Z06O28$""[`AB3H]@T"2AQ/5NDLB1S",1\DEYY]XDDDDH
M#S7>TE*U*S+NIT]!<F9*?MBOR4Y+Q`V''E9JE3<"8@OC:Y%@Q"Z>@H#^5)]%
MCA.2??LZ=2LL#`EX5H<SLJY"AO%UP2\'3^Z!"@D`L>AN>J=8"T-=!S`0']3#
M7+]Q36#_`+K=0/\`LG5T!_,"^B!_Z8^+_P"6K7;_`(TLA`?U'M0-/;%U7LRX
M-.M3+1MZ_;#NR0>I=S6A==*DZY;U=I[T6'&,G5*54(4>4G('KH+CX=?=(#[H
M(Q`*`^/-V:R]QEW*5S7K,Q:SRO<GVHVI].ID>\;0TZI#\?46ZY"C/STU1/C&
MP[$DJ]7Y*2$Q4([T")&E)66B1(A)?+&@#T)U2^F&=TS9$*H0[(@<Q6KU2DWH
MCLO"MK2Z5MZE5!YQV(73`JMYW)0XKCD1]UT!YZ68QYIR(0'Y'^_N[_RU>^!L
M?1_2K3OEQN#2"Q=']0*G?LI=MZW=3JY=E=J-6MJ:MU^C1J-0Z8*/1Y(08IC\
M3L_,Q(CSCKO"`[Q$#]K/T4?_`$(O+)_AMS%?Y_=0T!^C1`$`0!`$`0!`$`0!
M`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!
M`$`0!`$`0!`$`0!`$`0'\V_Z9[SNNZD<RFAG(M:56?CT#E^MN+JCJ7)RL=Q^
M6CZGZER<"%;5/G'($5\1)RVK$EQ%ANQ'77X7QU$`#'FD#Z3<F_T/GD;OCE5Y
M?KXYE;QYCI#7B]M*;/O/5&E6A?%K4.W:'=-V4F!<$U;M.I=0L.JSDL+<@U&'
M(Q?63$0Q(\N^^T!Y@`]E?P-+NJO^?7-G\YUE?<S0'SV[U'Z)WRA\M_(9S"\P
M/*/<W,#7M:-%[2=U(D+>ON[;?N:A5VTK7GI6H7_(NTNC611JC$JL*S7)V9DS
M#C8S$!UTNEUXL`]?OH77/1\D=9=>>0"[ZQ&=I.K5%.MVC\I,QR92#>]D2;E/
MU#HTBY$BLASE?L]^5GPY#=]-RC1GGBT!H'[-N^3@1IGNGN\;@2\*)'CQ>3'F
M'<A08+CT2+$>.F5Q,=<AN`O/O'<`U`?BM^A#U*2@\TG._2HL=UR?J&@NG,Y)
MP#[Z-+TW4&>ASK[F_P!2]48+1N>0']'M`?A4^F^Z@6_`T5Y%-*S.0#=53U1U
M4U`AR'K1\)=M^AVG1+<C3GJ0"?41*C<+CG$6>DZP-Q8!]<OHH?\`H2.6O_#O
MF)_S[7Z@/D%].!_<DY!_^\;6;_LS9Z`^Z?T9[_0M\G']Y+[_`,X]U(#[QH#^
M8-]-%_TF&BW_`)2+._SD:FH#^BKR.?\`@IY/O_*WR_?YIK20'\UCZ8?_`*7>
M6_\`+%HU_P`9WN@/Z>6@G[A>BW_=-IS_`-CZ,@.^71^MFXO[Q5?_`(OF$!_*
M>^BV?Z>'3[_!?FB_[`76@/ZEFN7[BFL'_=;J!_V3JZ`_F!?1`_\`3'Q?_+5K
MM_QI9"`_>QWYW/G=/=R]VQKIS$:=&#"U9F!;^F.DD[-2T*<DZ-?VHE1%(D;D
MF96/#BR\S\EJ0Y.U*%"B.O0H\Q*0X;XX'WD!_/I[BWN8:[WX^KNOVO'-!KA?
M])TNT]N.DQ-2[MI,[*UK5O5;4V]Q.5GXL@7!=$O5Y*EP(%+DXDQ/3\:7G(CO
MK8,*%"'%QPP/W`Z._1>>YBTA,C,1.5^;U3J4HY"]=4-7M2;]O&'4(T-PN^NF
MZ&[7*;;+O&7FER%)0X9+&NEB`_/[],*TLY6.6#EBY&N7KE_TBTIT:FZKJQJ'
M?PMS3FT*!:L>:MJV+,DK:B3U1>I,C+SM3ABI7-!AB+,Q(CP+@`)9Z('W:^BC
M_P"A%Y9/\-N8K_/[J&@/T:(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@
M"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@.@ZK:
MF6=HOIEJ#J]J%5H%"L73"S+EOV[JO,Q(4.%3[=M2D3=;JTQQ1HD*&]$<DI)_
M@=+P+[Y#HQ(0'\D7D%M*\.^E[^RU;WU"EWJG3]6.8RX.8[4R4F7O6R]*TGTX
MJ)NZ5M9YZ(X!$ITC;M$IEOP'7V<<-Z&X6O/,(']?5QQR$XY#AN.PX<-QUR'#
M<=#KCCC@#KKCCKH`====#`!@`@,T!IKCM^C7;;U=M6XI"!5;?N:C52WZ[2YD
M%Z6J5&K,C'IM3D)AT$%Z!.24R_#?#<77B@/XU>J5'U$[DCOH*X[0'*A)3O*-
MS/2US6LY"XX3UUZ-U*HP*_1)4#UD%V8D+VTCN%R6BN//<#PF7W'\0\`!_7<K
M,KIESO<I55DZ158-:TCYJ=!9V6IM:DWX4S#F[*U?L:)#E*C`>@Q'H,2*Y3*Z
M[$`#Q'&ZQJ`_DQ:>W7SV_1M.\MGZ[5+!C2]RV7-7)9L_2+LD:A*Z:\QNB54J
MKCIFZ%7X$%YR-2+B@4N5GI*?E#$F:7/0G!%AEZ'%@/@?J8N#Z;SR].:=Q)JU
M>2#6:9U9>I@,*A7!J#9$CIW!K)AXNQ+KIL*H7+-4QR-]4*-!BO.['3B@/S*]
MYC"[QSO%=&;B[YGG/ID+3G2*J7_96@G+E8$6EU2@TB;MJLN717_@^E=`JD5Z
MH/V-0A3X\6:KTT]&B5NI3#Y=B/B&?5`?O'^BAG__`$D<MG1??,2#T?M[7X<>
MPH#Y`_3@7A]J7D'=:.(ZBZSO!UH:0+:LX$@9D`O!O6@/NG]&=>=>[EODY+KS
MKP%%OUTET@@/.ZD76Z\Z69/.O!A&PH#[R(#^8)]-$>=/>9:,.!YTON\H]F//
M.@CB=#VI.IX=)=S`>+I9O84!_16Y&B'N2?D]>=(>=>Y6N7TNO`@@@Z36D001
M@00@/YJ_TP]YW_\`5X@.\3K7>6'1DO!H:Z#4[W87AF`6(#^GGH&0="M%B"T'
M273D@C$$&SZ,P@H#OMT?K9N+^\57_P"+YA`?RG/HM;[A[]_3MX/ND1+7YH?5
MD/`A]NGUV/C@(+'FN`G#9B@/ZEVN1`T3UA)+`-+-022<``+2J[22@/Y@'T0)
M]Q[OC7WG7G7G7^6G74N/!X$/@U*R'@72"QX%W'#8@/WN]^7R'7-WC'=L:[<O
M&GSL"+JO`AT'4[2.4FX[LM*56_\`3NHBLR-O3$P^/5P#=-'>G:9"BO$.09B<
MAQ'CPNE`?SO.Y6[Y/5'N)]:-;]&]?=!+SN+3'4"NTJ7U?TOCPG;,U8TYORS7
M)^G2UP42GW-+2LM-SOP"<?E9JG3D63A3,(0XKD=PPW>,#]/FK/TU/D>HEIS$
M;17EJYBM2;^F9&+\3T.[';,L*VH-6><=$K+UJN2M>NJJ.RK\9YCSTG3YE\LP
M=Q!0'Y9.]$TK[V'GYT@N[OH>=33V9TUT9?N:Q-*])K`J$A6K?>M_3NY8M3BV
M_/6%9-1@QJE(:=0*H^'9FN5-^%'K-4GQ$<]:X\Z7`/V:?0_-7[;OSNDJ?IM3
MJQ#F[DT-UWU8MJY*.]&<,U1Y>]*O"U'H482X`BPJ?5(-S1WH3Y:[$CPHX!:X
M\`!^J)`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!HKFM>V;UM^KVG>5NT*[;5
MN"1C4RO6S<U(I]>M^MTV9=X9BGU>C567FZ=4I&8=P?A1H;\-\9@H#Q5IQRQ<
MM>CM=C73I%R]:&Z67-,4^/29BXM.-)K"L>NQZ5,Q8$>9ID:KVS0*74(M/F(\
MK"??@O1##??AND@ET,`\Y(`@"`\!Z@<J?*[JQ<D>\M4^6W0/4N[YJ6E)*9NK
M4#1[3R\KDF9.0A^ID92/7+BMVI5.-+2<'T(4-Z*78;N#H`0'F"V;8MJRK?H]
MI6;;U#M*U;=I\M2;?MFV:3(4&WZ%2I.&(,G3*/1J5+RM.IE/E83H=AP8$-R&
MXZ&.@!`>-M;N7;0;F4M*+8G,!H]IQK):,3UCSE"U%M&BW5)RD6*Z'(DS3?C:
M3F8U*G'G!P^NEGX47APXF(#T@TX[E'NGM);LE+XL+D(Y=*1<\A'=FI&HSMDP
M[DAR<PY%$9R+*TZYYFLTN`]#BN@N\,`<)`8Q@0'O]?FCVDFJ=KR=D:G:6Z<Z
MC673H\E-4^T+\LBV;OM>1FJ=!?EJ?,R=`N"F5"E2L>0EXCT."^Y"=>A./%UT
M@$A`;6PM.]/M*[9DK*TPL6SM.+-IL6<CTZTK"MBB6?;,A'J$U%GJA&DJ#;TC
M3J5*Q9Z=COQHSSD)TQ8K[S[S7B2@.O:G:&Z)ZV2])E-9M'M+=7)2@QIF9H<K
MJ=I]:5^R]&F)R'#A3D>DP;JI%5ATZ--0H+CL1^"''GW70'B0`@.T658MD:;6
MU3;,TZLZU;!L^CN17*1:EE6]2+5MJE.1XT29CN4VA4*3D*7(N1IB*]$?$*$Z
M'GWB\<22@.U(#PAJ3RS<M^LM:EKEU?Y?=$-5;CDJ?#I,G7]2=*+#OFM2E*@Q
MH\S"IDM5;GH-4GH%/A3$S$B.P7(@ANOQ'G@&O$D#S#2Z73*)3*=1:+3I&D4>
MD2,I2Z32:7*2]/IE+IE/EX<I(4ZG2$I#A2LE(R4K"<A08,)QV'#ANAUT``!`
M>%]1.5SEEU>N$7;JSRZZ$ZH76)*6I@N;432/3^];A%-DWHKTI3Q6KEM^IU(2
M4J]&?,.%ZSU;A?>X0&E`>;I24E9"5EI&1EI>2DI*7@RDG)RD&'+RLI*R\-V#
M+RTM+P77(4"7@0G`ZXXZ`ZZZ````@)GW'(KC\**XY$AQ''G(D-]T/N/N/@NO
MN/N/`NO./.EA!P(0'@>QN5;E?TONJ#?6FG+?H+IY>TNY/0H%XV-H_I[:5U0(
M=4A1(%2AP;AH%NT^K0W*C`BO.1P[&`C./$/M!*`\YS4K+3TM,24[+P)R3G($
M:5FY2:@PYB6FI:8AO0H\O,0(KK\*/`CPGRZ^X\"Z\Z2"""@/"&GO*WRRZ1W&
M;PTHY=-"=,;M,E-4TW3I[I%I_9=QFG3ST)Z=D#6[;M^FU/X%./0'#%A>MX(A
M<=X@6!`>=D!Z<<RG=Z\C_.%'A3O,WRM:+:RU:!"<@0KAO"R:5,72[+PH8AP)
M;Y5R<*3N1Z6EG!^90S-%R$<7`#B@/&&B'=&]V9RX7#"NS1CDBY>[-N>6C.3$
MG<'R#I]PU>GS,-YU^%,TVH74:Y,TV:@O.`N1(#T-]P^](:4![VWE8UE:BVQ4
M[)U!L^UKZLRMP8,O6;1O*WZ3<]L5>7EIB#-R\"IT"MRD]2I^#+S<M#BN.Q83
M[KD2&Z\`"Z"`.J:8:%Z(Z)0:Q+:,:.:5Z12]PQ9./7X&F&GMI6#!KD>GN1X<
MA&K$*U*127*G%D8<U%=@O1@^80B/!U@>+0/*B`(`@"`(`@"`(`@"`(#@O.@N
MNEX!YYO""0"\P-/",RP(#E`1PHT&,'S!BPXHAQ(D%\PGW8@<C0GBY%A/ETD.
MQ(;X(>=.((84!R[$AOO1'''W'GX3P=BNNO.O/0WGG'8CKL1T$EQYYQX/`',$
M%`9H"*%'@Q_6>IC0HWJHK\"+ZJ(Y$]7&AL]9!B<!/!%<;BZ6$;4!S#C08IBB
M%%AQ#!B&#&$-]U\PHP=<?,**'23#B!R(Z>$L+"#M0$B`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@/DYWRE?U<J/*?;?+KR
M[WK%TZYB.<K7_1[EMT=OV7?FA&L6K3]<F-5;VO>+"D'W9Z)3[5TITKK\U,>K
MQ$-UFT`@?+O2WO*=<.9[G,Y%.8V7D*OIYRUZ271;7=\\W&G\W)5:G/2G>`<U
MVGESSVH=GQ?7ER3GZ9RU:O:6V':T.9B.OF+.WS%$N\!ZSB`]J+.[T[G#O:B:
M3\RE+Y=^767Y+^8+GML+DYTO?J6LUX2?,Q0+>K7,K/\`+?6]6;ZLM^RC8DY/
MU2OT&>F)2UZ?5!5*/",%^<?F'')OX,!O*GWH_-+3[?YGM186@&ALS8M@\\-;
M[N3EMI$SJK=]*NC4_F)J/,=;>AECWYJ[7(]FS-JZ1Z)R4"X3'JKT#XYK,U.2
MK\.4@N"++.QP/'O,Q6>\`=YM^Z4E[PM_E/<YJ8U]\_E+H\"S;YU@>Y<(ENGE
MAD9RF75=,.KVI*:D1I^F2T2,X_18,*)Z^:$)Z'/P(41^)!`^B?+?J?-]YKW<
M-J7Q=D6\N7JI\RFE5W6G?$UHM?'Q?=^G]6EJU<>G%[SNE^H,_0XLU2GXE0H,
MY%I%1B2(G927C0HC')ASC=`^0^A=Q:%\B4WWA?/GR-Z0UFUN[7T!Y49ZTH=K
MT*XJZ-/N<7FYTANVNS-=UGTC%S5&MNFT+1ICOR+N#48O?!;KJ3\S,NO3T&BF
M=C@>SW=W5;F-Y3.8:0Y:.=.#HSJ9KWS]VQK9SL5?F.T/NZ\:P[5;STWJ.EMN
M77II?%H7G+O.VQISIOIY?UL6_8%3HLQ#HL>ET*)+Q9.#.OO3$V!]KM3K(<U5
MTQOS3N'>5YV'!U#LNXK1%^Z9UJ5H-_VI+W11YJDO7-8EQ3-/J\K1;JI4&=,Q
M3IXRT<2TTY#BAQXNA`?EEA65;7+%;O>;<R'=)VE<NF7+-R[]W)S"Z55K4"E5
M^X[ALOF=YZ]-W7J_1];-,Z97IZLC4>Y>6>BT*X*9<]_NM<NJXJH_37(D^:1,
M188'M!H9RY:`\D?/#W6L#DPG9Z5I_.1R_<Q$#F<F9.\[@O&%S)6786CMD:IV
M5S1ZDQ*I6*K*5[4>2U4JTC*NW9P.34Y!O2-*/17X#\"%#`]K.[UL.TM+>??O
MD;+L6E_)VTX>O'+!>;E$AU&J3E/E[FU(Y6K/ON_*S+N52>G3*3-SW?7)NH38
MAER&_,1WGN$-0'I[1.7^<Y:N](T\YC>9RPN73F$F.\`YMM3J9RVZW63<>I0U
MXY;IRE:`U^KZ06;$H=6JT>P+]TA=T4T8G9:IS]'DJ=$H]PU<QXGPV6F1&A@?
MI.0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0'C
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M-K%8M7D8U2H5]7YJ/7(=SWC=U3@SLS'BRU?JERP8=0AS,J_`B2<]"AQY8P8L
M-QYT#J6D'(1RCZ$#2I_2[1NET&=T3N+4F[M,JU4;DO>[[DMRY]8+?E[4U*KT
M2Z+TN:X;BKU5NVVI2#(S$:I34X^[*P8<.&7'7'0`._TGE9T#H'+W/<JE`TZD
M*!R_5&V[GM";TWH-6N.BTU^VKTJ%5JEU4B'5:9696XI:5KT[7)QZ8]5..//N
MS,1QO`\74!X4T#[L_D9Y8I*]*5HER^6W:-!U$L.:TOO2UIVX+YO.SJ_IY/G\
M_6=-6;?=TW-:T*@3L,F'&EX4I#<BP7GH3S8;SSI`\12/=)\K.D.C7,I8?)U;
M$ORRZI<PNAMT:#RVNAJ%^:Q7=IA9U>I-2IM,HVG\+4N_ZG.6I9EJ3-3>G:?;
MM&GJ31H,["@Q1`XH,/A`]T[,Y<=*K&Y;K6Y4*/19X:+VEH_1=#)"@NUVM4^I
M1]/:+:<O9<.GS%QT:?IM?ASTY0Y?ACS<"9@S+\1]Y_C#SS4!X.Y:N[6Y(>3Z
MK5:L\N&@U&TSF*W9\_8%2D9*ZM0:_;T:S:I4I*KU&WX5J7==UP6Q)R,[4*?"
MB1/42<-][TG2]PQ(@>`O\L7=T<EW)M=UUWWRVZ$T#36Z[PH\.V)ZL0*Y>5S1
M:'9D*JQ*]#T_L&!>=R7%*:8Z<.UR(9P6[;D.ET3X2[#?^"MA0N`#V)MO1G2Z
MT;UU:U%MVRJ/3+UUVG+6G]7J_#<CQIF_9NRK0DK"M>+7(,U'CR<04>SJ=`I\
M-V'#AN/0(8#X>+20/5+EZ[KOD,Y5=4'M9-!N7BWK&U`EJ?<-(MFI/7)?ET4C
M3:C7=,.3-TT;1ZT+QNNX+/T9I%Q188$Y+6K(4>#,0?S%]TP?S-`>_:`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`
M(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(#^0)
M^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"
M]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#
M]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@
M?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(
MY<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?
MN2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H
M!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%
M"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^
M#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^
M@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F
M(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<
M?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2
MH!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^
M%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]
M^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]
M^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?
MF(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y
M<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N
M2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!
M^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"
M]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#
M]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@
M?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(
MY<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?
MN2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H
M!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%"]^#]^@?F(Y<?N2H!^%
M"]^#]^@?F(Y<?N2H#X!(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(
;`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g891272ex2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272ex2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#4@*1`P$1``(1`0,1`?_$`2(``0`"`@(#`0$`````
M```````#!`(%`08'"`D*"P$!``(#`0`#`0````````````0%`0(#!@<)"@@0
M``$!!@,$!`8(!Q(6#@8'"0$"`!$#!`4&(3$'05$2"&%Q@0F1H;'!(A/PT>$R
M%)=8"D(5U187UQKQ4F)RLB,DU"8V)S=7=[<8F#F"HL(S-$1D=)0E-45UM4:6
MUD<X>-@9DE-4A%5EA:7%5F9VMKC2<[25AH?B0V.#T\1G*#KRHZ1YQBE9$0`"
M`0(#!`0(!PD,"`,%!@<``0(1`R$Q!$$2!091<3+288'1(I(3DP?PD5/3%%24
MH<%"4G(SXS05X2-S)'34)355%A<(L6+B0V-$9(2"@QCQLT4V-[+"M"8X":*C
MP\3D=;7_V@`,`P$``A$#$0`_`/W\,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,!\.>^![[FQNZ+N3EY
MMRZ^774?7N/KQ1]6;GB+T_N2A4*-9UK:.0+1GKKJL>4K$C.JK,6%2KH7->K"
MY2#"@24142,D%Z0/9'G?[TC1/DTY%;6YZ8%!K^M-J:J_8=D]!K!LF;D9"Z-9
M*]KFFG3]A42WIF>3-2TO,3-MS<>J1OQN/$3*2480X<6)PH4!MN0CO*](.=KD
M3TTY\J]*4[EKT\U!G+WITU3=6[\M:3DK8G;(U`NBP)E$]><U$HE!CPJG-VQ$
MF)=2DP%^KBA*D!22P'NG):U:-U+3]6K-.U:TSG]*T!)7J9)7Y:TUI^@+G8-.
M057G`JL2W$A=0F(<`/F<8RTH]\H`@7*!JSI7==X7)IY:^IFG]R7_`&;"AQ[O
ML:@7G;E8O"U($5<.%"C7);-.J4S6J%"BQ(R$I5-0(04I8`Q(8#2P=?="9C4-
M6D4OK5I+'U80N)#7IA!U'LZ+J&B)!AJBQD*LI%95<B5PH2%*4#+/2D$G`,!8
MOS7+1/2RJ4JAZGZPZ6Z<5JO2\6;H=(OS4&TK0JE9E8"EHCS-*I]PU>G3=1EX
M*X2@I<%"TI*2"<"P%>YM?-"K*LZBZB7EK3I+:6G]R184"W;ZN;4:SZ#9U>C1
M^/U$&BW/5:S*T2J18WJU<"8$>(5<)=D6`[5-ZAV!3Y:TYR?OFSY*4OV:E)*Q
M9J;N:BRTM>DY/R$2J2,I:<>-.HA7'-3M,@KF84.3,9<2`DQ$@H!+`="1S+\N
M,2S:SJ+#Y@-$HFGUNUH6W<%]HU6L15FT*XE*2A-!K-SIKQHE,K2EK`$K'CHC
MDD#AQ8#OM=U"L&U[-BZC7-?%GV[I]`IDI6X]]UVYJ+2+-@T:?1!B2-7BW/4)
MV7HD.F3D.9AJA3!CB%$$1)2HA0>!HY+6G1RI:?#5JG:LZ9S^E1$-0U,DK\M:
M:T^*8L]"ID)0O.!55VXZ)4HZ)=)^$XQUIACTB`P&5,UFT?K=R7A9U&U7TUJ]
MW:>22ZE?]JTR^K7G[DL:GP@%1)^\*'*U2+4[9DH:2"J+.PH"`,RP'H'HAWO7
M)IS'Z3\W^JFEFH,G)T_DRN#7&VM2I34&I6U;<6>&@]O2]P75?MN0*7<5PSU8
MTDF(,[!3+5Y$),*,2H"&%@)(%7N]>\,JNO?(3R[<VO._3](N3>\N8.#7ZO;-
MF77J%3[1H=7MB)<U4EM/JO0(VH=5I]0F8MYV;#D*M!E_618BY:=A14@(BH2`
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M+5J5_4.%`X?7Q:Q9TG58UQ4R'!XAQJCRR`EX>P&<GK/H]4=09W26GZKZ:S^J
MM,EESE2TSD[ZM>:U!I\I"A"/%FIVS(%47<<I+0X*@M2XDLE(27DN8#`ZU:-B
MR8VI9U:TR&G$M/JI<QJ`;\M;ZR9>IHJ*:0NG1KK^FOTBA3Z:LH2I@JCB()@B
M&[C]%@.+OUMT8T]N"V;2O[5S3&Q[JO54-%FVS=]_6K;5P7:N+&^#0DVS1JU5
MI*HUY468_&TB5AQ2I?HC'!@%TZV:,V-=UN:?WKJWIC9]^7@88M*R;IOVU;?N
MZZ3&CJEH(MRVZM592LULQ9E)AI^#08O$L%(QP8#UJY<^8[7S5?F:YR='=3=`
M[/TRTOT`N:P*/HSJ?0M=K#U(N+6*F752*Q4:Q4KMTRMF/%N?2&/3/@,JN6@5
ME$&)-HFU)AA1EXBR!['6/KMHAJ;7Z[:FFVLFE6H-TVOQ_7-;5CZAVC=E?MWU
M4<2L3Z>T>@U>?J-(]7,J$-7PB'#<L\)QP8"I/<PN@-+BT27J6N.C].CW+=%3
MLBW(,]J99<I%K]Z46;A2%8M"B0YBM0UU6Z*3/1T09FGP!$FX$5:4+AI40&`\
MO+6F&E2UJ2A"$E:UK(2E"4@E2E*)`2E(#R3@`P'BFQM>M#-4*_6[4TTUGTGU
M#NFVDK7<=M6-J+9]VU^WT0XZ9:(NMT>@5BH5&E)AS*Q#48\.&`LA)Q+F`KU'
MF&T!H\2E0JOKCH_2HM=NNI6'1(51U,LN1B5F^:+,092L692D3-;A*J%UTF;F
M8<*9IT$+G($2(E*X:2H`@=COS532_2R7H\WJ=J186G$K<-5@T*@3-^7A;UH2
M]<K<P[X/1Z/&N"HTZ'4ZK'XAP2\$KC*?@DL!\YNZJ[PV[>\-MWG%K=VZ<6WI
MQ$Y9N=_6KE3H<&VZY4JY"NFWM+Y:UYFG795(E2E98R58J?T_6F-!@\4`>K24
M$/(`'C_O@N^2TU[HVT]&:G<NCMYZ_7MK56+[-#TZL.NR%"K%+L72VVH%RZBZ
MAU*:G*56RBAVO+U&2$5\!*."/$BKBPX<"(6`^DVG',5I%J7H;I'S$4R];>HV
ME^M=G:=WG8UP7-6Z30Y.H2>J-)I=6M"E_"YZ=@R:J[4OIO!ET2J(BHJYHF$D
M*7@P'<;2U8TMO^M75;=B:E6!>MQ6+/"F7M0+2O*W;CK5G5)42-"%/NJE4>HS
MD];T\8LO$2(4W#@Q.)"@YZ2X#26_K[H3=E\U#2^UM:M);EU+I`FC5M.[?U'L
MZLWS3!(@JG34+2IU9F:_)"32DF+ZR73ZL#TG,!\V^4+O/QKKS9]YCH#K!2]+
MM&K*Y&]>-)=%K`ONI7O]*H^I,YJ;1[XGX4&N&Z(U/I,K<"YBT$IDY626I<<1
MEI"5&&%*`^J\_>UF4JYZ%9-4NZV*;>=TRM3GK9M&?K]*D[GN.2HL'X16)RA4
M&8FX=5J\K29?TYF)+PHB("/264C%@/7#5'FLM6'H?S"WWRP5[1WF8U6T2T^O
M"XY72JWM<].:-)SMX4"C5">I-IWM>D6L3E&TVEZE/R7J8TY53`@RR0I2RD))
M`$6D/-12H_*_H?KOS8SND?*Q=.I]EVS5[EM6XM<=.ZW95N7=6Y!$W'M>W]5(
M57D[0O0(?Q08TC'BHB(+DE;BH@>U].J-/J]/DJM29Z3JE+J<I+S]-J5.FH$[
M3ZA(S<)$Q*3LE.2RXLO-RDU`B)7#B0U*0M"@02"]@+C`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`?EF[Y/3BS]9.^C[C+1_4"F0:U8VJMF=Y%IQ>%(CA!1/VS?'+O(6S68`XTJ2
MF*J0J:S#4X\$0)4,0P'QB[MR4U^YF^9CEV[L37VW:A-Z?_-_T\Z>H.IE=JRT
M1J%JC?=O5^LV#RGJ5*Q.,0!IX*P9JB`O$Q2)2,4DHQ8#I_+AK5HE8G<H]R%I
M1JORW<J.M%:UPYD.<BDZ>ZI\^-V71;W)GR[U.W]8;ZE:]=6LDA;\1-/N:?N"
MF7,)>DRE1X8$/X-,Q4KAK3Q,!X*M&L4=7<]_.8[5M2M:'3VFE$YHN5>M6=2^
M6,7%*\L,G,W)KA:\O4:MH/2;LG)ZJ2-AUHV])(IRS$B(C2LG+^I6N`B"6`^L
MML\I?+YR-=\%\WCJG*W8@TNJ?,3RQ<PT;7NITBNU^K5C6B=EN79=VQ*Q?LU6
M*I/1;GN.KW#7YF;C3$7TH\RF7P`EI<0@/A[S#Z_:`:P6!H'S"\OVA'=R<FUS
MP^\RM*-:&FU@W9J9=7>OT6-;FIU6BUV]M>;JJL]#@TBS*O5YR'-QH,_"B0(<
MW$DDRD<+2(;`>U'>:SNDNJO>2]\?H)JK,<CU#NK6:].7'3C3WF*[PR\[ITYU
M3Y5:);.F=KS]:N7ESIU-L:^A5=/:@)I?P2+3Y^B1YL&7C34&9E(ZT*`\S\Y6
MG^G^D_>D<J6BM9N;NT5\FMD=UC8M'Y.+C[PFV[EJW('>TU4ZY)Q-3[ZTZ@Z;
MW%2M/Y;6"^*I%G:DFH3<]$EC(Q81"U3*Z4L@=/UCY8+1HW=\=RURPW3S.:5\
MWFBE[]]>K3REWIRX77?<MIK1M)=0ZQ&MNZ]']/+VK,U+W6FF42K56LP(,Y)S
M2A"3/)3`CQ"@15`>S]H]U=R`5KOG^^!Y9Y[E\MH<OFC7)!IIJWIEHK*5ZZ9'
M3NR-4;IT?M&!4M0Z1;<K78<LB[*=#N&?B4Z:C>M-+B528B2PAJB)*`/FI'O?
M4VM]U+\VXA:@W'I#-<J\+7KG$HVJM0YMY*^KFY2(%^V;K/<5'Y>Z'S'T^RYZ
M2J<[85$MR%69>G2L6.B4A2\*8$?\A08Z4@>QNMNC=KZ8=T'W]ER6%S4<A.L^
MF^J]Y\D-[0=".[NFKKF>6_EQOZ+KG:TA6HMJRMQU"M4F@'4>2D)*)\`IT[,I
M@Q:9PD0(4*5@(`]T?VC_`"K\JO>Y=PU9^A6EM,LVWN;SD\YG+3YH*>NKUNNI
MY@:36.6VJ5*NKU377*E/JNVH7-/7)-QZA'C>E-+3!>`):`(8':_FYFB7=S2.
MN7>@Z"7OIAR_GFII'.YS>:86II#>=O2-5O=/)K2ZK8M.59D&S;FAS\E4])9"
MXJ4J#$@Q8$9`C(X8I(4AX&Y^<(6EH/I?S>6KS?+U@[O34^_>6?DNBVU<G=D=
MX!(RT2U]1-'ZM>-WU*FWCRP4285"DXNL]<CR,Y29*#(0?7PETV73ZT"(B`L#
M]%FC^H%O:J=U#8VH]IZ4SFA-I7CR'4^O6OHS/*BKBZ6VU.Z%^LH5C0H\Q`E)
MB9I]M4D0I65C1(,&)&E8<-:H<-2BA('Y"^2GO1^1[13YL7,\H5PZKVOJ#S9:
MF:*\VFB-H<K%IR56N_5*KW[KKJ7J]0["E9^V:13)PTV3^"WA)U<QXZX:52@2
M(!B3*X4!8'FOEAT%U#Y6.?\`^:^Z(ZX24W;FIMA<B7.;'O:B5-0^G=F5"X]-
M=5KVC6Q.I'KE2]9LBF5\T^-#1QB#&DXB$\03B!X,[MVLZ4<G_/#HURU<NL[W
M?O>4W!S#4KG(U0Y5N?;0F7AS'/EHE>-4TNOZMPX/-_&/TQF_I3<2*JJE)E:I
M'AE")B9C!85+"48#SW\WGJ/<_P`SI'RGU76B8L>=[YJI<RFNRKAF;T5?4QS7
MQ->)^OZJPHD>XTP":R++5I-$?/*K`^M],\8YFOZ:<3`?&JYN;KERM'YLMK!R
M$UW4*0I7-[3^=VX$U70*+2*RF^+>D*!KQ0+MJE>N*013O46_;,C2I)<H9^:B
M0I?Z9\,@%&9(AL!]..]LG>7/E9YZM?>=2K5WN]^\&BW30N4[1S7WNY.9\%7-
M]I!.2%BV#3;>F>3#BA5&JT]%>HE6DZ].SM/E3#@KG)A2D3*H2E0P.>\HNKEV
MY5N\;U]YTYR+R(=XF-<-7.66P-9^0KF#@/[Q/EFOJB46UZ;1:=RJI2NH5:GR
M\!,:7F9F8DH"90Q3`E%(C_!C,L`YE*GK+1K@^>'U'EZC5^7U+AS'(\F<F+/5
M-IN:4TSG(5>E]8XTHNF?DZ#"E]+(]<^%K21ZJ3$RH$%)+`4;3IG=L_ML_F[2
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MQ)Q%'(?,?`'@?2_YI%#T\@\J'/S`TC%41I3`[S376%IE#KHK*:Y#T\3I[I"+
M*36D7&$W"BJBVO@WP@3X$YZWB]</6<3`>GW,I=G-=S]]\]SOWGRO\DEN<^>A
M?)CRU7/W;,W0KFYC+"Y?+7M2^=>*#6D:\712:M=\A6OKENV%!G+BM.;@2L$?
M!I6#`B1EH)@)6!\M[VUKOR<^;@ZU<@NO:)ZU>8CNV.\8TEY>[ZMV-6).8KMM
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M=OID)?3[F@J,A#C4VI:U5VHQ)6I1X\68,VF+)*"A'$94<`9ZV63I!(\C/<U<
MSM3Y@N0*L:M<KO=C2]T*[O\`[QR6@5#1WF$TQN:5J<"HU_3"GU*8@TZ?UHGJ
MA0)RFT^5@HB3<S/2=/6(D`2Z1,`?M)[K+5:U-<.[MY/M5;%T/1RVV;>.B-IS
M]L:'2T68F*5IS1)6#%IE/HEMS4W+2<S.6?%EY%,S18\2#"5'I,>7B%">+A`'
MOVP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P'4ZO85C7#<MK7G7[+M.N7A8QJILF[*O;E'J5RV>:
M[*HD:V;6KL[)QJI;YK,E#3!FO@D6#\(A)"(G$D.8""E:<:>4&X+ONVAV'9E&
MNK4$2`OVYJ5:]#IUP7N*5+19*EB[ZS)R,&HW**;)QUPI?X;$C>IA+4E#DDA@
M.F57EQY>:[IQ):.UO0?1FLZ1TV=54J=I95=+[(J&G$A4534W/*GY*R)NAQK9
ME9U4[/QXQBPY5,0Q8\1;^):B0+7V`-!_I#=5J_83TC^M>^H5`E[VMO[&]F_2
M&\8%J2LG(VO!NJC_`$F^E]PPK;D:=+P9!,W#C"3A0(:((0E"0`.SS>FNG-0K
MUG75/V!94[=&G<K/R.G]R3=JT*9KUC2-4DH=-J<G9U8C2"ZA;,K4:="3+QX<
ME$@(C0$A"P4@!@.@1.5[EGBUZZ;JB\NVA<2Y[YJ%.JU[7'$TDL!=>O"JTBJP
M*[2:G=-85;YJ%P5"F5N6ASDO&FXD:)!FH:8J"F(D*`'PLUE[A/5B[=4.>*KZ
M-=X%$TPT7[Q"\+@N[F.TXU"Y1M(]?M0)9=UTR>HU?HFENMEYW'2Z]9-$32*K
M,2=)@F0FC098PS)E,>$(Y`^ONDW(/RNZ8<K>A?*'5M*K.UFTBY?K)H%EV1(Z
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MZ":+4+2FN1H4Q6M,J-I;8U+T]K$Q`F)>:@1ZI9<E0H%MU"-!FI.#$0J+++4F
M)"0H%Z4D`=TG--M.JA<-H7;/V#94]=>GTI/T^PKFG+6H<S<-D2%5DT4ZJ25H
M5J-(+J5M2E2I\-,"8AR42"B-!2$+!2`&`U5)T9T>H.H==U=H>E&FM%U8NB0%
M+N;4^DV+:].U#N*F),J4TZNWK)TN#<E7D`9&`1!F)F)#_&48>@EP&KU$Y?=!
M=7JS;]Q:LZ(Z0ZH7!::@NUJ[J)IK9E[5FVE)C&82JWZG<M%J<[1E)F"5@RRX
M9"_2SQ8#RQ%EY>/+Q)2-`@QI6-!7+Q9:+"1$EXLO$0842!$@K28:X*X9*2D@
MI*2YSF`\.6=RW<NVG=:A7+I_H)HM8UQ0`I,"OV=I;8ULUJ"%@A0A56BT*2GH
M84%%[H@>]@.^5*P+$K-VV[?U7LJTJK?5H2M4D;3O2I6Y1YZ[;7DJW!,M6I.W
M;CFI.+6*)*U>7/JYJ'+1H2)A'HQ`H8,!TZQ>7S032ZY[@O;3/1#2'3J\[M];
M]=5W6+IK9EHW/<WKXZ9J-]<%?M^BT^JUGUTRA,17PF+$XH@"CB'L!/2=!M#:
M#J-5=8:'HQI11M7*ZB/#K>J=)TZM"G:C5B'-(]7,HJM[R='@W-4$3$/T8@C3
M2PL8%[`:B>Y9N6^IU6^J[4N7W1&H5S5&%`@ZF5F>THL.;JNHL&5GY2JRL*^J
MC'H,2;NZ%+520@3,--07,!$Q!AQ`Y:$D`7:UR\Z`7)J%1]6[BT-T>KVJUNID
MT6_J;6M,[+JFH5"33DI13TT>])ZB1[DIB9%*$B"($R@0@!PN<P&50Y>]`ZOJ
M7):SU70_2"IZPTSX/]+=6*AII9<[J73_`()#3!E?@5]S-%B71*?!H*$HA^KF
MD\"0`'`,!V^CZ>6!;U<N^YZ!8]GT.Y=08LA'OVX:/;-%IE<O>/2Y6)(TR-=]
M6DI*!/W+%ITC&7!@*G8D8P82RA#DDA@.H:<\O>@6CU8KMPZ2:'Z/Z6U^Z01<
MU<TYTTLNR*Q<05'3,J%=J=LT6F3M7"IE(B'X0N(]8"L\6`V,/1/1F%:UVV-"
MTCTQAV3?U7J-P7W9\.PK51:UZUZKQI:8JU;NVWTTD4FXZO5)B3@KF)F<@QHT
M=<)"EJ44I(`[[*TBDR-)EJ!)4NG2="DZ=!I$I1962EI>DRM)EY9,E+TN6IT&
M$B3@4Z!)H$)$!*!"3"`2$A(<P'B&S>67EMTZF:=.:?<OFB%BSE'N&H7=29NS
M=)[#MB9I=UU:G1*15+GIT>B4"1BR5PU*DQ52LQ.PBF9C2ZC#6LH)2P'8X6BN
MC<&V[RLV#I+IG"M#46KU.X-0;5A6':T.V[ZKU:5+KK%;O*AHI0I=SU>K+E(1
MF9F=A1XT<PT%:E<(<!4O+0?0[46DVC0-0=&=*+ZH6G\:3F+"HMY:=VA<])LF
M8I\O+RDA'M&G5NCSTG;<:1E92%"@JDD050H<)"4D!(``[?;-CV591KZK-M"U
M[25==PSUVW2JV;?I-!-RW75(<O"J=SU\TJ4E#6+AJ,*4A)CSLQZR9C)A("UD
M)#@(+3T^L*PEW%$L:R+0LR)=]PSUVW8NT[:HUNKNBZZH4FIW-<2J/)2:JW<-
M1*!Z^=F?6S,9PXUES`=0JO+YH)78]X35;T0TAK,SJ%5*#6[^F*KIK9E1CWQ6
MK5B18ML5>\(TW18T2Y:I;D6.M4A,3ICQ9-2U&$I!)8#N,S8-B3EYTW4:<LJT
MIK4*C46:MNCWY,VY1X]YTFWIV,N9G*#3;HBR:JW(T6;F(BHD65A1T0(BU%2D
MDDE@/&](Y7.6:WZK/5V@\NNA5$K=3NZDW_4JQ2-([`IM5J-^4&/,S-#O:>J$
ME;\&;F[NHTS.QHDI4HBU3DLN,M4.(DJ42!W(Z<6[04:BUC36W[*T^U"U&EH\
MU7+ZIEE48S]:NJ7IDU(6]<MZHD$TB=O>-0HDP%)ASDWQK@A4),6&%D@#T&[K
M7NSK-[MCE-K'+;-7Q"U[N#4+4?4?5?6O4VO6/3K51JE>.I,>!+52+4K-%6NB
M3E:9+VQ39*F_!ESDS#C(EUQ"$"*8:0/=:RN7'EYTVMJZ[+TZT'T9L&SK\A3,
M"^+3LK2^R+6MJ\X$[+3,G.0;KH5#H<A2[BA3<G.1H45,Y"C")#BK2IZ5*!`I
MW5RP<M5]4BS+?O;EYT-O&@Z<2\"3T\HEU:2V#<-(L.4E4PDRTK9E-J]OS<E:
M\O+I@("$2*("4!"7`.#`>;)>7EY27@2LK`@RTK+084O+2TO"1!EY>7@H3#@P
M($&&E,.%!A0TA*4I`2E(``<P$S`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`>CZ^9.^$J(%-
MMHN#W_`ZB[^V>3?&#YRXHE7<L_%+O']&1]TG+;Q=[64_*A\V:^+S.7Z@EU-M
M=W\Y5(X?^]`W"YSQQ:'X%CT9=\DQ]SW+#SO:ST[?S94B\TE_H?PTRU2YSR9*
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M3ZKL_P`1../*WIO1GWS/^!?*?R^N].W\T2HYL=1E%WTJM%W\XU3ZKMU_Q!XU
M3\WIZ_DR[YB7N-Y12KZ_7^G;^:)T\UFHA.-+M/\`H&J#_I=LKW@\:I^;T_HR
M[Y'G[DN5$Z*_KO3M_-%E'-/J"ISZ7:H>7?R#4_JL6V7/_&G_`+O3>C/OD>?N
M7Y6BJJ_K?3M_-%U',]?RAC3+6[)*I=6VJ-UM\^\8E@[>G]&7?(TO<[RPLKVM
M].W\V7(7,M?:\33;8=AE)U+;_P`J;VE1YVXK)5W+'HR[Q%G[I.6HNGKM9Z5O
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MMDJ'V2T[^7VQ_?3BOXECXI=XQ_<#@WRFH]*/<)SK1=#@?@5%S=_(TX__`-N8
MN=.*O\"Q\4N\:SY"X,EA<U%?RH]P#6BZ"Y\G11B/Y7G,B?Y^;27.W%DNQ8^*
M7>.7]Q.$?*:CTH]PR5K-=`)`DZ+AM^#SG;_+S<'SUQ=.FY8]&7>,_P!Q.#_C
MZCTH]TP&M%TD@?`J+B/]SSGY>;B^?N,IT]7I_1EWS']Q.#_*:CTH]PX.M-T@
M%TG1#B[^1YQW_MVYN$O>'QJ+IZO3>C/OF5R)P?Y34>E'N&"M:[I3_*5$._\`
M(\Y^7FBS]Y/'DL+>F]&??-H<A\&E*CN:CTH]PQ^S;=+A^0:(_#^5IS\O9M%G
M[S^8(NBM:7T9]\Z/D#@J_P!YJ/2CW",ZWW4'_D*AX%W\C3GY?V-PE[U.8DZ*
MUI/1G\X9_P`/^#?*:CTH=PB.N=V#^4:%O=\&G<OZ/:%/WN\RQDXJUH\_Q)_.
M'>'N[X'*C=S4X_ZT.X0*UVN\/_(-`>\._(L]@"[_`(P:)/WR<T1E16=%Z%SY
MPE0]VO`9*KN:KTH=PA7KU>`RD+?R+S\%GNS^N#0-1[[N;+4-^-C0Y_B7/G3K
M/W8\`C&JNZJOY4.X1'7Z\L2*?;^&7Y%G\M_]4=C5L_?QSC%5]1P_T+OSIF'N
MPX!)8W=57\J'<*AYA;T?A3[=<_,RL_D-O]46X2]_O.:_W'#_`&=WYXD?X6<O
M?*ZOTH=PX/,->@`)I]NO.0^"3_GJ.31;G^8/G:.6GX=A_P`.[\\2(^Z?EN23
M=W5^E#YLC_;$7L\OI]N.&?Y$J&[^R319_P"8OG=)TT_#?9W?GC/^$W+=*^MU
M?I0^;(U\Q5[A/$FG6V][@#*5#+?A4@W"7^8_GI9:?AGL[WSQF/NFY;;H[NL]
M*'S9".8^^"\_2ZV@`_.4J&/5_3-N4_\`,ESW%56FX9[.]\\=/\(^6OEM97\J
M'S9$>9*^7N%-MK!X_D.H[\/ZYY-%?^9CG[ZMPOV=[Y\?X1<M;;VL].'S9S^V
M0OMP/TNMG^@ZE]5&?^ICGZE?HW"_9WOGSI'W0\L-8WM97\NW\V<?MD;[_P"#
MK9_H.H_51L?^IGGWZMPOV=[Y\V_P?Y8^6UOIV_FS-/,??1Q-.MEW\YU$>6J,
M?^9GGZE?HW"_9WOGS2?NAY8BL+VLK^7;^;,OVQU\_P#!MM]7P.HO'_.;9C_F
M8Y]>>FX77^#O?/G/_"/EI_[[6>E#YLR/,;?`<?I=;3CM^"5!SQO/TS:7'_,E
MSV\7IN&>SO?/&?\`"+EK+UVLK^5;^;./VQM\O/\`2ZVR'/PE*ANVOJ32[?\`
MF+YXE%2>GX;7^#N_/$6Y[J>7(R<5=U?I0^;)$\Q=[J#_`*76W_0E0^J3=H?Y
MAN=GGI^&^SN_/'"?NNY>BZ*[JZ_E0^;)1S$7LH$BG6YT?D2?W[?Z8M*A_F`Y
MTEGI^'>SN_/$9^[3@"_WNJ]*'<,AS#WJ2`:?;N+_`.5)_,?\H[6E6_?USC)X
MV.'^A=^>.<_=MP*.5S4^E#N$B>8.]"Y]/MW'/\BS^![:BUG;]]G-LE5V=!Z%
MSYTBOW>\$3IZS4^E'N$HY@+S>XT^WG'`'X+/O?\`^\<FG6O?)S1-)RLZ+T+G
MSAPN<@\&AE<U'I1[A9@Z]WA$?Q2%`!&3I6>\&-0:PM>]KF2;2=K1X_ZD_G"O
MO<F<*MNBG?\`CCW3@Z^7@\@2%OX;Y6>QWN=4&L;?O/Y@FTG:TM7_`*L^^09<
MJ<.5:3N_''ND@UYNXEQD:`,\?@L[]4&GV_>+QR>=O3>C/OD6YRWH(+"5WXUY
M"<:ZW:YYDJ"]V0EIW\OM86N>^,3SMZ?XI=XJ[O"--#)S^->0Y&NMV.),E0?Z
M&G?J@UI:YNXG<C5PL_%+O$*YH+,943E3Q>0C^SQ=K_Y`H/2/@TZ_K_J@UC;Y
MCUTTJQM_$_*5]ZU&VO-J/L[W<\@R%!</YEGMO_*#6%KC.JFE50^)^4K9WYQ;
MI0Q5KQ=P<Z0H./\`,L]L_P"4-[6%K77KF:C\/&0KFOO0;24?N^4KJU^O!+W4
M^WR7@#\BSW;_`%Q:PM7)3SH5]SC6JAE&'Q/RD:^8"\DC"GV\?]ZSSO[8M,A:
MWG1LK[O,NN@_-C;^)^4@/,)>CB13[=P_F2H?5)I]G0VYOSF_AXBON\W\2@\(
M6?BEWBG$YC;V2\"FVWT'X)4"/%4VG1X1IGMG\:\A77N>>+VTZ0L8?ZLN\4U\
MRE])XG4VV,,GR=1W]%4:5#@.DEG*>/A7D*N[[Q^-PRMZ:OY,^^5%\S=^)>ZF
MVO\`T'4OJJ&D+EW0M8RN5ZUW2NN>]'F&&5K2^C/OE%?-)J`D%U,M1^.<E4_J
MJ_%IMGE3AUR&]*=ZM>F/=.*]ZW,+5?4Z3T9_.%")S6ZB(_K5:9_WC5-[O^%V
MF1Y,X6\YW_CCW2)=][O,L,K.C]"?SA1B\W&HZ/>TFT.V0JOU8#=H\D\):KOW
M_CCW"!/WS\T1C7U.B]"Y\X:Z+S@ZFH?PTBS,!_P?5_JTW>'(?")9W-1\<>X1
M)^^[FN.5C0^A<^=*$3G+U03E1[*VXFG5?LRK328^[_@K6-S4>E#N$>7OSYM6
M5C0>A<^=*:^=35)+_P"DUE$OP_I=6,O_`'VW2/N[X))5=S4^E#N$:?OYYPC_
M`,OP^GY%WYTJQ.=K55&5%LC^"IU9P'2/IXVS]W?!/E-3Z4.X19_Y@.<HNGJ.
M'^SN_/%8\\.JP?\`TDL;#_BZL_5UB]W?!*T=S4^E'N'"7^83G1+#3\.]G=^>
M(%\\NK"<J'8QPVTVL_5UNG^''`OE-3Z4.X<O_4-SO]7X=[.[\\1_MZ-6G/\`
MI'8F;OZF5K#_`)^;/^&_`OE-3Z4.X8_]0_.WU?AWL[OSQRGGHU9)<:'8FUW]
M+:UL_P"7F?X;\"^4U/I0[@_]0_.U:?1^'>SN_/$G[>35C/Z26([#'Z6UKZO-
ME>[?@7RFI]*'<.L?\PG.K6.GX=[.[\\9(YX]5U*X?I)8K]KJ;67`=/\`3[!G
M^&W`J_G-5Z4.X=__`%`\Y4K]'X?Z%WYXNCG;U4>`:+9!>YQ%.K+NK^KC;3]V
MO`HJJNZGTH=PQ'_,#SG+_E^'4_@[OSQ>A\Z6J*\Z-96[^I]7^K>YH<O=[P2/
M^\U/I0[A(C[^^<7G8X?Z%WYTNHYR-3U._I/9>_"GU?)_]FFT_P`/^"_*:CTH
M]PEP]^G-TE7U&@]"Y\Z;*#S>ZE1#C2;.V94^K;<_Z\EH]SD3A$,KFH]*/<.\
M/??S9)XV-#Z%SYTV/[;#4?\`X*M'^@*I]5VX_P!R.$_CW_2CW#O_`(V<T_(:
M+T+GSITZ+%LEY!E[OZ73E"Z<WR+?QNY<-2Q6I^.'=/MQA9YB3[6@]&]WS3QX
M]BA1?+WEB=D[0=G1\`:'=N<*RDM37KM]TEQM\QY;W#_0O=\UL>/88!)E[UQP
MPG;>Q)_Y/V-%G/A+>*U7I6^Z3;5OF79+AU/R+_?-5$C:?D@F7O@XY?#K<VOS
M!IV3:[_"*]G5?';[I.M6^9UE/AOH7_G"HN-IXX_D:^AU3]N8_P#-S-_A'1JO
M2M]TE1M\T_C\-]#4?.%94?3QY_(U]X9CX?;3O[6M7.?!JO#6>E:[I(5GFO9/
MAGH:CYPC5,:=.#Y:_,]D];3\]O\`2W`!F]P>F6L]*UW3#L\V?C\,]#4?.&(F
M=.L?R-?;W/\`Y/MKK_X-R;&]P?HUGI6NZ:3L\UI=OAE/R-1\X9)FM.7'\C7X
M1TSUM#P?TM9O<'Z-9Z5KNG)V^:OQ^&>A?^<)8<SIT3A*WWU&?MK=_8YF]P;:
MM9Z5KNF?5<U/.?#?0U'SA>3&T^V2U\`9_P`GVV[^US2U=X,UV=7Z5ONB4.:/
MQ^&>AJ/G"PB+I^7.E[WPP>9ZW,?^;FSZW@R?9U?I6^Z1IVN:/Q^&^A?^<+\*
M+86`$M>NYYGK=.WHI_2VT;G!Y/!:KTK?=(%VWS,U5SX?XH7^^;%$6Q0"Z!>>
M3Q^3;>Z-U/VMVA<X0GV=53\JWW2'*',FV7#_`$+W?+\"-8^#H%W]L[0';MD@
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MWW3/J^+_`(VE^*YWB,1;8>[U5Q=DS2NK/X,T>3X17LZJOY5ONF/5<7?X6E^*
MYWCGUEL./XU<+@K_`'12GDNW?!6BW)<'4L8ZNOY5ONF?5<6Z=+\5SO$,:):[
MGF'<6]XF:2'>&5Q:!.7!:8QUF?XUKNFT+?%T^UI<OQ;G>*_K[6R,.Y/Z)I7A
M_D1HDWP/>?FZWTK7=.WJ^+MUWM+Z-SO$:HMK$G\9N1W\\TG'_P#I-[0W+@.\
MVXZZOY5GN#<XN\-[2U_)N=XA7$M5[O57*<`3^2J1MV?R(6K;DN7O6-N.OK7\
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MJ?PFF^;,QCS!GO:'T+W?(..RW%'J+MP`>?A="_*+@W";Y+S]7Q>G\)IOFCJE
MS#GO:#T+W?(O666!C+W<\YGX70WYYO\`@+5]S^Y*?YOC'M-+\T''F%OM:#T;
MW?.?668X?C%WN(_W90_RBV%'DIKL<8I_":7YH[PCS#3M:#T+W?,.*RWO]3=_
M]&4)W_L+9W>2?D^,>TTOS1MN\Q?C:#T;W?)$JLTY0+N_HRA.[1\!R+8DN24L
M8<8I_":7YHTG'F%1QEH/0O=\D$2RSA\'NT'^>Z&,!L_D+8VUO^Y+=5;XQ3^$
MTOS1PW>8<]_04_(O=\D*K,2.$P+L<<?Y+H?:_P#(+6$7R6\?5\6]IIOFQN\P
MO'>T'HWN^9`V8`_U%VG!Q'PNB.<\_P`Q-,MRY.<4E;XM[33?-$&\N/NXTYZ&
MOY-[OF879B.$"#=;B]P,W1-COYB:7:_N@\?5\5I_":;YLBW%QUNKEHO1N]\S
MAQ+-#P(-V=LW1-AR+I)IT/[IU34.*>GI_FR')<;<J[VCS_%N]XEXK.P/J;K#
MR/Y;HN'3_(33[+Y3K16^)^GI_FSE./&JXRT=?R;O>)1%LX@'U-U..!_)5%=A
M_O)KJTN6J44.(^G8[A7W%QA2IO:6OY-SO$XB6@0[U%TX`8_"J-X?Y#S#6FG7
M+JBJ0XAZ=CN$:ZN+[9:7T;G>+4*+:?\`M-S@O_W51L7;<)-VUK?3KE_"D-=7
M\JSW"HU"XDY.KT_Q3[QP8MH\1)@W1LQ^%4?-[L?R'@UK97!-Y4CK*_E6NZ5D
MUKU7&Q\4_*9"+:22`85T9@/,U1L'_P"\\FMK,>$;(ZOTK7=(5WZ:\W9^*7E+
M'K[3=_&;FS_W51\MF/P3$%KJQ^RMD=1\=ONE%?\`I"=).W\4O*<F/:0`'JKF
MQ&R:H[QM_P!R-<Z>&A<$XJ_GTP\A675>WG5PR\)$F-:3_P",W.][OY*HV7]!
MM=:=:.N"N_''R%5?WJ8T)/76D]WJ;F)RQF:/E_0>QK>U'3X44Z=:\A27]VDL
M_N&*XUI8$PKFRV35'=_['O:TLQMYI2^X55V=E*K4_N%`Q[0>?QFZ=N'PJBYD
MY_R'L:ZL15,"FORTNWUOQQ\A"N/9X>^#=0?_`#71</\`^BVM80C-885*J]/0
MUQ5[XX>0IJF+-Q?`NO\`HNB#_P#)%K2Q"]FMS[I4W[G#75TU'QP[I0CQ[+Q)
M@7:7#9.4+=GC(M:6HZFO^[IU2\I2W[G"5%J2U6/^M;[IK8D>R-L"[\O]VT#\
MHM/C;UE4T[7Q2\I2WKG!-L=9Z5KNFOBQ[%<7P+RP?_+MO[,\Y!I<+>LZ;/Q2
M\I37Y\">.[KO%*UW#718UA@DF7O3?A/6]E_[OZ&L]/;UZA@]/2O1/O$+UW+]
M.SK_`$K/<-1,3.GV9EKX<<G3]M[NFG$-/A#B=:5T]>J?>(%Z]RY3SH\0].SW
M#3QIK3LDOEK[V?R_;0S#MM-:7"'%*5KIJ=5SO%-=U'+#JG'B7IV.X:N/&TXQ
M?+7]UBH6N/+3#N:3"WQ;!J6E]&YWB%*]RM2CAQ+T['S9K(L?30YRNH(VX5"U
MLNVEM*A#B_XVDI^3<[Q#G?Y4H_,XGZ>G^;-;&F=,4X*E=1']%1M0X;/ZU-+C
M;XRE@]'3\F[WB%>O\I[8<4]/3_-E"+,Z7$8RNHV?_"5I?4IMMWC-<]'Z-WO$
M*Y>Y0K5PXKZ>F^;*:IK2HA0^!ZCY./\`3*TG[?\`BEBAQFJ\[1^C=[Q$E?Y-
M2['%O3TWS9KUS6E3W?!-2WOS%3M$?]$-WW.-?C:/T;O?.+O\G?B<7]IIOFS'
MX3I4/Y4U,QS_`*9V@=V']2&.'&?QM%Z-WO#U_)WXG%_::;YLQ5-:5)*2)34Q
M^?\`5.T-_P#8AL;G&NG1^C=[QJ[_`";OI;G%\OE--\V2IFM*S@)74O`X_P!,
M[0...WZ4Y-E1XTMNC]&[WB1"_P`G4['%L_Q]-\V2IFM*RH$2NI0+W?U2M%_]
MJ6RH<:Z='Z-WO$KUW*"K6'%?3TWS9LTS6E^#I/49X<<:E:>(=T4EL7+?'$JN
M6CI^3=[QM"YRCLAQ7'_7T_S9M8$SID["5U$SVU&U7C_FO)H-RWQG\;28_P"K
M=[Q,A<Y2:PAQ3#_7T_S9MX,?38E)$KJ!B'8U"U]G_)C1W#C">,M)Z-SO$VS=
MY5Q:AQ.GY>G^;-Q+QM.CP\,M?N)&)J%L[^BF;&XSM\6:Q>EK^3<[Q-C<Y764
M.)>G8^;-QZ_3_P#VB^O_`'A;?U.:+ZGBO3IO1N=X[>MY8_$XCZ=CN'>(LG:0
M4I]VU,'$?G24?^GPW\#RAP[*6HG['](?>*M3QU/'0V?M2^8-1&D;-4>)5W53
MZ(_G/4<C_P!X6A7+?#F\=3<]C^D)=O4<>^H6:_RK]`:V8D;*(<;PJH`'_4Q1
M_P#\C#1IV>&_6KGL?TA-LZGCZK_1]C[6OF#7Q*?8[N+Z\:L';?K*6<0'?]9!
M@W/U7#<_I5SV'Z0F0U7,.SA]C[6OF"A$D;&Q!O2K8`_W$+_PES;'JN&?6KGL
M/TA,AJN8DL>'6/MB_FY753K&>[Z]*N\X_G'6=@_[3M!=GA3?ZW=]A^E)'TSF
M3+]G6/MB_FY3B2%B\9`O>L!^SZQ8AZ3C]<[/4\+^MW?8?I1]+YEK3]G:?[8O
MYN<?2^Q,'7M6'X!_UBKQZOS4,]3POZW=]A^E.=S5<RNG]'6*_P`L7\W'TOL,
M9WM6#_\``L0^6Z&SZCA;_P";N^P_2G/Z5S+_`&?8^V+^;DR)&Q'`_7K5SL_.
M,L/']\^QM?4<*VZN[[!_.CZ3S+_9UC[6OYN7H4C8QP^O6KD'``V1$`'5^:4A
MI'J>%TK]*N^P_2FTM3S&UAPZQ7^6+^;EU,C8Y][>-6X1A^<E8Q_OE;"L\+^M
MW?8?I2#+6<PK!\/L5_E:_FY<A2-E`^C>-5?N^LM?5_UD;I&UPQ/'5W/8?I2+
M>U/'VL-!8^UKY@V4.2LWA_/=52[_`+'*&S_O$TJ%KAGUFY['](0KE_CR6&@L
M_:E\P78,E:`<Z[:F>NSU#9_WA+3+<.&K#Z3<]C^D(CU/''_R-G[5^A-A"E+1
MR%U5-[]MHJ&6)_K^6[J'#/K$_9?I#A*]QMY:&S7^4_H390Y:U"X?714GN']R
MBAD__C[I9ZOAOUB=/X+](0KE[C3Q6BM5_E/Z$V4*4M5X?<M04[`?F64-F_Z>
M-TMQX=7#47/9?I")*]QE8+1VD_Y1^A-E#E;6X?1N*?RS%LKV_P#+;==WA_UB
M?LO]LX2O\8VZ2U]H_1%E$"V`7FXY_)V-M*^K+9W>'O+43]E_MD2=WB^S26O;
M_HC8(EK:X1_3^>+P"_ZVU8_\\L]5H'CZ^?LO]LKI7N*;SKI;=:_+_HR=$M;3
MG_3Z=_O<4/\`I@MGU.@^7G[+](8]=Q/ZK;]O^C)DRUNK>!7YW`8?F>4';OZ[
MME6=!\O/V7^V<[E[B>[^K6_;?HS,2=O$C^G\]@X_G>(>YV.-6;G.SP]+&_/V
M7Z0Y^MXI]6M^V_1F9@V[_P`/SNP?G>5V_P!=LFA2L<-<G_&+GL?TACUG%/JU
MOVWZ,C]1;@/]7YT8?]7E.<'/?_39H[L<-K3Z1<]C^D,^MXI]6M^V_1A4"W0'
M_3^>`.(_,\K##9_3;<T6[I^%[V.IN5_@/TIAW>*/+36_;?HR!<"W%8*N"=/3
M];JCGM_JN,G-!GI^$TJ]5<I_`?I3I"[Q3>_5K?MU\V8&7MH#\\,\<`[\SJNS
M^NX:+/3<(Q_C=W[._G3MZ[B?U6W[?]$1_!K:!QN*>..7UN*S./\`PNT*6FX,
MW5ZR[]G_`$QCUW$Z?JUNO\-^B*JI>VG^C<4^G,86VK9F?ZLM67-+P3UCKK;V
M?U;],;PO\437\5M^W_1$426ME_YXI\9._,TK:,_ZLM`N:3@6]CKKWV5_/DRW
MJ.+4?\5M>W_1$:I:V7/-R5#(O/UM*^K+5U[1<ON-'K[V?U5_/DB>HXONT>DM
M4_E"^:(/@UKJ2\W)4#N_,PK:<!_5K8&@7-!R[]?O_9'_`#@S;U/%TL-):K7Z
MPOFB(2=K`E]R5`O_`.S"LAG_`%Z:%/AW+B=/VA?P_P"C?\X)BU/&$L=':^T+
MYDKKD;45@;DJ`!#L+77MZJWN#0I\/Y:JW^T;_P!C?\Y)4-5QK=7\3M9?65\R
M1&1M1Y/URU!R2'?F65@`/[.-#N<-Y7Q7[2U%7_T3_G)O])XUE]"L_:5\R8+D
M+3X7?7+4#Q/)/UK*+P[<:YDT7]F\KO!\3U%/Y$_YR;0U/&G+]2M?:5\R0?`;
M32/SSU%Y&?UJJR/_`"XT>?#.56Z?M/44_D+_`)R;O5<<KAHK/VE?,D0I]IDO
M^N:HN>3^=56[^SC0[G#.4_[4U-?Y"_YT9^E<;7_)6?M*^9!D+2']T]1`W?6H
MK#_GQN2X9RJUAQ34T_D+_G1UCJN.M?J5K[2OF3'X#:3W_714>KZU%_5QG[*Y
M5_M34_87_.C;Z3QWZE:^TKYDS3(VGLNBI?WJ*\']7&P^%\JI8\4U-/Y"_P"=
M&D]5QW=H]%9^TKYDX,C:G$_ZZ*EC_P!E58C##^KFQN]OAO*E,.*:FO\`(7_.
MCG]*XV\/H5G[2OF20R-J*3^>>HO&WZU5?5S>TRWPWE7+]IZBG\A?\Y,+5<<K
MCHK/VE?,DHDK5<[ZYZCB[^Y96!=B/ZN;6G6N&<KTJN):BG\B?\Y(5_4\9]:V
M]':^T_H3+X#:I"2;FJ)<\?G65M_Y<:9;X=RRJ?TC?I_(W_.2+/4\7K^J6OM"
M^:,_@=J.XA<U0W#\RRGASG_U[:5'A_+B:7[1O_8W_.""[_%M]KZ+;^T+YHR,
MI:I4$BYZC@X@?6LHA^?_``WM:QT^@Y<>*U]]_P#:/^<'.YJ.+85TMKV_Z(G$
MI:O"`+EJ`>_^Y=>+NCZ=M<V=#P*OZ]>:_DK^?(,[W%-['36_;KYLS,I;`XN&
MY:@,!E;"_OO]F^AK6UH^!*E-;>S^K?IB)>O<3VZ:W7^&_1DB):V'!URU`G%_
MYF%AXR?_`%;R:VT^CX-^#J[OV?\`3%1?O:_>=;$%_P";^C)!*VSB#<E04[/\
MS*GXY?UZ:WL:/A*:IJ;E7_P/TI5W+NLQ_>8U_A/]@Y,I:Y4/S1S^&(_,RKZM
M-;VM-PO9J+GL?TA"O7-73&U'+\?_`&282ML%`_-%/AW_`&:5B.D?3IKBSIM`
MLKT_9?[917YW]L%Z7^R<?!;8)(^N.>&7]S2OJTUUI;.C5M?OLFJ_)_[97797
M&WYJRZ?W#GX+:P`=<4^"203];2LW8O\`Z<X-<Z>SIJX3;_\`!_M%1J&Z.JIX
MS`R]L8_FDGP=A^ME6'_/36]FS:JJ2?H_NE)?W%"57]PKK@6SA^::H#;^=A1Z
M3_7H.>UK:A!.BK\7[I27O44=9M?^']TK&6M;;<M0&)_N75M/]G&N;$**J6!3
M7EIZT=V5?R/]HKQ92U2?SSU!V']RRB_M^GC3H*>Q*O7^X55[Z#O8WI9?)_[9
M3C2MIN+KHJ(Z1:BL/^?6M=/ZY?@+TOW"HOPT#7ZQ-?\`E?[9J8DM:1*DF[:H
M78$?6BK_``@#6]OU^%+4?3_V2FU%OAJB][4W%A\C^D*,21LYQ'UV50'>;04>
MC;<+3(SU=:*U'T_]DI;MOA%,=7=K_`/YTUD23LUY!N^JX*+_`,QJR/\`Q$YI
M4):SY&%/X3_8*;46.#_7+J_[?],:V-*66K'Z\JJ!D[ZREG+_`.)0]K6Q/71A
M3U$,_E?]@K9V>!)XZZ\O^V_3&JC2-D$8WI5P`\C\Q"SM_P"\SFG6Y\1R6GA7
M^%_1E9JK7`%A]/O)_P`E;_\`ZYIXU/L5Y/U[U@8O_.)$.1?A^:EI\;G$4J?1
MK?MOT93ST_+N+?$+^7U3_P#R#61I"PGXWU67X_W!+/ENH9-TC=XGDM-;]M^C
M(=RQRW3^LM1A_P!&_P"<&OBR&GQ>^^ZUUBP(FW_XK:5;O<4^JVZ?P_Z,@W-/
MRU7^LM13^1O^<&KCT[3P'TK^K8P=AI[$/3_UM#3(W>+4_5+7MU\T0[NFY8WL
M>)ZC[$_YR454W3@X&_ZV_P#6[6__`,7-GUO%?JEK[0OFB%=TW*^?[4U"_P"R
M?\Y-=%IFFX('V0:YN+].(G7A^;`8MM&]Q6J_BEO/ZPOFB%/2<K5_K74T_D+_
M`)R5ETK3C%^HE>3A^IQ$.']^#VD>MXM]3M?:%\T<WI>5/[5U%?Y"_P"<F(I>
MFS@/LAUWH_0WB;L_SX,];Q;9H[7VC]$8^C<J/_XKJ?L+_G1PJEZ:G/4.NY?J
M;Q,7_P#Q@SUO%_J=K[0OFC#TG*C=5Q74U_D+_G1*BDZ;`_IA5W,9Z<1-V7Y\
M6>MXM]3M?:/T1WMZ;E6M/VKJ?L+_`)R3HI6FKP1J#720]WZ'40>+Z[]C/6\7
M7_*6OM'Z(F1TW*[_`/BFII_(7_.38PJ=IR<K_KF/_P"G<08?WW$,G>XQ2CTE
MK[1^B),='RPG1<3U%/Y$_P"<FQA4W3U*@1?]<<\_XO5Y;OSVEH5VYQ9K]4M5
M7_'_`$1,MZ3EG^TM1]B?\X-O`I]A8.ORM'=^8!8S./\`=7YFBRN<4_"TMOV_
MZ(FVM)RW1[O$;_V-_P`X-]*4^Q"<+XK"@,,;%6D/'_Q0=K1Y7>*;=-;]M^C)
MT--RZUAQ"_\`9'_.#<_`;(_ZZ5?^\=7^$S<?6\1^K6_;?HSM]%Y=_M"_]D?S
MYM9@N)`W>4#VF^N>4JXR/OIBJLTT56'65#RM"F\R?:CAB:B94`_HP[2,/&T.
MY<E@3+.-36Q5@##V\FY;\B?:BJI/(U$:(`#B'G%VWK+9WI$^$$T5E1L<2,1G
MT]'4U<YRJSMN2K@L"HN)B_W7C9MS9O,;CZ"0+!S+NHCP;FQOR1I.$TL@]#L<
M<^DGJV!F_/I.>ZS.'$3EQ;3A@#@&;TC./07(<4)/OL-SQ[F32(SFS+2H;2$M
M^\)V=)9O//:0;L(UJEB7H9<XA[WXOP?N#=+<Y-])!OI)*ALX:B0<3EF/&6F6
MI5PVD&XG1T-A!6'C$D^`^QS38MD"438PE9O?B<^L^TTA.N9Q:P-C"4.(!Y#P
M,SOV]>#;,AWHXT1MX*Q@_BZW[3TOW-M;;J0Y1CXS90HA<[TL'E_0&[.K(MR*
MVYEM$1X'OGGR=.1;%60YI-X9HV:(CP!Z60?N\K2%D5LK<=YUZ2VB(D#+;M/5
MTML/51\)R8Q27HP)P.+\]V/0VT:URV'.[;2CYM:U)41U/S+E$!^T-QNU:1':
M;R,RL8E^6;C[?5N:')><QNOH,07D;\O`7;\WM'>;,T9DM0RW=.#W.#FA7.U@
M:TD\D5HN&.9S+O(T&YEXSM:BM['H,`L<+P0_+I[>IH-QO>?0=W"*(.(@G+;C
MT^VT*?:,^KAFRNLJXCC[[Q)W-57?SDEX3DJ*XNLP40,7C#!_0/O&KKF,B7:V
MUZ2"*IZ>AP?T9X=K5UQ)K'I)4WYI6!!#]AZ?`.UHEU).ABWDF8<0)+MF`\[0
M)K'')D^CH8*(+NIP)W;^LM7W%23)5OLIL@S"CL)<D><X]#0[B1U55XSE^#R<
M#AEF!GT`-"N*DL#*7G4156]1PPQ?D_#;X@W":5*,[9+PA3CEX>GPYD[&@SBM
MIA+I*ZPIY<#X-K:I.F&1(@XTQ(^%3\B]FZ\SI6-/`2)"WXOZG,DFUCD<YN.[
M@2I(VYY>!M[<5FB,T$8.>-K^W[UIT8JE%DC;/K)RXO43BX$'<X8@];3[*PJ\
MBNOX76C($N2[(/:;;BDDNDB36)R@^_&:5'QOZ>EIMN.'A(,^T^E,Q)`4,<1Y
M&LM-%'&YB3%61[1U[?$UWI\L2ON=HF"W.^^G+SAKBQ!;<B+>Q9,D@Y$899Y;
M0UQ8BE1])2ZGM/K.03CCD,-KWY=;FO-.E@V5-Q8MF7&>(!XZW;?*UO8BMI`O
MY$BE]+]Z0_9EU-=V*+(\]J,O&8^L`).8P[&O-)V$GTE7>[3ZCCU@`3B_'/H=
METM?Z>*2P*?4XJK(C$"E*Q?O=['-<6*UB>?U/YN9#&4`XO\`<<UO8C6:KD>9
MOSP?2BL5ASB7/+\=A.3^AKVS'S:%)?DUYVTK18@)<#LV]76T^W!K9B4U]^<:
MV/$(!)#AUX`9-<::*E3X;2IU,U3#,U$98>%#/%Y!\9:ZMQ2I0H=3*L)5Z"C%
MB`G,G#9Y\VEVU5Y8E%>:H:B,L/5F_//'`[`TZW%^(HM1-X_#::J,O/-V.'7V
MM;:>,7;\94WFD\33QXI.0/6<,QUOS:RLQ6;S*34S;E5_#`U,=?""]YZGNW-+
M2KB4]VXZM/(T\51+R7]?E<]I%N.)`NW,*+(U4:(GT@2>TGL.YIMJ%<LB#.;3
MKL-/'6.+$OPQSV;<2TZ$4UB0[URLL'7`I+6-I.1<V7"**V]/8LBA$4DG$C++
M=X]K%%;RH09W'CU%1<0/<]^.T]72W<C>LD5C&`)#]KNP;>H,,^LD8JC>DEYR
M#@.WKVN;(=R99AQB0`_:.TY]CB&$J$V6D17*>,2<"/">K!A,M3>"\)L8$4$C
M80<1M>-V/2R2PQS+.#Q-M!6_B!WX>0M$N)?&3826%#>RJGE(.0`\KNW%H<UC
M383;4FE@=BDRX8':]_6<#V.:'=C159/M2:=$;'UA^_>1N%$3-Y=)Y3CK'&IY
M+MG9XF^M2<%NGZ";<G]TT,S&])V0!/;F2T*Y%)X%M9@I,T\S&?Q..1!)Q:)<
MMK`FPM*#JC61HH"223A]YM;A-*.!+M)N2H:M12M)4I1!.X[&C2NN.5">J)%)
M:PDD/.!Q)V#:W+<3Q+&BIX2K$C.4X/+LG[0_$]3/5K:%"*'PC#%_CQ/WC9=N
M*-96U(>OPS+G;\NQM=R)K]'AM;)H<4`/R]W+`;6>K^(?1X>&AL(!02YYV''#
MQMW4$CC*W'(V,*,D8/+\7.4VS@NDB7;46J[2]"CIVJ5V[>ILJ*CBBNG94E0V
M$.,D!X4H8;\/!L;O:>>TCSL1QKD7X48/23Q;P1T^XTZ#P(4]/;Z7B;&%&#\"
MMQWGLZ\VDPG5T>1"N6DL#:PHH.?$3[/.TB$4U5D*=N+Q9M8<8)2""HO+G.Z#
MB_K;>4(V\8D25J*=-AL(4<$8E0PQPWOP;DYO81;MJ..>!>AQ4`>^.&3%.69!
ME;1?AQP``2II"FZ8$:6GCB\:U+,.8P.>9V#H;93=*D64**J)D1_2QQ\#O$]L
MJXSA<INEGUX(.&Q[:.3>!',#'P\PSZNDAN;A5U9E59FB,'ARL7>SJQ+VCRMQ
MJS&;H<JB#>2[IS+NMH<X*N!ENF",%K2MZ2I0P))&PX8'H`:).Q&M&;1>YYQ'
MQ)2E(Q<=V;MYVM#NZ>%6\<#;UDLV5U+&/"HN#WX[>C)H-RQ!8XU9GUDMM"#B
MXB\*+B`#CV;FH[\:79>!LF0T\)15UUJ\0HI.#R[B\(<U=>@EYRS.JMQCD8Q^
M#A"02\YE^_S-7SAAO'>-N-SS7D52$I1@2<7#S-$G%/SF=(V8ITZ"L5!*B`27
MO>">EW@#0+RZ,B0UYI$J*22'G)P?EF7GH<T"Y%-DB"\Q(B5$X<`\A3ACF]W8
MT*ZJ5H;)UEX#@Q3PNQ^BRZGES09+\)G6#\XB,1PQ)>X8^5W4W!JKIM-\V9I.
M1+\22.P9^%N4K$*48?0<DIQ>3Q>)[:JREAL-HMTIL,']7C]MMO51Z3;>9EQ`
M!^/%VNSZVU=E/J-)R>Z0KB$8]+STO[<1@W2UIXO#8<HS;.4Q"I(V%SMN>&;6
M%K3PEG4.;3)!$.+P=F\/#@_K:7&S&*45D0;\MZ;$.(<1B'/.T/'G:5"TGXB/
M=1,E0XN$DN+B\=CWOZ6G6[:PZBNFZ2;72<Q.$1$%YQP(Z0_S-9V+,:X$:Y)U
M\1D2D)&)P#_#F-K7EBS'=IX2#.=95+""GA=Z7HN/L+65E42(5^XZOI,T<(.9
M#WE^P^)KC3K>2J4E^XW5O,X*AB7JV8/R+WO[6NM/%)I%3=N-5:"EAX+S@[M`
MR:VL9TV%7?U$]VN!D8@*1B=SQLQP>[K:\LQPWEF4-Z])X/I(C$<2`3Q.`Q.S
MI:^TJ6XGX2ONW&\3'U@P#R"_?ADU[IU5I;"HOS>*V&)6D$JXB"-C\VNK"I)+
M846J[,EL9!%C)>`27'(OQPZ&MK&>!YS402J53'2=O0'[6N["=/"4E^":H5%Q
MDY$G+>[VFL[:Q\!Y_5-PFXK*AKXL9"B02<,NT-;:;"B11ZBXUF:J8B(1AQ%S
MC[>;75B&^TF4FIO-1EU&JB3*?2<I6>YWWK6=NQ&,E0H+UQYT-;%BHQ/$K,])
M<?=:=;MJE"DU%QUH:>8C)!/I*RV^PXM.LK=C1=)3ZBZV:B-'3EQ*Z,=C6=O,
MI;TZHT\>8#B`58>,NZ<\6E162*347));V!I8TWGBK>?*TBVDI4162O2I5T-5
M%F$XDJ/G'8TZVG2A`N7I4=*&IF(P?@HG#:7;7X.WM,BMU4(4[TJ^(U2ILB(H
M9@!X../1FVR3:(%R_+*B*<2:((.8).6#NCI#%%U1$=UY.A`N9>\OW9[=^+\V
MZ-/*AKO8^`@]:@EY41Q'?AT]C*/H-=YMX&0*"[TE/<['+/M;%)#?HZ$B8P"@
M`5'$.W9''K;-'XSM;N2I3PER#%RQ+R\GKQ91K'H+",]UUVHVD*(`0H$[/",V
MUG-T?22XZJ==F!N(,0<1Q.T]>SJ+0KDY5)MO43>Q8G8).("`2\8#'+;UMS45
M+,LK%Z4HNM,SL$E%XRX['.=N!+1KT4T6%N[+,VSND^$M!)'K)'D^:6'G')SA
MO;ZTI2JZ^`_0Q:5)&BCGB)).9('0[#R-"D\"YTT:YFGCC/'<3V%S1Y3WL"QI
M@D:J85Z)QVD>X.UHMUU3)%CH1K5+<,#UD=#5\G5EA&VI+$H+B#B+SOQV=3;^
ML>Q$]1HJE91>Y1S!+GYN!<6P[CV&5&O4<*(#SN=Y7^5BFWL,N-#$$DN.&./3
MTN'4SUJ62Q,;C9,@]>3@<`7!BN-C<-A!6[!YZS[KVD>LP6!'G';A4V*-AWCZ
M'V=#/6MX-$.Y&CW2RA6(`.WP-ARZ2+.W5N1LH"MRB\;#[.ANUJY5THB)<K2C
M-O!/%PDD@C</`/&TZ$L/`0YP39=0ISQF!U;V[Q=7T%?--5-M`B/=Z1!RV;/#
MF]IMF3I380)Q63R-FE7HARCF,'#<\[&[79N45@1W!-%^#$(=NWN\&#1Z+;F1
M;L,'%Y&RAJ>YYRQRP;%>@KI05:%M"]I)Z&D1R.,HUJBRF(>%[SGDXMLJY(BW
M(O,E1%?@3@1NZ64>TA7(I^:6`KA2X'`AX)PQV@=!+#3U*Z3!Y>_;T>+%CH':
M2S9RE9!'@\63N@-PEVF%:1*5.'3AV#W6A3IB_"8]4NDR20HO>[T3TXX!HUQT
MEB/5TQ;P,"0?1R+W$O!P?CT9M$NO&IA6]YUV$"\2I)<-H._?U8M!N/)[3;U>
M)"!P.=V';CM:AU$?WV7665I?O23V(QB*(=CN`&'4T"<394>!BM04C/:'=2?-
M@T"[&F1TL87/$1<0X>+9F.LM!G'82J8T*9+N)9S5@/<[6AW(UKT&V;\"(BH'
MAZ!CM:MNPW6Z[3M%5BNDX6<SL#N$[25#=LP+0KBQZC-*>:C@`)`?C@0=PVGK
M:%<BG@=8YT1$I+SVXCHW'KZ&X[E%X3ID<E3L\W9=`ZA@Q6UTXF%B<N)`/""'
M/V!W8<6YRBJXLVJB-V+W#JP<V*0,U,^$D/"7/V@C>Q)9Q9K-K=.'8N5F/9AX
M6DP@<7ABCA(<XG(XNPR]S8TZ"PKM#I(S67@D#+L?AZ7B;O&.52'<7[XS)&22
M-@)?M=T]32K,,2--XF:#B4[021[G06L;=M5565US"3ZPLO+GYY=8\[6%A/9F
MB)==&NHR?D\Y8]A]GA:\T\4T0+F$B9"G!6.#L>C;X&L+6+(6HQKTT^\8&*\8
M%SL>O8]S6^G6ZTBEO+,!1+@][LW[MG66NK$:T94WEYK9F3B$C/,'S%K>Q;3Q
M*:^_,?14X*W/PV$'H.UKRQ6A17LBN5O4HG<"",<6O=-;6XDND@7FXLX2M^.P
MY^WO:\TT-VCVE1J94JO!]XC*P=KWAKNRJT?04>H=8/P%.+%#]SL\3@-WA:WT
M]NKS*'43>ZWT%147`N()>\><X;PU[93P7@*.].CWJ%2)$"0\O43AGY\VGVTZ
M'G-=+]];3V&O6L$DA[W=!#6VGC5]!Y[4RWE3H-5,Q/?`ES@2!UAKK3IJ4>LI
M-0ZQEU&JB+RS](8Y9[,&NK<44%^=%@4(JW8/V?>=1+2XK#,HK[56:::B.)<7
MEPQP[>MIVGCA6I57WNNK--%5F2K'S[/$T^WE0IM1-K!&HF%X*<2<#T=(\;2X
MQK1[2DO/!IFCC+)VY[=H<YX:1!*M7L*FY+[AK(I`VOWO\[6-E-JI!NS>)JYA
M2=A?XB['Q-)BWM(5R;;Q-2\<9*E$.!ZL"-@#;8TP(%R;?G(J1E/.9P>KH.&(
M/:V8UJJU(<IXI/)%$QMAPVN.(\327TF5=VI$8BXE^_#9M\C9,>M:=:8$PC=?
M"YQWY]6]L4QHC&_66]M)8<5Q=F2<,?H0_)L4?B),6FB[#4Y6;WXCK=YPV-C)
MT)56\;B`MZ4O.((!V[N'K!:-)5.T<T;J65Q`@X89/Z0T2Y'[I.MRIXCL$LL!
M*1D'>-WF+<855>LLM-*J;\)OI")Z;ATN/LZ6X7<JEI;>PW/KE=/A+0"1O,\H
MQ_XXKTA@".W?FWUD3EM/T2V8T=#13"G.2_)1QR?B3Y6B7);"ZT\:I,TDW%X>
M)QS3D.AH<I;2S4,%X#41HWH@8O)?U!Q:+=N51)MQJ^LUZHCDEY`PP['^TT)N
MLB;!8KP%.("23QC`[OO&V<Z$Y0;*I6YP*@7$O=UX8!L*>)EPZ&8*B\/T6>!Z
M@7N#9<T]AA6Z+,X2LN'I.><.H;SF]F^LZ#U;Z29*G?1`!V]V._I9OU&Y7:64
M1R][PX%VQSL,,L6[JXLFCC*'QFQ1'47>ET/&3_.V=^.=*$.<&U0O0HI.'K`[
M>1CNP<VDI;R(LE7(V,&(>))]8DXXCJR#=;3QZB-=@FC;PH[G>D#CD-AVX-80
M=5U$"4*OPHV,*(<Q$3^%<\YX888M(C--T1`FG5I])L43`07*4,@?86DVYM.I
M`N6TUX:FQAS/$`Y:>G?O.]IDII["*XU-A"F",2M.&.W8<L1M;GU'"Y'#PHNI
MG,AQ`';AD&RL,R#<M[SK4O)CD@>F`'`]/WK24U0BSMI8;2Y!F7)=QIP)Q.W)
MM98LB7(.M<"5$P"IW&G`/>,VRDB'.+R+0C88J'0?,V<=F1SW'TG'KAOZ#[!L
M+8I0QN'`62KB*@7Y=`ZN@MPEVC.Z]ARN+PX%8.TCIRQ\#1);>L*V9"-PA[\2
M".S#!H=Q-OQ&'!MXY&!C]@XG/[79M&N*C\1C<=3CC!!](.4<3T`^=H-W"AN[
M=%F8E9#E!0((#@.OIRP#5%Z%929+MX02\!`N*%NX5`!)<X[W>ZT"Y'I-TL"(
MQ'GAXG``O.\N\[0KL:1KX3I:[=48&)P@`D'B(ZO8'XM`G!T)741+7B\$'$I&
M'3B>C%H4HF%T!*>)(](>]?VO.;0+T*N3V'>&53EQ*DH"@[?T\.+VKIK:;M?A
M,X4"$O!&!=V9M%G;PZS>&#H0E3DY@$``>/%N'JJMNITI4C0@J+U*S+\MKO;;
M/JZ&7A@2D.'OOX)HTK?GO::XF#Q_M@\`;'JO`QB9I.T*?BY[LNQB@HRJ:RR.
M%)<<WCV%IUM?$:5."KB#G[,]G7U-+A&G4PE1U."X%SP?$\.'E#2HVZM8D6\_
M/=#A"^$NP<7^#>TR$<.HBW,>LY3%X5N[7;]^]IT(-I,K;F+:\)RI3U@@@`EX
M[,\FL;"QJ1+RQ3\!E$7D7C'9LQ]UKNQ;\1!GVJ#UKX9Q<<MV6SI:RMQIB\F0
MM0J-]1Q"5[XE0&WQ#PM:Z55HBEU!BE1]:?2<,NS[QKRS'SDBHNOS&2+C@$8A
MSR#MR+O&UI9MTQ\)3WEYCITD:HX5U[#EX6O=.L*%#=Q(517$^D#@'AV?FP;T
M&FMUMK':56JE27A,!$+DN4"]^&UKK3JF93:B>#1"N,`5%X!<XO[-O2UU85:4
M*+4S\QQ\!2BQ2GZ)^WV@UQ8MJ3J4%Z:6%"N5DE_$"7$X9=76UW8P6)2ZB>-2
MC&6_*(/'X6LX0IAM/-:R7[ZV^@UZEGTQQ@D#;B_R-:6+;P=<"@U,G)5^&1JH
M\4N+E..U^/9FUS8CYR;H4FH=(2\*-7$BG$\8'LV-<VX)+K*&_)+`U<:8&(]8
M"<0X;PTNW&F)1W]K-3'C$DGC#G?>AK&S"BJRGU$O.KX#41XI3B8@+\.A^SPA
MID(U93ZFY5-&FF9@A*O3`P+AY^QIMN.THKTO-?4:*+,;2L=3LC[32H6ZM/85
MDY85S:-9%F'/4]XZ0'`O=CBT^-:4(-V6S:S6QY@Q$EQ&YVWK3T-WMJB*VZVY
M>(U2XSB_B#CACB_RN;JDED1;DJ5="JN*<1Q#:'X=/0Q=I>$@2G@JE13R[TQL
M(+O+UM(:IB;*2V&!4[Z,%Q(RR#]O0]B6U#>`C](][PD=N)Z64PH8K3!%F'%>
MH.4,'8]+CY6PZ5)%F550NPXO"07YO'7F06V:JJ$V+RD;:6F'X_@7>UVM#NQ:
MPZ"2IU9OX$;A`62_HRS/@S:'.-<"9;E@F;Z6CB)PJRP(=UJ\S1J4;1:Z2=8R
M\#-](*_'#Z0]K'P-#N/S66-N=4;GUOX+Q>XT&A)];X#RW-*QP(=OVGM[&^L&
M4J+$_1O!+>.N3*\\LR-KGYX=&#0[DMFTN=/#>I0T4RKB>'Y`/[<.G<T*<L6]
MA99(T\4G''V!HLY8DBU"AKUJ)/1B_P`.30[D]W(F06%2M%5B7;,<]NW%E:X[
M"T22BC7K7B<<<7^$/=M;"KF;466TC4HJ=G@'@![G^VRK8HO`2I>7![AD]^[R
M/>V:O88W54F22<,7X`=@962VF4HKH)TX!SP\E^&+O`2W=-HB2C7!%Z`5$$O!
M=[,R2&RR#<1L(3R3EEU.QZ2V%AFV1J;V"+\+B>1@=Q]UNT)TH\2/<A]PV<$D
M$/V##/'#;O:?">]'`@7%G0VL!9VYG(@%NT).M-I`N1V+,V"%>D'X^S+$--@^
M@A7(UQ+\$J!P=L?@_K:7!IJC(<HT=#:(5Z/8?%T-OEU$><:9EB$1L`>K=@1X
MGMG$A78_=-I#](!SG`#8W=/`BRC3,E2IV'@<X>VV^'00YIUJLB9*B3]".K=X
M`VN"(<X2:+*5['OZ3EV/;-4<O52>;,>,Y/Q&&!!SVDL,[C)H:R"'[G/S><L,
ML@T>5*NICU<SE9Q>\G<_+#/+H:),.#2\())`..1[`?.T6YF%"3ZB/B?PXG`A
MP?GO)S>T6YF^FAE6Y9X')B%Y(/HY)'3BT&Y1T#MNN.1CZU_"D/&#O,U?<CBW
ML.BPP("L`J=L.#LLG=I<&@78//8;Q=3@*'K$I..!)\I>2T&XJ1JS>U7?J8J.
M/$=^`Z!N'6T.[$E+H.'O)VA+_#N:ODMH?3TF28CG#)W8#GEO<T*[;=6]AVC6
MB1PI3L7N)._:0U==AC7\$ZIU=#,Q!P#-^WV=30Y1=:F8KSBHH\1=LV]?G<V:
M+Q';)$W$X;MS]@_!=);5+>?@-<V0J5^&SVY=C1KD&YO=H;T,'MIN3\`H9H.+
M_2[.C>VT8/>\ZAK)>:2\>_'9AD[81C[X-(A;:R.#700H44D#'K/1L.+3X13C
MAF;/%',53LL"\=0P\(Q:3:ACCDR'/MLQ00H#?T[CLZWM+A![V-,/ND6>9P_,
MXO!=TN._:TZTDFEL*Z>$WUDCR\'-P>[?M>.EK&Q%)TV$6[CU$:WN2!D]_6_8
MUYIX/,@7/QCA2G@$8%Q!=[FUK&VL:/(@W\WU&(B.<D[G]8\3\6MM.E7#`I=1
MBG3H,3$(.9Q=Q=&[PM=:>-9;NTJ+R\UD<1;R\G++IZ,-A:XM*C147G2#ZP%'
MAQ#B2?#[KVNK"2^(H;V>!@M1"U%[B0G#8<,&]#I(_O5=E64FKE2[CE0B2K`X
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MTRKJ(TQ`]X^^O?TO.!+9HF:SE5X5+$.(Y(.U_MX':V*(D6I5Q1LH"GI).X]>
M6W?FV*;-I-A*N*R-E+%W"7NXB!T>1H\TJ-/,DQDJU6PWT&)GEFYVS`8EW26K
M[D:8DRW*J\!O)->#NW'>=G86B7%1KJ+332\QTZ3L\BMZG[?.[%_6U?<+.TZO
MP&\]8?OO\*?;:!4D[T>@\LS1/&H8.Q`&[++PM]7MR<=T_2/:LNN*Q.M3?$2'
M.=Q';TN:ON3^,N]-9G'8:69X@_+$#S@=+1)S5,"8[4UF:F,OA`)WG=M#\>IH
M\Y*M25;7F^$U:XPX3B7`X^SL:!-[SPR)48UHD4EQ@HEW@RPP\C='-4H6*:94
MB%2E/`&:G8[NS8SUD:>`9NI@%J3F`,AF\XG!L.[%+':9S)8<0X;?#F<VQZ^W
MTX&'5$HBX\0Z0,7##`];/76Z[3*)X<0OP<<0_'`/R+3%C%.F!SE:DE5T1<AQ
M5!R2!B3@'];9K4A7+4J5HLS808BPXN#BYSR278>!M9*6PBNVTZEZ'$4%'T4X
MNVY^1NL%7#:1KEN3;:9L(<50S^BQQ+\&FVU+=HMA!N6I;#:0HY+@[(;#CEO;
MM&5'X2!.#3;>1LX44EQ(3EA[,0YIUJ2:PS(4K4VMF9L(44A7T)&`S/FVEI<+
MD8]HA7+<JU-HB(>$DA.3SCX&Z*Y%Y,B3R)D12/H1EB2=G1B6Z+SE781+BJ;*
M%,@A*<`'>9N]'0BSCA4L>M4<4!+G.S=CY\&*K1!NQ62,Q$B!Y4E+G;W[0QD6
M>"+"8QQ<XX9;'=H#9.;27@`BD$`.ZMK]V&QGCQ%-JS)$QB%O47.&`#1)7(J3
M7A-=]9;3,Q^,@`OQZCO=U-'DZK`;\?&9^L4YSP<,.O?VM'E%MU1F$MYT1CQ*
M'EZANZFC78R6!T::S(S$)R<Y1<`#MWM7SA+(;KKX2)44X;"A(?TO\^+1IP=&
MMIAP;Q0*R>'`!Y23U\(QZV@W;4F9498F`B@+*CM"P_H</$T"Y;ENT1U@FGCT
M&1C`DO<<@GPY#M:'<M2<:+.IV3P,BHI+B.@@':_/I:!.VVW3(SF1J4HJ<,'8
M]6.``QS:'<LW,:[3K#"*,U$J4$[!AV[3X6@ST]S-Y'6-4CE3PCQ9YXM!G9N1
MBV]K.D&D1`D#B.#@,?/EFT:C?4C+DF!%"CVY8X[<6RH-]1LFD9$*5C@=V+<I
MIINF9AW(HQX%[AX6TK+H'K(DB`H'%SMV>>#;1JWCF:SN1W3!3TJ<';<'YC`Y
M[VD0A)O#(X^LBS',/#L@K;CCB>C#-IUNW*M*8F/6)$:R5$])`SV.&'3O:9&S
M-TE0CW9IRJCF$2'@X[O(0TRW9F]F!$G..>TR)<H$[0'GM`![&F6]-=SHBONR
M3J9>M2E0.8>[V>%K*S9ENY8D*Y<C0@4OB!2G$@D@/V/V%KJS%I>`@W+D5@]I
M$J([`X$N['CJ=FUA9LW)I2B0K\X[OA,`M0<%#$/X2#F[,'K>UUI;$T_"4M^<
M:$1B$@JV*2XXXC'`Y#)KFQ8G&2=,BHO3C1QVD:UJ)`#G!P&.9=CL>]K6S:G)
MU13WKD:.N9GZW!RMV'2KW&OK-NBP6)17I1K5$:XBE'/!PQ>_%WE:[TJI;735
ME%K)+UK:RHB)4921L=D,<W9#+<UUI8NE2AORCLS*:IAS\3B\`Y//MM<V5YT2
MEU/G1>Z4EQ"M3QB02"\X=637%ETP10WXRC'SLRK$C*&#^$8O=T8>-KS3I*&.
M+*'47HIT>91B1U=!&_%^WH:PMT;J>>U=;D]^/9*2XQ*3LP.)+B?;:VLY];//
MZI[M33QXJ\0"Y1!<\X'SM>:=4:JLB@U%V*@][.AJHD9:"2H`[#T?>M91DJUR
M10ZB[%HU4:8/$0'8O)\QZVGVG'"I2:B[&M:X&LBQU?1!YQQ?X,.QI]M;RK'(
MIKUQ5ILH:F9BKX<0EP4\!^W[UK&W3/I*?47(TQ9IHT93E$NQ][CU]&;38QQH
ME@BEU-V,HM+.F)IHLSPD\0]+:[V9M)2Z,BFN22CG@:N9CO&1>02#GAM)ZPTJ
MRJ.C(<[D6J)FN]=^-ESB<2'OQZ,LFF*+:(-^Y%89,U<Q&4[(`\69>[R8MMN2
M($[D4]UUR-:M:R\X8=/7BYME%J2(>_&M"/UI`Z#TX=.QI+2K@;85"XJP`X[2
MXO.6[+VF43QIB'**PVG"8F"NL%SR\8^9S'NF'.,:5+D);\"0]X[?%M#:NFPZ
MV[B6%3:0%$`#//;T-BL?&3[=Q)T9M82BD!X`&?@<YN,X_&3(.CHS;0HA<5#/
MKWD>8-`NVVW@3+;62.P22B7;>O<2T&Y"4G0LM/<C"+WND[+3UYOR!/7T%H-V
MS<H6=J:>69O/6J]A/MM#^BW?!\9,W9'F";(XE.W>';V-]5MSLGZ4X=HZW'5A
MVJ'4XO=VM"NYOJ+[3])HII>*G['%W0T1Y,DR9I)A3R!O+@/&T:YL-[2PQ-3$
M>`<<P1U'SO:)M?63[4<*LUY40H];G=3:4+'U<:&*E.<[8_Q]K-J2&Y%;"&(L
MC-V&/;F_:VDZ+`*$:'*(C^'BP!W[79`>%N9E6X,D"W;?>X;'8N<V-@]5#H+*
M%N#WO?EL\SRUE"4J(Q)/*E"Q#C8NSZ`-_6V^]-8U(MV*EFL#90E[G89I?BYM
M[<G-D/+!EZ&HNZ\1C['-(AVB/<2KAD7T*6"'@^7<'AIUJE'TD"<7O.N3-A"6
MH;P>I_:YL))R*ZY&CH\C;05G#/+)V_I#3;!!G0V$%2@[!SSCGL]IN\]G61+B
M\VC-@E:@-KG/<1GAO;K#$KIQI)I9$\.(<W=?I/\`*6EQ[*(\U6J>1<0LYN'A
MQ:0FVJ$*2E5_BEM$11`+L'[_`&VV1"N1H\J$PB*>,O#L;'B(4HRVY%D13P]`
M>X[,_.SJ1C=0$4XN+WX$!P\>ULTZ0XIX&067`O=@#OV8M77(KUCZR)*$G-M9
M5.$Q2'["3AM.+L>UL;J"@RT(SWA1=AVG''P-K))+PG2S%J7G+8<B(7/.`4X#
MH`+1;L6\\B5_I,2O/AR&(Z=YQV!H$XO/XS7K*ZEXN3]$'DXX;W>%HTX_A!-G
M(62C#/B`Z@'`;&B33R,K#,X)Q+]V'2<O$T"['"B1NC$/]$G#$/[3ETM"G]RA
MTBJX[$6PL$DY@!_1Q/P:!.#2\(\!&F)Z;W]':7X]C<9Q6[X3NEYJ)0=K\R"!
MNP>-^QH$U54V&YF"\/)WX;_O6A:B*=O$V;V$*B]^X^SQ/:#N12Q,HX0!@_:]
MW3O+'&-,<C#98"@$@%8#QDY^#19Q\[!&M&R/C3Q.?A]^]QL49G=="8*!R6%.
MV.<V8Q\ZISN)J.)BHX'H_A3L/2"TJW!O%9G#:5DJ*>MWA&1P:SC&J_UC9XG"
ML"3U=F`/:TZRFXJ+S(TLVCA"DJ&!R\?:TVU%U;(EQT>)@I;PH$N(.!SP>YW8
MUA!94(5W-D2HA]%YP&!\+3K4%7=977.@Q,1P2>Q1?D_(-.MITW7F0;V,O$1J
M6%$D*QPQ[';6N]%']Z36=?OD.^W1,B6LN3O!5AT$#VFN]/&LDUD4^HIMVD97
MAB<`,>G'HR:V@GE0I;RQ:ZR,Q`"'@E.*AT.S#VM-.OC*;4-T\)&J*7=()=TX
M^5KJPI5K^#0I;ZVHQ]=F!@0D#JV>`M<6(TBJ9%%K,9E940E*03B"0>C8&N=.
MJ8(H;[Z,RE%B$X<0>,3AX/$UUIX.J=,2KN]EO85UQ#O&&S!X+]K7%F*R:*35
M./BVFOB1,%#\%D.O?L:[L+S:GE-7)*3>PIJB*`)<1TO:PMI]E%/<=*U**XI(
MR+NOH/MM;Z>/G)L\[K))UKG^X:J8621B]S\=S\,6N[2VH\SJFMV5#43,3!>)
M>X`#JS:;&K="@O-T?0:F(HC%Q)&#]G3N:=;[..91ZF6-&S7QE%_9[>#6>F3]
M73PE1>ECX34S*B0\$N?V.#65E-*DEB4U^4G6IIXZBXC#`/!Z=_2YI\4J5_"*
M:ZZ)]1I)I9.&;\L>I_8W6">TJ+C5&OB-9&60`\@88]#MC^MIUI*E:8D*XTNH
MUBHG""XYOW-+A%I9%=<FVZR-='BX#BQ!.`]UNJH\B#-M]93*P.@.<=V.6S!L
M8KPHC3EC5D06]VQ[T@8$.#FZU3-7.5,1Q88;W'IVEV[)L8KJ-E)Y[3E)<"[/
M-^[$X'9B&U>)JY5='F682\`7N.';M>"V'3,[Q9M8,7B4EY=[GMMA9T)MN6]3
MIJ;B&MX&T9.[6Q/:6=N5:-YFUEU@I<]X?X?:R:%=S1,MRH_"SL4BKT0X[/$T
M)OSO`3(2.S21#SLW_@AYB&XW7@7&F:=&N@W7K(?WT>/VFC%AO,\RS2P5*#\D
MG%^!PW]K?4Y/(_2I#M'68\0.`>[TB_'$A^!ZL6A7>T^HO[&#-#-J=Q$8G?LQ
M)]IHFPE[N]@S31E/(.;R<.P^TYHL\SM;AC1Y&N67A6!&X[MI[6B2>+)Z61K3
M$>LAV6#8P2\)9;F"(E+"4Y^D\GHS=M9EB@X+QE9<4$`YEX.&0>=N+:3HAN1,
M1%WY@EYW#S8-RQH;J$4C+U[W;1D[H&`.;8HO&9W$68<4O<Y^3L,.W')IBE*B
MH<IP=*EI$1QP2<<,,!['LWV1)K'P&TEH@!)6.$<(=EV/)..#=[$FV^DB3@JU
M=390XP'4'.P:;;KO(B7(*N&1=AQ7NPZNAIUO`BS@JE^%&+_>G([CX,6Q'ME?
M<MQD\:FS@QGD'A4,'-/L=!6W(;N#R-E#C!P]]X_"W26:ZR)<3:52ZF."C#$N
M]O/<W>.=7D0+T'6M'B6(<8D#)^YWL#28OS:["%*-'3$MHC*`R:5%*AQE%,NH
MC>C[TG'I.[L93$@W85P=3GX0K((./2V:)[2&[:_"R+"8[@']6`\KV4Z#FX1J
M9)C/()!<]X'3CY64P"C$G];AD7N`Q&7M-%E!.3?A(TD]YTR(U1'$</$2,WY#
M>>QL;D6Z/(Q2702^O!#R_(]&Y^W)N<X)+PFRJNLS$;!Q?LR'3U[FCSBGU'2+
M3`C>#(;2=O@Q:#<ACX1)51@5%X(!P]\=V#G>$M%G'8LC55S,DKP<YSU8/PR#
MWYO:%<C3,Z84,RL8/RQ+QLP<[H=V-#NPI"J[53"S`6'$D](]C\VK[D:.FP[K
M\4Y$0Y%X!)?O?L=V-$N0KB@\ZG*E8X#(;MC\<O9FT:5M4:VT.L'@FR?U@<$C
M`X/.&.#W;W/\30)0Q;?91UBMK)%+`2`_''P`[,<R6BSMQFO.,K$C201Q'KZS
MN'0T=Z>.VH;V`$E^#CEDX`='2]BTT7G6@S)01PC!YWGV/;E.Q'>=$S-6C@J`
MS"1[.MN?J%T,SO,Y"T@%^!R>,`X[\6VC9BGBF:3JXXG'K!Q!Y#]^#B,'/Z2]
MI$;&ZL$\R*\");QBD=3]^UI]NU%XXF5X3!2B4D./$0X88##+87A[2K=NC2QJ
M1[J\^JR(H1*<%`C<_;O<TZ,%XR)>I4CB+`)?B%><CIR:9:56G0@7,F1*6Y66
M&0PPPVEK"W!5J5US&-=J9`I2B.%Q<X'_`&/:YIT$NT1+F=4.)Z!@Y6'1LVM>
MZ2*5M4R9!OO#P&,6)@DN+W*>[%V`:YTT7@GD4^I6;VE92RY;P7$`AW6.G/%K
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MS$=3BY+P<7=?2=S2H1KCM10WY4RR-6N.I_I`Y'V9M8V[2W=M2DU$TVZFOBQG
M/]$OZ>GM:TT\$X8YU*:_.LJUV&KF(H`.8^\R:RM1KBT4VHN-(T\6*ERLSAEA
MCN&QIJBGF4M^Y@\5@C1S,0CZ$@^3HS;M"+J5$YMTRJ:V-%>D`##(N'EQ:PM6
MUND.Y*KHVC4QXSG\(.`P]L;,FDPBVL40+TU6CI0UL2(3F<CAV8]3;;B($YTQ
M>94,8N4DO?B<,MV_)BA5Y$*4UO9Y$?K7%RA]]<=SW].;=U:6=&F9W^@>N&S8
M7/PR&]LNRO#0R[LB:%$&()PZP\8O#<;ENCPK4T<W6N%29*MF+W@^7%M=PEVY
M;-AL)>(H$8/['X9-A0)=N6[BLS=(64\+GN+O%FW*=&F6-N=/&;B76['',]AP
M\S0;E<"=&6%=J.QR"\`]^_P%H<\\"9:FY+$[/(K?V.Z]K<;M*5+C2SHL&;KU
MO2GV=K1RRJ>88Q+U^!S?4W<[)^EF':1UF:5Z3LGGP89;'![0[N;ZB_L+SC33
M2G`X[`_K>_M>T-Y$Z"JZ]!HXJB",=Y\7NM'N/%=!.M13212B+("NGQ88M!EG
M0E0MJ:9IE1#QJ4_$G:<,?<;*2+)0P2*L2(HX[R7X](\S.A#=(@IY5L"4^-^S
M>YM+F%!NAY*"7D/'A.\MQ;^(VW=CS,H1<X$OV/VDD9=0+$ZF&J(MHB%+W$OS
M&;NHG)S=-^7@H9QW<2Y`B*<'DXD[\/`V'<:?@(5RW54QW2\(JG)Q>XX@DN</
M;#2M*]Z3V8$*4<,:T-A!C%0&.\N>2UC:PD<+D:IYU1?AK(PP()Z</$T^WD0I
MQKTU-A#6K#/L)P._I#8@_/(,EBT\JE^'%4[-68W^')IU@@WX5\XOIC+(#SM=
MM<'MVGLZR!>A54=2U"BJ&1)RVX=+M[=(D.Y$N0XR@3GB['87/VM+CV5B5]Z&
MTLIBJ>\E661>[%I2QC14([2I0NPXRN%W$4CH\V#9HMN9%N13Q6++"(JGEQ5E
M[,VQD0)P;='D2>L62,3F/9@RIIZI%A*R!F>LESCT=;&ZF-Q(Y]>4X`OZSD[I
M;7<3Q9R<%6K8]<2"0>O$X9/=@][8W%TF-W&K,#%?AQ'`8G?[N38E"F*S-6J8
M]),B,5#,O._=EBT2Y;2C4YK!T.1$(VG#$9G>T.Y&N>;-UE3:2ICD*2D[\<]Q
M(:-*VDJHTVN@5%+^+8E[F@WHX^$W708KBGA<"<1T[?O&AW(X5\)E+SO`<H62
M`'^]`>7_`'W-H%^%57:;K.I82O,J.WT<\&@-/8;>`D0HD\1RP`&)#@_A\C<9
MP6-#JG@D2@D>EGCACGU^5H5V/W3L^@$E2@'X`%Y\9(Z=@:'N=(R1(#N]'+;@
MD#SEM=QO%FH3$>K$N#SVX9EL[K>"-E@64NX7[/=;G*&+J8;Q(HCE.<<G[^AM
M5%>$)T,%)6$$X$89D[PVRM1DZ5,3=8T*Q5X#U^B0TB%MIT.#1:*WI&.Q^>8>
M,>QI5NW54VFC(3$..QQ#\=A=CUAI/J_.:VFDUF8Q5DI0X@8*ZQDTBU&KIT,@
M3[124OC&&!!<[8Y[QTM-L1W;E%DR!>PJ]A@I14`G=MVOV#L+6$8[N"R(,Z49
M@8A*07XX;<G9AI=M8^$A2P?@(5Q2"3L#G8Y@CQ->Z.-(*F=?OD*_DUM,%1'<
M)?@KB\(<<&O=.M[/!E/J,45XD4D$/<%88=;\/$UU:C1(I;_3T%-40O*22,2X
M[R_/+<UA96*92:C[G[IC$B'A'I8C!^>63FNM-&D:E->QQ1`J,1@3B'8;,,L7
M8-<6+:<%UE'K%Y[?@*:HZLR3B2=OLS:XT\:8(H-1X"HN,HJ(>[HV..T;VNK"
MR>U%-J?S4GX#`QE/S>3EB<0-I.PEK>Q!//,\UJ984V,UJHI!5@0"2\[<\L78
M->V$Z'EM7+8:V)&4\XJ\#64(TPH4EZ;>.!K8L4JVJ/81GT]+6NEC55R/.ZR=
M:Y9?>-7'C%[G$$'L':.AKBTJ9'F-7A!NI1B1#]^.6+NCRM86[:WEG4H[UQ[N
M"-4N(H/#U>^+GO<-C^MIRBWF4>I=<64(L53\2!UG=MV-9Z1)0PK6I37VE*IJ
M)N+Z/OS[X[<\\]S6D(-%/J9MJAIUQBX@'`>5I,89291WW1/:Z&IF(JWX$OWX
MY>#`M)A"+:=<2KG-4\)J8\=027$N&>)Q)PZ7C%IT"ONR3JS6JBJ(>X[0YY[?
M*TJ,<,"#<\Z>/0:^9BGAS(<H.<3TCSMLU7K(5R=,2EQ**L2_K)&9\A;:.=,:
MD!RJ][:8Q%/^B+B0XGQ`M(QRH;[[;J1E12%;?./;8JY,SO,S"REWI/\`1!PV
MA^&#<9I[RP.<I;SJ7(44X#8\=&'MMHT\R5:N/)FV@1/2`?MV^/PAM6G1DV$J
MT?A-S#B/"2_)SNI_G:%<I1D^$FWB;>77OVJ:%<618V9MK'8=BE%$!.)V[>DG
MPM"EF3+,L=T[-(9X$N>'[]_G;A>>!;:9T9NVX%IZU]!YIF'@E^)V;'CW2WU-
MW,C],$'YQU>;/IDDX8E^P'(]!:'=S9?Z?/`TDTK%^67@R!\K0GD6=B-<>@T<
MRK%)!S)\A;A+83K>TUL18*".C'K.+^UH3[39/@L$S4JQ4Y[BY_D9786"MU1$
MYZ1CM)=ED6SO&7;\)"7`G'%0`/0'Y>!N5QUH8]73:<JB#A?D[Z'<[>W'/J'J
MS&&M^>&TD]666&+9;=,!ZK>VEGC`20][N'#)[^D@MSWC>YA#J+L"(D#,8O\`
M1\[W/;*EC0A7*-EDQ4N2=YZ?'UM-T4MZ;3Z")<\^*V%Z66.-&#@%8''R.:UM
MM5PQ1$E+)9F[2I'$[B!PW9%IUM*C(5RGG+(NH6'#$;G8MK!^>5\ZXI%Z#%``
M>_KQQ#3[&>#(=V+E@71&2X>EM&#MG@;M/9UE?>C6'C+D.(EP]+JPW[&ZQS9`
MEAD641$]8Z]_D:5%O=1&NOS74MIB(<XY8.+RTI9(ANC5*EN%%!3@L#')SSX2
MV:=*(MRF]0M0XOI%RMFY[8I0@3RQ)_6Y/6'/&QVUL''J)!%#P=GM,QVX&N69
M`J*.,A^U^6S=D_%NJAA4Y-JKH/6#'%P?EOPSZFVW/#B8K\9QZW%[]CAV[6UE
M!)9XFDLJ$R(H<[J)\+_(T.Y'9L.:Q)DQ07G>]V&7B:"^U0-.E")47A6\'$EW
M8W%JK?087W"0Q1@!D.%_B+LF@78UK+PFRR\)P8H<5'I<.P;AM:%<BTZ(V\!F
MB)@`<W@/_`X9#I:'<6+6RATCT=!<X@]S\R>S:U;)?A/-F4\&R9,0/`&&_J;@
MXXG6&2D6%J#G;R/<':T2>UG:(0YQ)VO=[;1&WZQ=%`WB"L*ZL3^&.S)S@&W2
MJ_`;)4(H:L>EY\C9;W<##9="@$C>[)HDTW-LT9DE0+WCQMKNFK=#E7"4D9$]
M9VMM&+WL#1MT*B@XXYY>#VVGVG7/,YUV$!BO`V#'#<7@ORVM-C!4PS,M8'"E
MO!_@3VX8]K9>+\)'DZ2:V$8B/"1U^9XZV[PCO+>Z"'>PDB$J#R_L\1?YVFVD
MU21"O=AL@,3A5C[U^77GCGTM/C'?*^6,/"8%?#M<#CCB[Q=+3H1;57F0KG:H
MLRNN(`I0R]$.S(R]IKK1Q?JHR?3]\@W^DK+BO2D'%Q)?V##`;6OK*Q704U]K
M/80>MXR`2X^BX^-^`&;6]I4CTHIK^#9&N("7/<0<^H[G#,-9V%BFLJ%+J-K(
M51!PN?T]1!..637-I/!["FOJCJLF53&`?T@/[0[=O:XL0I!+$HM9VMY=!25&
M#W$Y/['A^[I:ZTL6G5%%J,M[:4UQL0-A'27#P-<V<XU*35.MJ?40+C$#/#(;
M>G<UO824J+:>5UC2B_AM(8JWC`[,NE^]S7NFRQR/)ZN3R-;'B$8@[!AX>AI\
M$ONE--U33->N+@0HXN/H[L.@8M;:5)Y9+RGGM9MIG^X:N+%2"2<`[`':0]^Q
MKJU%JC9Y;55::**XX.+Q@2!G[33[:KB4=^6[@\371HB<2I3]^SL:9;HG@4>H
MKO8&DFXB./`N]'Q/[6MM)V-[;4JM0VII^#(T<W%0[K.#G[BUA;;="EU;?9-6
MJ('/!<`,`[;BTZ$5F\2DOO/J-7,1`'X^D<,7X;SVM(A''>Z"HN3V=!JH\3A2
M'*P=NW;,FG6FJY$&ZTWX#7F,<3Q8=3O-L:7!T1"N]JBZ"E,1`0!F`O#Q]`+;
MTJL,RON-/(HF(Y1&8+NC;EDV8UKCTD232GX4(BTN(?D7O^^D.=L:2L70SZU+
M9B<<8'3B7C\#OW,6.&PQZY/"AB5<!207@#Q$EP['-SGVJ&LI[V+1<A+`&XO'
MD>&X?A>`DPQ=4;266.(/.&3^H-A]E]1.@]Z2>QLWT%8`27YN=L=N?U-53VD^
M/;734W$`N?B[%_;D]H=PGVI4=4=BDR\I.]+^IH3S?63K?W#M5/4"3CN)/7AL
MZFCWNR6NGENNIO.-'WX>-H]2TWWT'F>.O%1!WC%OJ=N4H?INAGXSK,X7J.]Y
M'7CCAUEH5SM/J/0:>B-',>]7Y]A#RT"Z\,"RMTWC1Q59#`XGR'QM!N-X$ZTL
M&:J(K%>6T^'[UH<W@3:8(H*/I/(&+\-HZVPJEBNS3P$"U%V>&/E]QL5%/C*A
M7B0-P>=^+SX"V),RT8%;AAB\N'7M);%:NNPT)8<0.&1(!<[:,W]K:NKZC>+J
M<IB$*)PQ=GMQV8Y-K'%>,@W*NJVEB"LNS`&/0<\^UI44G+Q$6YGX2XF(](P&
M`V['8;VZII98$%Y[39P(A+@`D8@]>&P]C=K;?2R/=5<>@V*(BG#%.'F:=!NB
MSR(<L,<<2XB*7IZ=PVMW@Y;U:G%JALH,0].!W;/"TRTY;N#69#GEL-DF(<'.
MP<02,&EQK7$KYJF#+@BGA^@(+\'![VEPKB0[BS)D12[WOB]UI4*;JR(,EB6$
M1<,'OW$>3%L[3C<B\U3`EAQL<L<=GLV--CT8%=<K39F6$1B#TNW'VVD0BJ5>
M1P4:XNE#(QR,#NZO*<6V:CX#6Y%4PH9HF"!@<3M.0W$XN<V-V+>)"NQ=*]!E
MZ\@["HNR^];2F/0B%ZN3E6I(F-Z+\"]3QAEETMC[B,[KKF9HC8C(JX2]XRRQ
MS;2Y7=Z%4WM+S\<J&2HP`)&9.SH#AM:%<3I59$JB9Q"C8N>'CTCEDX8`/VM#
MFC5I5R)!&>HD@.Q`R>_#IVLHE"FTX.F]0E$4CK>,NIV]HEY5P65`Z5,C$>X`
M8;SDX.Z6C**I5HT\.TF0M^.'H@`[MGB:%?BDJ45:FZPCX63H4]Y?D3V[_&T2
M<8OS4D&Z*AG#B>D7OR`'CS:+=@O!@:.J19,5Y'6';MCSGX&@S@LW2AO%M+PD
MOK#AU*\&/3FT244U5I&U3-"GCL'8,?&W&32P1AR9)#5CAD\O/9OW-A16;-:L
M+B@8#$NV%X[6XRIO,V52+UR^CP-J;4)4Q02`<.DG!DE54-)IJ)Q$6'@;-A\&
MU[;03WL#@LR)9<`</,0\-8036#S-]ZI'QC$88.=U%V'7BW51Q3.%[LM^`A6?
M>NZ7D=F.#3K,4U3:5[=2K&60Y2=C@78[7O&]IMO"A`N-U:>52LM?$'[1F[?T
M8[?*UA8M4=5D0KE=VGA(/6$I#\W.=O=GX0U]8A%;$0I-J3*JXIP)^A(?TNP\
MA:WTT8N"22*YUJTR$Q27GKP.QW:UYI8Q246D56H>#3(%1'>D,7`#8<07>!K>
MW"/0J(I[[V=)%$CNX2-AQ<[#'K:PL6U6BIB4E^M:,@7'>'[0%`##HV/:]L02
MV*A37ZK#PFOBQG@NS!<[:1CB,<0T^"5<"EO)X[V*H5!'+R2'X[LSNSS:WTL*
ML\]JOPB*)%>@N<"D;O9BUW8@]Y98GG=1O+-MK$HQ(Y<'=CO*`_%K>S%)["CU
M6*9"N,2'$NS)QW[.MKJRENUP/+:VB6%,S6Q8Q>0<,!XMN;3-U.?@H5-VBQ*0
MC@E66`S.WPGH:UTT=R)Y[6-4:6?[AKX\88D.>XY>'`9-;VHMI,\OJI8-=!JX
ML<[,]N&6_HQ:?;5/&4-Y5JS5Q8JE/R`#SCMZ6F6U7K*B]1+PE"8BX9!1.UPR
M\+6%F+4,\*GG]2ZS\1HIB*HO<-O9V-.MP:6+*/44:K4UL59`4"4Y9=...;38
M/S4BDU3K%TR-),10HEQ&X=8[<FE6ZK/:4[;RV&JF(F/"\.&>+MG6TV$L")==
M<MAKEK4]R2,?#['-9Z2CMNO20;TJ/Q$(B>F7C-[RYXZ\VD[N/@*Z:PSQ*D:+
MB>%V+]V&_([RV8I4:VD+/,I*6K$;2YS81FBS)412`"<P])&_IZF*J=#+2R+,
M-9VAX&.6PXLV^`%Q*B4O<`Y:788D./B+1+KI'`[VGT[3:2Z]VS^*#F@*3KFR
M;!^;3K-M#42$8XY^QW4RYVGT$BQ5Q3VF]@*)`&>!\Q#1)THBYT^:.QR2O>%V
MP^5_@#1;B1/B=HD"1B_-V6P8^VT6Z76EQ53L#<*(L3S',*!4IQVGRAOJ4GD?
MINA]\Z_,G#%WOBX[<SM[&A7.T^BA?V#2S1#HAZ`#[-^;5]SLEC:[1H8N:3L?
M_$EH-W"A86\C41"_C=T^#/Q-#N,F["@M7I;'N[/O6Q6BH6$<BI$+AF<"<!EF
MPR52K,`[!CU'SDMJP1%3]KAD,=@&)[6Q5&&F90U'+`89D_0N_P#1;#QQ,QBR
MX2.@G#P%WD;2V\'UFDH)K94EAEQ=@7G`8X=`W-*AC6I`N0JJK(N)3B%/P.*@
M_#L'D;K5;%@1)V]Y>8;&$0"D`G`NP)<0W6V\'T$><'3J+B<#B2'XX'R]+3K;
MP1`N1=6BS#7A[\AQW^S:TB':(THRRHJFS@Q#P@\71G["TVUD1+D=NPV,.(K)
M^6+3%1-$&]%4J6PMZ#B0'';EO:5%T="#--8&:(F`'&7@8%[28Y+(@S33RP+*
M(A/T>73C[3;41PFJQ:69,(A&:@'=)\S3+3QQZ"ON0^(E1%!43Q8.Z=_6TJ.6
MTY6X-X4,U11O/C;9>"E3$X/Q$B(P(>2Y^`=GAEUMBGQD&<=UNID(F+@7G><W
M9%M7%[2*X.K>RI,(@Q`).+LWYAFZ\S5PD\3GU@1B_8XOW]C8<:K'(VMVY*57
ME0Q$9Y#SB7G;AN`W-%NQ6/0=GX,@F*02'XGKP<!TM`G'=>.1@L)B'BS>`[,G
M/8?$QQ\U-9$:6$WTU)TQ'#C4HO>7#8YSVCW(UP,OH1.%X/?F#AX,.K%H4HMO
M#(Y9OP$R3@$@_ANDO]L-%N1Q.L<JDZ5%X0DG$[3B7G(]#0G#&AA]+.>+A6OT
MLAGM\6]N3AOK(YUJ68:\`3F]+O%Y&B7K;;W4E0WSR)#$?_#.Z3T]#090HL4;
MI$T-9X<]@).6]N/JUFTC#I4)6>+`D#':0_#%[-Q/8C*2,BL;'=H+<I66Y/!&
M>HQXNGRL]3X$8Q,@L;>QP+:NP^A&)98F*EE*@#BD]KL!EX6VA;H\D<FD^L1(
MCT``[,#VC!I]JW66-#59E?BSQW/Z#@XMWC:I)*BI4Y7NR^H`\2207.?[.UI=
MJU)/`K)53144I[WEPQ<[(]!'0<FF1M/>32(UY5J5UJX5$/<]WA>UK8M-M25*
M%;/&+*L17"07Y^Z[V;VN[%NJQI4AW,_$48J^!1>20>$XX[AY&M+,/-451217
MS?G5700>LX2<2Y6#NAWE#7.G@Z+>V%5J*.JVE9<5W$07`['ESWA_8US;CO).
M)37L8^%%>)%#W/P(#SD??;&L;$'E^$4U])MIE6+&X7$'-X=TX.\K7.GA*E"E
MOXX/,JF(DH)Q?P^3##M:QMQHZM8%+>JJU*PB'''#/;GO:YTT4W2.9Y[5I5DO
M`118KTJ(P)S'M%KBS![RQP/.ZA-&O7$4,0YV6W[UK>S%;R92:MQW65XJQ@]9
MR>HO/EW->64DLD>6U;5,36Q5NQ*AC@'$D=N/0TIQK+PE+?E%%$Q'%6.`&0)?
MV["UKIXM4P^%3SFLDG7=^&!KX\4![O?$/PP\[75J%4JY'EM4\).IJUQ%8CB]
M([7^';FTV"5<,RCO3CNXFM6L\1XE8!^#WY-,MQ;R6!2ZF3RC7X,I18A()&(R
M`/M88-8V8N,<2@U-R/K*/.AHYE:B0`7.)?CM\.QID$VZ%)J)1I2N)K(BG!1*
MR2'OQ:=:AM>12WYNDJ]&!IXJDOZLL'9[_`TB$'5,I[DFDTLV:R.4AX>]^+\R
MX?>--@MNQ$&Y-HI+>/2?U#9T8;&L;*\SQD&]-5\XJ*B8G8[#H._JR:1'[I`N
MRJZ1J4XBW*=L5AVG;VOS;%7O$-R5?&1K&6.(Q!/C!8Z9HZ;\:F(40_''$''Q
M^')CR3&_'XBU"6X!QQV@Y.?AV-EXHY2G67FO874*]$%Y]\,-F#W-#NY->$DP
MFL]AM)=6/1D?`7-7K"1-B^C,W4'Z'+9CM;,\&ZDVQE0WTL<'YCSO<YHESH9<
MZ;&G0=DD<>')[B.H`M&N9KJ+")VJ0SPSV^SJ#1+A<Z0[`W`L3S#,%!)>`"\X
M>#S-]2ESLGZ;H??.LSBE!1#_`$>(N&P8XEH5S!OJ+^P:*96KT@\NV=3SAVO:
MONY>`L;7:\9IXI.>X9=8+0KNPL;>TTL11`4,'G#Q.:%<SKX28J[OB-<M:N,G
M83@_H&/D;&%/"B?&M%U%"+$4%<(.TX;/8X-E95%74P*@\[0X=KC[;:RQ1(LQ
M4FTS%12_+/Q``X!N9W]7#H"5#`<(P&/1M'B92H=N"R+$-8+P<3OW#8,FU@W3
MQG"<:/P%@*!(X0X`X'?OP(P>TNV\<>@A7(*N.183$2X/&6![,#L;K1O817&F
M%#8(BEV"7.QSR#OPK;VZ*M70BW;>TOP%<0><<'8XXX=&QIUO"F&)`N13V%R&
M0\O0#T9>9I,'YW01Y6TE5HMPU#A<4N(.0)RWO`:;;=%XR#=@T_\`5+D.(1B_
MWPP]CL6EIXKK(-RW1><L"Y"BDI*2[[W9DTI,@WH*M4L"TA0^^##-Q=XFDQ[*
MQ(<H1;Q)DK!RAA_7[C;X;"+*$E5_@DR8B"'%`?T[_`]I=O!YXT(DX++`S"T#
MZ$#P_P#HM+CEBZG"%N2>!EZQ)<.`''?[8;.!SN1Z3GUA&0<-@'L+,=A#N0J_
M-6)(B*%8Y`#M(P>6[**HF\R%.,DVMI.B*ES@'/+R<>@[AFYLN*84))5>9*8B
M3@`">GQ[,@VDH)JB1FC6+R(S$2EP=T$^P-'E!-8FKQ.?6!.(SS?XMW0T&Y#I
MR-4\:DB(H`3TAW:,7Y,W4X8+%HXM><Y$J8_I$/P!W['/&S<&ARBXO%8F/P2R
MB,3B_P"A</$XY=+1YPHJ)><:/(N(BO>H9<(<?!EU-$NPPW=J.F2H9(C*XACM
MZ,\#NQS:#=M_B])K+LUVF:HA*B0?H<]^\MM"R]U-K`PJ)8EI$5X(/X$=3W=&
M+VB7+5&\#,"="C@[<7>%HMRS%846)NV6$J]$[``#UY]#<EIT\T:X'"%DEYP`
M.6>SJ;9::$=ANJ$A6-_B/M-$NVI[[45@'78<<8W^(^TW+U-WH,><9)6'_>^T
MV?5S2\Y&)5W<2**IRP1EMZ<FZV[*E&M,3F9+4.$8X%[O".C>TV-E)5IB<\2M
M$47*QPP[1@TBW:4LUB<[CP?30@1%+B`<'%W2G:.PM,A:I1M%;<63*T2(0H8X
M$#RAQ[&FVK.VA%EBGUD$59S?B",.OS%K*Q;5<$5L\'3PE6)$*@.A)[>ESL&N
M[%JFS$AW<)5-?%7Q`X^D'>1K"-MQFL"ONX-TR*IC$AS\<?&';NAK73Q<<)+`
MJM1@Z["#UH*@GH/@&6QKFU!8..12W\*E>)$"2[\%ET9[FL;,&\:%-J.G:BM&
MB)<_80=FW;LV.:XL1JJ?A%+?Q=/`4O6#%V7",.G![L&LK<&G1Y%->>&)"8X2
MH$C/#KV;FN=/;RH>>U23<J9_N%>)&!"@[%Q]F375F&54>=U":PJ:U<8\3@`4
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M2K`!SL-N.?0W:-N2ZRGN2>2\11BQ!PD#-Y=GEX&EVX956&TA7+BC+SF:]40G
M`G%V`PR\#6%M*,:4*^[<3EYY75$2#BD..6Y_@P8U3%$&Y/H>)16MRG9@'`G8
M223X'MMG&NTBREM\)DI;P4NQ(!3CM&;(TVAR>9"%/(.QYQZ2-VQF#JN@Q61:
MA%X)*1D4^SL9%X4,-T=-I;@K4]ROOP)&\8@M"N=E]9)@_B-E!6KB#BX;,?$T
M*B;)EN;HJO$W\%9(3X_`V)]ILM;&1V26(X,MN/27AHL\RYT^RAV.34!P.PP)
M5X2]HMS-%C$[1(+Q+O#X6B7$7&DP^'4;_C5O\0:+5EF>89E0XSB,U>,!OJ7N
M=D_3=;^^=<FG\71Q*\K0KN;+^SL-',Y*&)!=CTN\30+B\VO@+"UC+QFIB9;R
M_'I<"T&[FBQMYLTD8`<3@7^EB=F[R-!GM)B[/B-7$]^>HGM^\9CNXYDY?>-;
M$]^Y1<YY=[N]L]1G_08DE(+B`X##>[9X6UF3-*DVT^@Q"B]+L7%[LR2!F>TM
MI3)$O=B2IP'X(E[9:66PTHGU'"%$*(>-KSX-K<X;>LXW%7$O(5Q@/(P>[LSR
MS>TN&\F0;B5:(G2K+#V@>D]#=6F\R-**>+I4NPD@#%0?D>ENEMO$BW*O#8;"
M"4@.&.X`]IZ6G0K1$*:52W#4<78=!Z,F[P[1RDDU1XHMPU+"<",RTVWV?`5]
MQ)O'(L)B+`'%U8#8TV.>#P(%^-8JO268<0A6T/<,FEQ;>;1!N*J9;1$+W!0Q
M:5!NBKD1)1Z5@6$1%`^^#BV7X41YQ3P:P)0M8.8#3(4PZ:%?<BO"#$B'Z(-*
M@DU5G!44MN1R(BR4\2AF/*V:(YS2V5)5+<'@$]C8701I56W$D0H\(*B[#JSR
M:="$'%/;0ARAYS=,3E452>$#+,!PS>>EMG"#&YTF<.*7NXL78O['MI.,5'P'
M*XO-\!D8@>X9DYX8#?VM#E':NR<#(1'8/?F/X+8_J:'>4?&$JNNPEXW`.()(
M#R-@VNZ6RHK<PSH<GC+P`1"'!^).`S<'>TT.]!5JNT:/[A.(G"G`YO>['<_;
MT-%:Z,S6M7B7T1G`I_`AW1D\^TT>ZEGM-J8U,T+``>?HB<\^@=+0;D4J^`PZ
MLL(B`NWNQ\6_8&[1BW;6&!K+`G1$]\?P8[3EAT-'N6E%-LW@L"\A>`Q&1?U>
M9H$X8[P9*%@C<`!FS=2,I4.89>7G)Y=X&T:J9K0E)W-S=M5Q-7/8CAY9ZN)K
MOR,T$/Q;G<M)QP$IUC1YD,0\*W['GS,MPHO":D2EN`/T)SZ,1Y&GPBF@T8*4
M'$;W.ZFZPMXU(US;U%,J<!CO[,FL;<(RIAD5\W4K+4\@[7>/W6E68)3W7DR)
M)YE9<4@NV/'WC6=FU&M56I6WL$WX2FJ-F'YI.[Q#J:ZLPWJ8$6ZL*^`JJ6Y&
M)#CT[/O<FEN-9T6PKI>=UE-1/I$;-FU[O<:UTT75)E7?>#CM*JE\1!00`'YN
MV=.+7%J,51=)27\F01(HX@\@'Z+)W1U%I]BJ*;4=*VE*-%(P)R&&7AZ6N[,4
MXUIB4VH71F4?6%)>][TCL/2UE"*G+'(I;S3Q(8D8<(?D'X898Y8M;:>*3PR/
M/:O-TV+[Q7B1`7`'%SAYO&UW8K5*AYV_5=14BX8OQ=T8GVVN+$4\RDU;5&55
M+<DO5UXC`-=:=O)9'EM;E4J+BEQ)QS`RV]N;391EOTCD>:UC;N-5PH:]2WDI
M#\!T''K>]K'36\:RS_=/+ZQUBZY_N&NC1"5`=.)<US:C1IH\QJG2,GTE*.4X
M!^QYQVM.@JNM,2@O2E1T-3,*!>#V^(^1K&U%M5VE)J-YRJ\S6K4>%1&0)`!=
MBTVU&+7G9U*/62\[Q&LB;GXY*Q=['-/M=6)0ZB;ICF:J,4\2@,VEQ<J5>92W
MVTI)&NBE(Q&+L'8/>W:"E)^$J9R=/":R(GB*B=ISR<!U--MPE@B#<=,371EE
M)<"'8=+NW8"TI88$"\U.6&="%2P0Y_0[!^U_6VWA1!E5.K*14]7"\8%QW/ZV
MPL"-.?G>;DCE1>[[\GR;W,>#KTC??QG#_24.DD8X%^3NI[FQDS&^Z%J"?1>X
MXC+:"#ULR?@#FZU+D%Q.`>\N..('WK0KE54DPE@;.%@L.ZO"]H2Q:Z:DNWC0
MW\`>]#G=/E#9N9LN[!V"66Y)'6/'FT2X\47.FR1V&44\H&SA_BB6BW,T6*R9
MVBGKS=[,VBW<RXTJPK\-AO\`B5O\0:-1%D>9YA`XU9^P-]2%RY+=/T[6;49)
M,Z]-'A/#L"E8[??;]S0+EUUV8EW9@JHT,XO@(`&"GO\`&T64G*+J65FVJT-%
M,15)03V;7O/FQ:'<Q:+"W!8FD7&+E%V]_;[K09[43804L&:^(OTSMP=UG#VF
MUWFEU$I8,H1<5/Q)>\]`)]UF\T28VHR57TF)`)..0&6W%Y;G<N-)$NW:5IU6
M;(\$J!!+B7^+#J>6Y^LE7PG3,E"B,?8]WD`;/K&W0T>=-ADE`)/I',$[MCQG
MEYVW7FK#-D25R2+*3P8#(/./@QZVZ1N2741Y+>)0KB+GD.&S#PXMWMW'-T.4
MH1BJYLN0X@2,22>T^=I4$\:$*XONEZ!$)/4.D''M:9"."QQ(=R&#9=]<D#,M
M(MI[Q&HRP(F3E''<<.O-IMKL^,BW(T=&6^+!(XE;`]_CS:7&M=A`NQ4E5DR8
MA!3GL]F;3(E;))DXB@';GN+2HI[J([CL9;]8`GZ+QGSMT5MO:0KLVJ^`S$4.
M!*E8C)YW[,6GV[6TK+DYT=%M,O6)/T2AVN\[291W(X'*TW.?G=`$0!0])1Q&
M9?YVQ!.69O<6#H2JC/'"DD@;<?;:1'3QE3>J0IQVO,S]=PI2223A@]X\#VZT
M4<%DC@TVZ;`8Y64D9CK`<,=[V&C5,SDQ>!Y!)41V!_;FVMQ*F)SN*L?!4Y$=
M6TXDIW['=+1W%25,D1MQ-EE"P.(DD9GP`98MQE8A-=1ON1R1FF*#GD[#J>,'
M;VWEIXJ*H\*'&=M5VA*WJ>\^^<,2_8Y^+1+EB#=*NII**:H6D$<+WOQ.&P8#
MIP#1)Z>,94C4>JC0MPXCR\??1[.QH5VRE'_6J;.U&A*%XC/!Y`W=)Z2T6=B.
M-:FFXBPE>`<<2GP>ZR-5'<_`1QEVJ;"=$0C+(J'FQ:#?FV_`=%@O"7$122$]
M!>>W)_4T1-R=)8(PL2PB(\.Z,.EWG8[:?2;4H20HI)R&9\C/5(T>)*J,!F/`
MW*22E0Y-I.ABF,I3\!AU^VVE#7>)A$&&_P`72V:)ARP.%>GB?9['-O"VGCM-
M%-IFO7%(`VC'#M&.;3X:>--M3??(3'(X@<B4N.Y[FZJ%)4(MZ<L4N@KJBDX.
M&T'M:9;CNOK*RY=:2973$?F3@`1T@NSZ0]IENVFZD>3>?25(ZR"]Y=Q>$8.[
M6L=/&B\)#O=CPU*RRE0!>7\)QZO&]K*W=G![*$.3V,I&(]+CL(?YMN6#6MBW
M&XE.5:LK))QDZ=!5$7TEI.`&`\&W%KS3Z9.CJRKU*:;H5%K"%!Q.(Q'@Z<\&
MM;>GB\ZIK(IK^-44X\5Y>-^W=X>AK&QI8[7\*%->VQ>917'*W9'WPVX;MN]K
MNQIU3&M"EU&#KL*9B$).).(Z3GLQ:=&S"M,50H]1))M;"O$BY#$X[>GMQ:UT
MMF.$JNIYO62:;I\,"JN(.(/)<,/9BUQ9A1J2S/.:BY-56%#&+$?]$H9;3NZV
MLK6\WD4&JOSHU15*<2(#@"<B#G[;7VGAE0\MK+]QO84E14\!#R78XO?Y6G0@
MV]YYGG=3<E)N>%:4->N-PDN>7G'>[$[VLK4=UGF=:Z5KM\AJXD=2HN.`)=F7
MCQM8VY8I;3S.IE@U@59A0XCB1D<^AV]I\)R366!2ZCLX&NB+2HD8XOQVGIS:
M?"<DL3SFJNN+J:R8BF&HI!+G`[7>5K33P4K>]MJ5%RERKD:HQ25GB?CB_':<
MLVL+<:*NUE3J(12J\RA%=Q$O=T/=D\Y/:5"*:H4.K25MM9T-?&4G,%63S['M
M(M))E%.4HQ?@-;$45`N*AB1F0=NXY-/MT*^<V\S61E<*^`DEZ7E^>9PSV-U<
M%)552'.6/0RJHC,%3R</`?X9L)..#(-RXXQ*BE!)!>7C/IV^SI;9P2(6\T_`
M%1<>+>'!WA\!!;&XG$QOO(X$5ZMF:@7Y=F]C@FJCUCVEZ`LE)Q+P?*?=9**S
M\!T4JJI;EUN5TO'B]LM&N6U3'.I,A%)4V&T@J>H*ZO.&@RMQC*A,AA1(WT**
M2$^$.]G0W&YVF6MF[*J6P['*N*23F<G9-$N+(O-/-_$=BE`/0`)Q3YR?.T:X
ML2PMS;BVSM$BY._%WG\S1+N9;Z2[)X&[]<GI\'NMQH6]6>;9A?IJPVGR#S-]
M1-SLGZ>[&21UR<()>-Y_%-7W.U\.@N;.9H)OTL-H&'4\MP?9?46=GM(TLWC#
M.'WHP\S1)YEA;R9HU#T5!_2/*[PM"EFR;:V,UT08DO<[`#L>?`VFWQDBF/C*
MBP=CP'EYWO>V$3;>2(\!Q$;`.S/!N5W82V1X\0&>.?0!DW$QL,N)P?OP=TY>
M(ME9'/;X"1)<79.<3Y0TE=+(,R11]+B(<C`CIW'#'$EF?4:Y8+,DAJXGDC+#
MBV^1NUE><SG<PCX2S#5L2'X#H=GO:P@GTX$&=72I>@Q%/<YV_KW9-*C@E7$B
M7.RV6PI0>\`];FD6]W>5,R+5%N$K>@.?UX[M[3;2\WQD:YGAT%T*#P].#_9L
M:5&M2!*NZ3!8)]Z`[:/O&F1JLRLG54J2!9XLG^!ID:;B(DJ;S+G&HI`=L&T>
M<-V3@0II-M>$X6MSN(!X'A#SC@"&G0>&#P(5R+S1P(F](=O]@;O<KN^$X6HM
M7&MM!QA^"1[.QMK*E5,VN)X]!)QJ<7)`\#622I7-D"XU@<^M]%Q`R[?(V':;
M=2.]YLX3%+C@YQQ(Z'/&38=I+-F&NDE5%X0"YY)<3DY^S)M)VJKP&MR-8'"(
MCSQ'8?1'0"\G+!N3MI85Q.*1,F8*B=V+O%YV.TDL6;42ZR01N(I<<'#'MQ&3
M9<:0=>@CS\VI(F+Q*`&14Y^]XRR:#.-,$<TJ8LN^MX88=M+L\PX/V9-'DJJA
MT2J6X<1P>3B0'!VXCH:+<MK>?4:RQP1,B(02<R21X`&A7+;=.@P^@L)B<7"X
MO'"\])>,.QN4H^;N[".U23+P5@[:5##<"YH%V&#708KB9A>(`+@'X[SCXFC>
MK-UAB6X:^EP\A;/JS#=25"B2X%P>>W!M=PT;)<@\[&X2M>=M.,GYQAZU"?HG
M/_`DY=C8]2S&)F8N#^+##9O[&1M^=0PTZ'"9C827'H.'B:5;MTD:4(8A]$'8
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M#;T'LV-::9+!'F-<FI89_N%0K"E8;GD=([`UU;K&..1YS456\]A!%B9![WAX
MPV;1DYI]EMM4S*#4[6\OW2I$BI&>&&>.>_`-=V*I8'E=9O;Q37'#GESR]Y=G
MXFL(1;1Y^_&66PHJB@DNR+@#CX,FGV82EBSS>O3=:_#`UT51$0D8XX#+K&1:
M?;@E)-GE]115J48\0EQ\';F,FGQ:K4JM2Z1R*2UX!P><NSP-/M1;\Z1Y;5UJ
MZ_#$H3"B<2,0,'?>-;:?\W195*J?FK>-3%40"_P[NG)IL&FE0J-1)4Q9K(BE
MO.+]^0ZBTJ#QH4FHINR>VGWBG$62X`YY!WBQ#2+3S*&;;3J:V*LI)>7..(S!
M&PX!IT%@B))*AK8YXE/<`2,.EQ/@:1'#`K+G:PR*Y41TA[\^CRADE55(5Q;T
M?"5EGTSMXO*Q8KPHC-;-I@<7C=E[.MLQ9S\('T0RQX@-C\,&>`4H;"![W%+@
M03OQ&1PR;7-'6WV?&7H/O@,W@CP8^-[<+BP+"/A-K!S>.GLVAH4^U\1)6#HC
M>2X>YQ<=N][W^1HESM,L+6$H]9V*64`GJP[7M%N;"]L9'8Y10`AC;P^51:-<
MS+*UV6=GD2_$[_,6B7L_$6NDS^'@-JW,O#SO,H]-6.T^,`-]0]SLGZ>K"P1U
MJ;20LX[3^*]MH%WM4\!=6323/HE^;P/*3YVCOL,LK2I)&CFCZ)Z"_L>7M#F6
M4,JFE67)/A\`#0Y9LF6LUU&I7%`B*>.CJP]IN>9WRQ*BXG$1L2"H]H+8R9,M
MK!=9&N*$OP)RW;%.;G=>3)C,!EQ`[L-V>#VXFK,0K;UX[#L'8RII+.AR%O["
M"H]C\6DK'$A3S)G\9XGN`?Y,2>G%MC3+K)$*/T)`]')SR7N;M924GTG.YV<2
MS"P>`0%$A^WJ\K38)5=2#<Q2-A!0LN]-(P)Q#3(9(AW4MUEGA4`>):#EEGFT
MB':Q(BI4N0EJX??#/K:9:BFL]I%N26\71$(`#QXNW8TR*5:)D2:\TE$0`#$>
M$-+@FMI7R1DE0>25`'<TZ%=U$*=5-DJ8KW8@NP>\;/(]N]70B7$ZTZ212U+/
MOTAP=BYI<755(EQ+,A4I20_C27ES@[IZVEIU=#C&*4J>`X$57HXC$NV88M(M
MP6]BZT-+E,>HF*U??T^`>VUC;6%2NFDB,Q.':'8![^CM;#C*N:(S;JZ'"(YX
MAPD.*ACAAET-KZM9O,+I995$"4YC'',!Y;64)-"[64:!,1Z7DX@`#P#8W%PW
M=N)QRR.!%>\/W]0.`[2SU;>+>`K3%DZ8WO1N`PZ7YEMG&JIL(LVW)O83PXF+
MWAX4[Q8'H#0KL,&D$JOP%U,3#>_'R>)H:6)LWL)TS#RG:#PA^#MC;.WYN\\S
M5X8EX17/3M+WG<]S0;EJJSR-4MI;@Q,!A]"[QAH\[6[&K9PDO.;+?K,G%Y*L
M3XG-`N6Z^,RE4L(5Q>B-CW];VX^I:VAI^(M)+PY^X]?2VKM[#"1FF92"X#%Y
MW.&&76V8V&\7D:N-3(QGEY!>VLK5)4J<I+$P4OB=ADVOJGTF*&()V8'?GXFV
MC:J\68E@C+UH!X3GT9'J;HK#3K7`YK%&2E.#B<'>#$>5IMN%'X`RG%^BZ7.\
M`;IN5GXR/-^<T4^-W"_,/<6DPLNKH5^I6"96BQ`E*EG%SGCM'MM/M0WFHK,A
MQ='X"A$CO>,B3AC@01U8EIT;34DUT'*\JQ?04X\<!Q`Q=T8/W]#6%NS5;M2N
M?:H4%Q>)`.T%.#\0X^0EK.S;<4NBI!NK%E+U[E*Z2<,,#AB.AKK3(JM0JQ93
MC1,"0=@[2]W8UQ!8)]!2W,G%E&(?6>B\`DO)\>74UAIX-.I37\'0KJ44E[P7
M`@>7-KNRJJA37Z5W65HD<`<)..!\/1T`M+W*7-X\_J8["JN,'!+WG';O:TL1
MQ5-AYC6U4GL_]A45$X3@1BGHW-<VFE&AYW4/M-%.)$))(.`/0=GMM/LM.10Z
MEX.GPQ(XJ?1>%!Y!]GC:\TZ\W$\GJY/?=/AB4EN"??`D8]K_`'6L;<73,H+[
MZ,RB8O`HOV]63VL()THMAYO7*LG7X8%:(LJ#P1T=74'-+MVW52;P/,:C;TFO
MB`KXAQ)#CEV>ZUC"$:IE1J6DNET*$;\;>]0..>\M.@_N'E]36KH4UQ7@D%^?
M8[I<UA8CO6Z^$H[KW6:R.O-Y`4=[LNIIEN*<5T5*?4RJO":>*M0(Q!S&#MA:
M;;BDW0I;V3KM*L9:MX&1Q=M#2;4<RHN4I(UZR\YA^+R';7[&G06"($ZIU*$9
M!?Q!0?PN[7EM\B$W7!E<JZ7ORZ,W@]3$R#<5%4JK6,3D<3V@>1P!8L)4(TNT
M8\?I`NS&'6<^MLY,UW:HD3B1UD/[7MG)FE#8RY*4XN.8\;:M>=XCK#(N2ZO2
M_@P[M!P;C/LD^.:ZC;05#C?F'C\2T*YVGU$NOG_#I-[!+G=#SXDAH=S,L+?:
MBC>2YP=TO:+<S1>:?+XCLLD.(HZ$^0N:-<S+.UD^L[7)#A`Q?B/(6AWGCXBT
MTG3\-AM^'I;G4NMX\\3'OU^S<WU$W.R?I]L9+QG69WWQZS^+:ON]OQ%Q9S-!
M-%^&YS<'V7U%I;[9HIC$`;WO\!/F:%/`L;;JC4+22E6\/?TNP:'+-]9+M9I&
MDC!RB<,'^%M-E/`=Z;/"48A<0-QZLR6UV5)UOLD:B\EV+AY5'S-RNY)$MF;G
M!XVOP\0('4W,U\!%L=L.[9@7O;&PT>+J$OP`?CB7YN#CXR6E>`A3>)..CWH>
M\[W>TVSP7A.?AVF:27J=NSV^%NME4?A-+E-VK+,(\..;R'#-1._-IMM8D"YC
M3H-A")VE0PQQ.`V#/!ID%E4B7&MUE@/&+UGKQ!:1#=WB+5$Z%*=M`?T^VTVT
MH[OC(=RF]XBVE1'WXX[<7>-I7FUR9#E)-$P5]^XNAWG>TR*7209>`Y!"B<5C
MK+O!FTR#\U$2:>\V`LI)"23B=N.>UQ:3'+Q'*<$L7M)027>DO)^9:7#LD.73
MA0*/"G:IY&>.]IT-V4J$=I9F`6\@.(Q&.6W>_!I]J"669PN)4?42''Z-7^R:
M9".P@3QV$94DX'UA\!\K9:2>-"*XXO88>MX"$NS.9S`)=F\,>Z$DBP8HX0\D
MX#%[_*6YR6!I<?FX`1CPX'$;LLAGCFV*16S$X=81&<]_3EGLRQP91/%FLG5T
M1.B*\@Y!WG'3G@VLEO+=1'E@Z%J'$)?BX<0Z\MN.31+D5'%YG2*HL<RYZ[#`
M[#Y![W'-H]JW2[6=,@ETF<.(0XE^:7;@YV)Q;>[;JMAI/%E_UW$<\,B7[=FW
M)H<K3BVW0+#,V$.,Y"3@]V#O.T7=WLZ4.,NTT3HC8<+]H>=H?CF_-H]VU5U5
M*&2[!B%^!QV^SI:#*-)4V&K>PM^N"1PI+B[/#`',/?FVT8)XM*AH1PU[W8G'
MS%NM%X`3&.[`.?T_>M%FEO.F1SE6ICZ]7X#Q^VVM#7$R$=^!X03AAT]9;:,:
MLQ+(B4O(@OQPQW;7M*A;PV&JP,S&XL"<AGOZ.MIBM)+)!JA3BQB\O5D'8'PO
MQ9&*WJ-(C7*;S*,2,21C@'D;RTVU;JTL*D#4KS45XD;C0L/Q/OO"'.Q:5;LN
M-U-4H0&J.I1B1/2`R'C!``[&LK<:8.E3G.FYXRE&7Q/RP2>H].;386G&6!7W
M<'7P%#UKD/)P?GMSVXY-86HT1`GBB@M?IJ#]IV^3%K?315$5-][K:V%:)%(2
M<L0.IY/7G@UI;B\UDBFU.3:*:XN((+B\;<\!AGB&L].GM*74MYE9<?$OW*<!
MUXO#VO=.HT5"GU$=Y5695B+"O2VX/=N\+VE;M)4//:EO/:48A(((.(?M:STT
M$V><ULJOP_N%.)$+\2IV;@3@[,.?DUS:@J)859YO4+"3VD2XQR'@W@]2LPT^
MS&,70\]J_N_ND42(IV9\)P/A:[L1JJ[#RNJ:4L2FM:@]^T98]KGEK:W&.907
MVJ8FO5$!5Z1)V`OQW[3D&F12V'G-?EA\,"")$("N%_"[8\G+K<TRRL4WM/,7
MXUJ4BMX+N,$^S%Q>UG;M[94*?4;NZ:Z*HN4D[SB=AV8M+A!5WMAYC5NDFE\,
M2KQ!*"1F"7@X^`/:9%;JIL//:ETEXC6S,5*@"00XX%P#^@O.+2;>"H46I;KO
M;#4Q%)*CB78;1@>C%I=MT*6\VVUB5HJ@79D.<-KPTBW+,@33290B8$N?YQN?
MDTZW/I(DGL95B*Q<7O(_@2/;;M2J*^?:P->HN4_'/%W2_'<7$-B/00KKK#QE
M=?OR_([`_##Q'`ACZ2(\P=G0>W'=X&R^DRB1*L0!EQ=H;-<CF_O%^"LN<<L,
M>LMAYU\!O!X%N74Y0&Y0/E;A/LEA',W$$^D.SQCW&A3[1*_"-]!/HI]FQH=S
MM,L;3\Z/6;R7."G;2X>+VFBW=A>:?([1(EWJ_P`*1_#%HUPLK.3.UR.7:/(6
MB7\T6ND^_P"0W3<2X/.TS@5*V'+Q-]1-Q^:?I_L9(ZS.^^[2?"I[0+O:\1<6
M<SKTR?2=O=YVX/LOJ+2UVC1QR`XG(''P$M"N%A:R?6:N(I/I.._R-#EM)=I/
M>1IHCN-6'HO?XAYRW.J^X2U!MX&LF0KC`WGR$#SMC_03K<'NTVD1(05<6#^%
MWAQ;G=Q523)..9((B.$$''`'/',MRQ.<D_%0K^L2[#:DGMVC+;BQ9UZ#%*/$
MD2\DJ&Y(':,/&W57895Q(\M-=>-,*DBBXA&[$]0R=VMU34O.V(Y.U)/$S"R`
M0-H>_:#N<W:RFFVSE*#E'>)X9X#Q$N>0`<^SM:9#&J1`N0E@DB_#BA0<\G:<
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MG)S94'LS-7!Q6(5%/".([O#V,=J<L$<IY41EZYR'#+`<78,@V8Z>YT8G#<DQ
M"BO))>_'MR\#'8N]"2,.W/864Q@\#<[#=EB]M7:DEAF<O52JZE^%%#B7X<0Q
M\&QHLM-==7M&[)EE$0%W4</.W/U$[<M^:\RE!.L>LG$0.`!VCB/9DR>YG^"<
ME5XO,M0UX!^#G@#?M'B:KNS3E7\$9O`OPXA2A.UX>.S/RMS>ZTMTXR7G,M()
M&695CVN:/<6Q9BM"ZE?"`2<<<=VP'K:([+WMYKS37:2B(`EY.&#L&Z4C3(V:
M3Q,8<12CGAB'=C:N,7L,$[RW"<8[QRDE4/+:[L36B#]^3%%5PS,22W3!410]
M[B#L\&3VF6H[=AR7W`N(D@%)?MVC'+KP:;%5-Z[2NM?%Q[\.UX`>VDX)2P(E
MSM,H1%$E.PX^9IEA5PVD*^ZQ*:HGA3B<\<GGP-9VTFTMI`9`N*E[^G$=.#2(
MQ:=-I'D\&ME2E%B!(QPP+CX'!K.W%TIM(MU53IT&O7&2$\!/I/&&]I]K3791
M3BL*E4V]YTR-9%CA"R7^CQ>!SLL.EK;36+D522*[5*J;VE:)'"H:L?H0[IQZ
ML&M;-MN2C3,I+V5"@J,XN>_'`;BXG`N:UM6)5IM*>_M3^&)!$BO.!Q<KQNZ&
ML[%N45B4NH;@\L"#C/""#B,]F!.+6,;4Y2K3`\_JZ)X%=40E_#Z6)QW#)K/3
MV9)T>#/-:ZF]5%)40O><"YYV@]/:UG;MR<E%'G-0L)-%6)'2-P(.'OL/`,&L
M;-B:>)Y[5JJQ,(DR2.(@$./B<[8UW9E"*W3RNKBE+'X8E&)-`X'$C+/:>IK"
MUY\:H\_>55AB45K/$DG`<0<[%^+3[,<:[&>>US5'7X8&"XF"]SL^SJ:PM1\Y
M="/*ZENC=<"DJ.E.UW4"?,UE%-M%-J'YM$:^/$602X$%YSSW'#:TNU%[<CS.
MLE%2IM_=*7%Z)>7$/(=L&YI*C*2JLCSVI<=ZJ[-#612J(.'<HX>''L:3;A/H
M*&_*M37+2I))<,M^Y[2X6YYTP*B])I5>PJ15D``%W4,GM(MVI8E=.]"2?24E
MQ<7G/)^\OVX;6G0M2:JLB%.23*\53P2-@?U%Y;M"+6#*Z4UO4>THJ6#@.L]!
MQ>QVY1=2#=FDO&0*420KZ)Y[=G@)#;>K;5"+ZZ"DR7A*B1AD-NW%M=R5*;3*
MNQ,0%<1`WJ\(^\9N2,.Y`N0U.<%8$@'^&(\S8:=?$;PDB[*DK4X9AQ\!://!
M>,G1N09NX04_<7`[\`#YF@S[1,C)/'8;N"?10_8'GM"6B7.TRSL]N/6;^5!*
M0[[\3[/"T6Z7FGR.T20/XWT#'KXBT:YT%E:[+ZSM<B=FUX/9BT.]F6ND^_Y#
M=MR+@\[S?\;':WU$W.R?I]L??.L3N8ZAY0T"[V_$75G,ZY-X*'6GREN#[+ZB
MTM]HT4SD>WR-#GGXB?:R9IHF1[?(6A3VDVUFNK[QJR?24.IW:[VFY(GVGYQ0
MF#^/?P3OX8!LKLDZ&SK(8@XCCBYY=U$GQ.;A/*AWNY$120,,,^PN#:+8<NL@
M(!2<7;![73@]FSP&C;J6D$8XX`H#]F0'E;C'M_&2I_FEU'*E<45^P![M^P#Q
MM.M94(<UCXB1(<D*V[OP3SYVEQS9$>5-A('J*7G$'/IV[LFD6I4J0[KI1(N(
M4'9OW#H:=!2:2>1&=6W4N\7HY;!M;O;[1PW<0E9&0]G@:;#%(K+L:2)H:Q]_
MS&3LM^QK&W5RP(-"8+!!`QPSZVG0JGB<IK%LY!!`]+%V3FF6Y.JH0I-[QFDN
M!X5>+JWM80EYRJCG-U:,(BED^^_A1O+3;;JL"!/==:G#UN'I_P`*.GH:1.M/
M&1)QCO8'!*P/?_PH]IM[476NTCWHK=(515_?O$/::;"+973:2P,3%)'I'#L'
MD#3(I)+I,M_O?B.41@E!(.W(=F\,;JR%<JV1JC$G##?M?XFWABSC@LR5,0!+
MR<3CTG`-VK0Q5["2%%>\#![\-^71@VKQ-XI+%YDZ8H3AM&S>#M[&X2S9'FZR
M99A1WAW$\@X'!P\6+VU6.861>AQQB\N!&)Z=HRVMK>2<*>$CS\&.).B*\C=A
MAO&QJR[%/9@:5H741P/?9[!N+5D[+<J4P$4]F1?A1G@':[+H]QN,HN&"1RGA
M)FPA10!GB_#KP=V-SW)MY'/$LB*`DJ..T[,?=;,H/=Q6`"8G$>+H``_`[&Y;
MBZ!4LPUCJ]OW6PX+H,5H6?6?@?'[C<)P\[(XREYQQQ_@?'[C:>K\!K4X5$<"
M\>/W&RH-;#$I8$?K'[/'[C3(1V(TP*BHO`IY[1T;/&TJW!TK0SB\$8JB\0XD
M]'A<W25O&J1'NX-E6)$!=@YSW[=WE;O:MN..T@7NR:^/$*4J(]\YXZ/;P:PM
M1JTUF0\RB8P(!&8<]/;CV-.A!O9B1+F'54KS$5Z7CP>'!I\(TQ?:(S>-?`::
M)%Q+Q@>'LQ:]TB?J4^LK+JK5E.,I^+\RK'P-9V://(K;[JJ,H>L('""YX&&_
MQ8-8V8?OJ>Q%)>VE>*L'HQ&'9O:S@FI5V%+J:IUV%1<0X!^`"L.KI:PMJB70
M5&H:>&VA`9@A.)<`[`@9/WN:VL1K"M,#S^I5'1D0CN4<>$$O?@1CV;0T^"=$
MT>8UR=?!7[Q4B14DY@X9^P--TZEOJO2><U*[315B*>_#?M[06NK:DD>?U+3P
M(EQ"$@9[LO%@TRW!MU\!Y;6)[U7D:Z*MZL`0]W7Y&M]-"EO'.IY^[C5(JQ(@
M!2-O$/9DUC;BZ4VGG-=&E:?#`A))*CQ=0=O:=;PHCRVJHHMO,I1B]_%L)'8=
MK6%MXHHM2ZTIT$418"``H9!V&W##)IUI/'K/*ZO"6'PQ-:N(][P2-WE?@TNV
MO-PZ2DO0>UE%:QQ'T2]V\9>VTNS'`I-1AF4(J@0?1=F1U[6G17FE+?C7>IT%
M-2@0Y^.T>S<W2W7$J)(U\1X)VO)+NEYP:PLOS2//-=-#`E[\=CQO/F>"R2HR
MNNI5*`Q4Y[FZ/%8$*\JQJ1G!1':.IV'A;6)6R63)DJ(P'X'QO]IL_A,S':C(
M+`6?_6*!\;8,^0G<]Q&XG^&40W*6#1UAD;&33PQ'NP+QXG^)HMQ^:NLF6\S=
M0B>,[N#^(:%/M%A;[*ZS<02]*3^!'D#0Y]M]?WBWM=N/6=DDO>IZO./::+=+
MS3[3L\E[7XIH]W-%E9R?6=HD??#\*GSM"O9EII/O^0WC<BY/.\W_`!L=K?43
M<[)^GVQ]\ZQ.YCJ'E#0+O;\1=6<SKDV"5#K3Y2W!]E]1:6^T:*9!<</8YH4\
MT3[>TTL3(^S86ASVDVUFNK[QJU`\2B[:/9XVY;"?:[1KI@'UJ2XAZR>Q[VRL
MJ$V&7C,%9JSP`\:B_P`3<+N1(NY(`CA2_'`>-[W^!M-IPE785^$C`@N>59;!
MO[6=!KGB<)?ECF#T.P\C<8YLES_-_$3IXB1AB_=Y>H-.LY5(D\_$2E6">P!X
MZGEI=O%LB/L^&A*_WH&3W=).UI-JF+9#GL9:A#H<-K^C(;FG0DW2F5"*VZLN
M*B0T@#`X#)Q\[=K?:(^-0(L,C(G$[![;3+>2(%U.IE!BH]+WHP^B</!BUE;=
M'@5SKM)_6I"2'HR.T/VY8M-MM[V1RN9LQXP!EB[;]ZTZU)517R;WWT5,A$/"
M3Z+_`+SI:P@ZR70:2>*.%K+GXG#9EGUM-M-4RVD.;0"WC;[.UI.;IF1IM)F,
M0G@.>1\C2+<=NTC7FMTUREG\'[.UIEJ!6W,$JG'K%D.=ATO]MS2U;A2K>)E_
MFZ^`Y1$<""#GL[.ECC`@W68F*''$=AQ\N;;6[=9452/B2)BI('I#(9G'+KWM
MW]4EF=(K`L0HB0_T@,\2>K+%M7&N2P%>@Q]:HK(#W$^^+WNR.+\G-PE!5(\L
M)-LM0E\`/$]Q.6T]0)WEBA$YR;>"R+28BB02789`X>!M9VTXX&LJ)%]$3`'I
MP=FX]K0KEE98T.*566DQ'O)Q+G=HRVO<T.=NCVG5*BH;&!$`2EY>79/QW.S:
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M\9%$B\:,W*`+P#B\=#R7-.C:363(<\'X*&L4HN).9<2.T;&N=-;I:C&A`G1U
M*42(XC:"2\;1ED-A:PMV\:.M$5.HS:*450X7@_0A^\8^)K#387$OP:E+?P39
M35&`(!((Z_2R/3O:WA!/(IK^->G]TJQ(P<7$?18*SV=+3X035"EU":EXB$K2
M4N>[$9NW];6FEC^]T>6)Y_4NK*O'CF2`K8=CSTM8VXJE$>:UL\ZY_N%<K(6!
M@YPS[>EK#3PBYH\YJ&UO4(HBW$#B`[=CB=[7$<L#S^J=4Z_#$BB*W*&()SVC
MMVM*MU>%,#RNK;4L,2E$42K8,!B,/&]K6PFX5VU*"\\,2"*M*0G!))/03VXM
M96+;?G-.IYO7)UP^&!6,4;B'ORZ.UK"-N*2>T\OJHO%O(HQHI>7.(>[TL<QT
M%I=M*JJ4.IR5.@@C*]!^&(?AL+G^!IL))*GA/,:NBGCG^Z:]9?D\8%I,)K=*
M*^TV45'$AYV[=S2;<DU@4E\I1"[B#SEOVXC!ID'YI4:AJDEX/O%!:P,]X<1N
M._'8TJVRF<L,2NM0)+W/<7=+O.TVU@L"+=PDB-2DE/$EV`V;]H+;2\)`DZR*
M6`5L.WRMNL8T(-S&+,3F3AB#XG@>1M5G0K7D8I4X+.T<+A[-C9;\[K"9RE)X
MB7%WK"7]!>/*Q&Q?@<)]%7X)V+MK<;GW3O;R-C+$/P(?Q.\(+1+F7C)D,7XC
M;0??_P#W?\0&A2[7P\)/ADNLV\#WD/J'D:)<[;ZRWM=J/6=GDLAU>=HMW(N]
M/M.SR6#NG+L4T>[F65GLOK.T2/O@>A/G:%>S+32??\AO&Y%R>=YO^-CM;ZB;
MG9/T^V/OG6)W,=0\H:!=[?B+JSF:"8#U'H`/C+<'V66EKMFDG/>^'\2T*18V
M_O'7XOO5=1_$EH<MI*M9KJ*)/IGI4?("W+:6-K,UTS_'(?66;6389^/R$"_H
MNSRMPNY([W,D8#)'4/.VDLSA+X?<(BK`=*<?$'MNEB8..+WW8.M[G>5HZ[7Q
MDN?YM$Z5>F7',*\9]IIMK"!"GD9>^2@=)\#R/&TNWT>`B2;HSE)]-)V)/EP:
M1;QJB)<PBD74K&`)S>0.HM806"6VA%VLX/$,7!W7Y0YN\,94..%:$L)"^#%V
M9:9#P%==?G'/`K'+P^XUC:[17X@)4[9X?<:=&5'D<KCQ9F];O?;/-U--M.&!
M73:WWUA,4@$''';V-8VJ.2IT'.:39*F,>!7HC;MZ&FPP1"DL2+UZ@2X;]IWM
M,AVO$<)K$Q5,+<<,ND[FDP5?&1[L?-*IBE6)`>UC;MTCM*Z]%-(&*79#)NZL
MIXU,N*]73P$7&3M/L[&W]7%$*ZHI8&"L`]MX*CJN@CHB]8`0X/\`$W1MLV1-
M"622"7G'#=D6SNLWR+:8P3AM``Z`]H\H+>9"N/SF3".7XXJ>\#8[-S%:3VFB
M+D&,/HMH)'M=&+9=M169I<6%2\B-PXG'$!WD\`:/<MU\ZII!5D6X<3%^>[VF
MK[EOK.C+\.(,#T8]`]@:,[6)#GC)EI$P5!V3CEO=B\^!M?5KI"C3K+:8H<'[
M<O.VD[:41)[JJ68:M_0#U;"W#U?6<6ZYER&H#(]+_*/`SU?6*D_K4[//[3<9
M6?.9RD\3'UGX+Q>XSU2\)K4+BIX3GL\O4&S"SYQB3P,4J20]_B+2K=I)U;Q.
M=2"*M_FZAM[6L(6\?$%YN*-?%B`DNV.)Z]@;#AY]#6<MYOIH4E1N%PV/QQRZ
M6E6;6-"!?6!5BK`XCX!O=DUA;M+>2(6>!KEK])Y/7V[/`UA"VF\"-==(T\)2
M7%VI)!\VWPN:7"W1>,A2(5QPK+`NQ&/5AT-968X4*^XJ-]%#63,5SG'TGG+J
M:RL135&56IS;**HX4DC)1#@[(A[VF6[?[Y%;"EU&*9KXRG9X8C'LZFM[<*8E
M)J,)8$,0O=^%5BTJ"V%5>ETE<Q%`$G'#(]8:WT\5ZI=;/.ZG,J^N))^A<=C\
M6L+<:>,\WKHU?PZ"JJ.>,>F<A[/`UCIH>>ET'F]0FMZN1Q$BO*2Y^0?O<DM:
M0AFWF4&JBG%OX9D)BD/P&9:RL6DE4\GJL)T^&9"N,7X@9>=K73VUN5\)Y^_B
ML2E&B$\+C]$UI;2IU'G=>UL^&!`"M^)PQ]F32*JE3RVJKNR*T4D/PS+L\B.Q
MMH.K10ZIT2ZB&*3P![@Y+SMP=U-,MY>,\MJL;GPZ36JB`/\`2+LLL<6EPB]S
MP%)>2*:E$DE*MX(W'VBYI5E/:4>IK3`JQ2]^&._?OV--CV44NHJ][J*,0/#]
MCG=6XMWMLIY569KXI(P.?T/M>!K&SV2-=S3,$GAA+'3Q#IP#P?`W1XLKV_.*
MY5B.C#R^VR+V$2;P9B58!QWCP`@AL/M%?3,P>\KW`#SMEYHTID;!_H$=(/\`
M#!L;4;A&!'\%XR6YSS1WAV?&;&3]\.OS%HEWL^,E6LW^3]\WD'W_`/\`=_Q`
M:#+M?#PEC#)=9N)<>@GJ!\0:)<[3+:SVH]9V>2]ZGV;FBW?O%YI]IV:3#U(Z
ME?BFCW<RSL]GQG:I`%SG?1#SM#O9EII/A]PWO`KH;@7!YVG$NA@[&^HJYV3]
M/NGR1U:=S'4/*&@7>UXBZLFCF`[BZ0GSMP?9+2UVT:.<_C:O9L+0I9EA;.O1
M,CVCQ%H<]I,M+SEU?>*)'IGK)ZL`&Y(L;:HS6S/\<1VLVLF0^_Y"NOZ+J'E;
MA<[*.]W)&"5`A(W8=;@3YVT>.)PD5SM_"CS-MM-3'B'I=)0/`Y[<(KS_`!$R
M>%M>(E2HA2CNX@/`'>5IMI5P\)#F2H/H#J`'1B7M+@ZR9$>TE>$`',[!O.WP
M-)M85(=S$RA'%YS+R?"T^WL?@(TG3`MJX>$<71[,&Z6ZN9&VG*5)`P#P\XO+
M3K4<,>D@37G#B&/H^/W&L;</.(=$<I4G'!V[,M.MQ2;.5Q*K.3$'W[9N]QI]
MI1P*R:6^^L@X_?',<1Z-K3H1K)4(\^T9"(Y*AP[]ON-/M1I$@R54V0JBN^AV
M[^D]#6%O"3?@(TGYWB,?6>B?1V;^OH:9;P:9QNNJ*YB='C]QK"U+,@7,D<^M
MP=P[-_1U-WIM,M?O=?`1>M(?Z3CU#VF;LF0[J(?6XEP?TO\`<;K:MXU;V'*F
M!@5DD`E^(PP\P:0]V/6,$6H2CCL#B_Q/\38WFS23>1CZ_P!/A3L.?1NQ&QH[
MMUDVR/+.A9A1#B\O+\]QZNEMJ4P1HV7T1>`@YO#^'KZ6PH5=-IJTY(N(62Y3
M]P[-G4W*2,811L(2_;ZB&BW(;.@P\2VF-Q`#8,S]^'N-"E"KJ1WA)ER'$X1B
M<?H>L.<V/5F&Z%E,16!?F7D.&.SS-B=M;ISS+R%N#P=F'2"W'<;-2>&LJ]F1
M'@V-NHT,$_&K?X@T>>$F<Y9CC5O\0]IM#!P5J=GX@VT>T:3[)AZQ0.!\C2(+
M:<D<J6]+SV]FSM:P@MH9K(\0A1/2`.AX\;FU<=ZY7H(\Z[SIT&OB+XB'9>D"
MTNW&BKTD>ZZQ**XY2"G,'J]$/ZFF68UD16JXE>,MV79V[6L[4?PB%=PBWX36
M+B.2]^)\3381WG0A2Q>'05#%XB7X*!#AY/`TR,714R(,W_H*,S%)P)WA^_)I
MEBBS*C55:->J)F_:[L&SQM96,;D4RENRS16BQ#L+P#EAN?U[6N(4J5&H2DR&
M)%`QR+E#?AX,6EVH[RH4FHBTZK(AXSP8A_3EMZFM+2I%4Z3S^IQ^'@*G$'JQ
M<23Y2UG"*P\)YG6U3PZ?O%,K'K$^EN\_0T^PMVY&G2>=U$JJ53"-MZ_,UQ;>
M-3S^JR?PVD?K'`^CM.WJZ&FQZ?`>4U<JS^'20Q(C]CLMON-9:5>9O%!>Q175
M$27>D,"'>/H:RMJ6ZL#SNN2K\.@PX\3Z7B]QI&Y6+?0CR^J6#ID4(K@3@_%V
MY^UMX*K11ZC!+J,8GO!A@X$=8`P:9;6#ZSRNKG^^/#X5**@,7#>_:TRWA`H;
MSJRFI(>=^_J:58H4M_(JKP?N./F+3HI.)4ZA)[S\!4.`+\MK;05"EN*J*,R`
M,1OPZ@7EI]AX4(<\<"L2.!7#DY_A?[3=MI6SJIT*@4\DYG!_7BQ+SJ$2>3ZS
M@G!)V>D?Q38?:(72<`NXST)\[-J-'L+B2Y"3T><-EYA9/K)D9CM_%-REFB3#
ML^,V4G[X=?F+1+O9\9*M9O\`)^^;R#[_`/\`N_X@-!EVOAX2QADNLW4N'H0/
MP`\@:)<[3^&PM[7;CUG9I/WG4?<:+=+K39,[-(YIZE?BFCW<_B+2SEXSN,CE
MVH\K0KV9::3[YNFY%P>;IPEZL3F?,WU$RR/TYVF_NG7)I(*B=HXG?[)H%S,O
MM.W3QG79K/P>4MQEV&6VG?G&AF@>$#K\0+09YEK#LFDBC`X;3Y"T*6TFVLUU
M?>-.HGC.)V-IL\9V3:H4XV8ZSYF;2;;;P*T0D!?\"/"6XW%@B6\2%Y`21O\`
M,&Y+%&KR,%9CV?0MMM-"$'TA^&]IN4.T^HVJZ$@+U8[22[LW=#3;&53=)5+`
M+PGH3XR?::3:VLUDENU)>)ZCM`(`\32;>;(4TE4L!82ESO2(?U8C$M/MXT17
M-5FWX29^3\<&D0:3.,J&<,X'#;[32X3=,,B)=INY&9/0&L]-)N3KT%=>=%AT
MG!.&S(M96L6ZD*;>)7.;3[:5$5\W63,8WO0[#/+#86MK,5A@LC,Z-+J*X5Z*
ML]K65B,:8I%?<:W?&4UDO..W>W>BK@1Y;O@..)R3CLW];3+<,EA@1[E''81)
M5GCXVG+=HLBOE0JJB>FK%69V^ZW5..[D;;T=S(&(\8/[?O6EV^E9$6XTVJ'(
MB`%RE`.WGW6[RB]W(B5./7IP=F\9N=GUMA6\<0#$>\E?8_S/;=**-<"2&L8%
MXRS?MS#V.CV$&XZS=.DG,88!)QVN/A<XYMINJIJETEJ#$>7%6(&_,;-K:SCY
MM39M*)LX2\GG##;D1VMPHCD\2ZF*_`'!Y[=A=CBVK47L0+:(J4.QZ,/9E@U3
M>MMW94I2I'GVF3IBO<7E[WN?[K:>J9RHR_"B`X/V/#S[N]M)VWNF'@C80E;'
M]'4[VVY>K9I4M0E@>'V/\#-QF*DQB!_OO'[K8]4WT'.69QZP??O'[K/5=1K1
MCC!^B\?NMAV]U5P,26!P\;QX6V@MIS*<:*<@H[ACGOVY-96X[=AA=)27$?M?
MD3B_V$MEQ3G5;#E<HV^DHQE\+G'$/\S=H1KXR+>7FE"(L$*4_9O\C6&GCYZ\
M!&*:XQ`<HO#WGHV`#%K6TE3+`AWHIITSJ5%Q'C`O&('7M\#64(JN\J%9<P?A
M-;%B8X'=M\C65I1<,D0I4?70@]<!Q!1?D[:[KZ&DV[2=&DBMU*S*\18X%'!S
M@,'8X[&F6X;KRQ*+4K!])JXJ\1B[':?P/6TVWDWMJ4UZF/3^Z01EX8OR)#FL
M[/XSR*F_BR`*(0"\YOS_``36NGW96_&>=U**T2,LG,>^.QK&W'[AYK6)-OX;
M#$Q`1B"]W9EUM+MK%,\UJ(8RZ##C&9><3[,VLK<:X=)1:K#'X9D'K`21CMW;
M^MIL51'EM6UO5(8A>>SVVL-/V%UGE]4ZSPRH1+<`.MK:W)5/,:QO=J_A@0\1
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M^SXRT@E_H-W+^_\`X$O\#0Y]HDT2>'2C>P!@CJ\P]MH=SM/K+*UVH]9V>1&8
MZ?*YHMW+XR\TVWQ'99)+B,,'*=_LBT:[FO$6MA>8^L[9*/X<-Z&AWL_$7FC2
M_P!/WC?\)^^GP-Q+*B/-TZC%3NG/L+?45++QGZ;K6SK.MS0+S@<U?BF@7,R^
ML9(Z],(Q!/1AOQ+<9=AEMINT:*9&#]S_`!A309EM#LFDB)(2>@*/A27>5H,L
MWUDNT\5U&D4D\9W8>(//E;782$L45(X]+HXW>,-A;&3;>PJK&$3J'E;E=R76
M2V0?0CK\P;G$P\B-7T/9^)8\CGL('^D=P4#[/`W./:;-C,>^3U+\S3+/89N3
MI5@3N2?X7#S-+MX+Q&L\DB2'D.L'Q`M(M[2%>[31(A3P5':/.,.QIUO-$"6$
MGUEGB"7$[6[03<B,\6$1"4D##'8<=C3[<4DB-=2W3DJ5]^/A+6NE4=]Y9%?>
M6'C,5*4[WQR.TM96Z5>1"FLRN5*?[Y7A+3H4W40)+SF<1(B@,22\.Q)W%K6R
M\NK[PDDTNHA]:>%6`R+6%EX%?=@E%]925&+SZ(SWM*MXR(DXJAB8I<?1'A:=
M:BZG"XEND'KCL'C+3(PJ5THHK*BGC.`S+=8VVL\C9I;AAQ*^_*\):RT]O"K2
MH1;F>!&J*'$XD]/MM*<:+'(B-4,!&)(]$#$>5M6E0U9,J*!LQ=AC[C<WNFIF
MB(5`;-X&W<V<.@AS_./K)Q$Q=MW^7<V5!=!E(O08CB'Y...T#/M;6[&.Z)]D
MV*(A+G9/=UXX%HC2?4<2\F*$@';F!T[1U,44]@)X<7BQ.9S'1L=U-!NVUZQ]
M9&FGO5+B8@!&_?CBVGJ_`C1U1?@Q`\;B_?AO\;:7;3<*+,YNILX<3`G<,<^P
MM%]1<\!@(F`,22-CGL]1<\!FE20S*CBE((V$O>SU,_`:-*N)AZU>;S_LB[P;
MFQZFYX!@2IF"_P!)(=T/9*U.F-*&DTMW`G$4$8`;\_<;:W:=-AP=2E$42'[\
M.H;6GQMO9D*E):W`GI\.Y_:VRMO>>52/<?G,I15O<-N+ST[6EVK66"(UV6\C
M6QE\+R.SJ?YVGV;3WTVE0C%*)$>\;1F-^[L#6%NVV\,B/<R;\)25$*>H[/*[
M<6L+:V["NNI2ZZ%&(MY)&`P]SQM/MQK%-9%7/"O44U17%0.W;T]FYI]F.W85
MM^6=2NJ+L!>-@V.&;3HPK)=!4:A)IE.*L'/`\3O$TRW:K+"E"CU$:/P$,51W
MO]%6UK",%3+`I;TFF1PUOA>EV?[)K/3P\Q-9%%J75E&(K$AY]\=_2UE"%$>6
MUM4_']XP>79E[MY:7:MO?3_!/-ZAOSC(*&`)#^OH:SA;E6NPH]4_-^'20`@*
M)>-NT;PTR$7FU@>4UF+I\,R"+$R#W8/>#UM/MQW<*;3R^JJIT705UK+AZ1S^
M_>ZT^WF>8UE=WX=!@%>C[[Q];2'F><OKI*4>,@*<22YW3L+2[>SJ*K59+X;2
M"(M)2`_Q'<6G0^^>8UCJZ?#,J@D)4XD8'(D-VVGFM7FRJ(I!<K$/..).9:99
MP*'4JK9%$4XJ(Q#CVXEI]O)%#J<GU%2*<ND!WC;NBL;\QHJK4\#>"I)[`7-I
M)49#GDROF#U@^,AI%K&!`O\`_P!TC'\<\'\4VTB-L0/O#^&5YVR^TC:>3ZCD
M>^_@1Y2V7]\@O+QEGZ'P_B@VKS-NGK+$(/5V*/@);C/-$NQEXS92OOQ_!>=H
MLNR6<3>P1Z78KSM"N=M]1)?:7B-Y`#TI=L]H-$N=IEE:[4>L[/)C`'I=XPT6
M[Y2[TQVF1`/`_<K\4T:YFBVT_9?6=LDP.$EVU'C>T.[F7FD-^W`LCS/-E7&0
M>E_@&YOJ+GV3]-]K[YUV:4IY#_OPV??F@W,R]L;#KDVI3\]WXHN#<)=EEMI<
M9&BF'@`;2K'P*:#,M;;Z3411@O\`"N_A6A3^^2[7:2--%3PQ"`-Y'5P@-H\L
M.@E+,U\5[]_IO\;8)=O)=9`0.)8=F!^*;G=R7C)C*\0`(PS&3<D:OM+H(1Z2
M3Q8NP_A6=9H\",(3Z6'T(\[:+M,Z)9]9FY/$`[(*?GM=[32[5=TSY24!)ADN
M<\?BE8CP-*AG3P&LLTC-R0EPVJ`VY.#VDVR%/&;9,@)"7NP">G>&G6]E,RNG
MC<:\)R@\:AQ988;@]I4$DSDTE7K,R0,$AP]UI,)NF'20KLJQ\82`27M9Z7M-
M^`KKV7C.%&&`[H.]K*W%XD.:>)7?"?\`_P`33K<941`DGO,XB^K*0[S[BUU9
MP2ZOO"62ZBNK`*'06GV<B%=;W?&4%$`E^]IVGBYSHN@BSJU@1J47+<<`DD8=
M#6D(42JL2/=5(HK()+WG=YVF1@L"NNNE*%&)$5QJ><`H[![32HVU3%8AOS##
MUAW^+W&EPW4O`1+K55U&*5%1<<0YNV+V$9M&8&(ZQY6U<&UB:DA*1TG=CY6*
MR^@RH5Z@E?I#8X8#/$=+;*RT1)1I-]9:"TO!?M'E;#@ULQ-2XA>U^(#FX3MM
MK%&DZM%M$P$@#B><.S>]N:M>`YI-EJ'%Q>5/+\>IP#\FV]7X#:C+Z(CMNSQM
M#N6OWQX$:XTFZEZ&L*(><7AL>J\!'K4V"%A(!!<?"VL[7FY`M)F2D<+WESCA
MEAD<,<VX>K\!E13(8<0DO)>2?$YVYGJ_`;T1;$4@`<7B]QL>J\!QDEO&0B*.
M2O$/:9ZKP&,#GUBQF?$/:;$K-52AK*FZ<B,07\3NSW&S;M8T2P.1"N9X\`7;
MMH.T[-@:=;M*BJC1JA2BQE??L,#V;VZNPE)T1%N9LUZXRQB_>[SM(M6L,L2%
M=;2J4XD0J>7Y.]F33[=I*CH<5)/+,UT6(7O?B_!IUJWA1+$X7>SXR!44*#CF
M,.L^8X-*]73+(@W%3+H*,57"2XXD#P9[>IIEF#2HRINYOJ*:H@.)S?EO[>EK
M"$:*A5:C:527*+MF?C:9:3JN@J+KV%:*L$[GX[]CFL[5%LH5-]HIJ6IY<K`X
M;,FGVX)JNPI=31R(E3"X;D9CK&W'<6MM/:\S$\[JB!<5)<58'BRQ/:\!I\+;
M9YO6O%_#81JB(<7'9A@?::;:@E))GF]0FU*A`8J</2QZC[36$%L//ZF,J/X;
M3`J&;VFVU';D>6U47O4^&9B]!SS'6TANCIM/,ZEI3H^@C6$.'7TM)M]H\UK)
M1W?AT$3D</WK2:XGF=3*)5BI2\8;O(6EVWEU%/J<D81$IX<M_D:=;:IXSR^K
M[7PZ2J$CA/:W=YGG]5B5?1?B-OG.YI=AU10ZE8NA$>$%0(P(\>/E:?;R11ZM
M5@WMH0+`W9._BO::04L^RRFKA>0[:5/\+)K!,B3R966`"798^4MTL]D@WL_$
M1C^.>S9Q-TD1MAP_T'=)/E;+S1F79\1FGWW\"GRMEY>,A;/&30R51"DG!ZL.
MUL/M&_E+Z$@*PP]$^7W6X7,T2=/D^LO2^!)R((\9+1I=GQEI$W4`D*S>\>4%
MH,^UXB3M.Q2XP3U$>)+1;G:+*':BSLDH\`C8_=TAHMS,O-/D=HD@H>K<7^CC
MVJ:+<[1:6*[KZSMDB%$%Y<,//YFAW<R]TF7C-\Y7W[Q!HV\69YNFP"I0.TE_
MB;ZC9]D_3;:V=9UN:0,<_HOQ30;O:\9?V-AUV:`!PVN\I;A+LLM=-VC13`][
MTO\`(T&>9:0R9J(@<%?A?,6AR^^2[?;1IXP/K.SV>5N>TE;36Q1[W>5*\1+-
MC)EO)=94B%Q.QXS_`((MQO5H3'D0J4%`/]F!;D]IJ\B!&2NO^);8U9B/HA^!
M'D+<OPWX_O&ZS\9R/XX>H^1IEOL+K-E]\S^@3V>0M)AVV:R)"?>CI?Y!YFE0
M(,LVR3B<@#>,>IX:?;S17->>WX0@^D.SRANZ[1'N/'QDBU`%VUW@ZVE6U7JJ
M0[C\VGA(GDDEKC1KSGU$&[B<*(`QPP+6=O-D2>TK\0?F/"&G6VJ(@3[3.8JD
M\`]).6\;BUI:V&LD\"FM2?2])/O3M#3K5:8$*XGN^,UZE)>?2&>\-8:.OK'G
MD1I(XXD\*O2&6\;BUK",GTG"XG0@2I/WX>$--A!KI*VYL*$52?6*](>^.T-+
MMQ=*NIJT]W(A,0`9;?::7;MU=&1KD'5=1BJ*X/R\;3/5TC5YD91Z2/UKU`XY
MCH\[8HD;))$AB)&_Q>VV')(5.41'G!X!\NQM7)O+(@W'Y[ZRVF('@DNWY`=(
MS;!H3F/APC_9=!=DVLUYHDL"Q"7D]YQ'AP;D:&SAQ'.VG=T;NQB1K*5.LG3'
MQSRW^3/!M'"-:D">,VV;&#'PSQ)Z/)T-KZN)K0N":`V@G>'8.S?BVER$=W`R
MH[22'%>,2_,^S:][1]R)L2PXO3T;/86;D06Q$0[/QCVVQN1.,GYQ-#6D@N><
MMWMLW(F#E:TA)./L/6VLH*F&9K+(@]:D[?)[;=;=M5J<RE$C.&!V[-S2X0V#
M,B$QQAQ..\NQZNENKBM[#,B7HT;9`M6/3X@TFS!-/I*^]D:^-$<"7X#`.[,6
MG*W&BKF1E@48L1X+SCMZ=P'2TFTEF<I2JJ/.I4B1'###=YS@TR$:OP$6>?B*
M2X^P]`?T-.M6ZK>V%5=A5MKH*:XF)=CM&YI4$L"HU&TJF,00_$8]9VO>TZU!
M-XE->=$R&)&2<R[K(RV#-IL44]]U*1B#IS?AU]>]IUN/70I[^9&I3ST8-<6&
M_5IGG]4LW\,B.(<NMK&T\*H\QKG1OX;")2APG#8TVVE6K/.7YJDBN%`]&):=
M;5>LH]3--?#I,WC>,SMZFG6X+Q'E=6UOY_"IB5`/]FQMIOSSRNK5;KZC%:@X
M9YM*MO$\QK(O=^'01<0=M]CVDUQ/-:B+((B@\;,L^HM+@LNHJM3A%?#:8Q""
MG`@Y^1ID.R^L\OJ^UXOOE5_HJZBW>IYW5-U93>\GK/E+3+&3*6^TVR!9?Q;P
M#Y2UA#)%)J.R^HC4H$@[Q[;22CN)J+136?2/2%@=CSY`V98P(4NRRLKS>VV]
MG)D*]GXB,?QWL/G;>1&V!WH/ZQY6V>:,OL^(D`Q!_`@>-DLO&0O*3P!Z:C^"
M(\;'VO$;^5FP0'J/4[PEN%S-=9)T^3ZR[`#SUE/XIHT^SXRTB;J7'I?[$>`%
MH4UYS)7X1V6`,$])!\(#0YXMEC;SB=BE4\0/03CVM&N9EWILCM,D"/5]0_%M
M%N=HM;&3ZSMTB"0<,R/.T*YF7NDR1O?5GH:/0LSS9->DHX`8G+L;ZDKEM;I^
MFB%Q[R6RIUJ:"L<LR/X9S0;MM5=2_L7&=<G/1=O]$=&9:)->:V65J]*+;1H8
MY*G%PP)\A):#<196;TI9I8FIBDN5EM\`&+0I9%Q9BFM[:C2QEJ,10#O9]XW,
MD5Q-;%47#\.H>-M6W\9,MO+K*48DA0R<'^,DMSN;.LELAV)ZQY5-R-7D80]O
M6/Q+9>3-68GWR^KVVYKM,VCD![\_A3Y&F6^PNLV67C.27(1TX-)M]MF)$H<2
MK\"`.UI5O,@W,*G+\<\D^#$-/M9HKWA)]9D@N](]'C:5;AO3H1)NK,RD'TB6
ML;-J+P(=S(@4M[^')V>1]QI]GS)8;2)-5=")2B0XE^>9):SLQWFZD:<4FT1`
M/>UG:L1<4ZD2=N-:XXD<;WOLW%IUM4:1RG2J15X>)*B>D>=K;36E*6Z\B%=[
M/C*:T!YQ.;7%G30MRK%NM"-2N9647/'7YVL;<4J>$YW(*E"LN(4`D.R'E<TZ
M$$\"#<LQ104LE1)&9);9R<?-6P*U%QH8^L?A@TF$Z8D.Y".]F8*BE6#AGTM-
MA+UCW7T$&45'(PXB][;NRGM9S,O6'<&U^CQZ68H9B($N5M(>X=#9^CQ.$K:<
MF9)C*6XEP<=F`V9MGU$?"/5Q+J5O3U9MB6GBU2K-+D$HU+<.+@X.?@?;[6PM
M)#I9&DUDLRY"C':[,^,>VVWT6WTLYT+:"\O.#P\]C0;EO=FXJM$SC*VFZEQ,
M78@[<3NZFTW3*LQ+*3@-_P!ZVDH5CB)P2C5%V$K#,/<,?+X&Y>K1RH2PE.SW
M^!X9ZI"A<&0;C)4E0X2[3)41"AX`!>VIJ(D8J00X#+RMO".]*AB616XST>SM
M:0H45,3F5HQ#G/R'E;K%RBZI#$IJ7PAP[.PO;M&.\U)YD>YFR),R3[]P.P[^
MO'-I]BVE+:5U]46!5BK..6SS--5M,AU-;%BDG!V?A<YNMNTDZ$:[A&OA*RXI
M(=@\8/Z_#BT^W!4IB1W*N?0:^,L@G+9[;6%NVDE'80)_>*8B*>HYCV8YM,A9
MBWU%5J8IU(%Q!V@9;&FV[.*Z"BU$6DR%7IX^3J:7"RJT91ZC,K<+C[X]3\,]
MS3[=M;M"GOMD:XJDEP`V;_;:=!*"W%D4.I=2.)&][EGTM,LS:5#S.N57\.@B
M,5X(.[<6GVIMT6T\U?B_.(DK!/MX-86VXM%#JXM+X=)(2,W^/J:;;G)K(\GJ
MZ[_PZ3%2T#`G'HQ:9;TZN><SS>I?[X^HQ*X:G!YS`R=GO:=:TL<ZGFM6_-?P
MV')2D`N.0WC<6D_1H>$\QJI-1<MI`J&E>+\G9=K=H6E5+8>>U.IFU2B(HB`$
MYG(Y8;&F0BJ>,\[J9-RK\,RN"'$',X`^VTAV44.I=64U@(67;RTFS:BBBU#I
M*I44?3Z%`CQEIT8I(JM1V7U$*SP@NS2?;'F;HG@4UU8/J*ZR]0ZU^-*FVEV"
MN>3(>$*`)W@>`ELVG1>,CNVIK>>=",AT1_0?.W>2PJ0IK=C5'(#T=JO.V)8-
M'%7'*BZ2?WCG8\0`Q]G2Q[#*LQ>)82`D%0^_$^,!FVO2'!(N0L7'H'C46XW.
MTB5I[<=QO;4ORZ<0=CTC\4?,T:?8+&$4W0WDNC$$;`_^$]LM!F_.9.5M-U-_
M+J+D%P?AY&BSS98VK:=#LLL_TB`-OL#1)NM"ZT]M?&=IDE%\,$#)_@4T*]+=
M:H6^GLJC6.9VV1478#:/!C[;0KMQYEWI+:W3=^M.YH_K9=!:>ICTGG&90"HN
MP=Q>9OJ9N=D_2]#M5.M322\@8XG\5[K0KN;ZB^L9G6YY&..PC#M):!/"'B+"
M&TT4=.(`P&9[4EH-PL=/L-/%3@KJ('@<T*63/0:?L&DC(=%)W^0#/M;GLJ=Z
M59K8HV?@E?B@V%]XEVU5(IQ1B=Q`\[<[N29,>1`I+@G<\>?VVX[#5Y&$$>^.
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M5T(=SM$!CI27%;C^%)\@:=9CYU5T$&:=#`S0!P+QO<[^):5NLYT(C,*+_3..
MQWN-FAM1$R8OHCTMF[W&49QEF6(43><'XX='4RC-6TLRXF*<GNV=?6V4B/>D
MW'#(N0UX;MO4=S9HR*7(:]I.6?5O[&`S^%//""].T[QAT/:!=[;ZS6E'X2Y!
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MHCTMV+C[3=%;EF4&IP1@L@A)&():1;BT_">;UN;^&PP(S:QL1K)/H/-W_P`(
MB]LM90CC4H]5E\.DRZ/9L:PLPHJ[3RNK[7PZ3`^=K"SD>3U7YU]0W=8:;;R1
MYK5]A]3_`-!PK)74?(6E'E]7^;?40@E.(+L'-M#M(\OJ,SE<7T0%;E>EV%V`
M#28K!]93:B-7A\,2LO)I<2@U.;*JSQ8[=O7[K2(*C*'48LI$^D#N?Y2TI9%5
M>?F/J(XGT?9Y5-E%3=[)7B'WI&\^,%M_P65DLF8I]Y_!><MFW]\T78?41D/7
MVD>'B:1++QE?/L>,Y2'(4-Q6/&6UEL(D<T2K^@[&/82XY,M)'HGK+9VHU>9<
M@)]%/2X=G%FW"?:1)L=A];-I+)?LPXDN\"FC3[)/M9F\@)])WX$_B2YH$^TR
MP67C-W`3A#/2X]FUHUS-EE9V,[-+)=Q.W^<-$GL9<Z?8=JDD@F&\?0_Q1:!J
M,UU%UIMO6=MD0[(;F@W>SXRXTG8\9N/5KW>,>VW*J+BJ/.\T@%2G9GB+]V3?
M4S<[)^E>':1UJ91GB,5'RM"NYOJ+^QF=9GTN+\WD-!N=CQ%A#::".0<LA[1\
MS0+F2+'3YHT\4AQ+MCAX'-"EM+[3XQ-'%B`K.!P+O$W/90D>`U\7$@;E/Z\6
M(EV\D4XJ,"=N#O"YN5[)(F,KGWH?T^0-Q62,/(A2L!)#CAY,1YVVS^(T9#Q@
MO#CZ2B/"X-QCVGX4;)T7Q'(Q4%;PKQ--M/S:>$V7WSA0]&&?9O:5;[3,2RH3
M(SB=8\@:3;S(-W:8`O!.]Y\):?:S745MW/QF23Z1QP'!V.S:?9S741'VC!1>
M\[RUA8S.%SLF.SL+3(=H@3=9$:LCU%K739OQ$2[F_AL*WK4@D9](R:YM/S"+
M-8(BBQ@[WIV[MQ;O#,CR5&BB9A0"G##%W@:XTO:740[N7C*2YE;SEGN:ZCF<
M%F4HDRMYRV[.DM+M[.LTGL*L697PG+(;.DM-MYLC7$G4J*B**<_?=&.]NZCC
M41BJ)FOB#C(Q=@TJW#81;G:,5(=B_P`36=F'G8]!73R,7-*W$<CC`,W##DD2
M!;@'#8V?5HCRDV\"2'$X3EF?*V?5G)ILN^N'`"XX.R+9W#2:\TL(F4A+R.G,
M;M@9NG%&:9OC(P+@2[$;MN_%L;INE0M0U/+Q@"'^1JZZJ7'UG&6;-G".3OOW
ME<W,P7T^]#-S?\U&D^R6X1P[`6?1GTHX$J/1SQS9]'?2@3A3\7-%N6FIM5.<
MEB<OZ&U]4^DQ0Y"^$O(;>W#=G5FLUYIEZ\??3XFDT1Q*,8N'3[;@P$!C!*`E
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MMAYDM8(N)`,/#!Y/C;+S\1J\RY"+@@='G+<)]HE6.QXS92ZAAA]$GQ`CSM%G
MV2=:[5#>P".(EQR=XC[309]HL(JIO996""[#,]@:-<S996<D=FE@X/S><O`T
M2>PN=/C0[1(+2HH>G($=.!+0-1VEU%SILGUG;I%0.2=WE:#<PB7.E?FT\)N^
M+\"KP-P+;$\YS3BHY@`%^QY;ZFY]D_2S#M'6)GH)Q)(?EF[PM#NYOJ+ZQF=<
MG@_`[TM7S[#+&&TT$=+R.IY\#0;BP+'3[#31DX'M`Z<,VA/;T%]8[)H8B?37
MTEW:,_*W,D8IFMC81`-^#M@>"]B)=MX+K((A>#T.\:VY75@NLF,K1$^@"-H\
MWN-RVF-I3'O5$X)`)).``&)><@V5]XUI5T6?[A"2E2_1(("A[T@A[DDY;<6Y
M0HY8=`HUVE1DB?H>I?F:79QB;I?Z0KWL/K#2X=IF)&<-25&)PJ2IQ#^%0+GC
M![CM<TBTTVZ$*]&2>*:,4>]'5YPT^ULZBLN]KQA[@M_0.TES6-O-=1$_#\9P
M<FGV,R/=PB8C)ID>T0)=HJ18C\`<`"_I]QK33YLX36+^&PPBRLU+<'PJ4FI7
MUJ?60?A,M'E_6P_]LA>NAH]8C'-+PUU;C)06\FB"[MJY^;E&5,'1IT?0Z-T?
M65(V7A\A;O#,Y3S105D>HM<:7M+J(-W+QE)>9ZVNHY^(CK,I1,SV^4M+M_@]
M9K/9UE6+[T]0_%%IL,V1[CP927$`#NCQ!IL(/!O(U4THI%81=PR]F]I]FVUB
MZ$*Y-;VTPB1R[`#/;]ZUA9M2WO$5UR3V9$!C*.SP?>M*]5(X-R9QZT[O9X6>
MKD:T9,%D@99=/MMG<D<WF9!9>'N'LZV;C,$RHX2DNQ.&&P'PX/9N,UFO-.$1
M%*S+]H#\.IS]C8W)''`MPU'QX]&XLW&9J;*$LX;"!AY]K0;D5ONN=3D\S8(B
MD..S9[N+:470"W"FD*/"E:21F`H%0Q<<`7X%M[<4Y;#2ZGN%^''#L,WNV^WA
MFW?<ZB-1DWKE>Q_ML]7U"C)TQE<(]GG;A.S63P1RDG4EAF/&B(A0846/%B'A
MAPH,.)&BQ%9\,.%#"EK4X9`$MKZGP(U;45632CTMT1ROUT*(J#'A18$5!X5P
M8\.)!BPU.?PKA1`E:%..1`+8=O=5:(UDU*&]%IQZ5BC'C/1[.UM:(Y%&)&\+
MW>[FV*(%92\'OQV>'//-I,$MU$>YFRDN(]^[QN:3;B0KV2*2EEYWG-IL(X$0
MIQ5O.'8/*TJW&B\)&N=GQE-<522\'I(V'<"'XM+MQ^(AS,!,A0#\%8Y9;SM>
M,&L;4&HXE;<S977$]]NZ-H:9;CD5>H6927$+\'/VM/LQH\<BFOY,QXR[8UC;
MC0I-1F0%9XMF32[:>>PI[Y@22`3[,VF133=4CSVJV_#8<>W[;3+;22/-ZW-_
M#8-OLW-*M-;R>P\WJ,I'((>&L[=,ND\_JE@_AM.5':TR$HGE=4O.^'2<@@I'
M7[;=$UO>(\UJ6G<?49)S[0TFWDCS6L[#\?\`H,U9*ZCY"T@\KJ_S;ZB#V@V\
M.T>7U&9#]$.UI<'@UX2HO9D40N>1L:9M11ZI5;1`]RQUN\.'G:9;S9YR_M(8
MF9ZC^*+=HY%/=REU%1>9_"^=LHK+O89"?H?X+\06V?9*R63.4AR?"W2SDSD^
MR8?1'K'E+=9["'/\W\.@R=Z`/21XU-AYT(*S1DO9[-@9M\1*V(LPSZ.+W#`#
MKP#9KBV8EG@;""E[LRX'Q88=I;C/"2ZB58['C-E+HPV>_'M-%GV2?97G>+RF
M^@(QQS_^BIH,\9>(L(F^ETX)PZ^OV!HMS-EA:6".T2Z"$X8CQYAH=S)%WILT
M=FIZ<4X;WX;'GS-`U':747&FR?6=PD$O>X??3Y6A7>R7.DR\9O.`]'C]IN!;
M'G";AJXB].0/N-]3T[<W'`_2O;G'>.KS2'9X%_G(\[0KL)5?47VGG&6*R.O3
M:'E6UP#O"6@3A+=+&W)&CCIRV#+^%:#<A)$^Q<BJ59]$^6?233.6TMI=X:G6
MY0*M/7_=,.FVZNOR$&?]7+S4S])Z+(2D..B((*ZG.R\:-Q`#B0M))<`WS1R'
MRWP.WR_#B7'[%FY>UFIW;?K(J5$WN0BD\MZ2E+PIKH/Y<]\//W-][G*[P'DS
M6:K3Z3AFB]9?5F;A648^MNSDTU56X2A&FQITQ9Z;<S^FLKICK!7J/2I)$A;M
M8@REQVY+0D<$O+T^HH5"F9*63B$P9&JRT>&A(/HPPD-\;<^<"AP+F2]IM/#<
MT-Q*[;2P2C+.*\$9J22V*A\]>YWG&YSAR)I=?K[CN<6L2E8OR;K*4[;3C.3Z
M9VY0DWME4\/36F6H`M`ZC?6G5_K&X^'ZZ/50?I8\U`TH*XO7?"/5_3(^HX_5
M\'K,'M0_L+BZX9^V?H]S]E5_.X;O:W>FM-[S:TI7`]U:YOY7_;W]U/IUC^\F
M?T>K]9V/6=&[7U?GTWJ[N-"O;&FE_P!ZTNMUJU+3J]>I%O)4:U4)"'!7`IYA
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M*Q>$<7L5+[H(<)Y4Y"U&IO\`'K/%>%V]3=NSU*=SU5B,86]ZVO6>>J44WYJ5
M9X)UJ_&E)Y>=;:S7ZK;%.TTN6+6:`(`K,O&A2DI+TY4]+0YV2AS%3FYN#2_7
M34I%3$1#3&4LH(+G-4Z3D_F>]J;NAM:*\]3:IOII)1JJI.3:C5III;U:'LM9
M[U?=WH.&V>+ZKB^DCH=3O>J:<I2GN2<).-N,7<I&2<7)P235*G0KDM6Y;`N.
M'0;RMN?HU9ITQ)S4Q1:Q+F"J:EC&3$A\*D^L@S4E/)AE`BPE1(:@2`200T+4
M:'6\*USTO$K,[6IBXMPFJ55?B<99554\3T/#>/<%YEX2^(\!U=N_H+D9QC=M
M.N[*E'T.,X53<9*+6%4CVZYO[OJ=S2>G4.IZ$U/1T2B*RN4FZJBBI76X2X%+
M0NF27TFA("96E>BLHC<*P8J70T8O^1>?-?>UL-&KW"Y\/W5.CEN>>J1\U;BR
MCG1T>*P1\$>Y'@VBX/>XK+3<QVN.NX[2E&WZUJTT[C]9/UK?G7,56-5YKK*6
M%/"%O<L^O=RTR%5J3I=<JY"-!3'EXT^FGT5<S!6`M$67E:S/2$Y%1$27I(AN
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MC13\X:O4:#E;B.MT<G#5V=#?G"2SC.-J4HR5<*II-'U!UVJ_*EH1=-`M6ZN7
MZBU.!7Z-].(M4H5`H)%/DOIA,4^*%2T>/)S4:-#^#E;H:@2G`>E@WROQN[RO
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M)4+(2%QHD-!47`OP;T/,NEU&K^C6M-"4YTGELPCF\DNL^/\`W(<=X1P"'&M=
MQK4V]-I:Z=)S?:=;[I&*K*4O!%-GRWU$TPU"TNG96G:@6G5;7F9Z'%BR"IY$
M"+*3Z(/"(YDJA)1IJ0FE0#$3QI1$*T<0X@`0_P`M<X=K-+-+40<6^G;U-8']
M&\'YFX%S+9>HX%JK6IMP:4MVJE%O+>C)1E&N-&U1T='@;:R>7W6K4BG(J]EZ
M<7%6:1'"_@]75"E:72YO@)0LR<_6)JGRTZE*@03!4M((<][6^BT&KNTG"W)P
MIGDONT*3C?.O*G`[STO%=?8M:I/&%7.:_*C!2<?_`!)'2K^TQU!TQJ,"EZ@6
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MKM-I\S,R<U4/4RM*DQ/2:S#G)"!'K<U343D])Q4E$6#!*UPECA6`K!IL4H*D
MFD<N,<V<M<&O1L\2UMFU>G%-1JY/=>*DU!2I%K%-T36*JCQ?5;:N*CUZ9M2J
MT*KT^YY.HBDS-NS5/FH=:@U-2TPT2!IWJS-+FHJXB1#0E*C$XDE+P0380:@M
M^3\QK,FQU.FOZ-:^S<MST,H[RN*2<''/>WLJ*CJ]E'4\[27)SS/S],^FT#1B
M[$RIA^M3"FUT6GU)2'/#J//U66JH61]`8(7T-M]*L9;QY.YSYR?:O>HEQ"QO
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M#V1;T>Z+FTFNB0H<G`,W/ST`4RK&G2J$\<2:J,K1JA4)V2EX*0^(N)"2B&,5
M$!Y;E&[:G+=C);Q0Z;G+E;B-]:/1ZVS+4R=$GO1WGT1<HQ3;V).KV'1=/-,-
M0]59BI2>G-GUB\)JCRT"=JD&CPY=9D96:7$ART6,N9F)>&Z8B0%A"02I927#
M`MO-QMT=QI5)G$N,<+X/"%SBE^%B$VU%RKBUG2B>557H*UI69=M[7-`LVT[?
MJ5>NJ.N>@PJ%(PD&?4NF0XT6H)4F-$@PH7P*'+K,0J4D)X3BV9+<COSHH])V
MUG$-%P_2/7:V["UHTE6;[/G44<JYUPHCV%T.Y<;POK6J3TVO"SKMIU+M^JRD
M#4XR"9:5G[2DJA3)V>I<2<FX@FY:5^F:Y=`A*2F+QH42D;1`O.*3N)K'+PGF
M>8>:]#P[@$N*Z"_8G>NP;T]:N-QQDE*BP;W:NN5'F=LYIN6"N:-W9<4W9ML7
MC,Z1TJG4&,+RJYEI^6E9VJPX,M-0(]1EH4F2B%5(Z(2"8(X5+"2HYMI:W;B2
M=-]["'R;SCI^/:*U#7WK"XW.<UZJ-8MJ-6FHMO\`!5<]F1Y(YA[ZJ=>Y=M)Z
M1,\NU1TVIT&):T6G7_-PJ&*=5$R]LSB(<M13(0DU2'"N2`LSCIKU17#A/(B*
M<H9M6U&Z_.3:V%3RSPZSIN9];?AQ6&KNOUF]96_O1K<6,][S:VWYOFUHWL6!
MZQZ=Z(ZNZI2L:?L&PJ]<5-EXJY>+58,.5D:2)B$`8LM#J=5FI"1F)B&\<2(<
M1:D9*`+2)7(0[329ZSB?,7!.#S5OB6IMVKK5=UU<J=.[%-I=#:534U[3746U
M[IEK)K]EW)3;NGC"%/MZ)2X\>I5,1E+1!B4J%)IF$U2#$7"4`N75$0]*@_T2
M[*E%K>36Z2=-Q;A>LT;XAIM1:GH8]J>\E&-,]YNFZ_!*C/*O[5'F013/IHK2
M2Y_@XA^L,!*Z/$J7"[B_J0BIJJA6[Z`02M^#GX-P=VVWFBC?.G*KO>I6ML[U
M<_.W?2W=WQUH=NY*X,Q+<T-@RDY`BRTS*JO"7F96:@K@3$M,P+4KL.-`CP(R
M$18$>!%24J2H!25`@@$-B\OWMO80>?IQGRAJ9P:<)*TTTZIIW(4::P:9<YQJ
M94ZSS67O1Z+3IVK56I+M"5I],IDI%G)^>FXUHT0(@2TK+H7&CQ5EY<`<`2<`
M2VMF-;6.1RY'O6K')FGOZB<868>M<I2=$DKD\6W@CQQ<G+=KO:-`F+HN'3&X
MY"AR4K$G9^=3]+)Y5.DX2#$C350E*=4)N>DX$"&"J(M<,)AI!*B`"VT5:D]V
M+52RTO-/+NMU*TFEU=J6HDZ)><MY[$G))-O8D\=AZ]18P=[Y^'AW;&Z^H?0>
M@H?2Z%I?IRKN]%:BFS+>-]?2V)-_7;]+X?T^^$C4PT@1/IC_`"0/Z6?C'"_@
M]7@YN"4UJ5:7Q>*I\37>+<27O&?#?7W/H&]3U=?,IZC>RR[6/6>@LCI;J15;
M3@WW3+)N"I6A-56%0I6N4^3^&2\U5X\^BEP*?+2\O$B3\Q,1:E$3`3P05),4
M\+WM904(SW&TITK3P'LM5Q3AUK5?0;EZW'5J#DXMT:C2M6W@E3'/(WMY<N^N
M-A6Y]=UX:9W)1+;0B'%FJI%AR4U#IR(RDHAQ*M+TZ=G)NDPS$6$\4Q#A)2H@
M$@ES=[5VQ<GN0E%RZ/)TE;I>/<&UVH^BZ346YZC8L57\EM)2\39XKMNU;HOB
MMRUMV;;]7N>O3H6J6I-%DHL[.+A0@#&CK1"'#`E8(4^)%B%$)`(XE![36XVX
M^LN-1@MK)&MU.GTMAW]3.-NRGBY.B_=?@6)WK4/EZUMTNHZ;@OO3>X*#0BJ$
MB+6%"0J5-E(LPM,.7AU";H\[4(=.7&BK"$^O,,*60D/40&ZZ34::_+U=N<93
MZ-OBKGXBETW&>%Z^YZG27X3NTRQ3?31-*OB/!16.`X^PEKF":H;3S96$?A5B
M7IRX2?(6F6DZXY%7J-I&J,%`E6#B7YGJ.`:?;7G)_@HIK^1R\%(=[,FFQE'>
MP*349D!SP:99E':4]_,D2H!`'2_QEI*G&IY_59G)6G?M:5%IX(\UK<W\-@XT
MOS\70TNTUO),\WJ/PCCB#\VLX25:["@U63^&TD.32H9'E=5V_ATD>#@W7=K/
MS<J'D]3^<?4<@D.(WC'PM)MPE1'F]7V7X_\`09^L(!?B_;T.ZMC3%"1YC5M^
MK?4<`@Y;FWC"2E4\SJ"$YOW$M+A;F4]XPB))!+FET:DJE'J7B5CZ*@3L=XFE
MVD>>U"Q9!$(>3LX2>QY;M'(I;NWJ*RL3AM3AX7ME%?=C+<(U`@I'X;\0H-L^
MRRMG"6/A.$D.<=^/4V]J22Q.$DU&C.`0%/Z3YW-O*<6TD1I6YRA1&22D\*3^
M")W.Q\>+8WXUJB(M/=K@B1:``"]^!+O`V=^->H[^JED3)22-P'MO'B#-^-.M
MF'9N=!L94`.>2\I)\)P#<YRBY561)L6YJ+3SJ;>6=AE[X><EH<YQH3[<)+$W
MD%Q4_P#`^!R?.]H+N1)T8NM-M3?RW"4PSL(#_9MS:-<DJLM+5J>">:.TRQ24
MX'?AVAHDYQJ76GM3PP.SR"2]/4?&2T"]<BVJ%M9B[?:VG<*>.)_9XGM`N3BE
MXRVTLDEN[:F^]7U^)N&_'I+:IYNF0>)6(.&/1T]K?56\C]*-OM'59W-Y&T@>
M'!J^YM?@+[2=E=9UZ9<.)W:>G<U?<RJ6<?`5J30YZYJW1K=IJ2NHUZJR-'DD
M`8B/49F'*PEG\##,3B4=B02W*SI;NNU=G16%6]>G&$>N32^Y6IKKN(:?A'#[
MW%=6Z:7369W9_DPBY->.E%X6?3;F%TMU1JMNZ46;H_184Q2-/XTE5C,Q*U2:
M2$52W9>4D[:3ZJ=FI>)%7"`CQ8BP"GB6,7O;YSYRX!Q_4:+AW#.6K2>FT;C.
MKG"'GVTHVL)-5IYS;RQ/Y#]V'./)^CXIQKCW/.H<==Q.,[>ZK5RY^]WY2E?=
M81:2?F12>-$]ATOGGLB;KNG-F:D1:<)*LVQ,2]/N*60I$PJ3I]RPI=,6#$F8
M*EPHT.F5Z#"AI6E12?7J()!:L]Z_"KFKX)IN-RANZJPU&XEC2-U*JJL&HW$E
M7+SFST7^7/F&QP[FO7\IPN^LX?K(RG8DTX[T[#E1J+HT[EERDTZ/S$GD=.F@
M_N['=$/]E8-!>/N;74O_`,4>AM?_`*K'UO\`_P":0\E(`T2U]&WUE1)_O*B>
MTVONQ_\`E?B_367_`+@[?YB?_J)RS^3#_P#%HV/(-4TT?1K5JL*ETS@I%:75
M/@JU!"9@TZT).=$$K*%A'K#!=Q./"][FZ^Z2]]&Y:XCJ''>5NZYTZ=VRG3QT
M*[_,KI'K^>^!Z!3<'?TZM[R_!W]3*%:85I7*JJ>M5FZ^ZEZUZY:*(OJJ2,S3
MJ=JI2*Q1J9(4J2D(%)74(\&`92#'@0DS<W+R\LD(09A<6(22HJ)+>+X;S;QK
MF?FGABXK.,K,-?"<(QC&*AO-*B:56DL%O-O;7$^5>.>[7E/D#W=\P3Y=LW(:
MJ[P:[:NW)W)3=Q03>\TWNQDY.KW%%9)*B//VO8?SX:'=$"PCX+@N=O:<U?\`
MU2X7U6/_`'ET^,?=Q_\`ISYA_*UG_N=.6.<;F1U2TOU3H%I6'592WZ7(T>D7
M1450Z=)3DQ<$Y.SL]+*DJI$GI>8X:;#E::E'!!]7$5QDE?HH"=_>'SCQS@G'
M+6@X7<C:L1M1NR\V+=R3DU26\GYM(THJ-UQ>"IR]Q?NKY0YOY0U'&N8[,]3J
M[E^YIX5G.,;,80A+>MJ$EY[E<;K*J5$E'&5=;WBDI)S$'1&X?@T.'4IU5PR<
M:.D#C5)\-MST*64MP4N'`F)B(4`Y%:MY;E[W+=N:X;JZ)7I*XF_!^]R2\3;I
MULE_Y7KU^U/F#A>^WI+:LR2V;W[_``<J;'*,4GTT70;'O#8<U%@Z$PI"#%F)
M^)/W.B1EX$(QXT>=4BTDRD&#!`48T6+,%*4H<>(D#:TOWK*;CPQ6DW=<KFZD
MJMO]ZHDMK;V$'_+/*S"?,4]1)1TZMV'-MT2C74[S;V)1JV]BQ-A-6QS?3,Y1
MKNU$YB+"TFBS$>7F9*TYVK2=,D2B`N#$7(S<A!E(5-GE+2>&*A4S.'TG%632
M9:/GJ<[>NXMQ33:*4FFK3DHK#\%Q2W9>%;TNLA6>*^Y6U9O\%Y9Y9XCQFW&,
MHRU$;<KDZNJ4XS<G.%,XM0MY5H=-[R22EDU;2.J)A0A/35-NN0F)E`'%&E92
M9H$S+0BOWRH4&/.Q5(!.'K%;RVGO.MP^D:*]1>L<+B;Z4G!KXFW3K+?_`"P7
M[KT?&=(V_H\+NGFHO9*2NQD^MJ,4^I=!Z,:,_IP:4_KC67_XBI[>*Y>_KC2_
MRBW_`/;1\[<]_P#R9Q;_`/UNI_\`<S/JWS3:<\O-W7U:M9UIU5C65-TRVS+R
M]MPI^0DC6Z(FK3<Q%C\46G3M0`BS*UP2J`0IR?1<K%OE[F;A_`-7KK5[C&J=
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M?#(M3?%B*A+6$PPE/#Q$MZWF'B.JT-BU#2O=E<K5TJTDE@JX8U/A_P!S7)O`
MN:N)Z_4<=MN_:TBANVW)Q@W<<TY2W6I/=4,$FE5U=:(\9<S5P3FI'(WIMJ!=
M")68N::GK(JL>>A2\*`/IC-PY^E5*9A(0D(ED3\&(M2X:.%`)````<UUR6JX
M%:U-VCNO==?"\'\9?>[[0V>7_?)Q#@7#7*/#HPU$%%MOS(N,X)MY[K22;Q\.
M+.EV1:'.#<&E%D3\[K+;&@^G%(H%)I]JJJM0@VU49ZD(ETII,]4XLM)+C%<W
M*(2J&F8FX1B0P%>I'$2<Z:UQ2>FA*5V-JPHI*N#ILK_[?$3N-<3]U^BYDUEF
MSPK4<8X]=OSE>W(N[&,Z^?&"<J4C*J>[!T=5O8'D;G5DIR9Y1-/9ZY+@HE\7
M+2[DLQ,:]:%ZB+3:W-QZ55Y"H56F1X(,,RU5AGB5P.0I6+L`ZSU2;T<7-J4U
M3%9/P^,\S[KKMJW[R=;9T%F]I-!<L7Z6+E5.W%3A*,)IXUADJXI&^N?5ZY-$
MN132F\;/@R/US35JV';5+J$_`AS4*CJK%-*H]31*14*A3<>!`DR(<.)^-&(I
M*EA24E"N\;CMZ2#CG1(A:+EO0\T^]GB/#>).?T&.HU%V48NCGN2PC58I-RQ:
MQI5*C=5X:Y!-1+NU6U_U5O2^JE#K%QSVF-`D9N>AR,G3T1I>EUF2DI0&4D(,
M"40L04>F4H3Q*)+L6WLR<IN4LZ'H_>]P;AW+_*'#^&<)@[>BAKKDE'><J.4)
M2>,FWGE5X(W>A_--JU??.?5M.:Q5Y*%I_$G]0K:D+0DZ;(PI&E2UF0:K$I4_
M+3@EQ4EU**JD?CZEQ3#6F,I*4)2E`3-W5ZNNTJ^:.1N`<*]W-OC&GMR?%E'3
MW)77*3E)WG'?BU7=W5O^:DJJB;;;=:VIG-/JO;W._;&D=`JE/H^G=-OFR[4G
M[:E*7(*A7!"O6%2)NLU.JSD:6B3J:@(]=4J`8"X2(:H040M2XA5WA;@[#F^U
M1_<,\%Y'X#J_=I?X_JH3N<7GI;UV-QRE6V[.^H1BDTMVD,=Y-NM,$E3QMSO2
M-UTSG4THJ>E-&AU'4FH6Y9M6H<F):#,0ZE<=*KUQRLA'GX4:)`@+EX%/D$"/
M$B1$(ART#B4M*4/&]JCTK4NSO%C[O+NCO>[;6V>-7''A$-1=C-U:W;<K<&U&
ME75RDZ))UD\$ZGGJR;+YMZ%JU8U?U>YK-.J=&GZ[39BJZ1*KTO#-<I$[,>HF
MJ#2*#]+*1)19V/#6J'*Q($.(H1@DB(H@D\6[;BU&+ZSR7$.(<D:G@FITO`^"
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MJ)!J%75)TF0ARWKX"Y:`$050UH'"2A)'.]%3@E:LSC)/.G[A5<SK0\3X=:T_
M!.`:W1:RS-4GZJ6,$FFIM1K*3='O.KJGCB>-^0J3MFG<QW-K(67,2,U:,K5I
M6';4Q2X\*9ID2C&Z[I7))ITQ`4J!&D8,)8APE()0J&D<)(<6Z:Y3^CVG/M4Q
M^)%E[QKFKN\K<%N:]26M<'ZQ25);WJ[==Y/%-YNN-<SU/Y(%?_MI4L;Y[5GP
MBE7#YFF:Q/Z&WX(_>/:^\''D&?Y.F_\`M0/8N3U`N^UN\DN:UJ!6H].H-^7C
M;E.NZFH@2<:#6I.E:<IG)"%&7,RT:/+F6F8JE!4%<-9XB"2,&A>K4M$IM8I.
MGQGE9\-T.L]U=K5ZFVI:G36)RM2JTXN5^DJ4:3JNFIT/O!M9-2I?5.\M((-T
MS4/3B:MZSYV8ME$G2Q+QIE4O!JJEQ)WX#]-%)549:'%*?7\+T@.=@V^CLQ<%
M=IY]7B6GNRX'PF7!['')64^*QNW4KE952JXY5W>RVLCS!SA)5$Y,N7*&A7`J
M-%TN@I7@Y"HNFU10%E^#DE3VXV4_I%SIQ_TE%R0]WGKBTGC1:A__`,^)W+G&
MU`NGELTDT8T]T@J*[/E9Y,U2X]6I<O*B>13[8IM,49>6C1X$:%!F*O/U3X1,
MQ@GUT12%>EZ:W\[$%>G*4U4K^1N&Z/FKC>OXGQN*OSC22C)NF]<E+%I-545'
M=BLE7+!'I-9FMG,?J_K!IC4+9B4VY-5+3HE<M^W*E,TFGP(42F5&6G45:JW-
MQ&!3#\#DIQ7%,!$(`I1Z"XBG+D2M6[<'O54&?(.NX#RKP/@>LM:M3M<&O7(3
MN14I/SHM;L;><L6LJO;BDL/HAI!:/,/:^KE%C:J\S%DW(N<AU$5O2R%6H<>I
M3B)FES4>5^E%&B2%)$K&D)@0X_'`ET#U$-6:26BS=MP>Y!I=)\7\<UW+&LX+
M<CP;A.HM*+CN:C<I%4DD]Z5953551R>+6T\+2LI*T_O-8L"3@0Y>%,F:J$9$
M)*4I7.3VDRYF<CD`#\<F)A16LYJ6HDXENE']$KL_=+Z=R=WW3)W&VU2*ZEJ*
M)>)8+P$M5U(LK3'O#+RKM^S$O3J/.VY2Z#*UZ:052M`JE2M*UU2T_-+2A:I6
M6F($O%E5QG<,(3#UD0^-01MSN:9*"JZ^4UM<,U_%?=E8TW#DY7XW93<%G.,;
MERJ72TVI);:88T-[K]ICS(B3U"U+TGUPG=1M-;KIM?F*G9<.I0)Z')VI5)29
MAU*GVY+?TQMZIR4A3HJT0E2IE)SU8]$1(CRK:S.S6-NY#=N+;X?"1.7.+<K[
M^FX5QCA\=+Q6S*"C=W6JW(M;LIOS9Q;E1O>WHUSHCXZK6"D$>](!#L1PN]%W
M6UGNR/FE^$^ND%3NZ[6K)U%B'P:OEH$%_227A_\`NGPM>_\`JH_R_P#^W-WR
M\7U5-->0&X;_`*'+2$U6K6C7Y4Z0BI0C'DH=0^N6-*RTS%A)4A402RYCC"0I
M/$4\)(!+;ZBTKO$HVG7==%AU$#F31V^(<]PT-YR5FXK2E3!TW$VO'2ALN2W5
MZ_-?=--<Z%JQ6$7<BFIAR<&9FZ?3I6*NE790ZTF>I<>%3I64EHLI!7(*,(%'
M$E,4IXBD)`WXEI[6ENVI6%NM_P"E-8D7FWA>BX)Q#1W^&0]4Y8T3;QA*-'BV
MZXX]1X[Y%)>3TZY8-<=;*=(2\]=TD;N3+QH\$18GP*QK4EJK3*<I8=&3)QZK
M.Q(T="5#C'"2_A21TXCO7=;:TLJJ#:__`(G2OQ$OG.<]=S!I.%3DUIGN8>&Y
M-IOKHDE^ZST!N#FVU[NVSKTL:\;V-V6]?DO`A566K-+IQB4TP*C*U-*[?CR,
MO(KIJ%195,,PCZV"(9P0%`*'I+/"]';N0O6X;MR#PHWCA3&M:GI8<O<(TVIM
MZK2VO5WK-:--XX->=5NN=:YUVGK,N)AT[MK_`&FLTOC.\\V4U+<<LNEIEI-T
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M(D*]L#B`?_6`]CE-JC#SJ90TO)5T$.\+%]\UCE4LK22!AL=X0&5Q;,)5?@+(
M0Y)'3CV!G0;E^63D>@'L>6YS-[7:9LY5.&(QX_$XM$NY,G0R.P0$>D?PA?V)
M]IJ\EP_.1ZT;V40>&'T`=N&'C;E=VEU9[;.T2Z7OP<?='M-`GDB[T^P[9(HQ
M1CL\[5\\,2?*M%3H.VTY/""3]^&766AW,B?I8MRQRH=B>C[Z?#[K1RVQ/-$R
MGTC@K)6>UV/:WU9/(_2G;[1U6<2HG+:79[_*U?<S?47NER70=>FDJ]/!PP\[
M5]W(LX;3RCR_7)8UF:G4VZ[^G)B3IM!D*A,TQ4"FS53]97(\%,C*^LA2<.+&
MA)@2LU'B)7PD"(A.37W*.NX5PSCUOB/&).-BU;FXTBY5N/S5@DVJ)R:?2D>'
M]Y_".8N/\HW>"\M6XW-9J;L(W-Z<;=+*;G*CDTG6481:KV6S'5GF%O\`N;4"
MYZU:-\WA0[7F)X0*!3J=6*G29>'3).7A2DO,F0@QX:8$Q/F$J/$!`5Q1"#B&
MY<P<Y\7U_&=1JN':O4VN'N=+<8SE!*,4DGNIX.5-Y[:O$<F>Z_EK@_+&CX?Q
MSAVAU'&(VZWISM6[DG<FW*4=]I[T854([*1P/+5@<QEFUS0J\M,=;+DK\Y7*
MC"K\C3:K-R-5N":G)&H2Z9NDQXL]"1,*^%TFL%7`(RDN1#AN+AAZ/@W.O#-5
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MPJ,_)5RYS/KH\M*TB?J$*:^$6JBDPDF9E842!`7\,001%4@!+E/<]WE^1^:>
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M1>$@NQ^0>/\`-/!]?SUH>.Z:<Y<-L*UORW))K=E-ND6MYT4ELQV'PYR7[N>:
MN#>YSB_)W$+-N''M8]0[4%=A*+]9;M1A6:;A&KA+-X85I4\6\W&IMGZMZLP[
MJLB=FJC18-IT:DF9FI":IJU3TE.56/,(1+SL.#',-,.=0Y12`5/`R>U+S_QO
MA_'^/+7<,E*>F^CQA5Q<<4Y-X22>U8T/7>Y+E'CG)7)KX/S#;A:U[UMVYNQG
M&XMV4;<4W*#:K6+PKE3I/)O-[KKISJ_1]*).Q:E4*A&M6)58]:3.4>?IGP9,
M[*T&%`0@SL*$F8BE<A$XA#*DI<,<0UWS]S1P?F'3Z&'"YSG*QON=82C2J@DO
M.2J_->53R?N0]W/-7(^MXUJ.8K5JU;UBMJUNW87-[=E>;;W&]U4G&F]1OHP.
MQ\S7,II[>]?T,N/3V:G*Y,:;7!,7'4Y2HTJ?I$)9AS-M34I)>LGH,/UD28-)
MBI4886F'@7EX:QYPYQX3Q/5<-U?"92NST=UW)*4906=MI><MNZ\JT*7W4^ZK
MF;E[AO,/"^9X6]/:XKIE9MRA<A<>,;\92I!NBCZR+5:.6*H=PU8U)Y-]:JI;
M>J%Y73?`K5MTB'(KT^D:9.P)BK0I><C5.#2YE:Z9&D8"C.S"T1(\M4(,.+#(
M!B!P4+?C/%N0^8;UGC.NO:GZ1:MI>H46G*C<E%^:TL6ZN,TFMIY[D[E?WW\B
M:35<I<$TG#_H&JON2UD[D'&VY14'<C2XIOS4G&,[,G&6476AX<YQM=+`UL@:
M8QK(F9^)&H,E755N3GJ;-R1ID>K"@&7DDQYB'#A3L2$J1BI4N#Q0_1!"B%!J
MWG/F'AO'_H<N'N5;<9[Z<6MUR4**KSI1XK`]G[D^0.8N1+O%K?'HVU#47+7J
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M`%)FIJ-.Q$U.)!3(1D"'$!1P1%%1+G#%TZ6NT]S@EO1Q;]?%1JJ/9X<AP3DO
MF#0>]G6<V:BW!<%O>N<)JY%M[\8J*W$]Y.JQJE3IR/*=T:T\K7,1I'8%OZPW
M==FG=?L*#)19BFT:F3TU\,GI6DPZ3/?2Z+`H=<IL[(S\&'Q0"M,*8ERIQ=Z7
M%9O5\/UVGMPU,I0N0627@IA@U]]'D-%RG[Q.1N9==K>6--IM=H=;*24YSBMV
M+FYQWD[EN491;I*E8RSZ*>/>87F+T*O7EIMO2;2Q-?I4Q;5R4&!2K>K=,GA&
ME[<MLU23@3TU5E&/(1(T_++A1^`1UQ0J*4J`*5.[3U>FNZ56;%51X)]"\)8\
MG<D\W<*YZO\`,?,+LW(W[%QSN6Y1H[MW<DXJ&$DHNL:[J5%59HZKK)S#Z87?
MR>Z8Z/4*K5&/?EM_6.*Q3HM%J,K*RIM^FSLM4BFIQH29"80(T5(A^KB+*P7N
M&+I/KH2TT+:KO*GW"7RWR;QWAOO*U_,NKMP7"+_K]R2G%M^LDG'S4]Y8+&J5
M#I7(UKCI[H7?]Z5W4BJ3U+IE<L^6I%/F).DU&L%<]!K,"=5"BP:=`F(\$*@(
M)2HIX20XD%S^]F:@ZRRH6'O6Y6XQS5PC2Z3@MN%R_:U+G).<8>:X.-4Y-)X[
M*U.H:$:Q6+8?-O'U=N6>GI2QX]S:G5%$_"I<W-SJ).ZH-P(H\2+3)5$:<28A
MJ$+UB0E2H;R\8%K.*WK2H;<U\N\4XGR&N7]'&,N)QLZ:.[O)*MIV]]*3HOP7
M3I*FI&L5BW%SI2VM5*GJA'T_@:DZ=W&NHKI4W!GS2;:EK9@U:8ATF,E$ZI<-
M=+C&'#*4KB)`(`X@&EP@_4[GX5&8X-R]Q32>[B7+=^,%Q5Z/46]W>3CO7'<<
M5O+#\)5>2/.^K_-[II'YP=)]=;)-3NJT;,M*';MP0UTJ:I$^I-2C79*515+E
M:NF37'F9"G7`B-#X_5PXL1!A\0>5#*L3CIG;GA)R\AY'@O(7&;/N]UW+7$MR
MQK]1J?60\Y3CYJMN.\XUHI2@TZ5:3K38=[OK5;D.G-9)#F@B7CJ#>-]0YNW:
MG)V!(4NJ2<A*5VAR\G(4VKSJJG1)!<K`I,O*HC*ETSZX*XT(J1#B<7JU:6[6
MHE'U22W>DH^&\%]Y$.`RY/5C2V.&N-R+O2E%MPFVY16[-U<FVE+<32=&U2J\
M#\Q'-=:]3YLM/-?-()J:N"FV/;EOR,Q"J-/J%"%37`J%S"O4?U<_+PYJ'!G:
M)7#"$?U?"F(MX"N#&?IM++Z-*S=P;;\/0>BY7Y,UEGDK5<M<<BK5W479M;LH
MSW:QM[DO-;55.%:5R7A/8/4C5KNY]?:O2]6-29N\J=>$G39*5JELP*;=U/GJ
MU!IY5$E:7644*4FJ54S+>L5"1'@3L(KA$)5$X`D)YV[/$M.G:M).%<\/OGE>
M%<%]Z7+5F?!>%*Q/0RFW&XY6Y*#><H[[4HUS:<71XI5S\'\O'.'IKH_K!K&#
M9\]2]`]5:U\*IM#I]/E5SUH09&#%D*?&50H$=<M'IU2IT=:)R6@Q%KA>@4>L
MX5)5WU&BNWK,,:ZB"SZ?'_H/0\S\C\5XYP/0_O\`&?,FBMTE.4G2[5IR6^U5
M2C))QDTD\:TJFMO.V?W75.GH]S(U$U)K$@N,N=@6#396XTR\(+7ZT4R%$B6?
M3JK#E4/]6E,2I)4E+@8N#VPI\5:W=V*?3AY?O$=:_P![UVTM)/2Z2$TJ.])P
MJ]F\_P!]E&NUTAXCQIR;\Q]D\O\`K#>%4K$E5)73.^)>;I$-<O"54:I;<I*U
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MU@R\G/\`J8D&92CUZH`B\`6I*7\(4\=XZ>Y]$]1/"=/NU/::+ES6/D3^[6KW
M;>N=B<<]Z*D[CG&K5:K*M*X5S/.?-YJ-R?ZN4*NZBVA6[BJNM57I-O4BDRB9
M.YJ73I6'(5&6^$3-:DY^1EZ2F8@414>!Q)BKXE<'"DD<;<=+;U=J2MS25E-]
M'W/&4')/#.=^":BWPO76[4.`0G.4G6W*3K%T4'%N5'.CR6VO0:7F0YA]+]2>
M6;1O36TJO4IJ[[1-E?3Z2F*+49"!)?2&RIZAU`HJ$S!1*3*TU&.D0_5*7QI>
MK`!EK3W;=^=R:\QUI\9WY8Y8XOPGFO7\6UL(+17_`%NXU.+;W[JG'S4ZKS4Z
MU2ID>793F6Y8N8C2:UK+YF(E;MBZ[21)J^F].E*TM,U4I.3%/BUBB5:AR537
M`3694/F92:@A(B*<./@0L1W8U%FXY6%6+*&7*W-G+/&;VOY45N[H[U?-DXX1
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M(34)/%!C`^L2I4%2<M[=K40LJ-NGK4_*=]'POF?A/*.FT7#?50XO9NRE*,G&
M490<IO=J_-J]Z+S65-Y'G*V==N5OEBTYOJC:*7C>FIUPWDA<>1IM8E:A"IE.
MJ0D9B1DHLS%FZ%;U-ITG!$R8DR8,.--37`E)R24:RT^JU-R+O148KX>']P\Y
MJN`<V<U\3T]_CMFQI=-8P<HM;SC5-I4G.4FZ4C5J,:M]-?D^I02A(XPH@!Y?
MF0`-A+GEK.C/EUNKJ?05/,7I<GD47H8:K4_LCF17)?2KZ25$R7K5:AFY!$^F
M_JOI=\'^E7I/]9Q<?H<+VB1TM[Z>K]/WJOWJ'QE=Y=XH^>WQW<C^S=ZN]O*O
MYG<[.==[P98U-79G,-IA1N2"\-$:A5JC#U$JPN>%(TM%%J463B_3:XT5*3B&
MK(@FG0X7P3%95$2I)!#B7/D?1+\N(QU$5^]*F-?!T''B/`>)7N<K7&81C^SX
M[E9;RKYL*/S<\_`1\D?,1I=HA0-8*=J'5JC39J[4T"+0T2%%J-7$W]+J=7Y:
M:A%<A!BHEXJ8E0A<(BE"5`YX%W?BFAU&I=N=A54:UQIG3R'#F_@?$>,7]+/0
MQC*-K>WJR4:5<6L\\GD:SDVYJK0T;IUWZ8ZKR$Y.:;WM'BSIG9.375!29Z>I
MZ*1692J4N"^9FZ/6:=!A)68(B1(42&?04F(2C.NX;=U3C?T[I?CTX52Q5'TI
MFO-G+VHXG<M\1X>TM=:PHW2J3WHM/)2BV\Z)IYX8P:OU#D+M33F^*9HM+7%>
M>H5VR4O)V[4JK`N*9I]DI%3E)R/&DIFY)>F(D^"5@*AA4.'-3:P1#*PA2RTO
M1PXW=U$):O=C8@\4J5EAMI7[R(NACS9J-9;GQ1PMZ2VVY);J<\&L5%NN/4MM
M*FDU#U$Y4*CRD6E9UH6O(2NNLI*6DBI5"':4Q)UN!6928EE7;4JC=RI1$&IR
M-3@HF!#0)F,%>NA@0T</H=M-I>*+BLKUZ3^A5E1;V%/P4H[&L-B(]C2\;AQR
MYJ-1-OAK<J+>JJ->:E&N#6&Q9/$]`5E3SF`,!L;U5F"SVEAJ-I&HGA<\X@;3
MT--4$U5YE-?R9$]66/C;M")3:C.I+Q98AIMJ&S84U^E3EX<,1GYRTJ,:MU//
M:K-_#8"0-HSW];2K<<D>:UN?PZ`"-X:;;BD>;U'X1D%*!#B1U$C8TJ&3*#59
M/X;2UQJ#CQ'M)([6GP2H>5U/;,A$S>,';/=+=H+$\SJH>?AT$Z2"D$;_`&VF
M6]AY;6*B=?A@8GWOA\[2UDSR^L_-RZOO$(+E/]FULH\QJ"7/'?[C6%O-=14W
MPHC@.(VMN^T46HS*:\?"?*6EVB@U.9!$]XK\(?XINR*>Y^$5_HO]C_%MLB!=
MR.5>^_V7XIL2[/C(5S9U$(&*ND'RGVVS^"0;N+2.2`Y/2IWB4&1Z3$MO490W
M`G$.](/?T'!B^^879H6UE_"XC8VNP1\I9`#B-ZB_R>!L]'48;Q\1?EP'9CH#
M]Q.'7BW.1ULYU-M*)Z0?3?V-$N]DG6T=A@I>3A]`?(7-7K[Y,AVUUHWTK#P1
MU#S^9N-S:75E><=HE4$/>'O.&'2T*>%$7.GV':I*&'HSR/@XL^US0+F?@+11
MJD^A';I%!X7.>Y278;GM`N9>,LM+'''(W7"O[Z/!_P#1;@6NXCS=,O*B\;"Y
MYR^\;ZLGD?I-M]HZQ-N<#DY1[2]J^YF^HOM+DD=<G0XJVY'HWN:ONX)4+2-*
M,Z_&&US@2[^%+0KNPE6\T:>/BE8V#$G:>KL#063EV?$::)BL];R-SPYS1GM+
MF.27@1IYCWPZ%$/.WI\+;+I+"WDNLH3`X@IV;@[M+LVYO(ZWMG65%I]%)\/@
M/M-H<HY$(]Z?9]$PSL*$1)))(PXG'Q-W62,O[QBA/A(5XF/)=8CF9.<E^]!\
M6#;V]J,RR,%Y)_#^8-WM$2X8`>D>I_C:PALZB(\GUF2@Y)ZX9\)>T^UFCDNT
M#DUC8(E[(J1/?'J\S2X]HBO,A.8:UTV;\1$O=I]1!&S\'G:YL]@@SV%>.H)A
M@G=ATGA+75KL+J.$E5HU,0E0427EQ:;:S\1#N9>,UD3;^&]MK+39D:X:R+[_
M`+3Y6M+7976:;"M&R[!Y6FK(U*43+M\Q:YM?FX]1"GVWUE(J<EW:>II]OLFJ
M*<18V[2,&E2CO*A&U7YOQD)4D@XY@[]W4W6U#=17D!6D;?+[3381PH*5.>))
MV^(M(4%0XO,<2=_B/M-G<0J<%:0,_$?:;/JT]ISN8Q+,&(XCK`/F;/JETG&A
M>]8GV/\`:;'JETBA/"C#8-CO.W&4%5G*2Q+GK@HC>.OVNAL;B,4+L&("X')Q
M]UM+D:1.=Q>:6>)._P`1]IH]&1RQQ)W^(^TRC!B5)?GXC[39HS1YDT**E(4,
M\1O]IE&8,U1@!EY?:;>"K(UEV2/X0-P\?M-WW#E0I^L3['^TS<0H9%;TAV7E
M+\&W2V$:Y@V55J`RSQ]CVF685="!>R*?&/6/WO<.PM,FO,H1=A#%6XX[\>W8
MV81V$:YV:>$HA2<W^(M+A':0YY^(A4I+\_$6E*VMXK;FWJ(HBTX=/M!IUJ/W
M"JU&TBXT[\FE*.TI[^3`4E^>T["W:$=I2Z@B.9[3XVL;4**I37\QL[&[Q6T\
M]JOA\1P_!WLVM*MPQKTGF];F^O[QDG,=K3(Q\VO0>:U'X1.,PW2WDR@U63^&
MTL[`TZ&1Y;4=L>TW:WVCS>J_./J,T*X0-S\1X6FV]AYC6JL7T_N$RO>]A\C2
MEDSR6K_-RZB`>^]G2V4>8U&1(G%/:?*T^ULZBHO&$3)7LV-T?:*/49E=.8_#
M?Q1:5;VGG]3F_AL(HN2_PJO*INT<BHN9,@`Q!Z1X@?;;=9%?=R\1D0''K/D4
M?*VL]A$N[.H@`]\=WG)]IMWD0+G;1RM.#CM4\=6+:)X&LCB$/1`/WX^=MMGB
M&2\1=6D>BX8O`\0;&Q!9>(L!.#M[_P`4"SI,-T9?E4'/9CX.(>TW.6:.UG.I
MNY%+L?P2?#Z6'C:)>[).M_?.R2^W#-)\!>]J[,EP[<:]*-])>D$EV``=XO,6
MYW-I=V761VN5`X7OP?[N[>T&YFBYT^%#LDB5/3ABX'PDGSM`N/SBXLK>5&=T
MD``!TN?T9^VT"YD^LM]-!-5-SZ/W[Q%N-"QW$>9)H`*4[<>+Q/#?5B\C](]O
MM'6YH/2"_(EWA:OGF^HOM)DCKLX\\0.&'G:NO=DM(/,ZY'&+CB3EU.+_`"-#
MN["5:SB:>,,"#DXX=6(:$\V35BE4TD7WRMN_9B#B/`T9YES'8:F8S&&#QY?=
M;)8PV=944EYB/W)\H=Y&YRP.U[)=9`I."<-N/4[W6T.5"L$@I.'LX7^4,\AB
M6"*,4$DN^_)\@;OL'D(X8SZ`H#M+9E@O&;+,RX?1#]W"1VMF&;1F63(E@<(Z
M%AI-K:1+FPB=B#O2?$6GPV=1$>3)",%/^^I([-OA:?:S.7X1@K)K#3D6]V2I
M$]\>KS-,CVB(\R`YAK739OQ$.]VGU?>(8V?@\[7-GL$*>PU\TH$`#8'=KO,U
MS:["ZCD]A07[T]1:;:S740;F7C-;$V_AO;:STV9&N&LB^_[3Y6M+7976:;"M
M&R[!Y6FK(U*43+M\Q:YM?FX]1"GVWUFLBEW@>1U-/MY&B-?&6=F;P3[338JK
M(^I_-^,@XU...P[`TJ&97LK%2GY^(>TTJ"JDC*R,@I3L_$&[I45#A+-G/&K?
MXA[39,'!6=IP?N#%F:3[)9A*R=T#L.3;'(M\:M_B'M,`3%/$7[/8]N$NTSE+
M,V$)9PZW=N;\M[:F#8PE'!V&'CR;$LC2YV2?C5O\0;0CECC5O\0]I@.0M3L_
M$&P<I=HS3$4E^WP>TPU.%QE<)[-V\=#9CF8>1!ZY7L=[3=#F1\:M_B'M,!,%
M'@!W>VW>"JDB+=[3*BEDO=EY6G6E14(%[)>,IE9X@[/R89-(>1%(HZG/Z,NL
M[60(US+QFOXU8=;3X1_"(<\_$0+6KBSW;FEVUM*Z>WJ(XJU>CC['!I5O)%3J
M-I#Q*QQ\0:5!5=2GOY'/$IV?B'0TF"QJ4NHS)]O8T^&12WS@9#M\I;I^$4&K
MS^'0<>V/.UA;C]T\UK<W\-AFGWP]FQI+5(4/-ZC*1.,PVMO)GG]5D_AM+.P-
M.AD>6U';'M-VM]H\WJOSCZCD9#K]MIMO8>:UF3^&PE27H=N?Y"TO8SR>N5(R
MZOO$8]][.EB/*ZC(R1DK\,?,T^UF4]TXB9*]FQNC[12:C,@2/2`Z7^532K>T
M\_J'BR*)D?X+RENT<BHN9/X=!$D$.?MQ["V^PKKN)DH8$_AB/&&TEC*A%O9I
M>`B0/17T@CR^VW261`GVUU&41)<G>"XCL/M-I^#XS268AH!2C8<2_J>V6\/$
M),ND#T7;7_Q+&L$;;"RA#TGQ]3WLVLT>+P-E+H<D.S<,.@K;D\9([6S;RR/0
M>/OZ1X-O8T.]@B?#+QF\EWO(=]"3U>BXM`J2X=N/6CL$D'<&`Q`>W.YM+JS2
MIVR6!(.#^K#=YV@SV%UI]C.S22/22`"[''M<T">9?:;L,[A(`@8)R*7M!N9>
M,M].JJAO<?OI;A4L_5^$\US27J.3SY\B>IOJUP/T=V9J+Q.MS8#B"-JLNL^)
MH5Q8LN=-*KP.L3@=Q/!V=?LQ:%<2HBZT^+9U^,,4Y9G8,<#@T&ZE1LL+5-TT
ML8!RB1M.>Q^YH+6+1/AAGT&EB`%1PQ(+NK9AO;,XQ3I19%A&5&J]!JXH!=AD
MHD^SL:%<)T'D4IG!(&1.[`NXGDGPMQ2JV=KK-9%/HN!+QU]/C;*H<JOIQ*8>
MXO)\+O9FV*(VBW3$BB#`NV</7FV5]XR]I$E+G#\/Y0QXIG.KS#CP@O.\OW%3
M@YNUCM>(ZQ;HZ]!SPCAB]!P\#VGVDMXXW?P2(#`'H(\)>TZW2C(C[37A(\2I
MS\"'>-WG:=92KXB+-T=?"$O=VEK"RE3PE?=;KF55OXGOS`\36.F2<W7H(]MM
ME=?T75YFM+25?&<[O:?40)VM80R(5S8:^.XI479J/G:TM9+J.4^TC7J]Z>HM
M?6$J9$*[EXS71=OX;VVL*)9(CLUL7,]OE+2[!I/(U\8EQQ.0\K75B*:C@1;C
MI4I+)X1B<]_06M(I;JZB(:]62NHM,MI;IDJ*]\>SS-,HB-J?S?C*<1X)=A[Y
MNMM8U(!`&FPS,G+QO'A;+BVZU.#S#Q]^'A;&X^D&22'YCPMTM1:GB<[G9)0H
M`C$9C:TJB.)8X_P7C]UE$"1"@_,'!Q/LZFUHN@XRS+H4'9NWXN91=!J9IB$'
M!?\`#,45T&L^R6X40NQ)\.1]UMMV/0CB3\?X/^&]UF['H0)TJ>D>EXVB7+=9
MNA@D2L)>]6;MONMIZM^`8'*H@(<_QCVVZ6H4GC2AK*E##B&\>%I.['H1S*_$
M/OP\+9H@1*67D<?\-T-SI6?@.%Q+$A4K+TM^UI<%3%D&XE@0*5GZ7C;O2J(<
MTL2-2@?HG]9;-OM%=<R*H(>,1["UA:541)D"R./,;-K2TMA73V]0)&&(V>9I
M%M45&5.HVF*B.%6(]A:;:S137\B+9[.AI<%YQ2ZC,R)+\RTJ&7C*:_F8/.&)
M\/2TQ)5*'59?#H)4$DEY:9;VGF-;G\.@F3[X>S8TJBW#S6IRD2,MI49YK5-[
MKZ_OEM.7LZ&F02W3RNI;J/:;;\/Q%%J.WXCD9#K]MI5O8>;UF3^&PR0<QO!\
M3VE[&>5UZ_>F_!]XX'OO9TL1Y/49&:!Z/65'QN\S3[6SJ*B\8Q/HOPI\[3[:
M3CCTE1=R(DOXQGAGT8-O1'G]13$P5[\]1\KFQ$K;B6X^HA6/$$^?VF[["CEB
MWUD:GA&9?Z6T[7EN><R+=[1$X[]Q\!(<W1Y$:-*OI,B\E1Q(>`?"68**"6).
MA.3C]"3Y6P^R:7%5,L\+DAQ))'C.YN;?G$:TWC4N0TG@.)]\7X](&#:UP)MI
M+=-E*I/3N/0[<W.[@_$8FO/370;F5#L3D\8>S:U?=;W?&3K'WS?2H!7Q.P<?
M:'@>T5Y%U""2I38=@@)<YV&`PZ_::+*3<3O85:>!G:)(#A(])[\SV-#N-U1>
MZ?*)VZ3&,/++SO:ON54BULJ62S9VZ12.%^/O@.UH%QNFW,O--&2=6S><(WGP
M^XT'>98GF>:S4<O,XM]8M#]',)K>.M3(?B\N>KPOSV[6AW%1LN;$LJ'6IY))
M4XD8>#'R8-"N9%[IIK&N9UZ.,L,CMZCO:#<VD^U.C\!I(Z<%.QP?C[-S0?PF
M3XS5,32Q1Z1/0[MVGH;:YGXB?&2HJFIBO*G#($CKQ#0+G9KX2PA)>(HS)>']
M'N'QMQ7:9V;;9K59I>_/`[WY/\#9\"-=I"E/HJ!&.3^I/MAL5.FPAB!SP.GQ
MI!\[91AD(2X]JO`RG^@TH.'T,-CAV!3_`#-VT_:?4=(_>,G#TL,P'].;6%KM
M'&[DNLK)#T=6/F\[3K69%EVV1CWP_#>=IMGM>(BW/OF(!#P=BBUA:R*^YB5H
MF8ZFLM+VWU$>UM*T3Z+J\S6EK/QG.]FR!.UI\<F0KFPUT;WAZ_,UI:R75]XY
M3[2*"O>JZBU_I^R0[N7C-=%V_AO,6L".S6QMO;Y2TJP:3R-='R/4/*UW8RB0
M[FTIK]Z.L>0M:+)$4UYR5VM+M=DR5%>^/9YFFI59&U/YOQE*,<7=):5"/Q$!
M=)#DTVW`R5U1`"0[(^S8VTK<JX9'&2\YF/K!N\?N-CU<C6C,DQ,<O'[C;V[<
MMXTN=DE"R\8;1M]QN^Y(X$_'T>/W&;D@2PX@?Y1YV>KD<I+$N")V^SJ;'JY&
M*,R3$!(P]G@;*MRJ:3[)>AJ/7OQSW%L[DCC4EX^CQ^XS<D"PB)Z(P\?N-'G;
MEO,P#&`S'L\#:^KD*`1@HN`]G@;>%N6\:RP1EQG=X_<;MN2.97X^CQ^XS<D"
M)<3$X>/HZFU4'O>$X7-I`I>6&_;[C2H1=$MI!N;"%2\#AX_<:5ZOS/"0I[2$
MQ'G+QLMP?C(%W"/C(./'+Q^XUC;A14VD*977$](EV[;[C2(P:>)7S^\<&)GA
MNV^XTJW$JM1M.0M[@[/IZ&FPBEB4M_)DFSV=#=H=HI=1F<GWWLWM)AEXRFU&
M9AN]FUIBS*#59/X;"5&9]FUIEO:>9UN;^&PG3[X>S8TK\`\UJ<IDC9MY,\UJ
MNR^O[Y:3E[.AID,CRFIS'M-G\/Q%'J.UXC(9#K]MI5O8>;UF3^&P#,=OD+3%
MDSRVN_-2ZCD>^]G2V$>2U&1FGWO:KRM/L[.HJ+V1Q$S/4/*UA;[)47LG\-A@
MD>DH]/G;8\_?[-3!0>M0&;@!VDMA%=>HH2Z*?>(8@>3U^1_MMW611)9D<0.`
M'3Y'CS-SCC(BW<R,!SM[QXR3XFWED1XY,FX1V%8PZG^)DMAB)80@%Y_##JS]
MMDLD:M5B^IEDIP2!T8^%[<MK(MK)EQ*!P^S$\0;"[)-MX1-E+(<.ERCAUEM+
MF?B,T<I>`VT)!2D'>M+NTD!J^YV?&6.FC3"69O)4;_!U`X>$M#;+J,:X;3L$
M`%R<\PX[=CP6BRR)%B.7A.S28.'WTJ?CO#0YEYIHT6.9W"2'O,-CO&YH%WM%
MQ8CAX3M].'HD'[\#AX_(U?<R+FQ!F\]#>?`/::"6FY'H/929H5KO5^;>43@7
M_F;N,YC>)9OK7>ET-/UN/LKGD/T'VN)<73QX=.O\/8[QUN9H5JY?7_)IQ.!M
M>Y3M>["5:)<TO#ZNNLCE\E=\A<6.*<9RCPRXZ?\`4:?O&@F:!:2N+BU$DA@/
M[D[I/;A*-"GI.'47\<C[*[Y"XTW%N-JM>%7&_P"4Z;O&BC6Y9QSU'D=O]R-U
M]+\I1HD]'PVK_CL/8WNZ3X<6X[_9-VG\JTW>-1&MJRR"#J7(`8X?6?=V[HDV
MA/1<+J_X]#V-[NDR/&./J/G<(N_:M+WC41;:LA^.IT@-_P"8R\#LZ))LST7#
M/KT,OD;WD)L>,<Q?V/=^U:7OFMBVO8H`/V4:>,3_`'%WEO\`YQW%H5S0\+:I
M]/A["]Y"=:XSS%2G[&N_:]+WS71;6L5;P=5*=L_N)O/>/YBVO;BM#PJK_I"'
ML+W=),.,\QO_`."W7_W>D[Y35:MA.'Z*M.#G.)LB]<P_^8=CVS]!X5G^T(>P
MO=TZKB_,=/ZDN_:])WR'ZUK#"3Q:KT[:[\P]ZYG_`'CN+/H'"LOVA#V%[NF?
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M8?YP:=#2</WT_ID<ODKOD(\^+<Q8_P!#7?M>E[X5:EA`G]%NFXX_G%O?JV2'
M0TZUI=!3];C[*[Y"!/BO,']CW?M6E[Y55:E@D/.KM-`'_8.^3G_O!K'3Z;0J
M3IJHO#Y.YY"-:XKQ^N'"+OVK3=XK+M33[TOT7Z;E_P!0KZW?V/:QM:?1U_6(
MY_)S\AB[Q3C]77A%S[5IN\0)M33[']%^F_W@WU]3VFQL:6C_`(Q'T)^0AW.*
M<=P_HFY]JTW>-<NU-/2\'6.F9G#[']^;_P"Q[65NSI\/WY9?BRZ.HY3XGQW>
M7]%7/M.F[Q2C6EIV`1]F2F)]%_Z7U^G?C_4]KRQ;M4PN+T9$2YQ+CE/ZKN9_
M6=/WC7*M+3LDOUHI6>7V/;_^IS3MRW^/]QG#]I<;_LNY]IT_>*46T-.,?T::
M4,_\7>H!W[J<TJQ&&R5?$S27$N-TQX7<^TZ?O%"-9^F[B_6NE#`?XNM0=_\`
M8YKBS@HTQ(MSB/&<?Z,N?:-/WBFJSM-G8ZVTD?\`RYU"W?V.:Q3=%@1OVCQC
M^S;GVBQWC7+L[34/'V<*2,#_`(MM1#O_`.+&EVY2W>R_C1G]H<9_LVY]HT_>
M*2[/TT!/Z.=)^+744_\`1C3K4IN78>7XR(^HU_&';QX;//ZQ8[Q3B6;ID5/.
MNM(&)_Q::C_4QS3(.[LM/TH^4A?3^+_V=/V]CO$9LW3)_P"GM2/BSU'^I;3[
M3O)5=E^G'RCZ?Q?^SI^WL=X@596F!)/V=:1G^IGJ1]3&RY:BOYI^E'RG)Z_B
MU?ZOG[>QWCCZRM,/U=:1\6>I'U,;&]J/DGZ4?*8^G\6_L^?M['>,D65I@%?I
MZTCXM-1Q_P!&-M"6HK^9?I1\II<U_%G'^KY^WL=XF%F:8/'Z.E(S'^+74?ZF
M-UW]3\B_2CY2/].XK_9\_;V>\3?69IC^KG2/BUU&^IK8W]3\B_3CY3/TWBOU
M"?M[/>./K,TR!>-<Z3\6NHWU,;._J?D7Z<?*:/7<5K^H3]O9[Q9A6=IHH%^N
M=)5C^IKJ*/\`HP,]9J?D7Z</*8^G<4^H3]O9[Q819FF?%^GC2<OU-M1?J:SU
MFH^1?IQ\II<UW%-W]0G[:SWBP+/TV3EKE21_\MM0SY::SUFI^1?IQ(_TWB?U
M&?MK/E.?K1TW_5RI/Q:ZA_4UGK-3\B_3B/IO$_J,_;6?*2)M+3AP_1QI/Q;:
MA?4UN4IZBOYE^E'RF?IW$_J,_;6>\#:&FYSUPI/Q;ZA?4UL;^H^1?I1\IGZ=
MQ/ZC/VUGO!-H:;@O^SA21_\`+?4/ZFMF,]17\R_2CY366MXFX_J,_;6?*2?6
MGIO^KC2?BVU#^IC==_4_(OTX^4Y?3.)_49^VL^4Q^M'37]7&D_%MJ']36QOZ
MGY%^G'RF/IG$_J,_;6?*0KL_38J/Z.-)^+;4/</^+6*6H3KZEU_+CY3G/6<2
MH_XC/+Y:UY3`V=IH<#KC2?BVU$^IK2(3U.?J'Z<?*0I:OB.W13]M:\IBJS=,
MP#^CA2/BWU$^IK2O6:K<PL/TX>4ASU6O;?\`$Y>UM>4A-F::#'[.-(S_`%-M
M1?J:VUJYJ<WIV_\`QP\I"NZK6M?JLO:6_*0"S-,A_CRI'7]C74;ZFM.C=U?U
M:5?X2'E(<]3K6_U667REORF/UDZ8D/.N5(?^MKJ-]36[*_J_JTJ_PEORE?/4
M:NK_`(O+VD/*8*LK3`#]/.D!_P#^FNHQ_P"C6DV[VMJJ:67M+?E*W47M4ZMV
M&O\`QP\IB++TQ'^/2D8?_IKJ-A_S87M,]?K5']4E7^%M^4J;UR_3\T_2CY3/
MZSM,W?IZ4GXM=1OJ6VD-3KM[]5E[6WY2GOSNMXP:\:!L[3-_Z>E)^+34;ZF-
M)CJM?3#22S^5M>4J+[GMC]U&2;,TR('Z.=)/3]C748/Q_L8TKZ7Q"OZG+VMK
MRE)J558NG_L)469ID\_HY4GXMM1?J:TN&LXCC313]K:\IYW5PM-NLZ>)]!.F
MS-,W_IXTGXMM1-W]C6DK6<2W/U*?MK7E//:BUIVI5O)?^&7D,_K,TT_5PI'Q
M;:B_4ULV]9Q*CIHI^VM>4\[J;&DW77416/R<^GJ+*;.TT=^G=2C_`/+?43H_
MXM:7#6<3I^HS]M9[QYG4:70-XZN*_P#*N^0Y^LW33]6ZDY?J<:A_4UL_3>)[
M_P"HSR^6L]XIK^CX;O8ZV"P^1O=TY^LW35P_1NI.?ZG&H?3_`,6M(MZ[BF'\
M0G[:SWCSVJT/"FG7B$%_Y%[H_),H=F::%:1]FVDG/#['&H8?_P`VM+6NXK1_
MT?/V]GO'FM;P_@SM2KQ.VO\`M]1W22)9FF@5AK921C^IQJ'M?_Q:V%KN*_V?
M/V]GO'F-1PO@-,>+6_LVI[IP;-TU`=]FZD_%QJ'T?\6M.MZ_BZ:_HZ>7R]CO
M%7?X5R__`&O:^RZGN'!LW37B_3NI/O3_`(N-1/J:T^'$.,;O]6W,_K&G[Q47
M^$\N[KKQFTO^TU7<(OK.TU'^.^DAZ_U-]0_!_4UCXCQE+^K9_:+'>*6]P;EI
MQQXW:I_(]7W"/ZSM-C$(^SA2<SA]C?4/(=/TM8N(<9_LV?VBQWBNU'!>6/5R
MKQVRL/J>L[@79>F9_P`=])!)'^+C40[_`/BW:W;]H\9I_5MS+ZQI^\4RX)RM
M1_T]9^Q:SN&"[+TT)`^SA21G_BWU$.;Q_P`&C>VL>(<9S_9MS[18[Q%N<#Y5
M;_K^S]AUO<(U69IJDG]'&DCT?U-M1-ZL?ZF-E\1XS5+]FW/M%CO'!\"Y4I_\
MP6?L.M[A-"LS31[EZWTE0?Q#]#?4,8XX_P!36S+B/&:_U;<^T6.\87`^5$G_
M`/F"S]AUO<)A9FFG%AK?20DJR^QQJ'VX_2WH;#XCQG+]FSK3ZQI^\:O@7*FZ
M_P#\P6<OJ.M[A<-F::**7:V4H`'+['.H6S_DYN?[1XSC_1L_M%CO$:WP'E/9
MS#8^PZWYLN"SM-G#]&JE98?H=:@[WO\`ZG;F+B'&*?U;/[18[Q+CP+E2F',%
MG[#K?FR]!L[3E)3^C32_>N=]CR_\<7DXT[<W*YQ#C%:?LV=?Y18[QWM\!Y5;
MK^W[-/Y#K>X;:!9^G92/T9:6IRQ_B^OX99#&G]+0;FOXM2G[/G[>QWBTL<"Y
M6K5<=LM_R+6=PWDO9^GO$.'6"F'(#\P-]C/KI[1?IW%:/^CY^WL]XMK?`^65
M&KXW9R^IZON&_E[0T_#OT6J8<B!]8E\8]3Y#H:-+7<4I^H3]M9[QVM\$Y:36
M[QNUA_T>K[AV&5M2PP,-5::>GZR+U&9Z9'<T2YK>)X?Q&?MK/E+FQP;ERB_I
MFU]DU7<.R25LV."EVJ$@H#_L7>0VXG&1:%<UG$J_J4_;6?*6MC@W+],.+VF_
MY+JNZ=LD;;LQ.6I,@K$96?=H?X9-H-S5\0H_XG+/Y6UY2WL<(X%7^MK3_P"V
MU/=-W];=H?JC2/\`>E=7Y4:#]+U_U2?M+?E+#]F<"_M2W]FU/=/+<U:2RH_F
MDLL;N*Y94>$>K;ZZ?V>_E]+[5>0^^2WQN-:O2<0^SR\IUJ;LZ(3^>BQ`'G.Z
M90;7_P"U8-#N<-E5_O\`I,OE5Y"WL<>47AH^)?9I>4T,S9<4E?YJ]/Q@/?79
M)C;F?QIH5SADG3^,Z/VT?(6^GYAA1UT7$V_Y-+RFCC6/$44_FNT\=C_=A)@O
M(+O_`*EHL^%2Q_C.B]M'R%A;YC5/U'BF'_2S\II8MB17*?>.G(/I#&\I(89?
M[3G@T%\)GO?K.A]O'R$R/,D&L=!Q7[+/RFGBV#%XB?KSTU&!<#>LD_%^/\8;
M:7"95_6=#[>/D)UOF>+=/H'%LOJD_*:^/I_%=A>NF8<3G>\B!M_^PV-"EPAT
MQU6@S^7CY";:YHM[>'\7Q_Z2?>-9$T^B^E^;?2\>B/[N)`.__D=+<EP:57_&
MM![>/D)UKFB";7[.XQ]CGY2I$T]BEWYN=+L/^W4@'X8._&,\&?L:7UK0>WCY
M#NN:8?V=QG['/RE4Z>1G'\W6EBO_`([D.D?[0V/V//ZUH/;Q\AG^],/[.XS]
MCGY2NO3N*2>&^M+,0[&_*?N!_P!HV$L7!I_6M![>/D,/FFW_`&=QG['/RD/V
M.(IQ^OO2K$J=^;VG[1B/Y';*X-+ZUH/;Q\AI_>B']G<9^QS\IA]CB,`/S=Z5
M/<'_`)O:?F]W^T-WL\'EOM_2M#[>/D.D>:84:_9W&?L<_*<C3B,Y8^OO2H^D
M#^?RG_\`X'2TZUPF2E^LZ+VT?(<KO-,&X_T=QG['/RG`TXC/_/WI4XC_`*^4
M_J_VAI<>%2H_XSH\_EH^0BOF>']G<8S^J3\I7&F\;C/YO-*=H_/[3]__`*AI
ML>&2JG](T?MEY#C/F:']G\7^R3\IRO3B+@?K\TIVC\_M/'E@=+3;7#FE^?TG
MM5Y"!+F2%?ZOXM]DGY2HK3>-PJ`OS2C9_=]3MA>?_J&L=-H&I/\`?M+E\JO(
M1;?,<%+]0XM]EGY2HO3:.0K\WNDV6W4"G[OYW:RMZ%IK]^T^?RB\@N<QP=?X
MAQ;[+/RD`TUCC^[[23XP:=^5FFQT;I^=L>FB%/F*#I_$>*_99>4UT33*.]3M
M0-(O?*<_4*G`Y[?R-@6L[>FI3]\LY?CHXSYB@VOXCQ3+ZK/RE&8TQCE_Z(6D
M`]';J)31M/\`,S7=BS1=NWZ1%N<P0?\`R/%,_JTO*:U6E\=Y_1$T=S_5&IGY
M7:?ZK_6A\9P?'H_4N)_9I^4J1=+H^/Z(NC@SSU'IG3_,S2;,*?A1^,TGQZ-/
MU+B?V:7E*$72R,1^F/HT,!GJ13!M_G9K>S@HD2YQZ&/\2XE]FEY2HO2J.X?H
MD:+Y_JE4S<?YF:RC+#)_$1OV['ZGQ'[/+RFLB:41R_\`1)T5R.>I=+&_^9FE
M6YTC2DOB,_MV/U/B/V>7E*2M)I@D_HE:*;/\9M+?D-GP9K&Q<6_C&>6Q$?4<
M<BX4^A\1S^KR\I3BZ2S#_P!,S1$8G/4ZEC/_`'KFUC:NQKV+M/R60_VU';I.
M(?9Y>4B^Q),?JF:(_&?2_P`JM/CJ(Y>KO>@_*8_;</JG$/L\O*1G228>?T3=
M$/C/I?Y5;#U"KA;O>@_*<I<:A7]5U_L)>4@BZ2QP0_4W0_+;JA2AY95GTC_A
MWO09C]M1^J:_V$O*8)TGCO\`TS=#_C1I/Y5;:-_'\W>]!FD^,Q:_5=?["7E,
MQI/'>/T3=#\Q_C0I7Y5;I](?R5[T&<_VQ'ZKK_82\I/]B>8_5,T0^-"E?E5G
MTA_)7O09K^V8_5=?["7E,OL3S'ZI>B/QGTK\JMCZ0_DKWH,YOC$:_JNN]A+R
MEB#I1'`5^B7HD<=FI]*/_P"59](?R=[T&8_;$?JNN]A+REE&E4<'],K1/+]4
MZE?E5GKW\G>]!FESB\=W]5UWL)>4D^Q7&_5*T3^,ZE_E5GK_`/A7O0?E(_[7
MC]5UWL)>4?8KC?JE:)_&=2_RJSU__"O>@_*/VO'ZKKO82\I*G2N.X?HDZ*G_
M`.9M+_*K:/48_F[WH/RF?VM'ZMK?8R\IS]BN/^J3HK\9M+_*K8^D+Y.]Z#\I
MG]K1^K:WV,O*/L5Q_P!4G17XS:7^56VCJ,?S=[T'Y35\6C3]6UOL9>4X^Q7'
M_5)T5^,VE_E5NGK_`/AWO0?E-/VM'ZMK?8R\H^Q7'_5)T5^,VE_E5GK_`/AW
MO0?E'[6C]6UOL9>4C5I7'>?T2M%!_P#,VE[OYU;'TA5H[=[T'Y3C/BL77^+:
MWV,O*<#2J/C^B5HI\9M+_*K2H:B*_P!U?]!^4ASXG'#^+ZSV+\IBK2J.0?T2
MM$_C.I?Y5:3]*BH45K4>S9"GQ*./\7U?LGY3`Z4QW?IE:*?&=2?RNV]O513I
MZK4>S9`N<15/S&J]DRM]BF/^J9HEG^J?2G_^RM+CK%2OJ=37^#?E(LM?&OYG
M4Y?)ORC[%,?]4S1'XSZ3^5V[1U<:5=G4U_@V0)ZV./[UJ/9LR^Q/'/\`C,T2
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M`%2M%?C,I?Y6;,.**C_BVM]C+RGG]3HFXO\`?M.L?E%TEI.E,P[],C1;XRZ9
MT?S*TJ'%HT_5M;[&7E/,:CAS;_/Z3VJ\@^Q3,?JD:+9?JETO\JMG]K1W_P!6
MUV7R$O*4M_A;<OUG19?+1\AR-*8[OTR=%\_U2J7T_P`S-)M\7CA_%==["7E/
M/ZK@\FOUK0+KOQZ.HD@Z4Q^))^R1HOA_^I5+Z?YF:7^V8T?\5U_L)>4\SKN!
M3=MKZ9PU=>HBOO$B]*XY6':D:,9C_&53'[?YF;"XQ'ZKK_82\IYF_P`NS:_7
MN%?:H=/4<'2J.\_HCZ,9G_&53-_\[-/M\:CO+^*<0^SR\I5WN6YM_K_"?M</
M(<?8IF.)1^R/HQ[TC],FF;7_`,S--AQR.[^I\1S^KR\I4:CEF;5/VCP=?]W#
MR$2M*9CT?T2-%_?$_IE4S:_^9>EMGQN-/U/B/V>7E*:[RK-K^LN"_;(='41C
M2B8]9^F1HMD?\9=,?B2[^561XW'ZGQ'[/+RE7J>5)N$E^T^"9?78=TS5I1'*
MC^B1HL\9?HETS8</Y5Z6ZOCL:?J?$OL\O*5/]T)J#_I3@7VZWW3#[$\<J!.I
M.BV:O\9=,>_$C^56PN.12_4^(_9Y>4B7.3KF']*<"^W6^Z1JTGF'J_1)T5<4
MN/Z)E+&U7\S=+97'(5_4^(_9Y>4CRY.N8?TKP'[=;[I*G2>82Y^I.BV0_P`9
M=,_*K8_;D&Z_0^)?9Y>4/DZY3^M>`Y_7K?=)$Z51@M)^R1HL[]<NEOQQR^#,
M?'(X_P`3XC]GEY3$N3;FXTN*\!K3Z];[I;&ED=X)U'T8VN`U)IF>0_E?H;E^
MVXT_4^(_9Y>4C6^3;E?ZUX!]OM]TNITMCY?9&T:S/^,BF=7^YNEL_MR.'\3X
MC]GEY27#DZ[3^M>`Y?7K?=+\/3",\$:BZ.$<+@[4:FG([/R-T-QGQN+=?H?$
M<OJ\O*2[7)]S=_K3@7VZWW3;0-,8PX0-0M(%/4DX:B4T_P#Y=H4^,Q?_`"G$
M/L\O*6MCE"<,?VGP3[;#NG8)732,"\W_`*2G##AU`IQS&'\K]+17QF-/U77^
MPEY2WM\IS:H^)<%P7UR'=.P0-.(P"/S=Z4O!`_/[3S@-WY':++C$6OU77>PE
MY3K:Y4NUJN)<&^V0[IOY?3R*`[Z^-+B'_0WU(%Q_H=HMSBT73^+:WV,O*7-C
ME622KQ#A%?Y7#R'89+3^*'/O330EV/#>TBKP?C#0[G%([U?HVL]C+REQ8Y:F
ML5K^$NG_`%</(=PDK%BI`_-AITH/'O;QDB[?E!Z&@W.)QI^KZO/Y)^4M-/RY
M.N.NX73^50\ANOK(B_\`6[3W^^^4_P#P6@?M!?(:KV3\I8_W<?UWAOVF'D/,
MDSIU?:B2FS+K.>5!J1\DNWUW_L/BM/U;4>SEY#[V(<S\LI_UCHJ?PUOO'7)O
M3/4%1/!8MW*Q)_.]5#M>_P#D;-HL^`<7EC]%U./_``Y>0N;'-?*B57Q/0I_P
M]OO'7YC2W4A3W6!>)RP%N58OQ+_Y5+1)\N\8;I]$U5%_PY>0M-/S?RC%NO%.
M'^WM=XT<?2C4S`C3R]7[0FV:N1D?YEWM%GRUQIUII-5[.?D+*USER:ECQ;AW
MVBUWC31](]42"[3F^%8DO%L5AY?_`+TZ6B3Y9XW7#1ZOV4_(2USKR8ECQ;AO
MVBUWC41M'M52K#36^STBUJR1_P"Q[6YRY:X\_P#DM7[*?D)T.>.2(_\`QCAM
M?Y3:[QK8VCFK!P^QE?I'$HO^M2ME^/\`.;0Y\K\P4PT.K]E/NDVWSSR,DOZ9
MX9G]9L]\UT31G5M04[2^_P`EP#OK2K>_^<VY?W6Y@3K]!UGL9]TG6>?.0ZO>
MXSPM8?6K/?*2]%M7G)=I;J`7;K1KG3G^0F?W7YA^HZRO\#/NDG^_W(-/ZZX7
M]JL]\IC136`!3M+-0NC\R%=Z_P#<6.+9_NOS#]1UGL9]T?W_`.0:?UUPK[59
M[Y6.BNL941]BC4-V&(LZO;,,_@.YG]UN8?J.L]E/NG%^\+D7+]L\+^TV>^1G
M1/61&`THU#4'%WYCZ\<7_P`XMG^Z_,'U'6>RGW31^\'D;^V>%_:;/?(OL*ZS
M.QTFU$PQ_.;7M[W?R"W2WRQS!%O^(ZOV4^Z;0]X?(RJGQGA=*?6;/?.?L*:S
M>D[2?47TG9V=7\\1_N'+!I5OESF!/'0ZOV4_(<Y^\+D>5/Z8X7A_U-KO&!T4
MUF<':3ZBY$?G.KV&+\O@+3(<`X[1IZ+55_@I^0C3Y_Y(QIQCA?VFUWS`:(ZS
M<;_L3ZC#WI_.;7G8N?\`RBTR'`N-[JKH]37^#GY#3^_G)#C7]L<,K_*;/?,8
MVB.LP!X=)]1E..'YC:^?)(M-M<$XTHXZ34^SGY"!/GGDJO\`6_#/M-KO%,:(
M:T^D/L2:CXC_`*F7!G_0+6.EX/Q92>]IKZP^3EY")_?CDR+PXMPU_P#<6N\5
M5:&ZTD*_0DU(>X_W&5_=_.#6$.%<43_5[V?XDO(:W.>.3FW3BO#?M%KO%?[!
MNM8RTBU)/_P7<'Y1:?#AO$:8V+WH2\A`ESORBW3]J<.HO^HM=XH1="-;2I1&
MD&I9!43A95P'-Q_W`UC;T&M5*V;N7XK\AB7.G)[I_2O#\OK%KO%.-H)K>I[M
M']3?>NPLFX3O_F!KJQI=2EC;FO$R+<YRY1:PXIP_V]KO&N7H#KD\D:.:GG'_
M`*CW%]3VG^HO_B2^)D>7./*:RXGH/;V^\4HF@&NI)_0:U1=C_<-<?3_Q>TFS
M:NK.,EXCE/G+E7=PXGH*_P`/;[Q2B\OFNYP^PSJED,K%N/?_`&/:XLX*-2'/
MG'EAY<1T./\`Q[?>**^7S7K(:+:J$`YBP[EW''^IS6D';:59)>-&CYLY7W:_
MM+0U_A[?>-;%Y=]?<7:)ZK%X.5A7+T_\7-+MSLI8S7QHY2YPY967$-#[:WWB
MFOEUY@'EVB.JYR_N!N;=_8YIUK4:>$J[\<NE$:?-_+=Q;KXAHJ?PUOO%*+RY
M<P1+QH?JR<3E8%SG_HUK*WKM*L'<MX?ZR\IR7-/+/]H:+VUOO$"N73F$3EH;
MJT?_`)?W1]36EQU^C^5M^DO*/[T<L_VAHO;6^\1GESYA7/\`L&:M/.S[']T8
M?\VL>OT=?SMOTEY3C+F?EJO]8:+VUOO$"N7'F%B.)T,U;#L/TOKH^IC=8:W0
MM8WK2_\`%'RC^\W+?]H:/VUOO'`Y;N809:&ZMD_K?71]3&Z/6\/@MZ-^TW^5
M'RFD^9N6]W]?T?MK?>.?VN',-^H7JW\7UT?4QM?VGHOE;7I1\IQ_O+RY]?T?
MMH=XR_:Y\P_ZA>K?Q>W3]36?M/1?*VO2CY1_>7ESZ_H_;0[Q,GEQYA"`_0W5
MI[OU/KH^IK;?M'0?+6O2CY3C+F7EVOZ_H_:P[Q/#Y<^8-(/Z!VK.)VZ?W/\`
M4UG[1T'RUKTH^4Q_>3EWZ_I/:P[Q*.7;F#?^D=JQ\7]S_4YLKB.@K^>M>E'R
MFLN9.7MW]>TGM8=XR_:[<P?ZAVK']X%S_4YMOVCH/EK7I1\IR_O'R_\`7M)[
M6'E)/VNG,!^HAJQ_>#<WU-9^T>'_`"]KTEY1_>/E_P"O:3VL/*2#EXY@0`/L
M'ZKX?]@;G^IK:/6\.;KZ^UZ43']XN7_KVD]K#O'/[7GF!_4/U7_O!N?ZFMCZ
M9P[Y>UZ41_>+E_Z]I/:P[QRGEXY@27'1#5<#_N#<_P!36RM=P].JOVO21K+F
M+E^GZ]I/:P[QG^UVU_\`U$M5_P"\*YOJ<V_[0T'RUKTEY3G_`'BX!]=TGM8>
M4C_:\<P/ZB&JW]X-S_4YL?M'0?+VO27E,_WBX!]=TOM8>4Q/+MS`$XZ(:KX_
M]@;F^IK;+6<.?G>OM5_*7E(USF/@=6EK-*U_"P\I@>7;F``PT0U8+W_W`7/]
M36[1XCP^-/W^SA_KKRD*YS#P;9J]*_\`S(>4P_:[<P)P^P?JQ_>!<_U-;O'B
MG#Y.COV4ORX^4BRX[P=U_C>FQ_XD/*<'EUY@?U$-6/[P+G^IK=H\1X7%U^DV
M?3CY2'<XSP=K#5:?/Y2/E(_VN',!G]A'5G^\"Y_J:W5<6X:O^8L>G'RD67%^
M%5_6;'M(^4C/+ES`@X:'ZLG_`.`+G^IK6%KBO!Y04IZK3J7\)'RE?/BO#,::
MBSZ<?*9#EUY@Q_B.U9+W?W`7/]36[QXOP:/_`#>G]I#RE;J.(\/==V]:?_CC
MY3+]KMS"8_H&ZL_%_<_U-;=\:X,UN_2]-[2'E*?4:[2;C<;MMO\`*7E./VNW
M,([](W5GXO[G^IS:QXOP5.OTO3^TAY2FNZNS)]J/QHE_:Z<P+_TC]6,O^H-S
M?4YI4.+\#R>LTWM(>4J;UY/%-,S1RZ\P``?HAJQ@_P#N`N;?_8UNSXWP1/#6
M::G\)#RE+J?62[*;1.CEUU_S.B.J_P#>#<WU.:3#CW`TW76:7VL/*>=UEG4R
MKNVY/Q/H)AR[:_/!^PEJO_>%<OU.:2N8.`[E/INE]K#RGG[^CU\E*EF[C_JR
M\AG^UXU]_43U6_O"N7ZG,AS!P%+'6Z7VL/*4.IX7Q.46HZ>\W7\273U%E/+S
MKX[])/57(?W!7+]3FEPYBY?4<==I/:P\IYK4<#XS)X:34O\`\N?A\!(GEXUZ
M(>=%=50<</K#N0?]'-U7,/+K>\]?I*_PL.\4M_E_CSFZ:+59?)3[H/+SKT`'
M:*:JG''\PER?4YNJYDY=CEK]'[6'>*#5<L\R2B]W0:Q_^3<Z/R3.'R]Z])Q^
MPKJH"_;8ER;!_8[>6[+FCEYNCUVCH_\`C0[QYG6\I<US@U'ANN>&RQ<[I*GE
M[UZ4L$Z+:I@9_G$N3<1MIW2W5<R\M+_XAH_;6^\>;O<E<XO+A7$7_P!O=[IA
M^U[UZXC^@KJHYY_N#N7ZG-(AS9RY%U6OT7MK?>*R]R/SI7#A'$OL]WN@<O>O
M3E'["NJCR"/SB7+]3NEI]KFWEEPK+B.A3K\M;[Q3:CD+GF3I'@W%&OY->[A&
MOEYU[?AHKJH0#_U#N7+_`-W-O_>SE>G]8Z'VUOO%5=]WW/C6'!>*_9;W<,$\
MO.O86_["NJG;8=RN<,?^#MK;+FSE=+^L=#[:WWBIO^[KW@3K']A\6HU]5O=P
MR/+WKWZ1&BFJFQWY@[EVO?\`UN;,N;N6*47$=#[:WWBNN>[3W@J%%P+B[_[2
M_P!PP'+WKX#^DGJIDH_G#N7/9_6[:YBYMY7I_6.A]M;[Q%E[L?>'*G]!<8^R
M7^X8CEXU[4#Q:*:J^D`_\P=RC:7_`-;F+FWEBM?VCH?;6^\1G[L/>-O?U!QB
MB_Z2_P!PF_:\Z]/?]A751V']P=R].?\`2YLKF[E>N/$=#[:WWA_AA[QL*\!X
MQ]DO]P'EYUZ"B1HIJH_#^X.Y=P_XNWMA\W<L;K_I'0[?]];[QB?NP]XSCAP#
MC%*/_E+_`'"S^U\U[>/T%M4\/^PER[!_8YHO]\.6_K^B]M;[Q%A[KO>0G5\`
MXSC_`-'?[ALH?+[KJ4^EHSJB"=]C7&'8O>XT]L/G#EROZ_HO;6^\2H>['WBU
MH^`\8I_)+_<-E+\OVN+T\6CNIR0`[&R+A&9.^GMI+F[EQJJU^BK_``UOO$RW
M[L_>&DU^P>,9_5+_`'#:P-`];4%).C^I@](?W%7`,,7G^0,,VBOFKEUJGT_1
M^VM]XL[7NY]X45_47%_LE_N&^EM"]:4K#])-1P'8OLRX'99O^`M%?-'+U'_'
MM'[:WWB?#D'WA+#]A\6I_);W<.P0-$-8@$OTIU%#M]GUT>61:-+F?@&Z_P"/
M:/VL.\6%CW?\^1:KP7BJ_P"UO=P[!+Z*ZNISTNU`2\XOM*MCRR31+G,O`FJK
M6Z2J_P"+#REO9Y#YX35>#\37_;7NX=DD-'-5X9!7II?8`^_VK61MZ9-H=SF+
M@C:_CFE]I#REM8Y'YSCGPGB7V:[W3M<EI+J>D.5IS>R<0?2MBL)\LH&@W.8.
M#-.FKTU:_*0\I:V.2^;XK'A7$%_V]WNFW^Q5J9^IY>7][56_*C0_VYP?ZUI_
M:1\I9?W/YM_LS7^PN=T^U;?SN?WV&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`00YJ6C19B!!F($6/*+APYN##BPUQ
M95<6$B/"1,0TJ*X*XD"(E:0H`E"@1@6`G8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`>B?+6`.;?O'"``3JWR^O.TNY4-(P']@8#WL8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`>BG+7_E;=XW^NWR^_P#E1TC8#WK8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@/4;GWT%N+F>Y,.9C0:S
M;EN"S;ZU'T@O"D:>W5:U>J=L5RW]1I.G+K.GM4E*Y1YN0J,E"E+TIDBJ8$.,
M@1I81(:B4+4"!^0CYFWSM:KW_<'.WR>Z^:B:@7O>MM+M#6ZRX>I=V7#=-QTF
M7D)R8TRU8I`C7//5"HR4O3:HJVB9="THAQXT910%*42!XG^=G<VVO][<^G)%
MW?7*MJ;J+9]ZHMFGU*K4S3*][ELV9N34WF.ORFV/I];5?CVS4:?'G(U)IEH0
M9F71%*TP85=4L#TRP'Z0>]1LFM\J7<(\R6G5C7]>R;AT-Y/K<LRDZEINNX47
M]4JM:,.TJ)-W?-7<JHFXUW!7IJ6BS4S,JF3&B1)A;U.)#`?@E[IKN[N]7[WR
MQ]8+\T)[PFX].*;HS==MVC7Y35KF#YCI2>J<]<](GJS)S-'39TA=L!<I`EY!
M28ACK@KXU#A20\@#]UW<1=V;SK=VU9?,;;_.;S.47F5J^JUTZ>5BPZC1M0]6
MK_1:E-M6D73)5R3F(VJM%HL>F+JLU6I9:4R2%HBB`^*IZ4!@/MSJA?\`1-*-
M--1-4KFBB!;>FMBW;?\`<$=2@A,&B6;0*A<56BJ6<$"'(4Z(23@',!_,:^;8
M=Y)K[<W?76=3M:M;=4+NM?FMI.N]FSELW?J%=MQVC2;JN2G3^K=NQ*70*S5Y
MND4^93<5DPJ=)KA04*A0YQ4)#DK4D@?U'V`_F#?.2M4N96<[]BL:":3\Q>K^
ME=(U!I'*O9='D+:U1U!MNT:'5K]MJV:&JKQ*%;5;E9>'!3.U(3$SZB#ZR*Y2
MG*6<0/&W.%:??F_-Q=<-'-1ZWSHW=JOIYJ-4JA&M6M0-4=2=3M$]09NTUTR:
MN73S5#3+4V)!^E=5CTRI0U)4B$(RY6*N+3J@F8@13+@?TH.2;F?MSG2Y2>7G
MFKM6G+HU(UUTJM2_UT")'$W$MJLU6GH3<UKQ)M*4)G(EL7+`FY!48)2(IEN-
MP>X`>T3`>BG+7_E;=XW^NWR^_P#E1TC8#WK8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`?SI*?;_\`JEOG>E)D
MY>$BWM&N<Z_9A=)0#\"I\[:_.=)SDM!DH3_5R\M3+;YG9?U,-#_5H@TM&0<X
M#9=VC;:N]=^=+\TW.55H:K@T?Y4KTOR_+8G9@?"*5,PM,DRW+URWR\N1ZR'+
M34RBF(NF62D@&-2(JGO>\#]9/?\`/[S9WA'ZP-5_M]0&`_/?\R`!_:Y<^!<7
M'6S24`NP)%BW&2`<G@$>%@/W(,!\1/G&>OHY>>YMYU+AEIU4G6]1+"IFA5`3
M#B>JCS<QK7<U&T_KL"`L*2L+@V76:I,'AQX("NM@/YU5*TG7W<MG]P/WC,G)
M1:/4-4[RU`U?OJ>AP5H$_`T/YLTI@2\W$4D)B(K.CM:D(;C@N7B$!X8#^P3*
MS,O.RTO.2D:%,RDW`A3,K,05B)!F)>/#3%@QH41)*5PHL-84DC`@O8#^7O\`
M.$`5?.8-/4I!)-Y\AX``>22JP@``,226`^R'SV_5;3R6Y7.3O0^)6Z/%U6K.
MOU:U4D[<ASDO%KTCI_:^G5T6E5:S.2$.(J:D:35+BO&2@R\6*A")J-*1DPBH
MR\4(`^]GS>^RJ_8'<Q]W_0+EE9F3J4WHQ,WA"@3:5(C?2742^[PU!MF+PK`4
M(4S;=SRD2'_]FM+`?9-@/13EK_RMN\;_`%V^7W_RHZ1L![UL`8"A5:K3*%2Z
ME6ZU4).DT:C2$Y5:M5:C,PI.GTRF4^7B3<_4)Z;F%PX$K)R<K!7$BQ%J2A"$
ME1(`+`>@'^MQ[K+_`/Z,<DO[IS1W_"]@.\Z:]Y'W?.LU\V]ICI'SN<J>INHU
MVS4:1M:Q+#U[TRNN[KBG9>3F:C,2E$MZB7+.U6IS$&0DHT92(,):DPH2E$<*
M20![JL`8`P!@/2#G:[Q[DO[NFW[$N?G'UMI>CE*U-K-7H-B_"K:O6[:C<50H
M$E*U"N?`Z/8EMW/5D25(EI^6^$3,6##EX42:@H4L+BH2H#P]R;]\OW;W/]JM
M4-$N4OF-E=5]3J59E6U!GK9A:<:M6DN!:-"JE#HU5J_TROFQ+:H\1,K4KDDH
M9@HF%1U>N>E!2E12!]0&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@/PV_/4>6\P-*>3'GMM&>B6_?>E&JE0T*JE9IDTJGUZ)(7C3*CJ=IY
M4Y&>@*A3<"-9-RZ?55<!<)87"BU@K#B'@#VM^9P\L-(TP[M^^>9N9B2\_>_-
MIK5<TW.5$>G.2]CZ,3M2T^MNBST98,54S#O%5RSZCQ$*AU"&_$%@/K+W_/[S
M9WA'ZP-5_M]0&`_G-]RSW1?/OWD^GNN-W<G?-S;_`"V4#3"\[4MR]:16=2-9
MK&B715Z[0ZC4Z74H,MI=0:Q)3Z)"2E(D(KFU(BH*W(!22P']#SN-N[VYL.[B
MY:=4=(N;WF#I',;?UY:Y534>WKNHUYZE7O+T:T)VPK#MF7MR)4M3Z72:S*QX
M-9MJ=FC`@0S*A,R%!1B*B``?#3Y[5K]];?*OR?<M$C/B'-ZLZVW;JS6I*%$'
MK8M"T:L]-N24.:0/2^"35;U<1%1L5%DG_0L!X1^<:\EPTL^;\]UVF4IGJJWR
MBJT"L*YR8)];*2VI.A$S2KZFXBDI`A&?U+MZF&(_WT2*-K`?K![G_7X\SW=@
M\C6M,><$_5[CY==/J'=$X(ABJF;UT]I8TXO>-$6I2E>MBW=:4ZI0)>"6`_GH
M_.9[/KVH7S@Z8L&U;@7:5SWQ)\H%GVY=4*/-RT2V:]<UOVG1:/<$.9D(L">E
MUT:H3L.9"X*T14&&]"@H`L!X;[F/D-TMY]N]_O;E8[SG4+5ZYK^TT3J=&G;8
MJUWS]2K&L.I^A%U0J;=NEE[WO<,U4;OEZ/"H\A59Z.F2B0IR/*TR/#1,RQ(6
MP']9ZAT.C6S1:/;=NTJGT*W[>I=/H="HE)E(%/I5'HU)E(,A2Z53)"51"EI*
MGT^2ET08,&&E,.'#0$I```8#:,!Z*<M?^5MWC?Z[?+[_`.5'2-@/>M@#`>)=
M?;>K-W:$ZU6I;L@NJ7!<^DNH]O4*F0HD"%$J-9K5G5FFTR0AQ9F+!EH:YR=F
M40PJ(M"`5/4H!Y8#^,KS3=SAWEO)1I--ZY\T7*M=6DFE,C7:+;,W>%6N_3"M
M2<&N7%%C0*-(*D;4OBOU<KGHL!:4K$N8:2/24EX>!Y]^;F?OUO()^N;=W[$.
MHS`?V1V`,`8`P'\B_P"<[=X'^WE[S;4&V;2K?TST5Y28,[R\Z;B5F!&I=3N.
M@5.+%U?O*6$-2Y>+%KM_HC4^',PE*1-4NBR*P6`]K_F9/[Z_J+_F7:M?LHZ&
M,!_4A8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`_)#\\Z_
M>IM,O\]+2K]BK7-@/:KYJ/\`O(O+)_WVYBOV?=0V`]M._P"?WFSO"/U@:K_;
MZ@,!^>[YD!_DY\^'Z]>DG_@6Y&`_<BP'\R?YU;>FI7-AWUFAG*7HA;434:_M
M*-+M'M,[+T[EC)QOKAU<U7N"HZEJID6'4IV2IB!6:#<=OP(_KXT""(,%\1:4
M@J`'=N\@O[YTGS)<E&N>F/.AR86C2^6&G6M+:C:IUNWK(T>IU7M&VM(*I3]2
MHMRTN<H&J=:K,FBA)M418_P25C15R28T/A*5J#`?<3YFQK\-2N["OC1:=G#%
MJW+?S%WI19&35$"U2ME:G4NC:C46,E#RJ'"FKOJ=Q)`P!,)3MK`?G-^<(_\`
M[R_I]_WRY#_Q5A,!VCORJ'7^Z,^<5:6\]M@4V:E+/U,NO33FT@RE.3ZJ!6%Q
MZA&L#F0LI,='JN*>O--)JLS.`GB3#N9!)<H,!_3'M*ZK?ONU+8O>TJI*URU;
MRMZBW5;-:DE^LDZO;]PTV6J]&JDI$&$25J%.G(<6&K:A8+`=A8#T4Y:_\K;O
M&_UV^7W_`,J.D;`>];`&`,!^7OYWO^\X79_G#:%_VTK;`?@\^;F?OUO()^N;
M=_[$&HS`?V1V`,`8#Y)]^!S^0.[B[N#7O7JDU2#3]5J[1QI'H)"5$2F:CZQ:
MCRL[2K>JLE"4I(F%V-2H4_<D6&2!$@49:,U`$#^+W,19N<B3$_-1)B:C3$PN
M+-3DPN)'B1YN94N-$B3$Q$*E1)B.KB62HE2B\E^+`?K/^9D_OK^HO^9=JU^R
MCH8P']2%@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8#\^OS
MDON_>9OO(^0NQ]!>5&U:!=^H]$YEK#U*J=,N.\*#9,E!M&@V#JG0:C.PJK<4
MU*2$>:A52Z))`EPL1%HB*4'A!#`>>NX1Y.-=N0KNQM$N6/F2M^CVQJY9%SZQ
M5.X*/0KDI%VTV7D[QU8N^[*$N#7*%,35,F5S%&K$!:THB*,-2BE3E`@`>?\`
MO9^7C5'FR[N'F[Y<=%*33J[JKJ[I-/6E9%(JU:I]O4Z?K,Q5Z1-H@35:JL6#
M3J=#^#RD0^LC+2AX`)#V`_![RL=R-\Z)Y(Z)=EM\I]Q2>A="OJJT^N7=2['Y
MD=&Y25KU6I4I%D*=/SZ)RH3I5,2DG'7#24E/HJQ>P'ZPNXAT3[YO1V%S.#O<
M]3*OJ(NX(FD?V!A5-3K&U&^E":6G4C[)'J/K-0^D?#C/T/B^$K(C^I'JTCU:
MRH#Y::!]RWW@UR_.-KH[S?F3TWLR@\MTIKQK/J-:-5EM4[+N>X9FW:385T:=
M<O4.-;%+GIBL2TY"IT*A3,9"H2/@:I=25%Z`\#]BFL>G-+UATAU4TCKB4+HN
MJ6F]\:<U=,0<4-5+O>V*I;,^E:7'B092IK>'9,!^33YL5W4?>.]UOJUS5TKF
MOT^LZV='=;+!L6;H]5MC56S[V*]2--KEJTO1X'TCH-0F:A*R]4M>^:I$5-1(
M<-*3*0X:_26D`#UY[W?N-^\1YNN^NM/G6T0TULBO:`T>Y.56I35PU;56R;=K
M*932OZTS>2_K9JU2EZT5R2J5']4E,)1F`D&&_B`8#Z;_`#F7NB=9.]*Y>-!9
MSE@MRVKAYBM"-4:K$ILC<=QT6SY:J:4ZAT`RU]2"+@KD>4D$SDG<EL6_-P8,
M6(`J%"F.#TU`*`^B7<N:2\W7+YW<^@'+WSLVM2K8UJT(I53TKEU4:\Z%?,C7
M=-;9J$5.F%235K>G)^2EXE,LV9E:.J77$]:#2_6$!,5+`?5!@/13EK_RMN\;
M_7;Y??\`RHZ1L![UL`8`P'Y>_G>_[SA=G^<-H7_;2ML!^#SYN9^_6\@GZYMW
M_L0:C,!_9'8`P!@/YA/SPGO!/VP7.S9_);8U;^%Z:<G-%7%O6')S''(UC7[4
M.0D*G<0C^J_&)LV%9@IE,A<1,23J,S5()<2H,!Z*]X#R#1.2/N6>Z]NR[:(F
MF:Q\W^KNMW,5?ZIJ4]55Z;:=9T_TRE-&;1F(L1*)F'+4RP(J*JN6B)2N6J-=
MG$*#TA@/;_YF3^^OZB_YEVK7[*.AC`?U(6`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`>K6J'/)R6:(WC/Z=ZS<W/+-I+?]*EY";J=D:E
M:Z:8V/=M.E:K)P:A3)F>MVYKGIE7E(%1D)B''@+B04IBPEI6DE)!8#IM)[RG
MN[*]5*;0Z'SX\G%8K59J$G2:12*7S+Z-3]3JM4J,S#DZ?3J=(RMY19J=GIZ;
MC(A084-*HD2(H)2"2`P'L5JSK5H[H):@OO7+5;3C1NR#4Y.B"\-4KVMNP+7-
M9J*)B)(4D5ZZJE2J6:E.PY2*J#`];ZV((2BE)"2X#L5C7Y9&IUI4&_\`3:\;
M6U!L6Z9!%4MF\[)K]*NFU;AIL1:X:*A1+AH<W/4FJR:HD)21%@15HXDD/>"P
M'BG43FRY6M(;_H&E&J_,AH1IGJA=<&CS%KZ<W_JU85GWU<<"X:I,4.@1J%:=
MP5ZGUVK0JW6I2+*2BH$"()B9A+A0^):2D`>4K]U!L/2NSZ[J%J=>EJ:=V%:\
MHF?N6];XN"DVK:EOR*YB#*(G*W<-<FY&DTN55-3$.&(D>*A!B+2E[R`P'J7"
M[SGNW(\6'!@]X!R5Q(L9:(<-">:+1+B7$6H)0A/YMLU*+@P'N+;%U6Q>U!IE
MU69<=!NZV*U+B<H]QVQ6*?7Z#5I12E)3-4RL4J8FZ?/RZE)("X41:20<6`WS
M`&`,!Z*<M?\`E;=XW^NWR^_^5'2-@/>M@#`&`_+W\[W_`'G"[/\`.&T+_MI6
MV`_!Y\W,_?K>03]<V[_V(-1F`_LCL`8#T[[P#F^L[D+Y->83FTO<RT>G:-Z>
M5:O42C3,80$W7?<\85#T[LR%$XT+3%NZ^:I3Z?Q)+X29A40^B@L!_)8[J/E0
MOOO?.]?T[L_5.9J%Y2&HNJ-R\QG-5<\SZQ2YZPJ37U7SJ=,5&80]4G%OZM3\
M&A2\0/$*=K4'#A#`?JV^>]RDI3]#>[OD)"6EY*1DM1]=I23DY2##EY64E):T
M-,H,O+2TO!2B%`EX$%`0A"0$I2````P'R3^9D_OK^HO^9=JU^RCH8P']2%@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P'\JSYQWIM2]8_
MG&=3TAK=0GJ/1M5J]R5Z<5BK4I$NNJ4VF7Q9>F5KS]1IR)M"Y6)4)*3J:HD$
M14JAF(A(4"EX8#]'6F/S,SDPTNU*T]U,I7-ES/U&IZ=7S:=]4VG5"GZ4?`9Z
M>M&OT^X).2G3`LZ''^"34Q3THB%"DKX%%Q!8#S?\\4`/="RSP"[FLT5(Z#](
MM2`\;BXL!Z__`#-#G8^R[R5ZL\E]T5;X1=W*C?INBQ969CDQXNC>LLY5*ZB4
MDH<0JB1X5M:F25;5,*2>"!#J\I#<`4O`^6OSEM*?NBON[SPAZK-Y*TJ+@]0'
M-AJ4X$[0.(^%@/UK_.'`#W+G>`/#_P!!ZF''>-1;)(/6"&`_"_\`-^>X9Y9^
M]\Y;N9V_=8-5-:=+M0]+-3K?L:Q*KIS-V9,6Q!E:O9R:\N<N>V+DM6I3U>7#
MGU.*):J4TJ@CA"TJ/&`-GR,\PG-A\V\[XB-R,ZTZDS5U\L5T:FV596K%$1,S
MXTXN33O53Z6FP^8^R:%49N:@V?==N2=<EIVIIEU+BQ(<I/4F8B1S#A1X8']2
MI@#`&`]%.6O_`"MN\;_7;Y??_*CI&P'O6P!@#`?E[^=[_O.%V?YPVA?]M*VP
M'X//FYG[];R"?KFW?^Q!J,P']D=@#`?SYOGH_>`+GJ]H/W;UBU>().AP)3F+
MU[ARD5:8<>KU"%5*!H[:$XI'!Q&G4M55K4U+KXX:OAM,C`!<,.`]L/F?_+#I
M!RV<INI/.;JO?NF5N:L\U==5;-CR%P7M:E.K]N:%Z:U6>I\)421G:M!J-(BW
M]J'"GYJ/!BPT?")&DTR.'I4DL!X+^>O:AZ?WQHYR"PK*OJS;OC4[4S7:)4(-
MKW/1*_%D8<S:VG*9>)-PJ3/3<26AQE05!*E@!120&`^3GS.RZ[6L[O3M1*O=
M]S6[:E*5R;:JRB*E<U<IE!D(DW&U/T07!E(4W59J4@19N+#A+4F$E1B%"%*`
MX4J(`_J:R%0D*K(R=3I<[*5*FU&5@3M/J$A,P9R1GI.:AIC2TW)S<NN)+S,K
M,05A:(B%*0M)!!(+`6V`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@/Y;W?[UNC6U\YSM>X[CJU-H%O4#4_D%K==KM9G9>FT>BT:E4;26>JE
M6JM1FXD*4D*;3I&`N-'CQ5IAPH2%*40`2P']%2T>\:[OO4"ZK>L:Q.>+E'O.
M]+MK-/MVU;2M7F*TDK]R7)7ZM-0Y*E42@T2E7;-5*K5:I3D9$*!+P(<2+&B*
M"4I)(#`?"/YXI^]"2_\`G5Z*_P!H]1V`_)WW*=WW#W5/>"]UQS#7%6YV#R]]
MYCHM7-/[MJLXH2M(D57/K/>&C$[29R8`3+!%@:N:?6O7IB,L%4"DSX>H<:BP
M'OU\Y;__`'BON[?^YW)9_P";#4A@/UK?.&_WESO`/UGJ9^R)9+`?"CYD1_DF
M\[7^<18W[&L)@/E1\]9LB1H7>$\LNH4A`^"S]Z\IE-IE2F8+X:YF=LC5C47X
M+,J6EQ,Q!D;B@PPI[PF&G<&`_HK<KMZS6I/+/R[:BST4QYZ_M"M([UG(ZE<1
MC35U6!;]=F(I5CQ&)&GR7[7L!YU8`P'HIRU_Y6W>-_KM\OO_`)4=(V`]ZV`,
M`8#\O?SO?]YPNS_.&T+_`+:5M@/P>?-S/WZWD$_7-N_]B#49@/[([`&`_E&_
M.R;.NZM]\OJS/4:U+DJTDK1W02&)RFT&J3TJN)#L"32M*)F5E(L%:D'`N47$
M..(8#\UOV-]1/^H5Z?WK5S\HL!IZO;%RV^B!$KUO5RB(F5+1++J])GZ:B87#
M"51$P%3DO!$54,+!4$O(!#\V`JTJC5BNS*I.B4FI5B;1"5'5*TJ1FJA,I@(4
MA"XRH$I"C11"0N(D%1#@5`;0P']NWNJI6+)=V3W>TG'E8TC'E>2SEDEXTG,2
M\24CRD6#HW9T-<O&E8R(<66BP5)*5(4E*DD.(!#`>_+`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P'\JWYQUIO2]9/G&=1TAKE0GZ31=5:]
MR5Z;UBJTI,NNJ4REWS9FF=L5"H4U,Y#BRBI^2E*HN)!$5*H9B)'$"EX8#]/W
M*]\T/Y..5?F0T*YE;2YG^9BX[GT%U8L35NW[?N*7TK^D-:J]@W'3[EI]+K*J
M=9,I/BFSLU3DPXQ@18<80U'@4E3B`.U_/%/WH27_`,ZO17^T>H[`?#KF,Y+Y
MCF)^:-\@G,7:$A'B:G<D<WJ1JG)SU/"A5AI9=W,3J7:6J,I)Q87#'@0Z7,?2
M6X(\5*DF#+T"(H,!\V>>/G*E.?KO#>Y#YFXE314[QNK0?D>M35TI*?62FM&G
M7-GJ59FI<.-"'I2XJM?I2JI+H5C\"J,!6(4"0/W[_.&_WESO`/UGJ9^R)9+`
M?"CYD1_DF\[7^<18W[&L)@/FU\]QJ<O%YS>3:C)(^%2'+%<%3C)?B)>KZJW#
M*RQ*<P%1*)%<=KCN8#]^G(S2IF@\D_)Y0YU*D3E&Y6N7VE3:%)X5(F:=I+:,
MG'2I/T*DQ8)!&Q@/:5@#`>BG+7_E;=XW^NWR^_\`E1TC8#WK8`P!@/R]_.]_
MWG"[/\X;0O\`MI6V`_!Y\W,_?K>03]<V[_V(-1F`_LCL`8`P!@/PI?/AOTE^
M[Y_7/U\_\*::L!\B_F9/[Z]J-T\EVK7[*.AA\S`?U(6`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`?R\._>4E'SHJPEK4E"$ZP]WNI:UJ
M2A"$ID-("I2UJ(2A*0'DD@`,!_3Y%?H1(2*U22HD)`%1DR227``>N>22P'Y;
M/GBG[T)+_P"=7HK_`&CU'8#V@^;^Z;6CK+\WVY3](M0*7#K=B:I:+\P&GEYT
M>,[U=4M:\]9]:K=KT@HJ2H)^%4NHQ4`N/"2_8P'\T.W.72\N4+O=--^5V_3,
M*N/0CGUTQTZCS,="H4.JR%#UQMN%1;DDH1/"BG771%2U3EBD`+@3:%;6`_J4
M?.&_WESO`/UGJ9^R)9+`?!CYD_5J5;_)SST5RO5.GT2B4O7^S9VIUBKSDM3:
M53I.5TRA19F;GJA.1(,I*2TO"]*)$B+2A"<20&`^!O?3:U4KOJ._?L;1KE@K
M"-1+$%:T@Y.M,KOMV)],:)<,G3KFJE7U*U!I,U+&++S-H4:Y+RKLPFI0E*EI
MBCTM,ZE1@K2I@/ZL%!HE.MJAT:W*1`$K2:!2:=1*7+)=PR].I4G!D9*`EP`=
M!EH"4C`9,!MF`,!Z*<M?^5MWC?Z[?+[_`.5'2-@/>M@#`&`_+W\[W_><+L_S
MAM"_[:5M@/P>?-S/WZWD$_7-N_\`8@U&8#^R.P!@#`&`_"E\^&_28[OG]<_7
MS_PIIHP'R+^9D_OK^HO^9=JU^RCH8P']2%@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@,5K1#`4M:4`J2@%:@D%
M2U!"$@D@%2UD`#,DN;#:6+R,QC*3I%-NE</!F9-DP>N7,3K[*:(T2EJDZ<*_
M=%:G8(D:*%*2E%+EXR%5.H3:H?IP8?J084'[_&4,PE3?RI_FG_S,:/\`R[\N
MZ.[H='^U.<.(ZB*LZ1-I+3PDGJ+]UQJXQ4:V[3IYUV2S4)'S#[H?=3?]Y?$[
M\=3>^B<#TUM[]ZF=V2?J[<4\&ZTE/H@NEH\P6+>E%U"M2C7?0(JHE.K,HB81
M#BCAF9..[AF9&;AYPIN3CA4-8WAX>""WSI[N>?\`@'O0Y+T'//+,W+A6OL*:
MC+"Y:GE<LW8_@W+4ZPFNE554TW\>\T<M\2Y2X[J>7^*Q2UFGN.+:QC./X,X/
M;&:I*+Z'CC4[6I24)*EJ2E(S4HA*0\N#R7`8EO<)-X+,\]*481WIM*/2\$9-
M@V#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P'Y`N]Q^:ZWCWG//-J+SB4;G.MW1
MJ3OFW--Z%`L6?T/JEZSM*B6#9-%M%<VJXY35*UH4R*C$I'PA*1)PS""^!ZB.
M(@>@]E_,J]5[3O*TKJB]Y10:A#MJYZ#<$20'+M<DNJ=11JK*5)<HF8.N<<0%
M3"98H"RA822]QR8#]1_?/=V?5N]@Y.(?*M1=7Z=HC.0]6K'U,-ZU2RYF_98P
M;0D+EDHE'^D4I<UIQ?63YN`*$;X6Z'ZIQ0KB>`/.G=C<F,_W>O(KR_\`)S5-
M0935.?T3HMVTF8OZ0MR-:,I<2KFU%O"^T1H-NS%9N&-34R<.Z4RQ2J<CE9@%
M;T\7"D#XY]XW\W%I?.YWFFDW>+V#S"T;1:HVM5-#+CU/T]G=+)F\(FHUTZ)W
M3)3<G7Y6Y)2^+:10YJM6/1*71UIB24WZHT]$9Z^-4,`?:7O&^4>>Y\>2/F'Y
M1*;?4KII/:Y69*VI+7U.V_%NF4MM<M<E#K_PV/;\"KT&-5$+31S"]6F<@$&)
MQ<6#B!^-&B_,DM3Y23CV]-]YY*25HU*:@S=9HM%Y<;A1)S\>"!#1,QZ5%U]@
M4R;FH4%Z4+BI)2,'N8#]#7=,?-Z.3/NH;AF]6K4J=TZ\\R4_1YN@HUKU+DZ3
M(*M"CU.#\'K-.TQLRD)BTZS$UV6_&IR;BS-2JL274N73-HEHL:#$`^]K`&`,
M!Z*<M?\`E;=XW^NWR^_^5'2-@/>M@#`&`]->>WD0Y?\`O&=`YSEMYEJ==-4T
MQGKKMN\YB4L^YYNTJPJMVI%FHU(6*M)PHT42R%S:_60BDI7AM`8#YI\J'S:W
MNP>3#F&TPYGM$+4UDD-5=(JS/5VS9RXM7JS<%%@S]0H55MV954*/,2,*#/PC
M3:S'`0I0`60=CF`^^S`&`,`8#YL=XUW47*)WIM!TLMOFRHU^5BF:.U>Z*Y9:
M+'OFH65%@3]X25&D*RJHQ)&!,"HPUR]!EQ""P/5$*<?2+`>#.[_[AKN^^[0U
MNJO,%RNVYJE2=1JSI]7=,IV9O+4VJ7?2%6M<59MNO5*%#I4Y*0(*)U50M24*
M(SRI"4J2!Z18#[-,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,!\>._#OFLVCR13](H$Y/4ZJ7OJ/8]OHGZ?-S,C
M,RTO)SD>X(YAS,HM$>$J(:0A(*2,V_G_`/S)\4U'#O=Q*SI7.-[4:RS#>BVF
MDFYO%=.ZD?W!_P#M^\O:'C7O^MZWB4+=W2</X5J[SA.,9QE*45958RJG3UC>
M*/BWR1]ZKS0Z`SE(MS5:M537724Q)66F:7=<V9F^+=DAPPU1;5NR8?-S:9>$
M!PR=05&@J`X4*A'%OYT]VWOQYWY9U%GA_&)SXIP24HPW+CK?@FTEZJZ\739"
M;DMB<3^]/?Y_DY]T?O)TU_B_*%BSR[SBHRG&[IX[NDO2Q=-1IH^;&KSNV5&2
MSDIGV^^O>QN:N'#UIL6X):Y;2N#BD*/&A+4B8I$.DJ,O,4"K20XU4VMTV9*A
M-0%8B(KB!4DI48_^9_W`<_Q]\O$M/[U-%?X7S#;MV?4Z;41QAHY04]-*W*+E
M;G"Y&3FYVY2CZQSBWO1DC^`.5]1<]W_"(<L;J6ILR<KLHXQN7)/&Y%M)RA))
M*#:7FI8+(N2/-'9O*VJ?TUC3,"XK\NNE3-V6A8$":X9F&B35#DYZMU>*<:71
M(H*2'CUDPJ$KU8/I*']/_P"2'W`^\'3\K\:XE9L7%[IM/K;49ZQQ:M6]=<5)
M6+.]3UD[EM1E<W:QMM1<VG-)_P`:_P"??WTS]S_NC?OFL<)O\3U^GU-O01C%
MJ%KUE_>=B6HN9QM0FFI.*<GOQ@J-U7SAUZYE-=]1JS2*O<UVU.6D*?<M,JDC
M;5OQH])MR1$E,_"H"4R,O$!GE0UP1^.3"XRU`/)=@/L@X?RKP#@VC=G168.[
M*+BYSI*<JIK%O+J22/RZ^\#_`#.>_;WM\UVN+<W<7U<.'Z?56[UO1:24K&CL
M[EV,H[MJ#7K&J+]\NRN3=*N5%1?IJH-0%6H=&JH>ZITJG5`/S=.R<&9#\L71
M&_EB_;]5?G:_%FU\3H?ILX)KEQ/@VDXDJTU&EM7<<_WR$9??-JW(LPP!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`>BG+7_E;=XW^NWR^_
M^5'2-@/>M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P'S1[VO2^-J5R4ZAQY&27/5/3
MZH6]J%*PH2#$C_!J%4H<*L&&@8E**/.QEK.R&@G8WQ3[Y^7K?,7(FHLSC)RT
M]R%Y;KH_,?G;'^"W7P']4_Y-.<ER?[]N&^LFK>GXC:O:.3EV=Z[!NW7PNY"*
M72VEM/RRT73F+.V]-3DE**BA5+F)B$84-2C_`",I:`CT5$*!4'$#/(M_*ONC
MX!I'[U.6M-Q**>B_O%PY74TG'U?TRSO[U51Q<:UJJ4/MOYPYMG:X=K(QFU=^
MC74JNCKZN5,GTGD;NR^8VH<J6LUV4.^YB;CZ*ZAVS<%1KE+7'7"31;YM:ASM
M9MFJ4N#$!A2\[</P$TB/Z(];Z^"5/5#21^JG_/W_`):^$_YGO=MPSB'+D+5O
MWG\$UUBWI[Z23NZ'57H6M59N257*%A36KMIUW7;N*-%<E7ZQ^==#+C?"K=[0
M47%[-R"3I7>MSDHS3VO<WM]8X4>PAY8:GJ3KKS@5?62^?A4[<%["\:]68,6*
MM<M0Z'&IT6!2+;D"24PJ;0I,P9270"D.3Q%ZE*+6OOHY6Y%]S_\`E?TONGY,
MA"UP/A*T6GLM);]Z]&[&5[57:4WKVHGOWKLL<94244D?Q;_^Y'PW0:G_`"=<
M:Y<TT8M?3>&1M95E=6LMR=RCIYV$I/HZD?2&[-.(]PWK8UHTZ4C1IFX;JHM&
M1+H3#5%6J=GX<&:>@#^5I2*N*5N(*0=S?7!J>*^JTER_<DMRW;E)OP)8?&\.
ML_,QR][L=3Q/FK0<OV+4IZW7\0L:>W%13QN7(J<G%;8Q;E58;J;/TNR,I"D)
M*3D)=(1`DI67E(*$AP3"EH2(,-(&P)0@!OYCN3=R<IO.3;^,_2?H=+;T.BLZ
M*RDK5FU"$4LDH145]Q%IM"4&`,`8`P!@#`&`,`8`P!@#`>--6[=U.NFRIVCZ
M0:ET?26]XTY3HLC>M=T^@:GTZ2DY>;AQ:E)Q+1F+FM&%-Q*C*)5"1%,Z@P%*
MXPE;N$@>IGV#>\)^7YI?^XCI'^D"P#[!O>$_+\TO_<1TC_2!8!]@WO"?E^:7
M_N(Z1_I`L`^P;WA/R_-+_P!Q'2/](%@'V#>\)^7YI?\`N(Z1_I`L`^P;WA/R
M_-+_`-Q'2/\`2!8!]@WO"?E^:7_N(Z1_I`L`^P;WA/R_-+_W$=(_T@6`?8-[
MPGY?FE_[B.D?Z0+`/L&]X3\OS2_]Q'2/](%@'V#>\)^7YI?^XCI'^D"P#[!O
M>$_+\TO_`'$=(_T@6`?8-[PGY?FE_P"XCI'^D"P#[!O>$_+\TO\`W$=(_P!(
M%@/&5G<F?.]8U^:NZBT3G^L,W#K97[5N2]!.\EM`CR":C9UBV_IW2!1H$+76
M7CR4L;>MJ6,5$6+'*ICC6DI"N``>3?L&]X3\OS2_]Q'2/](%@'V#>\)^7YI?
M^XCI'^D"P#[!O>$_+\TO_<1TC_2!8!]@WO"?E^:7_N(Z1_I`L`^P;WA/R_-+
M_P!Q'2/](%@'V#>\)^7YI?\`N(Z1_I`L`^P;WA/R_-+_`-Q'2/\`2!8!]@WO
M"?E^:7_N(Z1_I`L`^P;WA/R_-+_W$=(_T@6`?8-[PGY?FE_[B.D?Z0+`/L&]
MX3\OS2_]Q'2/](%@'V#>\)^7YI?^XCI'^D"P#[!O>$_+\TO_`'$=(_T@6`WE
ML:,\]E-N6WZA=//!IQ<]LR%;I<Y<5MR7)W2K=G+@H<M.P8U5HLK<"-<ZHNAS
M%4D4+@HG!+3!EE+$00E\/"0/>)@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P'K#SI<R]L<G'*AS`\S]WQ(`H^BNEMVWPB5CJ`35JU2Z7'-MT&&D
MQ(2HL>O7#$E9-"$GC4J,`D$N#`?S>[)^>)]Z?*7W9]3O^C\NE1TV%W4B8NVC
MT?2&J2%7J-G0:O++N*ET6LQ+VB)@555',2'`CE"N",4J4DX@@?TY]+]1[3UA
MTVL#5BPZG!K5DZEV9;5^6E5I=07!J-NW91Y.N4><0H8.CR$]#41L)<P'>V`,
M`8`P!@#`&`UM9I%-N"D52@UF3@5&CUJG3M)JM/F4")+3U.J,M$DYV4CPU/"X
M,S+1E(4#F"W.]9MZBS*Q>BI69Q<9)Y--4:?6B5HM;JN':RSQ#0SE:UMB[&Y;
MG%TE&<)*49)['&237A1\`;PY+JAH/?,_:R)6/4M.ZA.S,WI]7%I5,(^E46(J
M(FWJK$*7"LTA"A#/%A&AA,09D#^:^,\BWN7N,1O:5/U,;BG9FO!)2BFU^'!I
M8O8DT?9!P#WZZ?WA\MPXA<G&WS#"VH:RSEY]*.[;5?S5WM8=EMQ>6/KS<?)!
M3ZE4HDQ)TV&F`J+&BPU+A1E^MA1HIC(3^-0>%T/B*27DDOQ;[V_=I_F=N<P\
ME:#B]V[):J[IH*[%->9>A%0NQS_'3:_U6G3$^`-;S1?X5K+NBNR3W)8/*L=C
MQZ53QGMYRR<K=+TV37;OFI!$LHR'TGI4)RDJ"4E$6HQT*,.$OA)APX8)><%=
MOQ-[\/>[J.;(:;EVS<E**N>NNOXU;CFUME)Y?@G\(?YT.;WS%RYHN4'/>L1N
MO67J9/<C*-F#=7FW*;5%E%UQ/>CE[Y?HB;ZBZQ7;)>I,@F8@V+38Z'1$Q)V7
M$O.7!,0EI_&W2Q,.5!]+TU1,/0?_`"MS3Q^,M.^$:25=YKUDEX,HI]>,O$ND
M_E#_`"T^XC4:?F/_`!7YKL.T[49QX=9DJ2_?%NSU4XO);GFV4\?.E<P\T]\F
M^/C^\PP!@.D:FU^?M/3?4&Z:48(JEM61==?IIF8?KI<3]&H,_49,S$$*08L'
MX1+)XTO'$EX>&`_%-\W^^<$\_P#WDO>%JY9^8]>B2M-!HUJ=?(^L'3B;M>OF
MN6E.VU`I)%6C715H9D_5U6+ZR'ZGT\"\.Q`_<@P!@#`&`,`8`P!@#`&`,`8`
MP!@/E!>??D]U!I[K#<F@-Y\Z&G5!U@M#42HZ3W)8\U0=1HE0I&H=)N"):M2M
MB9G)6RIBDF<D[AA*E5Q$3"H`6DGUG".)@/J^P!@#`="U4U*M+1C3#4?6&_YV
M8IEB:46'=^I-ZU*4D)RJS=/M*QK?J%SW'.RM+IT&8J%2F)6CTN-$1+P(:XT9
M20A"2H@$#IG+9S$:6<V>A>FO,=HC69ZX=*-6[>3=-CUNI42JVY/5&C+G)N03
M,3-$K<K)56G+,S)1!P1X2%N`+G$%@/.#`&`,`8`P!@#`&`,`8#K=Y791+"M"
MZKZN68BREN67;=<NRX)J!+1YV-+42W*7-5BJS$&3E419F;BP9"3B*3"AI5$B
M$<*020&`\-<I_-/HSSK\O^GO,[R^5^HW1H_JC+U^:LVNU:WJU:M0GX-M757+
M,JZIB@W#)T^L2'J:_;DW"3ZZ"CUB$"(EZ%I40/8E@/4_F@YUN7SD[J.@-*UX
MNBK6W.\S6N%I<N^D,.EVK<-SIKNJ=[Q3!MZC3\2@4^?109&:6#QSLX84K!&*
MU@,![8,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`?
MB4^>@<[OV/N6O0WD5M6HB'7]?KI.K&IL*!%X8T'333.<AP[7I<RA"G_![EOZ
M83,CB`_J&[$*+`?"OFH[HJHZ;_-KN3KG-^M5<IJY1]6ZYK)J8L4Y**P-#.8Z
M;DK;L.)4XX`F%TZBKMVW)Z!#<?5(N&.M;@E7"!^G?YH;ST?MCN[RJ7+%=57B
M3VHG)I='UIR*)N.B)-S6CU\QZE<.GT6&"I4PN6H-1AU2E(*L(4O*0(:7)2`P
M'ZR&`TMQW';]GT"L75=E<I-M6S;M-G*Q7[AKU0E:31:+2:?`7,SU3JM3GHL"
M3D)"3EX:EQ8L5:8<-`)40`P'CC3/F%T&UHGJK3-(-9]+=4:C0Y27GZU(Z?7Y
M;%WS=)DIN-$EY6;J,O0*G/Q9*6F8\)2$+B!*5*20"\,!YA8#QGJ9K1I#HO(4
MNJ:OZHZ?Z74RMSL6G4>H:@7?0;0DJK4($NJ:C25/F:]/R$&<FX4L@Q%0X:E*
M"`\AS`;NP]0["U2MF2O332]+6U`M"HQ9R!3[HLRO4RY;?G8U/FHLC/PI2KT>
M9G)"8B24[`7"BI1$)AQ$%*G$$,!U[4W7#1G167I4WK!JOIUI;*UV-,R]%F=0
M;RM^SX%6CR<-$:;@TV+7ZA((G8LK"BI5$3#*BA*@2YX8#Q_K/SB<JW+OI72]
M;];^8+2;3+22O0I>+;M_W5>M$D+=N9,Y`3,RB;7G!-1#<T::EU!<.'()F%K0
M04@@A@.A\OW/'R+\\U/JM+Y=>8_1+7]-/0B-6+>M"\*15:_3$<2O4S<];$:+
M+W%3D!2241ERR`#DIN5^Q9U-MVK\5.V]CQ)>BUVLX=J%JM#<G:U$<I1='1YK
MPI[4\'M)=1KWY6-$:W`MG4C7+2'3"L3TBBLR=NZC:AVK;%8C4R-,19<5&6EJ
M[59*>F)%<:7B0T1`@H*X93Q/!:9R]JM1RYOV=%.?T.XZN#>"E^-'#.E$^GK+
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M`1`DIBMSTH)Z84"'0X(6LO#AB&&3TOT[[Z3NHM5KID[*L3G[Y:*M=%1G8-.I
MM)G-1:;;T2ISTQ$]3`E*9,7**/)U&8C1,$)@1(A4\.S#`?3:!'@34"#-2L:%
M,RTS"AQY>8@1$1H$>!&0(D&-!C0RJ'%A18:@I*DDA0+Q@P%&MP:1,4:K2]?1
M)1*#'ID_!K<.I>J^ERZ1%E8J*DB?]>1!^!*DU+$7C]'U;WX,!\X>5/2#ND[*
MU9^GG)E:/)11M:OK=K4K\.T&5I<J_P#ZUYB+)FOPC]:,S%K'TGB1D0/A.'JN
M((XMC`?3%@.CZA:FZ<Z2VU.7GJE?EG:<VE3DE4]<U\7)2+6H4J`DJ=&JE;G)
M*20KA!(!6\NR8#YJ5WOU^Y^MVIQ*14N\,Y:5SD)7!$52;X1<$B%>M5!(%5H$
MI4Z6IRT%[HQ<GTCZ)!8#W*Y?N=#E)YKI::FN6OF1T6UQ3(I*I^7TTU$MFZJC
M()`>HS]*I=1CU.1"1GZV"ASP_,,![,L`8`P!@#`&`,`8`P!@/P\]UYSQ\@'+
MIWF?>[:#\U,_1H6MG,!WM%ZT/0:FU31"[-2%U*I5O4VZ+0ID&'=U$L>Y:-9Z
M(MV5*6AE4_.24.$5>N)"$J6`/J)SR]^QJWR_\Q'-CI+RN<D:^:33[NZ]/+"U
M1YZ]3*EK11]+U610K^D9.ORU!TUH,U;5P3%W5NBVG%CS\Y&4H)2J2FH/J`)?
MUL4#R_SF=]Q(<OM@=V%JCH'RXW/S1VWWF==I%-TZMBB793[,U#D(=UVK9=P6
M=2Z92ZG3JA;T_=%6J-Z0:?-09ZI4V2I\:%$B19GU:%$`?6G0N\-?;MT`M.\]
M=M'+>TBY@:I;-5J5UZ*T'42GW];]KW)#G*H*-;,'4FGR$M3*RB:D(,H8\[!@
M>IA18RPD*2AY`_&KR,Z\\[FIM!^<]V_S`:4IH%H2]E<X53OE4YS&Q]4I?E[U
M>E])]3(5-T"T\M^:IL.7N&R)VES]4F%5VG&G24%5*@P?@JO70_5`>8.Y_P"]
M1Y@N630/N4.5+5SDOE;?Y9N<2VJIHAHMS&2>M]$KM[5>^K?KLZ57!6M)*=;)
M%LVE5*K7Y6#*0)JI_#(L@M<[Q!:#),!].>=SOIM6-"M?>;+27E;Y1J/S,6MW
M=6BUG:]<]-ZW#K3!TLF+/MJ]*7$NV1LS2NCP[*N\7?>DAIU*3-<F8DW%E)5$
M.6BRX2J,@<8'VKY?-;K*YEM"='.8;3B+.1;"UOTRLG52T#48,.7J<*W[ZMVG
MW)3)6J2T*+'A2U4DY:HI@S,-*UIAQT+2%$!Y`^05M=]5*T[E>[US6_6K1.1T
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M1_5K3&$)`'F#DG[W;F4YX.;K7_EZT[Y$%4S27E6YO=8^7C7;F6J&N%!1:EOV
MAI^FXZ5959MVSZC;E'NF[M1[XN6A/G:-(HCR=!IL2%'C3L54Q#2D#WV[ROGU
ML_NW^4^[^9:Y[.JNI=8E:_:.GVF>EM"J<K1:MJ7JGJ#68-"L^T):M3LO.2M&
MEH\=<6;G)M4"85+R$I'B0X,:(E$)8'J_R>]Y[JSJKK/SB\HW-?RW6]R_<VW*
M#IA:FM=1M:P]5TZKZ7ZE:87S;!N&C5FU;TB6K:]4D:A0IV/+4VJP(\@M")B8
M2N#$B`1(<,#Y>Z'_`#DCF+U#M/N_M?\`4;NYZ9IURD<\/,K+<IDAJO2N92E7
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MU9TUN?2W4&R)K4&VK]L&[(]MVE5)A$O098)GY*9D@N7B1H!3%4J+$A0`/RX\
MV?>EZX]Y[4^YHUANODNJG+YRZ7=WQ^CM2Y:-6EZKV]?2]1Z!ISJ&;"NJDWM:
M<K2Z16K*NJ!59R'$E8B$S-.GA+3\.%$_(:(TR!_0/8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`<$A(*E$``$DDN``Q)).``#`?R4N=
MN\:WWY_SA`Z;V=-S52TWO+7RW.76Q)R3,RJ!3M"=)ZG&IEVWE++@(6N7E*I2
MZ56J^(H0DI3-IXL4L!_4*YA>5/3K7GD^U0Y.9^ER4CIS?FB%7T7IDBJ%^1*#
M3%6L;?M>:@0X*$E!MR/+RLQ"X`"E4NDI<0&`_EY=P+S,W3W6G?0TO1K5V:F[
M:MF_;ZNWDUURI<W%^"2-.N*8NI5`M&O5"!%4823;FI=)DSZW%<.1FID(/XX7
M@?UL6`^:/?,_O3'>/_YE_,/^QG<+`?C`^9!?Y2G/9^L=I7_X]K;`?T;6`_$;
M\]V'_P"R7R3G;^V*O</Z]-([_"Y@/IS\U#_>2.6O_OWS$_L[7ZP'R"^?`@?8
MDY!R[$:C:S`':XVS9SP_I<P'P;Y0N1?O#/G'%:L.G4BZ;9TFY8^231W3KEVM
M:[+SB5R:L"S85NVW)I-"M6WZ3`7-W5J/=ZH'TUK$5/J$084:73'C(AB50H#]
M-'<I?-F-7N[0[P>:YF=;-6=--7K&L?2FX*?I%5+&3<5&JZM1+QC(H-45<MKU
MJ42F4DZ/:$2;,&+#G)I$68F4^BDPWL!\-_GH@'^LQT7+@\\H]F@EV)`U(U.<
M"=KGL!_16Y&P!R4<GP`<!RM<OP`&``&DUI.`#`?S>_G;EQKLSOJ+,O&#)P9^
M/:N@W+[<B)*,M4*%/+H-SW;5(<G'BH!6B%,*EN`D`E(42&`]G.4ON9^?/YQ9
M7IOO&>\#YC:QHWHKJ!.52!HQ;],HT2XK@FK-I]0CR<M3]*[-J,[3[7L/32FQ
MY1<I!G(QBS=2CPES"H,8E4:(!V#O)/F>$_R\<O%_Z]<FW,1=>LE6TKMBKWI=
M.D.IMJT>F7!<5LV])+J-<BV/<EL1424S79.G0(TPB1FY.$F.B"4(C^L4E)`\
ML_,[>\\UANC4W4/NXM8KTK=\6/#TZJFJ_+_,W-4)FJU2R)RU*E3)2\[!IM0G
MH\:;-L52DUE%1DY,DPY&+(Q_5<*(W"`/W@ZY?I*:P_K6Z@_^$JNP'\P'YH$`
M.^.B```)Y:M=0``X!U3L@!PV8,!_3<YF^8"Q^53EZUFYD-29DRUCZ*Z=73J)
M</`I*8\U*6W2X\]#IDGQ8+J%7FX<.5ET`%2X\9"0"2`P'\KG22V^\*^=']X=
M7*%>^K,[;]B45-2OVO&H1ZI.Z2\M>DL*IKD:/1K,LB5F($I4+CG%SZ)"4*C#
MFZG-+BQYJ83#3%4D#]-TA\R9Y(H5L?`:GS:<S<[=OP7@-Q2=+TSI]%^&<*09
MA-KQ;>J,R)?C!(A&I%3B!ZPN>0/RN=Z]W4W,_P!P)S(:/ZBZ5:^5ZL6E>DU5
M:WH7K]8HJ5@7K1J]:,S3X]6M:[J=)3DW*T^M0(,Y+3`1!FIJ1J,HM04GT(L(
M`?TR.Z%YS:US_=W3RQ\TEV09.!?-^65,4O4(4Z&B#(1[^L:N52R+NGY.`CT)
M:!5:U;\6:$(`)@^NX``$A@/I.P!@#`&`,`8`P!@#`?F,[@:5EHW-YW_L2/+0
M(L2%WJ.I1A1(L"&N)#(KM^*!AK6@J2Y0>''I8#X^<Z>L=A<B'-S\YGTDYD)J
MJVG=/>*\L&G%0Y-96+;-SU&7UVJEQ:7WG8(H%FSE(I<[*3-2HMYW_#DHZ8D2
M&F'$I\T\NA$$#V#U9TBOO0:QOF?NDFIM'J%NZ@67KQIW(W?;E5@K@56VJY/6
MUI55YVVZK+*`7*5.WXE1^!S$)7I0HT!2#BDL!^W-@/QI<IC_`*V?G@V!_35Y
MLG8%Y_02U\R#GE[`>I%A_P"3U\S=P/\`E#5C8</Z?6D,<,&`\1\^UC\FO+[W
ML/?0UGO)YWF!I=-UIT<TJUFY/M.]*]6M6=&Z+S@\&FT2UZ_HQ,5G3ZDU>DW)
M&J]V1(%OPDU:7F9.FF#/Q#"4CUB2!^WSN]K*I6G?(QRD6;0])KDT&I-%Y?=+
M$2&B=XW;.7W=NDT"=M&F5(:>7->%0I5"G;@KUH&<,C-S$62E5JCP%`PD.X0!
M^5/O3N5742Z^^\LCDSLFF2D?EU[XVI\HNN?-)+0UQ"L4[N]*U?%5U*I_TN@J
M$"6E;HL&E4=<6;BA*8]07#3Z:P7`></G(6E6G$ESN]SSS$<R]<U&T\Y)[0O/
M771W7;5W2ZX;TLBK:0U+4*WK8C:?5.)>FGT%5RVC)5NH4V*(D>5*51).G3$(
M^BH@@>M4KH[HGJ[\WS[Y^H<@?+QK7;.F-_:X7I7[$O?4;5:]M;;MYNK8T(OS
M2RXKDYE[;1=UK6_=5%HUX4&UZBKX!%^F$PJ;D)GUDQ$C!:4@==Y,.<;17G`[
MY/N!ZAH;6JA=%'TD[L&^=+K_`*U%M>Y:'3:+J[0>7:_Y6^M-X-3K](I<K<%7
ML2)*RWPZ+3US<C#5/P@B.HK(`'U1^;IO^R-WX68'^N(YFR'@C^N0Q#][F`O?
M.L]*+KU'[KVCW10:)=-?MO0?FKT,ULU6E+,$^;BD=*J)#O&S[JKT@JEI7498
MT")>\M-1)J$!\!@PUS2U(AP5K2!ZV=U33^[PNOF?[QC4#N][4U^U=LJR^3ZB
MV%='/=JQS!ZNZIV[J;6+\I,.\U:,4*U=6;5D*I+5FPH%L05S,\*I-1)40_@Y
MEX*(Z%+`^+VE()[CKYN!@<.^SMA^!P__`&B=>\<LF`^CW.IS#V)R*=_%WE=Y
M\P<*Y[>H?.!W246R>6J8I]GW1<R]5]2J9;-CV[(:;VG#MFBU:/&KE<N"RJC*
MI,0)EY>8AH^$18*(L(D#T.U1THJE[?-5NZ(U-F:;>-0TLY=.<>5U8U^F+#56
M)>ZK8T85KUS+6==%Z4N?H:5U2DS%!F[GE$0YV"/62<6:1&24A!4`/KEW9.G?
M)'J[>O>]37=NV'KOJA:T]RST/0N3YVM5.8+5+5JC<RU\WSI1<%51IY:E`U4M
MBEUJFS^DE1^#TV:G%5.=5ZN)``1`@1H)6!^??0OFVTJOGDP^;N<E]&^N&'KW
MRO=[=;,+F`M2H6==-*5I=/U'F3NRH6=2+EK53HTG1I:MWK3+JF(TM((F(DX/
MI+/)C0X9EE,!_3U8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`?'?OY>=B%R']V!S):L4VHFGZ@WE;,3132<PEI1.'4#527F[=DZA)CU
MD-?K;;HD2>JI4@A:$R)4,0&`_GO_`#:7F_Y!N0WFJU8YK.=S4NIVE<E"TUB6
M)HC3J=9%S7G,QZQ?4^?K\NJ-'H<E-IILQ3[>IB*?",0\4>'59C+AQ`_;K]U7
M]RY\H2]?B9U$^HS`?S[N_DU_Y/N8SO'KQYL.0[4"H5VSM7Z1:%^75'^MFX;(
MJMLZST:"FD7#/2LM6)62C\58%&DJH)F!G.QXRBY7I*`_J$]SASLR/>!=W+RT
M\QBIV'-7G4+*EK&U:ETKXXU/U9T\";5O=,P,3#%8GI!-5EP3Q&3J$%1<20`+
MO?,_O3'>/_YE_,/^QE<+`?C`^9!?Y2G/9^L=I7_X]K;`?T;6`_$;\]V_R2^2
M?_.*O?\`8TCL!].?FH?[R1RU_P#?OF)_9VOU@/D%\^!_2DY!_P!<;6;_`,,V
M>P'V"^:IZ84?3GN9M`ZC3Y:5AU+4Z\=6-2+BG("`(U1J-2O:HT*2B3BPA!7&
MDJ!;TG*A[W(@)#V`_1HP'\P;YZ+^^8:+?YI%G?LD:FL!_15Y'/\`(IY/O\UO
ME^_8FM)@/YJ_SQ$/[W6`-_+#HV/#4[W8#^EUR;V!0=*N4?EATUMB6@REOV-R
M_P"D%KTF!`@I@0Q)T>P:!)0XGJTDNB1S",19)*E+422226`\UWM)2M2LR[J=
M/043,E/VQ7Y*<EX@?#CRLU2IN!,05C:B+!B%)Z"P'\J3YK'"1)]^SIU*RP,"
M7A6AS.RJ(4-12@2\'3^Z!"@D`N5#1ZI+@7AZ0<P&`_J8:Y?I*:P?K6Z@?^$Z
MNP'\P+YH'^_'Q?\`-JUV_MI9#`?U'M0-/;%U7LRX-.M3+1MZ_;#NR052[FM"
MZZ5)URWJ[3U18<8R=4I50A1Y2<@>N@H6$K20%I!&(!8#X\W9K+W&7<I7->LS
M%K/*]R?:C:GTZF1[QM#3JD+CZBW7(49<]-43Z8V'8DE7J_)20F*A'5`B1I25
MEHD2(25ESP!Z$ZI?/#.Z9LB%4(=D0.8K5ZI2:HB9>%;6ETK;U*J"D)B%)@56
M\[DH<5"(BTI`4J6<Y3SD0P'Y'^_N[_RU>^!L?1_2K3OEQN#2"Q=']0*G?LI=
MMZW=3JY=E=J-6MJ:MU=&C4:ATP4>CR0@Q3'XDS\S$B*0E/"`GB('[6?FH_[R
M+RR?]]N8K]GW4-@/T:,`8`P!@#`&`,`8`P%"3I=,I\2<C4^G2$C&J,PJ;J$6
M3E)>6B3TTI_%,SD2##0J:F%<1>M94HOS8"G5+9MNN3E(J-;M^B5BH6]-F?H$
M]5*3(5"<H<\?5OG:1-3<O&CTV;/JDOB05(7Z(QP#`79NETR?C24S/4Z1G9BF
MQ_A-.CS<I+S,:0F2`#,246-#6N5CN2/304JPS8"\P&LA46C014A!I-,A"LJB
M+K`A2$K#%57&0J'%74@F$/ARHL-:DJ,7C*@2#@6`C%O4!**9"30Z0F'1%^MH
MT,4V2"*1$+GQ*8@0>&07AG"X"P$-6M>V:_-TB?KMNT*M3U`FC/4&=JU(I]1F
MZ)/*]653E(F9R7C1J;-$P4/B05(7Z(QP#`;U@/D)IGR<ZVW#WRO,9S^:VTFW
MY+2JQN5W3+E6Y+Y:5N65KE7FZ+7*K'U&UVOBL4"6A@6?5C>G]*Y0Q%KF)RFQ
MU/X4CA8#ZT5BBT>XJ9-T6X*33*[1Y^&F%/4FL2$K4Z9.PD1$14PYN0G84>5F
M8:8L-*@%H4`I(.8#`69&1D:7)RM.ILG*TZGR,"%*R4A(R\&4DY.5@($.#+2L
MK+HAP)>!!AI"4H0D)2`X!S`:BEVC:=#1(0Z);%NT=%*$Z*6BET6FT]%-%2C1
M9BHB03*2T$28GX\=:XWJ^'UJUJ*GDDL!LY*ETRFJFU4ZG2,@J?F8D[/*DI27
ME53LY%_CLW-F!#AF8F8GT41;UG:6`M1H,&8@Q9>8A0X\"/#7!CP(R$Q8,:#%
M241(46&L*1$AQ$*(4D@@@N+`:>A6S;=KTP42V;?H=NT8+C1!2*%29"D4P1)D
MOF(@D*?+R\J%QSBL\#U'-[`<IMJW$2LC((M^B(D:9-">ILFFE2"96GSH6N()
MR1EQ`$&4FA$B*4(D,)7Q*)>\L!)/T"@U6=I=2JE$I%2J-$5.+HM0GZ;)SD[2
M%U"7^"3ZJ7-3$&)'D%3TI^-1C"4@Q8?HJ>,&`EA4:CP*8JB0*538-&7+QY1=
M(A2,K#IBY6:$034LJ01"$HJ7F1%7ZQ!1PKXB\%Y8"*A6_0;7IL"C6U1*1;M'
MEC$5+4JA4V2I--ES&6J+%,"1D(,O*PC%B**E<*!Q*))Q8"I"L^TH$::F8-KV
M[!F)VLIN.=CPJ)3(<:;N%$,0D5V:BHE@N8K*80X1-+)CA.'$Y@.Q,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@/YM_SSWG=3J1S*:&<
MBUI59<>@<OUMQ=4=2Y.5CH7+1]3]2Y.!"MJGSB($58B3EM6)+B+#3$2E<+Z=
M1``Y3R!])N3?YGSR-WQRJ\OU\<RMX\QTAKQ>VE-GWGJC2K0OBUJ';M#NF[*3
M`N":MVG4NH6'59R6%N0:C#D8OK)B(8D>76MX"G`#V5^XTNZJ_P"O7-G\9UE?
M:S8#Y[=ZC\T[Y0^6_D,YA>8'E'N;F!KVM&B]I)U(D+>ON[;?N:A5VTK7GI6H
M7_(II=&LBC5&)585FHG9F3,.-C,0$I*2E1<!Z_?,NN>CZT=9=>>0"[ZQ&32=
M6J*=;M'Y29CDRD&][(DT4_4.C2*(D5T.<K]GKE9\(AI]-%&C*47@/`_9MWR<
M"-,]T]WC<"7A1(\>+R8\PZ(4&"A42+$4=,KB<E$-`*EJ.X![`?BM^9#U*2@\
MTG._2HL=*)^H:"Z<SDG`/OHTO3=09Z'.K1O]2JHP7C<I@/Z/;`?A4^>^Z@6_
M`T5Y%-*S.0#=53U1U4U`AR'K1\)3;]#M.B6Y&G/4@$^HB5&X4(XB[TDN#\7`
M?7+YJ'^\D<M?_?OF)_9VOU@/D%\^!_2DY!_UQM9O_#-GL!]T_FSW[RWR<?V$
MOO\`9'NI@/O&P'\P;YZ+^^8:+?YI%G?LD:FL!_15Y'/\BGD^_P`UOE^_8FM)
M@/YK'SP_]]WEO\V+1K^V=[L!_3RT$_2+T6_6FTY_\'T9@.^71^=FXO[!5?\`
MM?,,!_*>^:V?O\.GW_=?FB_\`76P']2S7+])36#]:W4#_P`)U=@/Y@7S0/\`
M?CXO^;5KM_;2R&`_>QWYW/G=/=R]VQKIS$:=&#"U9F!;^F.DD[-2T*<DZ-?V
MHE1%(D;DF96/#BR\S]:U(1.U*%"B)5"CS$I#AK'`M3`?SZ>XM[F&N]^/J[K]
MKQS0:X7_`$G2[3VXZ3$U+NVDSLK6M6]5M3;W$Y6?I9`N"Z)>KR5+@0*7)Q)B
M>GXTO.1$^M@PH4(<7'#`_<#H[\UY[F+2$R,Q$Y7YO5.I2B(7KJAJ]J3?MXPZ
MA&AH*?73=#37*;;*>,J>40I*'#)<])<P'Y_?GA6EG*QRP<L7(UR]<O\`I%I3
MHU-U75C4._A;FG-H4"U8\U;5L69)6U$GJBJDR,O.U.&*E<T&&(LS$B*!0`"7
M>B!]VOFH_P"\B\LG_?;F*_9]U#8#]&C`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`Z#JMJ99VB^F6H.KVH56@4*Q=,+,N6_;NJ\S$A0X5/MVU*1-
MUNK3'%&B0H:HB)*27P)*@5K(2,2&`_DB\@MI7AWTO?V6K>^H4NJIT_5CF,N#
MF.U,E)E7K9>E:3Z<5$W=*VLI41`$2G2-NT2F6_`2MW'#5#07J4X@?U]4(1"0
MB'#0F'#AH2B'#0D)0A"`$I0A*0`E*4AP`P`8#-@--<=OT:[;>KMJW%(0*K;]
MS4:J6_7:7,@JEJE1JS(QZ;4Y"82""J!.24RN&L/Q2HL!_&KU2H^HG<D=]!7$
MT!%0DIWE&YGI:YK61"XX2KKT;J51@5^B2H'K(*9B0O;2.X42T5"E<"A,K0O$
M*``_KN5F5TRYWN4JJR=(JL&M:1\U.@L[+4VM2:X4S#F[*U?L:)#E*C`5!B*@
MQ(J*974Q``HCC2Y[`?R8M/;KY[?FVG>6S]=JE@QI>Y;+FKDLV?I%V2-0E=->
M8W1*J55"3-T*OP(*D1J1<4"ERL])3\H8DS2YZ$@1895#BP%@?J8N#Y[SR](T
M[B35J\D&LTSJRJF`PJ%<&H-D2.G<&LF'BF)==-A5"Y9JF(C?1"C08JD[$G%@
M/S*]YC"[QSO%=&;B[YGG/ID+3G2*J7_96@G+E8$6EU2@TB;MJLHNBO\`P?2N
M@52*JH+L:A"GQXLU7II4:)6ZE,+*8BQ#/J@/WC_-0S__`*2.6SHOOF)!Z/T=
MK\./86`^0/SX%0^Q+R#I>.(ZBZSJ"7AY`MJS@2!F0"H/ZV`^Z?S9U25=RWR<
ME*DJ`HM^I)200%)U(NM*DEV2DJ#B-A8#[R,!_,$^>B*2>\RT80%)*T\H]F*4
MD$<20K4G4\))3F`HI+M[BP']%;D:(5R3\GJDD*2KE:Y?2E0(((.DUI$$$8$$
M,!_-7^>'J3_K>(">)+T\L.C)4'AZ0:G>[BH9@%S`?T\]`R#H5HL07@Z2Z<D$
M8@@V?1G$%@.^W1^=FXO[!5?^U\PP'\ISYK6M![]_3M06DB):_-#ZLA0(6_3Z
M[%C@(+E/0"<-F+`?U+M<B!HGK"27`:6:@DDX``6E5WDE@/Y@'S0):%=\:M25
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MYT@N[OH>=33V9TUT97<UB:5Z36!4)"M6^JW].[EBU.+;\]85DU&#&J4AIU`J
MBPF9KE37"CUFJ3XB(]:A22@#]FGS/S5^V[\[I*GZ;4ZL0YNY-#==]6+:N2CJ
MC(,U1Y>]*O"U'H482X`BPJ?5(-S1U0EEZ8D>%'`+T*``_5$P!@#`&`,`8`P!
M@#`?GVYX>]SYO]#.\33W?7*!R#VYS?WO*<J4CS75$SO,-3-'+@FK6A7=<5K7
M#0K?D+ALZJT6IU>272I54K"3.F9G(DV4(@GU?I`?0/NSN\4TI[SCEFDN8?3.
MW+ET^J=)N^XM,-6-)KU]2;PTGU6M`2,2X[+KD67AP(,\(4G5)2;E)I,*`J/)
MS<,Q8,O,"-+P0/H,P!@#`&`,!\CZ?W@^ITYWU]=[LN)9=AITDI7(C`YJX-^H
M1<'V1HEY1=3Z18QMZ+$-9-L_6R*?4%Q>$2`FO7)!]=PO2P'UP8`P!@/D3WKW
M>4Z@<ADORLZ6\O\`H/(\QW-7SJ:S*T9T&TWK]Z2^G]GIG:=+TN8N.YKKN:/+
MQ_4TRCQ*_3H)A<<H@B;5&B3,*'`4(@&H[K'O.=2.?NQ.;&T]4N7F3T*YON2O
M5VX]$-9=&Y"^Y:Z;/GKSI\K5S;L[;MY_`X*)>D5ZKT">D5E7PN%!,F9B',1X
M,5!`&/=.=Y;K1S^7'SI:=:_<M-M\LNJG)AK32-$KSM.V=686KTC/7-'DJ_%K
M@%Q2=M6_2RBDSU",)"Y5<W!CI7Q!8`Q`^Q[`?&[O0^]!U*Y+=3^4[E8Y7^68
M\V/.'SG5N^I/2C3:HZA4O3"SZ);VFU,I]6NRZ;MNNJRDU!AP84I/J7!@%4I"
M,"3FXT29A^I1#C@>'.4COT+6U<Y%>=_FKYD]"*_RZZG=W7=VHVG7,QH=*W/(
MWE%3?5BR233:/95S?`J5*S4:\+C4JB0(<S#2B6J<)8,:++&',Q`.C]W9WT?,
M;S"\TVD/*]SM<F-)Y4*US><MG[;+DUN6U=49?4BF:@:9"5F*Y%MB\H"9&4F*
M!>\*SI:+5"A8EHT.%+J1,2,L8TN5@>Q%]]YMK[IEWQ&AO=K7ORL6K2M&^9&U
M[^N_1WF2EM9H%3N.XZ+IKH_/WS=D>?THDK5BQ+>BR-]4N/0T0YRIPEQY=`G(
M?$E0AL!])N:GF,L'E%Y<-;.9K5";$K8NB&G%SZA5U"8J(,S5!0:=%F*;;M,5
M$!0NM715S+TV0AN/K9R:A(&*F`].>YV[P2YN\[Y%;`YO+NTWH6E%:O2[=2;<
MBV7;E>J%R4N1@6->-3MB6F8=5J<C3IN-%GX5/$5:3"`0I3@2&`^HC`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`T5S6O;-ZV_5[3O*W:%=M
MJW!(QJ97K9N:D4^O6_6Z;,IX9BGU>C567FZ=4I&83@N%&AKAK&8+`>*M..6+
MEKT=KL:Z=(N7K0W2RYIBGQZ3,7%IQI-85CUV/2IF+`CS-,C5>V:!2ZA%I\Q'
ME82UP51##6N&DD$I#@/.3`&`,!X#U`Y4^5W5BY(]Y:I\MN@>I=WS4M*24S=6
MH&CVGEY7),R<A#]3(RD>N7%;M2J<:6DX/H0H:HI3#3@D`,!Y@MFV+:LJWZ/:
M5FV]0[2M6W:?+4FW[9MFDR%!M^A4J3AB#)TRCT:E2\K3J93Y6$D)AP8$-$-"
M0Y(`8#QMK=R[:#<REI1;$Y@-'M.-9+1B>L4BA:BVC1;JDY2+%2$1)FF_3:3F
M8U*G%('#ZZ67"B\.'$Y@/2#3CN4>Z>TENR4OBPN0CETI%SR$=,U(U&=LF'<D
M.3F$11&1%E:=<\S6:7`5#BI!3PP!PD!SG!@/?Z_-'M)-4[7D[(U.TMTYU&LN
MG1Y*:I]H7Y9%LW?:\C-4Z"N6I\S)T"X*94*5*QY"7B*AP5HA)5"0HI20"0P&
MUL+3O3[2NV9*RM,+%L[3BS:;%G(].M*PK8HEGVS(1ZA-19ZH1I*@V](TZE2L
M6>G8ZXT92(23%BK4M3U$E@.O:G:&Z)ZV2])E-9M'M+=7)2@QIF9H<KJ=I]:5
M^R]&F)R'#A3D>DP;JI%5ATZ--0H*$Q%P0A2TI`42`&`[195BV1IM;5-LS3JS
MK5L&SZ.B*BD6I95O4BU;:I2(\:),QT4VA4*3D*7(HC3$5418A0DA2U%1Q)+`
M=J8#PAJ3RS<M^LM:EKEU?Y?=$-5;CDJ?#I,G7]2=*+#OFM2E*@QH\S"IDM5;
MGH-4GH%/A3$S$B)@HB"&E<12@'J)('F&ETNF42F4ZBT6G2-(H](D92ETFDTN
M4EZ?3*73*?+PY20IU.D)2'"E9*1DI6$B%!@PD)APX:0E(``#`>%]1.5SEEU>
MN$7;JSRZZ$ZH76)*6I@N;432/3^];A%-DU152E/%:N6WZG4A)2JHRS#A>L]6
M@K5P@/+`>;I24E9"5EI&1EI>2DI*7@RDG)RD&'+RLI*R\-,&7EI:7@I1"@2\
M"$@)0A("4I````8"9:$14+A14(B0XB%(B0UI"T+0L%*T+0H%*D*27$'`A@/`
M]C<JW*_I?=4&^M-.6_073R]I=$]"@7C8VC^GMI75`AU2%$@5*'!N&@6[3ZM#
M148$52(X3&`C(40MX)8#SG-2LM/2TQ)3LO`G).<@1I6;E)J##F)::EIB&J%'
MEYB!%2N%'@1X2RE:%`I4DD$$%@/"&GO*WRRZ1W&;PTHY=-"=,;M,E-4TW3I[
MI%I_9=QFG3RH2IV0-;MNWZ;4_@4XJ`@Q87K>"(4)X@7!@/.S`>G',IW>O(_S
MA1X4[S-\K6BVLM6@0D0(5PWA9-*F+I3+PH8AP);ZZY.%)W(J6ED#\:AF:*(1
MQ0`<6`\8:(=T;W9G+A<,*[-&.2+E[LVYY:,B8D[@^L.GW#5Z?,PU)7"F:;4+
MJ-<F:;-05(!1$@*AK0?>D/+`>]MY6-96HML5.R=0;/M:^K,K<&#+UFT;RM^D
MW/;%7EY:8@S<O`J=`K<I/4J?@R\W+0XJ$Q82THB0TJ`!2"`.J:8:%Z(Z)0:Q
M+:,:.:5Z12]PQ9./7X&F&GMI6#!KD>GHCPY"-6(5J4BDHJ<61AS45,%48+,(
M1%!+@HO`\J,`8`P!@#`&`,`8`P'YAI__`/>W:+__`&?(O[.=68#T9[N/F1JW
M)7I'\Z;UYL22DIV!R^\Z_,I?^F-*G89B6^=04QM2Y*BP9N4A'U:Z8*]*4A,W
M#0OB7+(X!P^B6`\/=TUWH&H5<Y\^[-L"V.\"YD^=E/.UH=J2KG^TRUMH]PQK
M&Y>^8R2T\G]3[25HG&J^FEE46T:#)U62F*&92WYN>I$:4D8D52BJ/+F&!])^
M1Z[^;;O*^]4Y_P#5^N<Z6N^BO+=W=?-O0>7G23E@TBGZ11M*]6933^L7))Z@
M_9JIL](3<2ZY2[Q;:8BXBOR=!-54F!,0(4I`A$#X.:\=^'JY.W3S:\VUK<_/
M,%:?-'HEW@ZM..6ON][5H5R5'E?O?DNL"XZ-;=?^R!0Y+3:?LNMWO>$A'GYJ
M>J<[7X-7EXDBKX'#A&/+&$!]]>?BZ^9O7OOP>3;DJTOYT.9#E1T'UQ[OS474
MS4"2T%K]O4:XIRL4NX-4HDG5*-&NJW+II%O7;$33:=`55D2:Y^6E)54.6B0(
MBQ&2!\$);FE[R^A]T_![PJH]YOS4UO4SE2[QE'*99MAQ*C:LKIOJ/II2[LHQ
MJ-4UUEH=!7=6KMX5:I7`8:9BMU2=E)>D2T.33+J6I<RP'TQYX]%-:>8?YQSJ
MOIWH=S*ZD\J%T37<VJN.I:JZ0?2R5U!--M_5.-4*1:U'KM2A1IBW*;6+]^DL
M:J3,B8-0C4R4CRL&/+_"51D`>/3WT7-G1OFR&B_-+6M5IRE<TNI6O4#DTJ',
M3,4J5JMST*G0]0+T14M5$4Z')QX%3ON2T?LZ+*_"Q`B1UU0F>"53+B0/:;N?
MN?BIZA<X/>#\J6C'.1S#<[_*)8O+%;&OG+[KWS*P+JF]7[6ON6IM&MO52THU
MZ7C8.G=QUNE1;KN-$U(P9BGI@2*)-*)5X,>)%`\O_-H?VW_,MRE:5<^G-3ST
MZ]Z[1KHH>MVDUHZ'7+/4K['E*IM*UIF8434*]YU4E&N;4#5:7J-J34G3*C,S
M<.7I=OS:9&%`)"XB@/T"<S-.U97HW?5Q\NMCZ3WSS*6K;%9J.@]/UFA3$.QX
M=_1(,),A#K57IJY:N4:FS?J@(\22F)>*KA2#$2,0!^=#YL3'KM8JO>S77K\N
MK4WGVKW/C<B.<ZS$4NCR%@6?==/F+N-LT_3.9I%9KJ:I;*JI.W!"$:+'XDB7
M0B'ZV"F'-3('E+N*_P#+P^<)?_W(9KRZB,!^EM@/GOSTTSD\Y?J%4.]!YA].
MK?K&H?(KI-J=<.F^HTY-U&7N6W)*Y:!/T2H69:L-%0@T:-6=2)RKHHDH)F6C
M+5-5%"$%)6]@/R(S&@NJ-@?-5.\;YKM8I2-(:W=Y!JO2>="]I0P8D"+3[2U0
MYDM($6;+I@Q1Q0Z?7*#!C5Z7Q)3*5U""XI(`'N#J9,S=/[X'YK:*:50?6<C]
MY2$5$$%*?I?,<LU0@34(I0X"#\&)>,@`P'NQSR__`+RMW*O^;USJ_L7WXP'3
M>_\`.:;EVJG,%R+]W-S+ZOVEHORZ:@W#.<WW-S<5\5&-2:'=VD>ALW4(FD6B
M*"B3G16T:PZTTD">ET)3%EI6AB."?>J`W?S2342R;M[H>S+2MVY:/5KITZUH
MUOD;]H%.6?AEI3]TZ@UJ[+?DZI+^JAHEE5:VZG+SL`(*DF!&3B"](`_3HP!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@/S'<[G*CWH
MUF=\Q`[QGD6Y>-$]<J#%Y#Y'E;DDZOZU4W3>DV_>51U$N.ZY^Y*G1()^N2NT
MR@0#)%4M`5+_``Q$>(E$>&M#`>0^3ON3+VTP[J/G2Y/N8'52V[HYH^\+G==-
M3]?M5+:EY^<LZW]8M7J'"DJ`FB&;D:74JY;UF56G2L],1%2DHJ;G(\YZJ&B&
MJ$P'2^[(Y>.^DLS4#D7TDYH*)IYRR\H_=_:"W;I#=<KI9K30-2U<]-<E[1D-
M/-(JU7+9D:']-+'M_3^ETZ#50)V/)S<6>AK)A<,T8,H!?Y6^4'O(^0#O1N<Z
MM:+Z(Z/ZV\AW>#<REJ<P=X:J5O5^G6->_+S,5BHUJHZK0X.GDQ`CUJ]JLM=R
MSD*0E96$N5CHE9&,N;@J5,RZ0/4NR^[E[YOE-N3FQY+^2Y&FMA<K_-7SWQ.:
MJW.?FEZP42B:H<O^F%ZUVTZGJ+II!T<J5%J5=N:Z_K?M:%2X$:!",A'/KBJ*
ME$V%R0'U<U<Y)]?[M[]?E)Y[*'0J'-<N6D7)3J7HC>MRS5TTN7N65OZYK@U%
MJ%*DI6U(A%6J4G&EK@DRN:AI]4DQ%@D%#B!\6:KW*G/]-=RGK9R40;!L)7,!
M>W>:U/F=MZ@*U1MA-!F-)9JX[6JL&JS%T&)]*Y2J&#2XSY)1^$`)!X7D)8#W
M#YX^2SO2*!WN-\=XGR0Z.:-:M6U$[NU?+')VSJ5JY2K`G[HN^MW34HTU(T9$
M<*^`3UK34](5Q$2HJE:;4):FQY+X5`CS$**@#Q".X8YD(?S>_1SD'I]P6%*<
MZ.CNKTES<4.5FZR8NGL?5^5U#NRZ$:=3ETP("H1$*PKNBTGZ8)29%57A)5ZP
M29,<`?3_`)*[.[UO574SFQUUY\J):O+U9.H&CUM:3\O_`"4V/JU;^K]L6E<U
M/HDX+ZU<K-ZT.DRM.E9^\JQZE$E+HFHRX$K'CHF$`P846.!V'N%N3?73D'[L
MC1'EAYCZ)1+=U;L>Y=8JE<%*MZXZ9=E+@2EY:LWA=U#7`K='BQI"97'HU9@+
M6E"B8:R4J]($,!UOO7-&^\WF]7^2GFK[MFMPK\JW+E=>H\IK;RBW7K+4M)]-
M.8:RM0J#2J93)JX/7U:DV96*I8\22G529JBU1).8GH,U+IB*EUPH@'6^Y,Y$
M^:/E>_;R<RO.G)V!:W,GS_<S54UXN_3#3.N_73:VEUOP%UV/;EJBXX:X\G4Z
ME+S]VU+B^#1YR"B33+<4Q$C*C!`':>ZTY*=?^5CFI[W;576.@4"CV;S>\YDQ
MK/HA.4>Z:77YRM6&M=Y\$]6J?(*5,6Y/%%8EB9:9"8H*U!WHO('F[DCYH]=.
M:+FH[QA<Z+2A\H'+OKI;G+%R_34G0IB!>5S:JZ9693U\SU6JEQ&H?`ZI;-"U
M$J\.DR"8<JITS*S2#&XH"X;`?/3YQ-RA]XMS[:<\O_+5R@Z167J%H+*:C4S5
MWF9E[OUBM_3%&HXLFIRJK(T@(FIV5KJ;<F5KG*E49J#[V;13EP2(LLI@/8ZJ
M<M7.7WAG=8<TG)]SO:*:%\G>INHUMUC2W1RW-&+VC:D:;V_:]LV]9==TCNBK
MQI&),Q*=*4G4:D*EIJFRI*D4N00J$`J($@#T![OKNZN\OOKGLY*^9SO&--M%
M=&;0[LOE"FN6/1"0TRU&D]1JQKQ>D[:M1TWC:L5:%3YF=1:M,F;,J,68CR\T
MJ4F$5"%`]5*\$6-Z@#Z&<T7)1S`:H]]/W:7.K9U`H$YH#RSZ1<RMGZM5Z<NF
MET^O4FM:F6+=M#M2#2;7CJ^FE<A3-2JLNF+$@`H@H6I2R`G$#Z5:U\K_`"]:
M[HF*QJOR_:(:MW=(VS/4"W:[J?I785]5>ERBQ.S4I3*?5[LH-6G*?34U.=7&
M$*&M,),6(M?#Q*)('S/^;_\`(?JUW=_=U69H'K_8MDV3K<G435*Z;Z^LRI6[
M<*:W+5Z\JG.6C.5>ZK>A"'7IR4MB)+R\(QHD2)+2\-$$<*4!"0/MDP!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`>--6]3Y'2"RIV]ZC9^I=]2L
MC-T^35;NDE@7#J9>LRJHS2)5$>2M.UY6=J\W*2BE\<Q%1#*8$(%:G`,!ZE_Z
MPNT/DM\__P"XIUR_P;8!_K"[0^2WS_\`[BG7+_!M@'^L+M#Y+?/_`/N*=<O\
M&V`?ZPNT/DM\_P#^XIUR_P`&V`?ZPNT/DM\__P"XIUR_P;8!_K"[0^2WS_\`
M[BG7+_!M@'^L+M#Y+?/_`/N*=<O\&V`?ZPNT/DM\_P#^XIUR_P`&V`?ZPNT/
MDM\__P"XIUR_P;8!_K"[0^2WS_\`[BG7+_!M@'^L+M#Y+?/_`/N*=<O\&V`?
MZPNT/DM\_P#^XIUR_P`&V`?ZPNT/DM\__P"XIUR_P;8!_K"[0^2WS_\`[BG7
M+_!M@'^L+M#Y+?/_`/N*=<O\&V`?ZPNT/DM\_P#^XIUR_P`&V`?ZPNT/DM\_
M_P"XIUR_P;8!_K"[0^2WS_\`[BG7+_!M@.CZ><W^AVDMNQ;2TQY*.=NPK8C7
M#=EVQJ%:O(EK-1:9&N>^[FJUZ7G7XTI)6M"A1:O<]V5V<J$['4#$F)N9B1%D
MJ46`[Q_K"[0^2WS_`/[BG7+_``;8!_K"[0^2WS__`+BG7+_!M@'^L+M#Y+?/
M_P#N*=<O\&V`?ZPNT/DM\_\`^XIUR_P;8!_K"[0^2WS_`/[BG7+_``;8!_K"
M[0^2WS__`+BG7+_!M@'^L+M#Y+?/_P#N*=<O\&V`?ZPNT/DM\_\`^XIUR_P;
M8!_K"[0^2WS_`/[BG7+_``;8#>VOSVVK=5RV_;$#ENYXJ+'N*M4NAP:Q='*#
MK+;UM4J+59V!(PZC<%?J5OPJ?1*+)*CB)-3<=:8,O`2J(LA*26`]XF`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`?R!/NH7OP?EH'XB.7'[4K`/
MNH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7
MOP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?
MEH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'
MXB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.
M7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[
M4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`
M/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH
M7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP
M?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH
M'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB
M.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'
M[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K
M`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/N
MH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7O
MP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?E
MH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'X
MB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7
M'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4
MK`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/
MNH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7
MOP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?
MEH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'
MXB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.
M7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[
M4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`
M/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`/NH7OP?EH'XB.7'[4K`?`)
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
)`8`P!@#`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g891272ex99_2cov.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272ex99_2cov.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`-2`I$#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHKG-0^)'A+2;V:SU7Q3X<LKNW;;-;W&J0QR1GT9
M2P(/UH`Z.BN>'Q#\+'0M2UI/$FA2:1H\32ZA?QZC$\-HBKN+2.&PH`!/)IO@
M+XC>%OBEH"ZY\./$&D^)-(:5H1>Z9=+/&)%^\A*GAAD<'GD>M`'1T444`%%%
M%`!1110`445QVF_&/P+K'C^]\#:5XN\/7?C'38S)=Z'#J$;7<*@*6W1@[A@,
MI(ZC/-`'8T45%<W,5G;2W%TZQPP(TDCMT50,DG\*`):*X+X0?'?P'\>]&OM5
M^$/B.U\2:?IMU]ENIH(I8Q%+M#;2)%4_=(.0,5WM`!17+-\5/!2:]_8;^,/"
MRZUOV?V:=8@%SN]/*W[L^V*ZF@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`K\7_`7P"\"?M%?\%'?CGX;^,4]U;Z-::CK%]"
MUOJ"V;>>M[&JC<0<C:[\?CVK]H*_&#P#^S5X2_:E_P""C_QR\*?$J;68-,L]
M1UC4(VTJY2"4RI>H@!9D<;<2-QCTH`^XH_V8?@I^S%^S)\8_^$8L=7\0^$M9
MT2:Y\16@UH32W*6\+D1Q2#`C;#D@^I![5Q'[,GQM^&7[/W[`VM?%+X3^"?$-
MGX:LM8EENM'OM62XN[FX:>&V+^<0%VX*<!1PO3/)Z[QC^ROX,_91_8F^.6@_
M#&;7)[/6?#FI7UR^K7:SOY@M"@"[40`84=L^_3'RAX$_Y0K>,/\`L,O_`.G.
MWH`]F\5?\%D?"&GZ?I]]X+^'/BKQ)8BTMI=<O!.+>#2YY5!-OYFQ@[J3MR=@
M)'!/6OI_1/VP/`>O?LRS?'&R.JOX3M;1IKFV6U#7D,JR")H"@."_F$+G=MY#
M9QS7@?P&\/:5%_P24NHXM-L4CO\`P#K5U=JMNH%Q-BX/FOQ\S_*OS'GY1Z"O
M%/V1_P!H&?\`9H_X)@>(?&VG:5;ZUJ%OXQN+.PM+O)@\Z;[.JM)CG8O+8&,D
M`9&<T`>J:S_P5=O_``Q:VVO^*_V?/B5HW@:ZG6./7KPF+<K?=(5HA&21G`\W
MGL:]Q^/?[<?A3X+?`;PA\6-,TJ_\6>'O&=U;0V"VLRVSJDT,DH=]X."!&5*]
M<_2OAS]I/5_C]X__`&(I?B/\8OB[X('A/QG;65Q;>#]/T>%'N@\\;QQ)/C=Y
MB8WLH+$"-@3P:R/VEO\`E$I\!/\`L-1_^@WU`'T#XO\`^"R'@O0?$:G0/AYX
MNUOP5]K^S?\`"3AUMDG8#YO)C9</CG`9T)`S@5]3?$G]K3X>?##X"6/Q=US4
M9[CPMK%K;S:0MM#FXU!YTW111H2,.0"3N("A6)(Q7SQ^V=X>TO3?^"6R6FGZ
M;8VUK8^']`EMH88%1(7,MMEU`'#'>^2.3N.>IKXT_:OAOW_X)X_LK7'[]M%B
M:^2\`)V^<2?*S[[%GQ^-`'V5\)O^"IUG\0?''A72?$_PC\:^%-`\;:E%IVB>
M(IF,]M/-*VR/.8D4@L0"49\9Z'%5/@O)\'+_`/X*6?$2R\->"?$5A\1M(MKR
M[NM:GU<26,LC"%9WCM\91G$_4DCEN!GCZ;\/_&KX2P?#[P%+%XG\*+I&N#3K
M/PU;_:(W,L[!%MXHHADAU.T8QE".<8KXG_9P_P"4P7QG_P"P1>_SL:`/9?B3
M_P`%'+C1/'OB/PM\'O@M\1?B7)X1OIK'5]0L+9X;:*:)BLBH5BD+88$<A<XR
M,CFNV_9S_;.\*_M=_#;QG-X;TW4?#^N^&[.2/5M&U!E=X!)')L='&`ZDHXZ*
M05(('&?G3X7?M)?'S]LSXD_$.T^"?C#P5\(_"'@>[(/VS2H[V\G1GD"R2"0$
M9/E,SL-JJ6`^;K7G_P#P2^DGF^,'[3<FH:O:>(+I[*9I]6M$"PZ@YN;G=<1@
M<!'.7`'&&%`'I/\`P1(_Y(C\0/\`L:D_])8Z^A/^"CWBSQ7X+_8^\=:E\.);
MRUU+R[>"YN[,D2VUI).B3NI'*_(Q!8=`Q/&,U\]_\$2/^2(_$#_L:D_])8Z^
M[?BEX_\`!?P]\+_:OBYJFDZ3X>U6X33))-5`^S2O."HBDR"H5@&!W?+C.3B@
M#\K_`-C7]DG]F#]IKX+Z=9:CXKU:V^+<T<AU2(:P+>ZMY][;3#;N"DL>W:<@
M,>N2IX'H'_!3_P".WB/X,?#?P?\`![P5_P`)SI]SI%GIEP_CBUO9+6.\2**:
M`V[O'@F1C&LC#=VZ'K7G?_!17]E#X+?![P78_%#X`^*++PYK=QJ<'V70M-U=
M9XKL,<F:TVL7C*8#Y5B@'3:<9ZG]M+QGXF^(7_!++X/^(?B,T\OB#5-7T^2\
MGF7#W($-VL4[_P"U)&$<GN7SWH`^D_V6OVXX?&/P(\0>(/B)X.\9>';#X6^&
M;&?4M6U&-IVUK$#!Y8<JI=B8MW).?,!)'6N#US_@J[J&@Z<GB34/V>_B5:>`
MWE55\07I,"E6.%;!B\O)R,#S<$G&:]5\1_M)Z5\$OV"](\<^'QI7BN[T+P7H
ML<>GI<K+&99XX8$\X*<A`Y.1P3L8<'I\@_&3Q3^T'\6_V(-9^*7Q1^+G@73O
M!?BJP5H_"-CHT(>Z4W`5(%F(W++N7=M#,0%Y/!P`>I?\%"OVV%U#]F709/@O
M;>+X[+XE:?#J-EXNTV5[-=+6*ZC#P2LG*R,5>,J&'/&2#7:_\$\OVQ+OXD?#
M6S\,^/?#OBK38_`WA+[?J/C77+AI+;45B<*[^:ZY)VL6R6;A&]*\#UG/_#D6
MQVY_X^8\X_[#9KUJPUR/7_\`@D+)IW@W5+2[UBW^';&XMK6Y5YDABE`N0R`E
M@`@=3QWQ0!IWG_!5-=9CUW7/A1\$_'_C7X?^&IF34O%,'[B*-5&6?9Y;8`7Y
MOF92`06"YKV]OVUO!FJ?LIZK\=O!EK?ZWH6DP;KC2R5M[J*82I$\$F<JK*7!
MSR"I!&017PE^P?X$^+OQ,_9H;3/A+\=_!_A7P\MQ?6NI^&+OP[;W5Q;&5FWF
M5V&XB1&#`],'`/RD#T'4OV;T_9F_X)J?'/P_!XXT;QTFH7HNS=:2`(;5Q):1
MM"<.WSC9D],9'%`'0>)_^"RGA&RTC3K_`,%_#CQ1XDB%G!/KLPN1;V^DRR_\
ML#+Y;!W'`SA5).`3SC3\:?\`!83P!8^'M,O_`(8^"_%7C6YDL%O-;@5?LD>A
M@G!CFEV."P(/*C9C'S<XIG[,WAW2D_X)(ZQLTVQ7^TO!_B&XO<0+_I,RM<A9
M'X^9@$0`GD;%]!63_P`$P=`TR3]@/Q[,^GV33:K>:S#?R&!=UU&MHBJDAQEE
M`9@`>!N/J:`/JKX,?M<^!/C)\`KKXM6EU+H?A[2(ISK<=_CS-,D@4-*C[<[O
ME*LI7[P9>,G%?.,__!5I[O2;_P`7>%O@7\1-8^&&FW;03^+581Q@*V"VS84'
M4<&08R`2#7Q[\#[;4[K_`()1?'9=#\XF/QG9R70CSDVZ_83)GVQR?85[!^RS
M\*OB_P#&K]D33M%\$?M`>"]'\"7NF7>F7_AN?PY;RRZ>DCR":&:0X<,V]GW$
M@X<$'H:`/M;XA_MK>#_"?[+,7QU\*V=YXI\-7'V<0VD,BV\^^6<0LC[LA'1R
M0PYY7C(P:^>/%_\`P61\'Z2+2Z\'?#GQ5XET1(K?^U=6$XMH+.XD0,UNK%&$
MCH25R2@8J<9&#7$?'?X&)^SU_P`$JO$OA2W\7Z7XWA_X2:WNH]3TO'V<;[Z$
M&)"&;.UD;//WB1CBO6-)\/:5:?\`!(*XAM=-L8H9_AC->RQI`H$ER8C(9F&.
M7W@-N/.0#0!C?MO_`+<5OJ?[(ND:Q\&M.\726OQ3TZ9K3Q)ISM:GP^UO<PB6
M.=TR4<DO%PP!P<$@U)_P3>_;+O\`QI\/-*\$_$#P_P"+E7PKX<O=3U#Q[K-P
M\UK=1Q7!8YE=<_*DF,ECQ$?3CR/X;Y;_`((H^,`-QQ/<^^!_:L5?37[`&J^$
MO$?[`WA'P_XEU?2'LI=!U:WUFV>_1&AMC<W`G\SG*`1R`DG&`P/<4`<GIW_!
M4BY\8-J^L_"SX#_$GQCX"T2Y:&[\1V*]`HR6$(C8?=(;:7!`()VU]Q:%J\7B
M#0].U2TCFB@U*TBN8HYTV2(LB!@&7LP!Y'8U^3GC7X=_&+_@FGX5E\>?L_?$
M[0O%_P`'M2U6.0:5>LDHE,V%1M@RKDA54R0.K$*"5`''Z??!CXC)\7OA+X0\
M;164FG+XIT:VU'[)(VXP&6,,4SW`).#W&#0!V=%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7C'P]_9(^
M'WPR^-WBGXK>%K?54\6^+Q<?VB\]^TD'[^599-D9X7+H#U..@Q7L]%`&!X_\
M$:7\2_!&N^%/%,<TNC^(]/FL+Y(93&[0RH5;:PY!P3S7E&F?L7_#72?V=[_X
M*VEMK'_"$:E,9YT;46-R9#,LV1+CCYT7C&,#&.:]VHH`\Z\-?`7PGX3^!X^$
MVDP7H\'C2+C2C%)=LTQMYP_F?O>NX^8W(Z9XZ5RO@S]C7X7>"O@7JOPBM=&N
M=2\$:U<27%Y::E=M-(\KE#O$@P593&A4K@@J#UKV^B@#XWT3_@D]\`](@U""
M[LO%.L07=O)#;1:CK3.FG;^KVZJJ@/Z,V[\Z]*\7_L0_#'QQ\"O#'PDUVVUI
MO"/A&X6XTQ8M29)U<"09:3'S?ZY^".XZ8KWZB@#SKXC_``$\)_%/X-R?##Q5
M!?-X5DL[6T\NWNVCF6.W*&+$G7(,:YSG/?K64_[+7PYN_@-9_!W6-$.J^!["
MU$%O:WMPSS1X8NLBRC#+(&8D,I&,XZ<5ZU10!\E?";_@E_\``WX0>/;#Q=HF
MG:_JNJ:3<K=::FKZIYT-I,IRCJBJFXJ<$;RV"`>O->J>$OV5/`7@KX]>(OC!
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M<VIB_P!4T)7&PIC`QQCC!!(KOJ*`/F[X._\`!/[X0?!?P7XS\*Z+IFJ:WI'C
MZ"*WUR/6[WSS/%%O,:KL5`FUG9@0`P.#G@5Q&B?\$GO@'H\EZ+FQ\4ZM:74$
MT5O9:AK;/#8M(I4RPJJJ1(`<AF+8(!ZBOLBB@#R70/V7/A]H'P`;X,C3+C4/
M`CVTUN]I?7322LLDK3%O,&"&$C;E(QM(&.E<=^SG^P9\+?V8->US5_AW!K=W
M>>(+!M/NO[8O5ND%LSJ[1*@11M)5<[LGC&>M?1=%`'QEXI_X)+?`'Q)K]QJE
MC8^*/#BW4A>2QT;5_*MN3DJJNCE5_P!E2`.P'%>NZ%^QM\,O#7P`UCX-Z)IN
MHVW@O7G:2_C&H2-<32LR,9/-.2#F*/H,87&*]PHH`\S\'?L\^#_`WP,;X2:%
M!?CP<^FW6G/%->,\[0W)D,O[WJ"3*^".F1CI4'P8_9L\%?`;X6WGP_\``,&H
MIX=U"6XEN$N[QII7:=`DGS\8^50!C&,>M>IT4`>._`_]D[X=_L__``^UWP5X
M'TVYN?#OB6YDGU2TU>X^V"X,D2Q.C!AC840#&/6O#-9_X)%?`'5-9GOK*W\8
M:/;W#EGT[3];Q;X)SM`=&<+SC&ZOM6B@#P^__8V^&5]^SRGP533=0M?`L<JS
M+!!J$GG^8)_/W^:V229,DYXYQBNLB^`WA.'X%GX1I!>_\(:=".B>2;IO.^RE
M"A'F==V#UKT2B@#R;X?_`++WP_\`AU\$+KX2Z3ID]]X)OH[F.ZL]1N6G>99V
M+29?@CD\$8(P".>:\Y^"7_!.?X._`?7]>U;PE9Z]?R^(M'N='N[?5M2\^$6=
MQM\V)555.&"@98DX[\U]/T4`?&=C_P`$F/@)9ZU;W<]MXOOM-M9_.BT.ZUYW
MLE.<XVA1)CU^?G)S7V'IFFVFBZ=:Z?I%M!9V-C"D%M;01A(X8T`5451P%```
M`Z`59HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@#SEOB7?K_RZV?_`(]_C43?%#4!_P`N
MEE_X]_C6%(VE=QJ7YQU`[:1Z:G^<=?//$U_YS[F.7X/_`)]?U]YOM\5=17_E
MSLO_`![_`!IA^+&I`<6=C_X__C7..VCYY&J_G'41?1O35OSCK)XO$?\`/PWC
MEN"_Y\_U]YTI^+FIC_ERL?\`Q_\`QII^+^IY_P"/.P_\?_QKEW?1?35_SBJ(
MOHF>FK_G%4_6\1_S\-5E>!_Y\_G_`)G6?\+?U/\`Y\K#_P`?_P`:#\7]3`_X
M\K#_`,?_`,:Y/?HGIJ_YQ4%]$XS_`&O^<53]<Q'_`#\'_9>!_P"?'Y_YG6?\
M+?U/_GRL/_'_`/&G#XNZF?\`ESL/_'_\:Y$2:(>VK_G%3P^B_P#47_.*G]<Q
M'_/P/[,P'_/C\_\`,ZT?%O4B?^/.Q_\`'_\`&G#XLZEG_CSL?_'O\:Y-9-%S
MTU?\XJ?YFC9Z:M^<=/ZYB/\`GX92RS!+_ES_`%]YU@^*NHG_`)<[+_Q[_&I!
M\4M1/_+I9?\`CW^-<FCZ/_U%?SCJ97TCL-4_..K6+K_SF3RW!_\`/G^OO.J7
MXFZ@?^76R_\`'O\`&GCXE7YZVMG_`./?XURZ/I/IJGYQU*CZ5W&I?G'5QQ5?
M^<REE^$_Y]?U]YTZ_$:^/_+K:?\`CW^-/'Q"O2/^/:T_\>_QKFU?2_\`J)?F
ME2J^F=AJ'YI5K$UOYS&6!PO_`#Z_K[SHE\?WI'_'O:_^/?XT]?'EX?\`EWMO
M_'O\:YY7TWTU#\TJ57T[M]O_`#2J^L5OYS*6"P__`#[-\>.;LG_CWMO_`![_
M`!IP\;W9_P"6%M_X]_C6"KZ=Z7WYI4@;3_\`I^_-*7UBM_.9O"8?_GV;?_";
M7>/]1;_K_C0/&MW_`,\+?]?\:Q=UA_T^_FE.#6'_`$^_FE#Q%;^<AX3#_P#/
MLVAXSNST@M_U_P`:0^-+H?\`+"W_`%_QK'W6'_3[^:T%K#_I]_-*REBJ_P#.
M3]5H?R&O_P`)K=_\\+?]?\:0^-KO/^HMO_'O\:Q]]AZ7OYI2;K#/_+]_XY6,
ML7B?^?A2PE#_`)]FP?'%V.EO;?\`CW^-(?'%X/\`EWMO_'O\:QRVGYZ7WYI3
M6.G_`/3]^:5SRQN*_P"?O]?<:+"8?_GV;)\=7G:WMO\`Q[_&F'QY>=K>U_\`
M'O\`&L@G3\=+[\TJ-FTX?\__`.:5S3S#&+:K_7W#6#PW_/LV?^$_O<_\>UK_
M`./?XTA\?WH_Y=K7_P`>_P`:Q-VG,>E_^:4C'3@3G^T/S2N6698Y?\OOZ^XT
M6"PW_/LVC\0KT?\`+M:?^/?XTP_$6^_Y]K3_`,>_QK%8Z9Z:A^:5&6TSTU'\
MTKEGFF8K:O\`E_D:1P6$ZTOZ^\WE^(E^?^76T_\`'O\`&D/Q&OQTMK/_`,>_
MQK"5M,YP-1_-*1FTOTU'_P`AUA+-LR_Z"/R_R-5@,)_SZ_K[S;/Q)OQ_RZV?
M_CW^-'_"RK__`)];/_Q[_&L$_P!EGMJ/YQTA.ECMJ/YQUD\XS/\`Z"?R_P`B
MUE^#_P"?/]?>;W_"RM0_Y];/_P`>_P`:/^%E:A_SZV?_`(]_C6!NTOTU+\XZ
M3.E_]1+\TJ?[8S3_`*"?R_R'_9^#_P"?/]?>=#_PLK4/^?6S_P#'O\:!\2;\
M_P#+K9_^/?XUSP;2_34OSCIP.E]O[2_..JCG&9_]!/Y?Y"_L_!_\^?Z^\Z#_
M`(61?_\`/K9_^/?XTG_"R;\'_CUL_P#Q[_&L'.E_]1'\XZ0G2L\C4OSCJUF^
M9_\`01^7^1+P&#7_`"Z_K[SH/^%D7_\`SZVG_CW^-._X6-?X_P"/6T_\>_QK
MGP=+]-2_..EW:7C_`)B/YI71#-<Q?_,1^7^1B\%A/^?7]?>=`/B+?$X-M:?^
M/?XTX?$2^/\`R[6G_CW^-<\&TSTU'\TIX.F>FH?FE=<,RQ_6O^7^1A/"8;I3
M-\?$*]SC[-:_^/?XTX?$"](_X]K7_P`>_P`:P`=-STU#\TIX.FXZ:A^:5TPQ
M^-;UJ_U]QS2PU#^0W/\`A/[W_GVM?_'O\:>/'MX?^7>U_P#'O\:P-VG>E_\`
MFE/5M.]+_P#-*[Z>,Q3WJ'-.A26T3<'CV\/_`"[VO_CW^-'_``GMYG_CWM?_
M`![_`!K#W:=Z7_YI1NT[_I__`#2NR&(KO>9QU*<$M$;G_">7G_/O:_\`CW^-
M'_">WG_/O:_^/?XUAAM._P"G_P#-*3=IP[7_`.:5W4ZM1[R.*>FQN_\`">WG
M_/O:_P#CW^--/C^\_P"?>U_\>_QK$WZ=_P!/_P":4POIOIJ'YI7=!MG)4J26
MS-P_$&]'_+M:_P#CW^--;XB7PZ6UK_X]_C6$S:;G_F(?FE,9],]-1_-*Z813
MZ'%4KU5M(W3\1[X?\NMI_P"/?XTP_$J_[6MG_P"/?XU@,^EXY&I?G'43/I7_
M`%$_SCKKA2@]XG%/%XA?;-]OB?J`Z6EG_P"/?XU&WQ3U$?\`+I9?^/?XUSS2
M:3Z:I^<=0.^C]_[5_..NF&'I/[)QSQV*7_+W^ON.C;XL:D!Q9V/_`(__`(U$
MWQ>U->EE8?\`C_\`C7-O)HV.1JWYQU7>31,=-7_.*MHX:C_(<D\QQB_Y??U]
MQT[?&/5!TLM/_P#'_P#&HV^,^JC_`)<=._\`'_\`&N5>30_36?SBJ%Y-!]-:
M_.*MXX2A_P`^SGEFF-7_`"^_K[CK#\;-6'_+AIW_`(__`(TQOCAJPZ6&G?F_
M^-<@TF@>FM_G%432>'^XUS\XJM8/#_\`/LYY9MC_`/G_`/E_D=B?CGJX_P"8
M?IO_`(__`(TP_'76!_S#],_\?_QKC&D\/$\C7?SAIC2>'O37?^^H:T^I8;_G
MW_7WF7]KYA_T$?E_D=H?COK'_0/TS\W_`,:4?'?6#_S#],_\?_QKB#)X=]->
M_P"^H:42>'?37OSA_P`*:P6&_P"??]?>3_;&8_\`01^7^1VW_"]]8_Z!^F?F
M_P#C3E^.FL'_`)A^F_F_^-</O\.^FO?G#3TD\/=AKOYPTG@L-_S[*6;YA_T$
M?E_D=P/CEJY_YA^F_F_^-2)\;=6;K8:=^;_XUPXD\/\`8:Y^<-31OH'8:W^<
M59O!X?\`Y]FL<VQ__/\`_+_([9?C1JIZV.G_`/C_`/C4R_&+5&_Y<M/_`/'_
M`/&N+1]"R,#6OSBJ='T/L-8_.*H>$P__`#[-XYGCO^?_`/7W'8?\+?U/_GRL
M/_'_`/&BN4W:+Z:O^<5%1]5H?R&O]I8W_G]_7W&R]II_.=3/_@(_^-5WL].S
MSJN/^W-_\:INW6JTAYK\PE-?RK\?\S^C849?SO\`#_(O/9:;WU8_^`3_`.-0
MO9Z;S_Q-R/\`MQ?_`!J@YP*K.U82J1_E7X_YG3"C/?G?_DO^1IFQTL]=8/\`
MX`O_`(TTV.E?]!@_^`+_`.-9):F%O6L_:+^5?C_F="P\OYW_`.2_Y&N;#2P>
M-9/_`(`O_C1]ATOOK.?^W%_\:Q&;YJ7?4^UC_*OQ_P`P5"5_C?\`Y+_\B;0L
M-+`_Y#!_\`7_`,:466E_]!D_^`+_`.-8F[@TY6I^TC_*OQ_S&Z$_YW_Y+_\`
M(FZMEI8_YC!_\`7_`,:D%EIF?^0N?_`)_P#&L%6YJ5&YP:KVD?Y5^/\`F8RH
M3_G?_DO^1NBRTT?\Q8_^`3_XU,MGIO\`T%3_`.`3_P"-80;%3*V15JHOY5^/
M^9C*A+^=_A_D;B6>G?\`05_\DW_QJ1;33Q_S%/\`R4?_`!K%1JD5N:TC47\J
M_'_,PE1E_._P_P`C<2UL/^@EG_MT;_&I5M['_H(_^2K?XUB(U3JU6JB_E7X_
MYF$J,OYG^'^1LK;6/_01/_@*W^-2);V7;4#_`.`S?XUD(^!4J$]:T4UV_/\`
MS.>5*7\S_#_(UA;V?:__`/)9J=Y%GG_C_/\`X#M_C66K4_=S5<Z[?G_F9.E+
M^9_A_D:@@L_^?\_^`S?XTHM[/_G^_P#)=JS`U/#4G)=E^/\`F9NG+^9_A_D:
M/D6G:^/_`(#M2>1:'K?G_P`!VJANQTYI-U8RFOY5^/\`F0J3_F?X?Y&@;>T'
M_+__`.2S4GD6G_/^?_`=JHL?2F[N:YY3C?X5^/\`F4J;_F?X?Y%XV]GWOS_X
M#-_C2&"S_P"?\_\`@,W^-42W--=JPG./\J_'_,T5*7\S_#_(O&WL\?\`(0_\
MEF_QIIMK,_\`,0_\EF_QJD6XII/%<DYQ_D7X_P"97LW_`#/\/\BY]FLA_P`Q
M#_R6;_&FFWLC_P`Q$_\`@*W^-46-,/6N2<X_R+\?\RXTY?S/\/\`(OM:V77^
MT3_X"M_C3#:V/_01_P#)5O\`&J1/04QC7'4J0_Y]K_R;_,T]G+^9_A_D7UM;
M'G_B8_\`DJW^-!M+'_H(G_P%;_&L]>]!.:YY5(?\^U_Y-_\`)%J$OYW^'^1>
M-I8C_F)'_P`!'_QIIM+`_P#,2/\`X"-_C5`G)I*Q=2'_`#[7_DW_`,D4HR_G
M?X?Y&A]CL/\`H)'_`,!&_P`:/L=A_P!!(_\`@(W^-9I.:2I]I3_Y]K_R;_Y(
MKDG_`#O\/\C3^QV'_02/_@*W^-+]DL/^@D?_``%;_&LP'%.!S51J4_\`GVO_
M`";_`.2#DG_._P`/\C1^R6!_YB1_\!6_QI?L=@3SJ)S_`->K?XUG4X&M%4A_
MS[7_`)-_\D0XR_G?X?Y%\V=B/^8B?_`5O\:4VECC_D)?^2K?XUGL>E':NFG4
MA_S[7_DW_P`D82A+^9_A_D:(M+'_`*"/_DJW^-/%K8_]!$_^`K?XUF*:D!Y%
M=M.</Y%^/^9S3C+^9_A_D:/V6QSQJ)_\!6_QIPMK+_H(?^2S?XUFEN>*=GI7
M73E'^1?C_F<LXO\`F?X?Y&C]FLB/^0A_Y+-_C1]GLQ_S$3_X#-_C5#/RFDSZ
MUZ5*4?Y5^/\`F<=1/O\`D:'V>S_Z")_\!F_QH%O9_P#00/\`X"M_C6<3Q2;J
M]"DUV_/_`#//JW[FE]FL_P#H(G_P&;_&D-O9?]!$_P#@,W^-9VZD+<UZ-*W8
M\^HS2^SV7_00_P#)5JC-O8G_`)B/_DJU4"U1ENM>A21YU:7D:#6]CWU$_P#@
M*W^-1O;6/_03/_@(W^-9[-43O7?3B>?5FK;?G_F:)MK#I_:A_P#`1_\`&HVM
M=/\`^@I_Y)O_`(UF,]1N]=L(>9YU2HOY5^/^9H/::=WU4_\`@&_^-0O::;WU
M<_\`@$_^-9KO4$CUUTX/O^7^1YU2M'^5?C_F:3V>F=]8(_[<7_QJN]EI?_09
M/_@`_P#C69(_%5W?K73&F_YG^'^1PU*\?Y%^/^9JO8:3_P!!K_R0D_QJ%[#2
M>VM_^4^3_&LEWYJ!W]*Z(TW_`#/\/\CEG7A_(O\`R;_,UGL-('_,</\`X+Y/
M\:A.GZ.?^8\?_!=)_C6/))S4#/ZUK&E+^9_A_D<<\1#_`)]K_P`F_P#DC:;3
M]&[Z^?\`P6R?XTPZ;HW_`$'S_P""V3_&L-GYJ-I#6OLI?S/\/\C%XF'_`#[7
M_DW_`,D;YTW1L<Z\?_!;)_C2C3=&[:^?_!;)_C7/[^*0/1[*7\S_``_R)^LP
M_P"?:_\`)O\`Y(Z%=-T;/.O_`/E-D_QIXTW1NVO'_P`%LG^-<ZK\U(&I.E+^
M9_A_D:1Q$/\`GVO_`";_`.2.B&G:.!_R'3_X+I/\:FCT_2.VN'_P7R?XUS:M
M5B-^!64J<OYG^'^1M"O#_GVO_)O_`)(Z2.PTG_H-D_\`</D_QJRECI6.-:S_
M`-N#_P"-<U$_-6XVK)TW_,_P_P`CJA7A_(O_`";_`#-_[#I7_08/_@"_^-%8
MNZBH]F_YG^'^1M[>'\B_\F_S-^0XJLYS4TIJL[<&OQV3/ZM@B&5\DU"QS3G)
MJ%FKGDSJBM1I/UJ,M2D]:B+<UG<Z8H4M\U(6[5&S8/-)OJ;ZE6U)]WZTX&H`
MU/5J+@T3!N:D5N:K!N34@;%5S&4HZ%P/ZU,C9JFKU,C5I%F+B7(V]:E0Y-54
M;UJ9&K:Z.:<2TK8Q4RO50/S4ROZ5I&QSRC<M(U3HWO52-^*F5LCBK31SSB3A
MSFI`V3S596YJ16JC"2+);`XI=Y`J`OQ2AN#4MF;5R8/D<T;B.E1*U*6J&9V)
M-YI`V#S48?K2[LM6$T6HC\YZTTMBDW=:86KEG<I(<6.,4!N#49;BD5B`<5S3
M0*X_-,8\T!_6FL>17+)&B',!^51$TYCC@5&QKCFC1"J>M#&D'>C/-<LT7$,<
M4I3UIA;<13]U8V-DD)L'<TFT>]&W/4T;/>BP678"H`R,TVE8;1US30<T"'@Y
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MU^+29_7=-$4E5V;G%32-55FRPKGDSJC'4';%09R>*?(_%19`Q6-SIBA3UH#8
M-1EJ:S>]3<M1)B<4H>H`WO3E:BXG$F#\U(KYJN&YIZM57(E$N*]3*_%4PW2I
MT;(K2+,G'0MQMZU.C\U3C:IU:MKG+.):!R14P.`.:JHW2I=W`K6+.:4=2TCU
M,C^E5$?BID:JN8RB6%;FI-^.:K!N:E#9ZULCFE$G5_6@/S4(:G9]ZB1FXDP8
M"E+5`7H\SCBI,VB8-[TJN`<U"'X-)OR:QEN/E)S)D]*:S>M0E\4,^>M830TB
M3=FF[LYIA.!2`GG%<\XC2'!L-FAGYIA/-(3S7-*):1*TF33"<C/K2,U)G(KE
ME$T2'+WH:D4T$UR3@58*<>::3R.*7=BL^0=Q",449S12Y!W$-)MIU`/%'(1)
MNXT&G`TRGKT]S5PAJ2Y"D\BD)ZT-V!I#TKKIP.>;U'`T@XI`<T$\5VTXG/-C
MB^>U"/UXJ(G%*K=:[J4=3EJ/0DWY-!;%1YP::7KT*<3@FR4M2$U$7I-_I7H4
MHGGUGH2;LTTMZ5'YE-+UZ=&.AY55ZCVDJ-F_"FLU,9J[Z*/.K,5I,<5$TE-=
MN341>O1IQ/)KO<5WZXJ!WI9'J!VYKMIH\NJP=^*K2/3W?BJTCUVP1YM26HCO
M5>1^M*[U!(_6NF*//JR&.]0/)0[U"[^E=,4<$Y",]1,_XTC/4+OUK:*U.6<A
MS-S3&:F%Z8SUKRF/,2;\T`_A4)?O2JV118ER)U.#4BMR*KAJ>K\U#1I&1=5J
MG1N*IJU3HU921T0D7H6JW$U4(6JW$U8R6AV4V7,FBHMU%9'1S'22G@U3DZFK
M,IX.*J2'@U^(3/[$IH@D;.:KMP<]A4K'DU"YX-<\CJBM2-SGI4);FGLW-1$@
M'BLKG5".@$XIK'BFELFFNU1<NR)<C`Q2AJAS3E;WI-C<24$YS4J@U`&YJ97[
M&M3.428$BID>JS'%2(U5$PEH6XWJ>-N>:IHU3HW-;(YI*Y:#XQ4P?=5,-S4\
M;8K9;'--%E7Q4R255W5(C9JT82+2R#/6I`XJFK5,&&WFM4SGFB<2#-+OZ8J!
M6R:7."*3U,FB?)I<FHO,I=]*QDU8E5O6@9SFH=XS3P]9RBMQZV%))-*V149?
MF@O[USS!7),\4!N#49?BD#\5SS*2'[L&D+#-,W9.*0FN:5Q]20L,TN\;:C;K
M2@\5S,I-CPX`I2V>E1CO2KRU<\XE)MCJ=N'?--IN#6?*4D/WBC>*929J-2')
MDF\4;Q4=%-)L3=QP.:7=@CVIH.#2'DYK6$=2;#W<9%(6R*8W:@'M753B<\Q^
M\`T%QCO41-*3Q79!'/,=NR*%-1[N*17SFNZDCFJ$C'K3"3FD+TUGKT*://F*
M<TF332]-+\5Z-&.IY];84MBF[^>::6S3"U>E21Y5;<>\E,,GK3&:HW;BN^E$
M\RM+0<\@R:A:04UVJ(MS7H4T>36>XYY/2H':D9N:B=Z[:<3RZK$DD%5Y),]*
M)'J!WXKNA&R/*JR$=\U!(W6E=_6H'?FNB"//JR&.35=V([U([56D?K]:Z8(X
MIL1F]ZA9^M#-4+/R:V6AR3D.9Z87IK-S3&;TJUJ8\Q)GBE5L"H@W`I=U.Q-R
M=6]*>C5`K4]6YJ9(N,BXK58C:J:-TJQ$W-8R1U4V7HFQUJY$:SXSTJ[$>*PD
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M^N*`_/-2T%M"9FY%!>H2]"O7/.(D3$G&10#QWIH?BDW?6L)Q+0\'GG/UIQYJ
M,M\M*&XKFE`.H_-+NP.>*C5Z&.36')J,D5A@\BG!AG.:A7O2@_-BL)P+1-N^
ME&:92DXK/D&!/-)1S14.F9L,TX&FT54:>@AV1ZTW=R>12`8IA.&-:0AJ!(QZ
M'UI-X]13-U,SS75"&IA,D9AZTI/'UJ)J4O79"!S30.>N*:K>M!?BH]U=M*!Q
MU6/+TQFII<=Z86KT*<3SZC'EN*;NIC/Q2!^*]"E$\^JQ^ZFEJ87IA>O0IH\N
MMN/9JC9^#36DJ%GKT*<3RJS'.V>E0%_6E9N*B9O6N^G$\FNQ';%0NX]12R-U
MJL[<UW01Y%9@[=:@=N*5VXZU`[UVQ6AY=5C6:H7;GK2LU0.W-=$$>=5EJ-=O
M>J\C')I[M4+MQ73%'%.1&QR.:A8G/%/9ZC9JUL<<Y:C2W6HV8]@:<QYIA;BK
MBC%L?NX%"O\`Y-1DTH/%%A7U)E8]JD4G/>J\38/-3JV:31I&1:1JGC)!JHIJ
MU$W`K"2.JFRY&>15R%JHQ'I5N(UA+8[J;+>:*9169TG53FJ4IYJU,:IR'FOP
MF9_9])D$IXJK(:L2G-5I#P:Y9,[8(A8U7)YJ5C43&L;G3%C32$TCMS3":AFB
M>H\GY:16I"<"FJ:394D3J>:D4\\5`K5(C8/-:)W,V3EN*>C8%0\8XIZ'M6D4
M8R5RRAJ=&JHA_2IT;\ZW2.:2+&>:E!R*KAN*D1N:V2T.:991N*>&XJN#4@:M
M81.>:+`;(`IZ'BH%;B@-Z&MDSGF60V#2[_6H(VYYIY>K,VKHFWTTN:A/3-/#
M<"@PDB16/-`?FF!L@T*PSQ4LFP\O2J],W4I:LI*X)$V[BDW<U'NI-WK6$X@F
M3%N*56XJ,-4BD8KGE$8*WK3P?EYIBD4;OGKG:LQ[$JFE'6F$^E*&&:PF-2).
MIIU1;N>M.S4,:=Q^:*;QCFF[AZ?K4<IGS+L244S(Q[T5<8Z"YA0<4QN6-+NJ
M(\L:TBK#;)`>U,_B_&@-BFYYKH@<TI"N::S4C-4;-Q77`PFQQ:HRU(S4PMUK
MMI'!6'%J8S4W=S0S<UZ-)7."H(ST;OEXIK-3"W%>C")Y]1CB_-,+\TPO4;/[
MUW4HGEUY:CV>FLW%1L]0.V:]&G$\FO(F9JB9J9N.*B9J[:;U/(KL=(W!JL[4
MYV]Z@=J[8*YY-5W$=^*@=N*<[5`[5V0/*J[C&;FH7:G,W-0.W-=,$>;5&NU0
MNW)I9&J%S73!'%.0C/S41;K0S<5&S=JNQR3`MS32::3Z4TM6L59&3=AY:A6J
M/=2ANM#T)3NR=#S4Z'UJI&WS5.IYK.3-46D-6HSP*I(:MQG@5E,Z:;+D1-7(
M3TJE":NPGI6$COIO4L4445G8Z3J9SZ51D/)JY,:IR=#FOP6;/[3I%=ZJRG@^
MU6)3P:K2'`KFF=U-%=SBHB:>QJ,\#BL3IBB-SDTTFA^M-K-O4TBM1Y.`::#1
MVH`%)LTE$>#S4BMS4`-2`\BM(LQDB<MTQ4BG&,57W=*D5LCDUK%F<D6$-3H:
MJH:D5N:W3.::+@;'>G*U5T;(Y-2!B*WBSEFM2PC5(&JJK\U(6/4&MHLPDBT#
MQS2AJ@#DCK1O/K6T4<LT3AL'K2[\FH`Q[FG!^16MB+$^ZEW\5#NXI-]*QC)6
M)U?BG!^:KJ_!IRMS2:(MH3;\=32E\5"6Z9I2U9\HDB;=D4@8U$'XZTXM@UG.
M!),']ZD5^*KAJDSQ7/*&A21(KTN_YC42M4@P`#CFN>4`D2;O6E#<TU2,&E7&
M>E<\H:B'!N:F/'I4.12ER>YJ/9E+0DSGK24@/'-+D4<A#N%*#BDSZ49/I5QA
MH*Q'NI.II1[TTGG':J]F(4G%1ALFGD@]:B.,UO"!SSW!FYJ-V-#GFHV:NN$#
M"8K-49?KBER"O--..XKMI0.*J-W\T,]-)&:8S=:]"G&QY]05GIA?CBFLU,+5
MZ%-'G512]1L]`;)-,)%=]*)Y-=ZB-)S3&;-#D5&[8%>E2B>17'9^6HF:D+'!
MP:A9R#UKJIQU/)KL5VJ%VI'?GK4+N:[H*QY51BNU0.U.=J@=JZ8(\FJ]1K-4
M#-S3V;FH&/)KJ@CSJK&.W-0NU.=N:B<YS75!'GR8PG(J-FI6-1LW6J2U.:;$
M8_E368=J0MS3?6MDC%L?FE#=:CS2J:30HO4GB/S5,IYJO&?FJ93S6+1LF6D/
M2K41X%4D-6XCP*SDCIILNP'D5?B/%9\'`J[$:PDCNIEO=13:*S.HZF;I5.0\
M5:F[_2JDG0_6OP.9_:U,K2G@U5E/'X58E/%5I?NFN>1WT]BN]1%CBGOTJ-NE
M8/0Z8HC<\TPG-*_6FGI6?4TBM1YSCBE'/UJ/<<\TH.:33-&T*#3U/85"#@_C
M4@/2JBS-HFS3D/\`.HL\5*HXK9,Q:)T-.0\U"AJ0<5LCGFBTAXI^ZJ\;<=NM
M/#G.*Z(G-):DP/-2;ZK[L&G;OI6\$S"2L65/(STIQ;FH`YP*<K9'-;P:.6:L
M2%\#-`<Y%,R#2=.E;71DEH3[Z3S*BW8%+P156,9(E5^/6E5^>*ASBA7YI.+)
M:T)]Y[TI?/>H=V33B>>*CD9*)5?FG%N14`;FE+9Q2:)L65>I$?@Y-5E:I%/!
MS7/-6W'<E1\]:E#<555LFIE;UKG:$W<F#9[TY6YXJ'.TX'>G@]ZQE$+:$N[W
MH+^E1@G-/P*CE#F'J_`I=],&`*3=1RF;9)OHWTS-!--)!<`_K368$FF4$XJD
MKB<DA2U1LU&[/6F%N:Z81,).XC-49:AC43GCBNJ$3"<A^_@4PM2;N*C+8KMI
M0.*K)"L^34;/S2,>>*C<UW0CV/.J,<S]JC+4UCD4T].M=].#L>?58H?KZ4UG
M]*;G::C)&:[Z43R*^X.U1O)@4KU$^*]&D>178X/D5$S<TFX@<5&SGVKLIPU/
M)K".W-0NU*\ASVJ)VYKLC$\>L[`S<"HG;FAG(XXJ(O71"+/*JC&/K4+'DT]S
M4#]:ZH19YM5C';FHG.>E.<U$QXKH@CSZCL,8XJ-CG-*QIA-6EJ<LV(6YII/K
M2%N:1CTK1,S'4H-,IRFDV)71-"WS\U.I]:K1=:G4UE)&T664/-6XCQ^%4DZU
M<BZ"LIG32+T'2KD76J,!X^M7H>O-8S/1I(M;J*;16)TG53=ZJ2=*M3=#51S7
MX',_MBD5)JK2'BK$U593@8K!['?3V('J$]ZD8U$U<\CHB1.<FDSS3G&33&&!
M674U6X`THZTT&@&FRY(7=S^-/4\BHAUIP/-.)$D3@U*#\M5]V`*D63CIUK6.
MYG):$J&I0W(S4"&I`>:V1SS)D.!Q4@;)_"H5;BG!\5T1.:2)J7=40:G9KI@S
M":)U)P.!2EL=:A$F*"YZUK!'+4U)M])OJ)6R>:<:V2,K:#]]/#\"JQ?\:>&P
M!G%;J)A)$N__`#BA7YJ+?1OHY266-^:<7]ZJ^9R.*=YE+E)2+`?FE9\$5`'X
MS2A]WX5FXD%H/4B-Q54-Q3Q)D=*QG`EEA'S4BMS59#3U?GI7,X:@BT6Z<\T\
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M/%19^7BE<Y%1%\`YKJ@CR:S$9N*KNV#R:>SY-0NW/-=,5H>958QS@5&QXXIS
MM43'BMHGGU6-9N*B)P:<_P#2F9]:T.5L:Q^:@GFDII.*$A)C\YIP-1@T]!D4
M@3)8C\U3KUJ",8J96RU1(N++*'I5R(\#Z541>G-6HC@5E-'729>@Z5<B.2*H
MPGM5Z'M6$CTJ):Q12;J*Q.DZJ?H:IR=ZN3]ZIR=*_`YG]L4BI-U-59NI^M6I
MCR:JRC)_&N=G=3*K5&W2I64DFH3WK"1U1&$TQONBG'BF-T%9=36.XB\8HZ`&
ME[4F>E#-&)T)IP/2F`Y)^M.%.*9,EH/)X%/0TSM3D/-:I&3)D-2]*A7Y1S3A
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MC:.Y<7^M6HZJI5F,\XK.1U4BY!UJ]#UJC#P15Z'K6$CTJ19HHHK`ZCK)ZI2]
M*NSU2EZ5^!S/[:AL4YNIJO)5B;K^-5Y*YI'92V*[57/4U8;O59N]9,ZXD;4Q
M^E/:F/TK/J:PW`]329Y%&>3FD[_C4E,;W/UI^>!3!U-.!YJX@R3-*ARPQZTW
M/%"'!'UK9;F$B=J`1FF[@QX.:7-:F+'H>*>IJ-#\IIZ'!YKH@<TT2`XZTX'/
M2H]P]:-P]:ZH'+(DIC'!HSFF.V&[=*Z((QFM!VZEWU&6]*;N-;I'.UH3;Z3=
MZU%N)I-WTKHBC-+4GW^](9:AS[T;O>JL9R)0_M3]PJMNY&:?N]_UHY1$RM4C
M2<C%5E<`\FG%@<8-%F06E;BI%;BJH?CK4J,`.M9SCJ2]RPCU(KY-54:I489Z
MUC4AH2RR6Y%2JV157=TP:D#<5@X,DM(U.W5720#N*?O'K4<@$NZC=4>[WHS[
MTN0"3=2[O?\`2HMV.])YE7&&A$MQ[M3-WR\4USGI3"^T5I&&I$MA7:H=WS"E
M+>]19PW)KIA`Y9#V:HG>FN^#P:8[9'%=,$83$9^.M1,]#'BH68UVTUL<]1:"
M[\-2,]1EOFICN/6NN$3SJ@N[%(7XJ,MCFFLV1P:ZZ2U//J#BXSS2,W%0EO6D
M9N.*[::U/(K[DF_'>HRXS3=U1[LUVPB>+7'NPS3'.:"?6F/VS79`\FOL`/7%
M1R'FEW@`\BHW8'H0:ZH'C5F+)TJ!S3W88ZU"QKHBCS*PT'DU&Y^:E)QG-1LW
M/6MXGEU=QK&H9.0,5(Y]*A8Y%;1//JC<Y'TIII3Q4;'FK.20G\1H/!H)Y%(<
M]Z%L0B1#\O-2+UJ)>E2K4L<=R5*D3[PJ)#@"I4^\*B1M'<N)5B+K5=*L1#YJ
MSF=-'<O1?>%7H>M48OO"KT/6N>1Z=(LT445@=1UD]4I>E79Q5*7I7X',_MJ&
MQ3FZU7DJQ-U-5Y*YI'92V*[=ZK-WJRW>JS=ZR9UP&-TJ%NIJ9NGXU">IK)[F
ML`]:0'@4OK314LMB=S]:<.M-]:<.HJX`.;I^-*.AIIZ?C3@>#6R,)K4<E/J-
M#4E;)F/0>G3\:=3%.!3B?2MX'/-`>E*.E,SZFEW8%=<#EFAX?'%,=LD9II;F
MD)YYKL@C"0X,!07&#498"D+<'Z5NEJ8R0X/1OJ+.:-W-=,$8I:DN\YHW5#NI
M"WO5V,Y+4FW@4A>H=WO1N]Z+`60W`IR-S5</P*<C$TK&9;W?+3T;CFJ^[Y>:
M>K<4G&Y$MRTC4\-\U01M3MW)J*D-"66@_I4JGBJBMFIE:L7$DGW?2G[JK!N>
MM2;JSY`+*MP.E+N^E0*W`YI=WO2Y`)';Y>U,W4UFXZTW=[UI&&A$MR3=4<C>
MM&[WJ*1N35QAJ1(`^,TQCUIH;K4;-S71&.AS202-36;`ICM37;BM((PF#-FH
M6>E+<5$S5W4UL<]781F'>HI&H9JB=ZZH1/-J#W;BF;Z:S<5'FNRFM3SJA(ST
MQG^4TUVIA;BNVFCR:^X_?25%NJ3(KMBCQ,0(S8IDC9`I)&^;BHRU;Q/)K;`W
MW33`:<S<5&#S75`\:L(YIF>*5SQ3,_+73%:'EU1C&H6Z_C3VZU$QY_&MHGEU
MMP8\5$QJ1N]1/U&/2MHZ'GU=QK'O41Y-/;I3!UJSDDQ`>13V^]3!]X4]NH-'
M0E,5:D':HQ4B]JGJ..Y(G05,GWA4*=!4R?>%9R-X[EM*N1]!51*MQ]*RF=-(
MN0=/QJ[#U%4H.E7H>U<\MCTZ2+%%.P**Q.HZN?H:I2CTJ[-T-4I:_`YG]LT]
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MMS55&J16R:SFM"2R3R*D5N*K%NE2JW%8N.@F3!N:DW"J^XT_=4<K)W+`?CO2
M[OK4(?`'%&\U'*S(FW9HS46^EW<548@+NICG(IN[ZTUFXK2$;,F6PC&H2?FI
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MY;'HTBS1116)T'6/SUJG**N2]?PJI,,9K\$F?VQ!Z%*4<FJ\@`&:L2]34$OW
M37-+8[Z6Q4<<U6/4YJT_6JS=:Q9TP(6ICCBGM3'Z5E(VB1GI2+3L9'%(*2-'
MN-/4TH_K2'K0.M5$&2G#+]*:#2C[II!U%:+<QD.IXZ4P]*7.%%=$3!BK1W-(
M#BC//%=43"H*QXJ/<?4TX]ZC-=<#FF.W'UH)]32=J8[8-=D$830KG(IA``-(
M[<"F%N#75!(SZ"YJ,GDTF^F%N370DCGEN2$^M&>*BW4;Q6\5H0]B3-&:BWTF
MZJY3,FW^].5B>YJOO]*>C$T6(+"N<CGBIE/&35-6PU3H_%+E(:U+".?6I5<@
M]:J(U3*U1..@F62YXY-2*YXP:K%NE2JW%9J.I+V+2MZT[=FH$:G[JKD))`^.
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MY'XTP]1]:V@>74W!ZB)YJ1N:B/%;1."H-<TT#+<TK<`4B_>%-G)(7:`3Q0WW
M12GK2-T%")0X5(O:HQ4J_P!*DJ.Y+'TJ5!\PJ)*F3[U9R-X[ER/^E6XAP*J1
M]<>U781E:RD=M(MPC%78.M4X>HJ[!U%<\]CTJ18P:*=16)T6.JE'-4YNXJ[+
MUJG-]ZOP2H?VK2*4HY)JO+TJU*,XJO)PIKGD>A2>A3?K4#K5AQ4+]*P9U0V*
M[K41&[@U,]1#[QK*6YM%ZB$?+D5$M3-]TU"M)%B=S2@4G<_6G#I51&Q0<Y':
MCN*1>]`^]6BW,I;CFI"Y&.E*W6F-71`YV2+S1G%(II#UKKI[F%0"W6F4X]*;
M79%(YIB$U'(26_"GGK4;_>KK@8R&XSUIC#'%/SBHG;FNVFM#%MV#`]Z81R:`
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M:PAZTUL9I<\\TUZVMH>55&$XI`,FD)S0.AK6!YE0:W7%1,<U*?O?A41[UJ>?
M+4:1FFCAA3Z8.HHZ&,D.!SDT-SBA>AI3VH1`JU*M1+4JBI8X[DT8R15B.,9S
M4$0^:K4=9R-XHFB&35Z(=*IQ]*NQ=!64CMI(M0]:OPC%4HA\V*O0CI7+-GI4
MB>BBBLCI.LE'-5)5SS5V:JDGW:_!YG]HTF49015:7H?<5;FY-5I!7.ST*>Q3
M>H6J=Q4+=*P9UTRL_6H^]2OUJ,]:RD;1W&GD5$%P*F/2HNB\U*-$,[FG`<4T
M$$G!!IX^[^-4@$'4T#[U"]Z0,"QP0?H:T6YG+<<3DTUJ=36KI@<[%W8-!;FF
MT'K753W,)BEN*87QVI6.!3&1DQO5ESR-RD9KM@<TQ=PJ*1@#3ZBEZUU4S&8T
MR9XQ43-S3NYJ-NIKMI[&#$9MM1E^O:GR=!4!;DBNN*N8L5FY'--.2*:[<BF[
MZZ81$]AV*=DU'N^M&ZM>4SN2&E0]:BW4Y6ZT<IF3`\T]6P*@#\]:=O-'*9RW
M+"-4BO@]*K(U/#?-2E$5BV&R:F1MM5%>I4D!X!!/L:S<78;V+/FU+NJINJ3S
MJSY3(GW4HDV]NM5_-I0Q<@(&8]@HR318S>Y.9=W&*0M4!8J2&#`CJ",8H\RK
MC'01)DTQFYQ2;AZ4QFYJN43`MM%0E\FG2-Q4!;YJVC'0YY;BLW-#GBHW:FN^
M.];PB83!SQ4)/-*S@BHBWO75")S5=AS'@TS.*"W!J/=]*ZH1/.J$FZFMR<@T
MW?1N^E=*B>=4'8/K0.O6F[Z-];P1X]?<DSS[4GF>U,WT5TP/(Q`$Y-*O6DI5
MZUO'<\3$`W2FA\4YNE1^E;QW/%K;A36/.*=36^]^%:O8\NJ,P:"<4XTQJT@>
M55&M49[U(W6HSWK4X9"4T?>IU-7ES0MC&2'#O0>HQVH'2E/WJ#,51C.>M3)T
MJ,=34JU+*AN2Q=:M1CFJT76K25G(W@3Q"KL(^453B&!S5Z$<"L9G=2+4(Z5>
MA'053A%7H!S7+,]&GN6-M%/X]/THK"YV6.IF4\U4E&%Q5Z;O5.49K\+F?V92
M*$M59?:K<M10VLE]=0V]LI:6X=8T`[L3@5SM7.Z,^579Z;\-/"&BGPRNI^*K
M2WN&U&[$-MYZY`!.U0/JV:X7XG>&H_#'BVZMK2,16DZB>W4=%5NH'T8$?E7J
M'Q!\+:S)HFA:5X2M#+%II61W$BIAT`"]2.^35+XVZ-+?^&--U>6$Q75IA+E.
MI4.!D$CT8`?C7M8O")8:5-0LX).]M^^I\CE>9R>80K2J7C5<ERW^'7W=.ESQ
MN7P]J:Z2-4-C<#3B<"YV_)UQU^O%1Z?X=U/5[6XN=+L;BZ@M!F>2-<B/C//X
M<UZO=?\`)O<?^^/_`$HIGP8_Y$?Q9_NM_P"B37G++X2K4Z=W[T>;\&>[/.ZT
M<+6K<JO"IR+?:Z5_74\GL]"U'4;&YO+"RN+BULQFXEC7*Q\9Y_"M;3/#VK^%
M]<T2^U?0KF:*>Z0P6TBC-R?[@'.#[$5Z/\"+D67A'Q%<-&)1;OYFP]&VQYQ^
ME<?I/CW6?&7C?P\NN3I)#'JT<L,21A1&20,`]2,>M33PM&%.E4<GS2VVMN:5
M<PQ=6OB*,81]G3W;;N[QO96\^O;S*_Q-NKCQ)XNM88/#]QI%VT"1):,J^9.Q
M8X;"\=\#Z5BVO@+Q%>7LUE;Z->M<VV#,A0+LR,C))QR.>M>E>/?^2[>'_K:?
M^C&J;XQ_$76O#/B:&PT&=+.&*%+B0K&"9F)(PV1TPN*Z*V%I<U6K6D])6T2U
M./"9EBHT\/AL+3C[T.;5NRU^;?\`6IXW?Z7>:'?M:ZO:2VUS$06AF7!(_J#Z
MUWOQ:UN35+71XIO"\WA]D#,KRJH\T8`VKM[#CK[5T/[0$27%KX9OBBK<3*ZL
MP_NX1L?F33_CWYWVCPG]C0R7&7\I`NXL^8\#'?G%7+">QC7A&6BY>VM_ZZ"I
M9DL95P=:<$I2Y^KT:6OEKYWL><6?PW\47]N)[70[YHF&064(2/8,0:P=0T^Z
MTRZDMM2MYK6XB.'BE0JP_`U[?_9OQ!>\MKW7?%&E:,6=66SDF"J1GE=H&#Z=
M361^T?!&FLZ/,J@226TBNP[@,,?S/YU57`0A1=175K;VZ_D5@\ZJU<9"A-PD
MI7UC?1K7=Z/Y'EN@6T=YKVFV]RH>&>\ACD4G[RLX!'Y&O;?'C^!O`6I6EGJ/
MA2"X6[B,AD@1?D7.#P2,FO%O"W_(SZ/_`-A"#_T8M>\_%?P]X7U?6=/G\8ZZ
MVEM#;D+;J0#,F[).<$^W%=6!A^YDXVO=;V_4YL[J)8ZC";ERM2TC>_EL</\`
M%CX=Z5H>FZ;K_A0-%8WLL:O`6+*-XW(RYY`P.16[\=M`U#Q!>^'+;0K&>\G\
MB8E84SM'R<D]`/K7-_%;XCZ?XDM].T3PNK_V982(QE92H<J-JA0>=H&>3UKM
MOC;XYU;PG8Z1;:!,+1[Y6:2<*"X";<*,\#.[]*[?W352VVFWZ'E0^O1GA.=7
MG[]N;M96OUV/!]<\/:GX9N$@U^QN+&61=R"5>''J".#5G2?`?B+Q%`+C1M'O
M;FW;[LNP(C?0L0#^%>K_`!,OG\2?!+1=6U4(]ZTL+&11CYCN5C^.,XJGI&F?
M$74?#>FRRZ]8>&=+AMT2U\YQ"S(!\I;`/)`[G\*<:$5*RNU:YW?VI5EA^=\L
M9*3B[MVT[):L\@UK0-3\-W(@UZQN;&5@2JS)C</4'H?PJ>+P7KURM@\&D7TB
M:K_QYL(^)N,Y'MCG)[5[3\<[>23X6:)-J=Q;W]]#<PJ]W!RDI,;;F4^AP#5G
M6?%]YX*^!WAV^T98A>SVMO;Q3.H;R=R9+`'J<+BNJ-&*T.=9M6G0IRA!<TI.
M/6WJ>&-X'\0-JMUIJ:1>O?V48DN($4,T:'HQP<8-1V7PZ\4:IIQU'3]"U&>R
M(++(L>-X]54G+#Z`UZ[\`=?OO%/CC7M0UV87-W+IT2/)L"[@K`#@#'04OP[^
M*FO^(OB[)IM]/&NES&XB2S2,!(1&"5*G&<_+S]:WC%$5L?BX2J148W@DWOVN
M[?H>-:)X#\1^)X))]!T:]O(86*O(J!5W#J`6(R1Z"L:?3[JUO6LKFVN(KQ)/
M+:W:,B0/_=V]<U[SXE^*FO:9\9[;0],EAM=)M;^&V:UCB7;,)-I=F.,YRYZ8
MZ?6L_P"-4-_9?&K1;CPE;B769K>&2%-@822JS@$CTVCDGL/:MXNQ5+'UY32J
M124H\RU_,\\B^$GC.:V\^/PYJ7ED9`955L?[I.[]*Y6X@ELYY(+N*2">)BLD
M<B%60CL0>0:^E=`TCXA6?BO3KGQ=XST>(23J9M),XS+&3RJH%`SZ8[]ZJ:]X
M<LM6_:7T]+J&-HUT]+R1",B21`P4D?4+_P!\U<9=SGIYK+GDIV:46_=OTZ:G
MC-M\+O%UW8"]MO#VIO;%=RMY8#,/4*3N/Y5@6=G<WEXEG9VUQ/=R/L2".,LY
M;TV]<UZU\6_B[XGT7XE7UKHNI2V5II3HD=NJ@I)\H8EP1\V2?RKH_P!G=1KM
MWXM\5WXM5U.XG*B4KA(=P+N1Z`DC\!5:I79<L=7IX=UZD59I-6OU[GD6J?#;
MQ5HEB;W5=!U""U0;GDV!@@]6"DD#ZUG:%X:U;Q,TR^'M.NM0-LH:7R$W;`<X
MS]<'\J^B?`=[<Z'K=W<^+OB/H.NV-Y$P:U-T@".2,%06P!C(P/6LGX!Q6<'C
M'Q['H[I)8QS*+9XSE3'OEVX/IBE?1G/+,ZL:=232;C;57MJ[==3PG1]*O=<O
MTL='M9[R\DSMAB7+'`R?RQ77>`?AQ?>(O&B:9K.GW\5I:R[-3*?(UOE&*Y/;
M)`JU\`V_XNW9^Z77_H#5V.E:[?Z?^T9?6%E=216>HWY%U"N-LH6`E<\=CZ43
MWLC?%8JJI3IPMI&]_P"OP\SCOB=\-;KP;K%Z^EV5_P#V#!Y8CO)B&&649&[_
M`'B1TK:^(/B%KWP'H=K+X2GT91Y1BOG1`LH$9X3`S\P.[GT[U%\>_%>KMXPU
M70VOYCI*"%Q:8&W.Q6STSUYZUTWQD3SOAEX'CSCS#;KGTS;XJ+;7.:-2<HX=
MU=6^NO;\SRO0?!NN^)XVET#2KR\A0X,J*%3/IN8@$U4O-%U/3]3&G7VGWD-^
MQ`6V:$[VSTP!U_"O;_C5XBOOAYH/A_1_",SZ;"R.K20`!ML84``]LEB2>IKS
M?1O&WB[Q;XQT:?2_)O=<LH'@MW:$89"&W-)VX#'GBA0NKFU#%5JL'5LE'6VN
MNG<IM\+O%RVWVAO#^H"/&2-J[L?[N=WZ5J?!)"GQ.TV.52KH)PRLN"I$;9!!
MZ&O4_!^E>--.\5VK^+/%VEW2ON\_2Q,"[`J<;5VC!!P>.P-<_;01V_[3$BP*
M$#AG8#NS6^2?Q-39''+&2JQJ4Y6?NMW5_P!3B/BM:S7WQ1UFVL(9;BXEN$$<
M42%F8^6O0"LG4_AWXGT:Q:\U/1;V"UC7<\A`8(/5@"2!]:]+M?$FE^&/C_KL
M_B!T@BG00Q7#CY87*1G)/8$`C/O4GCGPUXUM+#5=2\/^)GU[1+R.0S0;PQ6%
M@=P4<J0!_=(..U4M"XXJ=/V=/1+E6KOKZ?\`!/#?.'O7KZ>%=&;X!OK1TZW_
M`+4V$_:]O[S/G[>OTXKQD/QQBO>8S_QC&Y_Z9G_TIJI+8VQ\FE3L_M(\<C\.
M:K=:4-2M=.NYK#S1$+A(RRER<!1CDG)`J?5OA_XDT*P^WZOHU[:V8P6E=00@
M/3<`<K^->R?#O79O#7P&OM4LXXI+BRFF>(2C*AMX`./;.:F^"WB_5/'FC>);
M/Q9<?VA'&@VLZ*IVR*X9>!TXXJU)I-]$<E7%U8\\E%<L7;S/GRQTR\UF]2TT
MFUGO+J3[L4"%V/X#M[UH^(/`GB+PS:K<:[I%Y9V[$#S74,@)Z`E20#]:]?\`
M@K''X:^&'B;Q):1+)J">>$9ADA8D!5?IN))KRN[^*_B?4M(U'3=7U)[^TU-0
M)5N$!*88-E",;>G3I6\.9RLMD)UJDZDE%*R9R+`CZU&01_\`KIS.-Q`(SZ4Q
MVZ5V11578#D@^U-P:&/!I@?'0UTQ;/.J#J*8&XIV1733NSSJFXN:,TW.32_Q
M5U1B>/7W%I=PQ33TI.WXUM"*/(Q`_<*`XSWIJ]*#U%;QBKGC5U=#RX/%-IIZ
MTH-;I'AU]Q::WWOPIU-;[WX55SRJHUNE-/:G-TII[?6M8'F5=QK'FHV&*<_W
MJ1^E:G$U<;@D9H52&R:<O3\:*?0PD)C)_&C'-+1_C2,A]2*">E,`J:(=:DN!
M+&O-68Z@0<U805E(W@6(ZNPC@54B'2KL(RM939WTD6X5J]`N#S5.`<5?AZBN
M29Z-):D]%.VT5A<ZSJYAG-4I>]7I>]4I17X;-']D4BA**V/`M_IVD^)[:^UV
M1H[>U#.FV,OE\87@?7/X5E3?SJJ_!K*$W3DI+H=-2DJU*5-NRDK:;ZG2>+OB
M)JNI:_>7&BZGJ%K8LX%O''*T8V@`9QV)Y/XUM:!\1;"]\#ZEH_C6]NY;F<2+
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MT\]-STKXJ^.M(\6:9H$.BS2RR6`;SP\+)MRJ#OUZ'I5OXA_$O2M5UCPM?^'V
MDNFT:4RRI)$T>>4('/\`NFO*EZT@ZBNAX^K-R;M[UOPV,*61X6G&G%7:AS6U
M_GWOI]VQ['XJ\2?#[Q7J%MK^JW.JR7=M&H.G)&1YA4Y"G(P.3R0P!KG_`(Q^
M-M+\:W.DS:')*XMH'$P>(IL9BI`YZ]#TKSQJ0]*WEC9U(RBTE?>QEALEHX>K
M3FIR?)=13>B3Z;%O0[N.PUO3KJY)$-M=Q2R$#)"JX)X^@KLOC/XQTOQEK6GW
M&@32316]J8W9XF3#%B>A]JX"D:KIU9*FX=&;5L)3GB8UW?FBFEVU%#!65CT#
M`FO1/C+XXTCQFVC?V!-+-]CCD$V^%H]I;;@<]>AKSE_NTRNBG4<8.*ZF&(PL
M*E>%9[PO;YZ'I'B'QSI&H?![2_#UM-*=3MFC\V,PL%&TL3\W0]16WK7C;P/\
M1O#>F1^,;S4=+O-,7+0P1DAS@!MORD$'''0BO&7JNYKT85I6U['FSRBCHXR:
M:DY73UO+?IL>K_$?XB>&O$'PZT[1/#`N8'L;F,1VTL9RD2*R@ENA)!4]>]4O
M&GC_`$;6?A+X?T'3YYGU.P,'GQM`RJNQ&#?,>#R1TKR_O^%,;K75"HV1#*Z,
M(Q2;]V7-OU9Z1\$/'6D>!M;U*X\1SR017-JL<;1PM)E@V<8`]*Q_AUXMT[PY
M\3DUK5I9(]/$MRQ=8RY`<,%^4<]Q7$/3"?E%=4-13P5.4JDG?WU9_EH=IXE\
M6Z;J/Q@;Q#:RR-I?]IV]QYAC(8HFS<=IY_A/%==XN^,6C_\`"W-%\3Z&)K^P
ML+3R+@&(QMAMX;:&QR`P/Z5XL_)IK\+72H7(GE]%J-[Z1Y?EL>\:OXM^%S>,
MXO&?VW6=0U0RQRK8K$RI'(N`'.Y1@`#.-Q&1TK!\:?%VQ'Q?T[Q7X4:2]M+.
MUCBD1XVB,@^<.OS#/1N#ZUY#16L*2.>GEE*+NVY:<NKZ=CZ$\1>*/A!XSU%/
M$.O-J`O]B^=9K%*IFVC@.H&#QQD,.E<K\-OB_IG@SQ=KK2Z?+%X:UR<LEO$@
M+6H!.SY>A&TX('MZ5Y.#Q1FK5%6L1'+:2INFY-IZ:O;T/9;NT^"EI.^H0W.L
MWH8EUTZ)9`N>NWE00/JU8_P7^)=A\/\`Q-?/JD4JZ3J:;&,:[V@VL2A([C!(
M..><UYD32!N:/9:68/`Q=.5.<G)/NSZ'T?QS\+O`GB47WAF*[NI]0D;S[LQN
MR64;9)"!AGDX&`#P>N!BN&N_']E;?&1_%-@)+G3UOA*!LVL\938V`>^"<9KS
M;?4BM\HYJ722(IY?3@VVVVU9W?0]C^+VO>`_%5O<:QX?NKR?Q#>>4NPJZ(JK
M@$L",`[>.M1_$KXAZ-XG\">&=,T6XF>^TP1?:%:%D"%8=IP3P>?2O(T;KFGJ
MV3Q25,(8&$%!7;Y=K^EK>A[\WQ)\$_$?PS8V?Q':YL;^Q`)DC5^6Q@LC*#PW
M<$?RS6)IOQ$\)>#O'VGW?A'3[A=%@L6M+J4H?-E+-N\P`G)(P.N.,XKQ_/O4
MFX4O9(RCEU**<;OE=]+Z:GND7BCX:Z+XT_X2BTO=4U"_NYS)Y9C;9:E^'<Y4
M$X!.!D^U8Z_$/0U^-Y\2_:)?[(*;?-\AMV?(V?=Z_>KR/<*-PH5(<<OIJ]Y-
MW7+J^AZ7J/B'P?XD^).N7WB7[;)HVHHHM;B!65XG"H-^WKCY6'0]>E=-8>._
M!GPT\,:G9^"K_4=:O-2!VK.I5(VVD`G*@`<Y.`2>*\.W"DW4>S%4P,))1<G9
M6TOIH/!P`/2O5D^(NB+\#F\,M<3#6"I7RO(;;_K]_P![IC;7DVZF,>:IPN:U
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M$R=-0BT@)P#4>ZE)XIM=*B<50DR,=:`PQU%1T5TP5CSJFY(6&>#1N!-1TJ_>
M%=43QZ^Y)G`-`.12'I0O2M8GCX@<#BC.2*0]*6MX[GDUUH!ZTJ]:0]:5>M;(
M\'$;BTP_>_"G#J::?O?A0>55$;I3#3VZ4QJV@>95W&OUI#VI7I#_`$K5G(Q%
M&?SHIRT@%'0YY[@.M+W%(*=B@S'#M4\50@5/%T_&H*CN2H*L1CI4,8JQ&.:R
MD=$2S&#Z5=A'`JM&.E6HATK&9WTB[!TJ[`.E4[<<5?@'2N29Z-):D^VBG;:*
MP.HZJ7K5&45>E'K52<<FOQ"9_8U)E">JSBKDW2JD@XKGD=\"K*,DU6<5;<56
M8=:P9TTV57ZFHCU-6&')J&05C(Z8RU(G'%1=Q4S<K46.*E&JF#4P<BG+UH;B
MJ0AHI.]*.M'>MHD@_2FGFG-3:Z(&4G8;2-2TC5U1.>3U$?[M,I[_`':973#8
MYY[D;U7;^M3R'TJ!NE>C31E/8B[_`(4QNM/_`(J8W6NRFK&+('IC<#\*>]0O
MTKMI'/U(VZ_A37^[2YZU$S5VQV$]@HI"W'%1Y]ZV@02$X-)NIF[WHW>]69,>
M6XYI`1FF[OQI=WM3,V]2;\:>IP!S4.X>M/5N!BDT(F1NO>GJ<FH4;KFG;AZU
M/*#V)P>:DR*J!AGJ*?G-'*9EC(HR*C5N!R*7</44<H#]U&[ZTS=[T;J.4B6X
M_=]:8S<U'GWHW>]-0N2*[=*8Q^4T.W3-,=AMK5*QC,,Y[TF>:;N]Z":U@<LP
M8\\TQSG%#'FFL<UO$YJNPH.:6F#L:=NYKHBKGGU!:*3=1FNA*R/,JNPM*OWA
M30<TM;1/)K;DAZ4+TJ//-2+TK:)X^(%/2BBBMH[GCXB6@4Y>M-'4TY>M;(\+
M$.[`=333][\*<.II#]XTTKGE5-AK=*:W2AZ6MXQ/,J;C'Z"F]OPI\G2FG[M4
MSDGH"\B@4(.*7TI]#GEJ(!3@.E)_C3@*1-ARU/$.*8@R/PJ9!TJ.I421*LQC
MFH$&*L1CFLI'1%%N.K<(Z56B'`JW"O%8S9WTD7+<<5>@'(JG`*OP"N29Z5%:
MD]%+MHK$Z3J9152<9-=)+I&G]]<M!_V[R_X54ET;3SUUZS'_`&[2_P#Q-?BT
MJ4O+[U_F?UU2Q,%W_P#`9?Y',SCBJL@ZUTSZ'IISGQ!9?^`LW_Q-5Y-"TSOX
MBL1_VZS?_$UA*C+R^]?YG='%T^S_`/`9?Y',.*K-U-=0V@Z6?^9EL/\`P$G_
M`/B:KMX?TG_H9K#_`,`Y_P#XFL'0EY?>O\SHABZ?9_\`@,O\CF&%12CBNF;P
M[I/_`$-&GC_MSG_^)J)_#ND8_P"1JT[_`,`I_P#XFL94)^7WK_,Z8XVEVE_X
M#+_(YAONFHZZ<^'-'Q_R-6G?^`5Q_P#$TW_A&]&_Z&K3O_`*X_\`B:2P\_+[
MU_F:?7:7:7_@,O\`(YD#!I&%=(?#>CC_`)FS3O\`P"N/_B:0^'-'_P"ALT[_
M`,`KC_XFA4)^7WK_`#']<I=I?^`R_P`CFAU-+CYA71CPWHV?^1LT[_P"N/\`
MXFD_X1S1\@_\)9IO_@%<?_$UM&A+R^]?YD_7*?:7_@,O\CG3TIM=(?#FC]/^
M$LTW_P``KC_XFF_\(WH__0VZ;_X!7'_Q-;QHR\OO7^9E+&4^TO\`P&7^1S1Z
MTC=*Z4^&]&_Z&W3?_`*X_P#B::?#>C?]#;IG_@%<?_$UTQI2\OO7^9SO%T[[
M/_P&7^1S;_=IE=.WAO1B/^1NTS_P!N/_`(FHSX;T7_H;M,_\`;C_`.)KIA3E
M;I]Z,IXJG?9_^`R_R.7DJ!NE=8_AG12.?%^F#_MQN?\`XBH3X8T3_H<=+_\`
M`"Y_^(KT*<78RGBJ=MG_`.`R_P`CE/XC3&ZUU!\,:'G_`)'+2\_]>%S_`/$5
M&WAC0\_\CII?_@ON?_B*ZX)F+Q-/L_\`P&7^1RCU#)WKK&\+Z$?^9VTK_P`%
M]U_\143^%="_Z'?2O_!?=?\`Q%==(P^L0OU_\!E_D<BYQ4!;FNP_X1/06!SX
MWTD_]P^Z_P#B*B;PCX?[^-](_P#!==?_`!%=D7H#Q,+;/_P&7^1R1;KUJ//I
M76MX2\/_`/0\Z0/^X==?_$4W_A$?#_\`T/6D?^"VZ_\`B*VA)&?UB'G_`.`O
M_(Y3=1NKJ_\`A$=`_P"AYTC_`,%MU_\`$4?\(CH'_0\Z1_X+KO\`^(K:Z_I,
MS]O#S^Y_Y'*;O6ESZ9KJQX1\/YY\<Z1_X+KK_P"(I?\`A$?#W_0\Z1_X+KK_
M`.(HNOZ3,Y5X7Z_<_P#(Y??3U;('6NE_X1/P_P#]#SI'_@NNO_B*>/"?A_'_
M`"/.D_\`@NNO_B*+K^DQ>WAY_<_\CFD;&:=OKI5\*:`/^9XTG_P777_Q%._X
M170/^AXTG_P777_Q%%U_28.M"W7[G_D<SN^E.S72#PKH&?\`D=])_P#!==?_
M`!%/_P"$5T'_`*'?2?\`P7W7_P`13NOZ3,_;P\_N?^1SBM\HZ4N[Z5T7_"+:
M%_T.^D_^"^Z_^(IR^%M![^-])_\`!?=?_$4KK^DP]O#S^Y_Y'-[OI2$^]=/_
M`,(MH/\`T.VD_P#@ONO_`(BD/A70<?\`([:3_P""^Z_^(HNOZ3(E6A?K]S_R
M.5S_`)S1NKI_^$5T'_H=])_\%]U_\12_\(IH./\`D=])_P#!?=?_`!%4FOZ3
M%[:'G]S_`,CEF:F%LJ:ZI_"N@<9\;Z3_`."^Z_\`B*;_`,(IH'_0[Z3_`."^
MZ_\`B*KF7])F,ZL?/[G_`)')[J7=75?\(EX?_P"AWTC_`,%UU_\`$5'_`,(G
MH)Z>.=(_\%UU_P#$5I"2_I,YIU8^?W/_`".68\T*<UU'_"):!U/CG2/_``77
M7_Q%`\)Z`.GCG2/_``777_Q%;1E'S^Y_Y'/4J*W_``&<N3P:;NKJSX3T#_H>
M=)_\%UU_\12?\(EH'_0\Z1_X+KK_`.(K>-2*[_<_\C@J21RVZ@-[UU/_``B7
MA_\`Z'G2/_!==?\`Q%.7PCX?Q_R/&D'_`+AUU_\`$5LZT;=?N?\`D>;6.6C.
M2:?74#PEH`Z>.-('_</NO_B*4>%-`S_R/&D_^"ZZ_P#B*TA6C;K]S_R/,K19
MRW>I%Z5TW_")Z!_T.^D_^"ZZ_P#B*D'A30<?\CMI7_@NNO\`XBM8UH^?W/\`
MR/(Q%.3[?>CEJ*ZK_A%-!_Z';2?_``7W7_Q%+_PB>@_]#MI/_@ONO_B*VC7A
M?K]S_P`CQZ]";3V^]?YG*#J:<O6NH_X1/0<_\COI/_@ONO\`XBE7PIH(/'C;
M2?\`P7W7_P`16WUB'G]S_P`CQJV&J=U_X%'_`#.6'4TAZUU?_"*:#_T.VD_^
M"^Z_^(I#X4T'/_([:3_X+[K_`.(IQQ$+]?\`P%_Y'F5,'4MNO_`H_P"9R1ZT
M=A75GPGH&?\`D=])_P#!?=?_`!%'_")Z#C_D=])Q_P!@^Z_^(KH6)A;9_P#@
M,O\`(\ZI@JM]X_\`@4?_`)(Y)QP::WW?PKK7\)Z#@Y\;Z3_X+KK_`.(I?^$2
MT#;SXVTG_P`%]U_\10\3#L__``&7^1RU<#5[Q_\``X?_`"1R*_=IP%=7_P`(
MEH`&!XWTG_P7W7_Q%`\)Z!_T.^D_^"^Z_P#B*/K,//\`\!E_D<_U"MWC_P"!
MP_\`DCE,=/K3P*ZD>$]!)_Y'?2?_``7W7_Q%2?\`"):!T_X3;2?_``7W7_Q%
M+ZS#S_\``9?Y"^H5N\?_``.'_P`D<N@X'TJ=!P/:NE'A30<<>-=*_P#!?<__
M`!%2)X5T+MXTTH_]P^Y_^(J'B(7V?_@,O\BXX"M?>/\`X'#_`.2.<CZU8C'(
MKH8_"NA[O^1RTL_]N%S_`/$593POH@/_`".&F?\`@#<__$5D\1#S^Y_Y'1#`
MUN\?_`X?_)&'&*MQ"MJ/PUHPZ>+M,/\`VXW'_P`35N+PWHX`QXKTX_\`;E<?
M_$UE.O#S^Y_Y'=2P57O'_P`"C_F9$`J]"*U(?#VDCIXHT\_]N<__`,35N'0-
M*!&/$M@?^W2?_P")KEG7CY_<_P#(]"E@ZBZK_P`"C_F96/845O?V#I?_`$,=
MC_X"S?\`Q-%8>VCY_<_\CJ^JS[K_`,"C_F;LNAN?^7W2Q];Q:J2:!(1_Q_:3
M_P"!R5=E\.:L<XTV]_[\FJLGA?5R/^09??A`:_()4_[C/ZGI5E_S]7X?YE)O
M#TG/^GZ/_P"!Z56E\.2?]!#1?_!@E7)/"NL_PZ5J!_[=VJK)X2ULCC2=1_\`
M`=O\*PE3?\C_`*^1W0KK_G]'\/\`,J-X;E_Z"&B?^#%*KGPQ*2?^)CH7_@R2
MK3>$-<Q_R!]2/_;LW^%0/X-UWMHVI_\`@,W^%8NF_P#GV_Z^1T0KQ_Y_1_#_
M`#*S>%Y?^@EH/_@RCJ*3PM+C_D)Z#_X,XZG?P7K^>-%U3_P&;_"HG\$^(&_Y
M@FJ?^`K?X5DZ3_Y]O\?\CHCB%_S_`(_A_F0GPK+C_D)Z!_X,XZ;_`,(K+_T$
M_#__`(-(ZD;P/X@`XT35?_`5O\*8/!/B'G_B1ZK_`.`K?X5/L7_S[?X_Y%K$
M+_G_`!_#_,B/A.4G_D*>'_\`P:1TC>$Y>VJ>'_\`P:1T\^!_$1/_`"`M6_\`
M`1O\*:W@;Q%_T`M6_P#`5O\`"A4G_P`^W^/^17UB/_/^/X?YC/\`A$Y?^@KX
M>_\`!I'1_P`(G*3_`,A3P]_X-(Z/^$&\1Y_Y`.K?^`C?X4I\#>(\_P#("U;_
M`,!6_P`*VC3?_/M_U\A?6%;^/'\/\Q#X4EZ_VKX>_P#!I'3#X3E_Z"OA[_P:
M1T\^!?$9/_(!U;_P$;_"FGP+XC)_Y`.K?^`K?X5M&F_Y'_7R,I5X_P#/Z/X?
MYC3X2F/_`#%?#O\`X-8Z3_A$IO\`H*^'?_!K'3CX%\1X_P"0#JW_`("M_A3?
M^$%\2?\`0!U?_P`!&_PKIA3?\C,)5XW_`(T?P_S&MX2E(_Y"OAW_`,&L=,_X
M1&;_`*"OAS_P:QT]O`GB0_\`,`U?_P`!'_PIC>!/$HZ:!J__`("/_A73&F_Y
M69RKQ_Y_1_#_`#&2>$)O^@MX;_\`!M'4!\'38_Y"WAO_`,&T=3/X"\2G_F`:
MO_X"/_A4+>`/$W_0O:Q_X!O_`(5WTUY&4JT;?Q8_A_F1-X-FS_R%_#7_`(-X
MZA;P9,?^8OX9_P#!O'4Q^'WB?/'AW6?_``#?_"H6^'OBD]/#FM?^`;_X5UPB
M^QBZR_Y^K\/\R)O!4_\`T&/#'_@XBJ%_!,W_`$&?"_\`X.8JF?X=^*NWAS6C
M_P!N;_X5"_PY\5G_`)EO6_\`P"?_``KJIJQC[57_`(J_#_,8/!$X!_XG/A;_
M`,',51MX(GY_XG7A7_P=15(/AQXKP?\`BFM;_P#`)_\`"HV^&_BS_H6=<_\`
M`)_\*ZHOS$ZJ_P"?J_#_`#(6\#3Y_P"0UX4_\'<5-_X0:?\`Z#7A3_P=Q4YO
MAKXMS_R+&N?^`+_X4G_"M?%O_0LZY_X`O_A6\/4CVJ_Y^K\/\P_X0:?_`*#?
MA3_P=Q4?\(+/_P!!OPI_X.XJ:?AMXNS_`,BQKG_@"_\`A2?\*V\7_P#0KZY_
MX`O_`(5T*2M\1G[5?\_%^'^8\^!IQ_S&_"G_`(.XJ3_A!Y_^@WX3_P#!W%33
M\-O%YX_X1?7?_`%_\*3_`(5GXO\`^A8UW_P!?_"J3O\`:1#J+_GXOP_S'_\`
M"#S_`/0;\)_^#N*G#P/-C_D-^%/_``=Q5%_PK/Q?_P!"QKO_`(`O_A3U^&GB
M['_(L:[_`.`+_P"%%[?:%[1?\_%_7S)4\$3#/_$Z\*G_`+C45._X0F;_`*#7
MA7_P=15$OPU\6_\`0LZY_P"`3_X4[_A6WBT?\RSKG_@$_P#A237\PG45OXB_
MKYC_`/A"9_\`H->%?_!U%3O^$*F_Z#7A;_P=15%_PK?Q=_T+&N?^`+_X5(/A
MOXL_Z%K7/_`)_P#"G=?S$>T7_/Q?A_F+_P`(5-_T&O"W_@ZBIR>"IQG_`(G/
MA;_P=14S_A6_BS_H6M<_\`G_`,*5?AQXL&?^*9UO_P``G_PHYE_,'M%_S\7X
M?YDA\%3]M9\+?^#F*C_A"Y_^@SX6_P#!S%3/^%<^+/\`H6=;_P#`)_\`"C_A
M7'BS_H6M<_\``)_\*7,OYD3*HK_&OZ^8?\(3/_T&?"O_`(.HJ/\`A"I_^@UX
M5_\`!U%3/^%<>+?^A9US_P``G_PH_P"%<>+/^A9US_P!?_"JC)?S$^T7\Z_#
M_,5O!,_;6O"O_@ZBIO\`PA4W_0:\*_\`@ZBH/PW\6'_F6=<_\`G_`,*0_#7Q
M8`2/#6N$_P#7D_\`A577\R,IU%_.OZ^8O_"$S_\`0:\*_P#@ZBIG_"#S_P#0
M:\*?^#J*F_\`"M_%W_0LZY_X`O\`X4?\*W\78_Y%C7/_``!?_"M8M+[2.:4U
M_.AW_"#S_P#0:\*?^#J*C_A!I_\`H->%/_!U%31\-_%W_0L:Y_X`O_A2_P#"
MM_%P_P"98US_`,`7_P`*UC)?SHYZDM/B0O\`P@T__0:\*?\`@ZBH_P"$&G_Z
M#7A3_P`'45(/AOXNS_R+&N?^`3_X4O\`PK;Q:?\`F6-=_P#`%_\`"M.9/[:.
M"I)=P_X0:?\`Z#7A3_P=14]?!$X'_(:\*_\`@ZBIG_"M?%O_`$+&N?\`@"_^
M%/7X;^+0.?#.N?\`@$_^%7SK^='G56A?^$(G_P"@SX6_\'45*/!$^?\`D,^%
MO_!U%2#X;^+/^A9US_P"?_"E'PW\69'_`!3.N?\`@$_^%:QFK?&OZ^9YM7T'
M?\(1/G_D,^%O_!S%4@\$S@?\AGPM_P"#F*H_^%;^+/\`H6M<_P#`)_\`"I%^
M'/BL?\RWK?\`X!/_`(5I&HO^?B_#_,\FNO[K%_X0F;_H,^%O_!S%1_PA,W_0
M9\+_`/@YBH_X5SXK_P"A;UO_`,`G_P`*4?#GQ4>OAO6Q_P!N3_X5M&HO^?B_
M#_,\FM!O_EV_Q_R$'@F?)_XG/A?_`,',5*/!4RG_`)#/A?\`\',5'_"N/%6"
M?^$;UO/_`%Y/_A0/AUXK_P"A;UO_`,`G_P`*U55?\_%^'^9Y%:B_^?3_`!_R
M%_X0F?\`Z#'A?_P<Q4C>"9L_\AGPO_X.8J7_`(5UXJ_Z%O6__`)_\*7_`(5Q
MXJ/7PYK?_@&_^%5&JK_Q%^'^9YM2A+_GS+\?\B,^"9S_`,QGPM_X.8J!X)G_
M`.@SX6_\',5._P"%;^*CU\.:W_X!/_A2?\*X\5`\>&];_P#`)_\`"ME67_/U
M?A_F>?/#RO\`P)?C_D-;P1.1_P`AGPMS_P!1F*E_X0B;:/\`B<^%O_!S%2-\
M./%9)QX:UO\`\`G_`,*7_A7'BOC_`(IO6_\`P"?_``I^U7_/U?A_F<U3#2_Z
M!Y?C_D-;P1.<?\3GPM_X.8J!X(G`_P"0SX6_\',5*?ASXK[>&];_`/`)_P#"
MA/AQXJ/WO#>M_P#@$_\`A1[9?\_5^'^9S_5I?]`\OQ_R`>"9\_\`(9\+?^#F
M*I?^$*G/_,8\+_\`@YBIH^&_BH8_XIO6_P#P"?\`PI__``KKQ3_T+>M?^`3_
M`.%+VJ_Y^K\/\P6%E_T#R_'_`"'KX+F'_,8\,?\`@XBJ5/!DP'_(8\,_^#B*
MHU^'?BG_`*%S6A_VYO\`X5-'\//$^.?#NL_^`;_X5FZJO_%7X?YFD<)*_P#N
M\OQ_R)(?!DP;_D+^&C]-7CJTG@^;/_(6\-_^#:.H(_A]XE4_\B_K'_@(_P#A
M5E/`7B7OX?U<?]NC_P"%9RJK_GXOP_S.B&%E_P!`\OQ_R)X_",O_`$%?#I_[
MBL=7(O"DH`_XF?A__P`&D=58_`GB,==!U8?]NC?X5;B\$>(0O.AZJ/\`MU;_
M``K&=5?\_%^'^9VTL-+_`)\2_'_(M1>%I1_S$M!_\&4=7(?#,O\`T$=#/TU%
M*K0^"]>`YT74Q_V[-_A5R'P=K:]='U(?]NS?X5RSJ+^=?U\SOI4'_P`^9?C_
M`)$W_"-R?\_^B_\`@P2BG?\`"(ZW_P!`C4?_``';_"BLO:+^='5[!_\`/I_C
M_D?2-%%%?(GZH%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!135D5RP1E8H<,`<X/H?SIU`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`>2_`TG_`(3#XS9)./'QZG_J
M%:?7K5>2?`W_`)'#XS?]C\?_`$U:?7K=`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`5P?QW\"7GQ,^#GC'PQHM]>:9J
MFKZ1/%I]Y:7#02P707="P=2",2*F<'D9'>N\HH`_,K_@CG\;O$/B.]^)/P_^
M(FLZQJNJ:<\.J6?]J7DEQ+$`3!<)ER2`&$/'J3ZUSG_!4[XK^,/%/[2WPW^$
M7PFU_6])OOL\*S+I=_+;>;=W\X2-9/+89VI&C#/02&LJWLQ^R=_P5Y1`%L?#
MGQ&NV,9)VHT6I*?P`6]7'MMJ;]D+2O\`AJO_`(*7?$/XJWP-SH7@N[N+JP<\
MJS#-I8C_`+](T@]XZ`/L[]LRSN_AE^PAXULO#>JZI!=>'?#=K;6VI+>2+=$Q
MRPIYAESOWL`23G)R?6OS+_9._9O^/7[77@S5_$G@GXQZCHUKHVJ'3Y8=5\1:
MB'=_*23<OE[AMQ(!R<Y!K]0?^"B/_)EGQ5_[!$?_`*415\[_`/!$L'_A0/CH
MXX/C`\_]N=O0!]#?L/\`[/GC_P#9V^'^O:+\9/&4?C34]2UDWEK=I?7-UY,/
MDQIY>Z<!A\R,<#CFO=O&7B2W\&^$=<U_465;70].N+Z<L>`D4;.WZ*:V*^8_
M^"DWC[_A7W[&OQ!GBD,=SK=M%H\&#@L;F58W`_[9&0_A0!^>W_!,+]I/Q9K/
M[8R:=XZ\3ZYJMGXWL-0@6VO]2FGABN/^/E2B.Q"G]TRC`Z-BOVEK\"?#_A9O
MV:=7_9.^*2)]G_X2$MJ.H2XV[UCU-PV3[VLT8^E?OJK!E#*001D$'K0!^,O_
M``4<\4>-[S]O&+P=X.\:>(_#UOKD6C64*6NJW$,$$DX1-Y1&`ZMDX&36+\6#
M^TU_P3;^('A_4]5^(E]XHT/6I6>W:74KB]L-0\HKYD$T,W,;[6'*\X.5;@XU
M?V]@3_P5#\*@<DZEX9_]&15[5_P6W\::+_P@7P]\*+=VTGB!M9EU)K97!DAM
MEA:/<PZJ&:08SUV'KC@`_0GX2_$2R^+?PQ\+>--&1HK/Q/I-O?QQ,<F+S$#%
M">Y4DJ?I76UX+^P?H5WX<_8^^%-EJL;17!\/17!1@00LS-*F0?\`9=:]ZH`\
MD^!O_(X?&;_L?C_Z:M/KUNO)/@;_`,CA\9O^Q^/_`*:M/KUN@`HHJCKFMZ?X
M:T:]U;Q!>6VG:9IMN]Q>7=S((XH(D!9G=CP%`!))H`O45XO_`,-H_`;_`**_
M\//_``?P?_%5M^#/VF_A-\1/$5MH/@3XC>#M?UJ\#FWL-/U>*>:4*I9MJ*Q)
MPH)/L#0!Z;1110`4444`%%>5_&[]J#X9_LYMI*_&+Q/!H$FN>:;"-K::X>81
M[=YVQ(Q`&]1DXZU0^"O[7OPG_:&\07VB?"'Q4FO:GIUF;VY@%A<0;(0ZH6S)
M&H/S.HP#GF@#V.BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/S/_P""
MU7PV0^#_`(>_$O3)/LVJ:'JC:1++&VV1DE5IH6!'.4>%\?\`70UZ5_P2`^%U
MOX-_9<;Q2VR34?'NKSW<L@ZK!`Q@BC)]F25O^VE9W_!9W_DU?1?^QRM/_2>Y
MKT[_`()?_P#)D7P\^E__`.ET]`&[_P`%$?\`DRSXJ_\`8(C_`/2B*ORG_8L_
M8\^+/[1G@'7-;^#_`,2(?!FFZ;K!L[JS?4[RV,TWDQOYFV!2I^5U&3SQ7ZL?
M\%$?^3+/BK_V"(__`$HBKYV_X(E_\D"\=?\`8X'_`-)(*`/IW]C#X'^-/V?O
MA!-X8^+/BF/Q?K<FL7%XNH)=SW`$+I&JQ[I@&X*,<=/F^M?)/_!;7QXUI\/?
MASX)M9"9-:UBXU.:)>I6WC$:?FUPW_?-?I=7XQ?\%.]4U_XP_MW>'/`WP[M%
MU;6]`T^PT_3K'<FV6\E9KD@[B%`Q)&#DXPO-`'JO_!3KX,CPG^Q'\%&MX=DW
MP_>RTJ;8.%6:R"R$_66!/S]Z^]_V7?'_`/PM']G;X=>*'<23:MX=M'N6W;OW
MZQA)>?7S%>OS)_:>M_VW_'WP1\26'QU\*:-_PA-C`NHZI);)IXD@CMV$OF*8
MY2_&W)VC.,BOJ/\`X(^>/_\`A*_V4#H<TI>X\':_=604GE89=MPGX9ED'X4`
M?%'_``4OT"Z\5?\`!0VUT32;PZ=?:PFAV=M>`D&VDE"(LF00?E+`\'/%8_[!
M_P"SCX7^/'[4OB7PI^TGJ.M7FN>%?-N/[,EN"1JL]M/Y<\4\K$N0IVG:N"P#
M<@#GL_V]O^4H7A7_`+"7AK_T9%6O^V+%+^QQ_P`%)/#/Q3TF.6#0_$MQ!K-T
M(^!(LA-OJ,8]V7<_UE%`'["6UM%9V\5O:11P00((XHHU"JB@8"@#@`#C%2U#
M97D&HV<%W8RI/;742RPRH<K(C#*L#Z$$&IJ`/)/@;_R.'QF_['X_^FK3Z];K
MR3X&_P#(X?&;_L?C_P"FK3Z];H`*\X_:0\-ZGXR_9_\`B-H7ABSDU#5]8\+Z
MA:6-I&RJT\TD#JB`L0`22!R0*]'HH`_FO^+?[*7Q8^!.@6NM_%KP7J'AS2KV
M[%G!<W$\+J\Q5G"81V.=J,>1VKUO_@EA_P`GN>!/^N&H_P#I#-7W7_P6L_Y-
MR\(?]CE%_P"DES7PI_P2P_Y/<\"_]<-1_P#2&:@#]]:***`"D)P.:6OF;_@H
MA^T#_P`,^?LR^(;_`$RY$'B/Q*IT71-K8=9IE(>5?^N<0D<'^\%]:`/R&_X*
M&?M`']H3]IKQ%J.FW/G^'?#C?V+HFULHT$#,'E'8^9*9'![J5]*]\_X(F?\`
M)P/CC_L36_\`2RWK\[:_1+_@B9_R<#XX_P"Q-;_TLMZ`/V6HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@#Y5_X*.?L[>,?VF?@;IGA7X6PZ?/JUKXB@
MOY5OKL6Z"%(9D)#$')S(O'UKM?V(OA#XB^!/[,_A'P1\0([2'7=&^U_:DM+@
M31CS+J61<.`,_*Z_C7NM<'XK^/?PU\"ZW-HWC7Q]X/T'5K=5:6QU'6H+>:,,
M`RDH[`@$$$<<@T`<U^UY\,M<^,O[-WCKP7X(CMI=<U^P2"S2YF$,9831N=SG
MIPIK\T_AK^PA^VE\'-)NM+^%OB>S\,:?>W/VFXMM.\4+$DLNT+O("]=JJ/P%
M?J%IO[3'PCUG4;6PTGXF^`[V^OID@MK:#Q!;2232.0JHJA\EB2``.I-==XQ\
M=>'/AYI`U7QYKND^'=,,JPB\U.\2VB\QL[5WN0,G!P/8T`>&_L/>!/C5X`^'
M^O6?[5&OR>(/$%QK)ETZ=]3^V^7:>3&-N[`Q\X<X]Z^?/A9^Q-\41_P4+U3X
MV?$ZTT:+PRVL:C>V/D:FLTP5HGAM`4`XPA3/IMK]!-$US3O$ND6FJ^'KZTU/
M3-0A6:TO+2998IXV&0R.I(8'U%<_XE^+W@?P9XAL]!\7>+_#6BZWJ`0VFG7^
MIQ07$X=BB;(V8,VY@5&!R1B@"_X_\+Q>-_`GB/P[<@&+7M)NK!\^DT3(?_0J
M^*_^"9?[*'Q7_96U+QU9_%>UT:+1?$<%I-:O8ZDMPRW,+.""H`P"DG7_`&17
MW#XC\2Z3X/T2ZUCQ7J5CH^DV*A[J^OIU@AA4D`%W8@*,D#D]ZX"/]J?X-2R*
MD?Q5^'A9V"J/^$DM>2>G\=`'QE^U3^PQ\4OBW^V[H?Q0\'VNB2>%=/O-%EED
MN-26*;;:NAEQ&1G^$X]:]B_X*1_LBZU^U7\,/#\/PZATY_%WAK5?-M6O9Q`K
MVLJ%9X]Y!Q\RQ-_P"OK+2]5LM;T^"^T6\M;^QN4WP7-K,LL<J^JLI((]P:M4
M`>/_`+)/A7QSX#_9]\(>%_C-#:1>)O#=G_9TCVMX+E)H(B5@??Z^4$!]U->P
M444`>2?`W_D</C-_V/Q_]-6GUZW7DGP-_P"1P^,W_8_'_P!-6GUZW0`4444`
M?GK_`,%K/^3<O"'_`&.47_I)<U\*?\$L/^3W/`O_`%PU'_TAFK[K_P""UG_)
MN7A#_L<HO_22YKX4_P""6'_)[G@7_KAJ/_I#-0!^^M%%%`!7X<?\%:OV@?\`
MA:_[1!\'Z+<F70/AO$UCA6.R2_?#7+_5<)%[&-O6OUP_:F^-]K^SO\!_%OCF
M[:,W6F61CTR%R/W][)\D"8[C>P)_V58]J_#O]B'X*7?[4G[5&AZ?XD$NH:;'
M=OKOB>>7YO-@C<.X<^LLC)'_`-M">U`%O]I_X`K\!_@-\!!J=K]G\2>,K#5-
M;U@NF'7S6M?(A/<;(=F0>C,]>]?\$3/^3@?''_8FM_Z66]=;_P`%Q%">)OA$
MJ@!1I^J@`#I\]M7)?\$3/^3@?''_`&)K?^EEO0!^RU%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%?B#_P4%\(VGC__`(*7#PQJDL]O9>([_P`/:=<S
M6^/,CCFAMXV9<@C<`Q(R"*_;ZOQ4_;>U*TT;_@JGI&H:O=065C8ZYX9GNKFX
MD"1P1HELS.S'@*`"23T`H`^N?`O_``1\^%O@'QOX?\3Z9XN\>7%YX=U2VU&W
MBN)K4QR202K(JMB`':2HS@@U=_X+&#_C$.+_`+&RP_\`1<]?3NA?M)?"CQ1K
M-GI'AOXD>"-4U34)1#:6=GKMO++/(>BHBN2Q/H*^8O\`@L9_R:''_P!C98?^
MBYZ`,3_@CG\;CXY^`NJ>`=4GWZE\/K__`$56;)-A<EI(_P#OF43+[#:*\)_X
M*7`?\/#?@]P.;;0__3G+7G?[%6I7/[*/[0/P1\2W<\B>$?CAX=-E>2R'")*]
MT\&W/3Y)XK=R>RRUZ+_P4N_Y2&_![_KWT/\`].<M`'W)_P`%&1G]BCXJ9_Z!
MD'_I5#7YO_L!?L`^"/VNO@QXJU[Q=K?B/1-=TO7VT^RGT]XFA6,6\4@+Q.A+
M'=(>C+P!]:_2'_@HS_R91\5/^P7#_P"E4-?/O_!$S_DWWQQ_V.3?^D=O0!\Q
M?`#X@>./^"='[97_``JOQSK4E[X)U'4H;+48=Y^RR07.W[/J$2$D1NN]2V.P
M=3G`(_:^OQI_X+4:.NE_M#>"=:M0L<U_X51792=Q>&ZEP?R=?RK]=_`&LGQ%
MX#\-ZJQ8G4](M;HEA@GS(E;D>O-`&_1110!Y)\#?^1P^,W_8_'_TU:?7K=>2
M?`W_`)'#XS?]C\?_`$U:?7K=`!1110!^>O\`P6L_Y-R\(?\`8Y1?^DES7PI_
MP2P_Y/<\"_\`7#4?_2&:ONO_`(+6?\FY>$/^QRB_])+FOA3_`()8?\GN>!?^
MN&H_^D,U`'[ZT444`?D)_P`%G?V@#KWCCP]\)-#N";+PU&NJZVJ,</>3+B"-
MA_L0DM_VW]J]@_X)'>!O"7PE^"NH^-O%OB#PY8>)/'MSF.*YU2!);?3X&98E
M*ELJ7D\QR.X\OTKXK_X*;>']4O\`]M;X@S6.F:C<0L;#;)%:NRM_H4'0@8-?
M+?\`PB>N?]`;5?\`P"D_PH`_1C_@M7XHT;Q-XD^%#^&]7TO5E@L=4$IL;R.?
MRR7ML;MA.,X.,^AKD_\`@C/XCTGPU\>?&MQXCU33M*@D\(,B2WMTD"LWVNW.
MT%B`3@$X]J^"+[2KW2R@U.SNK0R`E!/"T>['7&1S3;'3;O4Y&CTVUN;MT7<R
MP1-(0/4@#I0!_4Y!/'=01S6TB30S('CDC8,KJ1D$$<$$=ZDKA_@9&T7P3^'R
M.C1LGA;3%*,NTJ1:Q\$=J[B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MOQ"_X*"^$K7Q_P#\%+U\,:K+/!9>(K_P]IUS+;D"2..:&WC9DR"-P#$C((S7
M[>U^+?[:$B0_\%8-`DF=(XT\0^%F=W8*J@+:Y))X`]Z`/L?X2?\`!)OX8_!W
MXF>&_&WA_P`4>-[O4?#.H1WUM!>3VQBD=#D!PL(./H15?_@L9_R:''_V-EA_
MZ+GK[/B\6:'/*D4&LZ5)+(P5$2]C)8GH`,\FOC#_`(+&?\FAQ_\`8V6'_HN>
M@#Y^^)7P:D^(O_!)+X6^*]%C?^W?AK%)JT$L?WQ:M=RI<`'L`/+E/_7&O%/C
MW\9HOC]^T+^S1XV$JR7VHZ-H,.J@$'R[Z'4Y8YP?3+J6'LPK],/V"-`L?%7[
M!/P^T778%N=-U?0+RSO(6Z2127$Z.I^JDBOQI7X::A\&?VQM(\":TTKR^%O'
MUG:1,Y/[R(7D9CD`[!T*/_P*@#]I_P#@HS_R91\5/^P7#_Z50U\^_P#!$S_D
MWWQQ_P!CDW_I';U]!?\`!1G_`),H^*G_`&"X?_2J&OFS_@C1XCTGPQ^S?X]O
M?$FJ:=I-G!XO=Y;B^ND@CC46=ODLS$`#@\GTH`\9_P""W%U&_P`:/AY;*3YT
M7A>21QC@*UTX'/U1J_5WX26<FG?"GP7:7.WSK7P]812;3D;EMT!P>_(K\6OV
MG?&MO^W;^W[HNC_#1WU/09KRRT#3;I$($UK$Y>YN0#SL!:=P?[B@U^YMO!':
MP1PVZA(H4"(HZ*H&`*`)****`/)/@;_R.'QF_P"Q^/\`Z:M/KUNO)/@;_P`C
MA\9O^Q^/_IJT^O6Z`"BBB@#\]?\`@M9_R;EX0_['*+_TDN:^%/\`@EA_R>YX
M%_ZX:C_Z0S5]U_\`!:S_`)-R\(?]CE%_Z27-?"G_``2P_P"3W/`O_7#4?_2&
M:@#]]:***`"BBB@#\E_^"XQ_XJ?X1#M]@U7_`-&6U<C_`,$3/^3@?''_`&)S
M?^EEO77?\%QO^1G^$?\`UX:K_P"C+:N1_P"")G_)P/CC_L36_P#2RWH`_9:B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBD)`ZD"@!:**Y+XA>/(O!&GQ
M.D7VJ\N'`B@!_A'WF/M_6N+,<QPV7X6>*Q,N6$5=O^MWV1OA<-5Q-:-&DKR>
MQUM%9^@ZW;>(M)M]0T]B8KA<X/5#W4^X-7R<#)X%=%"M3KTXU:;O&23375/9
MF=2$J<G":LUN+1116I`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!7PK^U/_P`$M[']ISXTZO\`$&[^(EYX?DU:"VB-A'H:W*Q^3"D6=YF7.=F>
MG&:^ZJ*`/S<^'/\`P1GTSX??$'PQXIC^*E]?/X;UBTU);5O#B1B<P3+($+>>
M=N=N,X.,U]:_M>_LS0?M8_"9/`]YX@E\-1KJL&H?;8K(71)B5QLV%UZ[^N>U
M>W44`>=?L\?!Z/X`_!CPO\/[?5)-;C\-6SP+?R6X@,^Z5Y,E`S;<;\=3TKP?
M]H3_`()V:'\=?VB?#_Q:M_%5QX<U'27L)+VQBTQ;A;^2TEWHY<R*5)0)&>#P
M@-?7M%`'G/[0_P`'H_C]\&/%'P_N-4DT2/Q+;)`U_';B<P;94DR$++NSLQU'
M6O@6'_@A[I*E4N/B_JKV^\,\:>'$7/TS<$`^^#7Z@44`?.7[*_[!_P`-?V3W
MN-1\'0WVL^)[R'R9]>U9E>=8R<F.)5`6)3@9P,G`RQ`%?1M%%`!1110!Y)\#
M?^1P^,W_`&/Q_P#35I]>MUY)\#?^1P^,W_8_'_TU:?7K=`!1110!YC\??V<O
M`_[2_A>P\/?%JPN]1TS3;\7UO';7LEL5F".@)9""1M=N#Q7G?P?_`.">WP6^
M!7Q`TWQI\.="U2RU_2EE6UFFUFXG11)&T;Y1F(/RNW6OI*B@`HHHH`****`/
M%OV@_P!D'X9_M/WFB7/Q?TJ^U*;P_'-'8&VU*6U"+*4+Y"$9R47KZ52^`/[%
M'PJ_9F\3:AK_`,)-'U#3M2U.P-C<R7&J37*M"9$DP%=B`=R+SUKW:B@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`KP7]M;Q!=:'\#KQ--EE@N-0OH(%E
MB<HR#=N.".1]VO>J\>_:O\+MXF^"NL^3&9)M,,=X@`R<(WS?^.DUYV;PG/`5
MHT]W%_D>_P`*U*5/.\).K\*G'\_\SY2^"/[5_C;P'-!:>+[B;Q/H60K)=/FX
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M0D:^RC`KU[6_#S7NJ:?96\;,]U<I$%`Y)+`?R.:_5Z/!N'X3P]'`N7/-03D^
MB;;O&/DMD^N^BT7\1^.]3-Y9[2PM&LU3E",G&.B<FY+6VKV5D]/(^Q=)NOMN
MEV=Q_P`]X$?\U!JW4-G;+9V<$$8`6&-4&/0#%35\4]]#]?I*2IQ4M[:A1112
M-`HHHH`****`"BBB@`HHHH`****`"L+QIHFK^(-!EL_"WB*Z\+:@[HR:E;6<
M%T\:@Y90DRLAR.,D9':MVB@#Q[_A4OQ-_P"BZ>(O_"6TC_Y'H_X5+\3?^BZ>
M(O\`PEM(_P#D>O8:*`/'O^%2_$W_`*+IXB_\);2/_D>C_A4OQ-_Z+IXB_P#"
M6TC_`.1Z]AHH`\>_X5+\3?\`HNGB+_PEM(_^1Z/^%2_$W_HNGB+_`,);2/\`
MY'K`\1_M[?`CPEXWOO"'B#Q]:VGB+3=1;3KJR.G7;&.Y5]AC++$5X;C(./>O
MH"@#Q[_A4OQ-_P"BZ>(O_"6TC_Y'H_X5+\3?^BZ>(O\`PEM(_P#D>O8:*`/'
MO^%2_$W_`*+IXB_\);2/_D>C_A4OQ-_Z+IXB_P#"6TC_`.1Z]&\;>+K#P!X.
MUSQ-K_G_`-F>'M.GU"\\B/?)Y4,9=]J]SM4X%4OAA\1=)^+GP^T'QEX3^U?V
M/XCLDO++[5%Y<OEMTW+DX/XF@#AO^%2_$W_HNGB+_P`);2/_`)'H_P"%2_$W
M_HNGB+_PEM(_^1Z]AHH`\>_X5+\3?^BZ>(O_``EM(_\`D>C_`(5+\3?^BZ>(
MO_"6TC_Y'KV&B@#P;0/V>/'/AF]UR[T;XV^)89_$>H_VCJ+-X:TEO,N/)BAW
M`&#Y1Y<,8P.,@GN:V/\`A4OQ-_Z+IXB_\);2/_D>O8:*`/'O^%2_$W_HNGB+
M_P`);2/_`)'H_P"%2_$W_HNGB+_PEM(_^1Z]AHH`\>_X5+\3?^BZ>(O_``EM
M(_\`D>C_`(5+\3?^BZ>(O_"6TC_Y'KV&B@#Q[_A4OQ-_Z+IXB_\`"6TC_P"1
MZ/\`A4OQ-_Z+IXB_\);2/_D>O2O%_BBR\$>$M;\1:WYW]G:!IUQJ%WY*;W\J
M&-I'VKW.U3@=ZR_A7\2M'^,7P\T+QIX0^U_V-XBM!=6?VN+RI=A)'S+DX.0>
MYH`XG_A4OQ-_Z+IXB_\`"6TC_P"1Z/\`A4OQ-_Z+IXB_\);2/_D>O8:\\^)/
MQS\-?"KQ?X#\->*?[1_M+XBZH^FZ-]FMO,3SE"D^:V1M7YUYP>]`&#_PJ7XF
M_P#1=/$7_A+:1_\`(]'_``J7XF_]%T\1?^$MI'_R/7L-%`'CW_"I?B;_`-%T
M\1?^$MI'_P`CT?\`"I?B;_T73Q%_X2VD?_(]>PT4`>7^'?AKX_TK7+*\UOXO
MZYK=A;RA[C3IO#NF0)<KW0O'"'4>ZD&O4***`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Y/XL_$.P^$_PT\3>,=<95LO
M#FESWL@/\91"54>Y;`_&NLK\ZO\`@LO\;_\`A%?A'H/PWTJ?9?>,KO[7J"JV
M"+.W((!]FE*_]\&@#YETS_@LE\:4UJTEU?3?!SZ5]J4W$,6FR!S#N&Y5;S/O
M;<C..M?LQX1\4:?XV\+:3X@\/S+<:;K5E%>6DJG(>.10RG\C7XG>._V19=&_
MX)J^#OB2M@RZ]'KDFJWS>7\_]FW6(HLG^Z"D3C_KJ:^U/^"0/QU_X6'\`+KP
M/JUP9-6^'UUY4(=LLUC,2T6.^%82)[`**`/O2BBH+V]M]-LYKO49X;6UMD,D
MTTSA$C0#)9F/``'<T`3T5A^'_'7AOQ7/+#X7U_1=8F@0/+'87\<[(I.,D*Q(
M&>];E`!165K_`(JT7PI;Q3^*-7TS2()GV1R7UVD"NV,[06(!.!G%3Z+KNF^(
M[!+[P]J%EJ=E(Q5+FSN%FC8@X(#*2,@\4`7JAO+2&_M)K:\C66"XC:.6-AD.
MK#!!^H-9_B#Q;H?A.**3Q3K.EZ/'.Q6)[^\2W$A')`+D9-9GBOXJ>#O`WA=/
M$?B_Q/H>D:#*`8M0NKZ-(9<]-C9PY/HN:!IM.Z/G;6_@O+X$UZ:R2-I=(F<O
MI\Y&?D/\#?[0Z>_6N0U/X(175RSPPC:6)!(Z@U]0^!OC-\-_C7;30^`/%OAO
MQ2L?,L%E>I+(GN4SN'UQ3M=N_!_A"Z6UU[Q!H>D2RIYD<&HW\4+LN<9`8@D5
MW<+YA6R#$U)X=VA4W7IM^;^\^KK\45L32C[7XX]>_P#P3QGX7_"J'P[)<ZA+
M$$V1^7$/?^(_RKT_P!\/S+XA_P"$@U6+;';Y^PQL.K$8+D>W:N\T_2-/NK:W
MN+9X;JUD020-&0T;J1D,".&!'.:AUCQ[X8\-WZ6&O^(=#TN]=0R6UWJ$4,C`
MG`(5F!P3TKNS3.ZV.JRJ2>KT^1^:X[)UF6;K,,5KRVY5Z;-^F]NYOT5A>+?'
MGAOP#I!U3QOKVD:#IP_Y>M1O8[>,_1F(!_"O/?#_`.U_\%/%&J+IVA?%#P9<
MWKN$2(ZI'&78G`"EB`3]*\,]X]?JCKMY)IVB:A=V^WS;6UEE3<,C<J$C/XBK
MD<BRHKQ,KHX!5E.00>A!IEU'#+:S)>!#;O&PE#_=*D<Y]L4`?FM^PI_P4.^*
M/[1G[1L?@?Q_#X931FTZ\N"UA8-%+OBQM^8N>.?2OTNKQ?X7?#3X"^&/&*ZA
M\(-)^'EIXF$,BB717@-SY;8\P?(2<=,U[10`451UK7=-\.:?)?>(=0LM,LH1
MF2YO+A88T^K,0!7D6H_MJ_`G2KLVU[\5O!8E4X(CU)91UQ]Y<C]:`/:Z*Y'P
M-\7?!'Q.C9_AYXM\.^(Q&,NNFZC%<,GU522/Q%==0`4444`%%%%`!1110`44
M44`%%%%`'YQ?LV?'CP+\-/VH/C_X7\=6.J7>L^*_BM)%I;VVA27L2%Y6C'F2
MJI$8WL.N,#FO3/C7^VYX[\.?$#XG:=\%_!/AWQ!X<^"-C;7GC2\U?498)[GS
M5WM%9K&I`9$#99\\JW'`W:W[#VGW=E\8OVI'O;6ZMX[KXFSR0--"R"5?WGS*
M2/F'N*^;_C'JG_"@_B;^UWX;\9Z;KCWOQPT:&3P,UGI<URFKRRQ2QM"C1H0'
M1YL$$CA#ZC(!]/?%?]M34_#^D_`;4OA+X1@\5I\;W*V=G=WWV66`M%$\:[\%
M5(:4AR<A0A.#7T1X7N/%DG@&TG\8V>AQ>,C8%KNTTZXD:R%U@X1)'&_9G`R1
MGKQ7P?KOPSU_X?1_L%>'=<T^[&I>'=39=62.%G%G(88&9)",A=I)7)[J:_16
M@#\O_@9KGQ$U'PI^VM%XWTK0K?3R=??5GM=5EN'L]3^S28MX%9<-;[3(=Y(.
M548YXZK]D_\`:5^(WPR\,_LT>#/&/@WPU%X`^)&F_P!EZ+J-IJDDNHK)"F1-
M,A4(JL60A!DA6Y;(VUH?#'2+^+P/^W>LEA?(U]X@UUK16MG!N`;68`QC'SY[
M8SG-<OHNB:DOAW_@GTK:=?@Z?=S?;!]F?_1_W4/^LX^7\<4`>Y?%W]K_`,>6
M/CGXGZ7\"O"OA77-(^".EQ:AXQNM=U":"6[9XVE:VLA&I`=8D<EWR-PQCIGZ
M*^#?Q/T[XT_"SPOXY\/12V]AXGTV*]C@E8,\!8?-&Q'!*L&4D=UK\S?BM\/O
MAA\,OVH?CY<_M3>#O$&OOXI,6L_#Y+0ZA'!K4DB.7LPUKQO,C(AWYQM8\=_T
M>_9S\.Q^%?@;X*TVW\*+X&6+2(I#X<%Y)=?V6TG[QH#+)\S%6<@YYSD=J`/!
M+G]NJ_\`#7P=^.GB/QOX>TVR\4?![Q))HD6E07#F/4"[(EG)DC<!(S,>/X5)
M%=/\1_VF/&WAN+X0>"_#'AOP[)\7_BO9FY-CJ5Y,FFZ,D4`EN7F9!YKA<E%4
M`%BK<\8/SC^TE\&+WQ-_P47\)^$-(FC;PI\4?[*\4>+M/3^,Z/\`:%#2#LKJ
M%7W9O:ND_P""AWPX\/R?M$_!GQ_\9](U74_A/:6M[I'B6XT];C.GNRN]O)(;
M?]Z$+OU']PCG."`>BZ%^WE-;_L\_%SQAX[\-65CXU^#6IS:-K6CV5\7M;N]$
M@BA>&1AO$,DC=P6`5NO%1?!W]KOXGZ_\:/AC\/OB_P"!?#&AR_$/PK/XB2_T
MK4I9@D'EO)$GEN/DD`4!U+,!D$'L/#M6^%>A>.OV$?CU+^SK\+]1\*Z+JNK1
M3:([W-Y=W7BBSL9XY/MHAN/WD>5\W:HR3M/4UH?!KXFV?QE_;)_9TUGPCIFO
M#2-"^&%SIM[>W>F301)>I;R":!7=0&V,`I8?*2<`G%`'T#^SI^TY\1_V@/B+
MXJL+3P5X=TKP;X'\7ZGH>KZU+J<C37"P`B!;>';S)NVM(6(4*P"Y.<>@_M2?
MM`_\,]>`=.U'3-+CUWQ+XGUJUT'PYI<MQY$=S?7#$)YCX)6-0"Q('8#C.1Y%
M_P`$Z-.N].L_CN-1M+JT,_Q?UJ6+SX6C\Q"8\,N0,J?4<5E_\%2OAO<^,_A5
MX%UPZ1J&O:%X+\:6>H>)+#3T=IWTU@4G9-GS<`@$KR`V[(QF@#L/AO\`M5>+
M3XQ^*GP[^,F@>&[/X@?#;P]_;T4N@7<TFG:I:M")%V^:!(A4LBMG.=W&,<^8
M^`_V^/B?K8^"7B7QA\//"FF^`?C!K/\`8<,MGK$LU_#<F9XQ-L*A5BRN0IW,
M0K9*Y45G?L_:!\)=2N_C1K'[,GPYO[+PQ9^!I["+QM=7NHL^KW$L3/):1077
M)$?EIEASD`="*\U\.:#JB_LS_L-PMIFHB:Q^(\;W49M7W0+]LG^9QC*C!SD\
M8YH`]F_:4_:I\:^(_&OQK^%?PO\`!VC:QX<\!>`KN?Q;J5Y?R0W7^D6;'%JJ
M@H619`VU_O;'Y7C+?A+^T#<?`C]A3X!0>%])MM>\9>.Q9Z!X:TZZN#!`]U-(
M_P"]F<`D1(.6P,G('&<CRWXH>))O@G^U%^U;8^*-$UZYN/BYX$7_`(1`6&FS
M7"ZE(MB8F12BD#:3(6)("B)L]LX'Q2^%LVL?L1?LI>(_%>@:SJGA7P+J,#^,
M;"SAE%S#ITS@2RX3$BA1'@E<$;P<CK0!]:?#?]L+5;:]^,GAKX\Z)HVF>+_@
MMIG]K:B_AZZDELM4LF@,RO!YP#HV-JD-GEQSU`^7M6^.7Q"^/WQ+_9%\7_$S
MPCH?AS2?$'C>ZO/#TNE7TDS-;@QQE+A'&5DRH964X93G"XP>T^%/PY^'OQ!\
M`?M%Q_LH_#6\TW1-1\(2Z+HWBR[O[]Y/$US);.\D$<%URJQR!$WCJ2*\C^%W
MQ"C\=Q?L4^&-%T7Q&NH?#KQ+-9>)7GTF>**PN`R!8FD9`I8HN\@$[01G!H`_
M6^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`*_![]I;Q%=_MM?M_KX?\/2M/I=QK<'AW3'0DJEI"^V6;
MV!/FR9],>E?K9^VY\:T^`G[-/C+Q-%,(M3ELSI^DC/+7<_[M"/\`=R7^BFOR
M-_X)K?%+X8?!CXRZMX\^.>O'39]/TUH-&0VDEPTD\QQ))E0<$(",GKO-`'[7
M>,OA+HOB[X-ZI\.9K>--$O\`0FTA(\8$<?E;$(QW&`?PK\3OV$OB1?\`[*/[
M:4&@>+Y'LK*^U";PQKR.=JHQDV1R,/\`9E5#GL"U?IS_`,/1_P!G/_H=IO\`
MP4W'_P`17Y1?\%`/'7P\^(G[1=WXY^`^M'4+#Q!;PW5\RVTENT%\GRNP#`'Y
M@J-D=R:`/Z#J\E_:WY_9<^+/_8FZG_Z3/65^Q=\;H_V@/V</!_BN282ZG]D%
MEJXSRMY!A),_[V`X]G%:O[6__)KOQ9_[$W4__29Z`/S3_P""(W_)8OB+_P!B
MS#_Z4K7[#5^//_!$7_DL7Q%_[%F'_P!*5K]AJ`/SD_X+;?\`)#_`'_8UM_Z2
MRUZK_P`$F/\`DRKPS_V%=3_]*GKRK_@MM_R0_P``?]C6W_I++7JO_!)C_DRK
MPS_V%=3_`/2IZ`/$?^"WW_(@?#+_`+#%W_Z)%?)WPG^#WQ<_X**3Z'HNB7%K
MHW@OX9Z-;Z3#=7SO]DM"%YPJC,D\ARQP.!C)`Q7UC_P6^_Y$#X9?]AB[_P#1
M(KVO_@DUX5MO#W['6AW=O'&MQKNIWMY<R*.7/F>6N?HJ`4`>5?L6_P#!,CQ1
M^S?^T7%XQ\=ZWHNN:/I&ER_V9-ISR(SW<F$Q)&P!`5"QSDC.*\`_X+5?\G"^
M$?\`L55_]*):_9VOQB_X+5?\G"^$/^Q57_THEH`_5O\`9XX^`GPY_P"Q6T[_
M`-)DK\D_^"OM_P#V5^V!H=Z$$AM/#UA-L)QNVS2G'Z5^MG[/'_)!/AS_`-BM
MIW_I,E?D1_P63_Y.KT__`+%:T_\`1DM`'6_"W]DSXM_\%)M0/Q1^-WBR7PQX
M.G=H=$@6$S'R4.W;:P%E5(P1@R'EB"<&KW[1/_!'.]^'OP_U3Q-\'_&%UXFN
M-%M7NKG2-1LEAEGB1=S>2Z$@M@$[2!G'6OU!^`?AVU\)?!#P'H^F(L=KI_AV
MRBC"C`P(5Y_$Y/XUV>JPI<:7>13*&CEMW5U/<%2"*`/RH_X(^_M2^(]2\7:C
M\(/&FI76J:6^GO?Z`]W*9'LWB*B2!6)SL*MN"]!M..M?J9XL_P"16UG_`+!\
M_P#Z+:OP[_X)IH+;]OO28H!LC1]60*/[HBDP/TK]Q/%G_(K:S_V#Y_\`T6U`
M'XD_\$F1_P`9L1?]@;4__9:_:OX@>-M-^&W@?7?%7B640Z7X>T^:]NG)Q\D:
MEB![G&![FOQ4_P""37_)[$7_`&!M3_\`9:_;KQ%X<TOQ;HEYH_B>PM=4TK4(
MS%=6=U$)(ID/\+*>"*`/PJTV\^+O_!4?]H:;2KG69;+1T+W?V=W8V&@V*MA<
M1CAGY"Y^\S'J!T^P;7_@B-X"33!'>_$7Q9+J&SF>*RMTCW>OEG)Q[;J^EKS4
MOV:/V)]3U"],G@GX=:KKD2K=0VN?M%RBDLH\E-S`9)/W0*\V\4_\%>/@#H*R
MC2;WQ+K\T?W5LM(9%?Z-(5%`'YN_M4_LI>._V`/B#H&M>%_%5S/8:C([Z)X@
MT[=:3QRQD%HI5!.&P0<9*L,^A%?LC^QQ\;+G]H3]G/P?XUUA8UU6^M6@U+RQ
MA6N86,<C`=@Q7=CMG%?DQ^WY_P`%`]'_`&O?#&@>'?"GA'4-#L-"U0W_`-NU
M"Z1YI28FCV;$!"CYLYW'H*_0C_@DM_R97X;_`.PMJ7_I2U`'V11110`4444`
M%%%%`!1110`4444`%(5!()`)'3VI:*`"BBB@`HHHH`0J#C(!P<CVI:**`/`_
MA]\!M>L?VL?B-\7O'5QID\.JZ39Z%X2MK:1Y)+.QC`><R;E`5GE4,`I/4\U[
MV0"""`0>H-+10`@&!Q0``,`8%+10`4444`(JA1A0`!V`I:**`$P,YQR*6BB@
M!`H4`*``.@%``'0`9I:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHK/\0Z]9>%M!U'6=;G2VT_2K62ZN
MIF.`D<:EF/Y`T`?DQ_P6C^-XUGQIX5^%VDS[H-!@.JZJJ-P;B8;8E/NL88_]
MM*]"^!__``1]^'WBGX1^$]:^)6L>+[7Q-J^EQ7FHV]G<11Q0/(-XC`:,GY5(
M!YZ@U\9_"RROOVW?V][2]U=&DMO$_B5]3O4/(AT^`[]G/811J@_"OW_CC6&-
M8XE"(BA54#``'04`?`G_``Y@^#'_`$'_`!W_`.!L'_QJO+OVF_\`@DGX&^''
MP,\6^*OA7JOBR^\1>';$WT-K?3Q2QSQQD-*N%C!W>7N(P>H%?J=4%]90ZE97
M%I?1K+;743131MT=&!#`_4$T`?D5_P`$8/CK_87COQ+\+=8N"MKXC@_M/24=
MN!<PC$JCW:/!XZ^77Z1_M:(TG[+_`,5U12S-X.U,``9)_P!&>OPT\=:;JW[$
M_P"V==_V2)(9?`WB47=AV\^R9MZ#W5X7VGZFOWT$VB_&WX3F2PF6YT'QMH9\
MJ5"#N@N8>O'?#4`?E)_P1)N(X_C3\0(78"2;PS&47^]BY3/\Z_8NOY[]`U3X
ME_\`!-S]IN2YN]+87FER2VSQ74;+:ZW8,W5'[JP"L&'*D#T(K[GN_P#@MUX&
M&@&2P^'/BQ];,7%O-=VZVP?'_/4$L1G_`&,T`1_\%N]?M8OAG\-]$:1?MMSK
MMQ>+'GGRXX"A./3,JU[/_P`$F/\`DRKPS_V%=3_]*GK\Q_VFM4^+O[4/A&__
M`&@?BO9IHOA.UO(-(\/6.QDB*R%B5MU;EE&"6D/WB?;`_3C_`()+_P#)E7AG
M_L*ZG_Z5/0!XC_P6^_Y$#X9?]AB[_P#1(KZ'_P""7W_)EO@;_>N__2AZ^>/^
M"WQ_XH#X9#O_`&Q=_P#HE:^A_P#@EZ0?V+?`V"#\UW_Z4/0!]6U^,7_!:K_D
MX7PA_P!BJO\`Z42U^SM?C%_P6J(_X:%\(C/(\*)_Z42T`?JW^SQ_R03X<_\`
M8K:=_P"DR5^1'_!9/_DZO3_^Q6M/_1DM?KO^SN0?@)\.2#D'PKIW_I,E?D1_
MP63(_P"&K+`9&1X5M,C_`+:34`?LC\+/^29>$O\`L!V?_HE*Z&__`./&X_ZY
M-_(USOPL.?AEX2Q_T`[/_P!$I717_P#QXW'_`%R;^1H`_"[_`()M?\I`=+_Z
M[:O_`.BI:_</Q9_R*VL_]@^?_P!%M7X>?\$V6'_#P#2N1S-J^/?]U+7[A^+/
M^16UG_L'S_\`HMJ`/Q)_X)-?\GL1?]@;4_\`V6OU:_;3^.UU^SG^SGXJ\9:*
ML;:S#&EII7F+N5;F9@B.1W"@L^.^W'>ORE_X),L#^VO"000=&U/'O]VOU4_;
M=^!EY^T/^S;XK\(:!L.MO''>Z4KMA9+F%@ZH3_M#<OU84`?DI^Q5^R#J_P"W
MGX_\4^(_B9XIU2#2=+E236-2!$UY?7,Q8JBL^0O"L22#@8`%?I+X-_X)5?L\
M>$FBDNO"]_X@FC`W/JVJ2R+(1ZHI5?R%?FE^Q-^V+JW["OCGQ+H7Q`\,:E=:
M+J\J)K&F[?(O+*XAW!9$5\`G#,"I(SP<\5]P^*?^"T?PGT[26D\)^%_&.LZD
MZ'R[::&*UC5\<!W+L<9_NJ:`/,/^"O/@'P!\(_@]\.O#/PX\-:!X;EN]>FNO
M*TZS2%Y(HH"A+,!N89D7J37TA_P26_Y,K\-_]A;4O_2EJ_-?]J+3OCE^TOX4
MU']H7XKZ(^B>$+*:"PT>R=7C6*WD8A3!&WS&/=]Z5L;B1CMC]!?^".OBZTUK
M]E2718+A7O/#OB"ZCN(<\QB4B5#CT.X\^H/I0!]UT444`%%%%`!1110`4444
M`%%%%`'RA\8OVF_BMHO[2MU\*/@=X(\)^*+JQ\(1^))#J^JR6<DR&9HFBC(!
M7=G9C.!R<GBO4?V7/VC=*_:=^%Z>*M)TZZT._M+V;3=9T>Z</)I][%C?&6P-
MPPRL#@<-R`00/%[+_E*[J/\`V1V/_P!+Q7B/P(^*&H?!7X/?MJ^+_"87S-`\
M=ZE)I!VAXH[J1VB5P#P=K-$Q'HHH`_32BORQ_9U^)^O6'QB^!%]\,[CXUZZO
MC&V,'Q2F\36=_+IUW//$K)=1/+NC15D>0JT>T;57U.?9/V9K75OVDOVHOC%X
M[\<^+/%L=I\,?&7]B^%M"L=6DM;*"*`R!_.A3Y9=X5<YZDMGM@`^ZJ*_'3Q1
M^T/XD^)^F_$[QWX=U'XS2?%K2O&CP>"(/#UG>S:-IVFP2QK]FD2(F!F:,RE]
MZDD[3_$<_2OQ.&O?&S]LGX2>$M<\4>.?"&A>*OA,^IZUI.@ZS-IQ>=FE8HX7
M[K!BH)QNP@7ID4`?>U?/>F?'+Q+=_MRZQ\)I1IO_``BECX"BUV(BW/VG[4UP
ML9S)NQLVD\;>O>OSRMKKQCIW[(%I\4S\3OB3<^*?`WQ/&@Z-YVOR&VCLEG4;
M)(NDI8L26<G@!?NC%?0'QG^&3_%K_@H3XXT,^(_$'AN'_A3B7#SZ'?-9SRND
M_P"Z5I%^;RPY5RH^]L`/&00#]$:*_+'_`(:S\<6/_!,7P+JL^O:VGB;Q%XH'
MA2X\06SF:_CLUFE+21M]XS>3&(P?O'.<YYKT/]EOQYJ^G?M"^.?#/PYA^+(^
M$-_X*DU"R;QO:WP>PU6'8K^5-<Y8;U8L5#`$]!\M`'Z%U\^_M:?M%>)?@D/`
MF@?"OPS9^)O&OQ&UP:7I46HRO%9VV-H:69DYP&DC&,C@L<_+@^6?\$P_#6K>
M*/@9X<^)_CSQKXT\4Z_J=M?:;#;ZKK$DUI:6RWK?=B)^:4M'DRN2V#M&%&*^
ML/B/;>*KOP/K$7PLNM'L?%CVY&DW&KQ/):QS9',BI\Q7&>GM0!XO^RK^TQXE
M^/GA7X@6'BCPWI>A?$7X<ZQ<:-J6GV]TTEC-<JK>6ZR<L$9U93]X@+D$Y`JS
M^R)^T+XJ^.\7Q#L_B1H6AZ#K7@#Q1+H-Q%I%U)<0RO&H+L&<`D;L@''(KR'_
M`()=J(=*^,UOXN-[+\3H/'MROC>YD=&MY[G<^QK?:JXCR)>",YR>A`&[_P`$
M_/\`D=?VF?\`LK>H?R%`'V+7S/\`M/?M.^+OAO\`%+P!\*_@?X:T7Q%X^\?1
MW%S"VMW4D-G96T(8EY/+^8EMDF,$8V'KD"OIBO'?VD-?\#_!GP;K/QG\7Z'H
MUUXA\#Z/,FD:C<6Z&Y$D@*1VT<A&Y1))(%('9R?6@#R?X7?MY'6?V:_B7\1/
MBCX871?$'PFU*YTK7=)L+CS(KB\C*+&L3G.T/)(J<[MN"<D58_9P_:S\?>-/
MBKIO@']H'P9HGA75?%OA2/Q5X6N-&O7FBN+-C\T$RN25F4')QQ\K<#@GY=\:
M_"75?A?_`,$E/%NI>+Q,OBGXB:M:>)]9W@AU:ZOK<QJW?/E*C$'HSL*]4OI7
M3_@H%^RZ$9E#_"J97P?O#[-<'!_$#\J`/<IOVB?&VC_MGZ7\'O$7AWPY'X:\
M1:-<ZMI&K6U[*]VT,2'B6,@*K&1'&!GY<'.:]-^/WQ?T[X"_!SQ7X\US8\/A
M[3WFA@=L?:;@_+##_P`#D9%_'-?/?Q'_`.4H_P`)/^R<ZG_Z,GKBO^"A7QJ\
M&VGQ@^'WPY^+6J'1_!NF6%SXLU4R6DLZ:G=HLD.G6F(U)P)0\C9^7"KF@#Z5
M_9!^-FK?M$?L]^%_'_BFPT[3=3UT7)FMM/W^2GEW$D2[=Y+<A`3DGDFO9:^0
M?^"5'BG3/$'[&7A2QTBY\^Z\/7=[9:BGELODS&X>8+DC#?NY8SD9'S8Z@U]?
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%5=4TJRUS3KC3]:M+:_L+R,Q7%K<Q++%,AZJRL"&!]#5JB@#D?"WP@
M\">!]2.H^"_!?A30-0,9B-WIFC06LNPXRN]$!P<#C/:NNHHH`****`./\3?!
MSP%XUU1M3\8^"?"6NZBR*C7FI:+;W,I5>BEW0G`[#-='H^C:?X=TNUTW0+&T
MTW3K*,16UI:0K#%"@Z*B*`%`]`*NT4`<SX\^&7A/XHZ0=,^(OAS1_$5AU$.H
MVB3!#ZJ2,J?<8->7>'_V$_@#X8U6/4M'^%GA9+N)MR--`]PJG.>$D9E_2O=Z
M*`,+7_`GAOQ7HD6C>)_#^B:OI$!5HK"^L(IX$*_=(C92HQVXXJQX:\*Z+X,T
MF/2_!^D:9H>F1,SQV>G6B6T*,QRQ"(`H))R>.:U:*`.?\6_#[POX_AMX?'7A
MO0?$4-HQ>WCU73HKM8F(P2HD4X)'I5[P]X:TCPCI,.E^%-+T[1M,M\^39V%J
MEO#'DY.U$``R>>!6E10`5RGBSX3^"?'E]%>^./!_A?Q#>01^5%<:II$%U(B9
MSM#2*2!DDX]ZZNB@""QL;;3+*"STVWAM;2UC6*""&,(D2*,*JJ.``!@`5S/B
MGX1>!?'.I+J'C7P9X5U^_6,1+=:GH\%U*$&<+O="<#)XSWKK:*`(K:VBL[>*
M"TBCA@A0)''&H544#```X``[5(RA@0P!!&"#WI:*`..T'X-^`?"VM+K'ACP1
MX2TC5D+%;^QT6W@G&[.[$BH&YR<\\YKKI8DGC>.95>.12K*PR&!Z@CTI]%`'
M(>&_@[X#\&ZL-4\(>"O">AZF$9!>Z=HUO;3;6^\-Z(&P>XSS77T44`>;_$[]
MF_X8?&:99OB?X&\/>(+E1M%U<V@$^.P\U</C\:Y[P5^Q?\#OAYJ2:AX2^&7A
M6TO8VW1SRVIN60]BIE+8/TKVFB@#.UKP[I7B31Y])\1:;8:II5R@2:QO+9)H
M)5!!`:-@5(R!P1VK-\(_#CPG\/Q<CP)X9\/^'!>[3<C2=-BM!-MSMW^6HW8R
M<9]:Z.B@`HHHH`****`"BBL/QEX@OO#.A2W^B^']4\3W4;HJZ=ILD"3."<%@
M9I$3`ZG+?3-`&Y17D/\`PNOQA_T1+XA_^!VD_P#R91_PNOQA_P!$2^(?_@=I
M/_R90!Z]17D/_"Z_&'_1$OB'_P"!VD__`"91_P`+K\8?]$2^(?\`X':3_P#)
ME`'D'QG_`&?OC9)^U/=?%C]G[4OAY:-?^"X_#;'Q*URSVI\]I7F2.)"K$?)C
M<2#SD5M?#;]AW3O!_P"RCXO^$GB'7I=7U?Q^+N[\0:_Y.#)J,X7$R(>=J,D9
M`)R=I/&<#T7_`(77XP_Z(E\0_P#P.TG_`.3*/^%U^,/^B)?$/_P.TG_Y,H`\
ME^!'P6_:"T77OAMI7Q:\5>&M+\$?"G3I+**'PM?W1E\58B$-O]L1U552-%5L
M<Y;/'.1+\+_V>OBG\"OVEO'FL?#NX\%W_P`+/B?KL>LZM%J,L\=_IDOSF98(
MT78Q9G8`EL8VY^Z<^J_\+K\8?]$2^(?_`(':3_\`)E'_``NOQA_T1+XA_P#@
M=I/_`,F4`?.EG^R;\=?AG)X_\!_`WQ5X6T/X<_$+Q0VN1^(?M5S!K7AY971K
MB*!(UV,Q6-44[AP3G&>/:-8_9\U^\_;#\$?%.VU"QE\.^&/!$^@W,=S,[7LT
M[R2,)/N[6!#C)+`YSQ71_P#"Z_&'_1$OB'_X':3_`/)E'_"Z_&'_`$1+XA_^
M!VD__)E`'S1+^P9X]?\`9%U;X6C5O"_]OW_Q%;Q)'<>?-]F%J95?83Y>[S,*
M>-N/>NR^-/[./QCG_:5\1?%GX':EX*5M2\!KX;BT_7)IT,KM(2SDHA"%,JZG
MG)7:0`<CV7_A=?C#_HB7Q#_\#M)_^3*/^%U^,/\`HB7Q#_\``[2?_DR@#P%O
M^"?FJ)^P]X7^$MAKVF6WCOPKJJ>(;+5BCFT&IB9Y"A^7>8]LC1[L9X5MO\->
MI_"7X?\`QMUGQEXI\6?M`Z]H5@NH>'ET;2/"/AJ_N)M-A?):2]E\T#]\S':,
M`X3()Z5U?_"Z_&'_`$1+XA_^!VD__)E'_"Z_&'_1$OB'_P"!VD__`"90!F?L
M6?`_7/V=/V=?#?@+QI=:;>ZOH\MV\TVG.[PL);F25=I=5/"N`>!SFN>_:I^#
M'Q3\7^./AWX__9X\0Z99:_X%N)_M6A:W>7$.GZO!*%&V019R5&_J/XL@@J,]
MI_PNOQA_T1+XA_\`@=I/_P`F4?\`"Z_&'_1$OB'_`.!VD_\`R90!R7[&?[.G
MB3X&:/XWUGXIZEI.I>./B3XCEUS6O[(#_9+9GR5AC+@$@%W.<#[P'.,F_P#L
MN_`77_@IXA^,%]XIN]+NHO'_`(YNM>TT64CL8K>7[JR[E&']0,CWK>_X77XP
M_P"B)?$/_P`#M)_^3*/^%U^,/^B)?$/_`,#M)_\`DR@#+_9H\9^*OB;JGQ+\
M6Z]J;3^#;WQ7/IW@NQ\E`L5G9?Z/+<*X&YEFG24C)(`7(QNKSS]N_P#9V^*O
M[2#>"M)^&=WX+A\+>'=175M4L?$-Q<*FJ74;?NHI$B0YA5=^1N!)D[;0:]1M
M/B_XIL+=+>P^!?CVV@B&$BANM(15'L!>8%3?\+K\8?\`1$OB'_X':3_\F4`<
MOK/P9^(?QW_9A\8?#W]HZ]\'V7B3Q$DD%I=^$XI_L=O&GER6S,LOS%EE0E@.
M"N`*X/\`9T_9@^*6G_&?0OB)^TCJOA2XO?`7A!/"OAFT\.O,ZSQC(>[N&D48
MD92PVC@ELX&!GV3_`(77XP_Z(E\0_P#P.TG_`.3*/^%U^,/^B)?$/_P.TG_Y
M,H`P?%OP%U_7?VS?`WQ:M+O2T\.^&?"=YI%U;22.+EYI6E*LBA=I7YQDE@>#
MQ7L7BWP[#XCT#5+3[/:275Y8S6\,D\08*S(0,G!.,FO._P#A=?C#_HB7Q#_\
M#M)_^3*/^%U^,/\`HB7Q#_\``[2?_DR@"E^QM\%-8_9Y_9V\+>!/%\^F76L:
M+]I^U3Z<S-#(9+B21<%E5CA74'([5[77D/\`PNOQA_T1+XA_^!VD_P#R91_P
MNOQA_P!$2^(?_@=I/_R90!Z]17D/_"Z_&'_1$OB'_P"!VD__`"91_P`+K\8?
M]$2^(?\`X':3_P#)E`'KU%>9>'OBQXHUG6[*QU'X2^-]%MKJ4)+J%Y=Z:T-L
MO]]Q'=,Y'^ZI/M7IM`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`?@/_P`/2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4
M`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#T
MO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z
M'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_
M``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`
M\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E
M_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`
MT/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X
M(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",
MU\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?
M6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/
M2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_
M`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#
M8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`
M&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ
M7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]
M#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""
M&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-
M?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4
M`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#T
MO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z
M'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_
M``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`
M\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E
M_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`
MT/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X
M(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",
MU\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?
M6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/
M2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_
M`*'V#_P0V/\`\9H_X>E_M)_]#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#
M8_\`QFC_`(>E_M)_]#[!_P""&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`
M&:/^'I?[2?\`T/L'_@AL?_C-?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ
M7^TG_P!#[!_X(;'_`.,U\GT4`?6'_#TO]I/_`*'V#_P0V/\`\9H_X>E_M)_]
M#[!_X(;'_P",U\GT4`?6'_#TO]I/_H?8/_!#8_\`QFC_`(>E_M)_]#[!_P""
M&Q_^,U\GT4`?6'_#TO\`:3_Z'V#_`,$-C_\`&:/^'I?[2?\`T/L'_@AL?_C-
M?)]%`'UA_P`/2_VD_P#H?8/_``0V/_QFC_AZ7^TG_P!#[!_X(;'_`.,U\GT4
M`?6'_#TO]I/_`*'V#_P0V/\`\9HKY/HH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
#`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g891272ex99_2pg05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272ex99_2pg05.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/@+&`P$1``(1`0,1`?_$`*(``0`!!`,!`0``````
M```````(!`8'"0(#!0H!`0$``P$!`0$!`````````````P0%`@$&!P@0```&
M`@$#!``&`@$"!P````(#!`4&!P$(`!$2"2$3%!4Q(C(C%A=!)!A10G%2,T,T
M)1D1``("`00!`@4"!0,$`@(#``(#`00%`!$2$P8A%#$B,B,'01510C-#)&%2
M%J%3-"5Q1!<(D7)4_]H`#`,!``(1`Q$`/P#[EXA`8\N3*7I\:UK@^JI64]'.
M#X\HWAQ,61-Y=110_P"4R+#&["=F)5BPD)]!EE"P`\.3`BZ?S_X)^*?$<G4?
MY'Y1C[%ORA^=&V;[]BO:LDS$W[9X@^VDPJ\*I0TIH*]&I20#;'W4-V_1?(O+
M,Q5>&,Q;U)Q84)2*T)-*X"VE7NAXO"&<G2$=I_211)*F`F->X;4U=GH"VLV+
MHAH"FYR:2TV3EW8%N>'D$@<TO7"K`\@6/)>#QYSGN[L=,9P'TY](_P#`WX@M
M8J,)8P-(\3%.W5ZI[./M[]P;]Q7U[R%FX`V&[SN3(CUV]-9:_P`@>8JMS>7>
M;%LG+;);!OV)3-=9?3MN"9E<>FVWQC?UU7BKF%#5#6B8$N50W)8\".]U7W9<
MG!GPP+%?HH[?</9PX(SZ=,`_#&,^O-<_Q)^.#R!94\36G(E?;=EGS\IM/I1C
MFOWY_P!0Z,16F?\`M?+$1\=5(\R\F%$5HMLZ(2"8C8-NM;N\`^GX"[[G\=_C
M.WIKH*K"!$I2T)4;1@2E)X^D+)P<L[0)HJN/<H^5C.5.1=K6N4C,+]>N<B_-
MUQZ<IU_PI^*ZM%>-KX2F%!2,<D`CGL*L0\[.-"/GW@:3V&U'^TBGXQZ:E/SC
MRMCYM'=9+R.P<SL'J5H!78GZ=ON@(B7^D>FTZY"K*"#`I+%'$>0*TDF0J0Y-
M6=#4DR."HDQ`O]GT"[GAP(SITSC./R]O#/PK^+')=7;A:9(L5\FA@SSV-.9;
M#LHN?G^FZV(8Z/U.(F-IUX/F_E0D!C=9R6RL8^@>ATXXUB^GXJ'T'^/\V^N1
M%:09,H*5D1U(6I)=FM\+-P<LR(+LRM)K$V+<=RG.,FI&@X1`<9QVY!G\V,Y]
M>35_P[^,JMX<E7P]4;X9!%X3^YRBW5IECT/WD_K72(JT3\)7.Q1/QUXWS7RE
MR2KMN,E)5VHF-@]5.;#VA]/P-L0<_K$QZ3$>FJ4BIZ\3`*+(BZ(H!+"CC!6`
MG+OR,+>\8D"-MQG*K.?9(>,8/QG]?=Z9SD/IRA2_!/XCQW7['!4U2G$IQ82/
M9$CCT6HNIJQ//>%+M1#ACX\HB)F1B(U.WS_S!Y$;;S2(K9V9]`]7L3[<V?3\
M23\DQ\-O6(W]=5)M:08\\]2;'4@SU*V2.!YF35F!&+9>W%M,D49Z*<8P-U;B
M@E#Z=,!#C\F`Y]>77?AK\86+;;SL-4*XZU?LF<\^16,I5&E?;,\_KM51%#)_
M1<;!QU`OS;RE2@2NXR%`NLL8V#T"HR6UA^GX*9,F/\9GYMXUQS6,#R:D/_C:
M/W4`HX)(/W5F,D"B*<U+&\@QA3TS]2G.$$OKUZ]WYN[/KR(?PI^*@;7>&$IP
MVI.-E,QSCK_9Q,,9Q^?;_"$SA'^WE,SO/KKK_G'E<+8KWK.ML6(.-@^;W905
MC?Y?[I1$E_\`'IM&ND=55\8E,1CC"(24UO<&DPG)RWM$W.CKA[<$N>BK`O;5
M.N,'"SUZ]WX9QCTY"W\&?B1]$\8[!4RH,I6:A!/9Q*M<MQ>M)GY_H?;B+#(^
M),C??;TU(/GOEX/BR-YD/%RVQ.P;PQ2NE9?3\15\D?IM^F_KJO%7L,&<$\3"
MER<!S/>0F>ZKZX<U306PJ%G_`,CIDPUG*"1G'Z>S'X=?7FL?XH_';+47CQ5:
M;<7FW>?S[^Z=3''M?OR^ME(1K%/PE<;;?KJH/E_D@KE0VSZY0*9C8/Z0NEXA
M]/PATR<?KO/QV]-4>*M@`4N46(TCPERECZ+).#EO;\6*J\KH\3U^5W8"UJQ9
M&7Z]<Y_5UQZ<S0_"/XI72C'!A*<4H3CDP$=FT+Q+9=C0CY]XBFV9-/KN,S.\
MS'IJS/G7ELO]S-UG?SL'OL'U6@X6)^G;[H?*7_3:=<1U57QA)J<<81")/3R5
M(:7DU;T&GF!Q2B2E9_VNO:['$A$9T]0YQ^7MY$W\%_B-U5E)N"I%5:C(I,?N
M;$K+-%V17/S_`$VV@+&Q_OC<>,ZZ'SWR\&"X;S88)UCB=@]"J1(UI^GXJ$I@
M?XQ/S;ZK4]=PM*N/<D["E*7*G%L=E"@)JO(S7%F:A,C8J%@2C(.](UCR2''3
MMR'/7.,B]>:M/\3?CK'Y5^<I8JNO+6K=>TUL2SDRQ4KE4K-*>?J2JY$H?TV*
M9F)*=]57>8>2OJA2=;,JH):H1V#:%N;#FC].^QMB#G]=_2)B/37GXJ:NPI`H
M<1=%A(!K2LH2/>7=N&M&]9D29'U^5W>V4]9^1UZ]V1^F<Y#Z<QH_`OX?C'QB
MHP%+]NBB-+K^YQ]J%W]Q%'U_1[W_`"9_4F>I3,>FKD^?^838FU-YON)>3N6P
M;]II]N1_3\93]O\`AM\(W]=51]9P52M/<3HZD,6J5#XJ/49.68&8HDB8M&^&
MYQA3@&!.*8H(!],8QC&/R].:%C\-?C"UD69>QAJI9)SKKC9\_(FY)(U[QSL>
MW*R@!4R=O4(B(VC4"O-O*4UAIJN,BL`($1V#:!K%)HCZ=_ME,S'\9GUWUQ#6
M,##DH08XDP(D]B4E9P<LZ@/C)`DS"9C_`&?Q;2!9"7_C.,_FZYYR'X7_`!<H
MEFO"U()+<>P)CG\IXH)7CBCY_C3"9%/^V)GXZ]GSCRN8*)NLV(7C/H'J-DN3
MX^G^X4;E_P!-M?AM80(\CXIL;1C(^N7M/M9-68#]<YN?W"]+Z*<9]M2Y_O9_
MS@7X9QCTYP_\)_BJS3_;WX2F5+V3ZG">?'VUFU[UZ?K^AMO[Y1_W/6)CX:+\
MY\K4WO7=9#>X&[[!_44OI`OI^(J^2/TV^,3/KKM.K:#GC]PZ/)!C^U5OG=DU
M7U^U7MF&98M]%./W#VS'LBQ^GM_QU]>6+/X>_&=MTV;.'JF^;[[LE//>;5JM
M%.P_Z_K=5B$G^A!Z;;^NN%^:>4*'@NXR!]N"/@']);>X`^GX"WYX_7?]=O37
M055D`(`065&D8`)B8ZG(#@Y;^V3$E)BR.EASE5G/1J4FB$7U]<YST%W8].5$
M?A#\4504NO@Z8`@,<"]NSY1Q)DS&Q'S_`/TS(I3/QC>8F9CTU*SSORUI$;+K
M)(RL$7H'K-L8"Q/T_P!T8B"_AMZ;3K]!5T!+2*D((VD"D7`D):HG!RWM.!*U
M`54A"+/RN[&',\&!#Z9QV].@>W'IR1'X5_%E7'6,17PM4,9:&]#EQ+(%D9,H
M.]!1S_\`LE$2?\(B('C'IKPO.O+#L+M%=9-A4UY$M@WB:H\:^WR_VAF8C^/\
MV\ZJ"ZYA1*PI>7'TH%A#H@>23\&J^X#HUM.6)O68QE1D/N)6G/L!QT[>WUSC
M(O7EA'X?_&E;(+RJ,/5#()NUK8''/<;-.K-*JZ/GVY(JS*5^FPA/PW]=0GYE
MY,RN50[;)KFAB9'8-I4UO>P/IWV)OSS^N_Z[>FJ$%35V44,D$71!*&A1M@P8
M.7=!(&]QR[(TV>JK.>PAQ%DW'^<B_'.<>G,Q7X'_`!`FN516!I16*FJK(_<V
MFNBS-Q2=N?T!:F7Q'_<]9WU;+S_S$SAA7FR<--D3L'UL7U&7T_$E_)/Z;?#U
MU4CK."F&Y.''4@C<GOBG(\G+.N3Y*3\=],S_`+/3N<2<=H_\8Q^GIR^W\-?C
M![RLNPU4K!-OMDIY[RS*+ZL@4_/ZS;7$`[_</I&VH!\V\J`.H;C("!0.VP?3
M6GDB/I_MSZC_`-=]=G]<0GWRU/\`'TGOE',:@LSW5>,A/C:82-C,Q_L=.YN2
MCR`'_7&?S=>2C^(?QJ-H+HXBK%M;J+1*.>XLQBI10./G^JJDI6J?T&9B=]<?
M\S\GZI3[MG40O&8V#U&R7-\?3_<*-Y_U^&VJ(^IZ\4I"D)\71&)"6Q6S%DY.
M78"!L7N?W*M'C(56!9+.<\>]G.<]V!?AG&/3F78_`_X@M4`Q=C`TBQX464A#
M[G&*K;7O6(]#^@K?W]OC#/6)CX:LJ\_\P18*TJ\V+!/!TEL&\M!72!_3\85\
MG\-OC&_KJL'6T'&I,6#CR02DUP=74PW)JON$X/C4%D=E.<?([>]:U`P2/'3M
M[<=<8P+UYH,_#GXQ;</(,PU2;K+5RR1SSW)^0K13NLGY]N5FL,);^A#$>F_K
MJN/FGE`IBN-QD)%*E1&P>BT-ERA^GX`V9./UW])F8]-=1-80).B3-Q,;2`1(
MRH\2F3X.6Y`45%%&54>`'(E619PV*,]X.N<Y%G]7=R-'X6_%M;$)P*,-5'#U
MPH@M.[)`1QK.ZC$1)S_XS?G#?>9+U+EKMOG'E;K)W&763985B2+8-YFT/&Q/
MT[?='TG^$?3MI_6$"[30?QM'VGHY&@-Q[RS\Z.6K,+Y&1G_9Z]KJK#@9F?QQ
MGT#D./3G,_A3\5R+!G"5)%J,DD_K^9>79#LF$_/\+C(@G?J4QM$Q'II_SGRO
MD)>]9N+*[(]`]#J!UUR^G^T'RC^G\=YUS*K."D*,JBHZD`HRZ$O63<'+.[[1
M.V"9R5GJISCW"VP62<8_3VY_#KZ\FK_AS\8U;G[A7P]4+OOU7><<]_=)JS24
M_P"OZUU9E`3\(7.T1^NO&>;>4M3T,N,E/1*=M@_I$SN(/I^$L^>?UW_7;TUT
MEU97Y)991<91@+*;FYI+!@Y;T"W-+B!W;DN.JK/[:1R!@T.?U=V/7.<>G*J?
MP=^)J]<*J<'3&LNE6J",<]HK4[,7*R8CG]";40\(_1GKO.I#\[\N8<L.ZR3)
MS&S.P>K&KE3"^GXFN9"?TV^$1/KKN.K2#*!J##HZD,&J-D)R@635G4TV5E`)
MD(Q=%.,8RZ%EXP9TZ8QT_+TY9L_AK\87&.;:PU0V6#R),F>?SEEQ$<E,_/\`
M_=$1A_\`NVC;;42_-O*4B`+N,@5C7@?0/2*LS->/I_M3,R/_`%WT_K2"_,3N
M'\=2?,2JH\M(/]U9WEJHJDRACQV,?)[<C;$@L@!UQG&<?J[N(_#?XPC(JRT8
M:K&239H6`9\_(78Q,UZ#8^?ZZR)E2Y_V3,%RT_YMY3[8ZGO&>V,+`$.P;2-H
M^=B/IWV:?S3_``GZ=M41M15P>WFM1L50C;SF8Z/&I<G+L`&S*'K,B.09SA7@
M>"AO6<J.N,]V!^F,X#Z<RG__`*__`(:LX<\`_P`?HEAF8V<>2ON<9I3<G(>W
M]#WZXNS-B(B=Q9.XS$>FK2_R%YFJV-]=]L6QLQ8@M@WAPI]O#/HVWA/V_AMM
M\8W]=>J;7T-//`J-8DPSRW%S=P&9-5]0N+PU"8W-5C&%&`]ZMJ'DG..G;@.>
MH<8SZ\^BL?BS\?6[*[EG%USLIN/M@4R>X6+-4J3VC\^T$RJ1)G;T@)GC$3.^
MJ"_+O(U*E"[1PJ4K5,;!ZK2WO6/T_`&QSC]9GXS,>FJ0FL($G)P03&T99(4T
M71X+P:LZ830LT1\7)]5.<]K.:+(B_P#(L_K[N9E;\)_BJG6BG6PE,*PHQB(&
M.>T*P[)=C%Q\_P!--LRQ,?H?J7*=3L\X\K<SM9=9+).R>^P?5<CC9GZ?BZ(V
M+^'\NVNK^J*]^,-'_&$7QC$;Z@&3[R[M$CDRL"Y](SGY7=VN2LL(QYZ]<9Q^
M7.,>G(I_!GXE*D>.+!TYI,KY!!!/9L2<JT7Y%<_/OQN-`3=^I%$>L1Z:D_Y]
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M:MEY[Y<;IL%>9+B<ULSL'JQRH2TOI^)JB`G]-OA$3ZZYG5?`5"A4J.C2,:A:
M;*#E1F35F,G&S1-\24#%C"G`<9>$^.TSIC&,?B'MSZ\[L_A#\47'OLV<'3-]
MDLH39GG\\YH(#*[QSV_SAB(?&VQ;1,1$^NN%^<^6*2M"[K(2H:T#&P>D4RYU
M8^G^R7J/\?YMXU^_UA`LG$'YC:/)R9SC#R0/W5G4MTAB#ZN,+,?[/3)K0@_:
M+Z]0B#^O`L^O/6?A+\4ML*MLP=,K*<ACKP%/.9&WB*\5<;8CY_ZE2O$*44_R
M1$%RVUY_SCROK-7O6=9HLI*-@]57&=MD/I^#6?,7ZQ/TS$:X**LK]4E$B41I
M&:E&R+(X(D1RWMRR.#P4_K&_.<*L"]E0[D@/%GKW=P>F,]OIQ?\`PE^*LI3*
MAD,+4=3+&/QTB4LF)I6;(7+%;Z]^MME8-.-]Y(8C?C&VNT^=^6H?%E-U@OBR
M%C>!#^LM,H!GT[;BDI"/TVG?;?UU5'UQ"5)B@T^/I3#%3PZR!0/)JO&37E[:
M/H75?GHHQC!JQHQ[`L8Z!P#].,9]>6W_`(A_&MJPVV_$5BLNR5C(&7S[E=MT
M_P!OL6)F#_J-I?XTS'I"O08CXZ@5YGY.D`6JVR`7657&-@]$I;WJ7]/P!OSQ
M^LS\9F/37055\"(`063&T98$I4;(3AP:LZ%$Q`\Q3&BP]5.>H6D\T0B^O7KG
M/YN[E6O^$_Q544E%;"4P375C%+B.>P+PS2=BPCY_II-(F(C^4IF9WU*SSGRQ
MI&;+K)(RLD4[!ZS;&!LS]/\`=&(@O](]-M,5?`L)U"3$;1_'5))"A4%>\MR$
MU)*U*=9(B!9RI[NUU4I2QF=,XSC(<=O3UXG\)_BJ:;L?.$IS3L5\DA@3SF#3
MEVK?DUS\_P!-UREL?'\Q#$QMI/G/EDN"Q-UG<ME<QG8/0ZHD%<OI^*A(H'_2
M?7?5657L-(7%.13$F`N(=4CX4IP:KR,#LA9_H$BW&,J,AR:2S_L8QG';D'XX
MSGUYH)_%/X[1E`S2L56'*KR"[PM^?E%Q5+]N78^O^H-'_&B=MI5\LQ/QU79Y
M?Y(VJ5)ELYJE7-$CL&TJ-W>8?3OM+ON?QW^$[>FO)*J*N"4OP2HJA`E^L;6;
MV<'K^WZQG>@R%L2=<J\BP6C>@X4!SU[N_P!,YR'TYA(_`7X=JT8QE?`4@H#2
MJ5(".S:*U&Y[^FF/GW@*US_(5^HG^NWIJ^S\A>9M?[IE]LO[V.WXK_JN3[=A
M_1MN:?MS^FWK$;^NJPRL8&:J"M,C:,2H*N6+@G9-68$%7.B,)I8?C&%.`X$]
MD8[3?3H'_LP'/+K/PI^*FY!>59A*<Y%-C*O!GS\@=FQD,JP9Y^A7AF8=M_&9
M'C,S.JX><>5K1-8+K(1*Z@3&P;<*)<J@_3\$EZC_`!_FY:[?ZXA/R@+?X^D^
M46LC"\!WNJ^X*R&$')HN?T^1VY$SD'C"7C..@N[J/`L^O+)?A_\`&AWHR9X>
MJ5\7XQT'/.2[<-!QBS]3]9I0P^G?TB2DB@B]=1_\S\GZ)K>[9T$NRN8V#;A<
M*"LC]/\`>(8DOUC;Y=HU0F5+71R`IL-BR$:`EM6M!2;)R[L`VN+R"0+DG7"K
M`\EJ7D&%`LYSD7?CIU[?3F6[\"_A^QBAPC\!2+$C2LU(5/9Q]M<N#D+2?KWD
M'W!&PS>=R9$;SMZ:M!^0/,5VRO!?;%LG`Z2V#>6+3-<#^G;<4S*X]-MOTW]=
M5XJXA(U(U@H^ERI,<'!V&=DU7W"<75I"Q."K/^QT]Q4T!P0+TZ8!^&,9]>:Y
M_B/\;MOEDV8FM.0.Z^X3/GY3:M4XQ]A^_/\`J-I1%8I_[4;1M\=51\R\G%,5
MQMLA`I6J(V#;K4WO6/T_`6SSC]=_C,QZ:Z2JQ@9*8M&5'$8$Q),>3E%8-6=H
M"8HK/71TO&<J<B[6I6I&,OU]<B_-UQZ<JU_PM^+:M->/KX6H%-2L:L`CGL(8
MAIOQ@Q\^\12:PV(_VD4_'4A^;^5L<5@[K)<16"F=@]9M`(6)^G^Z`B)?Z1Z;
M3H*L(&,I22*-H\E*T4C;E`,FK.AJ*6J<+)&G%_L]<`=5(<#,Z=,XSC\N0\\9
M^%/Q6VNZHS"4RK6*N1K,&>>QHRSHL9)4_/\`3<?$-='ZG'*-IT'SCRL3!@W6
M<UMKL&=@]#J#PKE]/Q4/H/Z3'U;ZYDUI!DZDM63'4@%)3LA?"S<&K,B"[-K0
M8P(EOJISC)I#.:(C&,X[<@SZXSGUY*G\.?C*O>'))P]4;PY!=Z#^YR]VFG./
M6_U/ZQI%-;?X2N=BB9]=<L\U\I<F:[+C)25<T3&P?TF.AYA]/P)T0?\`'?X3
M$>FJ5/5%>I0E@3QA&4$EC;HV5@)R[\C&TNV'QN;L9RJSGV4KKCWL9_7D7IG.
M0^G*='\&?B7&RN:&#IJE6*KXT)'LB1HU;,6Z]:)Y[]2K(BT8^/*(B9D8B-3.
M\^\O>1$Z\PB*TRS/RAZO:KH8SZ?B2ODG]-O6(B?752;6<%.,/.-CB09BE3)5
MAX\FK.IBF8(RV^2G9Z*<8P)V1%!+'TZ8"''Y.W/+3OPS^+[%AMIV&J%8=8R#
MS+Y]R=E4#5R+)^?ZK=<12R?]D0(\=1+\V\J4`+"XR``*P#&P>@U#EE:/I^"C
MF2'^,S\V^OS-9001Z55F.)/?1&1\U*9[JS&23(LD,0Q\0<84]O5L2&B`7UQG
MKC/YNN?7G,?A;\6C8KVQPM2+%4\>2BCG'66)62L;(['M_AK,A3_MY3,[SZZ1
MYOY5"F(BXSJ;%B"C8/FBT<'8B?E_NG$27_QZ;1KH'5->C2C1#C"(24QN5-(R
M<G+>T3<M=?NU23.?E=WMGNN/>SZ]>[_/3TY69^"_Q(Z@>+9@J<X\Z3JA!]SC
M-:Q;]\],_/\`0VW'N#C]6>N_Z:E'SWR\7Q9&\V'PX6Q.P;]@*Z1+Z?B*ODC]
M-OTW]=5PZ\AAAH3QL*41H7%:[!'[JOKAQ<6H#(M5>BCIDQ0U%A)%C\.W'IC&
M?7FJS\3?CIUGWC<36*U[U]OE//?W-JH-&P[?G];J@C7.?A*XVV_754?,/)07
M*AMG"Y2"MM@_IK;+@'Z?@+9DX_7?]=O35*&KX"%-E(&-H\)\E1XCVO>6]/:B
MAXE,>!U^3W8PUGBR(OUZYSG\W7'*(?A/\5KJQ2#"5(JP&."!CGM`X@Y/&Q'S
M[Q[,IF4^NX[S$[QZ:GGSGRR7>XFZSNY6"WV#XVAXV)^G^Z/H7_3;76.J:]&0
M8E'&$62#DD@0&%>\M[1I)4J+72`C/15U['-62$8_\ASC\O;RNS\$_B)M0Z#,
M#2FFRM>KD'S[2C)O&S?7/S_39>(M9'^^-QXZ['SWR\6B\;S8:+*YQ.P>AU1D
M*Y?3\5!,C'\8GYM]5Q%=PM,N4.1#"E+7*W-&\*%`35?>:Y(&K+(C5BQE1D'>
M0UBR3C&,=N0YZYQD7KS7I_B?\=T,I8S=+%5UY6U<5;<V)9R9817FHII?/M)!
M7(E1Z;;3,S$E.^JK?,/)7U0I-MF55:#2([!M"V-[C"/EWV)OSS^N_I$[>FJ`
M-3UX!,!&&+HL)2VYO:0$^\M[0MS4[B?F]+URJ[LEIG<63\9Z]V1_CG./3F,/
MX&_$`41QHX&E%`:2:D!]SC%9%R;ZD_7]`7)FQM^K/4IF/35LO/O,"?-DKS>\
MG,;,[!_4:KH87T_$DQPG](CX1$^NJ@ZLH(H5J%QT<2&*U1CZ:H.R<LP(PR3%
M@)?1YQA3@.,N1180CZ8QTQC\O3EZQ^&?Q?;OMREC#5#R#V7S,YY[D>36*KY3
M\^V]I8B#9_48B(VC4*O-_*DUPJJN,BNN$0([!Z16F91'T[_;F9F/^N^F*S@H
M1E&8CB3`R5;*N*%@U9U`JCJ7*)E.Q_L].YO2Y[`8_#./QQG//0_#7XP6U;UX
M:K#E/HO"8Y[BW&JE%`X^?XU53*U?H(S^ND^;>52)!-QG$EN"?0/4;!<W1]/]
MPO6?UW^&VN!E7P$Y/A*9&D8DX6T]GP5DU9@.&U4Y_<GI/13C/MF.G[V<_J[O
MPST].0M_"7XI?3C'MP=,J443I\/GX^U9:]\:?K^@K?\`D3'Q[/6)_370><^6
M+=WA=9#I<+M]@_J"KI$_I^,*^3^&WZ;^NNXZM8.H%WG1Y(8++FY/.<Y-6=<N
M;NW8:7)7GHIQ^XK;@X*%C]/;^&,9]>6+/X=_&5QLNM8>J;9NVKDS//>;-ZO%
M2VZ?G^NQ7B%,_0ACX;^NHU^:>4)'BNXR!Z%I^`?TE,[5A]/P!GS1^N_QG;TU
MTE5?`B,$!*C:,&$H8V`C&#EO[88@88;&\8ZJLYS]2,T62^O7KU_-W8Y7K_A/
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M2.P;2HG=Y!].^TN^>?UW_7;TU0%5/79)>2BHNB`6)&V-X@8.79QE$SK\N;8G
M]56<]B1?GW0_YR+\<YQZ<S$_@C\0UZ\U48&D-::M:MQCLVZ*EF;=97U_0FS,
MN&/^YZSOJT?G_F##AAWFR<,8S?8/K<OJ87T_$U_+/^GPVG5096,#-&(PR.)!
M#$)_&(63EGJ*4`R!_P`Y_P!GIU<P9Z&?]/\`MZ<N._#'XNL,)KL+4)AED"*9
MY^LY4>.1F?G]9N#Z._W1\-M1!YOY4`P`760,0B/@'PJSNC^7^U/T_P#7?7?F
MNH5E2!7E@2_)+5,RX!ONJ^X*N/HA-S,=C'R.WN0(AY+!Z=,ASZ]<^O+/_P"(
M_P`;Q='(QB*WO@LTK`G\_*'8]$U:3(^?ZJU>92N?T"=IWU%_S+R:$S7]VSIE
M;@F-@^BP?8X?I^##B"G_`%^&VO/.J:NU"0I"=%D0TA#4:R%$Y.78"!J.=?NS
M$6,A58%DL3K^]USGNP+\,]/3F0_\"_A^QCPQ;L!2+'KH>Q%?W.,5/=^^Z/0_
MHBW]^/UAGK$Q'IJVO\@>8IL%:7>;%@GPZ2V#>6PKH@_IVWZOD_AM^F_KJM,K
M:#FJ#51D>2"4'KGQS--R:K[AKI*V`9WU1G&%.`][DVEA*'CITP''4.,9]>:+
M?PW^,'VV7G8:H5MMF_8,IY[D[*5QJY!D_/MO;KB*W?H0Q$[1/KJL'FGE`)%`
M7&0D5(7$;!Z!69+D#]/P6R9,?UW])F8]-=9-901.D2H28XD`D0XC84I&#EN0
M$XB!GNQO`>Y3D6?JC/4'7.>[/Z^[G*/PS^+ZV,1A48:J.*K1CX4K=D@$8HX9
MC]HDY_\`%.(->^^Y1$GRUTWS?RIUAEIEQDV&^YY%L&\^[C:S_+_=CT+;X?R[
M:X_U=`?:-)_C2/VCF^0-1H/>6]!M\J<,.L@39_V>O8Z.&/=,S^K&?0.<8].0
MS^$?Q3*6(+"4Y2VKD:QQ]SYD99T6,DN?G^%QT0QWZE/I$Q'IKK_G7EG,6>]9
MS%U=L3L'HRJOJKE]/Q4OY1_3;XQ,^NNPNM(,2HRK+CJ0"@3K]YDW!RSNRZX:
MQ,N%O3*G(?=PUBR3TZ=O;G\.OKRRC\._C*M=_<D8>J-[]P&]SCGR]V-2:(OW
MY_U!J3-<9^$+G:(_77!^;>4L3%<[C)3%?HVV#^EV]W#Z?AVQS_CO^NWIKJ*J
MV`$`*+*C2,`"6]H:R@X.6]`-["X`=6A-CJJS^1"XEA-!G\<BQZYSCTY51^$/
MQ/52NO7P=,$*ITZ@#'/8:^/LQ<I)B.?T5K40]<?HSUF9U(SSORUI$;+K)(G.
M;,[!ZL>N5.+Z?B:YD9_3;X1$Z[#JS@BC*@1T<2&95"D8E&<FK/W12[``R/(N
MBG'3[;!8?<Z=.G3\O;R>S^&/Q=<ETVL+4/W'[EV;\_G_`'CC^Z;_`#__`'>(
M]_\`NF(F-M<+\W\J3`0NXR(7%>!]`]/:;^W_`)?[6\\?^N^N7]:P;YQ#E_'D
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MNV_KKUSZ^AR@_"H]B3&'A<'EU"9DU7W8<)`U"9'A5C&%&,8&N:AY)%CIVX#G
MJ'&,^O/I;/XL_']RT%VUBT':5<M6@*9/<;%VJ5*TT?G]"=5,DEMZ0!3Q@9G?
M6<KR[R-*I0JT<*E*5;;!_3KMAR1^GX`V(./UF?C,QZ:I2:Q@:<O!),<1@*"3
M%$^`8-6=,$P?(A10OU4YSVLHA9R7_P";/Z^[F;6_"GXKIH&M6PE,*XJQ:H&.
M>T+PARS%!'S_`$T3F33'Z%\Q<IU89YQY6T^QEUDG)6BWV#XW?_*GZ?[W\W\/
MY=M=&*HKS"02'^+HOB#0/;8(GWEW;E!(UQ;D]ILY^5W=CBN*"8//7KUQZ9QC
MTY7G\%?B,J!8PL%3F@=6_6()[)B491XV<@J?GWXVW@+7>NY$,>L1Z:E_Y]YA
M[B+7OF^XAJ6P6P?77"5I+Z=MUA,B/Z;3Z[SKT"J]AA*X3D4PI@+ANH'P2C!J
MO(\NI;0>P@6],J,@]T+0I&1TZ=O8+\.O3/-=/XI_'E?*SG$XJL.6+(#>EOS\
MO>#3/'C8^O\`J128=:)VVZBD=OA.J9^7^2,JQ2.V<U8KRB!V#;JEHOD/IWVE
MHB?\=X^.WIJB+JNORDY24N,H@IR4+.V%%8.6]H$$?<Q/+,FQG*K(NQO<QY.!
MZ]>[/KG./3F6G\'?B:O37CT8.F--52C5`([-AKXVU-V@J/G^FK:(GI_43F9W
MV]-6C\\\N-Q/.\R7$US)G8/4["H2XOI^+%1`3^FWPVGUUR.JZ`J#U:DZ-(S#
MEXI4-69DY;U/%-R<$2K(L858#C[DK'0SIC'3_L[<\]L_@_\`$]QUA]K!TS;:
M_=>V9Y_/^^1$9:"CGMM?B([XB-BF(F.,^NO%^=>6)4M*[K(4J*L!&P?+%*>5
M7;Y?[,^H[_'^;?5637D,3_-]EA3%_9%(R%W0U7_L%-\<41%&`?51GI[$<5&)
M<9QTSD`NN>HL8%C4J_BK\>TBM%4Q==97A5#YB3W;",>6+5S^?UD,>4U8GX]>
MV\R4045V>7^2.ZNRV<])&0>@?+++`VSF/E_FL"+9W_FC:/EWC5-7!028V(`"
M"D^/O9(/VRHX=%0=PWU>,1F6H\9@Q#-$+N$IZ]JP6<G!QC`\8Y2_$5=5;Q`E
M)4M(?NV3+BO&LQ0[ED+)$7M&D1$1S,F=N)X7SDKJXA;QB)O,V$S-01$1S[6M
M&\V(M3Z(7&W:,1&T?"%_%4?:G>1G5^<_3M?*:<::<::<::<::<::<::<::<:
M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::\E
ME9T[$BR@3*'!45E4M6>ZYKU#BJ]Q>K.6&EX4JAC-PG*,.R$HOKVE%XP`.,!Q
MC',/QW`5/&L=.,I-MN3-A[N5E[;+.5AQO,88XC.%B3)%*HG@E4`I0BL!&-#)
M9%V4L^Z>"5GU@&R@%8[`$!$\1B(Y3$;D7Q(IDIWF9G7K<W-9^M$WE2VL>:,V
MQT,JK_\`19=H36=Q%7X^WD_*\:;MS*HKVKH*4XLRV/2/:BD[1^)8[S94@9&M
M"C1&'@6H#EF`-YAY85!-;"P-[R3*4G.:::OC\6%(`1-K+S+R*U12%@$O=W*.
MXURA@RF*BX5*9)DLMY-+T>,U;U-(3=?GD5.<S,#%<J]BQ:8W<H``1%=2UM^0
M1=<`6]O-0C:.IGD_OZ`5[!H%M]0&VE[VS:[IMS,-9YI6%#ULS3>]=>M>),G3
M0V0V%5:.:UVKKFU;$BK@D7(Q'1J.19R`M1X*.2GJBTPM"PZ)QB9;4-'D]/QN
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MFV"`7R<VZME2JZ4MLV(0QU9+D#+-71ET$^N]359!-A:!20[FY[Z<Y!"@()-(
M2VG$6)98:A-<"&+C:Y$(SVM/E>UL=R+Q>@1JY6V#49J=`]T'.PGZ',+#'9K2
M5CIY8?&%4/:768I9ZVRE4.$N!>6N3,L=/%DL!A63"#`&Y9%%O&8W(9"REDNQ
MV61CBKCL3VV;*@<B$C$]908L6,@;`<IAPMREGO$:%''V<AF\5@ZT#+LLNZ2F
M<AZ0G'V%5;8-.)F8ZV-B1<L657J$FH>U<04W+.?)?1U7'O2:S8+>4'4(JLH&
MR(RF<8*TO*VSWS9!_71&`4M5[=$)9)'*772DER4EL<VLLDM$E4+2#"UIR;)A
MY5FW0>C+7<!4XV\[3S7[;"$S\[V=#K$65$WJ6-'JK63*S8-`J&LXG0L`Y3BT
M,A6O83'^1LF:^%OX9V3EK?A617*J+%V!7V'%C>Y7A:4"\G$P05)LF`F+M^>7
M:3PO7/<*;5UI=L@PW_J\LK:#'55<R;7@;<99MV)1BK0I2]5EM+(HM+XZE.5M
MQKRF8I":\$E.:<LD@9PC0D9_59NKP\X8E./+^1SAQV]25965?M@P82(F"&PL
M$,%DI)A036*0#&AK56XJG:LL\DEZ,91PI9=_"([)H#W?="9@X$I]M:*08,-`
M:K=U=A5UOSXG\F\$CBMEBUITI?T3F,>+@C'L,8CB]8R>/Z]6'8IHV^"P:9'5
MQ==F!FDOGRT)2A$QURIL-S:&YP2*'G"`DP1V-::U'(94J^`:+<:Z[-6HPIF.
M^W]F9I;DM1"ZO%A06K;E(Q:V;Q-V(D=\<3R&.P07<^(#E58\KEE28Y$%1('+
MK\+@C(:I=+RKI,YO/!3(36:2F0/EQ;R60*XW.?U\3K+NE$VB)S_8&DK4M%="
MXRU5G4\CI.`JIH^.DFN.JKAD>&-DEK/V$Q]W85*Q06ZG$I%/UZX0"^?,7Y7<
M\(;Y)V2C'/P5B^J2,T,/IME0.LJ0F#FV-@#D>HI4Q2VL0]D*9`[E;DCR;]E4
M,6,BG+4ZDB`BX9]VE=E;R$HD00*6+)PV(6Y?8OL1$,#E#+Q<[^0RJ-48)#]K
MY7L4U2!;KW:V];9=&R,J<[-02K6ESN!UQ'@,\XD-DV-<IYU=PV6Q=N`FE:%K
M7.F%91K=A=@1PB_L_(%S5HPMB>O*86EAJ5U(K'W+,A=JB4SQ0,J:Q]Z+5<0$
MN\)3`M4L(`BQ\;3?9S;XH0;<?E<YE5TYAA,2I>/,URN":7,`]J@;?/C*/NE$
M-)G*-2MEWE_J.NHQ:[Y9>MFV]=/E7T:1L\EKR616DDLYLG7<4E:8JX6K!4Z"
M^W&.-Y#"Z/Z'Y\<D[E')HF"K+#EFR;W%AS"H65P8L&(L5\Q3QMM<3!E3L7Y,
M:LM)<FMRF$IH\Z1VY$EES$8XR5_&+G-/K!BIAU2_3L6*3O5:[<55PURUBZ%N
M2P5D+(]XJLLQ*)!A;%QS-9/DEH2KI+8$2?F.S%;U7E>47.7(IO9(LF2.;OLE
M)5L3IRL&YQD,T84""Q)8\-QV,A=3&UE1E`R8I<2@8SG$5BK:59M4D+E]VOFA
MQ:P7(?Y5J4L>SV[&$M4J0L(ES',3QEBX&#DIVK47#=QE',[&O%7L':RW80E/
M13IE7%I/6N#;V3-D>M:5NDN#=]N$;^.^^2F`1IBB`'O7S:-KMV4)YL]..N+K
M#*V9K>@T"K5:F0SVUYDYO5M-U*DU6QF+2,)'MNF#DED9QQ:9BRZ+!A39C*$1
M/<#1+%KK)=8L<6B%07L)*EV%&L;463:!B%-==MLP&7K25?9TR*&PQ1E*6"_W
MAU4!/&8MO!,6=J[P(JG5*)["M.L)J*VE3WJ>)*C`=?;9V1Y(;\M:L]2;QDVO
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MFVV8LK"#"6A+R5,-(X%?"9EJXK(>^]O+@:>0M$.+K%(Q;>D!7#"/B`*'A882
MI>9(KS$UU04V".#N:5^7#6YMC)\\K>%7GL#747JV!W9<D^IR(Q$YCH&K+*;<
M/,1D]GMUD6!7$N7.*]E":L,C\6;)+*$Z5.8::V@#C&13W*QXV\Y&4VK8U&0&
MB5LMRK3:/KV4LE0QK8CN3V-6DT(ERX>Q9%MJ*O++E=4U`)F4=6>\:GRA8A5<
MV+<1]D@E<PQ+E@#'";B4R4BP1Y:H+`\M].0%POSK0VSDOA^M#54,RMNS(BQ4
MH?!6.J;KCXI/#K;1'O\`>L>DCO%R&<.3E[40VBEZ4K]WZ49/[G/64[%2`/+#
M[)4YU^(839B13=0Q2I`^F6R:S8Y8"U$.`"*!?*9F(GBDY664EF#GWQVL,.3K
M@KT)U8H,I@8=U0MH@LRX6)3#(&>@FS$QK*!WDKU^,M!OK^/,MIS:*JYG#ZK6
M7I#8JTO5/-=RV"WHW6$U%\@,F(L>22UX;G%.:K5L4;=H]'0GE_>.39D>,9Z5
MC[[7'6E1!:WM"@#D1FT5&2&WTS)<04@@(9LV2KU&D)`A[3B1UQ-NO^WJR:RY
MU2J5[;)@2B4U;8<ZSCY0/:3H^BI4FS>B/F.J(?/K$$>\O]-NK;*9/(-<-R(!
M7E>2F\(3:-L2JJ(6OJNLY511R-*ZM4JG4#M.:LB@$Y6+R4\=5M9CD@5J19(5
M'HS@&`!2086,)6SRYB*EW&HMU1+[;+,V+15!JI$^,39%HS)<R"OU1+0L&N)*
M-&*K3SECQZO][)5<A-1L+W9"^-:+9V#X1,BD$S',2B+(G,!-?D0Q,X==M@#=
M@XV^OJJD[QHI8Q.Y38./W;'X8B5/:):WIW5JE$,E=93RT:QG,7=&]4`8%;0_
M+O8,ZD*@$*`#*#:MTS13%K6"MQ2U9AZBZNU)<&"P&#$?+/JMH=M9P_.EK0B9
MUDU;Z;CB&O!'7ZDM6V(W4Y3@Y@2RB?CMO#$LA=A)?*Y2YD=X`^*2>[*WBMVZ
MN6X-I;#NVH4>TUQTYK9#9'`]<8NQLU9UE($[.&5F/M1TQ7TND[\N?0+419J]
M?E*%&F#@24:CN4BZQHA'X_P-^X(LSN5HQ=8V>0R*C:Y==8K&87$FH!:XI`ID
MY'KZ@W";F9+;SG+8NG'3B\8Y5:5QO/\`E>W6VT,DSDSK4;!%,06\1R[&.GU'
M]\:4_P!E+NNG?2Q;+VAL.UZ#KK:BP=?]>*Y?()KK'F!I9J]`TAE;\IDM;TM"
M+!DJU')UI[>WC6N@B`HB,^^!4HZJ><897#\?8G*Y#[V9RP/LBPIVD:8V6*IF
M(JX+ACU@1/Y"41,#UBKUY>^03'_.K>,Q\37Q="K3AJAWF"N/KBVRN2;S9`5Y
M(("!9O)$4D9CQ$=2UP;][8#N_P`AD5UV\C$PG5[4ILU7U2Z;:$)JYTIFTAM1
M1VQH^X&^P(-&=>$NRF::C:IV6$D2PE]90-:%&(Y4Y*S`Y$*OX<E^1Q/C]P)C
M(NNYZTJZ1^B:^)39E06K#:\I"JXE"Q@&R1!API8HF3F"L>4^TQV5R=9Q'1Q]
M?QU%E1*B#8S)6$&U56N#NR;$0SH4Y$03EPTV2T8#:/K68#'DYB939$G2))`:
MTMICZE0#$8A3/(T9(G-.B,&,P9B0E;D82Q9$+.08QG.<\MWAJ!=<%`B.C#3A
M9%]4K@IX27I'K([3/I'K^D:S,>=ME!!Y`1"_*0EHQ\!9(QSB/6?2"WB/6?3]
M9UZW*NK>G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FM=B#3R\A^1\>\DEV&K%]KMMH=]UYAM"$:XR)LE,1
MADAD;).7=Y2W:=L8ZH54P>YK'$`W%3_#B42EH1$(RTA!X,KQ38%LXBAFJEKD
M]^8;3.3&>J%>P*W%5<!,,YJZKUCN&2$F696\#4L)K%%FUGE'8F:Q=-7%G:/@
M42SN.XJL#F%,2N!8$UABL4#,*2UZC%QLAPYV6ZWENFXD>VS=)B:L%#->970\
M.KWZ/VTS(;/[`B,XG$T'(<O1F%BMZ)K]F0%I<-Y64Y:8P?OF>][8/,8YN.1E
MT;P?[JS'3OMM*EX\<A]N/CSA[+T,*?EXRA<;%\1[R$'>'&*@S"KCVW6DN)W!
MSK(55):4>G$JJE6EAOS@XNG/R</G@G/O%O/I99MS6\T[.1UJG$HW0J+=ND5S
M_0"F5):QG%34\TTNBKJR4Q%V1PRXZL61Q"I-(3-ID)=6]0X'#+7C'VC#7Q<M
MP]?%%4ZOW3&6,U,L("Z["<XMJ;$-4)B46E5V"E-D7<.*$<ZQ0!"<^8;^]LO)
MMR0XJYBL33$`D1:D\/D1RM=BVR)#*F7H)KD&DI*&M&'1RB1]FWO&A.+<V2U\
MVZD5XTS+KRJ"$2ZNY$&W].XO:57&1V;ND8>G)QH>'"M6+2RBYQ'G"/'89'MQ
MDLV5ITCFJ3+_`+,@>`!M8Z:N)RN0M4`8%/)54)8<D'OP]LRV:B5<%0J&)"X:
M'I]E*'K57(U]ZY<=6[#\CC*E.X0S8HW66%#$%%4I:E2Y!U>3)C(@T*L`<608
MMT'UF"R%:[:OWQ4S^ZW;<$DC;@UDB&XM+4M6TV*?Z*9)18*&344D?$L9<S98
MR6%!(0X59+1R-:=)(BEB;6>M,5'!0O#849DOGE"W:QJT^VD.^EY<O/U(F#)0
MO&,?!U[02R664_\`KD2F5NK&LI/LEXS`Q8*$,LKLSW+,L"[$NE1PLQKM.Z<-
MI%"YBI9#WI!VF-H26E/VX8,MF]KF\;T^NMMKBQ9'L7%R=MJTO&E+P8[7!1#B
M;1A)]'8D)$9K1+KN7=Z24IJR/(F+NJ,*'81[YEV784F.9I*5&D([J/#&9^GG
M,8,C*??18%L]AV8R-(Z%C[HPKKE*63%+<&!7F3(P>QSV-JP@;'C[_'<GL5,Z
MU92(1'2-?V=^OD4L$#[Q(G.J50O0/6-E*`6L:PB'''SUXJK/?(M>S8NVPC:R
M4VWO'4&];3)G#7-0:A136HB:R$U5G9<>;[U:LV/5PEU6-_Q4[6MB3BD2Y$6:
MK5'"&J'-B;Y8?_CW0,%&`L9$HW_^PO(E<DS/:(X7U#=/JN#]F#16*:7!4J.S
M>8_),S)7#V7F,'7QT]>X$A:1V(5$4G$UF[GSKL$V<7/&;1<QD,DUAXU'"H]R
M=@MK(=:E6)L;,2.*3NPQ+]6(<[[!,$NCD6CL97L-9[(.\W7YCE,2;$73*5$9
M<XJ^+$AXSC$3LF.-R=BIBF3BL$SQY$S&/&Y:L)D-EF7NF$SKO$$1[L$RQT*)
M<5'0+B'MX1QFOE51E;]?+NA<90,>BHXI&3"(0)0+Z8$4^U>?VI;+2N)/VZMT
M[COJ^FW0E_8=$KKT_C]\K&Z<7<KV!=G_`&`.@.5J]$^W_8,MF3HZ$P7,Y(^1
MF-,\G+:$A>7H'<0A*,R(/7V\5\G5H97%XG`.5QP..JX^NU0%QFPNM*V7-CB/
MM%??[AY3Q9TE8*/NP.Y;.,RC:/E-[RUZU-OW+C'P$#(+"80%6H$C$S)Q6KIK
M@4\AEY*(_M=G$<`WAXA45T2"UVPR]$D;I>Q-*JOT^CM?$U`G=IC5Y-0R0F61
M:8Q2Q%-AIF9<QNCRVMPWF/N,:5?.`WE!*<$OKGFN69R)9K)>3;K_`.17/*Z&
M?4R1F5KM8^6RE+E<X]Q7W>^=@.LR)9.["XQK`Q>.I8W&8#$Q##JX?!W\4WYY
M$K-;(+KK<P"CYJ]D1K+@&S+QB.42N>4S/HV3XJY+L!'[RD^P^R+=*]DKEJ>'
M4:@LZM:645I4]<U5"YPUV+B&QJD'RW[,?G!NG\L9DI\K&OFJA0YE)RR$1C83
MC(!05KC,2U%S`_9R`>04LN\G3+@L/Q\LBF@EC*9&H@&M@%B?:3&$USVS"Q#I
M=<W50QV281XU&)NX^O"/\=B@OJ!5BUS^X!79A8P#(4"%+W!=<>1D?F%>,G8W
M,@VLEK]N/4%F.NV#E4SA.HO<NBL0L6I7!DKB.O,<74[+:[.NQG'*:$6IW]2>
MTM:5R9Y4V*>P2R2.X?>"?GDA$X)7CA##\8K,7KO^1LPV>^6@.3"7"=KE4JR3
MJV40BN/#9M%LS):NH:Y.7'-K,DWAQ-6D/MYZH3-5S6P=>"[."K(N8NXELO-D
M3NBQ6D0@+-B'A7::OL;6&TZWMZM%LHU_JJ:5`K1WAJ^T7C&T,:G%@&V&:XZX
M-SM:T<<];7^$+%9[3&,B72QN;(_DM"I1KPA&,W87D93F+UY<,]O?IT:YLDAG
M([4%M4HYOR&S)>#9]V#:Q@\A`QA1`$C4NH&]30L@0IU?(6;8*4N5X_E9!(F'
MLN<D(@:`<N565F+3<7+9DQ$D&K0>WJ@V%N2]M6]I&6N"=G00-=LA$;<U_07)
MB3SF!QL$0)MFKW2'6C1#765D2"/@`%QRN:I-'3E!)1@&@``>R+-J,:B@>`9.
MWC7O[-Q2U_(^NRYUS8!-ADN'H,EB<`U#6"<E(MB"F-6K\Q=LU\MM'[^BBJG)
ME$2AU>N;3KB](=32)'<Q:R795]J>)1)1SU9<Y\8LZ66/;<MJO;%YAK)L_3D'
MI/:958=7_P!OW%-(["!2<@$AJ.US+)A#)3\L?VF9N215A?%Y:R)2S2OKFU"%
M.2`/`JJOI6\#D5P?BMG(#=BNJ>ID.%0*);'SV2ZNV%*EL$N+,[,@+2X9.UN;
MS@NT<]7@(\FQ]=R%M,8)'4YL.C>L'5(L0<?9('`OX$]3V<C+&KAX=XU"8]>E
M0UA=(J[TEV"9*Y*O:BVJFG69W6[,]30ALA@(Q65ZH;&*5,$>F<<CR4IT1*H3
M)WM29D[#>M2&*<\G=D98/9Y$$7,95S=C+J2M9CO8>Q+I2\`[9L55LKK)**ZZ
MSMA$"<R(VG/IU74["W^/M*KG3Q",7-AA++BI16=GK@X6M5DXNV.USI:B"/L%
M*^,;14U%U1MS=`O>4,XDEC:X:P7WLLG;)70EBZ0771-_RR@JFC,7B-.Q>'71
M=3Y#&=OK*4,4;']DG201[=4Z0X2;#HWGG""&]4&)\;P=_P`AD+MPKUO,/KR8
M1ME;-V7N7>7R:;D#"ZK5BJ*@DR-H<T5L'43NK%>1Y"CXH$X]=/$4L,BP,2T"
MI5JIJBQ4D]U"XI?:1,LE^T"+B3]Q3#V%ZO>,<&I=[WG8]5V/5C77]SV:OM;Z
MM-J]#B-A6->O;6]N_K%RV64S-QQ)Z+;PH<_!9OXDB?$)9@BR'PL.1=V77;;5
MXO/CQLCO6-J%N`>KF=EKG38NK"=K5I1NF0<!UN4"`N%HQ$1ZZG2++CDD+XU^
MBJHE%,'"PJJ6H1J',1-<6"H9,&19&"DC"!.>498KG2>9U'I@+5^O[\)2ST]U
MFLA>KBEM.12P8[-W>>SI^F<F;+`IV7/;BBD$*?TCZ)J7H$[XWN!J$&/CN*4S
M.!!]S?1DD4*%2O67AZ-6K7]JT.^NY2%0#08,$DX%[>=B>M@$##B.1C!0>A4M
M-#+9+-W2*<KDK3[$MKS[<T-9Q%+$;]H0:%K4N)8#09Q(I6,E'#JUCTEE&I&L
MMDTU2]EUK$K"GTJFT^9GMDHU[9M<:FE4VREP>UU'K$WW<6XPNLV?XV3TD?)G
M(LA6G&'"5B"/VN>>0R>8P2/'ZK'*K(IS6AKC]Q8E9R<G][97J$'(U^0D*`@!
MD60,\N,>==&>;G,@A)]Q`1I0/MU&:@XBQ@SW<G-+B5MD<9L3$[0J9@HC!K1X
M[]]-::'K#7*,^0"@3H!5[Z[2HM^9=%;/BEFS]\=)#()>I3V1+$_D$=&=UC3M
M)G\1KJD;&AG5KTI`$X%B<.3!#N9:ZW*RMG$$LK8\*M<`Y0E757&LII*Y;ME8
MP387)BDK!0TP*!@-58#_`"KMEGW)R5UEBR127;]UD,.*[8*"2?RBH&E#I%/(
M-IDH,>O6[QU[Z:XTXRT.Q>0#7]9"$=C2BT9))V?1:UH?;\XDDKE[I/'5+(9Z
MW>0Q8U%,;G)%Y92\")F2K5;21\,*HK)@C^>3:CVN.K`$`O$X]56J`[=6R5$I
M<V%%!0\?G)IK$DP3^!Q(B,@7EI46[N7R+9VNYJXVRXQ^0EL;*^4U^'&%\04*
M@DX9(A,[\BV*)8>._3ZS=+JKL2`6E>,*O^0V#=UDW@X3N)T>YT<K4/\`:CV9
M(I*F?V=?=%RDO9B9R-]I$H*4(<E(2BR30'&!R>+N;%<?'L/@*ZV"&'QP4A,F
M<NQ2B(@.1X#Q;,F<M*"D3*=Q!41QGAB[+_(,IGK#!(LG;]Q(0,QTEP%<J`I(
MIE`B`0H"CD'S\F,Y1QG[RCJQIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK01YDJ<G)B.&SB%[+[70B
MT=BKVU`U#HR&TALML/0T.K;$PN`Q7;MABB-,VQ"XU8LV<ZT4NYQJU_1*26]"
MU$X++ZE9,R\:JUG^<8C!W"DDWLO8N6R(V;?M>-Q1W'TEASXJAI4G<["H!Y%<
M&`D92$E+E[#U^(YG*J@!'&X%@5AA:^4Y2]:"C3LM;QAK1"Q;HBFH12GDEF\3
M[LX''FU6H2VM-DM*]<JYVQWZ,8MK-O\`$N>X\HWYWB4/,$U\HG7B92BXH2BL
MD_8U982Z/6/*6MJ]PQ2X>ZVJW+&$0B!8"/DGC21O^2G1R!0VCC,/F<DWZ@DP
ML?MF.Q]<NN1@O:Y%XVE,+YR"7)+<";#:N:A=#QJQE*Q&O(7+6#QB(F89'N1N
MW;EVR$'O`%8Q`6D-6L.O="K$C)+`DR;U*>K'IWR=;/:31NX[7N36:(ZKT_?C
M,ANZP9;>$[H>UI_8TYC)T!(NNQGJ26K)XU-HRP"=TS?)G=X6(,I,_%/*2BP5
MR?"-=EO$\U8R`A-C&9ZK4JV!6"Y:I]!EBRAD+$%M.DP*Y0V!AL#<@7DR964<
MYU8X[/8'V?(%93$Y%UE/(SB#I6Z*:UD981RJ+(V;*I4'%9%4)@#R[-1;DFIK
MS(_*-5>MKCMEOG)&`6O.S.V>S"^-;W;L5;'W9RGMKL$,U_@\=A5<;$1^)55#
M8,<^/`FIOCY*+*LEB"%4(XK!@!4O'*M>QB\]S84)P^(P]%9D9,864NR]S\@4
ML(IDI1C[$Q7*3KJBV(P,DM9ZN^06+"XQ%G9<W,KGK[9$%K4`8K'U8"*@@L1B
M9%][&PZWMWM8HCDAFR<#EFJ_(#(=<*AA;<VPR7[)ZIT]L?&=&IIN);.Q#BJV
M(L>XWZS6ZJULQBE82.(3D5H0.(6?*"6)W=GJPF5ZQEO6#1-R\M,7[^IC2?Y(
M_!>Y!-5WD%!88_K#C#SJUVJ]S<4(!%-60*B^RLT^]9LT&M6(,[-4;U1.`KY[
MVK3LG@BM7;H,,O\`&2YD7HH(>TB*S8I4[:5B!0I1R*ZRWR^&*5("$^3:3R2,
M11:[Z\M+=,)QY%Y%H5$6&.7*NE49DK5")*K;)[>3),%5/1E:K;8DPQ]]5J&4
M;05C*UE.1Y<0XS\D$&&0K+QXYN3$EG<'D<DR"#UJ!07D#$9^:.T+14TPAL].
MX74LZYVXG-F8?AF>1@Y9D.!N8ZN$[;38/)_MGM^<3_0@)R:X?QFQ`2IG&6;>
ME@S3R^E1"R?^/:NG:Z9ME7*X+NAT3KV?;-,L,A\FJFE<Q%499C;-T]8R23/<
MSGC;-4A;/"6*+OCGES+5$JE*=$B6.1&?BV_NF/K9!,291BYNW4*V=91'[E>Q
MPHJI&8*XTIH.?V'-2JM<3#["BZX;)=@:EJZB9VKJR::%5K)%:W.;BZF2EEB2
M*2JUU%:&J9+&V\V$B45FD^%A=*;R,;53>WY54=->.UYE[U'Z)UUO\;;/]DH=
M4$SC##>TC>65=`K;BKW7[VWU_:\1;8PZ.)#6A=9"C<2$(R3US<IS@GFO2QW;
M<L!?:"L74SZ,>ZRK[R^ER(>VTF(X2\J4$`VZX>D<QFN^QR""AR1S2Q]2Y6B7
MV+^.R;JZ_4)8_'.4D%\BCB%6_+0FI:/BW:=[%-`BP@V^#$()8AX+$8((!"P4
M7D'>8+&,YP6#)HBR^X6?3&1""'K^.<8YEF4@$D(R4Q$S$1MO/^D;S$;S\(WF
M(_C,1ZZE".4Q!3`[[;SZ[1__`!&^T?Z1O_IK4BR^6N'.%?W_`&`[Z^VO'#ZG
MVN:M)ZWK!0^UR]VS>6Q+H"/DIXHP(8M*7NL(XT+'*5H`IW(Z6*DX$V5!R[X`
MTPR,SXVO9R^,P%BA`SE?(IMG701<156IDT'6;3MBA8)FK<*S"@>*UUX-!V>T
M1CJR(4,SEZ.0*%8K"TJ[[%G:2@IL1)`I"HCFPV`=;VX3(-:RS"S4F0DBXR#R
MF'4'++IKS<VD6FJ)Y5E/1:\H^T4-;JG9!NL**SBP&^K(A"T:M^JJA7MCN-^G
MKND0$,QC8I:C\FB-3NQY91H@<5A+(56+Q<38SR\S1Q<5QX@+[>14]M7VSF$'
M)7&NV7'875)(P)$N8.-0NDJCT,O\:^&?C+]_N9,\DHQD**Y-E:X9`2L'+(90
MRPLID@YB7#G03?R.VG5TMDU.[-U-4FIDYF.LUG7[1\['L&*[(DR$08QK9366
M_FS%1U>=!)BA?92V``BCA\W:'$_)R9*Z'&A)PHJWZ]J]C<KC?'W0SS"B-<0!
M:F-38*Z_VM:*3)"&N>Q_H*'5$G([-$6`+8"]3934W$YC(*>/C%^X:3AO!5E/
M14.\\K*Q8Q*D!74WFX;1\"@!.`E@S&N[5RYKCKVX8*^WOL!L!K7=%?:;VG<6
M[D`W>M*Q9)3]XOZY,A8X3:^O<'<WN2TO6U8PB?JB5:DF$%15_;VT],UO3$%<
MJ&+&Q?*HG%^1+\6'LHKHT:E-+OO7ZF7>Z84VPR):QPV16Y'^,VS0>]J_;`OK
M$`I8]#KV1PL98";?M9BXV6UN2JMG%(`F,2A6X`#5@Q#`BVA-Q24/<QIC)FVZ
M]$9=L4\[8ZD1VY[=V@JC9IXK:[+.VRKS8:Q;)?*4VUA1A($,->]1:C7OCW1E
M=L<.?WEL7A(9FR%3-G9B!$OK8<<><:;?QBJ2RRJ*BBG&U,)1%U5Y"V_5R;&+
M!EIKBYE%>379`BJO;1)CT(A261$*SLU9>U%%W:L_>Y^Q[*Y7&%5&8Y0V'+J0
ML1'NL'5E4S-M8V)ZG6TV+"17SV]S'>%%$MX(EI:IJ"7)\NU&S?8>2W@^2:#-
M]=,]<PHU(TK!L;0RO<HG;F]DR9P3I%93TV1I(609D](J7=@RL?/4&U[5#.Y2
MV<5J6!KI8V2CD3.\]@X0&XP'6+F;R?;]DHE$"0G.O;4RL6*0D&/MYBX=9$!`
M\88H"8P6R1BR)@.'"5J8HR:`$U9<H&,AWE3DO\9J38E+K2F#H_=%VP^C8)<C
MQ=&&F^9(XSV6G02*67']:@U8O85]2/4F*QE.>HGZ.3'-O58%CR7DL)NCCL=8
M=E\=@,J,U<QF$B=58[.D)97FTH+I#(C7EE>(9)IFVI/-8V#479"ZEVU55BLS
MEJ!$^M@!L%;(HA8,&JX46/9%N9O);9)4BY=7FU9BN3CB99'FF]]\U?L32%66
M?J`V12N-AKI>J6K5W0;'QV:[&J,L[<X.([>>]=H=73Q#&^D0)4.%2US3V.L>
M69`>6<XM*4S(B`P>.H_>K'[?:GV^3G%V;T@,2T*X5_[-UOVQ0YT?*B4^Z0QQ
M`D7R<EQL9H#QM&SE:<>XQ=6]5K2R=U]Y6I$8.H.QDR`,I@@L15;(K:<+X0$L
MN_R-[?5_K/4H(6Z;'4MK/;%[MTMAE263=T^AT#BD-<TL>5*7.>'JIG(XNW.9
ML4*,+,3(@*P'JUIA19>!YZAS\KGW6+%6SB\:Z%9(:+;$\2CNZUQ,0"`C<R<]
MFR52([`129&N`Y:W,*"JCTYF_7FQC5VTKD)VA9FPX]&'.\"I8<FMV$YX#QZR
MY:A;J-Y%K'3Z.>*R9JHJ3L;(-K+#CFNL\G+K:[BUS<AS2.LK8'JYVQ`57\W;
M[*;`$Q`YT<`FN[&4%*>`9"@P(@AQ^GYNE7M>?5\!54%.A;\>G(C([SU>WQE>
MTQ1++C,Q+#ZI9+";V3R)9ERF?S_'.=CO$,IDK=CWF3QN9.I&^PC9)^08JO"V
M1)0)$H@):X"5<1D8,!$=[QF?F*31*Q7.@%5,P!DV0,N2[X-#*_L+9EBA,3F=
M9TD)J,46,TRQ/6LFFKY,9Z6Z82L<*CL2D3J:Z@R0I/3)NY:#Y*AROTZMM8F;
M?VD+UU"AEKT0;W(!%0(XA=:4*AL,-E.M"BDF/7QB"^SRE-&)LFJY84%9]BNJ
MDTI@5OEZ@9++)<I&DJO)2#^9-=OPA"7F?`?:M+RFVW"9C-(VP::"$DAVC(MX
MW05L7N&K95%X\V2-6ROU963%&.GK1(B,Y5)&X\]BP@<7PIQ-P$E=AIQD9I<[
MU+J(R=UYP='&9;'4B)/W);.16)B*A/JCW:)*!;7,A1Z%(7"GB)4*`MR'[4@`
M)60R?OHX,V@5>R+CWD8R<E1=.TA:@.<1,3->?7:YU7E,5-SK;*MUUZ6MM?5[
MX_(;O8RR=39.,2%S.FB588U4;-HJ&O\`+1!9FK5)@`2JT;W("U)1F#,D%BQ@
ML7>6ILQ"LX+B`[N&\FJ8<0&9XO9<@.#><Q$JX$8BQ?`XC?>&3\-189R<M8P2
MRY)1E\?:NM(H&2K5ZC.+'",%M82001K/DF2D9&0B/FU:;%Y?4$RM%%4M?42E
ML"?0F.4XOV+JR*W;&EU\5_*;F8X^]HHK5%/CBA+C;2*NR'_`Y6^/JZ`LS<2G
M-PE/7K`Y1<T*^("SF+513Q+!IRUC&A<&.8>XK2P7.M"$E[.B)J)0O89N:R1E
M-5B9[M4'9&4XNK>)1C:M8X,@"S@P[*CICVXUSD-[5QZY%HUT`2E!/W[2IC;6
M4_*I5EK7G5-4U)K_`'K;NN]]RVU4ZRN;"J>T)U7QS89%XR^21>&<L\.?FIML
M&`*U[>@1.C:ZE+$N$RP1A80FX"+/R_.XC.U[V.B&W:%6U=BNSUKW1K=4E2:)
M1*X*SS@4M(9)1QZ1(D<3]+6L4$X:TO,J9&-NG7I]RQ&7U'63F%V`,9@XZ0%Q
M$('`,F!$]_DF(34^](_*-)-:Y;++4VNIRQ:JH^V&';FE*.V\V;UX8D]S0^3#
MK`+),XM2-I0``7-AL!C=7)(>G$B7K$)Z<"@Y0F"64'0\@1431SWEOCG<SQ^_
MA*MG%-(C(%/>#7$(J.8V:A(K68$'411)&N6%RC'K#E:`T?',T*2R-'-V*=TQ
MVAI*JK4:S@XY":+PN`Y;,$82/%+`B"B=;]#[>7_%-(-#Y;#-@K?>&>OMSJI3
M[_V[<U]6S94LD)D[L^:5XSU."66G8$T41B--["2VN[\TE^TV83')>I9"G)^1
M_0PVDSS/QMCEK#PFUCF*"(#U?<9A6WGO8<#N]=1JFA`PULC9DD``0@8U6RF/
MMXS!>:5*ON#\NJVVF(S#"*O2JY6I54I2IDH0ZXILR!C"V374;SAPV98/TD:D
MU$8OG]O[9N<SOT\%XR=T/KNLIOL%L%*ZNA=;I#RT;4\1RDI]/G.NX*]S@Q!E
MU-*0LJ7#86HPF1^TGR((\>LEN'P:L38&)R3OOV)9Q:Q4L(F+JBV3=,17`X!A
MJ;`O+U*($06%J^Q&6S49"L8S0J*BNF4SP4^0`0;9(4D*GPPQGH-BA9"XYG$O
M-K#C=Y-GN]X?8=.S=[B6S<X\?4;@]D+=F6W2BS)A66PL6FJ8;0MA5@O:NJI]
M5EZR*I(PQIG`Q8@A#V)RR?D0U:!:1@L&,(+.,JW[Q^3,=7QDTD33LP3(KU;`
MM=[H[8IF3(322(435/K*D&&P%^K(U65[]O&U*_C0K;G"R!#900J[;-4U!"`J
M,?\`:6U=B#)P\E/<!K"NR2YK/%VN^]3#K_%IC7[;)9QM=0E>Z&/_`)$XEMY/
MKIETJG\Z@DBD\Z41^L9:P3^''O,;7%HXR8E:EAK^YGG$$XP<B3FA$#/T.:5F
M\?A\B.6JK'R?!/QN*A:X6`9*[9KA*SYJ'@ASV,23``'!`V%L%A;\-9GC]6AD
MLGB1H6CC!YW(9#U=V2S%UZK$Q,,%OW'(0#3`GN-3997=#HF=V3XUX;JG.4_:
M+:E^G<#-M;6+QLR_R!U7+'[:&:-J>ME%BI!1^959.H\R4L)L)4/K3#CPM3P)
M+(,K#T/LA1-N3AGAS\[1R6$+R@O'V1&=J/I853X#F-F<@W<5`)[B-I%@$,FM
M.P.!B=[BQ,A&WXV5?R-/B]?,1"\#FKUBRT><;U&XQ,=5@SB(DJC%7V"5F)CI
MCO9-9\I""MZI_*KL'4->:_T+LK!*AMO>J0:^MNQL_B[!L0TQ9UF%3+D"U8V&
MP2))=;H6ZS#92:+D"A$U5W'(TH9$XRR1.4I0EJDYQWT671C'^27\?A5E%7%/
M36N+27N'+L-D0&*X&2R>H1)5BW;L_M]9`ND%$XER&L7%-N/Q5;*Y,D5TYA[B
MH$PNM(H"0,BN3$,8A0";%UO;#E+%KV[#D`^>5[/]O-TDNHFGTCV\D-&6U-&Z
M-1N//KM5C(KK*/S^/GRK*-"UHI4*96`QL"3X$B=$C>X%M*I[<BSE'5(B7=H@
M\^>R(G3S-7!530^Q<R2:*FP917[K#10DC.`)W4;"$>:T-(8+F00N",=K!*7E
MZ;K]DBJ(KT'7&"8S+83643[$`,3PEBZX-=Q8U0D*R"#[2`#_`&Q-A[_^TK""
M:_T34=C6S+JU*M:P(Y;NQ<OI6&UG%U@T3>SE"F,,UJOZ021XD#\-<F1%"CK<
MG,+:E)@SRQ!`4.Q;JN5EKU*M('CZ!`!N+D$L-IM$!2$`8'(BDC?!.`E"RO,"
MR&S(9U"T-C!4,M;6Y5C(\Y4`B)KCI6ECX:V2`@(8LHA<0DX9),WE?7\^(7O=
M^^G*73FEZ<UIJNS+ZH&$Q26[3D.^SS]`->*I>9='5,K:ZQAEV*M:Y!.K-L97
M&0)W,HE3`(XTE-RT@Q<X(3!X)YG7;U.IB[WE,=L^&X]C5F\Q$'O964#;8U:_
M82V#6@N!L;:0N6QU`4D+H5HIJ.9<IX5DA'D.0#L2H>9K6@WG70ZRV%P2O<,6
M<`I*;+HA9G*^N4L=:E5>5>,W5-/'Y$8!K[9XD&_52RJ[8].I))*Y:XC7T*@4
M>"X3=L<4C-)9+/'Z:,;X\,B0LO+&WL"Y,[X4)W@9R<U'SZEV`97\FS/CK60/
M[/C57"9(E]X+#$+K0`?R2R6-AD.);%E7.!6T9@]8LY#KP=?*O67N+&7/&]8$
M!BNRGO)TFV2#DF%UFFMM<'\BE(-%';!#M@STZ9Z^F.F>N>O3IC_QQZXY\XSA
MUEV3LOC.\[S&T;>L[Q,3'_S$Q,?'?6G'Q]/CKY1M$JZEFT<UMX4I*\N0ZOLK
M:[;5WIK;A'Y-MD(O158T+3=CG1*%0V%Q1AVWF#[('IT>6K!9*6<P)N1KD*A>
M:D<%I*`L`I_'.&,\-P.;RIC6N5L'5RSCM<73=[[07*J&*.7J*O.,8*K9F:K$
M@KD28=9ERNO+I9>\JSU&CQ94+)1B9"KQKS2L!CC3D+*X7UG#!RB7,KBE9U4&
MU"#%4![=E];HWL+R80;3RO&O5NLGS5G83?BL810NP%E6$FD%YO!&O\S?++LB
MV8/1:NHE*"*5K8-;TS(6I')03\I_4-3N'*AG+(6B#C0\5J60\YP6>R*8K9.M
MC+6=6H=^84XH0=5=LX@)JL._;Q##KK&TN)$`<8N`5Z@\E%5/Q'R3!4R7=2DU
MX:QWS,)FY9MQCK,UH.#]XZBDKLPPNB28IS*YFI<M*;L:\I]KJ0,IKGIXT_3+
MM]+#\?B`<*V/021WE,\A;C(6EKGU;-4CJ"`(I+`TPH:[&2?[):PKX^2VGB1$
M/>`9YG8@7YL,*<#U6<[B+MT(/E(HFG[@R*P0B4C2>JO)5[8`;C-U994@[A+4
MV6KE@RS:A$FUL"S%\Y$9B75\F&/A4+#U@;JG9*JEM8R&J,0]DY"(3(E<D2\I
M<CGO\=JN&Z[LCUMI,=@-CJ!BM68O0!-*KAZKJ$Z2X;><+YQ5!TQ;J>CKHO2M
M.50*]4/IKZJ`E*:3"NY7CF@I^7HTKN+&-K&#_='P[DJ*U?WQ8\1Y`#H:=IX$
M="(@(LUHE[9K0)@'=\`P]W(5LOS6%;(UJ=:5C#"MMN8]>50,#)!"2319!Y#L
M/KJM`T*9:9*(=;D*\J]G60^ZXPJ#ZG1QUGER7;MMK78+(IV/RF:*GM_45-(`
M3-[;Y"CI!TQ8-#N3PPA3XDOQ69^3`7)18CIYY@DP.UBJZ$6\:<3CG^(EGJQO
M^R4J"Y6I%7L@$OA#";9CI8D[:V<"F96O[D0Y&1PTO1DY_P`ZKY'3Q3`3]V#]
M[CVY)3D$77R8%54FZL\:TJD6C+98N`/$[YY&MS-@EOC6#JA3%40UQV0GE_RR
MXXE:%]JVDA976K095#9ZPLLM;M5;;4#J693-P95S3,TK2V/RH`D*/+8@"XJ%
M2.UCDT#\D&S<:?\`PD/$:V:,Y"!<"LH-,:T/5!2`6ZH7(LKJ!<A5HT619:4J
MMQM1WG,JX+(+Z"+/J\J+!"Q<R2`LU&V;%@UD8A+$N5BK]%QL2)59:!I4]Q+E
M.=FKRJNT@=*4L1AU^9W#3[8797.I-37L*[BTEF2JV#9#,X:W2]%0Y]6_5&T(
M[2Z#+4R=_+FADA,1XPNQ'LI,X,S4QR7W'T:#QZ,IF,18R5!93!059../*K]Z
M8[S4.S17+EBH;G7)I58E33(%\Y5\8I&3LE]U6!O5J>2D=_MV'9"MBWA5W&/<
M>SO6UH?+O:04@^5<^L8914-Y3+(M:4:U-TQU1:X3%=DME]I-6&&216_#+$<T
M<TUF76M\VPFF-+Z8K\#]2TD9Z;=Q&NRA>UN[<X93IP-*Q.;\X.CB<=&375DC
ME+K?B*<^(D,3UH9[.)2^8/Y".<A4]H8=O>+=W!5*($N\VP<0W(BJ0>K&^0)Q
M9ER@>QCX^4DQ\W,TR+?=)*0ZA4<@QTB0CN)5JTJ!*I7+E!"1$C3G*E:M2:`E
M.F3)RQ&GJ#SC,A+*))*!D0A"SC`0XSG/,6S813KG;M&*ZR@DC(IV$1&-R*9G
MTB(B-YG5A2FO:*$B1N,H$1B-YF9G:(B(]9F9](B-?/=KOY(6#93RX09BJS;2
MI;<UWM+5'8AMAU&5-:\,FZBO)73MDU$M;K/MMAALG>S&:96S'W!],:274A.H
M;F!"44$)2I0Y$!U/&*W?@?(VY");;]KA\BD^.ZZU<F7JSJ8'/IW?Y5%]W;C/
M<<5B$PIJ:RKY5(T,AA%5S!+%Y:_C'+DYAMEQ4_=^XE1<2E-=E"Q6KD(FN(AE
M@6D%]0A`O-*U_9*&JG*G]=ZJ?)=N5YW;0V)K9C=$;#5C2QP_2E'*$K[+$4P8
MH7-UL0:;#=-=%Q[JXH&Q8L<R)<MS@A08M$`SKQ0\IB1\-F@NK%G#>%YG-,&6
M2L13F9:&,7!`LY@0'+X'90@2PFFGT@4#(/*UT+CO,HR%F"3=RF"P:Y6J&2YM
M:*K,I\2"#LKX^0CWL,)B>0D43+(+:"E\UT4412MHFNJ^NX;MI8=[[":\E4M9
M.R3/!ZD13/65[+9K'?&B^E]9J95/HBY'N+:0P%L%?N,E=W%S+2_3$>PL-34:
M9ULM%"SAC-]"Y@QRI[A(V%UXM-I.4%<);#K0V*UJ5!VKKLK5V6FVJR1(AFM?
M^H/)HSQ`A^/R:*(2N98M[K=&MD:Y0TQ3"EQ4MURLDV!)+S&JH+-AM=;\AN7D
M@VKD-C$UE2?CI>[`E3SJFEV9C\7GFR$4I69MRD=B8@.*[LUFDM<N[#7R^5%E
M'N486%.[N8XI"<X<D;*,)N";5"J-RW=2Y@IJT+V&4YD_-*T99+G&3%C\_O,<
M-=L7*B^U6ZR%-UIDH&5W6(K33!\3+K8Y@1@/G$V8AJ5=E=GHIU&X5FM-6T9H
M:0/!LU(7!F&`(+Y--K8?9&WLYO"H(')J=2[80W2+4.J*HN3$@L*8;#!;HHD"
MP,GW^ME8M:Z)S%SG>5$FDCS+3"8B;'U:5(VK""#%RKC#USR&!Q%=$KL>3YZW
MDK-0N4@D,?2-U>Q-H_BFO2_:K]P'+18M6PL"N4K(4)U[D3BIE+]II$K`X;$T
M)O!$0;1N6AFPL$QO]ZY:B_BZ8U98FLLN+AM'W,X;$M.=L;AV$L79^K;AHBO*
MAD>L4Q@D">GFK-@7*_H1*Y7+X:7/'-H:WA]H^B)"U*XA'G=HRK`L:`#&>X]H
M,>V4$T[M":UKQQ/D"#9][(W:O`E\8GV71!/6?*88EAN)8SQ&8-+1*((9B/;)
M6*>7#$6%\6GC:]W???BJTQZTK*-O1V]5Q,&)(!"4&#&PZ>O%GD)OZU&:U]+]
M+*.FJFJ;"W7M&8L$@N%M;6QTD=:TU4D!>+*M)S@29^0.4>!8L@:&HMI:%2U.
MI);3UWS/CGY(P7FO@ZJLWY0S'7).,+C<0[)VQ`I6;P!Z*E>J+!V-0.M65R]B
MIAHH!D+-9D+!N9$RQ7B=C/)$3R++]2A6Y#!K4ZV1R5A@3,0R$(4TUJG<&-X"
MR.OE$XRMB,QOQS6I5UD5U9FX5[RK8-45K75FG]F[87E<T6LV]I6ZHI&W6JIF
M.Q-HV054;#`(4PO9K\)K0B;2&HT:DEN-4I4I`Y,8^U8LL\2QB*[LA<63U&XI
M`*-2BICKIML0M]@P9$5X$B&Q8[`A"(GW;X+FXFI.)_?\FQJ48YXRUBH^:VVX
M0U*M6*X2JO)LL-B5Q'MT+F98R06H2"VG+RN7K&:KN>:R;3B`+YC2&ZM2Z5O,
M-KG;%?+V2>R^RE<&2N+S5<SD&M4!5/BR+#LEH!]8\,[!A6?\LL2I/\8`CYJ%
M0,D7C?M2/K\BN6TCR&()"JQM5[LMC(#K2ZM;AA08,2I';UF1]007QM8^<\+1
M44X3Q]64^5DE#>:V..H<0ODBR*A5(#(L%A6%1,K">R;Y4>5=R9E-DUP_:X*%
MVQL?V\:--:KJ^`6R@E$)MZQ)'!6ZT$+T3:,B@D#<(=&837KF!RFARF-J1L&"
MC0(L/'[(CJF-KVLW4QLXH0_<K\9,C%TDM*$XF8BW;EX`XV5"F877,418<_=/
MMA*(F;614&'LWCRG->&J4<;96T1@VNG*M97IU.GF(!=*PHQ,/<%6!)+L%:@2
M,5VY'O+!8&6J;Q6::N1<G8='N"GT@J&KZNV,.L>!W!<9,+:;`EKX5:TBHVKW
MF&5;744>BE;ZZJHHI7)2TZH)3>>:466?8JTV9:GB&868*_EJ^1M0+]TJ31QA
MDIUMCE19F08U3E)6"R89BL>,$V87%9`L7;R,YF17B,=6QI2U,]S&6<F1!7HP
MDNGA9WE,EV-%0K;VFP%CR*"6LVP"JIMTMT+E2ZH50GW`VNV.@FDM;T?25DI#
M*REMA:_5FZVI=MO338M=3L#?3X(W,$T0*Y&_*(`=(2C&L"0AL<#PE!'8\>1)
M^%T\%X_MPR5S*9ILN^PBOCZAJH*9,*]SMV7?>*K0H9]R]\2R$S+""#R$05Y*
M6:ST`-?$8K'TA97XV+=FUEVD\:Q"R:VS4*17D@:V%UZT2SMXR`SNJTJVDL;;
MNN;E>)G5,8H^55?=-CT'WPNUS[TA4@?H`F;4[G-8A*UM<4ZYN<;+=W3*<LM8
MT-ZO)Z,X!A960\H6:BKGC&/S%%[`#,46/5N,"Q2X<ZJ)%Q,QYRQ#3&!*8Z^L
M^6YR(>JLG5\DNX>VH&#C'H!LB9;&QB56B5L2P(>*7)Y%M(R3"@=X#<M0<8TX
M>;%\C=IZOYW"\A"^(4QI6BF5KS-LW]WFBY#KLW?D]=#8#+V^+QS8UKC42:X9
M%6%R-;8PTX(9`IL%%*BC^S`Q>82LJUXSF[VY@%.]C<;2,BEA<E4S??L$3)GN
M:PH0#NR"6$M*5@N9':SEW^RS&"6R`9-]F4R-D(B`@JB[*D5:7V]A2`RX^#%@
MMK(1,R4CN,[$J:OG8BNH$P@?&77A]U'HP#=6,_W8V1W;G4%MB:ME:(VZ*6#=
M;Q7SGJS.8&88XRM&MP`+M::7*I249[ZI/UQG-RUDJF1L1G,HM.,IY&2970F(
M*5PQAJJ(-9Q5@&.(0F!"6?;:M@2XBX:@/'-HOLX7$C:LWZC#[!L<HD9(8M$(
MM&7FU*$-&(<0!,]91*P$.4X4D#8=>7FNA;9%+GODNJ*:TO;KLL&#U[M1?L:I
M:76%,+#;V>F%KY5D+M%KJ]\0F1-*XK1$Y:QH'LKH)>!6$)>,>>+U&4A\JR-\
M2[Z5VCCU)>,GTV7I=8M'UN@H$A2L%=<QQ29=@+!WW-1^0VD6\9XU1HFN?W"+
MUPG)GC+L>B%*5`M5QY1-NP+(:)RP@&%P<IB0U(O<O?*U]:'2PR*^U.>;+BU.
M5BUVQ8]H6=8#U0U5OC<\.XF=OK&B)HEJ*W45P7\J/+[@QH\$?1!P:0`QT+-.
M`#F54?#GS-@6#4')5*4"`RRX]EN(*&4ZL\(LH1&_N&=ZY`HD1`]IF-?V`$I0
M`T/>/J6K`S/_`(R`J[<XO/B2*J3=XFN,(=+1@BF!$=YU[;)75<U);>,OD*B<
M[V$9M7Z]9M>Z_P!RM7YW/)R[5_&(EL.T@.S;[;5KG)7.'US8M"KUC<7(B6A*
M5\@LPW)@LCP:,>W@\8C#^17L!E;5>WX]G,O8QE2U!\QJWZ@1(L4\HDUU;=B1
M1.Q"L!."`=YC;&OO'R'QBGF,*)+\GQV'')-JCR!KD&S<ZS41`BU_LH<])R//
MFF9,O2(U("BARFE5MK6Y2KY;>SUD;0[)3*&:[5EL=OAL:X42RU-'?C.;G(XL
M?*TFQR*!1IO$C6KAJFR)NCADDPI(0(E'G!8*-&+2<%B\'6`"L/K/NV6V8F'(
M%3&K&N;^IC.8Q`+2HI7%@SY/<;``M6[URCE,C>SY!831J34J<$+7U';>L"[X
M6MJP&N_LB9/8NB%SUH'G,3MGIYWNY[B&%M_5[5=9SW[)85F-4]<<MO*(8:`8
M*^`NQ-YI1>O+SER4YR/WDO\`'\%$=H>U0;W9[?7#5$%S7-A,D-S@@@8$]Y^4
M)@SYCQXSRF%SO,CPVB"*N$OEAPP0A43'"8*9DO3UY#(Q`[3Z1L1[QZSM\-94
MY!J73C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C
M33C33C33C33C34!]H-"D6TMU:^7._P"T.S%:"UFG#;9U95G5X-;0UJ"Q$+9(
MX\IF$B3V5KA94W?7%VBLJ5MAI)CX%"F3CP:B(2K.Y4+O#,+"YZ?(%_?M=#:_
M!O\`3BM8%8V$1"^LX%\+B#9!Q8&"*%.6,Q$,MOE?'&^-[S7KN8IIM5_5EM=L
M/JLGM[5;UG"+5AU=)D(]ZW0,1%NWSX\#KPVD@VV[=NEM[2EC5A!)97-<L%3I
M]15T`AT:L##`*P`M[%<VIEON3DYS(^+H#%*MR7+E";*?`40DI>1%YKXP&8MV
M0>IK&3DU*2^#X_T$LART!("!+`71+),2AQ$6QM(!`0GONC(TZ5!H"->A9*RN
M!DXY624ZOWLB2F#.*]AB`&8Z@"9(5PTF,.3=!ZT5=KD@F6(&F?W.569)A36U
M;,G,A<9C95GR_*(EM*?9E*G88SU.&YL3%I&]O2EI&AI1EA3H$B8@."\7"<(T
MUXVHL*^,23#6I>_$3<7)K)DR-C&L*(YM<;&G`@)'(+`1J2+76RR%UAOR)I4H
MF'`Q,K1!0I8@L5J4L.9E"TK6OL8ULCVM898$JG0A!5VXMJ;J*=H-E[+GUO0I
MMK>2P&P@:V_U8WP&-/<@?X+%(TA@>N,%GK0WP-?)UN41O\A,6+O=[G0YP,Q@
M>(\2R<3A;>#B(?7O/"PTV?U)LK6*1?$KZQ@N@93U\/;P+#($BV18/>8Y9C)4
M,D4S7_;E.4E:OZ?38D3<LNWM.8-RTODX.'<TK#LZ())6M%/%]1<8G25Z53RZ
M9=43#>$@V7@FJ\M?*_6Z^5]?DFDRJ;N5FL:1LK5HMJ0."><N*M\;VR22U]C[
M2\*A*T+>G/*3#([Q;VXNM52!2VW0I,ITWLF>ZI48MJ30F0D`G[#CKB]RVVEH
MGJ6\`WB9<JS]V;;-L"I>2-1W@"/EN,3T\#=SYD&_MT2Q=<D)?*]WJ9)MYV`A
M\1=5,!,$_A>RVVD'<:?O^VMAJ,>&*244O54U)+W/G:BW(M&6Z6Z_R:.2Z)S,
MRR7GJ=,4,GD#8!7D#<Z(P``$/M&S8HC2&#EDU,..*.2VB;.-7TPJHZ5POKA7
MMT<;%/VMPY6,ML,GUTR!QDFY!CQ&!R-Y-XQC?B%U,C(V0Y24F4\8B4/EU2(F
M877#?66WWQQU5FT*EN2KK3OF@;$JR$S"M%TAJN3P=Q46S7MAS!!8$[C-KXM^
MN;6"[JI3-V\+J>^M?U$H)6F#,3.9'7'3RJXJEBT2_7&7:U5#JOJ*"&C#1ID)
M!(6%-0+W##5/6;>UDO)I&13!9";E=`6B)F0K6G6%V2GDX6V%`EV\%N@UDM21
M%#$FA((2M"U*4"XSA6>LT"I*>WE;\24V!*)Q=;36[;(Q2B5)Y*ZE,U.Q1RC<
M'C4=?I`!,\G`#AW7*SE+XZ."I2YN!QYRKH+H&NZS93@7XA$$:CR%R]L'!9R^
MXJJDQ"8X*``"FF%1QCA\TR1;^G0UTOS*<HXMFA113^:2)<+38M6.<C\Q0;#M
MG#>&P$"T`*QA<;V!JQ0MQUSK,]5M8]\7>LL>92:UY8WV)+IM$+=M^I&ZQY6]
M2"*Q9OE\TA,DK^0KZR:W(E,C)5,;FQHQ$X1E`7(B"SCY\@H3Q&/PJG[VJ./3
M7;;4$`=IBR(C>4,`I(R$H23S`&O%<6"768SJ4HND,[>S=A,'2MY`K"Z;9GJ0
MOK4OVX]!KD%$2R="U,CJETJAK>':<9(%X>ZEA-//U2K=E=KY\M4[*%;?0*VI
MNYZYFVO3NQF7Y1)5]D0%QBNMT5ASP<[NZCJ>URQDD[(%,6%*2C)28R1F15IE
M2MADXR!JOP5:S5K-7'(YIVQ:%BJV&]JF+8-BQR.5Q8DGF<ODQ42_&@%I^7;>
MB7+SA).V$S("3JXH!#PE,K-1I&K6@!`Q3]@-U3R9SR4[^+37B902UV*TY/;M
MNVI=2^NWJ?;-3J0P\%[*7ZG7\<HI]TCHX=`XE44)2UC(186-;0S1)`P"48R8
MJ0*1F&B'!RFM%2<)OCFT<F.14:)DSB]"Q5-DRM38[B)8ROJ;S0`&8)4L#D==
MS,V)LCE/\VK;Q;L:Q3?1?L;$S+JP"GJZQ84P;&+D7M,%&UIDI<CYLI\4U!VE
M'K2!?MBWOL);-LQ!@@CML98\F@3)<,3BL1DZ.;1)IK!)4-:5=3U:)V.8MJ9T
M'AGB27[98F*&Z?.]L&,=`UE1:/V>9HW$9*OD(>GYFG<JR?MVLE_<)BD3,`1(
M>V$2+9,$1%/A;V0*OE=KN.FG;J0AHA"AKWEBNTN(2*B*6B,;N89V(C<1<*YX
M:J9)XLJ0M6+6:U;*V;>^TTXM&K%E*+[FMU]K6/V1$JS5/31)P1RO4E#U52]9
M1`TB4L*-R&X$1S+FN5)P?.4JB@X+YUWL1]W%3-&_-ZI<)Z)GM*U1,SJ-^[+5
MA"986R%K"L7U&DCCEI4DZ]A#7D5FI7KO0"&SR5"[2X59Y<>+&,<N.LGL83Q"
M2!;0&9C67*7TDBU7V6RW;8-RWAM%=<4A#I6<'M+8)?5?WD%K][4M:QYCD7CM
M(5/2E=)CWA2SD"6O"AD4R%:`.2SUYA6>SDX794-N:ZDKM7^$66B,PQPK.6+5
M/K(*2+)[.A`*3+(%A`1C!15.H#%U*Q$<XV@<G61O]M+"42";$[=C&RDB5#'L
M:8K(A&1Y%RL-+XZXV;N%--QY9LILI84BG=3/U#/5/2_&N/\`21%,OR\UW-KQ
MJ;8SKI&K*;FU(]&!5A6@E&7A4:6`"U8J)#@KF73K*K^/Y3QNW'NZ&8)9V9;Z
M&3%`Q23&4](A*DM8H1$87,')F!NB&QJ7+MFS>QV0K%[5^*:3*W5$;`1RLF[]
ML-D^TE`12<D0>HI)83(ZM&!>*JG(0DK2/++GV)G]=Z^JU+MJM5$Z>J@55WK#
M(@)W!-&I17S5&Z7C+E8<BK\IQ%F.J;*63S+0,`#",8,#W9NG;OL%EEMAI>0L
MH>SB_/&+:ZTIBN8*V&*ZS8@14QXUXL&$;2W<BDJ4J1$-J+6`8&Q;FT^E$?8<
MZ;,VY)ASO:D)L$;)0-D:\R4Q*I$0@;EU8\>SOJO-%<O0[T[I7B0\GN"N6Q[8
M,>HTUS-E*T2PU,9*;(CNI,+O560RJ5F1H$Q,M3I$P2RR<%93%A)Q,FY":GL>
MI)5H#88XR$`<\8EWVI7#'3`[$;NR3Y$1\CGEKFZ#+MR;Y,(+)F)%(0$#(C_:
M$)"04J=HW!(KVGU&1F9F<J1W45;'KZNO8/\`Y/;%ODFN*$`@+9&)`FUS7PVE
M65*;E2TBIH@O7E+*&LQJ7"$I]A\=7]O<%6<&N*98,!8@92:Y)P%O`BUD^]L"
MYCYXR[F(D$1'R]'&%%*A$DEP#U#B9&9V+)#9R=3(D(B%11K%([PHQ.1(^SUE
MLE)C#.8M$MXX1,*B%Q$:O?#E6-95S4L&C.V.Y7W]$WG8%^U';#D_ZWKI_"I-
M;!#N59<;2M0M9@5,[0J7&OJL[*9RBZU8UFG9RV*D.,!#C3&VQ94"3$!%#$LQ
MGRR6[Z+)">AK)*6C(0$"%BN:+7'T)Y;#QXM$Z^S+-R#">68R%6^V"@(A=RI_
M2>H0$8WG8>:6PVN7&)Z8F2DLX2'QMU.=9M37)6=K[`4+9=6P:4UBMEE73"&N
M3A:]>S:0IY;*XW:^+?KRUB'E6\2<C*[#XV`:9*C/'GXCBG"$L)?-:P56S9)`
M@.*MUZZ&TQCKK2%7G[?KZ^#T&N&''8AZC9R*6DPB(IX>)6:":KBDK]>ZVVNT
M4"=@7V`%;R*#$J[A<(A!*>AJAX#"@7$1&J^TO')2MM(=GTLCFES)U6U-2UY2
M\M?$DR9G.10F%UJG/`R@KYZET4DZ[[)S<%`ESH;(12`#@K]3`>WD10J350S'
MGCU_;%N83DF&(CR.Q6Z8KP0R)*E212(`'7$[$<D1%,%%^K<FK?I9'K6QU'&6
MZ(0?.8-%XV,L=A04')S+2@)$PA8P`B,0,:PS='A_I"\VZ>()-?.U<>,M:IZH
MJNU7"`3NM8>HL3%(B*_K6:2%&W5!ED3/K&65V*&=N2(84[!%_P#8,2H02Q`N
M6[+[62=DX*5FW,KRL+CYE+NAQB6P+>R7"8@(RNU-A:]H.N*6_<U3Q^V/QU'&
MK^95#%V<:LYW%LT;.\E7EBI62X`RD@<B4V2B94YS4$2IS)6/CUAU1V[.K7AN
MP.S2!);:Z*2:Y*N32VMF6N[1LJ(Q]LC:.T7A1%ZG8+*A\F=D#.GRYMT2D<=B
MSD(&<'M`RQ"+S-7N^V!B`6N:,W[-Q"2Y$NJZXR6V>K<N3EM81'U7BM@!%R7`
M2(2-1M0&IK#)$-I&.K42</$6OJTQD*JV3`P`$E>RQ=7!#I6,";"B2Y9%LW4M
M39FRU,;)G;*;$PXRD$[ZFCE+0XVBRJ7D`)4C);I4.9(I+1DFLMV/?T*4@L0R
M).D$CP3@2+*48S1&5,69XR[;M[^X&Y7A,K;ZK6`_-$JX=9B79]R3DR(BB`*2
M3$*U?OM.]B0PX?82-@'$:_ZC&+DI7+)/F$P`F00$`(;%)2,LV./3I_3:CZ+O
MG9?8RNF1:T6)MB[0M]MK/NMWTJAWA$?%'D2]D1IFM*L0J'DH8E3CDY2I^2M%
MDW'9G.<9C4$(\9/Q-&X8@[EFS,1]7;:B(9M,[QQC;[8[;!R*(])VUSD)#)9A
M&>LB,Y5&.72[(WW-"6$:H.)F8W7!<(D(")`1Y011RG`1/BBU!)TZ4Z-?QJ0F
M4:\6.EM67%#<V@$KG<R*LI+::YPF#T1'R4KH%\D*,LA;@"4D9K>'XX1`Q^;E
MN;/_`+#!7NM7#QTTE23QW2$UTM4KD$S,E,$TGS/*))\0<S,;C/60<[(/SUN2
ME-SR*7>[8O;E$/)<L%4G!P`\5PL8*#X`1<-CXF.6[%IBS95M/K--87-[1K>H
M*)BMA9F44C=@-S-45LF2UL;(_%H?):M0D*W*4N4*^L&N2."P;>D:0F!"E^4:
M><%/QC7,7ELGE\@7<-FC%8%-CLW<3H>5U4_!!KCDDCF398YR'6I:X:VC>0)8
M>AA<</1%>^#Y:O89Z%)-7M&;[DQ;)(#@1D07*^1$PI$`LN>Z#%3"WK>M:.[;
M;:U,@OY+'4%RU76[S00:]FK?&HF5!DB9&XSS7R=6O71RJ*DA2GK(C)X^OR+&
M#P'EJ<!.Q2"L@\6>"R@^^P;'O82'3,#/N)W8N33*72GT@85V\)&)$H*#."UW
M9*\3ZEVFR:V3HK`*[@@2)8@V7[0M\.KE,N)C)-B3/=DB)"`K$,07+X=M8+:9
M)5$V6;;`T7"IO0<)URE4.HNQFB*M#S7]8J%"JMODK9%#9A),*XB<N59&E`O"
MR/\`A49A]0.N/;[+C[5VS;L7GN,[%C,U<KZP$@N_4%*UN%<A*SB55JZY2\7(
M7T@VNI-B)=.;4K4Z*:R*J0`*V/MT?22@F5+IM:])G!08\G/:WN42K$R<J-Q5
MYE.KJG'BSIRR5=O*9O<.P[V3>FK->:GV2@+D57,:5VA]8*U[A%9JVG1NHF9R
MC4["O<U!JLEM4)8LNR<,)[,,L0@9ZN676AR`KGI]_P"05LU'"(GVU^J-<5,1
M#>R"#>H@R5:BR$D'I$"1"76.6&._;(B.Y>-Q%K%P)_"Q1N=O<E_7PF"XN8`.
MK37L"/&8;S`#&XP>.B*H[6A]V,FR>T<7LELI.-:]VC(8M(*981;"5C#EKJOB
MS?9R-OH\I%$)`PJ'Q9\5[KDN"/!&%`L`4X[0=LXWS&_D+4`/LLG<7<?6W/IF
MXI0HBR)<_<`9K6L6KA_MVP`BQ)!N,U5T@7C\=2@RFQBD-16?,!+`KM8+)00R
M'MVK$A^0FH-H\BGLDIWU=N[NC3/O'5+'2LHV'V*I:NVYZC;\_M%)+J4&MG[A
M"I+&YC"LS1^NZD;K?5*>,R>*IE@"D*EO`X#R,#CA:5G!8<X(:O.5?(`847:5
M@7H&!7"UO&&##8#AL4P+"B`/DF-A(5P8P6M$&0O%V<2(_9MUV5VGR/M)#0E;
M50?+<88,R)F.S9&2#L@",2UU;?Z<6YM`MN^CK8T9J6\)8J@;!7.F/DF=F+6I
MMG=&L)D2:\+Y[:D\-FD<V`BUQPJTE#M(6E'5]=((Z,6$A0%"49ZH]//7F+=M
M661_Z;/QF8L6FH(Q!E1-T&)73("?98YE$>AT7F*5+2:/*40/:4_]F37QTPS,
MX$,=*X38ZB*;C*[%N.T$@BLNL9BF.=13GPO9D+[1A:Y=+O%S`G-PFSB'8C9N
M');VA,&B>V<0KR7P)HC>T;A"JZ;*N_E4\E$FK.7W=!Y`_0QI3H7!3!IA$S5I
M)01'B,/$:<9/>;3N/LUVUU-\8;DK%U6/8(^U2VR[O=$"N%FQ36;&VLXVU3GD
M,IZR("J8Z+M&C0D72'D=&@JI%]>\624C>51,G)KYIDCZ;$+BTN"C9VZU=?I-
MWC7@\)V>JC:N%WGL>T!UYJ9\I>FM9(LGU@;Z"BE0/"2/&.]71QG<=?$E@%)W
MYRA[8?ES53,#R$Y*45]F4BP(C@,ODZ[,UDK1MR&1S0#[DF2$,9T'9;5%<A*`
M":QVG0G>1`^0^ZEW&"CW]NHOQ^,P%:%T,3CK,-1PY2*V&"TO:R2A[6=RU_=B
M8.1Y,*N"V%OK(.NNMUS0_5J55)8>R.P)%ASV76I*D5J.DX@UJ754S#8DZ>)/
M'(4R3*Q*^F=?O"BOXXXDM"<1T?6-J8LK($A6"RR!AS<M01D?':/CCV3O7Q=>
MI9<KY2M$"X%YFPUPPY=N0%8D$V&#][[+B^6]6O\`'R._Y"%8`K6KK')JM^95
M>)"`"`6LY!8P8^X"K#'I21=!LMK$C;'BF/$7&J;KVE:0_P";>[=CZYT7)8Y)
MXQKW/%6H2&`2)5$W@Z2Q]NL&25CJ#7%R3)D02@9;F)*IE78H6IR1G>Y@O`>:
M-JS&1LC:RBEV37194""Y"`*92/'[P"B6$FNJPA41P4K/9L?=&#BD8/VM37>]
M-B[=*T]H%]UC66XNOW8<&4!9=R&P`R(M2QB)^T<CKW:K\2]5TVZZRJ8/L=M8
MEC>G\UL"24!7KC(:.=(1#8E9#2H8WRI%*%708WB2PE"UK5!+>YN:Y7-D9*@9
M8'_VLX!CU5^X-R,E883\E."+%-:>W)U:3K&!G`0"P>HJ=61-`)%O2/N0?N7+
MG)U:V238K0L$5WYH<J(JC:$W8BY##5SYSP=%ZS!J;+5KYQ-<4%&^LNU[XZ*/
MKE+K"C;9%9;TGU6M.Y;OAX)$YPQ5B;6W>2:=)YA/[)"WP5K`YOZ,5EO9K<)K
MPSE)S5X\C`:'``AXIVG465V5YVBKXPO`JCUV"DN,?$&,[\O<$.-0!LDI"18^
M(7$LW'J^D,A%\6<@'(^13F7P)%\SY.V8U_FDMZ:CMP2E%R,)JU/NSU%V8C8_
M$Y6\.20]77FSFV-?6)75A[&3>OKC87G7UUL:)L>UDQ_L"[*M+S-M=I9")1`I
M+,2R%Y![^R.\F;U"4D29W*[/6"L;JM6G2%C)JUL)4Q+1Y2/O*5#C[,+$KX$#
M:\#Q"Q2FI8F"9)M(F&16[+?>6[]NR(F=[+SDQB=^-6X2B0;*T;[R!J,EDBS-
ME'&1V7$K5*\TUQXZ]<ZFE%3RF!)IFR'4W4]Z59%6T4D*<DBY3LC+8C-[CM>5
M.3HV+93)+EF<CAQ)ZI\4..<FB5JLC)&(W`@>WR_<,3E,(40K'9/%4L;Q7$#[
M6C0&T**]/X]0;68ED%V<RK5B]"!DLY58M!:K7&--MA&8=E&2<!,6[S5PJ'68
M@1@NE<N!"U0E:@L-7`<.H58ZHKQ>59KXX:EN\+O'8ES=M.ZMFU%5ZND[A22X
M,LI&=N+`[.U96$VME&LS*J0IW&(LYI3VRIF.6&_6%!5.R@!JL*C3MY=]^WDK
M5T%,#+XVK3MKD9%;8I=L5GQ`2)*:N'OCK02JAPWYZQ=:>JM:5[I'1)&,#F;.
M3443N27V]_<@,GR[%MY%O-CN<',I6X)G?5=4_C`I"IY#`U1-B7=.Z[I*52R<
M:ST78#]7KC4VLTPF?\G"[22KB&"LHW/9`[H")DY$M!LV?Y=E@(5#+;/B`].8
MZQ,,9[*3.;XX;]J7;](LJQ_2JO"%<8%`S"$)3-B43::I?6Y[!8V&37)&Y==9
M9'&I:RQ9.S7B2Z+-TWE;)SXDI80S;,[?1#!KC9*'`H6+3*^+?XZ*SJQAU)<Z
MVF^P7W6BD'MEBK1LC[_39\@N,%JL1":=I[(63ZO`QTR931Q0X4A>&E1$3DZ]
M4<+Y9"8XXO/5]S3LW;M%<)*WX^K#"I12M:*B?;16E![DY15IJUS$H-D3"1YI
M?,"$V-D79FM;A(`[R9F;)LA,\+CSOR[Y1@H)!CD[:Y7*S.`,>!BP8/7FL>AE
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M75L&IQ+44GW;KL(194US7.AJA@V&HF*.O[</^/4/'HV@<?;1:!\"`N*Q74Q*
MF%$#%<.*76%2M"$J-=A@&LAZX#$K!XG:\A=?:YPVO=H-L8!)M50VNUTW;\?<
M=<%UC,L+N<6?YQ!71!+=;)-5;\VJ2\!"0\*8R.6D]!#^W$8:<,SJ6E-M=J?T
MPE;$O&-P&U2J37E*VR$BQ)1[6ON5$ZDSU!/I,:O&Y;/>=B5$%K.NS`1,3,5K
M[RMDYJ-YW(6>_N#*K,V%P+RB!CBOA=AWBWHA@=-?)/2$^N[6N=:YI;3;([/J
MBD4$=Y+/62]'M!*KJ:[;)NRN+AC<Z/LZ8-A#PY.IC>2_%.903T:Y*+&,8[3:
M=7NF]$\,:S&5<>=0=QK%3I'#*B1B)ARI1/*`<ARGE#6RQIDPBFJ\)M8\ZEHI
M;>+),R`VBVFP%URC0U\>G2?-)]72Y+:P@"A6D(4N!DK6.K%>55<]F7NS/=@R
M"=6C6]254\'SF6GR\MIB%-JIZX1U.R.;NE-E0ESPZ6.XJG4]P<EXU1P2.SV0
M%8!DNR2L4[#K$!JOR)W#F(V.3*K5J`N2C;DM*JL$OE!-[7V6,:PF^GKX;:LU
M;-AAG%.LY2@G;@,V;$V;+8&(]#>?4!",PD$UJZDJ4"Y@HFN'B@IE1"UD,:+H
MV,C`&S;0_=:I9*TO=/.,IH>]'.0.LGDCE7CA+J5DR.3QZ4N[^X"5M\Y33$!1
M"T:=(),G+3E$Q8]C,;&$FL6S\#4LU$',#R92MJ<E]1\1$`2S6]L2T`7:DCED
MV)9$'$UTPR+\PVZ`FC.36.RO<X#W%(ZIU;*Y@X8MB"I4Y6N&>VB*X#T2,L$[
M7E/CLED%9Y;&M>]BML61VO\`W&K?:"TI_P#VO7,:%#ET1(AI,_1JW2.UTPV!
M-(-:$8KY(U*8J><YI%!QI:4![0U>[DNSBK95+N!K.@)P.!=;="SB6#918;8=
M..:&_P!Z"L7&L79?]U$03V/M-2BJZCETNOT\P^&L_>\KC44A:/`3K&H8!=Y)
M<8Z24(QS2GBMDS*TIK]S;`2^VET[K?:TNL':226Q:RLZCIF;85)773[\T1^S
M*MEZIE<(XXN3$.41V9PA];WA@=%"-<U/[(\,ZY.;D)Z0SH'IG(%U/*AFL>YB
M,B-=M<B'@0MKOX]U=JV`Q9K.0`O4>8&`L48&,%%U\JMXMV%NK%V.<U+>,R8R
M#D'S2Y1K(&+8LM]I$H@A(EL@UD0S@Z=^-"O+'555.97?>R+AL=3MB-EE0[:X
M;Q3)MRIW5O9'Z+G,.8RJI%3KJW0=WC,F7(U;,VP-`A,$HRK``"_`5>+E1PX[
M*AE,8`UYE#DO6,F0VU6%BMR[!L,['&>,$OI<F:Q2?M)0+&"4#P.YBG8C(F5E
M##2:R.!B:QUWC82=<5BM0G!@$,(UF5D``;<OZPD><'\8],PM$ULZFSKWG#`R
M;@?\VFQDG<CK]V*!;X1_.(0.3RWUDT2J20]%(2R71.2Z."YS3*DI!92X",H"
M7'N+M,Q`X@:FV^%Q^1I5YG?U1DHMBZ&;3$$:XNV.ED0)[GR=+BC?4&0IJR19
M0GR0SF+%!]GAL/)V/FGP(8VV$7A1KKLJB.@EP8J4F2F=6BX>)VH#I0MG+'>N
MR<0G!&VDBW,@<M8'.C%+K5MK36&EU]/6N)DRBAI&T2*#S6&EX0*T4L2R54E*
MZ90*D8P@$&/$.?AJ^,JUS(UXRE=I#)[;NHW[#+3ZCI"`GA#VFQ;D]-L9VB;,
MB,1%O)P&5+)39$87DV4'&,?!5G'"L*UI$E)$#(!0":B(ZI1SGV\2PY*G0^)2
MGF='&3(_?>S[),(!M),]M:PLH$BIE]G5=V)9#*KCEB,+<KEU'2-AF4)F3&X*
M$J@F6-\B=$I)N`HEZ7!*?!76-L-Q2L6FI.RL7C;6.B/_`/11MO99;6?,;3$0
MYA&#J\HM1.Q$\RW*8KB57_W6;`Q,YBU2MNVB(X7:*TJ1;3^@,X5UB:IY59CE
M$5Q$IC5#&?$34<-?89+XQL7M<USFN-A;8V*KZ<G26D7R415]O9C,C=P08"R2
M4*\I9-`IRS&>P9E])=9`VA`7]:ZHLEE]L5`CQU.K0KS/M*V(;BS'?:;%!MLK
MT5W$'$AE5LI<M]<J]F2_JN9&\3[=6%YN0>R(%V1O5;IR,1LN]4KA5"TL"@E\
MC0L08AHMIS&_"L'Z2_U,U2BNGU7.U102P;0G$77S^P;!;E=I.,+?9)'EUD25
MQESZSHI!'(-$5S\UIWYV4')U#]EX=^AG8>M.``L(9GV&/Q5+%_*$4:0U5L`1
M$Y6'+KDAB.B#""VW!("<QS8)L(S*1OWLW>SK-R?D+`O:$S,AV"I:ID9F9;$&
M"@B1EI0$1`JA81`Q'FK]#I5K18^W.S-4['79>FP&RL42#5QG985"!J0Z9P-H
M=4=3%>W2>O=239ACL9*<#&_*=.[")-1J#3#RSE?:J#GDZ]C?#S\;QJU68BT=
MJ)=OS)SH6-HYD26N2L`H(X$,*`@`50A<G$V972RODM7,9<VI0I,5IA.VPUH(
MC!<08L*(69R7.-VE_<)NT#.MU/XI6?<*:U1,+/T?BWCI-:8=.$NX2RFD>N<#
M=MMK)F;"A'C+9'Z"G]Y1J;5%'+.(%*$!UGJECJ:H3D%*F8S)J@W&_0.GA<A;
MOX"Q8KX<5J_;*I0LF5;%>R#47+""4S'0]".:E2GW&QF6_%8A)9MNUD,E4BAE
MTJL9,[<G:M\C@6U34U;:R'0P+Y18Y`%CMBM'".8;G,K'<YK9J!`-;7BRITDE
MUBV[<MS*8V?;-XVZX1)3/YNGA;>H:(4S#:*WAM:U9#HU$FI680A;(W&V5`#`
MQ&#),.&,T56;A#CAQ5<!51BRVR<#)E+;+^/=8:;#-AL/@,;<NM8QQ2M8S(SR
M--?O!NLF2:NJNLJ-@$$5US,BE*UB``'*9,YXRQIS!-,Y$>.L_;BF=WMP2;-I
M"3:FUW![.8;C5':B^12.R*KD+'KO22M1&%HIO%7@RUY)M8@V6$D0KD:M`U0Q
M@BKCD91*A?E)@W)M#"IWN8G.,:>-S=4__8,"`)EA(O,O:T1@7+=6>KJ[5Y(E
MJY=I%7.16$Z]VTBL=RA"!RF`=5B:J6?0NY->1[KG(ERJ4.F20VB+GA$!`LB9
M(PG!4.@+3`HEL9#+8V4V,VQ8]I4"Q):*'80.OOPB376-BBKR?#T=,4%3Q<?3
MN#1D(,)#,JT:<983"2@&Y,,,BRU'&Y;QAWB34".+;8>Z"B2EPE8*#/Y]^LI[
M!!@R2ID"`1#BJ.O5/%/R&*\BK^4!8(LFBK63(\1A)Q5]%R0S!-GY9-91+I[`
M,NWL9/9J(%EZ8H*P8*&T_1^-JI=\M$ZDHTV'U&GGC)KC,;0J.YP.IB`N13QX
MV+L>NV1DKE?$5&,*'.&1V0RL2P(S,IQ8"`LVWF;=WRNUD;F3X(\I:FNFG=C[
M:00-;I;WFJ&VP?#EI8N*R>GCO.XGQ$.:"E>.XZJK&&]U";CWW:\R+&L(W2Y/
M0MDIJF(=KAGW+XF(XK@>,DR9^:#:ZS#4_4JG:"GLX56#*:_9'!$O>SG=Z?4:
M`AP?'1W;(BPNDB%EY5QF#M2\AH;1'A*%E&B+S@HD/0H&SY!DUY6\%A<F9!5K
MJ-I[=CV*2`-L-F-]V.8),(IF2G>.4R6\ZSL;4*K-IG`$JL77O!"YF5UUM9)`
MA>\1L`#M\HQ`B4E`QQVF9A<P]:>G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&F
MG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FM!'F2IR<F(X;.(7LOM="+1V*
MO;4#4.C(;2&RVP]#0ZML3"X#%=NV&*(TS;$+C5BS9SK12[G&K7]$I);T+43@
MLOJ5DS+QJK6?YQB,'<*23>R]BY;(C9M^UXW%'<?26'/BJ&E2=SL*@'D5P8"1
ME(24N7L/7XCF<JJ`$<;@6!6&%KY3E+UH*-.RUO&&M$+%NB*:A%*>26;Q/NS@
M9UUG1%F:>V"6VT]C8+9ZJ[\MZ-IYIB^]O;'LU3J#7T?K)Z*<)=$G?9.?6I85
MCMTJG3<F`I9&Y<F4EGNV#L=4Z/..6<>XFA^S9*5A4`K]H+<+'LY$NH-;'$(1
M##"34\EO,I%/84&,S/(Z=BHI<-S-0V%>BM0K>UDSD&D-NQ[J]!%/4E@UK(2Q
M0A'=%,!">1Q`9`W=WHU_T1IN76;<MI4[$Y*B@TZE-8UK9MR0JI'RZ'Z$LF74
MR%0,V5*#5[R[KE)R5-G#>WN1Q`U96?8'D8`"QK604AHUE<679)>ZX*.<+-HK
M)LC&Y<`Y24EMQ^68DH^,?28'"3E[R%VF>TP[+2D,MF.Z4$WE(\SD@")X@9P)
M,&2$#F)V&9C`UX>5W7RN]/7+<.D36'<Z',\EAD#?D.K]S4;.6V'3Z>&,[<QL
M4TE)]@H$Z$!,ADC:B5IVM(\R$KYY)Q;0:5[@@;]S&7$^38WQJH,'&8RHT*=I
MG)=5K#=T@<F`N.0*=YY*6X0VGL(!^;7S.%N5LA@+><R114/'X4LE:K[2=A25
MIE[A@)A8\E+!I?>)'.$L%?)W%)3&O.Q+K@=>,3E3-),MRVW)))#XVC@C[9+O
M6T!9</JU.7)I+,K4:ZMLUUC\1AC5A2K,4E1=:I6B)`02FP>>`&*%B)_=5T:,
MB5-AOW<W=8@M*'.$B$!=LQ\K!"E\N,N<`DV!B3U+29!XF<ADQ8JR*4S*50+C
M[7,4KA'(D[K4398]L1R!"V-A12/"=.VVVY^^CLPRO7IBK&E*NNY3.*F8&I)J
MCMA+KSM:S42B1-LNNNCZF5VOJ5K$QPF\D^OB-R?278Y0K:HVD,3JW56T`4HU
M0E%%3)7*KK0WFX9%Z3MIKQ`,=12IL6'B^'+-5>M>/'UK,Q*#L3:FK0L%=&51
M-;.[CD6%C%9%NQBFS5L/GDM%UK`52!B)4<-*T(W3K;0X`.F;+*)K"9:\+4_<
M)!2"R^\1.7;&7<V6EM+!=8]5](KZL>RIUM!4UZ,]<J)+;K/:]I;)2"53J)01
MS:A`DHC%K_)FANCS6<XLYZL"XM'S1K^\R&%QF*IA5NY6W9R]I-Q?V:X8JH2E
ME%Q@IAL,IO78Y0RL5V9MU*O!I]<15L*JT\E<R-J;-*C2QV-&TADRYK<A>(YK
M>U"'&CC96Q"!)#ETI<BVUA)!#6GL\U=VYF]P7+L!K5=50Q.H[WUV9ZJE<K05
MA;ZZ]JK>HA<J>6FPQ?'[`?:IHZ5E/Q!T'<"W%M<HJWB3X]DP@Y44;W@C171<
MP/[[3,Y4O(OHN`P@9&PA2'S*R$SAJB395,%/6P3Y`Q0;`3.;#+5+*HQMU8#%
MNC[M!`?*94+908N"0"5-%L3Q@9:I@;$#9*#`+6V=\A<6H2\M;M=877KG=-F7
M[?<.I9[+9I&BC<8I]%(6ESE3O)9G(3VQ[RL?VJ$L:QT21Q&G&N6D$=YYB%,+
M"KE;Q\!S_D/[*J974&G?>RQ(R005"M-@TA$;=C)F5+9/(5HERX8?:Q*6VLMQ
MP^`?F7[S8`J@K3$?,<W;84T&PO@E)N*1$Y$S9UM)2C6BPQ*\/(9%*RVEULU-
M@%?N=PSV];6=JXEC\U2)%'H;3I$:@#M9LG-?'<YL>1R6;MT.:<JP1Y&66,LH
MXD2]6W@4)1'^819YK*/J*$AQ];$W+IO^68*:L@H$J$B#LEMIJ:Q-Y"I)L]2,
MQE6O,WRPN%#*MB#LMOT:XIB=B@;CNOO9/KP`%BUJQXDQ\*/K#@)M"^M-=R<;
MAJ-BST-/2^HV?7^]G[7U07/I%#'>4R.90UG9W:7KAMU=O$QAK8Q)/Y"B"A-2
MR%U-58&9A06B.*$1SJLN'^*XSRAA0`Y1;VK5\96A+SK03#]![">FR!@'-8PH
M3![A9$CQ<)E/R:[XX0[^R56(F[_*9V`-O$!^,!">A@D?%D]W$TJD/FU-OWD1
M?+6N*U+5N5LV@KKQNU%L@EU>AEG:\2.#PZ$R"RV.0ML/E%G[$SYEM2'[2%5Z
M79+N6R-C=`VA0SILH%1[\H/),`45WX@H[J\)E+8S&?\`(;!SBTMCE5X"Y@5(
M)8"4NM7CKNV&\/[=U$I?`V&3`>6"-6<KAJ<-*M@JHEEB3O%J9;6"TX5$4!*4
M4:SDM,J3)R;&E,KZUJE3INWGNWNA347G=LJ=.]<T5,1J:/,8B1]F[J6S7]YV
M(@:G@YF2.C/34?T$LM@1N$G&C/4M*$4N-PJ1!+/&>249@0<D+HUJM6QFAE+7
MC+&*3L]B%"1D1'OTKY+KC%AV[(6@2X,:)B>VG-'OOOIT#$TID(%Q_*II&M91
MU]7>PH)K/;A$+EIL&>*IB1WM--Y5)6FCNO%^RW61'#--=F[)A%6UM:CQ>20=
M[9<+$/5(XA83OKRGK`463T^^'I?E$.!%@J)!AI,`M-8RL9]K&^5"*68G!9QD
M5,@=&U;5&TG`+JURN2%SZ9K/*J,G(*&T"6R*'-`^<AAQ9=9Q3LOB@BQ6IM4N
MQ\W"98;AJMBIN,Q8A-HNF);-4GP!M0+`ZNWFM\J<F*C%6[%(]:$P](+>NZ)4
M9"+C=;I`TWS)W*<S(ZOHM949UL_JU='W*I'J4EX^,H4V`@DI[;U6@8\EY*";
MQB\>^SE\7@<K$U<MFE`=18_>D):B;21NR/&*_97B&R2?=@GF`O)1=D+LY"Q7
MKXS-9.B1/1X_%DKA%'6!Q4:*;,4BB3-YJ;)JD7+J\VK,%D<<3+;\N]C")9\H
MPPE+\51\DTH\]*:41[0_>,+5)C"E*8P!?7.#"Q!&#..H<XSC&>8V0:A%![K,
MD-8$F1R)$)0,#,E,$,P0S$;[$,P43ZQ,3ZZM5Q:5A8IB"=)C`Q,0426\;1(E
M$Q,3/Z3$Q/PF-M?*'XY*YGNU>'I?.4/EX3PVW=B=E)54NWJ;R<;"M],0"GJW
MGBMFKZ"12"LVW,Z<I&H7ND85(^R=UXU)U2=4:$M4K"43U^A\?JLQ>#P;LB`I
M\AHX.G<M+MQW>_;8=)I&!F&*,)J.030)B;'!9-)929','D5RL'EN8K4H]SBR
MRQ4T"D36JN*JHS::TXZFJ.+$-Z>J'5R9*E"Q8\A'Z8:;F=L2]!.S;<IC-**(
MU9$IBT(3&63&K)%85<,WPPQFU#%D<2I2XIF7`-.%EE6]Z]![/[PQ=^.9<FJ,
M75R%@Q7>=7EEE/\`+59#&1U=OH#8ZQ!O8&P1#.'Q"9UQUDB^_'U^3<<B5@E\
MS/*Q$K"2*0G<PD622YYS,G(\X]"C4%R?,1H8?MJ+5X&UFHHB,5UB0%V$#;*F
MAE'6GFP003^B@1S#SV9L#&!95_$PY9<?3VO@_P#N<MX.D?D%*P_'S+;H6ZZJ
MZ5QV';6ZNQY/3`_,0*D(67`6#,G$R8SL,]9,HQ4J]W\@S%B72?R>WE$KC9N_
MT\^9_7PVZR^KUXYNI[<\5Q;B;*ZFHJ6F<-QK#&8"[2RQY?)(.>AESI9>5R^)
M$PB/0A[FAF8ZOC;>8L$I>EK*\$FXP28T@#D)V8,4G]S\;?Y',]0*RA4H47JR
M36OL<13'VX@.01$+-L3SCD2RB0CS(L#'Y2IB)@S?;HE;@X@85"89"8B)Y]O9
M+>8R)I6'$)-;&C(S/CWKL1MU!IA9!53ZPT0^4_5D<9'E^N+8W:ZR=>D3^N<F
MY4Z.J*!QJO\`3/9HZ2-\;)**(4JCEJ$TU<=@@A.;G'=G,*RU-)F1LBL:T/)2
M@@YFPPAX#O*B`!"&M.%U]F'W?5''TC6A[9+6(JTS-MTU$QNX<%)B)+C$N(H$
M_MB36E$0"`C[I#.M"%_[:;&W<CNZX+4DM[T!!"HY4]=:XV7JKL+;"7633K:)
MZ<RF.;-6W$JK-IK216Z:CD2UM4FFR6&R"#MR%2!M<TK0XFF8YO4<:*;U6O0>
M1>09#/5_9.MJB*=O'B2^RK7KD;4=IRNT@VV!B;+^/L+?$)`:=BU6*6,M*[O&
MJ.'N'=36(HMB^((T6B;'18%1*-35JK'S2D3=9KD,@PMLDL\BMIP^"W:\5134
M8V7B>C<:RV;=WM+[D3Z^L,DG$%A""36@T:^1UNJJU2;&F+*F]T]6D=SX4PE*
MCBDJ=T-%D62ZM^[0-D^2&AE#PVYE#KU8_JVI";?M88*"D!*NMI0J&'8%KI`Y
M2IL1!'QB\9D"]MXR#U6_,8QZ7-WY!7&6I[50VP(',,>N.V.M#%J60E8-!3(1
MLCBMX0"24;%=AEKI_$*WE-=1RS@N4O$G:366-R5D0OJ+#T'!ZA.G7%IG`LL1
M99AO>?GL+R/.0]9L_2/QW)6<9>*"?6L$F>$$7-D'UB*QB.9DP]A6$#V$10$#
M)3$:K8&U_P`AI(N4@F(<N3V*1CA`Q,G)EOP$`@2(V276(#)R4!$SJ(.LGD9A
MNPPMPI2^0!UI6G-4[B_IU)8M@OY`76R'-O9&E:_.X((E9PN$0`%\>4[>UMIJ
MM<\.AAQ6,I4R@T*7D"$D?C&.\@=!!;R5JTI=:!YLCV]B:X>H[PQCB$IX*@Q#
MC,0T]BD;C^O_`)"W`T2[A1CZMECIB5!$6E%8';LVV4"(AIN9*MA+<@$8Y3'%
M7YD$:/5S:W;+&IELKX!KKLB[ZV1MB136N$4SG+TV/#/"PS:6-$K=8N17T6'8
MSZE:S4;8?+9$00=A3AM,$`Y,5Y60ZQ3\89,0%[R=_!03,$"`.P2D&QB^9&35
M+8[BI1K602LG<?O:\(@7G,UC2YE0PE,+#&A`\G#[6+5B$J::ACI"=@[W(E_Z
M"!D`','=_<-RU!TQE>R&8(1)+)PT0A@KRJ2W14J)DER6D\,D1A$*PZ$-R->O
M0@E4@+RI,*2DJ#4:<T0"P#SC&(,K6O3FZWBV`F'9?(9**5<Y&.,3LQC+!AS&
M)%-9+K'7V#SZX7V!RYC-@#IWL>S/Y:#3AJN/.[8B)CG"@""%4%,3`L<PEH@I
M$A6;8,H(!G>!>OFSMVQB46+6TEK?9VW?)6"-U:]/M/;(VC%*>UW55K8\DD7Q
M[%JQ%K0Z;,U'65*PEU:'1O&\.<=7V6;E.D1/`CLG)^S7):WT.KQD%GB49/V]
MUMED>Z0P:<.!U@X6Q?\`E+E4JJXPO:2QA3P%BGG&;V6@E3\\0A:?CV6J:JPB
M*71[E:&UU09+L$ROS@S/(?=ZP(T^A\-9:)W3\ESCL09KK'/'UJ;+'%HBBR23
MRU(]Y$+M44U5[H`+8H9J^G<K6^,1`\);&E34ZEKT#8@;'#/P<9.4F)PB+[\N
MB)7U6K(1UTZT!`M/Y0LL)C%L35GUEQUI7/NIB(4F2%<LEW)0W;LKI15`CAER
MT1_:""(TJ$1(7V)VA:5NDN*!)G>V1(P3*H[-05EOE"WFOC92Q=1XGJ])88Q:
M]Q)+;6P=IZ$W97NPLSG,&5*AHF2&TC+MP:MTS@D;4+WQB=TKTXF(7)R/2(1!
MCV#3S2UA4%)F)MX&WYGE66!\0HE*61$=8M8Q'N8>3D/]Y[-%,UV8&DN+;S:K
MC(J`X=:N5[]3)T?&Z$5B\BR4D0D9<XK"A\UVH)9KE'O#=Q7!/.:M6!<NS$6>
M*U[W=/['J*W=9*4LJAY)-Y;44R@3*]09_LN4SF:V$M9U1.<A#-9193[)IT[R
M9*HP,E88YKU:C!Y8@Y,$'&,\^C\DIWJ.9=6R(UXLQQG[`@"2`@$EFN%B`\#"
M1*)XQ,[[E\TSK!Q-M5VJ3E]L,AS18+-N8-!A"T"@9D!X,@AXJGJ&(V5L''4D
M>86M/3C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C36J#?
M"C*6G^RNBTQNG<O9ZD)*TWTWD:JU15\7IEVJJ3["-\(GRT]9*'&6:IV\^)WI
M]K0YY1XP]25N:`)RLB;P)W'/OCF\:[*OE\VJ&UG-?METNENT+_;Q!,9!8R/5
M.QA`2R1;[R!(^A@!O`^YZ"M^%6:3]ZN%]Y2%SU>K8LG:#]N,H/M'[5SKE<=/
MMI9U^Z%D<8U-!]C3*HVKKJ6FV%L>A?VVF[&94=8,2*?#U4D#:Y2:#JELNL5P
M10=96I-R1X]`4FCA2^0HG8;8M<\I42DD*@TCW'%*@RD`(,AJZ<%W;1*8`[,C
M-+G([FZ2(;G3VS`+K=L*&5R:]]RI1`_D%=UQ"2OZC"*OQE=KCR**P1]Q,LA:
MYL>@&1_)JJVU:JK?-7MA&:\I*]PVFG6FK&;[4EL;(.52"-0!7%'0B6/C*F3L
M$J//=&QD&<<0`#8X"$8#&,)S<_D%DY$:QI"+9$*XL(F)C]60Y<K'X3Z$R!&?
M2/29]1^,?1>(-RR/**#L"H'YD;2Y2LYB`-D%'`2F37$1,[1/SC__`&C4%_)!
M2%`VA1]`CO+</9K7*C(]:NO:6)DTC&*I?&V=6THL6#9UW<;%S-]6;XDJ,A#8
M25LP6'(F:-Y-4Y^W*,*P#VOHIC*%^2ZEH9D?,3R3O:I^3J7<A5N7<9*)"2))
M.$>]IAN"^C9\B1_$8R,>'XULU*7(_$0P7^2[Y^X\;UI@I.!XG`<($F]*@9P)
MG;]GD([![6/MQ@J_ZFHD69O9JTAGBK;*9:;'4C<R*5WL-KA:$W;VXZ($.J)@
M*R8Y*VUB2E*%IH?82)B@CQ[>7=F+UT5A$4\>]Y2TU<B]LB()AP@3EK6-D8Z:
MHG+(EQ*FRT%=KAU,?`T*L'9[+UBNH8$#):CM-CB`]C`6*4B13V6&`J(!4,E"
M&,A:#UESBJ--)K)]+(1%=F[_`*CVC:IC?Q=!7%5T=3+KLD\Z;&)61M*HM1GM
MB@[7J5'B1(@".=@S"-(T161I,-7QPX0AQ8I<K&69;\=V17CQJ)-"Y`D3ABN5
M>`,)L%,M#(='.88.1F_#_<25CW<:JVY6K%DG/0+7%Y&O=DPP6CEO:VI7TB)R
MR%3C>\4Q/;4C$]7`IJ=!SC$RJ_&S())7%<PW96[(/N`EW<FI#!?;*PG*]I7'
M=!OH$P5D+9NSVA0,OJ("-]UR+R$6'>%D0,#(,KZ<M.+XV0S8OWEL:-CQC>KC
MHP^5)2E;2N<=[^/W-;9M]K><9"52<N9%_LA'6<AU[VKDA47E`\C@;1E;Q4.*
MQZ$+Y'_U!U.GICK$>R515@JG_E^X$H]S&IM::Q?5:.KMJHK2-CV%/;[0V"A;
M=O[+LQ"_(]B'FROX2C*BD@DB"0P.&-93'_%,A-C`(Q'TD(Z848:4W7Y8,UK)
M3<\-K1C1]KXJ3+L)]MO)!9YC%TC[)=8F]OTRSW7*QU>UV'H]O&HQ'VWE32R)
M38\AA%4BAVT+FIR=-4%=<+1[3E[@8FO,!V=_8?=V3K2F[ZT?#\A/C]CR#R%[
M?N=&%Q3;V4U1/'Z$:=&6*KVU3Q\EOGE9EH8QI"P2ANLA93JR4N#PMF[0JD`\
MI`%-R],XB`$V?QX=QSI,+8E^(UPJ"F/5N,;<#WS@E>ZH&M8"K#5HA=T[;C)L
M-4N\$3>1FOV]5D`OM=YAO>%OT(LC5?./'9T]A0PB&*AL8VB-%:A6'!E)H]D9
MU<<#O)5IM$HUY(=NT56HM5MAGW56T%4%T+4SY\NU5*6%%>\+3MX]"PQAKF+3
M!BW!7*SIS'A3-0Y&'!*6A/`YE"DP<-8WR=A3*\FK$8P`%/'K;A3LR36C(028
M0J^./4D*DJ9,LYS#$#N,&=F5TL0$<SIL\@N%:)G+=63"F0U5GZBZ6.J'=,"?
M#:@K2`A*WE4Y[=?%A4E#U/55U)-=]H=A=FX@\;)6\HGKIL3'X*P2B*WTEDJH
MNYD"4N-:[:^/Z@IRD9H#,Y7IG)N"041]284AR$(_(?!^(8&NE*1P(8V9HM&2
MY'2*P[83B3F(Z[(VIGL6%F6&SO(XA?&-ZXCRO-->93GINKB\'R\(LQ3JR!#(
MCQ]:4TXCI*4<!#B,,[)F*375GC81%/-E*-D[X=]3E^]*]&JU\=6)W*U)9-U\
MSQM*<75W>FZ@FNT38GBTP%F&AD$X657]X,S`B?=[@AK^+=U9?C:\9M8:VH^<
M";N,$I7;:F1J1]H9L=GNHI>Z%M[E/^"7+JF//)8KV&>2GD]T0OI_?A7O/;'M
M*L1-C?L*%33FI-OVDK3U0/NX@>V)FC/LPE\L6<RK='!<*@^(%;L7IVL'[YSH
MQBK)JBZG-P6<^R*)B>8S_9<LB.586YJ1+\/;?&"U`@EF&J%0$>/9C&?\>O?N
MLS-JQ4D[7U?XU(70`(5`QL;";P=:8N73,S76'4M;>[>3&3C,TAPTE-1-Q`ID
M8&(??,2,6-B=RBLJ/LUO<=*2L=I&LV>T9$,JTJ;QR5_'M*'JRMG;ZO*E)-"U
MJKQZ1+8Y@,:*5KR*#J]V/;6V*J83KU3^%LQ*J4XXF.BM5S?)EE.4'+8;E;D0
MQ_0^0S;5>S5/RJ!9Y1&%L>_>SC%DJ'`(N]4)XIY\.,W?8IBUUR7N/L\HUB4Y
MK/KU+6!@4>/_`+ZJ%)1O-;]Q]U/MI9)]C.KWD3[7O;[#MD>B/Z>W74%6>.V!
M1?1>9';)[!W7KV_S%(K\;-3VPQ$--!PB?^T\*:_:XFY,5!5*O5ROV_>3P@5Q
MR5X4^][66DWY'MF<L#.>K9<JC898\Y_82D',X1;_`&^*0=@HB.NMW31E??*T
MS>ZAGMG^KRX:%*SB,C96:Z_A_P"[F-Y0;2B+DY(^PW3(LM](Y"&\X%OL>4_,
M,KZMI-ZSUA-G72*\(S8^Q6Y4773>P;^D3A/;$97-PV,I>'/+ZN6**_AI]^4.
MY-TM8XHS%')V9<WQ)T91IC_;9%"XHE.O.^8\E5C"\'QM3(-(<;6P@1:>N"[K
M8"3R<=H)`K2VDLNIL&";<@L61"A,!C<Q[+@^<9)^/`"L-R\>U7.T(2777%<U
M]F37E79'8'%KJ^YS#MVP\!R-XXJ]HJO]`JBB&MEZ79>&O/\`"9"95-I64T-[
M3;F8@N7O&!IP-\=IVH'O[9F=OEY39<(Y]X-3_P"L(\79SZ3S<[]L)5F0FM:C
M%5PYU=Y9*?:![9RX438[O:RGKA`1](?:[>?+`\:&K7M,;CRAX3E;)$#^,+BQ
M%MD6EE)PO[4VX=)RPI'YSX,A,+@9(ZO1YIBM"UQ'V*<WY932V-*PE%.-H4DV
M07U(2QO+D>)58Z2QH=`)J0[$F&B))PO9T)N499.0@$7D`Q<9-AML`1KKKF*U
M<=DR,A,"A8P9<"..YD1!V(F8.'DR#$#Y`*B`K%L";CWM6"GMY;C)/84@OD(_
M87,R%>1W"4"N0,PXG./Q1^CC-XUL@)G,I3[+&ZJB810<E((462TR.T"U8)H0
MK4PX]M%)BIKVI0E#>#,^QZB09#U-Y!1BW/CN8KT)F*#<G4FPWY>Q-F*;AKBN
M#W&8),L9.ZVCS$8(A^@KUDAA^..T,3UQ9Z1]=F1)5Y?!\9Y1`S"HC8ESL1;3
M,^HQ=T;I"D*SVXWO?X!N)LYL+>CQ*:V3[50F](Q4;(Q125&1$*JK5L35P;5F
MCC5+:1`L"3(\,SNY,62<CR<6);WF\]Q1.3X.BK6&&^/_`+K>ZW%Z,]Z)KC(;
MQ$AZF<J(N:NN-A]KP7RB?,V)M\E2^\75E(Q:)!8<97-(B;[>-]C^@^S^Y#YG
M;W$E\NI!7P)8^VE#D]Q%K(3K%"I)"E1#@8(;J@N.X7Q>($.:Y4GB^7HV+U3"
M'`!8U1\D"U(%SX8E`/!I`"C!08F(_<HM,F/W;[JJ29B/JZYEMJ3+Y.^5\ETD
M+GO_`*S=^7%6O,A.^-*NN`BD2Y9<:7K(I$Q@:XC.T0+"V.RV19'5$+'KW:S6
MMU/3WCF(K"YK.4[5[)K-#C]KG\NV==G..J`ZP(MC164T$R`Y8]AUN2['#@`+
M:"F.48#.C:[^Q%T&')/4&._');5K^)JJ1[DF`F<`;O25!R?-:!B.H)B)[AK_
M`+F#"^GKF3ZIU#FX78O^2R<DB^//]Y]MRDCF$*BQ]'9,,*OUS:]AQ/JY=G%?
M;&NZ;5+XW%<.W`LU?L]L,V:8)]D'U+N;KO"F!S,UL77\6Y1DF=.,K>X[KRX;
M%@A2AVRW&R`+!.2:[P#`L*R@I/D`Y[C.VK5P$OX6:#;4_L_NN$*2V;)]<>O4
M,C%R#]M^Y]H>XD>G=G3M;R$E9N9!=6/;YA>*3[XJF\N;4]K$AOPEFS?8["WV
M0KM=$3W?SS,]]MJKKNT8GKZF0[*VYK@R,DE;EU1KZ)8Z'>H),'TQB3@KYED/
M]]Z^W_3R-,0666*,F*4S;GYAF/B'#,P`(:>3_?%9MMM'<WRT$V^M#)`999@9
MED038B1MSL0C,,%L!+I&-NV8CQIXDO%2J@*!\59[3FX>R855B=E[BHOFI3R"
M7PQ9IW!$'(S(06C3QYZWNC[JTT22;;_[<P_9\_;O:R026O8]#=*<QI#NF3(7
M<MZ@4E>+7TFG=:*+/4`2IAM*]6X_%$L4JA1TXE*$PDJWF>ZEXCB/^&<;C%>&
M@5#;<!<$@9N!$,D+`0-F6*;S*+G5$E882Y$]20-6SYAG%>0$-:B7D*PLG&QL
M"M]H:C7],2!A-?K9]E8U)9*QA(NB!U:&M.L5)27Q#5@IVS\BVX=?0=PVE"^W
MHWUI`]?%"5AV^7["$`*A,P'_`,';!G2MO8[Q*2"6*7(]0R'N!G<H5#:_C%%[
MQ!63G?"@\/,FK5CJ8X(IC871-&P8'$-@>,#7FVI0V.$\!B60=KBTJ8LRSF>9
MMSJY5;*U?_=PF0DP2+5"?JLB&9-45CF:$\.);(@%P8Q]`N^D7UG7:BK8AN)8
MTU9ZT/D-1,B*TV-"J-M-';G\YC26I9A%6ZM8&ZIQ3[^QL(%))22.&M'NY%A0
MB^![Q6,".^YY5BYP^]7R8LGO0A/KPL=%B2`?<=RY":ON19-F2#JD^107$HM8
M[:G@KWN.%K!#BVQ<[MH$ZGR04GU=,Q,%*Y7T\6=L+ZXDO2<&5W&(+4MI['Q>
MC["LO:+R-N$9JAJL^Q]FR8_&)6P5:^?8$UU+"F]@KBA*?<J1@V<N"@:"MV+(
M7)_"<G79^Q,5J2)%R^[@BJ8J!I^/%F3"\]42;`N0@"8U@N)K)>56%+I;KFH(
M$DTI*L)C/$@FK<J6\R9V+08<F8])P,0=;OD>@)5"8C>U,G<*PV+L+@N3"/VZ
MRR)AO^-KTUUW0#[,W"(.;U8!>S>P`4;R1;4:S'OEK;@4YA>$1%PN%]6`[^ZA
M;BD3&>J;P"-.`,E04WA45;QXVU%=M\`K>%+JJ8L)F3%R8.(56(BDH!4SN>2?
M:VB$PU9A)-8RM+5')UK#PY#8\S*P"Y(N(@#3C_R`$(6DTI7M%%29&N4D@Q[*
MX&ML;;%JG12?6[+G6I-E]B:2FL4TCA"F\8UJ2PJG9'9>FGSY6;7K>_GK-?[=
M=T$AP(A\+;!5\X1^R?9..R6;TP0('>1+IH9ZYGQ[O%_W=<9-#MXK>^]FG8BE
M<@_K]A-;W'4[V7MA7[D>'/E+C!>VSX_2PL@OR&0L3C+$=4NA?N(A\&+X*KM[
MR)D?>)DO<RSIGERB-GVKN*$QKM3.-6Q1X6N^*\C6*=%%/F?0B@>&XG#")#]E
M@+IURDZ>[\O&%?O=_O\`[O?S9\E_>ISEF?(MXS//[F_'X[1MQX?)QX[<.'R<
M=N/IMK!PL8V,<$8J9FIR/X\N7/F79V=GW.SLY=G/Y^>_+UUGGF'K5TXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
@XTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTU__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g891272ex99_2pg06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272ex99_2pg06.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/@+&`P$1``(1`0,1`?_$`*(``0`!!`,!`0``````
M```````(!`8'"0(#!0H!`0$``P$!`0$!`````````````P0%`@$&!P@0```&
M`@$#!``&`@$"!P````(#!`4&!P$(`!$2"2$3%!4Q(C(C%A=!)!A10G%2,T,T
M)1D1``("`00!`@4"!0,$`@(#``(#`00%`!$2$P8A%#$B,B,'01510C-#)&%2
M%J%3-"5Q1!<(D7)4_]H`#`,!``(1`Q$`/P#[EXA`8\N3*7I\:UK@^JI64]'.
M#X\HWAQ,61-Y=110_P"4R+#&["=F)5BPD)]!EE"P`\.3`BZ?S_X)^*?$<G4?
MY'Y1C[%ORA^=&V;[]BO:LDS$W[9X@^VDPJ\*I0TIH*]&I20#;'W4-V_1?(O+
M,Q5>&,Q;U)Q84)2*T)-*X"VE7NAXO"&<G2$=I_211)*F`F->X;4U=GH"VLV+
MHAH"FYR:2TV3EW8%N>'D$@<TO7"K`\@6/)>#QYSGN[L=,9P'TY](_P#`WX@M
M8J,)8P-(\3%.W5ZI[./M[]P;]Q7U[R%FX`V&[SN3(CUV]-9:_P`@>8JMS>7>
M;%LG+;);!OV)3-=9?3MN"9E<>FVWQC?UU7BKF%#5#6B8$N50W)8\".]U7W9<
MG!GPP+%?HH[?</9PX(SZ=,`_#&,^O-<_Q)^.#R!94\36G(E?;=EGS\IM/I1C
MFOWY_P!0Z,16F?\`M?+$1\=5(\R\F%$5HMLZ(2"8C8-NM;N\`^GX"[[G\=_C
M.WIKH*K"!$I2T)4;1@2E)X^D+)P<L[0)HJN/<H^5C.5.1=K6N4C,+]>N<B_-
MUQZ<IU_PI^*ZM%>-KX2F%!2,<D`CGL*L0\[.-"/GW@:3V&U'^TBGXQZ:E/SC
MRMCYM'=9+R.P<SL'J5H!78GZ=ON@(B7^D>FTZY"K*"#`I+%'$>0*TDF0J0Y-
M6=#4DR."HDQ`O]GT"[GAP(SITSC./R]O#/PK^+')=7;A:9(L5\FA@SSV-.9;
M#LHN?G^FZV(8Z/U.(F-IUX/F_E0D!C=9R6RL8^@>ATXXUB^GXJ'T'^/\V^N1
M%:09,H*5D1U(6I)=FM\+-P<LR(+LRM)K$V+<=RG.,FI&@X1`<9QVY!G\V,Y]
M>35_P[^,JMX<E7P]4;X9!%X3^YRBW5IECT/WD_K72(JT3\)7.Q1/QUXWS7RE
MR2KMN,E)5VHF-@]5.;#VA]/P-L0<_K$QZ3$>FJ4BIZ\3`*+(BZ(H!+"CC!6`
MG+OR,+>\8D"-MQG*K.?9(>,8/QG]?=Z9SD/IRA2_!/XCQW7['!4U2G$IQ82/
M9$CCT6HNIJQ//>%+M1#ACX\HB)F1B(U.WS_S!Y$;;S2(K9V9]`]7L3[<V?3\
M23\DQ\-O6(W]=5)M:08\\]2;'4@SU*V2.!YF35F!&+9>W%M,D49Z*<8P-U;B
M@E#Z=,!#C\F`Y]>77?AK\86+;;SL-4*XZU?LF<\^16,I5&E?;,\_KM51%#)_
M1<;!QU`OS;RE2@2NXR%`NLL8V#T"HR6UA^GX*9,F/\9GYMXUQS6,#R:D/_C:
M/W4`HX)(/W5F,D"B*<U+&\@QA3TS]2G.$$OKUZ]WYN[/KR(?PI^*@;7>&$IP
MVI.-E,QSCK_9Q,,9Q^?;_"$SA'^WE,SO/KKK_G'E<+8KWK.ML6(.-@^;W905
MC?Y?[I1$E_\`'IM&ND=55\8E,1CC"(24UO<&DPG)RWM$W.CKA[<$N>BK`O;5
M.N,'"SUZ]WX9QCTY"W\&?B1]$\8[!4RH,I6:A!/9Q*M<MQ>M)GY_H?;B+#(^
M),C??;TU(/GOEX/BR-YD/%RVQ.P;PQ2NE9?3\15\D?IM^F_KJO%7L,&<$\3"
MER<!S/>0F>ZKZX<U306PJ%G_`,CIDPUG*"1G'Z>S'X=?7FL?XH_';+47CQ5:
M;<7FW>?S[^Z=3''M?OR^ME(1K%/PE<;;?KJH/E_D@KE0VSZY0*9C8/Z0NEXA
M]/PATR<?KO/QV]-4>*M@`4N46(TCPERECZ+).#EO;\6*J\KH\3U^5W8"UJQ9
M&7Z]<Y_5UQZ<S0_"/XI72C'!A*<4H3CDP$=FT+Q+9=C0CY]XBFV9-/KN,S.\
MS'IJS/G7ELO]S-UG?SL'OL'U6@X6)^G;[H?*7_3:=<1U57QA)J<<81")/3R5
M(:7DU;T&GF!Q2B2E9_VNO:['$A$9T]0YQ^7MY$W\%_B-U5E)N"I%5:C(I,?N
M;$K+-%V17/S_`$VV@+&Q_OC<>,ZZ'SWR\&"X;S88)UCB=@]"J1(UI^GXJ$I@
M?XQ/S;ZK4]=PM*N/<D["E*7*G%L=E"@)JO(S7%F:A,C8J%@2C(.](UCR2''3
MMR'/7.,B]>:M/\3?CK'Y5^<I8JNO+6K=>TUL2SDRQ4KE4K-*>?J2JY$H?TV*
M9F)*=]57>8>2OJA2=;,JH):H1V#:%N;#FC].^QMB#G]=_2)B/37GXJ:NPI`H
M<1=%A(!K2LH2/>7=N&M&]9D29'U^5W>V4]9^1UZ]V1^F<Y#Z<QH_`OX?C'QB
MHP%+]NBB-+K^YQ]J%W]Q%'U_1[W_`"9_4F>I3,>FKD^?^838FU-YON)>3N6P
M;]II]N1_3\93]O\`AM\(W]=51]9P52M/<3HZD,6J5#XJ/49.68&8HDB8M&^&
MYQA3@&!.*8H(!],8QC&/R].:%C\-?C"UD69>QAJI9)SKKC9\_(FY)(U[QSL>
MW*R@!4R=O4(B(VC4"O-O*4UAIJN,BL`($1V#:!K%)HCZ=_ME,S'\9GUWUQ#6
M,##DH08XDP(D]B4E9P<LZ@/C)`DS"9C_`&?Q;2!9"7_C.,_FZYYR'X7_`!<H
MEFO"U()+<>P)CG\IXH)7CBCY_C3"9%/^V)GXZ]GSCRN8*)NLV(7C/H'J-DN3
MX^G^X4;E_P!-M?AM80(\CXIL;1C(^N7M/M9-68#]<YN?W"]+Z*<9]M2Y_O9_
MS@7X9QCTYP_\)_BJS3_;WX2F5+V3ZG">?'VUFU[UZ?K^AMO[Y1_W/6)CX:+\
MY\K4WO7=9#>X&[[!_44OI`OI^(J^2/TV^,3/KKM.K:#GC]PZ/)!C^U5OG=DU
M7U^U7MF&98M]%./W#VS'LBQ^GM_QU]>6+/X>_&=MTV;.'JF^;[[LE//>;5JM
M%.P_Z_K=5B$G^A!Z;;^NN%^:>4*'@NXR!]N"/@']);>X`^GX"WYX_7?]=O37
M055D`(`065&D8`)B8ZG(#@Y;^V3$E)BR.EASE5G/1J4FB$7U]<YST%W8].5$
M?A#\4504NO@Z8`@,<"]NSY1Q)DS&Q'S_`/TS(I3/QC>8F9CTU*SSORUI$;+K
M)(RL$7H'K-L8"Q/T_P!T8B"_AMZ;3K]!5T!+2*D((VD"D7`D):HG!RWM.!*U
M`54A"+/RN[&',\&!#Z9QV].@>W'IR1'X5_%E7'6,17PM4,9:&]#EQ+(%D9,H
M.]!1S_\`LE$2?\(B('C'IKPO.O+#L+M%=9-A4UY$M@WB:H\:^WR_VAF8C^/\
MV\ZJ"ZYA1*PI>7'TH%A#H@>23\&J^X#HUM.6)O68QE1D/N)6G/L!QT[>WUSC
M(O7EA'X?_&E;(+RJ,/5#()NUK8''/<;-.K-*JZ/GVY(JS*5^FPA/PW]=0GYE
MY,RN50[;)KFAB9'8-I4UO>P/IWV)OSS^N_Z[>FJ$%35V44,D$71!*&A1M@P8
M.7=!(&]QR[(TV>JK.>PAQ%DW'^<B_'.<>G,Q7X'_`!`FN516!I16*FJK(_<V
MFNBS-Q2=N?T!:F7Q'_<]9WU;+S_S$SAA7FR<--D3L'UL7U&7T_$E_)/Z;?#U
MU4CK."F&Y.''4@C<GOBG(\G+.N3Y*3\=],S_`+/3N<2<=H_\8Q^GIR^W\-?C
M![RLNPU4K!-OMDIY[RS*+ZL@4_/ZS;7$`[_</I&VH!\V\J`.H;C("!0.VP?3
M6GDB/I_MSZC_`-=]=G]<0GWRU/\`'TGOE',:@LSW5>,A/C:82-C,Q_L=.YN2
MCR`'_7&?S=>2C^(?QJ-H+HXBK%M;J+1*.>XLQBI10./G^JJDI6J?T&9B=]<?
M\S\GZI3[MG40O&8V#U&R7-\?3_<*-Y_U^&VJ(^IZ\4I"D)\71&)"6Q6S%DY.
M78"!L7N?W*M'C(56!9+.<\>]G.<]V!?AG&/3F78_`_X@M4`Q=C`TBQX464A#
M[G&*K;7O6(]#^@K?W]OC#/6)CX:LJ\_\P18*TJ\V+!/!TEL&\M!72!_3\85\
MG\-OC&_KJL'6T'&I,6#CR02DUP=74PW)JON$X/C4%D=E.<?([>]:U`P2/'3M
M[<=<8P+UYH,_#GXQ;</(,PU2;K+5RR1SSW)^0K13NLGY]N5FL,);^A#$>F_K
MJN/FGE`IBN-QD)%*E1&P>BT-ERA^GX`V9./UW])F8]-=1-80).B3-Q,;2`1(
MRH\2F3X.6Y`45%%&54>`'(E619PV*,]X.N<Y%G]7=R-'X6_%M;$)P*,-5'#U
MPH@M.[)`1QK.ZC$1)S_XS?G#?>9+U+EKMOG'E;K)W&763985B2+8-YFT/&Q/
MT[?='TG^$?3MI_6$"[30?QM'VGHY&@-Q[RS\Z.6K,+Y&1G_9Z]KJK#@9F?QQ
MGT#D./3G,_A3\5R+!G"5)%J,DD_K^9>79#LF$_/\+C(@G?J4QM$Q'II_SGRO
MD)>]9N+*[(]`]#J!UUR^G^T'RC^G\=YUS*K."D*,JBHZD`HRZ$O63<'+.[[1
M.V"9R5GJISCW"VP62<8_3VY_#KZ\FK_AS\8U;G[A7P]4+OOU7><<]_=)JS24
M_P"OZUU9E`3\(7.T1^NO&>;>4M3T,N,E/1*=M@_I$SN(/I^$L^>?UW_7;TUT
MEU97Y)991<91@+*;FYI+!@Y;T"W-+B!W;DN.JK/[:1R!@T.?U=V/7.<>G*J?
MP=^)J]<*J<'3&LNE6J",<]HK4[,7*R8CG]";40\(_1GKO.I#\[\N8<L.ZR3)
MS&S.P>K&KE3"^GXFN9"?TV^$1/KKN.K2#*!J##HZD,&J-D)R@635G4TV5E`)
MD(Q=%.,8RZ%EXP9TZ8QT_+TY9L_AK\87&.;:PU0V6#R),F>?SEEQ$<E,_/\`
M_=$1A_\`NVC;;42_-O*4B`+N,@5C7@?0/2*LS->/I_M3,R/_`%WT_K2"_,3N
M'\=2?,2JH\M(/]U9WEJHJDRACQV,?)[<C;$@L@!UQG&<?J[N(_#?XPC(JRT8
M:K&239H6`9\_(78Q,UZ#8^?ZZR)E2Y_V3,%RT_YMY3[8ZGO&>V,+`$.P;2-H
M^=B/IWV:?S3_``GZ=M41M15P>WFM1L50C;SF8Z/&I<G+L`&S*'K,B.09SA7@
M>"AO6<J.N,]V!^F,X#Z<RG__`*__`(:LX<\`_P`?HEAF8V<>2ON<9I3<G(>W
M]#WZXNS-B(B=Q9.XS$>FK2_R%YFJV-]=]L6QLQ8@M@WAPI]O#/HVWA/V_AMM
M\8W]=>J;7T-//`J-8DPSRW%S=P&9-5]0N+PU"8W-5C&%&`]ZMJ'DG..G;@.>
MH<8SZ\^BL?BS\?6[*[EG%USLIN/M@4R>X6+-4J3VC\^T$RJ1)G;T@)GC$3.^
MJ"_+O(U*E"[1PJ4K5,;!ZK2WO6/T_`&QSC]9GXS,>FJ0FL($G)P03&T99(4T
M71X+P:LZ830LT1\7)]5.<]K.:+(B_P#(L_K[N9E;\)_BJG6BG6PE,*PHQB(&
M.>T*P[)=C%Q\_P!--LRQ,?H?J7*=3L\X\K<SM9=9+).R>^P?5<CC9GZ?BZ(V
M+^'\NVNK^J*]^,-'_&$7QC$;Z@&3[R[M$CDRL"Y](SGY7=VN2LL(QYZ]<9Q^
M7.,>G(I_!GXE*D>.+!TYI,KY!!!/9L2<JT7Y%<_/OQN-`3=^I%$>L1Z:D_Y]
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M:MEY[Y<;IL%>9+B<ULSL'JQRH2TOI^)JB`G]-OA$3ZZYG5?`5"A4J.C2,:A:
M;*#E1F35F,G&S1-\24#%C"G`<9>$^.TSIC&,?B'MSZ\[L_A#\47'OLV<'3-]
MDLH39GG\\YH(#*[QSV_SAB(?&VQ;1,1$^NN%^<^6*2M"[K(2H:T#&P>D4RYU
M8^G^R7J/\?YMXU^_UA`LG$'YC:/)R9SC#R0/W5G4MTAB#ZN,+,?[/3)K0@_:
M+Z]0B#^O`L^O/6?A+\4ML*MLP=,K*<ACKP%/.9&WB*\5<;8CY_ZE2O$*44_R
M1$%RVUY_SCROK-7O6=9HLI*-@]57&=MD/I^#6?,7ZQ/TS$:X**LK]4E$B41I
M&:E&R+(X(D1RWMRR.#P4_K&_.<*L"]E0[D@/%GKW=P>F,]OIQ?\`PE^*LI3*
MAD,+4=3+&/QTB4LF)I6;(7+%;Z]^MME8-.-]Y(8C?C&VNT^=^6H?%E-U@OBR
M%C>!#^LM,H!GT[;BDI"/TVG?;?UU5'UQ"5)B@T^/I3#%3PZR!0/)JO&37E[:
M/H75?GHHQC!JQHQ[`L8Z!P#].,9]>6W_`(A_&MJPVV_$5BLNR5C(&7S[E=MT
M_P!OL6)F#_J-I?XTS'I"O08CXZ@5YGY.D`6JVR`7657&-@]$I;WJ7]/P!OSQ
M^LS\9F/37055\"(`063&T98$I4;(3AP:LZ%$Q`\Q3&BP]5.>H6D\T0B^O7KG
M/YN[E6O^$_Q544E%;"4P375C%+B.>P+PS2=BPCY_II-(F(C^4IF9WU*SSGRQ
MI&;+K)(RLD4[!ZS;&!LS]/\`=&(@O](]-M,5?`L)U"3$;1_'5))"A4%>\MR$
MU)*U*=9(B!9RI[NUU4I2QF=,XSC(<=O3UXG\)_BJ:;L?.$IS3L5\DA@3SF#3
MEVK?DUS\_P!-UREL?'\Q#$QMI/G/EDN"Q-UG<ME<QG8/0ZHD%<OI^*A(H'_2
M?7?5657L-(7%.13$F`N(=4CX4IP:KR,#LA9_H$BW&,J,AR:2S_L8QG';D'XX
MSGUYH)_%/X[1E`S2L56'*KR"[PM^?E%Q5+]N78^O^H-'_&B=MI5\LQ/QU79Y
M?Y(VJ5)ELYJE7-$CL&TJ-W>8?3OM+ON?QW^$[>FO)*J*N"4OP2HJA`E^L;6;
MV<'K^WZQG>@R%L2=<J\BP6C>@X4!SU[N_P!,YR'TYA(_`7X=JT8QE?`4@H#2
MJ5(".S:*U&Y[^FF/GW@*US_(5^HG^NWIJ^S\A>9M?[IE]LO[V.WXK_JN3[=A
M_1MN:?MS^FWK$;^NJPRL8&:J"M,C:,2H*N6+@G9-68$%7.B,)I8?C&%.`X$]
MD8[3?3H'_LP'/+K/PI^*FY!>59A*<Y%-C*O!GS\@=FQD,JP9Y^A7AF8=M_&9
M'C,S.JX><>5K1-8+K(1*Z@3&P;<*)<J@_3\$EZC_`!_FY:[?ZXA/R@+?X^D^
M46LC"\!WNJ^X*R&$')HN?T^1VY$SD'C"7C..@N[J/`L^O+)?A_\`&AWHR9X>
MJ5\7XQT'/.2[<-!QBS]3]9I0P^G?TB2DB@B]=1_\S\GZ)K>[9T$NRN8V#;A<
M*"LC]/\`>(8DOUC;Y=HU0F5+71R`IL-BR$:`EM6M!2;)R[L`VN+R"0+DG7"K
M`\EJ7D&%`LYSD7?CIU[?3F6[\"_A^QBAPC\!2+$C2LU(5/9Q]M<N#D+2?KWD
M'W!&PS>=R9$;SMZ:M!^0/,5VRO!?;%LG`Z2V#>6+3-<#^G;<4S*X]-MOTW]=
M5XJXA(U(U@H^ERI,<'!V&=DU7W"<75I"Q."K/^QT]Q4T!P0+TZ8!^&,9]>:Y
M_B/\;MOEDV8FM.0.Z^X3/GY3:M4XQ]A^_/\`J-I1%8I_[4;1M\=51\R\G%,5
MQMLA`I6J(V#;K4WO6/T_`6SSC]=_C,QZ:Z2JQ@9*8M&5'$8$Q),>3E%8-6=H
M"8HK/71TO&<J<B[6I6I&,OU]<B_-UQZ<JU_PM^+:M->/KX6H%-2L:L`CGL(8
MAIOQ@Q\^\12:PV(_VD4_'4A^;^5L<5@[K)<16"F=@]9M`(6)^G^Z`B)?Z1Z;
M3H*L(&,I22*-H\E*T4C;E`,FK.AJ*6J<+)&G%_L]<`=5(<#,Z=,XSC\N0\\9
M^%/Q6VNZHS"4RK6*N1K,&>>QHRSHL9)4_/\`3<?$-='ZG'*-IT'SCRL3!@W6
M<UMKL&=@]#J#PKE]/Q4/H/Z3'U;ZYDUI!DZDM63'4@%)3LA?"S<&K,B"[-K0
M8P(EOJISC)I#.:(C&,X[<@SZXSGUY*G\.?C*O>'))P]4;PY!=Z#^YR]VFG./
M6_U/ZQI%-;?X2N=BB9]=<L\U\I<F:[+C)25<T3&P?TF.AYA]/P)T0?\`'?X3
M$>FJ5/5%>I0E@3QA&4$EC;HV5@)R[\C&TNV'QN;L9RJSGV4KKCWL9_7D7IG.
M0^G*='\&?B7&RN:&#IJE6*KXT)'LB1HU;,6Z]:)Y[]2K(BT8^/*(B9D8B-3.
M\^\O>1$Z\PB*TRS/RAZO:KH8SZ?B2ODG]-O6(B?752;6<%.,/.-CB09BE3)5
MAX\FK.IBF8(RV^2G9Z*<8P)V1%!+'TZ8"''Y.W/+3OPS^+[%AMIV&J%8=8R#
MS+Y]R=E4#5R+)^?ZK=<12R?]D0(\=1+\V\J4`+"XR``*P#&P>@U#EE:/I^"C
MF2'^,S\V^OS-9001Z55F.)/?1&1\U*9[JS&23(LD,0Q\0<84]O5L2&B`7UQG
MKC/YNN?7G,?A;\6C8KVQPM2+%4\>2BCG'66)62L;(['M_AK,A3_MY3,[SZZ1
MYOY5"F(BXSJ;%B"C8/FBT<'8B?E_NG$27_QZ;1KH'5->C2C1#C"(24QN5-(R
M<G+>T3<M=?NU23.?E=WMGNN/>SZ]>[_/3TY69^"_Q(Z@>+9@J<X\Z3JA!]SC
M-:Q;]\],_/\`0VW'N#C]6>N_Z:E'SWR\7Q9&\V'PX6Q.P;]@*Z1+Z?B*ODC]
M-OTW]=5PZ\AAAH3QL*41H7%:[!'[JOKAQ<6H#(M5>BCIDQ0U%A)%C\.W'IC&
M?7FJS\3?CIUGWC<36*U[U]OE//?W-JH-&P[?G];J@C7.?A*XVV_754?,/)07
M*AMG"Y2"MM@_IK;+@'Z?@+9DX_7?]=O35*&KX"%-E(&-H\)\E1XCVO>6]/:B
MAXE,>!U^3W8PUGBR(OUZYSG\W7'*(?A/\5KJQ2#"5(JP&."!CGM`X@Y/&Q'S
M[Q[,IF4^NX[S$[QZ:GGSGRR7>XFZSNY6"WV#XVAXV)^G^Z/H7_3;76.J:]&0
M8E'&$62#DD@0&%>\M[1I)4J+72`C/15U['-62$8_\ASC\O;RNS\$_B)M0Z#,
M#2FFRM>KD'S[2C)O&S?7/S_39>(M9'^^-QXZ['SWR\6B\;S8:+*YQ.P>AU1D
M*Y?3\5!,C'\8GYM]5Q%=PM,N4.1#"E+7*W-&\*%`35?>:Y(&K+(C5BQE1D'>
M0UBR3C&,=N0YZYQD7KS7I_B?\=T,I8S=+%5UY6U<5;<V)9R9817FHII?/M)!
M7(E1Z;;3,S$E.^JK?,/)7U0I-MF55:#2([!M"V-[C"/EWV)OSS^N_I$[>FJ`
M-3UX!,!&&+HL)2VYO:0$^\M[0MS4[B?F]+URJ[LEIG<63\9Z]V1_CG./3F,/
MX&_$`41QHX&E%`:2:D!]SC%9%R;ZD_7]`7)FQM^K/4IF/35LO/O,"?-DKS>\
MG,;,[!_4:KH87T_$DQPG](CX1$^NJ@ZLH(H5J%QT<2&*U1CZ:H.R<LP(PR3%
M@)?1YQA3@.,N1180CZ8QTQC\O3EZQ^&?Q?;OMREC#5#R#V7S,YY[D>36*KY3
M\^V]I8B#9_48B(VC4*O-_*DUPJJN,BNN$0([!Z16F91'T[_;F9F/^N^F*S@H
M1E&8CB3`R5;*N*%@U9U`JCJ7*)E.Q_L].YO2Y[`8_#./QQG//0_#7XP6U;UX
M:K#E/HO"8Y[BW&JE%`X^?XU53*U?H(S^ND^;>52)!-QG$EN"?0/4;!<W1]/]
MPO6?UW^&VN!E7P$Y/A*9&D8DX6T]GP5DU9@.&U4Y_<GI/13C/MF.G[V<_J[O
MPST].0M_"7XI?3C'MP=,J443I\/GX^U9:]\:?K^@K?\`D3'Q[/6)_370><^6
M+=WA=9#I<+M]@_J"KI$_I^,*^3^&WZ;^NNXZM8.H%WG1Y(8++FY/.<Y-6=<N
M;NW8:7)7GHIQ^XK;@X*%C]/;^&,9]>6+/X=_&5QLNM8>J;9NVKDS//>;-ZO%
M2VZ?G^NQ7B%,_0ACX;^NHU^:>4)'BNXR!Z%I^`?TE,[5A]/P!GS1^N_QG;TU
MTE5?`B,$!*C:,&$H8V`C&#EO[88@88;&\8ZJLYS]2,T62^O7KU_-W8Y7K_A/
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M2.P;2HG=Y!].^TN^>?UW_7;TU0%5/79)>2BHNB`6)&V-X@8.79QE$SK\N;8G
M]56<]B1?GW0_YR+\<YQZ<S$_@C\0UZ\U48&D-::M:MQCLVZ*EF;=97U_0FS,
MN&/^YZSOJT?G_F##AAWFR<,8S?8/K<OJ87T_$U_+/^GPVG5096,#-&(PR.)!
M#$)_&(63EGJ*4`R!_P`Y_P!GIU<P9Z&?]/\`MZ<N._#'XNL,)KL+4)AED"*9
MY^LY4>.1F?G]9N#Z._W1\-M1!YOY4`P`760,0B/@'PJSNC^7^U/T_P#7?7?F
MNH5E2!7E@2_)+5,RX!ONJ^X*N/HA-S,=C'R.WN0(AY+!Z=,ASZ]<^O+/_P"(
M_P`;Q='(QB*WO@LTK`G\_*'8]$U:3(^?ZJU>92N?T"=IWU%_S+R:$S7]VSIE
M;@F-@^BP?8X?I^##B"G_`%^&VO/.J:NU"0I"=%D0TA#4:R%$Y.78"!J.=?NS
M$6,A58%DL3K^]USGNP+\,]/3F0_\"_A^QCPQ;L!2+'KH>Q%?W.,5/=^^Z/0_
MHBW]^/UAGK$Q'IJVO\@>8IL%:7>;%@GPZ2V#>6PKH@_IVWZOD_AM^F_KJM,K
M:#FJ#51D>2"4'KGQS--R:K[AKI*V`9WU1G&%.`][DVEA*'CITP''4.,9]>:+
M?PW^,'VV7G8:H5MMF_8,IY[D[*5QJY!D_/MO;KB*W?H0Q$[1/KJL'FGE`)%`
M7&0D5(7$;!Z!69+D#]/P6R9,?UW])F8]-=9-901.D2H28XD`D0XC84I&#EN0
M$XB!GNQO`>Y3D6?JC/4'7.>[/Z^[G*/PS^+ZV,1A48:J.*K1CX4K=D@$8HX9
MC]HDY_\`%.(->^^Y1$GRUTWS?RIUAEIEQDV&^YY%L&\^[C:S_+_=CT+;X?R[
M:X_U=`?:-)_C2/VCF^0-1H/>6]!M\J<,.L@39_V>O8Z.&/=,S^K&?0.<8].0
MS^$?Q3*6(+"4Y2VKD:QQ]SYD99T6,DN?G^%QT0QWZE/I$Q'IKK_G7EG,6>]9
MS%U=L3L'HRJOJKE]/Q4OY1_3;XQ,^NNPNM(,2HRK+CJ0"@3K]YDW!RSNRZX:
MQ,N%O3*G(?=PUBR3TZ=O;G\.OKRRC\._C*M=_<D8>J-[]P&]SCGR]V-2:(OW
MY_U!J3-<9^$+G:(_77!^;>4L3%<[C)3%?HVV#^EV]W#Z?AVQS_CO^NWIKJ*J
MV`$`*+*C2,`"6]H:R@X.6]`-["X`=6A-CJJS^1"XEA-!G\<BQZYSCTY51^$/
MQ/52NO7P=,$*ITZ@#'/8:^/LQ<I)B.?T5K40]<?HSUF9U(SSORUI$;+K)(G.
M;,[!ZL>N5.+Z?B:YD9_3;X1$Z[#JS@BC*@1T<2&95"D8E&<FK/W12[``R/(N
MBG'3[;!8?<Z=.G3\O;R>S^&/Q=<ETVL+4/W'[EV;\_G_`'CC^Z;_`#__`'>(
M]_\`NF(F-M<+\W\J3`0NXR(7%>!]`]/:;^W_`)?[6\\?^N^N7]:P;YQ#E_'D
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MNV_KKUSZ^AR@_"H]B3&'A<'EU"9DU7W8<)`U"9'A5C&%&,8&N:AY)%CIVX#G
MJ'&,^O/I;/XL_']RT%VUBT':5<M6@*9/<;%VJ5*TT?G]"=5,DEMZ0!3Q@9G?
M6<KR[R-*I0JT<*E*5;;!_3KMAR1^GX`V(./UF?C,QZ:I2:Q@:<O!),<1@*"3
M%$^`8-6=,$P?(A10OU4YSVLHA9R7_P";/Z^[F;6_"GXKIH&M6PE,*XJQ:H&.
M>T+PARS%!'S_`$T3F33'Z%\Q<IU89YQY6T^QEUDG)6BWV#XW?_*GZ?[W\W\/
MY=M=&*HKS"02'^+HOB#0/;8(GWEW;E!(UQ;D]ILY^5W=CBN*"8//7KUQZ9QC
MTY7G\%?B,J!8PL%3F@=6_6()[)B491XV<@J?GWXVW@+7>NY$,>L1Z:E_Y]YA
M[B+7OF^XAJ6P6P?77"5I+Z=MUA,B/Z;3Z[SKT"J]AA*X3D4PI@+ANH'P2C!J
MO(\NI;0>P@6],J,@]T+0I&1TZ=O8+\.O3/-=/XI_'E?*SG$XJL.6+(#>EOS\
MO>#3/'C8^O\`J128=:)VVZBD=OA.J9^7^2,JQ2.V<U8KRB!V#;JEHOD/IWVE
MHB?\=X^.WIJB+JNORDY24N,H@IR4+.V%%8.6]H$$?<Q/+,FQG*K(NQO<QY.!
MZ]>[/KG./3F6G\'?B:O37CT8.F--52C5`([-AKXVU-V@J/G^FK:(GI_43F9W
MV]-6C\\\N-Q/.\R7$US)G8/4["H2XOI^+%1`3^FWPVGUUR.JZ`J#U:DZ-(S#
MEXI4-69DY;U/%-R<$2K(L858#C[DK'0SIC'3_L[<\]L_@_\`$]QUA]K!TS;:
M_=>V9Y_/^^1$9:"CGMM?B([XB-BF(F.,^NO%^=>6)4M*[K(4J*L!&P?+%*>5
M7;Y?[,^H[_'^;?5637D,3_-]EA3%_9%(R%W0U7_L%-\<41%&`?51GI[$<5&)
M<9QTSD`NN>HL8%C4J_BK\>TBM%4Q==97A5#YB3W;",>6+5S^?UD,>4U8GX]>
MV\R4045V>7^2.ZNRV<])&0>@?+++`VSF/E_FL"+9W_FC:/EWC5-7!028V(`"
M"D^/O9(/VRHX=%0=PWU>,1F6H\9@Q#-$+N$IZ]JP6<G!QC`\8Y2_$5=5;Q`E
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ME9T[$BR@3*'!45E4M6>ZYKU#BJ]Q>K.6&EX4JAC-PG*,.R$HOKVE%XP`.,!Q
MC',/QW`5/&L=.,I-MN3-A[N5E[;+.5AQO,88XC.%B3)%*HG@E4`I0BL!&-#)
M9%V4L^Z>"5GU@&R@%8[`$!$\1B(Y3$;D7Q(IDIWF9G7K<W-9^M$WE2VL>:,V
MQT,JK_\`19=H36=Q%7X^WD_*\:;MS*HKVKH*4XLRV/2/:BD[1^)8[S94@9&M
M"C1&'@6H#EF`-YAY85!-;"P-[R3*4G.:::OC\6%(`1-K+S+R*U12%@$O=W*.
MXURA@RF*BX5*9)DLMY-+T>,U;U-(3=?GD5.<S,#%<J]BQ:8W<H``1%=2UM^0
M1=<`6]O-0C:.IGD_OZ`5[!H%M]0&VE[VS:[IMS,-9YI6%#ULS3>]=>M>),G3
M0V0V%5:.:UVKKFU;$BK@D7(Q'1J.19R`M1X*.2GJBTPM"PZ)QB9;4-'D]/QN
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MFV"`7R<VZME2JZ4MLV(0QU9+D#+-71ET$^N]359!-A:!20[FY[Z<Y!"@()-(
M2VG$6)98:A-<"&+C:Y$(SVM/E>UL=R+Q>@1JY6V#49J=`]T'.PGZ',+#'9K2
M5CIY8?&%4/:768I9ZVRE4.$N!>6N3,L=/%DL!A63"#`&Y9%%O&8W(9"REDNQ
MV61CBKCL3VV;*@<B$C$]908L6,@;`<IAPMREGO$:%''V<AF\5@ZT#+LLNZ2F
M<AZ0G'V%5;8-.)F8ZV-B1<L657J$FH>U<04W+.?)?1U7'O2:S8+>4'4(JLH&
MR(RF<8*TO*VSWS9!_71&`4M5[=$)9)'*772DER4EL<VLLDM$E4+2#"UIR;)A
MY5FW0>C+7<!4XV\[3S7[;"$S\[V=#K$65$WJ6-'JK63*S8-`J&LXG0L`Y3BT
M,A6O83'^1LF:^%OX9V3EK?A617*J+%V!7V'%C>Y7A:4"\G$P05)LF`F+M^>7
M:3PO7/<*;5UI=L@PW_J\LK:#'55<R;7@;<99MV)1BK0I2]5EM+(HM+XZE.5M
MQKRF8I":\$E.:<LD@9PC0D9_59NKP\X8E./+^1SAQV]25965?M@P82(F"&PL
M$,%DI)A036*0#&AK56XJG:LL\DEZ,91PI9=_"([)H#W?="9@X$I]M:*08,-`
M:K=U=A5UOSXG\F\$CBMEBUITI?T3F,>+@C'L,8CB]8R>/Z]6'8IHV^"P:9'5
MQ==F!FDOGRT)2A$QURIL-S:&YP2*'G"`DP1V-::U'(94J^`:+<:Z[-6HPIF.
M^W]F9I;DM1"ZO%A06K;E(Q:V;Q-V(D=\<3R&.P07<^(#E58\KEE28Y$%1('+
MK\+@C(:I=+RKI,YO/!3(36:2F0/EQ;R60*XW.?U\3K+NE$VB)S_8&DK4M%="
MXRU5G4\CI.`JIH^.DFN.JKAD>&-DEK/V$Q]W85*Q06ZG$I%/UZX0"^?,7Y7<
M\(;Y)V2C'/P5B^J2,T,/IME0.LJ0F#FV-@#D>HI4Q2VL0]D*9`[E;DCR;]E4
M,6,BG+4ZDB`BX9]VE=E;R$HD00*6+)PV(6Y?8OL1$,#E#+Q<[^0RJ-48)#]K
MY7L4U2!;KW:V];9=&R,J<[-02K6ESN!UQ'@,\XD-DV-<IYU=PV6Q=N`FE:%K
M7.F%91K=A=@1PB_L_(%S5HPMB>O*86EAJ5U(K'W+,A=JB4SQ0,J:Q]Z+5<0$
MN\)3`M4L(`BQ\;3?9S;XH0;<?E<YE5TYAA,2I>/,URN":7,`]J@;?/C*/NE$
M-)G*-2MEWE_J.NHQ:[Y9>MFV]=/E7T:1L\EKR616DDLYLG7<4E:8JX6K!4Z"
M^W&.-Y#"Z/Z'Y\<D[E')HF"K+#EFR;W%AS"H65P8L&(L5\Q3QMM<3!E3L7Y,
M:LM)<FMRF$IH\Z1VY$EES$8XR5_&+G-/K!BIAU2_3L6*3O5:[<55PURUBZ%N
M2P5D+(]XJLLQ*)!A;%QS-9/DEH2KI+8$2?F.S%;U7E>47.7(IO9(LF2.;OLE
M)5L3IRL&YQD,T84""Q)8\-QV,A=3&UE1E`R8I<2@8SG$5BK:59M4D+E]VOFA
MQ:P7(?Y5J4L>SV[&$M4J0L(ES',3QEBX&#DIVK47#=QE',[&O%7L':RW80E/
M13IE7%I/6N#;V3-D>M:5NDN#=]N$;^.^^2F`1IBB`'O7S:-KMV4)YL]..N+K
M#*V9K>@T"K5:F0SVUYDYO5M-U*DU6QF+2,)'MNF#DED9QQ:9BRZ+!A39C*$1
M/<#1+%KK)=8L<6B%07L)*EV%&L;463:!B%-==MLP&7K25?9TR*&PQ1E*6"_W
MAU4!/&8MO!,6=J[P(JG5*)["M.L)J*VE3WJ>)*C`=?;9V1Y(;\M:L]2;QDVO
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MFVV8LK"#"6A+R5,-(X%?"9EJXK(>^]O+@:>0M$.+K%(Q;>D!7#"/B`*'A882
MI>9(KS$UU04V".#N:5^7#6YMC)\\K>%7GL#747JV!W9<D^IR(Q$YCH&K+*;<
M/,1D]GMUD6!7$N7.*]E":L,C\6;)+*$Z5.8::V@#C&13W*QXV\Y&4VK8U&0&
MB5LMRK3:/KV4LE0QK8CN3V-6DT(ERX>Q9%MJ*O++E=4U`)F4=6>\:GRA8A5<
MV+<1]D@E<PQ+E@#'";B4R4BP1Y:H+`\M].0%POSK0VSDOA^M#54,RMNS(BQ4
MH?!6.J;KCXI/#K;1'O\`>L>DCO%R&<.3E[40VBEZ4K]WZ49/[G/64[%2`/+#
M[)4YU^(839B13=0Q2I`^F6R:S8Y8"U$.`"*!?*9F(GBDY664EF#GWQVL,.3K
M@KT)U8H,I@8=U0MH@LRX6)3#(&>@FS$QK*!WDKU^,M!OK^/,MIS:*JYG#ZK6
M7I#8JTO5/-=RV"WHW6$U%\@,F(L>22UX;G%.:K5L4;=H]'0GE_>.39D>,9Z5
MC[[7'6E1!:WM"@#D1FT5&2&WTS)<04@@(9LV2KU&D)`A[3B1UQ-NO^WJR:RY
MU2J5[;)@2B4U;8<ZSCY0/:3H^BI4FS>B/F.J(?/K$$>\O]-NK;*9/(-<-R(!
M7E>2F\(3:-L2JJ(6OJNLY511R-*ZM4JG4#M.:LB@$Y6+R4\=5M9CD@5J19(5
M'HS@&`!2086,)6SRYB*EW&HMU1+[;+,V+15!JI$^,39%HS)<R"OU1+0L&N)*
M-&*K3SECQZO][)5<A-1L+W9"^-:+9V#X1,BD$S',2B+(G,!-?D0Q,X==M@#=
M@XV^OJJD[QHI8Q.Y38./W;'X8B5/:):WIW5JE$,E=93RT:QG,7=&]4`8%;0_
M+O8,ZD*@$*`#*#:MTS13%K6"MQ2U9AZBZNU)<&"P&#$?+/JMH=M9P_.EK0B9
MUDU;Z;CB&O!'7ZDM6V(W4Y3@Y@2RB?CMO#$LA=A)?*Y2YD=X`^*2>[*WBMVZ
MN6X-I;#NVH4>TUQTYK9#9'`]<8NQLU9UE($[.&5F/M1TQ7TND[\N?0+419J]
M?E*%&F#@24:CN4BZQHA'X_P-^X(LSN5HQ=8V>0R*C:Y==8K&87$FH!:XI`ID
MY'KZ@W";F9+;SG+8NG'3B\8Y5:5QO/\`E>W6VT,DSDSK4;!%,06\1R[&.GU'
M]\:4_P!E+NNG?2Q;+VAL.UZ#KK:BP=?]>*Y?()KK'F!I9J]`TAE;\IDM;TM"
M+!DJU')UI[>WC6N@B`HB,^^!4HZJ><897#\?8G*Y#[V9RP/LBPIVD:8V6*IF
M(JX+ACU@1/Y"41,#UBKUY>^03'_.K>,Q\37Q="K3AJAWF"N/KBVRN2;S9`5Y
M(("!9O)$4D9CQ$=2UP;][8#N_P`AD5UV\C$PG5[4ILU7U2Z;:$)JYTIFTAM1
M1VQH^X&^P(-&=>$NRF::C:IV6$D2PE]90-:%&(Y4Y*S`Y$*OX<E^1Q/C]P)C
M(NNYZTJZ1^B:^)39E06K#:\I"JXE"Q@&R1!API8HF3F"L>4^TQV5R=9Q'1Q]
M?QU%E1*B#8S)6$&U56N#NR;$0SH4Y$03EPTV2T8#:/K68#'DYB939$G2))`:
MTMICZE0#$8A3/(T9(G-.B,&,P9B0E;D82Q9$+.08QG.<\MWAJ!=<%`B.C#3A
M9%]4K@IX27I'K([3/I'K^D:S,>=ME!!Y`1"_*0EHQ\!9(QSB/6?2"WB/6?3]
M9UZW*NK>G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FM=B#3R\A^1\>\DEV&K%]KMMH=]UYAM"$:XR)LE,1
MADAD;).7=Y2W:=L8ZH54P>YK'$`W%3_#B42EH1$(RTA!X,KQ38%LXBAFJEKD
M]^8;3.3&>J%>P*W%5<!,,YJZKUCN&2$F696\#4L)K%%FUGE'8F:Q=-7%G:/@
M42SN.XJL#F%,2N!8$UABL4#,*2UZC%QLAPYV6ZWENFXD>VS=)B:L%#->970\
M.KWZ/VTS(;/[`B,XG$T'(<O1F%BMZ)K]F0%I<-Y64Y:8P?OF>][8/,8YN.1E
MT;P?[JS'3OMM*EX\<A]N/CSA[+T,*?EXRA<;%\1[R$'>'&*@S"KCVW6DN)W!
MSK(55):4>G$JJE6EAOS@XNG/R</G@G/O%O/I99MS6\T[.1UJG$HW0J+=ND5S
M_0"F5):QG%34\TTNBKJR4Q%V1PRXZL61Q"I-(3-ID)=6]0X'#+7C'VC#7Q<M
MP]?%%4ZOW3&6,U,L("Z["<XMJ;$-4)B46E5V"E-D7<.*$<ZQ0!"<^8;^]LO)
MMR0XJYBL33$`D1:D\/D1RM=BVR)#*F7H)KD&DI*&M&'1RB1]FWO&A.+<V2U\
MVZD5XTS+KRJ"$2ZNY$&W].XO:57&1V;ND8>G)QH>'"M6+2RBYQ'G"/'89'MQ
MDLV5ITCFJ3+_`+,@>`!M8Z:N)RN0M4`8%/)54)8<D'OP]LRV:B5<%0J&)"X:
M'I]E*'K57(U]ZY<=6[#\CC*E.X0S8HW66%#$%%4I:E2Y!U>3)C(@T*L`<608
MMT'UF"R%:[:OWQ4S^ZW;<$DC;@UDB&XM+4M6TV*?Z*9)18*&344D?$L9<S98
MR6%!(0X59+1R-:=)(BEB;6>M,5'!0O#849DOGE"W:QJT^VD.^EY<O/U(F#)0
MO&,?!U[02R664_\`KD2F5NK&LI/LEXS`Q8*$,LKLSW+,L"[$NE1PLQKM.Z<-
MI%"YBI9#WI!VF-H26E/VX8,MF]KF\;T^NMMKBQ9'L7%R=MJTO&E+P8[7!1#B
M;1A)]'8D)$9K1+KN7=Z24IJR/(F+NJ,*'81[YEV784F.9I*5&D([J/#&9^GG
M,8,C*??18%L]AV8R-(Z%C[HPKKE*63%+<&!7F3(P>QSV-JP@;'C[_'<GL5,Z
MU92(1'2-?V=^OD4L$#[Q(G.J50O0/6-E*`6L:PB'''SUXJK/?(M>S8NVPC:R
M4VWO'4&];3)G#7-0:A136HB:R$U5G9<>;[U:LV/5PEU6-_Q4[6MB3BD2Y$6:
MK5'"&J'-B;Y8?_CW0,%&`L9$HW_^PO(E<DS/:(X7U#=/JN#]F#16*:7!4J.S
M>8_),S)7#V7F,'7QT]>X$A:1V(5$4G$UF[GSKL$V<7/&;1<QD,DUAXU'"H]R
M=@MK(=:E6)L;,2.*3NPQ+]6(<[[!,$NCD6CL97L-9[(.\W7YCE,2;$73*5$9
M<XJ^+$AXSC$3LF.-R=BIBF3BL$SQY$S&/&Y:L)D-EF7NF$SKO$$1[L$RQT*)
M<5'0+B'MX1QFOE51E;]?+NA<90,>BHXI&3"(0)0+Z8$4^U>?VI;+2N)/VZMT
M[COJ^FW0E_8=$KKT_C]\K&Z<7<KV!=G_`&`.@.5J]$^W_8,MF3HZ$P7,Y(^1
MF-,\G+:$A>7H'<0A*,R(/7V\5\G5H97%XG`.5QP..JX^NU0%QFPNM*V7-CB/
MM%??[AY3Q9TE8*/NP.Y;.,RC:/E-[RUZU-OW+C'P$#(+"80%6H$C$S)Q6KIK
M@4\AEY*(_M=G$<`WAXA45T2"UVPR]$D;I>Q-*JOT^CM?$U`G=IC5Y-0R0F61
M:8Q2Q%-AIF9<QNCRVMPWF/N,:5?.`WE!*<$OKGFN69R)9K)>3;K_`.17/*Z&
M?4R1F5KM8^6RE+E<X]Q7W>^=@.LR)9.["XQK`Q>.I8W&8#$Q##JX?!W\4WYY
M$K-;(+KK<P"CYJ]D1K+@&S+QB.42N>4S/HV3XJY+L!'[RD^P^R+=*]DKEJ>'
M4:@LZM:645I4]<U5"YPUV+B&QJD'RW[,?G!NG\L9DI\K&OFJA0YE)RR$1C83
MC(!05KC,2U%S`_9R`>04LN\G3+@L/Q\LBF@EC*9&H@&M@%B?:3&$USVS"Q#I
M=<W50QV281XU&)NX^O"/\=B@OJ!5BUS^X!79A8P#(4"%+W!=<>1D?F%>,G8W
M,@VLEK]N/4%F.NV#E4SA.HO<NBL0L6I7!DKB.O,<74[+:[.NQG'*:$6IW]2>
MTM:5R9Y4V*>P2R2.X?>"?GDA$X)7CA##\8K,7KO^1LPV>^6@.3"7"=KE4JR3
MJV40BN/#9M%LS):NH:Y.7'-K,DWAQ-6D/MYZH3-5S6P=>"[."K(N8NXELO-D
M3NBQ6D0@+-B'A7::OL;6&TZWMZM%LHU_JJ:5`K1WAJ^T7C&T,:G%@&V&:XZX
M-SM:T<<];7^$+%9[3&,B72QN;(_DM"I1KPA&,W87D93F+UY<,]O?IT:YLDAG
M([4%M4HYOR&S)>#9]V#:Q@\A`QA1`$C4NH&]30L@0IU?(6;8*4N5X_E9!(F'
MLN<D(@:`<N565F+3<7+9DQ$D&K0>WJ@V%N2]M6]I&6N"=G00-=LA$;<U_07)
MB3SF!QL$0)MFKW2'6C1#765D2"/@`%QRN:I-'3E!)1@&@``>R+-J,:B@>`9.
MWC7O[-Q2U_(^NRYUS8!-ADN'H,EB<`U#6"<E(MB"F-6K\Q=LU\MM'[^BBJG)
ME$2AU>N;3KB](=32)'<Q:R795]J>)1)1SU9<Y\8LZ66/;<MJO;%YAK)L_3D'
MI/:958=7_P!OW%-(["!2<@$AJ.US+)A#)3\L?VF9N215A?%Y:R)2S2OKFU"%
M.2`/`JJOI6\#D5P?BMG(#=BNJ>ID.%0*);'SV2ZNV%*EL$N+,[,@+2X9.UN;
MS@NT<]7@(\FQ]=R%M,8)'4YL.C>L'5(L0<?9('`OX$]3V<C+&KAX=XU"8]>E
M0UA=(J[TEV"9*Y*O:BVJFG69W6[,]30ALA@(Q65ZH;&*5,$>F<<CR4IT1*H3
M)WM29D[#>M2&*<\G=D98/9Y$$7,95S=C+J2M9CO8>Q+I2\`[9L55LKK)**ZZ
MSMA$"<R(VG/IU74["W^/M*KG3Q",7-AA++BI16=GK@X6M5DXNV.USI:B"/L%
M*^,;14U%U1MS=`O>4,XDEC:X:P7WLLG;)70EBZ0771-_RR@JFC,7B-.Q>'71
M=3Y#&=OK*4,4;']DG201[=4Z0X2;#HWGG""&]4&)\;P=_P`AD+MPKUO,/KR8
M1ME;-V7N7>7R:;D#"ZK5BJ*@DR-H<T5L'43NK%>1Y"CXH$X]=/$4L,BP,2T"
MI5JIJBQ4D]U"XI?:1,LE^T"+B3]Q3#V%ZO>,<&I=[WG8]5V/5C77]SV:OM;Z
MM-J]#B-A6->O;6]N_K%RV64S-QQ)Z+;PH<_!9OXDB?$)9@BR'PL.1=V77;;5
MXO/CQLCO6-J%N`>KF=EKG38NK"=K5I1NF0<!UN4"`N%HQ$1ZZG2++CDD+XU^
MBJHE%,'"PJJ6H1J',1-<6"H9,&19&"DC"!.>498KG2>9U'I@+5^O[\)2ST]U
MFLA>KBEM.12P8[-W>>SI^F<F;+`IV7/;BBD$*?TCZ)J7H$[XWN!J$&/CN*4S
M.!!]S?1DD4*%2O67AZ-6K7]JT.^NY2%0#08,$DX%[>=B>M@$##B.1C!0>A4M
M-#+9+-W2*<KDK3[$MKS[<T-9Q%+$;]H0:%K4N)8#09Q(I6,E'#JUCTEE&I&L
MMDTU2]EUK$K"GTJFT^9GMDHU[9M<:FE4VREP>UU'K$WW<6XPNLV?XV3TD?)G
M(LA6G&'"5B"/VN>>0R>8P2/'ZK'*K(IS6AKC]Q8E9R<G][97J$'(U^0D*`@!
MD60,\N,>==&>;G,@A)]Q`1I0/MU&:@XBQ@SW<G-+B5MD<9L3$[0J9@HC!K1X
M[]]-::'K#7*,^0"@3H!5[Z[2HM^9=%;/BEFS]\=)#()>I3V1+$_D$=&=UC3M
M)G\1KJD;&AG5KTI`$X%B<.3!#N9:ZW*RMG$$LK8\*M<`Y0E757&LII*Y;ME8
MP387)BDK!0TP*!@-58#_`"KMEGW)R5UEBR127;]UD,.*[8*"2?RBH&E#I%/(
M-IDH,>O6[QU[Z:XTXRT.Q>0#7]9"$=C2BT9))V?1:UH?;\XDDKE[I/'5+(9Z
MW>0Q8U%,;G)%Y92\")F2K5;21\,*HK)@C^>3:CVN.K`$`O$X]56J`[=6R5$I
M<V%%!0\?G)IK$DP3^!Q(B,@7EI46[N7R+9VNYJXVRXQ^0EL;*^4U^'&%\04*
M@DX9(A,[\BV*)8>._3ZS=+JKL2`6E>,*O^0V#=UDW@X3N)T>YT<K4/\`:CV9
M(I*F?V=?=%RDO9B9R-]I$H*4(<E(2BR30'&!R>+N;%<?'L/@*ZV"&'QP4A,F
M<NQ2B(@.1X#Q;,F<M*"D3*=Q!41QGAB[+_(,IGK#!(LG;]Q(0,QTEP%<J`I(
MIE`B`0H"CD'S\F,Y1QG[RCJQIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK01YDJ<G)B.&SB%[+[70B
MT=BKVU`U#HR&TALML/0T.K;$PN`Q7;MABB-,VQ"XU8LV<ZT4NYQJU_1*26]"
MU$X++ZE9,R\:JUG^<8C!W"DDWLO8N6R(V;?M>-Q1W'TEASXJAI4G<["H!Y%<
M&`D92$E+E[#U^(YG*J@!'&X%@5AA:^4Y2]:"C3LM;QAK1"Q;HBFH12GDEF\3
M[LX''FU6H2VM-DM*]<JYVQWZ,8MK-O\`$N>X\HWYWB4/,$U\HG7B92BXH2BL
MD_8U982Z/6/*6MJ]PQ2X>ZVJW+&$0B!8"/DGC21O^2G1R!0VCC,/F<DWZ@DP
ML?MF.Q]<NN1@O:Y%XVE,+YR"7)+<";#:N:A=#QJQE*Q&O(7+6#QB(F89'N1N
MW;EVR$'O`%8Q`6D-6L.O="K$C)+`DR;U*>K'IWR=;/:31NX[7N36:(ZKT_?C
M,ANZP9;>$[H>UI_8TYC)T!(NNQGJ26K)XU-HRP"=TS?)G=X6(,I,_%/*2BP5
MR?"-=EO$\U8R`A-C&9ZK4JV!6"Y:I]!EBRAD+$%M.DP*Y0V!AL#<@7DR964<
MYU8X[/8'V?(%93$Y%UE/(SB#I6Z*:UD981RJ+(V;*I4'%9%4)@#R[-1;DFIK
MS(_*-5>MKCMEOG)&`6O.S.V>S"^-;W;L5;'W9RGMKL$,U_@\=A5<;$1^)55#
M8,<^/`FIOCY*+*LEB"%4(XK!@!4O'*M>QB\]S84)P^(P]%9D9,864NR]S\@4
ML(IDI1C[$Q7*3KJBV(P,DM9ZN^06+"XQ%G9<W,KGK[9$%K4`8K'U8"*@@L1B
M9%][&PZWMWM8HCDAFR<#EFJ_(#(=<*AA;<VPR7[)ZIT]L?&=&IIN);.Q#BJV
M(L>XWZS6ZJULQBE82.(3D5H0.(6?*"6)W=GJPF5ZQEO6#1-R\M,7[^IC2?Y(
M_!>Y!-5WD%!88_K#C#SJUVJ]S<4(!%-60*B^RLT^]9LT&M6(,[-4;U1.`KY[
MVK3LG@BM7;H,,O\`&2YD7HH(>TB*S8I4[:5B!0I1R*ZRWR^&*5("$^3:3R2,
M11:[Z\M+=,)QY%Y%H5$6&.7*NE49DK5")*K;)[>3),%5/1E:K;8DPQ]]5J&4
M;05C*UE.1Y<0XS\D$&&0K+QXYN3$EG<'D<DR"#UJ!07D#$9^:.T+14TPAL].
MX74LZYVXG-F8?AF>1@Y9D.!N8ZN$[;38/)_MGM^<3_0@)R:X?QFQ`2IG&6;>
ME@S3R^E1"R?^/:NG:Z9ME7*X+NAT3KV?;-,L,A\FJFE<Q%499C;-T]8R23/<
MSGC;-4A;/"6*+OCGES+5$JE*=$B6.1&?BV_NF/K9!,291BYNW4*V=91'[E>Q
MPHJI&8*XTIH.?V'-2JM<3#["BZX;)=@:EJZB9VKJR::%5K)%:W.;BZF2EEB2
M*2JUU%:&J9+&V\V$B45FD^%A=*;R,;53>WY54=->.UYE[U'Z)UUO\;;/]DH=
M4$SC##>TC>65=`K;BKW7[VWU_:\1;8PZ.)#6A=9"C<2$(R3US<IS@GFO2QW;
M<L!?:"L74SZ,>ZRK[R^ER(>VTF(X2\J4$`VZX>D<QFN^QR""AR1S2Q]2Y6B7
MV+^.R;JZ_4)8_'.4D%\BCB%6_+0FI:/BW:=[%-`BP@V^#$()8AX+$8((!"P4
M7D'>8+&,YP6#)HBR^X6?3&1""'K^.<8YEF4@$D(R4Q$S$1MO/^D;S$;S\(WF
M(_C,1ZZE".4Q!3`[[;SZ[1__`!&^T?Z1O_IK4BR^6N'.%?W_`&`[Z^VO'#ZG
MVN:M)ZWK!0^UR]VS>6Q+H"/DIXHP(8M*7NL(XT+'*5H`IW(Z6*DX$V5!R[X`
MTPR,SXVO9R^,P%BA`SE?(IMG701<156IDT'6;3MBA8)FK<*S"@>*UUX-!V>T
M1CJR(4,SEZ.0*%8K"TJ[[%G:2@IL1)`I"HCFPV`=;VX3(-:RS"S4F0DBXR#R
MF'4'++IKS<VD6FJ)Y5E/1:\H^T4-;JG9!NL**SBP&^K(A"T:M^JJA7MCN-^G
MKND0$,QC8I:C\FB-3NQY91H@<5A+(56+Q<38SR\S1Q<5QX@+[>14]M7VSF$'
M)7&NV7'875)(P)$N8.-0NDJCT,O\:^&?C+]_N9,\DHQD**Y-E:X9`2L'+(90
MRPLID@YB7#G03?R.VG5TMDU.[-U-4FIDYF.LUG7[1\['L&*[(DR$08QK9366
M_FS%1U>=!)BA?92V``BCA\W:'$_)R9*Z'&A)PHJWZ]J]C<KC?'W0SS"B-<0!
M:F-38*Z_VM:*3)"&N>Q_H*'5$G([-$6`+8"]3934W$YC(*>/C%^X:3AO!5E/
M14.\\K*Q8Q*D!74WFX;1\"@!.`E@S&N[5RYKCKVX8*^WOL!L!K7=%?:;VG<6
M[D`W>M*Q9)3]XOZY,A8X3:^O<'<WN2TO6U8PB?JB5:DF$%15_;VT],UO3$%<
MJ&+&Q?*HG%^1+\6'LHKHT:E-+OO7ZF7>Z84VPR):QPV16Y'^,VS0>]J_;`OK
M$`I8]#KV1PL98";?M9BXV6UN2JMG%(`F,2A6X`#5@Q#`BVA-Q24/<QIC)FVZ
M]$9=L4\[8ZD1VY[=V@JC9IXK:[+.VRKS8:Q;)?*4VUA1A($,->]1:C7OCW1E
M=L<.?WEL7A(9FR%3-G9B!$OK8<<><:;?QBJ2RRJ*BBG&U,)1%U5Y"V_5R;&+
M!EIKBYE%>379`BJO;1)CT(A261$*SLU9>U%%W:L_>Y^Q[*Y7&%5&8Y0V'+J0
ML1'NL'5E4S-M8V)ZG6TV+"17SV]S'>%%$MX(EI:IJ"7)\NU&S?8>2W@^2:#-
M]=,]<PHU(TK!L;0RO<HG;F]DR9P3I%93TV1I(609D](J7=@RL?/4&U[5#.Y2
MV<5J6!KI8V2CD3.\]@X0&XP'6+F;R?;]DHE$"0G.O;4RL6*0D&/MYBX=9$!`
M\88H"8P6R1BR)@.'"5J8HR:`$U9<H&,AWE3DO\9J38E+K2F#H_=%VP^C8)<C
MQ=&&F^9(XSV6G02*67']:@U8O85]2/4F*QE.>HGZ.3'-O58%CR7DL)NCCL=8
M=E\=@,J,U<QF$B=58[.D)97FTH+I#(C7EE>(9)IFVI/-8V#479"ZEVU55BLS
MEJ!$^M@!L%;(HA8,&JX46/9%N9O);9)4BY=7FU9BN3CB99'FF]]\U?L32%66
M?J`V12N-AKI>J6K5W0;'QV:[&J,L[<X.([>>]=H=73Q#&^D0)4.%2US3V.L>
M69`>6<XM*4S(B`P>.H_>K'[?:GV^3G%V;T@,2T*X5_[-UOVQ0YT?*B4^Z0QQ
M`D7R<EQL9H#QM&SE:<>XQ=6]5K2R=U]Y6I$8.H.QDR`,I@@L15;(K:<+X0$L
MN_R-[?5_K/4H(6Z;'4MK/;%[MTMAE263=T^AT#BD-<TL>5*7.>'JIG(XNW.9
ML4*,+,3(@*P'JUIA19>!YZAS\KGW6+%6SB\:Z%9(:+;$\2CNZUQ,0"`C<R<]
MFR52([`129&N`Y:W,*"JCTYF_7FQC5VTKD)VA9FPX]&'.\"I8<FMV$YX#QZR
MY:A;J-Y%K'3Z.>*R9JHJ3L;(-K+#CFNL\G+K:[BUS<AS2.LK8'JYVQ`57\W;
M[*;`$Q`YT<`FN[&4%*>`9"@P(@AQ^GYNE7M>?5\!54%.A;\>G(C([SU>WQE>
MTQ1++C,Q+#ZI9+";V3R)9ERF?S_'.=CO$,IDK=CWF3QN9.I&^PC9)^08JO"V
M1)0)$H@):X"5<1D8,!$=[QF?F*31*Q7.@%5,P!DV0,N2[X-#*_L+9EBA,3F=
M9TD)J,46,TRQ/6LFFKY,9Z6Z82L<*CL2D3J:Z@R0I/3)NY:#Y*AROTZMM8F;
M?VD+UU"AEKT0;W(!%0(XA=:4*AL,-E.M"BDF/7QB"^SRE-&)LFJY84%9]BNJ
MDTI@5OEZ@9++)<I&DJO)2#^9-=OPA"7F?`?:M+RFVW"9C-(VP::"$DAVC(MX
MW05L7N&K95%X\V2-6ROU963%&.GK1(B,Y5)&X\]BP@<7PIQ-P$E=AIQD9I<[
MU+J(R=UYP='&9;'4B)/W);.16)B*A/JCW:)*!;7,A1Z%(7"GB)4*`MR'[4@`
M)60R?OHX,V@5>R+CWD8R<E1=.TA:@.<1,3->?7:YU7E,5-SK;*MUUZ6MM?5[
MX_(;O8RR=39.,2%S.FB588U4;-HJ&O\`+1!9FK5)@`2JT;W("U)1F#,D%BQ@
ML7>6ILQ"LX+B`[N&\FJ8<0&9XO9<@.#><Q$JX$8BQ?`XC?>&3\-189R<M8P2
MRY)1E\?:NM(H&2K5ZC.+'",%M82001K/DF2D9&0B/FU:;%Y?4$RM%%4M?42E
ML"?0F.4XOV+JR*W;&EU\5_*;F8X^]HHK5%/CBA+C;2*NR'_`Y6^/JZ`LS<2G
M-PE/7K`Y1<T*^("SF+513Q+!IRUC&A<&.8>XK2P7.M"$E[.B)J)0O89N:R1E
M-5B9[M4'9&4XNK>)1C:M8X,@"S@P[*CICVXUSD-[5QZY%HUT`2E!/W[2IC;6
M4_*I5EK7G5-4U)K_`'K;NN]]RVU4ZRN;"J>T)U7QS89%XR^21>&<L\.?FIML
M&`*U[>@1.C:ZE+$N$RP1A80FX"+/R_.XC.U[V.B&W:%6U=BNSUKW1K=4E2:)
M1*X*SS@4M(9)1QZ1(D<3]+6L4$X:TO,J9&-NG7I]RQ&7U'63F%V`,9@XZ0%Q
M$('`,F!$]_DF(34^](_*-)-:Y;++4VNIRQ:JH^V&';FE*.V\V;UX8D]S0^3#
MK`+),XM2-I0``7-AL!C=7)(>G$B7K$)Z<"@Y0F"64'0\@1431SWEOCG<SQ^_
MA*MG%-(C(%/>#7$(J.8V:A(K68$'411)&N6%RC'K#E:`T?',T*2R-'-V*=TQ
MVAI*JK4:S@XY":+PN`Y;,$82/%+`B"B=;]#[>7_%-(-#Y;#-@K?>&>OMSJI3
M[_V[<U]6S94LD)D[L^:5XSU."66G8$T41B--["2VN[\TE^TV83')>I9"G)^1
M_0PVDSS/QMCEK#PFUCF*"(#U?<9A6WGO8<#N]=1JFA`PULC9DD``0@8U6RF/
MMXS!>:5*ON#\NJVVF(S#"*O2JY6I54I2IDH0ZXILR!C"V374;SAPV98/TD:D
MU$8OG]O[9N<SOT\%XR=T/KNLIOL%L%*ZNA=;I#RT;4\1RDI]/G.NX*]S@Q!E
MU-*0LJ7#86HPF1^TGR((\>LEN'P:L38&)R3OOV)9Q:Q4L(F+JBV3=,17`X!A
MJ;`O+U*($06%J^Q&6S49"L8S0J*BNF4SP4^0`0;9(4D*GPPQGH-BA9"XYG$O
M-K#C=Y-GN]X?8=.S=[B6S<X\?4;@]D+=F6W2BS)A66PL6FJ8;0MA5@O:NJI]
M5EZR*I(PQIG`Q8@A#V)RR?D0U:!:1@L&,(+.,JW[Q^3,=7QDTD33LP3(KU;`
MM=[H[8IF3(322(435/K*D&&P%^K(U65[]O&U*_C0K;G"R!#900J[;-4U!"`J
M,?\`:6U=B#)P\E/<!K"NR2YK/%VN^]3#K_%IC7[;)9QM=0E>Z&/_`)$XEMY/
MKIETJG\Z@DBD\Z41^L9:P3^''O,;7%HXR8E:EAK^YGG$$XP<B3FA$#/T.:5F
M\?A\B.6JK'R?!/QN*A:X6`9*[9KA*SYJ'@ASV,23``'!`V%L%A;\-9GC]6AD
MLGB1H6CC!YW(9#U=V2S%UZK$Q,,%OW'(0#3`GN-3997=#HF=V3XUX;JG.4_:
M+:E^G<#-M;6+QLR_R!U7+'[:&:-J>ME%BI!1^959.H\R4L)L)4/K3#CPM3P)
M+(,K#T/LA1-N3AGAS\[1R6$+R@O'V1&=J/I853X#F-F<@W<5`)[B-I%@$,FM
M.P.!B=[BQ,A&WXV5?R-/B]?,1"\#FKUBRT><;U&XQ,=5@SB(DJC%7V"5F)CI
MCO9-9\I""MZI_*KL'4->:_T+LK!*AMO>J0:^MNQL_B[!L0TQ9UF%3+D"U8V&
MP2))=;H6ZS#92:+D"A$U5W'(TH9$XRR1.4I0EJDYQWT671C'^27\?A5E%7%/
M36N+27N'+L-D0&*X&2R>H1)5BW;L_M]9`ND%$XER&L7%-N/Q5;*Y,D5TYA[B
MH$PNM(H"0,BN3$,8A0";%UO;#E+%KV[#D`^>5[/]O-TDNHFGTCV\D-&6U-&Z
M-1N//KM5C(KK*/S^/GRK*-"UHI4*96`QL"3X$B=$C>X%M*I[<BSE'5(B7=H@
M\^>R(G3S-7!530^Q<R2:*FP917[K#10DC.`)W4;"$>:T-(8+F00N",=K!*7E
MZ;K]DBJ(KT'7&"8S+83643[$`,3PEBZX-=Q8U0D*R"#[2`#_`&Q-A[_^TK""
M:_T34=C6S+JU*M:P(Y;NQ<OI6&UG%U@T3>SE"F,,UJOZ021XD#\-<F1%"CK<
MG,+:E)@SRQ!`4.Q;JN5EKU*M('CZ!`!N+D$L-IM$!2$`8'(BDC?!.`E"RO,"
MR&S(9U"T-C!4,M;6Y5C(\Y4`B)KCI6ECX:V2`@(8LHA<0DX9),WE?7\^(7O=
M^^G*73FEZ<UIJNS+ZH&$Q26[3D.^SS]`->*I>9='5,K:ZQAEV*M:Y!.K-L97
M&0)W,HE3`(XTE-RT@Q<X(3!X)YG7;U.IB[WE,=L^&X]C5F\Q$'O964#;8U:_
M82V#6@N!L;:0N6QU`4D+H5HIJ.9<IX5DA'D.0#L2H>9K6@WG70ZRV%P2O<,6
M<`I*;+HA9G*^N4L=:E5>5>,W5-/'Y$8!K[9XD&_52RJ[8].I))*Y:XC7T*@4
M>"X3=L<4C-)9+/'Z:,;X\,B0LO+&WL"Y,[X4)W@9R<U'SZEV`97\FS/CK60/
M[/C57"9(E]X+#$+K0`?R2R6-AD.);%E7.!6T9@]8LY#KP=?*O67N+&7/&]8$
M!BNRGO)TFV2#DF%UFFMM<'\BE(-%';!#M@STZ9Z^F.F>N>O3IC_QQZXY\XSA
MUEV3LOC.\[S&T;>L[Q,3'_S$Q,?'?6G'Q]/CKY1M$JZEFT<UMX4I*\N0ZOLK
M:[;5WIK;A'Y-MD(O158T+3=CG1*%0V%Q1AVWF#[('IT>6K!9*6<P)N1KD*A>
M:D<%I*`L`I_'.&,\-P.;RIC6N5L'5RSCM<73=[[07*J&*.7J*O.,8*K9F:K$
M@KD28=9ERNO+I9>\JSU&CQ94+)1B9"KQKS2L!CC3D+*X7UG#!RB7,KBE9U4&
MU"#%4![=E];HWL+R80;3RO&O5NLGS5G83?BL810NP%E6$FD%YO!&O\S?++LB
MV8/1:NHE*"*5K8-;TS(6I')03\I_4-3N'*AG+(6B#C0\5J60\YP6>R*8K9.M
MC+6=6H=^84XH0=5=LX@)JL._;Q##KK&TN)$`<8N`5Z@\E%5/Q'R3!4R7=2DU
MX:QWS,)FY9MQCK,UH.#]XZBDKLPPNB28IS*YFI<M*;L:\I]KJ0,IKGIXT_3+
MM]+#\?B`<*V/021WE,\A;C(6EKGU;-4CJ"`(I+`TPH:[&2?[):PKX^2VGB1$
M/>`9YG8@7YL,*<#U6<[B+MT(/E(HFG[@R*P0B4C2>JO)5[8`;C-U994@[A+4
MV6KE@RS:A$FUL"S%\Y$9B75\F&/A4+#U@;JG9*JEM8R&J,0]DY"(3(E<D2\I
M<CGO\=JN&Z[LCUMI,=@-CJ!BM68O0!-*KAZKJ$Z2X;><+YQ5!TQ;J>CKHO2M
M.50*]4/IKZJ`E*:3"NY7CF@I^7HTKN+&-K&#_='P[DJ*U?WQ8\1Y`#H:=IX$
M="(@(LUHE[9K0)@'=\`P]W(5LOS6%;(UJ=:5C#"MMN8]>50,#)!"2319!Y#L
M/KJM`T*9:9*(=;D*\J]G60^ZXPJ#ZG1QUGER7;MMK78+(IV/RF:*GM_45-(`
M3-[;Y"CI!TQ8-#N3PPA3XDOQ69^3`7)18CIYY@DP.UBJZ$6\:<3CG^(EGJQO
M^R4J"Y6I%7L@$OA#";9CI8D[:V<"F96O[D0Y&1PTO1DY_P`ZKY'3Q3`3]V#]
M[CVY)3D$77R8%54FZL\:TJD6C+98N`/$[YY&MS-@EOC6#JA3%40UQV0GE_RR
MXXE:%]JVDA976K095#9ZPLLM;M5;;4#J693-P95S3,TK2V/RH`D*/+8@"XJ%
M2.UCDT#\D&S<:?\`PD/$:V:,Y"!<"LH-,:T/5!2`6ZH7(LKJ!<A5HT619:4J
MMQM1WG,JX+(+Z"+/J\J+!"Q<R2`LU&V;%@UD8A+$N5BK]%QL2)59:!I4]Q+E
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M9ER@>QCX^4DQ\W,TR+?=)*0ZA4<@QTB0CN)5JTJ!*I7+E!"1$C3G*E:M2:`E
M.F3)RQ&GJ#SC,A+*))*!D0A"SC`0XSG/,6S813KG;M&*ZR@DC(IV$1&-R*9G
MTB(B-YG5A2FO:*$B1N,H$1B-YF9G:(B(]9F9](B-?/=KOY(6#93RX09BJS;2
MI;<UWM+5'8AMAU&5-:\,FZBO)73MDU$M;K/MMAALG>S&:96S'W!],:274A.H
M;F!"44$)2I0Y$!U/&*W?@?(VY");;]KA\BD^.ZZU<F7JSJ8'/IW?Y5%]W;C/
M<<5B$PIJ:RKY5(T,AA%5S!+%Y:_C'+DYAMEQ4_=^XE1<2E-=E"Q6KD(FN(AE
M@6D%]0A`O-*U_9*&JG*G]=ZJ?)=N5YW;0V)K9C=$;#5C2QP_2E'*$K[+$4P8
MH7-UL0:;#=-=%Q[JXH&Q8L<R)<MS@A08M$`SKQ0\IB1\-F@NK%G#>%YG-,&6
M2L13F9:&,7!`LY@0'+X'90@2PFFGT@4#(/*UT+CO,HR%F"3=RF"P:Y6J&2YM
M:*K,I\2"#LKX^0CWL,)B>0D43+(+:"E\UT4412MHFNJ^NX;MI8=[[":\E4M9
M.R3/!ZD13/65[+9K'?&B^E]9J95/HBY'N+:0P%L%?N,E=W%S+2_3$>PL-34:
M9ULM%"SAC-]"Y@QRI[A(V%UXM-I.4%<);#K0V*UJ5!VKKLK5V6FVJR1(AFM?
M^H/)HSQ`A^/R:*(2N98M[K=&MD:Y0TQ3"EQ4MURLDV!)+S&JH+-AM=;\AN7D
M@VKD-C$UE2?CI>[`E3SJFEV9C\7GFR$4I69MRD=B8@.*[LUFDM<N[#7R^5%E
M'N486%.[N8XI"<X<D;*,)N";5"J-RW=2Y@IJT+V&4YD_-*T99+G&3%C\_O,<
M-=L7*B^U6ZR%-UIDH&5W6(K33!\3+K8Y@1@/G$V8AJ5=E=GHIU&X5FM-6T9H
M:0/!LU(7!F&`(+Y--K8?9&WLYO"H(')J=2[80W2+4.J*HN3$@L*8;#!;HHD"
MP,GW^ME8M:Z)S%SG>5$FDCS+3"8B;'U:5(VK""#%RKC#USR&!Q%=$KL>3YZW
MDK-0N4@D,?2-U>Q-H_BFO2_:K]P'+18M6PL"N4K(4)U[D3BIE+]II$K`X;$T
M)O!$0;1N6AFPL$QO]ZY:B_BZ8U98FLLN+AM'W,X;$M.=L;AV$L79^K;AHBO*
MAD>L4Q@D">GFK-@7*_H1*Y7+X:7/'-H:WA]H^B)"U*XA'G=HRK`L:`#&>X]H
M,>V4$T[M":UKQQ/D"#9][(W:O`E\8GV71!/6?*88EAN)8SQ&8-+1*((9B/;)
M6*>7#$6%\6GC:]W???BJTQZTK*-O1V]5Q,&)(!"4&#&PZ>O%GD)OZU&:U]+]
M+*.FJFJ;"W7M&8L$@N%M;6QTD=:TU4D!>+*M)S@29^0.4>!8L@:&HMI:%2U.
MI);3UWS/CGY(P7FO@ZJLWY0S'7).,+C<0[)VQ`I6;P!Z*E>J+!V-0.M65R]B
MIAHH!D+-9D+!N9$RQ7B=C/)$3R++]2A6Y#!K4ZV1R5A@3,0R$(4TUJG<&-X"
MR.OE$XRMB,QOQS6I5UD5U9FX5[RK8-45K75FG]F[87E<T6LV]I6ZHI&W6JIF
M.Q-HV054;#`(4PO9K\)K0B;2&HT:DEN-4I4I`Y,8^U8LL\2QB*[LA<63U&XI
M`*-2BICKIML0M]@P9$5X$B&Q8[`A"(GW;X+FXFI.)_?\FQJ48YXRUBH^:VVX
M0U*M6*X2JO)LL-B5Q'MT+F98R06H2"VG+RN7K&:KN>:R;3B`+YC2&ZM2Z5O,
M-KG;%?+V2>R^RE<&2N+S5<SD&M4!5/BR+#LEH!]8\,[!A6?\LL2I/\8`CYJ%
M0,D7C?M2/K\BN6TCR&()"JQM5[LMC(#K2ZM;AA08,2I';UF1]007QM8^<\+1
M44X3Q]64^5DE#>:V..H<0ODBR*A5(#(L%A6%1,K">R;Y4>5=R9E-DUP_:X*%
MVQL?V\:--:KJ^`6R@E$)MZQ)'!6ZT$+T3:,B@D#<(=&837KF!RFARF-J1L&"
MC0(L/'[(CJF-KVLW4QLXH0_<K\9,C%TDM*$XF8BW;EX`XV5"F877,418<_=/
MMA*(F;614&'LWCRG->&J4<;96T1@VNG*M97IU.GF(!=*PHQ,/<%6!)+L%:@2
M,5VY'O+!8&6J;Q6::N1<G8='N"GT@J&KZNV,.L>!W!<9,+:;`EKX5:TBHVKW
MF&5;744>BE;ZZJHHI7)2TZH)3>>:466?8JTV9:GB&868*_EJ^1M0+]TJ31QA
MDIUMCE19F08U3E)6"R89BL>,$V87%9`L7;R,YF17B,=6QI2U,]S&6<F1!7HP
MDNGA9WE,EV-%0K;VFP%CR*"6LVP"JIMTMT+E2ZH50GW`VNV.@FDM;T?25DI#
M*REMA:_5FZVI=MO338M=3L#?3X(W,$T0*Y&_*(`=(2C&L"0AL<#PE!'8\>1)
M^%T\%X_MPR5S*9ILN^PBOCZAJH*9,*]SMV7?>*K0H9]R]\2R$S+""#R$05Y*
M6:ST`-?$8K'TA97XV+=FUEVD\:Q"R:VS4*17D@:V%UZT2SMXR`SNJTJVDL;;
MNN;E>)G5,8H^55?=-CT'WPNUS[TA4@?H`F;4[G-8A*UM<4ZYN<;+=W3*<LM8
MT-ZO)Z,X!A960\H6:BKGC&/S%%[`#,46/5N,"Q2X<ZJ)%Q,QYRQ#3&!*8Z^L
M^6YR(>JLG5\DNX>VH&#C'H!LB9;&QB56B5L2P(>*7)Y%M(R3"@=X#<M0<8TX
M>;%\C=IZOYW"\A"^(4QI6BF5KS-LW]WFBY#KLW?D]=#8#+V^+QS8UKC42:X9
M%6%R-;8PTX(9`IL%%*BC^S`Q>82LJUXSF[VY@%.]C<;2,BEA<E4S??L$3)GN
M:PH0#NR"6$M*5@N9':SEW^RS&"6R`9-]F4R-D(B`@JB[*D5:7V]A2`RX^#%@
MMK(1,R4CN,[$J:OG8BNH$P@?&77A]U'HP#=6,_W8V1W;G4%MB:ME:(VZ*6#=
M;Q7SGJS.8&88XRM&MP`+M::7*I249[ZI/UQG-RUDJF1L1G,HM.,IY&2970F(
M*5PQAJJ(-9Q5@&.(0F!"6?;:M@2XBX:@/'-HOLX7$C:LWZC#[!L<HD9(8M$(
MM&7FU*$-&(<0!,]91*P$.4X4D#8=>7FNA;9%+GODNJ*:TO;KLL&#U[M1?L:I
M:76%,+#;V>F%KY5D+M%KJ]\0F1-*XK1$Y:QH'LKH)>!6$)>,>>+U&4A\JR-\
M2[Z5VCCU)>,GTV7I=8M'UN@H$A2L%=<QQ29=@+!WW-1^0VD6\9XU1HFN?W"+
MUPG)GC+L>B%*5`M5QY1-NP+(:)RP@&%P<IB0U(O<O?*U]:'2PR*^U.>;+BU.
M5BUVQ8]H6=8#U0U5OC<\.XF=OK&B)HEJ*W45P7\J/+[@QH\$?1!P:0`QT+-.
M`#F54?#GS-@6#4')5*4"`RRX]EN(*&4ZL\(LH1&_N&=ZY`HD1`]IF-?V`$I0
M`T/>/J6K`S/_`(R`J[<XO/B2*J3=XFN,(=+1@BF!$=YU[;)75<U);>,OD*B<
M[V$9M7Z]9M>Z_P!RM7YW/)R[5_&(EL.T@.S;[;5KG)7.'US8M"KUC<7(B6A*
M5\@LPW)@LCP:,>W@\8C#^17L!E;5>WX]G,O8QE2U!\QJWZ@1(L4\HDUU;=B1
M1.Q"L!."`=YC;&OO'R'QBGF,*)+\GQV'')-JCR!KD&S<ZS41`BU_LH<])R//
MFF9,O2(U("BARFE5MK6Y2KY;>SUD;0[)3*&:[5EL=OAL:X42RU-'?C.;G(XL
M?*TFQR*!1IO$C6KAJFR)NCADDPI(0(E'G!8*-&+2<%B\'6`"L/K/NV6V8F'(
M%3&K&N;^IC.8Q`+2HI7%@SY/<;``M6[URCE,C>SY!831J34J<$+7U';>L"[X
M6MJP&N_LB9/8NB%SUH'G,3MGIYWNY[B&%M_5[5=9SW[)85F-4]<<MO*(8:`8
M*^`NQ-YI1>O+SER4YR/WDO\`'\%$=H>U0;W9[?7#5$%S7-A,D-S@@@8$]Y^4
M)@SYCQXSRF%SO,CPVB"*N$OEAPP0A43'"8*9DO3UY#(Q`[3Z1L1[QZSM\-94
MY!J73C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C
M33C33C33C33C34!]H-"D6TMU:^7._P"T.S%:"UFG#;9U95G5X-;0UJ"Q$+9(
MX\IF$B3V5KA94W?7%VBLJ5MAI)CX%"F3CP:B(2K.Y4+O#,+"YZ?(%_?M=#:_
M!O\`3BM8%8V$1"^LX%\+B#9!Q8&"*%.6,Q$,MOE?'&^-[S7KN8IIM5_5EM=L
M/JLGM[5;UG"+5AU=)D(]ZW0,1%NWSX\#KPVD@VV[=NEM[2EC5A!)97-<L%3I
M]15T`AT:L##`*P`M[%<VIEON3DYS(^+H#%*MR7+E";*?`40DI>1%YKXP&8MV
M0>IK&3DU*2^#X_T$LART!("!+`71+),2AQ$6QM(!`0GONC(TZ5!H"->A9*RN
M!DXY624ZOWLB2F#.*]AB`&8Z@"9(5PTF,.3=!ZT5=KD@F6(&F?W.569)A36U
M;,G,A<9C95GR_*(EM*?9E*G88SU.&YL3%I&]O2EI&AI1EA3H$B8@."\7"<(T
MUXVHL*^,23#6I>_$3<7)K)DR-C&L*(YM<;&G`@)'(+`1J2+76RR%UAOR)I4H
MF'`Q,K1!0I8@L5J4L.9E"TK6OL8ULCVM898$JG0A!5VXMJ;J*=H-E[+GUO0I
MMK>2P&P@:V_U8WP&-/<@?X+%(TA@>N,%GK0WP-?)UN41O\A,6+O=[G0YP,Q@
M>(\2R<3A;>#B(?7O/"PTV?U)LK6*1?$KZQ@N@93U\/;P+#($BV18/>8Y9C)4
M,D4S7_;E.4E:OZ?38D3<LNWM.8-RTODX.'<TK#LZ())6M%/%]1<8G25Z53RZ
M9=43#>$@V7@FJ\M?*_6Z^5]?DFDRJ;N5FL:1LK5HMJ0."><N*M\;VR22U]C[
M2\*A*T+>G/*3#([Q;VXNM52!2VW0I,ITWLF>ZI48MJ30F0D`G[#CKB]RVVEH
MGJ6\`WB9<JS]V;;-L"I>2-1W@"/EN,3T\#=SYD&_MT2Q=<D)?*]WJ9)MYV`A
M\1=5,!,$_A>RVVD'<:?O^VMAJ,>&*244O54U)+W/G:BW(M&6Z6Z_R:.2Z)S,
MRR7GJ=,4,GD#8!7D#<Z(P``$/M&S8HC2&#EDU,..*.2VB;.-7TPJHZ5POKA7
MMT<;%/VMPY6,ML,GUTR!QDFY!CQ&!R-Y-XQC?B%U,C(V0Y24F4\8B4/EU2(F
M877#?66WWQQU5FT*EN2KK3OF@;$JR$S"M%TAJN3P=Q46S7MAS!!8$[C-KXM^
MN;6"[JI3-V\+J>^M?U$H)6F#,3.9'7'3RJXJEBT2_7&7:U5#JOJ*"&C#1ID)
M!(6%-0+W##5/6;>UDO)I&13!9";E=`6B)F0K6G6%V2GDX6V%`EV\%N@UDM21
M%#$FA((2M"U*4"XSA6>LT"I*>WE;\24V!*)Q=;36[;(Q2B5)Y*ZE,U.Q1RC<
M'C4=?I`!,\G`#AW7*SE+XZ."I2YN!QYRKH+H&NZS93@7XA$$:CR%R]L'!9R^
MXJJDQ"8X*``"FF%1QCA\TR1;^G0UTOS*<HXMFA113^:2)<+38M6.<C\Q0;#M
MG#>&P$"T`*QA<;V!JQ0MQUSK,]5M8]\7>LL>92:UY8WV)+IM$+=M^I&ZQY6]
M2"*Q9OE\TA,DK^0KZR:W(E,C)5,;FQHQ$X1E`7(B"SCY\@H3Q&/PJG[VJ./3
M7;;4$`=IBR(C>4,`I(R$H23S`&O%<6"768SJ4HND,[>S=A,'2MY`K"Z;9GJ0
MOK4OVX]!KD%$2R="U,CJETJAK>':<9(%X>ZEA-//U2K=E=KY\M4[*%;?0*VI
MNYZYFVO3NQF7Y1)5]D0%QBNMT5ASP<[NZCJ>URQDD[(%,6%*2C)28R1F15IE
M2MADXR!JOP5:S5K-7'(YIVQ:%BJV&]JF+8-BQR.5Q8DGF<ODQ42_&@%I^7;>
MB7+SA).V$S("3JXH!#PE,K-1I&K6@!`Q3]@-U3R9SR4[^+37B902UV*TY/;M
MNVI=2^NWJ?;-3J0P\%[*7ZG7\<HI]TCHX=`XE44)2UC(186-;0S1)`P"48R8
MJ0*1F&B'!RFM%2<)OCFT<F.14:)DSB]"Q5-DRM38[B)8ROJ;S0`&8)4L#D==
MS,V)LCE/\VK;Q;L:Q3?1?L;$S+JP"GJZQ84P;&+D7M,%&UIDI<CYLI\4U!VE
M'K2!?MBWOL);-LQ!@@CML98\F@3)<,3BL1DZ.;1)IK!)4-:5=3U:)V.8MJ9T
M'AGB27[98F*&Z?.]L&,=`UE1:/V>9HW$9*OD(>GYFG<JR?MVLE_<)BD3,`1(
M>V$2+9,$1%/A;V0*OE=KN.FG;J0AHA"AKWEBNTN(2*B*6B,;N89V(C<1<*YX
M:J9)XLJ0M6+6:U;*V;>^TTXM&K%E*+[FMU]K6/V1$JS5/31)P1RO4E#U52]9
M1`TB4L*-R&X$1S+FN5)P?.4JB@X+YUWL1]W%3-&_-ZI<)Z)GM*U1,SJ-^[+5
MA"986R%K"L7U&DCCEI4DZ]A#7D5FI7KO0"&SR5"[2X59Y<>+&,<N.LGL83Q"
M2!;0&9C67*7TDBU7V6RW;8-RWAM%=<4A#I6<'M+8)?5?WD%K][4M:QYCD7CM
M(5/2E=)CWA2SD"6O"AD4R%:`.2SUYA6>SDX794-N:ZDKM7^$66B,PQPK.6+5
M/K(*2+)[.A`*3+(%A`1C!15.H#%U*Q$<XV@<G61O]M+"42";$[=C&RDB5#'L
M:8K(A&1Y%RL-+XZXV;N%--QY9LILI84BG=3/U#/5/2_&N/\`21%,OR\UW-KQ
MJ;8SKI&K*;FU(]&!5A6@E&7A4:6`"U8J)#@KF73K*K^/Y3QNW'NZ&8)9V9;Z
M&3%`Q23&4](A*DM8H1$87,')F!NB&QJ7+MFS>QV0K%[5^*:3*W5$;`1RLF[]
ML-D^TE`12<D0>HI)83(ZM&!>*JG(0DK2/++GV)G]=Z^JU+MJM5$Z>J@55WK#
M(@)W!-&I17S5&Z7C+E8<BK\IQ%F.J;*63S+0,`#",8,#W9NG;OL%EEMAI>0L
MH>SB_/&+:ZTIBN8*V&*ZS8@14QXUXL&$;2W<BDJ4J1$-J+6`8&Q;FT^E$?8<
MZ;,VY)ASO:D)L$;)0-D:\R4Q*I$0@;EU8\>SOJO-%<O0[T[I7B0\GN"N6Q[8
M,>HTUS-E*T2PU,9*;(CNI,+O560RJ5F1H$Q,M3I$P2RR<%93%A)Q,FY":GL>
MI)5H#88XR$`<\8EWVI7#'3`[$;NR3Y$1\CGEKFZ#+MR;Y,(+)F)%(0$#(C_:
M$)"04J=HW!(KVGU&1F9F<J1W45;'KZNO8/\`Y/;%ODFN*$`@+9&)`FUS7PVE
M65*;E2TBIH@O7E+*&LQJ7"$I]A\=7]O<%6<&N*98,!8@92:Y)P%O`BUD^]L"
MYCYXR[F(D$1'R]'&%%*A$DEP#U#B9&9V+)#9R=3(D(B%11K%([PHQ.1(^SUE
MLE)C#.8M$MXX1,*B%Q$:O?#E6-95S4L&C.V.Y7W]$WG8%^U';#D_ZWKI_"I-
M;!#N59<;2M0M9@5,[0J7&OJL[*9RBZU8UFG9RV*D.,!#C3&VQ94"3$!%#$LQ
MGRR6[Z+)">AK)*6C(0$"%BN:+7'T)Y;#QXM$Z^S+-R#">68R%6^V"@(A=RI_
M2>H0$8WG8>:6PVN7&)Z8F2DLX2'QMU.=9M37)6=K[`4+9=6P:4UBMEE73"&N
M3A:]>S:0IY;*XW:^+?KRUB'E6\2<C*[#XV`:9*C/'GXCBG"$L)?-:P56S9)`
M@.*MUZZ&TQCKK2%7G[?KZ^#T&N&''8AZC9R*6DPB(IX>)6:":KBDK]>ZVVNT
M4"=@7V`%;R*#$J[A<(A!*>AJAX#"@7$1&J^TO')2MM(=GTLCFES)U6U-2UY2
M\M?$DR9G.10F%UJG/`R@KYZET4DZ[[)S<%`ESH;(12`#@K]3`>WD10J350S'
MGCU_;%N83DF&(CR.Q6Z8KP0R)*E212(`'7$[$<D1%,%%^K<FK?I9'K6QU'&6
MZ(0?.8-%XV,L=A04')S+2@)$PA8P`B,0,:PS='A_I"\VZ>()-?.U<>,M:IZH
MJNU7"`3NM8>HL3%(B*_K6:2%&W5!ED3/K&65V*&=N2(84[!%_P#8,2H02Q`N
M6[+[62=DX*5FW,KRL+CYE+NAQB6P+>R7"8@(RNU-A:]H.N*6_<U3Q^V/QU'&
MK^95#%V<:LYW%LT;.\E7EBI62X`RD@<B4V2B94YS4$2IS)6/CUAU1V[.K7AN
MP.S2!);:Z*2:Y*N32VMF6N[1LJ(Q]LC:.T7A1%ZG8+*A\F=D#.GRYMT2D<=B
MSD(&<'M`RQ"+S-7N^V!B`6N:,W[-Q"2Y$NJZXR6V>K<N3EM81'U7BM@!%R7`
M2(2-1M0&IK#)$-I&.K42</$6OJTQD*JV3`P`$E>RQ=7!#I6,";"B2Y9%LW4M
M39FRU,;)G;*;$PXRD$[ZFCE+0XVBRJ7D`)4C);I4.9(I+1DFLMV/?T*4@L0R
M).D$CP3@2+*48S1&5,69XR[;M[^X&Y7A,K;ZK6`_-$JX=9B79]R3DR(BB`*2
M3$*U?OM.]B0PX?82-@'$:_ZC&+DI7+)/F$P`F00$`(;%)2,LV./3I_3:CZ+O
MG9?8RNF1:T6)MB[0M]MK/NMWTJAWA$?%'D2]D1IFM*L0J'DH8E3CDY2I^2M%
MDW'9G.<9C4$(\9/Q-&X8@[EFS,1]7;:B(9M,[QQC;[8[;!R*(])VUSD)#)9A
M&>LB,Y5&.72[(WW-"6$:H.)F8W7!<(D(")`1Y011RG`1/BBU!)TZ4Z-?QJ0F
M4:\6.EM67%#<V@$KG<R*LI+::YPF#T1'R4KH%\D*,LA;@"4D9K>'XX1`Q^;E
MN;/_`+#!7NM7#QTTE23QW2$UTM4KD$S,E,$TGS/*))\0<S,;C/60<[(/SUN2
ME-SR*7>[8O;E$/)<L%4G!P`\5PL8*#X`1<-CXF.6[%IBS95M/K--87-[1K>H
M*)BMA9F44C=@-S-45LF2UL;(_%H?):M0D*W*4N4*^L&N2."P;>D:0F!"E^4:
M><%/QC7,7ELGE\@7<-FC%8%-CLW<3H>5U4_!!KCDDCF398YR'6I:X:VC>0)8
M>AA<</1%>^#Y:O89Z%)-7M&;[DQ;)(#@1D07*^1$PI$`LN>Z#%3"WK>M:.[;
M;:U,@OY+'4%RU76[S00:]FK?&HF5!DB9&XSS7R=6O71RJ*DA2GK(C)X^OR+&
M#P'EJ<!.Q2"L@\6>"R@^^P;'O82'3,#/N)W8N33*72GT@85V\)&)$H*#."UW
M9*\3ZEVFR:V3HK`*[@@2)8@V7[0M\.KE,N)C)-B3/=DB)"`K$,07+X=M8+:9
M)5$V6;;`T7"IO0<)URE4.HNQFB*M#S7]8J%"JMODK9%#9A),*XB<N59&E`O"
MR/\`A49A]0.N/;[+C[5VS;L7GN,[%C,U<KZP$@N_4%*UN%<A*SB55JZY2\7(
M7T@VNI-B)=.;4K4Z*:R*J0`*V/MT?22@F5+IM:])G!08\G/:WN42K$R<J-Q5
MYE.KJG'BSIRR5=O*9O<.P[V3>FK->:GV2@+D57,:5VA]8*U[A%9JVG1NHF9R
MC4["O<U!JLEM4)8LNR<,)[,,L0@9ZN676AR`KGI]_P"05LU'"(GVU^J-<5,1
M#>R"#>H@R5:BR$D'I$"1"76.6&._;(B.Y>-Q%K%P)_"Q1N=O<E_7PF"XN8`.
MK37L"/&8;S`#&XP>.B*H[6A]V,FR>T<7LELI.-:]VC(8M(*981;"5C#EKJOB
MS?9R-OH\I%$)`PJ'Q9\5[KDN"/!&%`L`4X[0=LXWS&_D+4`/LLG<7<?6W/IF
MXI0HBR)<_<`9K6L6KA_MVP`BQ)!N,U5T@7C\=2@RFQBD-16?,!+`KM8+)00R
M'MVK$A^0FH-H\BGLDIWU=N[NC3/O'5+'2LHV'V*I:NVYZC;\_M%)+J4&MG[A
M"I+&YC"LS1^NZD;K?5*>,R>*IE@"D*EO`X#R,#CA:5G!8<X(:O.5?(`847:5
M@7H&!7"UO&&##8#AL4P+"B`/DF-A(5P8P6M$&0O%V<2(_9MUV5VGR/M)#0E;
M50?+<88,R)F.S9&2#L@",2UU;?Z<6YM`MN^CK8T9J6\)8J@;!7.F/DF=F+6I
MMG=&L)D2:\+Y[:D\-FD<V`BUQPJTE#M(6E'5]=((Z,6$A0%"49ZH]//7F+=M
M661_Z;/QF8L6FH(Q!E1-T&)73("?98YE$>AT7F*5+2:/*40/:4_]F37QTPS,
MX$,=*X38ZB*;C*[%N.T$@BLNL9BF.=13GPO9D+[1A:Y=+O%S`G-PFSB'8C9N
M');VA,&B>V<0KR7P)HC>T;A"JZ;*N_E4\E$FK.7W=!Y`_0QI3H7!3!IA$S5I
M)01'B,/$:<9/>;3N/LUVUU-\8;DK%U6/8(^U2VR[O=$"N%FQ36;&VLXVU3GD
M,IZR("J8Z+M&C0D72'D=&@JI%]>\624C>51,G)KYIDCZ;$+BTN"C9VZU=?I-
MWC7@\)V>JC:N%WGL>T!UYJ9\I>FM9(LGU@;Z"BE0/"2/&.]71QG<=?$E@%)W
MYRA[8?ES53,#R$Y*45]F4BP(C@,ODZ[,UDK1MR&1S0#[DF2$,9T'9;5%<A*`
M":QVG0G>1`^0^ZEW&"CW]NHOQ^,P%:%T,3CK,-1PY2*V&"TO:R2A[6=RU_=B
M8.1Y,*N"V%OK(.NNMUS0_5J55)8>R.P)%ASV76I*D5J.DX@UJ754S#8DZ>)/
M'(4R3*Q*^F=?O"BOXXXDM"<1T?6-J8LK($A6"RR!AS<M01D?':/CCV3O7Q=>
MI9<KY2M$"X%YFPUPPY=N0%8D$V&#][[+B^6]6O\`'R._Y"%8`K6KK')JM^95
M>)"`"`6LY!8P8^X"K#'I21=!LMK$C;'BF/$7&J;KVE:0_P";>[=CZYT7)8Y)
MXQKW/%6H2&`2)5$W@Z2Q]NL&25CJ#7%R3)D02@9;F)*IE78H6IR1G>Y@O`>:
M-JS&1LC:RBEV37194""Y"`*92/'[P"B6$FNJPA41P4K/9L?=&#BD8/VM37>]
M-B[=*T]H%]UC66XNOW8<&4!9=R&P`R(M2QB)^T<CKW:K\2]5TVZZRJ8/L=M8
MEC>G\UL"24!7KC(:.=(1#8E9#2H8WRI%*%708WB2PE"UK5!+>YN:Y7-D9*@9
M8'_VLX!CU5^X-R,E883\E."+%-:>W)U:3K&!G`0"P>HJ=61-`)%O2/N0?N7+
MG)U:V238K0L$5WYH<J(JC:$W8BY##5SYSP=%ZS!J;+5KYQ-<4%&^LNU[XZ*/
MKE+K"C;9%9;TGU6M.Y;OAX)$YPQ5B;6W>2:=)YA/[)"WP5K`YOZ,5EO9K<)K
MPSE)S5X\C`:'``AXIVG465V5YVBKXPO`JCUV"DN,?$&,[\O<$.-0!LDI"18^
M(7$LW'J^D,A%\6<@'(^13F7P)%\SY.V8U_FDMZ:CMP2E%R,)JU/NSU%V8C8_
M$Y6\.20]77FSFV-?6)75A[&3>OKC87G7UUL:)L>UDQ_L"[*M+S-M=I9")1`I
M+,2R%Y![^R.\F;U"4D29W*[/6"L;JM6G2%C)JUL)4Q+1Y2/O*5#C[,+$KX$#
M:\#Q"Q2FI8F"9)M(F&16[+?>6[]NR(F=[+SDQB=^-6X2B0;*T;[R!J,EDBS-
ME'&1V7$K5*\TUQXZ]<ZFE%3RF!)IFR'4W4]Z59%6T4D*<DBY3LC+8C-[CM>5
M.3HV+93)+EF<CAQ)ZI\4..<FB5JLC)&(W`@>WR_<,3E,(40K'9/%4L;Q7$#[
M6C0&T**]/X]0;68ED%V<RK5B]"!DLY58M!:K7&--MA&8=E&2<!,6[S5PJ'68
M@1@NE<N!"U0E:@L-7`<.H58ZHKQ>59KXX:EN\+O'8ES=M.ZMFU%5ZND[A22X
M,LI&=N+`[.U96$VME&LS*J0IW&(LYI3VRIF.6&_6%!5.R@!JL*C3MY=]^WDK
M5T%,#+XVK3MKD9%;8I=L5GQ`2)*:N'OCK02JAPWYZQ=:>JM:5[I'1)&,#F;.
M3443N27V]_<@,GR[%MY%O-CN<',I6X)G?5=4_C`I"IY#`U1-B7=.Z[I*52R<
M:ST78#]7KC4VLTPF?\G"[22KB&"LHW/9`[H")DY$M!LV?Y=E@(5#+;/B`].8
MZQ,,9[*3.;XX;]J7;](LJQ_2JO"%<8%`S"$)3-B43::I?6Y[!8V&37)&Y==9
M9'&I:RQ9.S7B2Z+-TWE;)SXDI80S;,[?1#!KC9*'`H6+3*^+?XZ*SJQAU)<Z
MVF^P7W6BD'MEBK1LC[_39\@N,%JL1":=I[(63ZO`QTR931Q0X4A>&E1$3DZ]
M4<+Y9"8XXO/5]S3LW;M%<)*WX^K#"I12M:*B?;16E![DY15IJUS$H-D3"1YI
M?,"$V-D79FM;A(`[R9F;)LA,\+CSOR[Y1@H)!CD[:Y7*S.`,>!BP8/7FL>AE
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M75L&IQ+44GW;KL(194US7.AJA@V&HF*.O[</^/4/'HV@<?;1:!\"`N*Q74Q*
MF%$#%<.*76%2M"$J-=A@&LAZX#$K!XG:\A=?:YPVO=H-L8!)M50VNUTW;\?<
M=<%UC,L+N<6?YQ!71!+=;)-5;\VJ2\!"0\*8R.6D]!#^W$8:<,SJ6E-M=J?T
MPE;$O&-P&U2J37E*VR$BQ)1[6ON5$ZDSU!/I,:O&Y;/>=B5$%K.NS`1,3,5K
M[RMDYJ-YW(6>_N#*K,V%P+RB!CBOA=AWBWHA@=-?)/2$^N[6N=:YI;3;([/J
MBD4$=Y+/62]'M!*KJ:[;)NRN+AC<Z/LZ8-A#PY.IC>2_%.903T:Y*+&,8[3:
M=7NF]$\,:S&5<>=0=QK%3I'#*B1B)ARI1/*`<ARGE#6RQIDPBFJ\)M8\ZEHI
M;>+),R`VBVFP%URC0U\>G2?-)]72Y+:P@"A6D(4N!DK6.K%>55<]F7NS/=@R
M"=6C6]254\'SF6GR\MIB%-JIZX1U.R.;NE-E0ESPZ6.XJG4]P<EXU1P2.SV0
M%8!DNR2L4[#K$!JOR)W#F(V.3*K5J`N2C;DM*JL$OE!-[7V6,:PF^GKX;:LU
M;-AAG%.LY2@G;@,V;$V;+8&(]#>?4!",PD$UJZDJ4"Y@HFN'B@IE1"UD,:+H
MV,C`&S;0_=:I9*TO=/.,IH>]'.0.LGDCE7CA+J5DR.3QZ4N[^X"5M\Y33$!1
M"T:=(),G+3E$Q8]C,;&$FL6S\#4LU$',#R92MJ<E]1\1$`2S6]L2T`7:DCED
MV)9$'$UTPR+\PVZ`FC.36.RO<X#W%(ZIU;*Y@X8MB"I4Y6N&>VB*X#T2,L$[
M7E/CLED%9Y;&M>]BML61VO\`W&K?:"TI_P#VO7,:%#ET1(AI,_1JW2.UTPV!
M-(-:$8KY(U*8J><YI%!QI:4![0U>[DNSBK95+N!K.@)P.!=;="SB6#918;8=
M..:&_P!Z"L7&L79?]U$03V/M-2BJZCETNOT\P^&L_>\KC44A:/`3K&H8!=Y)
M<8Z24(QS2GBMDS*TIK]S;`2^VET[K?:TNL':226Q:RLZCIF;85)773[\T1^S
M*MEZIE<(XXN3$.41V9PA];WA@=%"-<U/[(\,ZY.;D)Z0SH'IG(%U/*AFL>YB
M,B-=M<B'@0MKOX]U=JV`Q9K.0`O4>8&`L48&,%%U\JMXMV%NK%V.<U+>,R8R
M#D'S2Y1K(&+8LM]I$H@A(EL@UD0S@Z=^-"O+'555.97?>R+AL=3MB-EE0[:X
M;Q3)MRIW5O9'Z+G,.8RJI%3KJW0=WC,F7(U;,VP-`A,$HRK``"_`5>+E1PX[
M*AE,8`UYE#DO6,F0VU6%BMR[!L,['&>,$OI<F:Q2?M)0+&"4#P.YBG8C(F5E
M##2:R.!B:QUWC82=<5BM0G!@$,(UF5D``;<OZPD><'\8],PM$ULZFSKWG#`R
M;@?\VFQDG<CK]V*!;X1_.(0.3RWUDT2J20]%(2R71.2Z."YS3*DI!92X",H"
M7'N+M,Q`X@:FV^%Q^1I5YG?U1DHMBZ&;3$$:XNV.ED0)[GR=+BC?4&0IJR19
M0GR0SF+%!]GAL/)V/FGP(8VV$7A1KKLJB.@EP8J4F2F=6BX>)VH#I0MG+'>N
MR<0G!&VDBW,@<M8'.C%+K5MK36&EU]/6N)DRBAI&T2*#S6&EX0*T4L2R54E*
MZ90*D8P@$&/$.?AJ^,JUS(UXRE=I#)[;NHW[#+3ZCI"`GA#VFQ;D]-L9VB;,
MB,1%O)P&5+)39$87DV4'&,?!5G'"L*UI$E)$#(!0":B(ZI1SGV\2PY*G0^)2
MGF='&3(_?>S[),(!M),]M:PLH$BIE]G5=V)9#*KCEB,+<KEU'2-AF4)F3&X*
M$J@F6-\B=$I)N`HEZ7!*?!76-L-Q2L6FI.RL7C;6.B/_`/11MO99;6?,;3$0
MYA&#J\HM1.Q$\RW*8KB57_W6;`Q,YBU2MNVB(X7:*TJ1;3^@,X5UB:IY59CE
M$5Q$IC5#&?$34<-?89+XQL7M<USFN-A;8V*KZ<G26D7R415]O9C,C=P08"R2
M4*\I9-`IRS&>P9E])=9`VA`7]:ZHLEE]L5`CQU.K0KS/M*V(;BS'?:;%!MLK
MT5W$'$AE5LI<M]<J]F2_JN9&\3[=6%YN0>R(%V1O5;IR,1LN]4KA5"TL"@E\
MC0L08AHMIS&_"L'Z2_U,U2BNGU7.U102P;0G$77S^P;!;E=I.,+?9)'EUD25
MQESZSHI!'(-$5S\UIWYV4')U#]EX=^AG8>M.``L(9GV&/Q5+%_*$4:0U5L`1
M$Y6'+KDAB.B#""VW!("<QS8)L(S*1OWLW>SK-R?D+`O:$S,AV"I:ID9F9;$&
M"@B1EI0$1`JA81`Q'FK]#I5K18^W.S-4['79>FP&RL42#5QG985"!J0Z9P-H
M=4=3%>W2>O=239ACL9*<#&_*=.[")-1J#3#RSE?:J#GDZ]C?#S\;QJU68BT=
MJ)=OS)SH6-HYD26N2L`H(X$,*`@`50A<G$V972RODM7,9<VI0I,5IA.VPUH(
MC!<08L*(69R7.-VE_<)NT#.MU/XI6?<*:U1,+/T?BWCI-:8=.$NX2RFD>N<#
M=MMK)F;"A'C+9'Z"G]Y1J;5%'+.(%*$!UGJECJ:H3D%*F8S)J@W&_0.GA<A;
MOX"Q8KX<5J_;*I0LF5;%>R#47+""4S'0]".:E2GW&QF6_%8A)9MNUD,E4BAE
MTJL9,[<G:M\C@6U34U;:R'0P+Y18Y`%CMBM'".8;G,K'<YK9J!`-;7BRITDE
MUBV[<MS*8V?;-XVZX1)3/YNGA;>H:(4S#:*WAM:U9#HU$FI680A;(W&V5`#`
MQ&#),.&,T56;A#CAQ5<!51BRVR<#)E+;+^/=8:;#-AL/@,;<NM8QQ2M8S(SR
M--?O!NLF2:NJNLJ-@$$5US,BE*UB``'*9,YXRQIS!-,Y$>.L_;BF=WMP2;-I
M"3:FUW![.8;C5':B^12.R*KD+'KO22M1&%HIO%7@RUY)M8@V6$D0KD:M`U0Q
M@BKCD91*A?E)@W)M#"IWN8G.,:>-S=4__8,"`)EA(O,O:T1@7+=6>KJ[5Y(E
MJY=I%7.16$Z]VTBL=RA"!RF`=5B:J6?0NY->1[KG(ERJ4.F20VB+GA$!`LB9
M(PG!4.@+3`HEL9#+8V4V,VQ8]I4"Q):*'80.OOPB376-BBKR?#T=,4%3Q<?3
MN#1D(,)#,JT:<983"2@&Y,,,BRU'&Y;QAWB34".+;8>Z"B2EPE8*#/Y]^LI[
M!!@R2ID"`1#BJ.O5/%/R&*\BK^4!8(LFBK63(\1A)Q5]%R0S!-GY9-91+I[`
M,NWL9/9J(%EZ8H*P8*&T_1^-JI=\M$ZDHTV'U&GGC)KC,;0J.YP.IB`N13QX
MV+L>NV1DKE?$5&,*'.&1V0RL2P(S,IQ8"`LVWF;=WRNUD;F3X(\I:FNFG=C[
M:00-;I;WFJ&VP?#EI8N*R>GCO.XGQ$.:"E>.XZJK&&]U";CWW:\R+&L(W2Y/
M0MDIJF(=KAGW+XF(XK@>,DR9^:#:ZS#4_4JG:"GLX56#*:_9'!$O>SG=Z?4:
M`AP?'1W;(BPNDB%EY5QF#M2\AH;1'A*%E&B+S@HD/0H&SY!DUY6\%A<F9!5K
MJ-I[=CV*2`-L-F-]V.8),(IF2G>.4R6\ZSL;4*K-IG`$JL77O!"YF5UUM9)`
MA>\1L`#M\HQ`B4E`QQVF9A<P]:>G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&F
MG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FM!'F2IR<F(X;.(7LOM="+1V*
MO;4#4.C(;2&RVP]#0ZML3"X#%=NV&*(TS;$+C5BS9SK12[G&K7]$I);T+43@
MLOJ5DS+QJK6?YQB,'<*23>R]BY;(C9M^UXW%'<?26'/BJ&E2=SL*@'D5P8"1
ME(24N7L/7XCF<JJ`$<;@6!6&%KY3E+UH*-.RUO&&M$+%NB*:A%*>26;Q/NS@
M9UUG1%F:>V"6VT]C8+9ZJ[\MZ-IYIB^]O;'LU3J#7T?K)Z*<)=$G?9.?6I85
MCMTJG3<F`I9&Y<F4EGNV#L=4Z/..6<>XFA^S9*5A4`K]H+<+'LY$NH-;'$(1
M##"34\EO,I%/84&,S/(Z=BHI<-S-0V%>BM0K>UDSD&D-NQ[J]!%/4E@UK(2Q
M0A'=%,!">1Q`9`W=WHU_T1IN76;<MI4[$Y*B@TZE-8UK9MR0JI'RZ'Z$LF74
MR%0,V5*#5[R[KE)R5-G#>WN1Q`U96?8'D8`"QK604AHUE<679)>ZX*.<+-HK
M)LC&Y<`Y24EMQ^68DH^,?28'"3E[R%VF>TP[+2D,MF.Z4$WE(\SD@")X@9P)
M,&2$#F)V&9C`UX>5W7RN]/7+<.D36'<Z',\EAD#?D.K]S4;.6V'3Z>&,[<QL
M4TE)]@H$Z$!,ADC:B5IVM(\R$KYY)Q;0:5[@@;]S&7$^38WQJH,'&8RHT*=I
MG)=5K#=T@<F`N.0*=YY*6X0VGL(!^;7S.%N5LA@+><R114/'X4LE:K[2=A25
MIE[A@)A8\E+!I?>)'.$L%?)W%)3&O.Q+K@=>,3E3-),MRVW)))#XVC@C[9+O
M6T!9</JU.7)I+,K4:ZMLUUC\1AC5A2K,4E1=:I6B)`02FP>>`&*%B)_=5T:,
MB5-AOW<W=8@M*'.$B$!=LQ\K!"E\N,N<`DV!B3U+29!XF<ADQ8JR*4S*50+C
M[7,4KA'(D[K4398]L1R!"V-A12/"=.VVVY^^CLPRO7IBK&E*NNY3.*F8&I)J
MCMA+KSM:S42B1-LNNNCZF5VOJ5K$QPF\D^OB-R?278Y0K:HVD,3JW56T`4HU
M0E%%3)7*KK0WFX9%Z3MIKQ`,=12IL6'B^'+-5>M>/'UK,Q*#L3:FK0L%=&51
M-;.[CD6%C%9%NQBFS5L/GDM%UK`52!B)4<-*T(W3K;0X`.F;+*)K"9:\+4_<
M)!2"R^\1.7;&7<V6EM+!=8]5](KZL>RIUM!4UZ,]<J)+;K/:]I;)2"53J)01
MS:A`DHC%K_)FANCS6<XLYZL"XM'S1K^\R&%QF*IA5NY6W9R]I-Q?V:X8JH2E
ME%Q@IAL,IO78Y0RL5V9MU*O!I]<15L*JT\E<R-J;-*C2QV-&TADRYK<A>(YK
M>U"'&CC96Q"!)#ETI<BVUA)!#6GL\U=VYF]P7+L!K5=50Q.H[WUV9ZJE<K05
MA;ZZ]JK>HA<J>6FPQ?'[`?:IHZ5E/Q!T'<"W%M<HJWB3X]DP@Y44;W@C171<
MP/[[3,Y4O(OHN`P@9&PA2'S*R$SAJB395,%/6P3Y`Q0;`3.;#+5+*HQMU8#%
MNC[M!`?*94+908N"0"5-%L3Q@9:I@;$#9*#`+6V=\A<6H2\M;M=877KG=-F7
M[?<.I9[+9I&BC<8I]%(6ESE3O)9G(3VQ[RL?VJ$L:QT21Q&G&N6D$=YYB%,+
M"KE;Q\!S_D/[*J974&G?>RQ(R005"M-@TA$;=C)F5+9/(5HERX8?:Q*6VLMQ
MP^`?F7[S8`J@K3$?,<W;84T&PO@E)N*1$Y$S9UM)2C6BPQ*\/(9%*RVEULU-
M@%?N=PSV];6=JXEC\U2)%'H;3I$:@#M9LG-?'<YL>1R6;MT.:<JP1Y&66,LH
MXD2]6W@4)1'^819YK*/J*$AQ];$W+IO^68*:L@H$J$B#LEMIJ:Q-Y"I)L]2,
MQE6O,WRPN%#*MB#LMOT:XIB=B@;CNOO9/KP`%BUJQXDQ\*/K#@)M"^M-=R<;
MAJ-BST-/2^HV?7^]G[7U07/I%#'>4R.90UG9W:7KAMU=O$QAK8Q)/Y"B"A-2
MR%U-58&9A06B.*$1SJLN'^*XSRAA0`Y1;VK5\96A+SK03#]![">FR!@'-8PH
M3![A9$CQ<)E/R:[XX0[^R56(F[_*9V`-O$!^,!">A@D?%D]W$TJD/FU-OWD1
M?+6N*U+5N5LV@KKQNU%L@EU>AEG:\2.#PZ$R"RV.0ML/E%G[$SYEM2'[2%5Z
M79+N6R-C=`VA0SILH%1[\H/),`45WX@H[J\)E+8S&?\`(;!SBTMCE5X"Y@5(
M)8"4NM7CKNV&\/[=U$I?`V&3`>6"-6<KAJ<-*M@JHEEB3O%J9;6"TX5$4!*4
M4:SDM,J3)R;&E,KZUJE3INWGNWNA347G=LJ=.]<T5,1J:/,8B1]F[J6S7]YV
M(@:G@YF2.C/34?T$LM@1N$G&C/4M*$4N-PJ1!+/&>249@0<D+HUJM6QFAE+7
MC+&*3L]B%"1D1'OTKY+KC%AV[(6@2X,:)B>VG-'OOOIT#$TID(%Q_*II&M91
MU]7>PH)K/;A$+EIL&>*IB1WM--Y5)6FCNO%^RW61'#--=F[)A%6UM:CQ>20=
M[9<+$/5(XA83OKRGK`463T^^'I?E$.!%@J)!AI,`M-8RL9]K&^5"*68G!9QD
M5,@=&U;5&TG`+JURN2%SZ9K/*J,G(*&T"6R*'-`^<AAQ9=9Q3LOB@BQ6IM4N
MQ\W"98;AJMBIN,Q8A-HNF);-4GP!M0+`ZNWFM\J<F*C%6[%(]:$P](+>NZ)4
M9"+C=;I`TWS)W*<S(ZOHM949UL_JU='W*I'J4EX^,H4V`@DI[;U6@8\EY*";
MQB\>^SE\7@<K$U<MFE`=18_>D):B;21NR/&*_97B&R2?=@GF`O)1=D+LY"Q7
MKXS-9.B1/1X_%DKA%'6!Q4:*;,4BB3-YJ;)JD7+J\VK,%D<<3+;\N]C")9\H
MPPE+\51\DTH\]*:41[0_>,+5)C"E*8P!?7.#"Q!&#..H<XSC&>8V0:A%![K,
MD-8$F1R)$)0,#,E,$,P0S$;[$,P43ZQ,3ZZM5Q:5A8IB"=)C`Q,0426\;1(E
M$Q,3/Z3$Q/PF-M?*'XY*YGNU>'I?.4/EX3PVW=B=E)54NWJ;R<;"M],0"GJW
MGBMFKZ"12"LVW,Z<I&H7ND85(^R=UXU)U2=4:$M4K"43U^A\?JLQ>#P;LB`I
M\AHX.G<M+MQW>_;8=)I&!F&*,)J.030)B;'!9-)929','D5RL'EN8K4H]SBR
MRQ4T"D36JN*JHS::TXZFJ.+$-Z>J'5R9*E"Q8\A'Z8:;F=L2]!.S;<IC-**(
MU9$IBT(3&63&K)%85<,WPPQFU#%D<2I2XIF7`-.%EE6]Z]![/[PQ=^.9<FJ,
M75R%@Q7>=7EEE/\`+59#&1U=OH#8ZQ!O8&P1#.'Q"9UQUDB^_'U^3<<B5@E\
MS/*Q$K"2*0G<PD622YYS,G(\X]"C4%R?,1H8?MJ+5X&UFHHB,5UB0%V$#;*F
MAE'6GFP003^B@1S#SV9L#&!95_$PY9<?3VO@_P#N<MX.D?D%*P_'S+;H6ZZJ
MZ5QV';6ZNQY/3`_,0*D(67`6#,G$R8SL,]9,HQ4J]W\@S%B72?R>WE$KC9N_
MT\^9_7PVZR^KUXYNI[<\5Q;B;*ZFHJ6F<-QK#&8"[2RQY?)(.>AESI9>5R^)
M$PB/0A[FAF8ZOC;>8L$I>EK*\$FXP28T@#D)V8,4G]S\;?Y',]0*RA4H47JR
M36OL<13'VX@.01$+-L3SCD2RB0CS(L#'Y2IB)@S?;HE;@X@85"89"8B)Y]O9
M+>8R)I6'$)-;&C(S/CWKL1MU!IA9!53ZPT0^4_5D<9'E^N+8W:ZR=>D3^N<F
MY4Z.J*!QJO\`3/9HZ2-\;)**(4JCEJ$TU<=@@A.;G'=G,*RU-)F1LBL:T/)2
M@@YFPPAX#O*B`!"&M.%U]F'W?5''TC6A[9+6(JTS-MTU$QNX<%)B)+C$N(H$
M_MB36E$0"`C[I#.M"%_[:;&W<CNZX+4DM[T!!"HY4]=:XV7JKL+;"7633K:)
MZ<RF.;-6W$JK-IK216Z:CD2UM4FFR6&R"#MR%2!M<TK0XFF8YO4<:*;U6O0>
M1>09#/5_9.MJB*=O'B2^RK7KD;4=IRNT@VV!B;+^/L+?$)`:=BU6*6,M*[O&
MJ.'N'=36(HMB^((T6B;'18%1*-35JK'S2D3=9KD,@PMLDL\BMIP^"W:\5134
M8V7B>C<:RV;=WM+[D3Z^L,DG$%A""36@T:^1UNJJU2;&F+*F]T]6D=SX4PE*
MCBDJ=T-%D62ZM^[0-D^2&AE#PVYE#KU8_JVI";?M88*"D!*NMI0J&'8%KI`Y
M2IL1!'QB\9D"]MXR#U6_,8QZ7-WY!7&6I[50VP(',,>N.V.M#%J60E8-!3(1
MLCBMX0"24;%=AEKI_$*WE-=1RS@N4O$G:366-R5D0OJ+#T'!ZA.G7%IG`LL1
M99AO>?GL+R/.0]9L_2/QW)6<9>*"?6L$F>$$7-D'UB*QB.9DP]A6$#V$10$#
M)3$:K8&U_P`AI(N4@F(<N3V*1CA`Q,G)EOP$`@2(V276(#)R4!$SJ(.LGD9A
MNPPMPI2^0!UI6G-4[B_IU)8M@OY`76R'-O9&E:_.X((E9PN$0`%\>4[>UMIJ
MM<\.AAQ6,I4R@T*7D"$D?C&.\@=!!;R5JTI=:!YLCV]B:X>H[PQCB$IX*@Q#
MC,0T]BD;C^O_`)"W`T2[A1CZMECIB5!$6E%8';LVV4"(AIN9*MA+<@$8Y3'%
M7YD$:/5S:W;+&IELKX!KKLB[ZV1MB136N$4SG+TV/#/"PS:6-$K=8N17T6'8
MSZE:S4;8?+9$00=A3AM,$`Y,5Y60ZQ3\89,0%[R=_!03,$"`.P2D&QB^9&35
M+8[BI1K602LG<?O:\(@7G,UC2YE0PE,+#&A`\G#[6+5B$J::ACI"=@[W(E_Z
M"!D`','=_<-RU!TQE>R&8(1)+)PT0A@KRJ2W14J)DER6D\,D1A$*PZ$-R->O
M0@E4@+RI,*2DJ#4:<T0"P#SC&(,K6O3FZWBV`F'9?(9**5<Y&.,3LQC+!AS&
M)%-9+K'7V#SZX7V!RYC-@#IWL>S/Y:#3AJN/.[8B)CG"@""%4%,3`L<PEH@I
M$A6;8,H(!G>!>OFSMVQB46+6TEK?9VW?)6"-U:]/M/;(VC%*>UW55K8\DD7Q
M[%JQ%K0Z;,U'65*PEU:'1O&\.<=7V6;E.D1/`CLG)^S7):WT.KQD%GB49/V]
MUMED>Z0P:<.!U@X6Q?\`E+E4JJXPO:2QA3P%BGG&;V6@E3\\0A:?CV6J:JPB
M*71[E:&UU09+L$ROS@S/(?=ZP(T^A\-9:)W3\ESCL09KK'/'UJ;+'%HBBR23
MRU(]Y$+M44U5[H`+8H9J^G<K6^,1`\);&E34ZEKT#8@;'#/P<9.4F)PB+[\N
MB)7U6K(1UTZT!`M/Y0LL)C%L35GUEQUI7/NIB(4F2%<LEW)0W;LKI15`CAER
MT1_:""(TJ$1(7V)VA:5NDN*!)G>V1(P3*H[-05EOE"WFOC92Q=1XGJ])88Q:
M]Q)+;6P=IZ$W97NPLSG,&5*AHF2&TC+MP:MTS@D;4+WQB=TKTXF(7)R/2(1!
MCV#3S2UA4%)F)MX&WYGE66!\0HE*61$=8M8Q'N8>3D/]Y[-%,UV8&DN+;S:K
MC(J`X=:N5[]3)T?&Z$5B\BR4D0D9<XK"A\UVH)9KE'O#=Q7!/.:M6!<NS$6>
M*U[W=/['J*W=9*4LJAY)-Y;44R@3*]09_LN4SF:V$M9U1.<A#-9193[)IT[R
M9*HP,E88YKU:C!Y8@Y,$'&,\^C\DIWJ.9=6R(UXLQQG[`@"2`@$EFN%B`\#"
M1*)XQ,[[E\TSK!Q-M5VJ3E]L,AS18+-N8-!A"T"@9D!X,@AXJGJ&(V5L''4D
M>86M/3C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C36J#?
M"C*6G^RNBTQNG<O9ZD)*TWTWD:JU15\7IEVJJ3["-\(GRT]9*'&6:IV\^)WI
M]K0YY1XP]25N:`)RLB;P)W'/OCF\:[*OE\VJ&UG-?METNENT+_;Q!,9!8R/5
M.QA`2R1;[R!(^A@!O`^YZ"M^%6:3]ZN%]Y2%SU>K8LG:#]N,H/M'[5SKE<=/
MMI9U^Z%D<8U-!]C3*HVKKJ6FV%L>A?VVF[&94=8,2*?#U4D#:Y2:#JELNL5P
M10=96I-R1X]`4FCA2^0HG8;8M<\I42DD*@TCW'%*@RD`(,AJZ<%W;1*8`[,C
M-+G([FZ2(;G3VS`+K=L*&5R:]]RI1`_D%=UQ"2OZC"*OQE=KCR**P1]Q,LA:
MYL>@&1_)JJVU:JK?-7MA&:\I*]PVFG6FK&;[4EL;(.52"-0!7%'0B6/C*F3L
M$J//=&QD&<<0`#8X"$8#&,)S<_D%DY$:QI"+9$*XL(F)C]60Y<K'X3Z$R!&?
M2/29]1^,?1>(-RR/**#L"H'YD;2Y2LYB`-D%'`2F37$1,[1/SC__`&C4%_)!
M2%`VA1]`CO+</9K7*C(]:NO:6)DTC&*I?&V=6THL6#9UW<;%S-]6;XDJ,A#8
M25LP6'(F:-Y-4Y^W*,*P#VOHIC*%^2ZEH9D?,3R3O:I^3J7<A5N7<9*)"2))
M.$>]IAN"^C9\B1_$8R,>'XULU*7(_$0P7^2[Y^X\;UI@I.!XG`<($F]*@9P)
MG;]GD([![6/MQ@J_ZFHD69O9JTAGBK;*9:;'4C<R*5WL-KA:$W;VXZ($.J)@
M*R8Y*VUB2E*%IH?82)B@CQ[>7=F+UT5A$4\>]Y2TU<B]LB()AP@3EK6-D8Z:
MHG+(EQ*FRT%=KAU,?`T*L'9[+UBNH8$#):CM-CB`]C`6*4B13V6&`J(!4,E"
M&,A:#UESBJ--)K)]+(1%=F[_`*CVC:IC?Q=!7%5T=3+KLD\Z;&)61M*HM1GM
MB@[7J5'B1(@".=@S"-(T161I,-7QPX0AQ8I<K&69;\=V17CQJ)-"Y`D3ABN5
M>`,)L%,M#(='.88.1F_#_<25CW<:JVY6K%DG/0+7%Y&O=DPP6CEO:VI7TB)R
MR%3C>\4Q/;4C$]7`IJ=!SC$RJ_&S())7%<PW96[(/N`EW<FI#!?;*PG*]I7'
M=!OH$P5D+9NSVA0,OJ("-]UR+R$6'>%D0,#(,KZ<M.+XV0S8OWEL:-CQC>KC
MHP^5)2E;2N<=[^/W-;9M]K><9"52<N9%_LA'6<AU[VKDA47E`\C@;1E;Q4.*
MQZ$+Y'_U!U.GICK$>R515@JG_E^X$H]S&IM::Q?5:.KMJHK2-CV%/;[0V"A;
M=O[+LQ"_(]B'FROX2C*BD@DB"0P.&-93'_%,A-C`(Q'TD(Z848:4W7Y8,UK)
M3<\-K1C1]KXJ3+L)]MO)!9YC%TC[)=8F]OTRSW7*QU>UV'H]O&HQ'VWE32R)
M38\AA%4BAVT+FIR=-4%=<+1[3E[@8FO,!V=_8?=V3K2F[ZT?#\A/C]CR#R%[
M?N=&%Q3;V4U1/'Z$:=&6*KVU3Q\EOGE9EH8QI"P2ANLA93JR4N#PMF[0JD`\
MI`%-R],XB`$V?QX=QSI,+8E^(UPJ"F/5N,;<#WS@E>ZH&M8"K#5HA=T[;C)L
M-4N\$3>1FOV]5D`OM=YAO>%OT(LC5?./'9T]A0PB&*AL8VB-%:A6'!E)H]D9
MU<<#O)5IM$HUY(=NT56HM5MAGW56T%4%T+4SY\NU5*6%%>\+3MX]"PQAKF+3
M!BW!7*SIS'A3-0Y&'!*6A/`YE"DP<-8WR=A3*\FK$8P`%/'K;A3LR36C(028
M0J^./4D*DJ9,LYS#$#N,&=F5TL0$<SIL\@N%:)G+=63"F0U5GZBZ6.J'=,"?
M#:@K2`A*WE4Y[=?%A4E#U/55U)-=]H=A=FX@\;)6\HGKIL3'X*P2B*WTEDJH
MNYD"4N-:[:^/Z@IRD9H#,Y7IG)N"041]284AR$(_(?!^(8&NE*1P(8V9HM&2
MY'2*P[83B3F(Z[(VIGL6%F6&SO(XA?&-ZXCRO-->93GINKB\'R\(LQ3JR!#(
MCQ]:4TXCI*4<!#B,,[)F*375GC81%/-E*-D[X=]3E^]*]&JU\=6)W*U)9-U\
MSQM*<75W>FZ@FNT38GBTP%F&AD$X657]X,S`B?=[@AK^+=U9?C:\9M8:VH^<
M";N,$I7;:F1J1]H9L=GNHI>Z%M[E/^"7+JF//)8KV&>2GD]T0OI_?A7O/;'M
M*L1-C?L*%33FI-OVDK3U0/NX@>V)FC/LPE\L6<RK='!<*@^(%;L7IVL'[YSH
MQBK)JBZG-P6<^R*)B>8S_9<LB.586YJ1+\/;?&"U`@EF&J%0$>/9C&?\>O?N
MLS-JQ4D[7U?XU(70`(5`QL;";P=:8N73,S76'4M;>[>3&3C,TAPTE-1-Q`ID
M8&(??,2,6-B=RBLJ/LUO<=*2L=I&LV>T9$,JTJ;QR5_'M*'JRMG;ZO*E)-"U
MJKQZ1+8Y@,:*5KR*#J]V/;6V*J83KU3^%LQ*J4XXF.BM5S?)EE.4'+8;E;D0
MQ_0^0S;5>S5/RJ!9Y1&%L>_>SC%DJ'`(N]4)XIY\.,W?8IBUUR7N/L\HUB4Y
MK/KU+6!@4>/_`+ZJ%)1O-;]Q]U/MI9)]C.KWD3[7O;[#MD>B/Z>W74%6>.V!
M1?1>9';)[!W7KV_S%(K\;-3VPQ$--!PB?^T\*:_:XFY,5!5*O5ROV_>3P@5Q
MR5X4^][66DWY'MF<L#.>K9<JC898\Y_82D',X1;_`&^*0=@HB.NMW31E??*T
MS>ZAGMG^KRX:%*SB,C96:Z_A_P"[F-Y0;2B+DY(^PW3(LM](Y"&\X%OL>4_,
M,KZMI-ZSUA-G72*\(S8^Q6Y4773>P;^D3A/;$97-PV,I>'/+ZN6**_AI]^4.
MY-TM8XHS%')V9<WQ)T91IC_;9%"XHE.O.^8\E5C"\'QM3(-(<;6P@1:>N"[K
M8"3R<=H)`K2VDLNIL&";<@L61"A,!C<Q[+@^<9)^/`"L-R\>U7.T(2777%<U
M]F37E79'8'%KJ^YS#MVP\!R-XXJ]HJO]`JBB&MEZ79>&O/\`"9"95-I64T-[
M3;F8@N7O&!IP-\=IVH'O[9F=OEY39<(Y]X-3_P"L(\79SZ3S<[]L)5F0FM:C
M%5PYU=Y9*?:![9RX438[O:RGKA`1](?:[>?+`\:&K7M,;CRAX3E;)$#^,+BQ
M%MD6EE)PO[4VX=)RPI'YSX,A,+@9(ZO1YIBM"UQ'V*<WY932V-*PE%.-H4DV
M07U(2QO+D>)58Z2QH=`)J0[$F&B))PO9T)N499.0@$7D`Q<9-AML`1KKKF*U
M<=DR,A,"A8P9<"..YD1!V(F8.'DR#$#Y`*B`K%L";CWM6"GMY;C)/84@OD(_
M87,R%>1W"4"N0,PXG./Q1^CC-XUL@)G,I3[+&ZJB810<E((462TR.T"U8)H0
MK4PX]M%)BIKVI0E#>#,^QZB09#U-Y!1BW/CN8KT)F*#<G4FPWY>Q-F*;AKBN
M#W&8),L9.ZVCS$8(A^@KUDAA^..T,3UQ9Z1]=F1)5Y?!\9Y1`S"HC8ESL1;3
M,^HQ=T;I"D*SVXWO?X!N)LYL+>CQ*:V3[50F](Q4;(Q125&1$*JK5L35P;5F
MCC5+:1`L"3(\,SNY,62<CR<6);WF\]Q1.3X.BK6&&^/_`+K>ZW%Z,]Z)KC(;
MQ$AZF<J(N:NN-A]KP7RB?,V)M\E2^\75E(Q:)!8<97-(B;[>-]C^@^S^Y#YG
M;W$E\NI!7P)8^VE#D]Q%K(3K%"I)"E1#@8(;J@N.X7Q>($.:Y4GB^7HV+U3"
M'`!8U1\D"U(%SX8E`/!I`"C!08F(_<HM,F/W;[JJ29B/JZYEMJ3+Y.^5\ETD
M+GO_`*S=^7%6O,A.^-*NN`BD2Y9<:7K(I$Q@:XC.T0+"V.RV19'5$+'KW:S6
MMU/3WCF(K"YK.4[5[)K-#C]KG\NV==G..J`ZP(MC164T$R`Y8]AUN2['#@`+
M:"F.48#.C:[^Q%T&')/4&._');5K^)JJ1[DF`F<`;O25!R?-:!B.H)B)[AK_
M`+F#"^GKF3ZIU#FX78O^2R<DB^//]Y]MRDCF$*BQ]'9,,*OUS:]AQ/JY=G%?
M;&NZ;5+XW%<.W`LU?L]L,V:8)]D'U+N;KO"F!S,UL77\6Y1DF=.,K>X[KRX;
M%@A2AVRW&R`+!.2:[P#`L*R@I/D`Y[C.VK5P$OX6:#;4_L_NN$*2V;)]<>O4
M,C%R#]M^Y]H>XD>G=G3M;R$E9N9!=6/;YA>*3[XJF\N;4]K$AOPEFS?8["WV
M0KM=$3W?SS,]]MJKKNT8GKZF0[*VYK@R,DE;EU1KZ)8Z'>H),'TQB3@KYED/
M]]Z^W_3R-,0666*,F*4S;GYAF/B'#,P`(:>3_?%9MMM'<WRT$V^M#)`999@9
MED038B1MSL0C,,%L!+I&-NV8CQIXDO%2J@*!\59[3FX>R855B=E[BHOFI3R"
M7PQ9IW!$'(S(06C3QYZWNC[JTT22;;_[<P_9\_;O:R026O8]#=*<QI#NF3(7
M<MZ@4E>+7TFG=:*+/4`2IAM*]6X_%$L4JA1TXE*$PDJWF>ZEXCB/^&<;C%>&
M@5#;<!<$@9N!$,D+`0-F6*;S*+G5$E882Y$]20-6SYAG%>0$-:B7D*PLG&QL
M"M]H:C7],2!A-?K9]E8U)9*QA(NB!U:&M.L5)27Q#5@IVS\BVX=?0=PVE"^W
MHWUI`]?%"5AV^7["$`*A,P'_`,';!G2MO8[Q*2"6*7(]0R'N!G<H5#:_C%%[
MQ!63G?"@\/,FK5CJ8X(IC871-&P8'$-@>,#7FVI0V.$\!B60=KBTJ8LRSF>9
MMSJY5;*U?_=PF0DP2+5"?JLB&9-45CF:$\.);(@%P8Q]`N^D7UG7:BK8AN)8
MTU9ZT/D-1,B*TV-"J-M-';G\YC26I9A%6ZM8&ZIQ3[^QL(%))22.&M'NY%A0
MB^![Q6,".^YY5BYP^]7R8LGO0A/KPL=%B2`?<=RY":ON19-F2#JD^107$HM8
M[:G@KWN.%K!#BVQ<[MH$ZGR04GU=,Q,%*Y7T\6=L+ZXDO2<&5W&(+4MI['Q>
MC["LO:+R-N$9JAJL^Q]FR8_&)6P5:^?8$UU+"F]@KBA*?<J1@V<N"@:"MV+(
M7)_"<G79^Q,5J2)%R^[@BJ8J!I^/%F3"\]42;`N0@"8U@N)K)>56%+I;KFH(
M$DTI*L)C/$@FK<J6\R9V+08<F8])P,0=;OD>@)5"8C>U,G<*PV+L+@N3"/VZ
MRR)AO^-KTUUW0#[,W"(.;U8!>S>P`4;R1;4:S'OEK;@4YA>$1%PN%]6`[^ZA
M;BD3&>J;P"-.`,E04WA45;QXVU%=M\`K>%+JJ8L)F3%R8.(56(BDH!4SN>2?
M:VB$PU9A)-8RM+5')UK#PY#8\S*P"Y(N(@#3C_R`$(6DTI7M%%29&N4D@Q[*
MX&ML;;%JG12?6[+G6I-E]B:2FL4TCA"F\8UJ2PJG9'9>FGSY6;7K>_GK-?[=
M=T$AP(A\+;!5\X1^R?9..R6;TP0('>1+IH9ZYGQ[O%_W=<9-#MXK>^]FG8BE
M<@_K]A-;W'4[V7MA7[D>'/E+C!>VSX_2PL@OR&0L3C+$=4NA?N(A\&+X*KM[
MR)D?>)DO<RSIGERB-GVKN*$QKM3.-6Q1X6N^*\C6*=%%/F?0B@>&XG#")#]E
M@+IURDZ>[\O&%?O=_O\`[O?S9\E_>ISEF?(MXS//[F_'X[1MQX?)QX[<.'R<
M=N/IMK!PL8V,<$8J9FIR/X\N7/F79V=GW.SLY=G/Y^>_+UUGGF'K5TXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
@XTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTU__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g891272footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272footer.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`!0"<@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/<[J\EAO+>VAMO-:7)9C(%5%!&3ZD\\`#'')%)NSL:1@G%R
M;V&K/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S2N^P^6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(+/J99`UA`H.
MW<1<DXR3N_AYP,$>N<<8S1=]@Y:??\/^""SZF60-80*#MW$7).,D[OX><#!'
MKG'&,T7?8.6GW_#_`((+/J99`UA`H.W<1<DXR3N_AYP,$>N<<8S1=]@Y:??\
M/^""SZF60-80*#MW$7).,D[OX><#!'KG'&,T7?8.6GW_``_X(1SZF2F^P@4'
M;NQ<DXRQW?P\X&"/7...M%WV!QI]'^'_``0CGU,E-]A`H.W=BY)QECN_AYP,
M$>N<<=:+OL#C3Z/\/^"$<^IDIOL(%!V[L7).,L=W\/.!@CUSCCK1=]@<:?1_
MA_P0CGU,E-]A`H.W=BY)QECN_AYP,$>N<<=:+OL#C3Z/\/\`@A'/J9*;["!0
M=N[%R3C+'=_#S@8(]<XXZT7?8'&GT?X?\$(Y]3)3?80*#MW8N2<98[OX><#!
M'KG''6B[[`XT^C_#_@A'/J9*;["!0=N[%R3C+'=_#S@8(]<XXZT7?8'&GT?X
M?\$(Y]3)3?80*#MW8N2<98[OX><#!'KG''6B[[`XT^C_``_X(1SZF2F^P@4'
M;NQ<DXRQW?P\X&"/7...M%WV!QI]'^'_``0CGU,E-]A`H.W=BY)QECN_AYP,
M$>N<<=:+OL#C3Z/\/^"$<^IDIOL(%!V[L7).,L=W\/.!@CUSCCK1=]@<:?1_
MA_P0CGU,E-]A`H.W=BY)QECN_AYP,$>N<<=:+OL#C3Z/\/\`@A'/J9*;["!0
M=N[%R3C+'=_#S@8(]<XXZT7?8'&GT?X?\$(Y]3)3?80*#MW8N2<98[OX><#!
M'KG''6B[[`XT^C_#_@A'/J9*;["!0=N[%R3C+'=_#S@8(]<XXZT7?8'&GT?X
M?\$(Y]3)3?80*#MW8N2<98[OX><#!'KG''6B[[`XT^C_``_X)=7.T;A@XY`.
M<51D4)U7^W;-BF6$,N&V(<<K_$3N'T'![]!4]36/\-^J[^?R-"J,@H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,Z<#_A(+
M([5R()>2@)'*=#C(^@-2_B1M'^$_5?J:-48A0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
=%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g891272logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272logo.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%,`;`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@#(\1:M)H]A'<1",EI`G[P''0^A]
MJ\_,,3/#4U."3=^IW8'#1Q-1QE?;H<U_PG5W_=M/^^6_^*KQ?[8Q/\J_'_,]
M;^R*?=_A_D)_PG5W_=M/^^6_^*H_MC$_RK\?\P_LBGW?X?Y';V]S%<)F.17P
M!G:>E?3PG&:NF?/3IR@[-$U60%`!0`4`%`!0`4`%`!0`4`<A\1)!'H,!(S_I
M`_D:\G-E>BO4]O)5>N_3_(\T^TK_`'3^=?-<I]7R!]I7^Z?SHY0Y#T;0O$$4
M$4H-NYSMZ$>E=]+.:>'NG!L^9Q>"E-JS[F_8:W%?70@2%T)!.21VKTL%F\,7
M5]E&+1YE;!RHPYVS5KVCB"@`H`*`"@`H`*`"@`H`XOXF2+'X>MRQP/M('_CI
MKR\SBY4DEW/;R1I5W?M_D>5?:H?[]>![*?8^LYXDH(8`@\'I6=K:%G8Z7]R3
M\*\:KN>/7Z'2>'O^0NO^XU>ID?\`OB]&>7COX/S1U]?>'@A0`4`%`!0`4`%`
M!0`4`>?_`!=D,?A>U*X_X^EZ_P"ZU<6,5X+U/;R17KR]#QG[5)Z+7E\B/K/9
MHMIJ4X10`G`]*YW0C<[8T8N*.@LO$5[$K;5AYQU4_P"-<$\#2?<XJF$IO>YK
MZ5XMU&"^5T2#.TCE#_C7H95A*=/$J2OLSBQ&7TIT[.YZEH-_-J>BV]Y.%$DF
M[(08'#$?TKZEZ,^/QE&-"M*G'96_(TJ1RA0`4`%`!0`4`<)XB^)MMX>URXTN
M33)IFA"DNLB@'(!Z?C7+4Q*A+EL>UA<HEB*2JJ:5S+_X7/9_]`6X_P"_RUG]
M<78Z/[!G_.ON*MYK8^*B)H=E`=/DA/VDR3-O!`XQ@=_FI.?UGW%H:T\/_9/[
M^;YD]+(J_P#"FM3_`.@O:_\`?IO\:GZG+N:?V[2_D?WD@^#VI``?VO:_]^V_
MQJ/J,NYTQXCHI)>S?WHN1?"K4(P0=4MS_P!LV_QK-Y=-_:1E+B"B_L/[T6;?
MX9WT,P<ZE;D8(XC;_&NC"X25"ISMF4\]I25N1G=:)I[Z5I$%E)(LC1[LLHP#
MEB?ZUZ+/GL565>LZB5K_`.1H4CF"@`H`*`"@`H`R;WPQH>HW;W5YI=O/.^-S
MNF2<<"LY4H2=VCJIXRO2CR0FTBO_`,(5X:_Z`EI_W[I>QI]B_P"T,5_.RWI_
MAW1]*N#<6&G06TI7:7C7!QZ54:<8N\495<56K1Y:DFT:=6<X4`%`!0`4`87B
M7QAH7A&WBEUJ^6W\[=Y2;2S28QG`'U'YT`<58_';PW>:NUM)!/:6*QLYN[@@
M#('`"C))/:@"M_PT#X>^W>6-,OS:YQY^%SCUVYS0!VFI_$+POI&C66JW>JQK
M:7REK9E4L9<=<`#MGGTH`Q_#OQ;T+Q1XFAT33K6\WRJQ665%5?E!)XSGM0!J
M^-?'NE>!K:VDU!)9I;EBL<,."Q`ZMR1QT_.@";3_`!I8ZAX&?Q6EO.EFD4DI
MC8#?A"01UQV]:`,CP-\4=,\;WES9Q6DUE<P1^:%E8,'3."01Z9''O0!GZS\:
M]`L-2_L_2K6ZUFYW[!]E`V,WHI/WOP!H`71/C-H]_K@T?5+"ZT>\,GE?Z005
M#]-K$?=.>.10!Z50`4`%`!0!S_C:SM;GPAJ\EQ;0RO#93&-I$#%#L/(STZ#\
MJ`/G?X.6EM??$:RAN[>*XB^SRMLE0,N0O!P:0'5?'/PEI6CKINL:;:1VCW$C
M0S)$H56.,AMHX!X/Z4P-/X(B'5/!FKV-_;0W,%I<%H1,@?9O3)`STY&?QH0'
M`_"6Y@LOB1:W-Q*L5O!%<.[L<!5$;9-`%/QWJVH^*M1/BBXC:/3;F5[:Q5CT
M1.N!^.3[D^E(#TW2M5L]*_9M+7DPC^T03P1#N[L[``4P..C\/WW@OX47FO3A
MX-0UMH[.->C16[98_BP7\L4#-'X`:?;7'BK4;R5%:6UM@(L_P[FP2/P&/QH$
M=#K'P0O-6\:W6K/K,*6-S=&X=!&?,4$Y*CM^-`'LX&``.U`!0`4`%`&+XO\`
M^1+US_KQF_\`0#0!\S?"_7=.\-^-[74]4G,%I'!(K.%+8)''`YI#-_XC^,G^
M).K6&E^&[&YN;:V+%<1G=*YP,X[`#U]30(]=^'G@^3P;X):TNBIO[C=/<[3D
M*Q&`H/?``'US3`^;/#6B7GB;Q+!H]@Y62Y<K(XZ)'GYF/MBD!Z=\<M,M-#T+
MPKIED@BMK82QHOL`O/U/4TP(?A;X6O?&4>FW6LC/A[1"PM("/EGE+%B3Z@$\
M_0#UH`]9^(7A=_%W@V[TR`A;H8EMRQP-Z]`?KR/QH`^<?"GB34OAMXM:>YLG
M1U!ANK27Y&9<YX)[@C(/^-(#U6?X[)J*I;>&?#E[>W\G"K(!A3]$R3^E,#U^
M)G:%&D&URH+#T-`#Z`"@`H`YGQ]J^G:7X.U-+Z]AMWN;66.%9'P9&*$84=^H
M_.@#YU^%-]IFF^/+2?6)H(;/R)$9I\;,D<`YXH`^J+.*SC@62QCA6&0!E:$`
M*P/((QUH`L=1@T`5X+"SM9#);VD$3D8+)&%./PH`=<6=M=A1<VT4VW[OF(&Q
M^=`#XH8X(EBAC6.->BH,`?A0`^@"K=Z9I^H;?MMC;W.WIYT2OC\Q0`ZTL+.P
M0I9VD-NIZB*,(#^5`%B@`H`*`"@"CJ.C:7JXC&IZ;:7HBR4%Q`LFS/7&X''0
M4`43X*\*D8/AG2/_``!B_P#B:`-F**.WA2&&-8XHU"HB#"J!P``.@H`?0`4`
2%`!0`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g891272new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,@"&`P$1``(1`0,1`?_$`*8```("`@,!````````
M```````)"`H&!P$"!0,!`0`#`0`#```````````````&!P@)`0,%$```!@$$
M`0,!`P@$#P$````!`@,$!08'`!$("1(A$PH4,2(505&1,B,6%SEQ=QBX@;%R
M<W0EM;8WMW@9>:DJ.A$``@(!`P,"!`0%!0````````$"`P01!08A$@<Q"$%Q
M(A-1810)H3)2<C.!P2,D%O_:``P#`0`"$0,1`#\`O\:`-`&@#0!H`T`:`T%R
M<Y`U+BYA2[9SO+"5E:S1FT6X?QD"5F><?FE9IA"-VT4D_<LV:KL7$B4P%453
M`2%-ZZC/+^4[?PSCV1R+<HSLQ,=1<HQ[>Y]TE!:=S2]9%@^*_&F^^7_(&V^/
M.-V44[ON-DXPLN<HU5]E4['*<H1E)1TAHWVO34TWC;G=@K/^'9W)6"K0A;):
M+:HH*TR5;*0MM@9J0'V(U&RUUV8'K1F"PB<7"0JM52)F!-4P_95W*?._&,;Q
MQN'+^(61SMVQX*NG%:<+/U5K<:8V0:[E!/ZYN*DG7&6C)SR/VY^1/'O.\7B/
MDC`MP<.^3E^JBU9CW55];'1='6$Y:+3L>ED6TY02/<P]GDT=C29E,XST9"OJ
MBO\`ZQL3PA&:,RP?&4.Q,BR1\S+2B:A3(>RB4QU?$H@7<1U&/:+SOR+Y2XK9
MQWGM/ZCR%@6Z2LA6X+)Q[)MUV3@OIA.MIU6:/3I"3ZR96GN;S/&'@^F7-]QW
M#'VGQ].";EDVI1KL2TE57ZRLG9_-77!2G)N22>AG6`N2-$Y#C=E*(A-$9T6<
M:0;MU,LDX\9$7\>#]J_8M0<KN4VBI2G*`+%24W(.Y0]-:_Y%QG<^-645Y_8I
MW0<FH]?1Z>OS,H^!_<9P+W#8^\9O`Z\N&W[/FQQG/(KC6[N^#G&VN"E*4:Y*
M,DE-1ETZI$B]1XO\-`&@#0!H`T`:`X$=OR"/]&@.0]?S_P"'0!H`T`:`-`00
M[+<5OLO\+<WU:+:.9&5CX"/N<?'-`$RSY2D3<?9G34J9?OJF6CH]8"E#[3;:
MKWRIQ_\`]-P+<-KBG]QUJ:T^+KDIZ/\`+2+U7\30/M;YGB\$\[;!ON=9&K!E
MDRQIS?I!95<Z%/YQE./7X=65)F#;+/'V3QIF?$)G+23@YM)^\;I"H,19H$R"
M:CRL3[=(=G$-/L3J)&*;]0VRI=E"$,%R?M<>&?%?DS)\C<)\IX=%M6Y<>PZ,
M9R2^]BMY%\OU./-]:[:K558I1:;BG"6L9:'1SW'<FIY-M^'LMEG_`%JK;GIH
MOIGVZ1E'^E_FO7XC"X#*=ZY9<M;M:&#29BL%5:@O8FA55V!T4F9?.!4?V)^A
MX%0=6*8F06#W#E$4F:2:11`/+RW+@>`>#>V/VYX&Q)8F1Y6W'>*[MRS8).RW
MM5WVJ(--N%-57;K%/Z[)3G+5M:<#?W1^$XW(?:[M>R9RJLY'#E&-=!M:_3"K
M)5BZZO10<6E\)=?4<CUO8_>UBL97M;AO].TMUZ1919O#Q(\95>/.V5>)?9Y$
M%_(JI>6WJ9$P?D'60O)>[K<MQQZI2;LKI;T_O?<OX&0/VZ?'.3PO@&^;U?!1
MJW'=85U/X3AB5RC*:_)V62AJ_C"0RS5:G10!';](!^D=M`'Z?MT`:`-`&@#0
M%/?Y2G(;(V1;=U_]3?'BYSM6R[S(SO3[!=9*K2+V.EH2B)V=O0:.607C'35Z
M2&E+=-/Y58H'(7VZR(F$"CH#R_BK<H\EU.;YR=3_`"0MDW/YFX>YEN5BI;FU
MR+]_,R=,+:W%!R1',UY=RO(*Q%>O<:RDF^YC@9*R;E'P*&X%QS0'0%"&'Q*8
M!'\P"`[?T[".V@.PB`!N(@`?G$=@T!QYE\1-N'B'Y0]?\6@/.E'\8PCW;Z6=
ML646U;J*OWDBY:MH]LV`H@HH\<NSD:I-P+^L)S`7;[=>5HUH_1CK%_<C_DCU
M7S^?P%^6+@]C:8%P_I)(IQ1;"Y-+MX=LLU=,8LSPRJR@UY\B=1NXAE%E3"FF
M!OV)#B4AA(``#QK?G>*^=/F'%K/M5Y$)5WU?!PG+O>G]LUW)?Z(O6SS-NN_;
M#5M/(I.6YXT?^/(ZMS[5I%37]?;T<^NOS,LQQP]K5*8R3.-21BTIP$$)1^W2
M1^L)&H;&3CV0@!P3,=10YC&'T((AL`[;:N?F/E_=.5V5SRG*R-'<ZXRU[>Z6
MJ<FOQTT1E'S9L.Y>:K,;9=PM>/QC&<G)K_)-R[5+L3]&XIQ4G_*F]/4F17("
M#I\#'0$"V0CX2&9D;,VR7B":#=,HB)CJ;AY'.;<ZBAQ$3',)C#N(CJG<G(MR
M\B65>^ZZ?J_]OE^!(]BV/:>,[1C[#L=$,?:L6M0KK@M$DO5O\6WUD_5MML^D
M+:JQ8SNTZ]8X&>/'JB@^)#3$=*&9+`.PHNRL7*YFRH#Z"4_B.O2?6,,SA1I/
M)^%\NXTA9L*S,Y%QC?:)$V00<B%>D[=5):OL)P09+-W@A$NI`CC9)1-3]G]T
MQ3;"`"UNEOKJRSUD\5++Q_S'G]#D=:9W,UHR6VO*#>SMB,(:=J]-@FM<]NU3
M,W(!]$ZK2R^Y%2(C]3Z$`WD8P#<W#ENT15<.EDFS=`@JKN'"A$6Z*8;^2BJR
MIB)ID*`>HB(;:`\&$N=0LQUTJU:JY8E&H[.DX*<C)=1L/YETX]TX.D/^4`:`
MR70'4YR)$,HH<J:9"F.<YS`4A"$*)C'.8P@4I2E`1$1]`#0%&+JI.?MJ^1IS
M3[(I--2=P/PMCGF+^/[U=(KB(&161F<48S=1PGW1*E)U6,M=IV+N=!])(J>A
MC`.@-?\`;>LYZ?/D6\1NRF$07AL$<O&K"!SL=FB=*+5.BA%8DSD1V4N[999K
M39.O6M),?$RTHW,K^L43`!?8:NFSULW>,G"+MF[01<M7394B[=RV73*J@X07
M2,9-9%9(X&*8HB4Q1`0'8=`4I/CR6VUSG=[WMP\W:+)-1,)EG*2,-%R\[*24
M=$HDY2Y#;IHQC%XZ6:L$DFZ94R%2(4")E`I=BAMH!^G?%)24/T^]@$I$2#Z*
MDV6`9M9G(QCMPP?M%@EX4`5;/&BB3A!381#<I@'81#[!T!'CXQ<U,V'I/X@2
M]@F)6>EGCC/'U<I-R+R6D7/L\A<JH(@N^D%W#E4J#=$B9`,80(F4"AL``&@*
M8G59POY4=RF4>7/!Z=Y17[$'"W$>>;?G_-KZ)4E+3:+M?+++RM"QG2&Z4O,H
MQCA@TCZO)/4$W9CL60IKKBW7<'0%("S;F[K-CNH3X^G9=A*BYXR-EMQ,5B]9
M)B;Q8E'U;E*U&R"U+B86L0<2PL$I'0A8IO&**N%V!FI'SITJJ9(FX%`.C]2:
M7QCYB8L'2OQ&EI^7E)Z5>K9I,[DYJ1>2LBY%/.>1D4@7>OUG#E4J2*92$`QA
M`A"@4-@``T'7XE0#I?XM<NNUG)/-#AO)\L\MX2X.T?-DKEKD<[H4V_4R9E*P
MSLQ8*A0,3QMDEW+Q!C5ACJY(/W*"Z;F/3.D"BS1RJ9L*`$F>X3I7_P"Q3C#'
MO9%UG<HN1%%FL?92IM1OE=N-NCI1X*5I.\"&GV<M6X.KM9JONIN.182\%+M'
MS-\B]*.X$(=(X%RPV?'_`"4ZAI?DH9#\!FLS=>UCRN\;1AEV98:?MW'R1L,D
MC%J`J+INC'R[M0&Y_/W"D(4=_+UT`F+X=-HLEIZNLCR5HL,W8Y!/F!DIJF_L
M$M(S3Q-J3&V(5"-DW,BY<K)MR'4,8I"F`@&.8=MQ$1`C1=NN;L@[L>R3D@U[
M$YCDYQ!ZX<)2C]A@/$-.G(ZN1>6H@)]Y!U9Y$K-UYZJ24U.PT*I.6"7>LY%Z
MT!ZW8-@02,4R`$=NV[XY&$>MCB/D'G]UX<BN3>&\K\9R5NY2,;-9.2=IST&\
MM<'7G[JO6FM0M/LM;L\2>8(\3$7#IH[(@9`R)14*<H#<2]I/((?C!G[)0ET/
M[3!>-80IKD,>T_XG?QC+QM_B8$7[?X:$K^)F">]KVOI?K/3VO:^YH":?R`^;
MA>"/5KR.R/#3'X1DW)4"&`\/G25(E(!>LL-WL$O+1@F.0X/*C322TR0Y=Q(>
M/+^40T!5DZK^ACN6K_#_`!CE[BYV9L>&50Y-5FNYPD<30[*^L9A,+-#H#5I*
MTN8AG],\E'M/*S7*4!\4$UP)MY`81`Z=I_0CW)V/B-DG,G*+LN8\T:QQAJUH
MS7%8HEV-^?SITH"(.>W/:DXEF8H-95"I).5S)B.SDC?P`!/X;`64/C9<Z0YP
M]66%'5BF?Q7+''4AN-N417<BXD7+K'<<P+1+`]$Y074/8L:O(I55<_E[SY-U
M]X3%,``)K^.LJFAWL]]+!<X(O5\JY:>(M%=R+J-6_*N]%6<$3,`&%)(7Z&X_
M9^U+^<-`/O\`D)6.&K/3+S^>3C]O'MY#"Y*ZR.X5(D#F9L]QJ\#"L$?,Q?<<
M/9-^DF0H;F$3>@#H#1WQ=/Y'W#?_`$C/G]XK+.@%(?#O12_?;MT7]LGO#R%Q
MXB*O@7W!2"6S@<J8GV\A(4YA$`WVW$=`/[[]?Y-W83_T^S?^V8/0$>?B\_R1
M^'O^<S7_`,]\DZ`4=\.0`_'NVT=@W_M$XU#?8-]OK,X>F_V[>N@&'?+>_DP9
M7_KGP%_OZVT!*KB=_P#GAQ-_XI"_W:'V@%G?#5=MX_JDRH_>*E0:,N7^5';I
M<^_@BV;8NQ"LNJ;Q`3>*:1!,.P"/IH"$F)N:7<M\A3DYR0A>!'*"#Z_.$?'F
MR-:\A;(J-]V_6!K/O9AG4W<A*QD>M<)^YV:,K;N46:-)&%B(AN*:`J*K&*JL
M!@?;/T3V_C1UU\F>6O,OM8Y<<O<D8XJM:6HM3NUCE(7&$C?K'?*Q5HA&0@K=
M<LD2,T`IS*ID4&Z[%0#E`XF,4@E$#:B8?_$`O_5D`_\`L41T`S;OKZFN:O;+
MG+A90Z#8<3UCA=AJRI6W-06:[SD5?)R=M%FC8NV/J_5XZFR[&1<5?&46JE$F
M6D&_NNY5R0P)D`#F`LQP,%$5>"A:U7X]M%0-=B8Z"A(MF0$FD;$1#-&/C6#5
M,/1-NS9-R)D+^0I0#0':;A8JR0TM7IUBVE(2>C'\-,1CQ(JS.2BI1HLQD&#M
M$X"19L\:+G34*(;&*80T!5?Z,^G7G%U+<T>7B<K8L06;@;G4T[^X[*$OMB=Y
M(B7M.N+]YA>P3%0?TYG$MY$U#G7\;+%2DE/%91(Q3*$2#<#2O.3I+[)\`]D=
M][2NF;+F/8V]9F<2$GEO!>1Y%A`MI&7LA6*UZCT3S[1:DW6BW>:BD9=5G(N(
MM[&2@BJU7,)$3)`8?FKJE[YNV3%MZA^SS/&$<24FFTBVSV#^*&")1M$5?('(
M-*MR;+&=AS/::XVM:+:E5N>=)NE=Y&=<``&*V:MC',MH!^_2EPSR_P!?_6QQ
M^XG9W<4YWE'&"^4CV)>@S3VPU54EQRW>;O$#&RTE#P#QR)8:QMP6`[5+P7`Y
M0\@`#&`@A\?OJDY0]9=@YZ2?(][BQZVY)Y9J=VQY_#:VR]G50B(5[DEP])8R
M2E7K98UX9.V-?;(D+D#""FY@\0\@&F=I/&K(O,7KXY7<8<2+5MODG-&*I&F4
M]>WR;J&K*<N[D8QTF:9E&4;+NV3,$FA]SD;+&`=ON^N@-3]*_#7+W`#K>P!Q
M2SJXISW*&,CY'-8EZ#-/K!5E`M>3[A;XO\-EI.'@'CD2Q,Z@"WFU3\%@,4/(
M``P@0,^/IU2<H>L:3YWN^2+[%CY'DAEFG7;'XXTMDO9S(Q$$ODE5\6PEEJO6
MOPUV);8U]LB0N0,('W,'B'D!+/OAX&YN[(NN^\\6^/;NC,LEV+(>+;3'N,BS
MTC6ZP$;3K0C,2Y7$K%P=C>)NC-$Q]D@-3`<_H)BAZZ`W=@KBCE''/4W1>%-A
M7JI\Q5S@V'':0=1LN\=4LU_##CFABNVFU8IL_4KWXVJ!OJ3,BJ^Q][V=_NZ`
MAQ\>OK4S]UC<&[OQPY/+XXE+I9L^W?(Z/\-[')6RMK56R4N@UULV=O9>N5IP
M5^=S6W0*H_3F("1B#YB)A`H";Z=T]]TO3]RMSQDCIWL.!<X\9>04V$U)83S5
M.1T"[A&C66F9*M0MA83LI46CF3H:4\Z9QTU$3B*KQDJ(.FH"/AH#</('J`[G
MNW+%MQ2[0.3^%<,PM2J-NG^/'$GC.W=EQ\^SQ^[TBTQ_:\[6]=&;5>P4))._
M;42;.YQ8J*JIFIF8F4!8#<%9ZAN>1?C>9$ZF[$I@QKR8/-,8>AS#+(=A?8OD
MJ/\`VHJ-G5X[E[(I2F\O#RJ<"299E;DC5TSN4$!\P*L84P+76@#0!H`T`:`-
5`&@#0!H`T`:`-`&@#0!H`T`:`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g891272pwc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891272pwc.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30!D`P$1``(1`0,1`?_$`+(```$"!@,`````````
M```````)"@$"`P8("P0%!P$!``$#!0$```````````````$#!@D"!`4'"`H0
M```%`P,#`0<#`P,%`0````$"`P0%$08'`!(((3$)$T%182(4%@IQ@3)"(Q?!
M%1AR0S0E-AD1``$"!`,$!`@)#0`````````!`A$#!`4A$@8Q01,'4=&R%&%Q
MH2)S-!4(D;$R4B-3)!87@<'A0G*2HC-C@]/C9/_:``P#`0`"$0,1`#\`?\:`
M-`&@#0!H`T`:`ZB:4].)E3T$VU@^-T_IVL5CU_?;3]];"X8T4]%^J?V'%>F3
M[1+CO>WM(-"KXS09*]KM1"+64`DY*"%"=@%R6G7?K!;JFB8NI:Q?ZSOC,U.G
M=*-?8:1W$5(R6KNZ-A:Y<W"!1I&+IF`2B`^F%0'<':I^M-<"M`U&K%<%ZSF/
MNE*<Y/I%\@LUXU\YRC^V&EE$MZ.*PG+SE!^K^K<`]*8(E9ZL?T!+Z.\_TW\:
MTZZR#>Z=K2IM5EDZ0ER$?+GU<QV?&*>;'"'B/"7O0<O*65>)^IW5+N)*II:9
M()!?.RIX=XLF6I:%]+^V`%`@5)\H4#IW]FO?"0^2B8'B7:N)/N)MWU#;[NE*
M]O?2M=,S<L=PCNWE34D!H`T`:`-`&@#0'1S]0A9O;T$(R1']_P#;U_\`76QN
M'J4_T3^PXW-*L:F5X)C>T@P<R1=%SHY'OTJ+[84EV7`B4-H#1))\4J9>_L`=
M8--4NCJ.LAMXSOC/H-TO;J-=.4<68=W:63]V7,-/4?=Q+W*`?U!\=<$U458J
MN)SJVRBP@T47X396R1`,XI6%N1:/4)>CP"JM]B:Y`/$N4S[%!*?;\AA#MKA+
MES!UCHUW&TU73J5\M<S58JHJ.5,=D#SYSCTEIZZR*B5<*67-8Z4R*.WP5%%=
M6&=LSEF612Y`GE4S.V"1DG$@59`2+.44E043%``/4AA_?4Z>]YWGI4Z@ME/-
MU!6.DSKC32WHKE@K'S6M<BX[VK`\A5W+#0K+;436V^2V8R1-5%2,45K%5%V[
ME%F]O]JM2UIN[!2OH;NW_5UUGZXK_8?&BN?NN>.^.3-'X<3PCE3C;,,WDC#X
MCG:Y8I!H`T`:`-`&@#48@MVY3"6"FA`=H!&2@F^(!%.Q[_`P`.MK7)&CFITR
MW]E2O2)]H8N_.WM(:XO)V3&R.3<AHGG$"F3O"Y"&JH3H<L@4#E_4H]]8;M2Z
M5<^^U3UDS%C-=LCTGT$Z9G5*:?HD:UT.[M./:5\PLJ9W];<3,I&^PP"=4G2I
MNO8:ZLFZ:>J:3)W>1-BO2B_I+KI&U,YZQ8[X!2+B)<]L-X^,!:X(I$PWBY5(
M"LG'H"=(8U?:I19P02@:OMIKI[6UIN[V.R4\UV"?JNZCJ;F9;;C/D3^%)F.7
M(FQJKO\`$*I1MZV:6;8^I=<$GN?1H[1G(;^)721S&_\`,[%`O7X:Z]TK9+RF
MJ+3"EGYDNM*OR'0AQF8[-AY@K[/=_9=4BTL]46GG8Y';V+#8@N[_`)2QGZ?_
M`-[:5*4W_<<-MK]-3;7ZOW]/UU],7=IOW=CD6'<NC'^7`QO_`'8U'QO4:O-G
MV<&9MC^R>FZY,MP-`&@#0$!K3IH$*8G'I0HF$?Y%`0J6O:M:=!IJ,=I,";<:
M@?(8:_$M0_7KJ1!"W;HW&MRXA$AR[828"H@`U$8QS10*=P*'3]1UMZF/=YB;
MLCNRIN*3UF7Z1O:0U1N:9B-3S)E9!Q+M$%D\A7B8R*BX%/M4E"B0U/<<`KK'
M[>*.<ZXS7RY;E8KEQ1%AM4^BK2.1--T2.3'@-0MVV)V'(#RDTQ#<4`,'U`>_
MMWU:=TH:KS%66_\`=7J.P++PT=,;#$RBQ&Y@5S)BW>M%G`R`'5*B<5#B@#,Q
M?4.!0/0@'IU]^K#O$E[(]X:K>B*&YKFREE[,3*U@W@UY)H<0244!PV`E$U!$
M1%0H4`/3^&N,L39+K_0*J-5.^2-D/K6EJ54N6VGF0:GR';D^:HH=]1'>C2I/
MI=^W?MZ;]FVE?1KO]7I[ZZS3PE>P=GF=W_AR=>!T-P)?><\$SYH[$Z>H>MA6
MG7OJW3!.0*:M`-T-2M/AH";0!H"`UZCWI[`I74DB97E>Q?R@S!Q+F;0XBS5W
MP>8U;ZLF29/;(N8+/G4(%@,J,VB$R,A%@9JN55,%$_5^;H-!IJS]<4%[N-B=
M36"8Z77K,8J*URM7*D<R1147'#>=R\A]0:$TQS$I[MS%D2JG2[9$YKV/E\5J
MO<U$8N3*[%%QC`:\!P&\^H!4M_<E`J<P[?\`D.W$:=*=?OGVCKH9-&\W(>LS
MH^F=_D/>GXW^YUE1OL:@5(;5H?\`05$>`7GP6=M/7R#R/(T]9`'9'&?FSQLH
MW.X23=$<L3WLH1VFHS,H4Q!*8#%$0IJO(T;S7S(D^IG.8JX_3/3#9\_\OD*<
M[G;[GW!?P+/0)-R.R_8H+F@N6#N#A!T%C$=:8EX"\6FF,[";9$XN89E;\0M.
M$0O"4G\:V?+S3ZX0:$_W5]*2RC-PJ^=.793&.<5#]1UWI1Z/T^VDEI6T%*^J
M1B(Y5EM555$Q55AC'PF/VZ<W.8:W.H=;+]=66]T^8LIK:B8UK6*Y5:B-C!((
ML,#TA'@GPN;[_1XHX%+ZE`$Q,368(#[NHQU=5W:+TC,1,UMHEATRF]1LF<W^
M:LM55FH[PBK_`-4U/SG:->%7$9B8IVW&C"S42!0OTF,[4:"'P,+9BGZG3WUU
M2?H/14S!UJH5_LLZB5YP\UEP?J.\.\=5,ZSM`XB<7MY52\?,3)@0Q3ALL&WD
MS[B"!BB4Y&Q3%VB%=:&:`T3*>V9+M5`V8U45%22Q%146**F&U%Q*/XM\T,8Z
MANV54Q3O,R"QPQQ+C_XYX!]'T?\`#>//0K7T?M*&I6M:T]#ONZU[ZO/O$W)P
MLWT>7+EW0Z(;#8?B5K_/G]M7+-Z>9UGM(KE``$Q%!&E?[29UPI4?:D4W7IJD
M684T723C?Z`BL=$Q2*B8IT=N\-_]92U$"CV]F@*I%2'$PD`XB'0!.0Z93CUZ
M$.8H%/3;[*Z`F%3;3<F<#&]A2&.'>GS'(42EK\=`1WT`1,`%.-``FX!W"(B!
M0`>WS#H"B:BHB)DMJB84-ZJ8F(!3=3`0Y@!,_8.PZA4CMV#8<4R35-1(@I-2
MJN1.")"M$Q]3TR"H.XX%$"_*'M']-()"!,>@J`U3*)3`BV!3^DI6R0F)U[[R
M]0#IW[:A6QZ"(N3?@5!<HE4!`3"*@UJFF0%*B`5$!!/>8E`#VTU*IT;"8[]Y
MR2F#^(!3H40`0H-#5$*E'J'Z>S4H:54J:#QAH3X"7:7W:C*V,88FG*AK;?R!
M<K>=;B=8N&H#EUS>Q^]M+-<K/,(R!XCQ\_BEY'+6:C&2*SF0G&S2!GW`2?KE
M`Q/J3)=#%V[3"&I-19/!CA]YR/([XN&P<=^:4="X<MS(%SW!#V%*Y.R/"9MR
M!=K!-9V=O+95.H=RV9*F5*@SCS2"4<4?F/2G0#!CPU^87F/P-Y[6-CG,F6<A
MWUA^_LJ,,&9WQYE2\[DOS[:4D[G0M<]S6^K.R<LK$3]@30J."?0F33?)G706
M!0JI#)@*A?D:7?YJN(L#C:X<Z\^XN8P[G+)N0HO'-K<<V$WA^?M6.MIHSF(M
MO/R42A#2C\%8.7036$71Q!8AAIU#0"T?CI\CO_"C\;JP.;6=;JG,F7=:\)?+
M>W2WY<D]/SN1\@R%YS,78MEN;DE59.5`\HZ3*EZYC'3:HIF,/0M!`;N_CH<W
M^4?*3S;1,_EC/.7;L@<EQ&=;TFK$G<AW:\L%NY?@TDXUM&62K+K6U'I1!ER)
M-TTFY2(ID`I*!WB`4[/\H#,_*>!\TC''>#,KYN@G3G$?'PMFV7CK(E^Q+):Y
M9H\B4QXRV+9EV[=1]+.OE6*BCZBQ2"8U0#I(+\\WWGMYH77E]QXYN.5__P".
MC6!&63B+/&1<>22;&\\D<A%8>%@L@P$-=K!RF2VK9MN_'#AB5>+5(HNHD8YC
M!M"@&//ENX"\C_$3QFX09?D>87+N0Y:YGN"8-G&;1SA=ZUI65.QT*TDDK>M&
M6C)=)RZ59.'!B*.';E87)4S"`[!$H"!ZC^.YRTY(<QO&EBG)W)Q)[+WU$24Y
M8+#(<DR382F2K?M)ZO'1MSRB:1$6[N1(V1(W7>)$*1ZJF*O4QC&$2+I%W4J8
M>H@`[>GR^\/CH";0$-:,R@8<?FV`/VUP*VA53[JRMM#W_P#J(2@5I[]:P*:_
MB;R#.,\2T'(2+ILP8L,D7FZ>OW:B23./9MR`JX>OG*QTT631%%,PJ+',4I"5
M$1`-`,-\Q'C^=WG!O!UQUMM8L1G7GA'?8,:S;(D!E#N,D1S9Q))$C"J-$(IH
MG'+.CN"`"*;<WJ&$I:B`#K?\VTY`P5P"5^91M_F///U&\IB[%AM&RP]`0.`&
M,!1`Y0$.@@7IH!,+PTX>R-YA"<.^.]]VPZ8>/_Q8VI==XYHB7$L\399LR;DV
M8G+LC;;<1B9TF#U%VI;Z;<JE3NHUH1<Y!2,Z*.@$U/#CR[PCX^?*'>W);+IW
MK#&V++4Y%%2@8A-!>;F))Q,!#VE:-O)+*)MSR3MR5`M#_P#834$OS;1`2/2O
M#?P3S5RXY(S?G1\B=O?[#GC*Z9F_%+!+R-:M(G#6#"(%;V7=#YB\;N)U"[5(
MDQR1:CAP5RFT<K++$*+HB2$$&OZYQ6C=W%;RJ<@8S+<:X1N#&?,V[[^EVE`5
M&7AW>639#BI-L<*)K(3]L2*3E(2U*(JT`:UT@3'`V^^(LK<6?(!QSQYGF-8X
MLR[AZ];?9WM'_?$39M[1UIF>L"J/X^;8S:4FS@)R*+5)\DKZ2S8P"50"T'4D
M'J6#LG\>[V2N2S./=UXRN&$Q(XCK5G8G$<C;+ZS[,D9!J>2;6\DE9ZJL#'OT
MFX"99J38HWJ`'(41#0'O0#7OT[4-T^?XAJ2(1*FH)#400##3\VK:XM?@00AD
MS^K=>60)L6()E`)$P('`"E'>!`,8`$W:HT[AJ08W>&SQA<Z?(!XO82V+$\EM
M\\?^-,]D>X&LW@>R[?CX11=!,IFTR5S?EMQ3"^'[2::KG(M&N9(\:Y3^59(Q
M>F@'.?B__'MX/^+V[29?L%.]<M9_09242PRSD210^KM^$G6C9M+Q5KVQ%`T@
M(Y)P5(X&=*HJOMBABE5*4:"!Q_.SX;KC\P&/>/-FVWF6#Q"IA.^+XNI^_G8>
M0F$)MG><+"11VC5"-`QDG3,T1N*8_00.(=]`90>*GQFV+XPN&4%QJM&1BI^]
M'R]R7/F#)S*.78!DG(MP)"R"?79K[WB4;$PS9FR:-C&.""+:A?Y&$0&[_%S\
M0.R<?<N(W//*;.EN9RQ+'7;=E[N\/V];TY"GN::DY9S(VW&SSY<A#%@60O!.
M\!N=)=4Z1`3.0!$0`>P-6*#9HDQ12(FT001;(M"`5,K=NBF5))-(""4$4R)D
M*!2%H4H!TT`@'Y<?QY^*_E+G7F8U;@N+!7*).VTH!OERVD0GH6Z642P4:6U#
MY!LZ2<`RD8^.J!!<LS-7X)#3U#[2%`!`O"'X>/+:T)MC:][^2UM9^$W#M3[R
MMW!K#*<5-2;)5,YE$X^)EIJ-M+ZQVZ*F"BCA-<NP3&$IA``$!W#XT_&!QQ\7
M.&YG$/'XMUR87?<2-XY"O:^)I25NJ^;N0:'CTYN4!$J$>S`C(VQ-%!),@$IN
M`3==`*/;0H7KV[=M`3:`-`:K#\D\?+P-SX<-Y(RXP3QF+UU_B!+%QK;5A2SX
M0$=]U"1P0B-SG>&`*J@FD5B%0`1%0!$0%B_Q(?\`].?MNWOK0L@?&.)LE`0)
M$8`M_$R"$208<]NC#`:>58FEZ@[+(@1,"=4S";:70#[X*4)LINH%*_RV4]M>
MM:>_0$>E1K_#I2G;=[?X]=`1]IM_\/DV5[U]OQK70$2_ON^-:?#0E?`'6GRT
MW=-W;W>W0@CUI\:=??6GP]N@)![%INW==M:_O7X?KJ`I$*U#MNH&_MVKTU()
-_;\*!_KH".@#0'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
